ReferenceID	RF_name
REF00000001	Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40.
REF00000002	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
REF00000003	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7620).
REF00000004	"Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)"
REF00000005	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6799).
REF00000006	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 050549.
REF00000007	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5697).
REF00000008	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7365).
REF00000009	"Clinical pipeline report, company report or official report of Shionogi (2011)."
REF00000010	Echinocandins: pharmacokinetic and therapeutic issues. Curr Med Res Opin. 2009 Jul;25(7):1741-50.
REF00000011	Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality. Ther Clin Risk Manag. 2005 Dec;1(4):299-306.
REF00000012	"Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)"
REF00000013	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6843).
REF00000014	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 062720.
REF00000015	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7105).
REF00000016	ClinicalTrials.gov (NCT00737867) Vinorelbine/Gemcitabine Versus Vinorelbine/Carboplatin in Advanced Non-small Cell Lung Cancer. U.S. National Institutes of Health.
REF00000017	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7403).
REF00000018	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4819).
REF00000019	"Carmustine-induced toxicity, DNA crosslinking and O6-methylguanine-DNA methyltransferase activity in two human lung cancer cell lines. Eur J Cancer. 1991;27(12):1658-62."
REF00000020	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6800).
REF00000021	Cefalotin - FDA approved drug information (drug label) from DailyMed.
REF00000022	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
REF00000023	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7063).
REF00000024	"Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer. 2004 Mar;40(4):536-42."
REF00000025	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4825).
REF00000026	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1807).
REF00000027	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
REF00000028	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 83).
REF00000029	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2644).
REF00000030	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6737).
REF00000031	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4726).
REF00000032	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 050347.
REF00000033	"ClinicalTrials.gov (NCT00765973) Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors. U.S. National Institutes of Health."
REF00000034	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7101).
REF00000035	Plant-derived compounds in clinical trials. Drug Discov Today. 2008 Feb;13(3-4):161-71.
REF00000036	How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
REF00000037	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6745).
REF00000038	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
REF00000039	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1456).
REF00000040	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4840).
REF00000041	Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
REF00000042	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6845).
REF00000043	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2510).
REF00000044	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6975).
REF00000045	"A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma. J Am Acad Dermatol. 2015 Jul;73(1):99-105.e1."
REF00000046	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
REF00000047	"Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)"
REF00000048	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6031).
REF00000049	Emerging therapies for the treatment and prevention of otitis media. Expert Opin Emerg Drugs. 2006 May;11(2):251-64.
REF00000050	2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
REF00000051	Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
REF00000052	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4793).
REF00000053	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4903).
REF00000054	Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.
REF00000055	Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92.
REF00000056	ClinicalTrials.gov (NCT01654939) Impact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients With Liver Disease. U.S. National Institutes of Health.
REF00000057	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7397).
REF00000058	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 064171.
REF00000059	"Drug information of Amodiaquine, 2008. eduDrugs."
REF00000060	"Drug information of Pefloxacin, 2008. eduDrugs."
REF00000061	Zosyn (piperacillin/tazobactam) reformulation: Expanded compatibility and coadministration with lactated Ringer's solutions and selected aminoglycosides. Ther Clin Risk Manag. 2008 Apr;4(2):303-14.
REF00000062	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 709).
REF00000063	"Drug information of Framycetin, 2008. eduDrugs."
REF00000064	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
REF00000065	Olmutinib: First Global Approval. Drugs. 2016 Jul;76(11):1153-7.
REF00000066	"Clinical pipeline report, company report or official report of GlaxoSmithKline (2011)."
REF00000067	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 050637.
REF00000068	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5667).
REF00000069	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4833).
REF00000070	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
REF00000071	"Drug information of Meticillin, 2008. eduDrugs."
REF00000072	Alpha-conotoxins. Int J Biochem Cell Biol. 2000 Oct;32(10):1017-28.
REF00000073	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022003.
REF00000074	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5326).
REF00000075	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2377).
REF00000076	ClinicalTrials.gov (NCT00822900) Progesterone for the Treatment of Traumatic Brain Injury III. U.S. National Institutes of Health.
REF00000077	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6823).
REF00000078	Approved antiretroviral drugs. Antiretroviral Drugs. Company report of AVERT. 2009.
REF00000079	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 071919.
REF00000080	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7345).
REF00000081	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1016).
REF00000082	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020250.
REF00000083	The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
REF00000084	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4920).
REF00000085	Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
REF00000086	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6844).
REF00000087	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 078729.
REF00000088	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7069).
REF00000089	Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study. J Natl Cancer Inst. 1990 Nov 7;82(21):1706-10.
REF00000090	ClinicalTrials.gov (NCT02112656) Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC) (OPTIMA). U.S. National Institutes of Health.
REF00000091	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4827).
REF00000092	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5692).
REF00000093	Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
REF00000094	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4916).
REF00000095	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 050497.
REF00000096	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7526).
REF00000097	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5535).
REF00000098	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2330).
REF00000099	Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria. Curr Opin Microbiol. 2005 Oct;8(5):510-7.
REF00000100	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
REF00000101	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5936).
REF00000102	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
REF00000103	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 065244.
REF00000104	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6912).
REF00000105	Fluconazole use as an important risk factor in the emergence of fluconazole-resistant Candida glabrata fungemia. Arch Intern Med. 2009 Aug 10;169(15):1444-5; author reply 1445.
REF00000106	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6785).
REF00000107	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7226).
REF00000108	ClinicalTrials.gov (NCT00846703) The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia. U.S. National Institutes of Health.
REF00000109	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4941).
REF00000110	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5464).
REF00000111	Abacavir (marketed as Ziagen) and Abacavir-containing Medications. FDA. 2008.
REF00000112	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5687).
REF00000113	"Clinical pipeline report, company report or official report of Savara pharmaceuticals."
REF00000114	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2568).
REF00000115	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6815).
REF00000116	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6976).
REF00000117	"Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)"
REF00000118	Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
REF00000119	ClinicalTrials.gov (NCT01190982) Efficacy and Safety Study of LEP-ETU to Treat Metastatic Breast Cancer. U.S. National Institutes of Health.
REF00000120	"Clinical pipeline report, company report or official report of Insys Therapeutics."
REF00000121	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7301).
REF00000122	"New drugs for the treatment of cancer, 1990-2001. Isr Med Assoc J. 2002 Dec;4(12):1124-31."
REF00000123	Nucleoside and nucleotide analogs in the treatment of chronic hepatitis B. Enferm Infecc Microbiol Clin. 2008 May;26 Suppl 7:32-8.
REF00000124	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7154).
REF00000125	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 86).
REF00000126	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 064200.
REF00000127	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2866).
REF00000128	"Clinical pipeline report, company report or official report of Elcelyx Therapeutics."
REF00000129	"Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)"
REF00000130	Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues. Antivir Chem Chemother. 2009;19(4):165-76.
REF00000131	"Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020988)"
REF00000132	"Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017692)"
REF00000133	A Phase III study to assess the clinical utility of low-dose fentanyl transdermal system in patients with chronic nonmalignant pain. Curr Med Res Opin. 2006 Aug;22(8):1493-501.
REF00000134	ClinicalTrials.gov (NCT00822614) Safety of Fentanyl TAIFUN Treatment. U.S. National Institutes of Health.
REF00000135	"Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)"
REF00000136	In vitro activity of plazomicin against -lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE).J Antimicrob Chemother. 2017 Oct 1;72(10):2792-2795.
REF00000137	ClinicalTrials.gov (NCT01970371) A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE). U.S. National Institutes of Health.
REF00000138	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5678).
REF00000139	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6852).
REF00000140	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5892).
REF00000141	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4802).
REF00000142	"Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42."
REF00000143	Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy. 2006 Aug;26(8):1099-110.
REF00000144	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4252).
REF00000145	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5890).
REF00000146	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6842).
REF00000147	"Clinical pipeline report, company report or official report of Merck."
REF00000148	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7096).
REF00000149	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3447).
REF00000150	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 060634.
REF00000151	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7519).
REF00000152	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2954).
REF00000153	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1015).
REF00000154	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5889).
REF00000155	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020677.
REF00000156	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7454).
REF00000157	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 061490.
REF00000158	Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs. 2008 Sep;13(3):511-22.
REF00000159	Disk diffusion test and E-test with enriched Mueller-Hinton agar for determining susceptibility of Candida species to voriconazole and fluconazole. J Microbiol Immunol Infect. 2009 Apr;42(2):148-53.
REF00000160	Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells. Cancer Chemother Pharmacol. 2006 Jan;57(2):171-9.
REF00000161	Inhaled Ciprofloxacin for the Management of Infections in Non-Cystic Fibrosis Bronchiectasis (BE) Patients
REF00000162	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6809).
REF00000163	Docetaxel: a review of its use in metastatic breast cancer. Drugs. 2005;65(17):2513-31.
REF00000164	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7719).
REF00000165	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5710).
REF00000166	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 204).
REF00000167	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 050317.
REF00000168	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 074690.
REF00000169	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7331).
REF00000170	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
REF00000171	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
REF00000172	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6812).
REF00000173	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2406).
REF00000174	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5713).
REF00000175	ClinicalTrials.gov (NCT00363688) Treating Patients With a History of Non-Life Threatening Allergic Reaction to Penicillin With Penicillin. U.S. National Institutes of Health.
REF00000176	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7242).
REF00000177	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 019616.
REF00000178	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6464).
REF00000179	ClinicalTrials.gov (NCT00764361) Safety Study of Topical Doxycycline Gel for Adult Diabetic Lower Extremity Ulcers. U.S. National Institutes of Health.
REF00000180	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 019500.
REF00000181	Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter. 2006 Jun;19(2):130-9.
REF00000182	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6391).
REF00000183	"Pain reduction with oral methotrexate in knee osteoarthritis, a pragmatic phase iii trial of treatment effectiveness (PROMOTE): study protocol for ... Trials. 2015 Mar 4;16:77."
REF00000184	"Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034238)"
REF00000185	ClinicalTrials.gov (NCT04136366) The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy. U.S. National Institutes of Health.
REF00000186	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2779).
REF00000187	Structures of muO-conotoxins from Conus marmoreus. I nhibitors of tetrodotoxin (TTX)-sensitive and TTX-resistant sodium channels in mammalian senso... J Biol Chem. 2004 Jun 11;279(24):25774-82.
REF00000188	"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017 Jul 1;390(10089):29-39."
REF00000189	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7739).
REF00000190	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2486).
REF00000191	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5343).
REF00000192	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3342).
REF00000193	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7327).
REF00000194	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 076104.
REF00000195	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5711).
REF00000196	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7955).
REF00000197	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
REF00000198	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6851).
REF00000199	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4813).
REF00000200	"Drug information of Josamycin, 2008. eduDrugs."
REF00000201	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7624).
REF00000202	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4565).
REF00000203	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4831).
REF00000204	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7089).
REF00000205	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7433).
REF00000206	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6837).
REF00000207	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 075259.
REF00000208	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5893).
REF00000209	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 061936.
REF00000210	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 38).
REF00000211	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6957).
REF00000212	ClinicalTrials.gov (NCT01083524) Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension. U.S. National Institutes of Health.
REF00000213	ClinicalTrials.gov (NCT02616484) Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency: (DCA/PDCD). U.S. National Institutes of Health.
REF00000214	"ClinicalTrials.gov (NCT02469337) Role of Preoperative Carbohydrates Drinks, Dichloroacetate and Exercise on Postoperative Muscle Insulin Resistance (CARBEX). U.S. National Institutes of Health."
REF00000215	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
REF00000216	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
REF00000217	ClinicalTrials.gov (NCT02421120) Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients. U.S. National Institutes of Health.
REF00000218	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4627).
REF00000219	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7641).
REF00000220	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
REF00000221	"Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018409)"
REF00000222	ClinicalTrials.gov (NCT00246610) Safety Of VIRACEPT 625mg Administered To HIV-Infected Women During Pregnancy. U.S. National Institutes of Health.
REF00000223	Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma. P T. 2010 March; 35(3): 148-157.
REF00000224	"ClinicalTrials.gov (NCT02383589) A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Rituximab Versus MMF in Patients With Pemphigus Vulgaris. U.S. National Institutes of Health."
REF00000225	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6882).
REF00000226	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6883).
REF00000227	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5046).
REF00000228	Companion diagnostics for targeted cancer drugs - clinical and regulatory aspects. Front Oncol. 2014 May 16;4:105.
REF00000229	"Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)"
REF00000230	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5082).
REF00000231	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5137).
REF00000232	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2427).
REF00000233	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5209).
REF00000234	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4357).
REF00000235	The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol. 2005;45:529-64.
REF00000236	Recombinant Plasmodium falciparum glutathione reductase is inhibited by the antimalarial dye methylene blue. FEBS Lett. 1998 Feb 6;422(3):311-4.
REF00000237	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4832).
REF00000238	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4830).
REF00000239	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7073).
REF00000240	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6805).
REF00000241	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4325).
REF00000242	"Drug information of Sodium lauryl sulfate, 2008. eduDrugs."
REF00000243	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 011270.
REF00000244	"ClinicalTrials.gov (NCT03830684) A Randomized, Double-blind, Placebo-controlled, Multicenter and Phase IIa Clinical Trial for the Effectiveness and Safety of Baicalein Tablets in the Treatment of Improve Other Aspects of Healthy Adult With Influenza Fever. U.S. National Institutes of Health."
REF00000245	ClinicalTrials.gov (NCT03667690) Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis (ReSTORE). U.S. National Institutes of Health.
REF00000246	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7476).
REF00000247	ClinicalTrials.gov (NCT01487174) KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy. U.S. National Institutes of Health.
REF00000248	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7944).
REF00000249	ClinicalTrials.gov (NCT02039726) An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects. U.S. National Institutes of Health.
REF00000250	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7000).
REF00000251	Nanocurcumin: a promising therapeutic advancement over native curcumin. Crit Rev Ther Drug Carrier Syst. 2013;30(4):331-68.
REF00000252	ClinicalTrials.gov (NCT00634049) Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi. U.S. National Institutes of Health.
REF00000253	"ClinicalTrials.gov (NCT02951052) Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults. U.S. National Institutes of Health."
REF00000254	ClinicalTrials.gov (NCT01232595) Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections. U.S. National Institutes of Health.
REF00000255	Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006 Oct;6(10):789-802.
REF00000256	ClinicalTrials.gov (NCT04105205) First-In-Human Study of Apramycin. U.S. National Institutes of Health.
REF00000257	ClinicalTrials.gov (NCT03439124) Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia. U.S. National Institutes of Health.
REF00000258	ClinicalTrials.gov (NCT03137173) Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections. U.S. National Institutes of Health.
REF00000259	Why Choose Cyclosporin A as First-line Therapy in COVID-19 Pneumonia. Reumatol Clin. 2020 Apr 16;S1699-258X(20)30044-9.
REF00000260	"Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol Cancer Ther. 2011 Aug;10(8):1394-406."
REF00000261	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7935).
REF00000262	ClinicalTrials.gov (NCT01614964) Studies of a Candidate Aminoquinoline Antimalarial (AQ-13). U.S. National Institutes of Health.
REF00000263	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2826).
REF00000264	ClinicalTrials.gov (NCT00355953) Vascular and Skeletal Protective Effects of Genistein in Postmenopausal Women. U.S. National Institutes of Health.
REF00000265	ClinicalTrials.gov (NCT02127710) A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC). U.S. National Institutes of Health.
REF00000266	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7731).
REF00000267	"ClinicalTrials.gov (NCT02322281) TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy"
REF00000268	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7966).
REF00000269	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
REF00000270	"Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021154)"
REF00000271	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3945).
REF00000272	ClinicalTrials.gov (NCT03592472) A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV). U.S. National Institutes of Health.
REF00000273	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7950).
REF00000274	Cancer therapy with beta-lapachone. Curr Cancer Drug Targets. 2002 Sep;2(3):227-42.
REF00000275	"In vitro antimicrobial activity of a new antibiotic, MDL 62,879 (GE2270 A).. Antimicrob Agents Chemother. 1993 April; 37(4): 741-745."
REF00000276	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5675).
REF00000277	ClinicalTrials.gov (NCT02537847) Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Escherichia Coli (SETAP). U.S. National Institutes of Health.
REF00000278	ClinicalTrials.gov (NCT01679847) Blood Brain Barrier Penetration and Pharmacokinetics of the Elemene in Malignant Patients.. U.S. National Institutes of Health.
REF00000279	"Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032169)"
REF00000280	Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma. Cancer. 2015 Aug 1;121(15):2612-7.
REF00000281	ClinicalTrials.gov (NCT01223027) Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma. U.S. National Institutes of Health.
REF00000282	ClinicalTrials.gov (NCT01262027) TKI258 for Metastatic Inflammatory Breast Cancer Patients. U.S. National Institutes of Health.
REF00000283	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7417).
REF00000284	ClinicalTrials.gov (NCT01523808) Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase)in Patients With Pancreatic Cancer. U.S. National Institutes of Health.
REF00000285	ClinicalTrials.gov (NCT01518517) GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia (GRASPIVOTALL). U.S. National Institutes of Health.
REF00000286	"Clinical pipeline report, company report or official report of Roche."
REF00000287	Overexpression of PIN1 Enhances Cancer Growth and Aggressiveness with Cyclin D1 Induction in EBV-Associated Nasopharyngeal Carcinoma.PLoS One. 2016 Jun 3;11(6):e0156833.
REF00000288	"Why have ten or so nontoxic, retrovirus integrase inhibitors not been made available for AIDS treatment. Biomed Pharmacother. 1999 Dec;53(10):484-6."
REF00000289	"Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005849)"
REF00000290	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7714).
REF00000291	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1465).
REF00000292	"Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000791)"
REF00000293	"Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001915)"
REF00000294	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4136).
REF00000295	Herpes simplex virus-specified DNA polymerase is the target for the antiviral action of 9-(2-phosphonylmethoxyethyl)adenine. J Biol Chem. 1991 Jan 5;266(1):238-44.
REF00000296	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7658).
REF00000297	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5433).
REF00000298	Upregulation of p21WAF1/CIP1 in human breast cancer cell lines MCF-7 and MDA-MB-468 undergoing apoptosis induced by natural product anticancer drugs 10-hydroxycamptothecin and camptothecin through p53-dependent and independent pathways. Int J Oncol. 1998 Apr;12(4):793-804.
REF00000299	Nucleic acid-binding ligands identify new mechanisms to inhibit telomerase. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3467-71.
REF00000300	RNA as a target for small molecules. Curr Opin Chem Biol. 2000 Dec;4(6):678-86.
REF00000301	The apicoplast as an antimalarial drug target. Drug Resist Updat. 2001 Jun;4(3):145-51.
REF00000302	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6298).
REF00000303	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7005).
REF00000304	Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature. 2020 Apr 9.
REF00000305	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5714).
REF00000306	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6690).
REF00000307	Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature. 2011 Oct 2;478(7370):529-33.
REF00000308	Isolation and characterization of an Escherichia coli strain exhibiting partial tolerance to quinolones. Antimicrob Agents Chemother. 1989 May;33(5):705-9.
REF00000309	p63 is a key regulator of iRHOM2 signalling in the keratinocyte stress response.Nat Commun. 2018 Mar 9;9(1):1021.
REF00000310	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4862).
REF00000311	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
REF00000312	Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein intera... J Med Chem. 2009 Nov 26;52(22):7044-53.
REF00000313	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
REF00000314	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5672).
REF00000315	Novel molecular targets for antimalarial drug development. Chem Biol Drug Des. 2008 Apr;71(4):287-97.
REF00000316	"J Clin Oncol 32:5s, 2014 (suppl; abstr 2071)."
REF00000317	Alkylation of DNA by melphalan in relation to immunoassay of melphalan-DNA adducts: characterization of mono-alkylated and cross-linked products fr... Chem Biol Interact. 1990;73(2-3):183-94.
REF00000318	UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res. 2005 Feb 1;11(3):1226-36.
REF00000319	Bactericidal effect of piperacillin alone and combined. Presse Med. 1986 Dec 20;15(46):2297-302.
REF00000320	Association of amino acid substitutions in penicillin-binding protein 3 with beta-lactam resistance in beta-lactamase-negative ampicillin-resistant Haemophilus influenzae. Antimicrob Agents Chemother. 2001 Jun;45(6):1693-9.
REF00000321	"Overexpression, purification and biochemical characterization of a class A high-molecular-mass penicillin-binding protein (PBP), PBP1* and its soluble derivative from Mycobacterium tuberculosis. Biochem J. 2002 Feb 1;361(Pt 3):635-9."
REF00000322	Neuraminidase inhibitory activities of flavonols isolated from Rhodiola rosea roots and their in vitro anti-influenza viral activities. Bioorg Med Chem. 2009 Oct 1;17(19):6816-23.
REF00000323	Structural insight into human CK2alpha in complex with the potent inhibitor ellagic acid. Bioorg Med Chem Lett. 2009 Jun 1;19(11):2920-3.
REF00000324	"Erigeroflavanone, a flavanone derivative from the flowers of Erigeron annuus with protein glycation and aldose reductase inhibitory activity. J Nat Prod. 2008 Apr;71(4):713-5."
REF00000325	Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5.
REF00000326	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
REF00000327	Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4706-10.
REF00000328	A three-dimensional in silico pharmacophore model for inhibition of Plasmodium falciparum cyclin-dependent kinases and discovery of different class... J Med Chem. 2004 Oct 21;47(22):5418-26.
REF00000329	"Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin. J Med Chem. 2005 Feb 10;48(3):737-43."
REF00000330	Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries. J Med Chem. 2008 Jul 24;51(14):4188-99.
REF00000331	Structure-activity relationship of human GLO I inhibitory natural flavonoids and their growth inhibitory effects. Bioorg Med Chem. 2008 Apr 1;16(7):3969-75.
REF00000332	Discovery of the inhibitors of tumor necrosis factor alpha with structure-based virtual screening. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6195-8.
REF00000333	Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8.
REF00000334	"Rational design of novel, potent small molecule pan-selectin antagonists. J Med Chem. 2007 Mar 22;50(6):1101-15."
REF00000335	"Baicalin, a prodrug able to reach the CNS, is a prolyl oligopeptidase inhibitor. Bioorg Med Chem. 2008 Aug 1;16(15):7516-24."
REF00000336	"Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36."
REF00000337	Ginsenoside Rg(3) decelerates hERG K(+) channel deactivation through Ser631 residue interaction. Eur J Pharmacol. 2011 Aug 1;663(1-3):59-67.
REF00000338	The formation of functional penicillin-binding proteins. J Biol Chem. 1975 Aug 25;250(16):6578-85.
REF00000339	Vinca alkaloid and MDR1. Gan To Kagaku Ryoho. 2008 Jul;35(7):1086-9.
REF00000340	DNA damage and homologous recombination signaling induced by thymidylate deprivation. Biochem Pharmacol. 2008 Oct 15;76(8):987-96.
REF00000341	Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy. Curr Allergy Asthma Rep. 2009 Mar;9(2):140-8.
REF00000342	Binding of cephalothin and cefotaxime to D-ala-D-ala-peptidase reveals a functional basis of a natural mutation in a low-affinity penicillin-binding protein and in extended-spectrum beta-lactamases. Biochemistry. 1995 Jul 25;34(29):9532-40.
REF00000343	Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature. 2007 Dec 13;450(7172):1001-9.
REF00000344	"31P NMR spectra of ethidium, quinacrine, and daunomycin complexes with poly(adenylic acid).poly(uridylic acid) RNA duplex and calf thymus DNA. Biochemistry. 1989 Apr 4;28(7):2804-12."
REF00000345	Antiviral drugs in current clinical use. J Clin Virol. 2004 Jun;30(2):115-33.
REF00000346	Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
REF00000347	Retinoids--which dermatological indications will benefit in the near future Skin Pharmacol Appl Skin Physiol. 2001 Sep-Oct;14(5):303-15.
REF00000348	Targacept active conformation search: a new method for predicting the conformation of a ligand bound to its protein target. J Med Chem. 2004 Dec 30;47(27):6831-9.
REF00000349	"Methionine and cysteine affect glutathione level, glutathione-related enzyme activities and the expression of glutathione S-transferase isozymes in rat hepatocytes. J Nutr. 1997 Nov;127(11):2135-41."
REF00000350	Fab antibody fragments: some applications in clinical toxicology. Drug Saf. 2004;27(14):1115-33.
REF00000351	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1227).
REF00000352	Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature. 2000 Sep 21;407(6802):340-8.
REF00000353	Resistance of Pseudomonas aeruginosa to cefsulodin: modification of penicillin-binding protein 3 and mapping of its chromosomal gene. J Antimicrob Chemother. 1990 Apr;25(4):513-23.
REF00000354	Antifungal drugs: What brings the future . Med Mycol. 2019 Jun 1;57(Supplement_3):S328-S343.
REF00000355	Staphylococcus aureus PBP4 is essential for beta-lactam resistance in community-acquired methicillin-resistant strains. Antimicrob Agents Chemother. 2008 Nov;52(11):3955-66.
REF00000356	A synthetic alanyl-initiator tRNA with initiator tRNA properties as determined by fluorescence measurements: comparison to a synthetic alanyl-elongator tRNA. Nucleic Acids Res. 1991 Oct 25;19(20):5749-54.
REF00000357	The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol. 1996 Mar 1;156(5):1937-41.
REF00000358	Immune effector cells produce lethal DNA damage in cells treated with a thiopurine. Cancer Res. 2009 Mar 15;69(6):2393-9.
REF00000359	Interaction of furazolidone with DNA. Biochim Biophys Acta. 1975 Aug 21;402(2):161-5.
REF00000360	2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
REF00000361	Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
REF00000362	The genomic landscape of nasopharyngeal carcinoma.Nat Genet. 2014 Aug;46(8):866-71.
REF00000363	"Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.Drug Des Devel Ther. 2015 Aug 26;9:4897-907."
REF00000364	Inhibition of fatty acid biosynthesis prevents adipocyte lipotoxicity on human osteoblasts in vitro. J Cell Mol Med. 2010 Apr;14(4):982-91.
REF00000365	"Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I. Biochem J. 2002 Sep 1;366(Pt 2):653-61."
REF00000366	Inhibition of lysoPAF acetyltransferase activity by flavonoids. Inflamm Res. 1996 Nov;45(11):546-9.
REF00000367	"PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models. Cancer Cell. 2015 Jul 13;28(1):70-81."
REF00000368	Aminoglycoside association pathways with the 30S ribosomal subunit. J Phys Chem B. 2009 May 21;113(20):7322-30.
REF00000369	"Effect of amodiaquine, a histamine N-methyltransferase inhibitor, on, Propionibacterium acnes and lipopolysaccharide-induced hepatitis in mice. Eur J Pharmacol. 2007 Mar 8;558(1-3):179-84."
REF00000370	Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121.
REF00000371	Effect of selective estrogen receptor modulators on cell proliferation and estrogen receptor activities in normal human prostate stromal and epithe... Prostate Cancer Prostatic Dis. 2009;12(4):375-81.
REF00000372	Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study. Melanoma Res. 2004 Jun;14(3):207-10.
REF00000373	In vitro antienterococcal activity explains associations between exposures to antimicrobial agents and risk of colonization by multiresistant enter... J Infect Dis. 2004 Dec 15;190(12):2162-6.
REF00000374	The streptogramin antibiotics: update on their mechanism of action. Expert Opin Investig Drugs. 1998 Apr;7(4):591-9.
REF00000375	"Some properties of the interaction between 2,2'-diselenadibenzoic acid and serum albumins. J Pharm Biomed Anal. 2005 Sep 1;39(1-2):263-7."
REF00000376	Inhibitors of tryptase for the treatment of mast cell-mediated diseases. Curr Pharm Des. 1998 Oct;4(5):381-96.
REF00000377	Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin. Chem Biol. 2004 Jul;11(7):949-57.
REF00000378	Neisseria gonorrhoeae and emerging resistance to extended spectrum cephalosporins. Curr Opin Infect Dis. 2009 Feb;22(1):87-91.
REF00000379	Characterization of a 30S ribosomal subunit assembly intermediate found in Escherichia coli cells growing with neomycin or paromomycin. Arch Microbiol. 2008 May;189(5):441-9.
REF00000380	Antistaphylococcal activity of gentamicin. Minerva Med. 1975 Dec 8;66(84):4505-26.
REF00000381	"The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. Cancer Chemother Pharmacol. 2004 Apr;53(4):296-304."
REF00000382	"Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. Eur J Cancer. 2002 Jun;38(9):1271-7."
REF00000383	Clinical relevance of antibiotic-induced endotoxin release in patients undergoing hepatic resection. World J Surg. 1999 Jan;23(1):75-9.
REF00000384	Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
REF00000385	The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):298-304.
REF00000386	Genetics of chromosomally mediated intermediate resistance to ceftriaxone and cefixime in Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2009 Sep;53(9):3744-51.
REF00000387	Thyroid hormone resistance and pituitary enlargement after thyroid ablation in a woman on levothyroxine treatment. Thyroid. 2008 Oct;18(10):1119-23.
REF00000388	An immunomodulatory activity of micafungin in preclinical aspergillosis. J Antimicrob Chemother. 2014 Apr;69(4):1065-74.
REF00000389	A link in transcription between the native pbpB and the acquired mecA gene in a strain of Staphylococcus aureus. Microbiology. 2006 Sep;152(Pt 9):2549-58.
REF00000390	Bleomycin and talisomycin sequence-specific strand scission of DNA: a mechanism of double-strand cleavage. Cancer Res. 1982 Jul;42(7):2779-85.
REF00000391	XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib. J Thorac Oncol. 2012 Jan;7(1):219-26.
REF00000392	"Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer. 2011 Aug;73(2):195-202."
REF00000393	"A new, broad-spectrum azole antifungal: posaconazole--mechanisms of action and resistance, spectrum of activity. Mycoses. 2006;49 Suppl 1:2-6."
REF00000394	Mechanism of action of aminoglycoside antibiotics.Binding studies of tobramycin and its 6'-N-acetyl derivative to the bacterial ribosome and its subunits.Eur J Biochem.1979 Dec;102(1):73-81.
REF00000395	"Clinical pipeline report, company report or official report of lipocine."
REF00000396	"Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacod... J Infect Dis. 2001 Apr 1;183(7):1126-9."
REF00000397	Activity of fluoroquinolone antibiotics against Plasmodium falciparum in vitro. Antimicrob Agents Chemother. 1988 Aug;32(8):1182-6.
REF00000398	Ribosomal resistance in the gentamicin producer organism Micromonospora purpurea. Antimicrob Agents Chemother. 1982 Aug;22(2):231-6.
REF00000399	Modulators of vascular sex hormone receptors and their effects in estrogen-deficiency states associated with menopause. Recent Pat Cardiovasc Drug Discov. 2008 Nov;3(3):165-86.
REF00000400	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
REF00000401	"Novel monoamine oxidase inhibitors, 3-(2-aminoethoxy)-1,2-benzisoxazole derivatives, and their differential reversibility. Jpn J Pharmacol. 2002 Feb;88(2):174-82."
REF00000402	Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
REF00000403	"Expression and characterization of E. coli-produced soluble, functional human dihydroorotate dehydrogenase: a potential target for immunosuppression. J Mol Microbiol Biotechnol. 1999 Aug;1(1):183-8."
REF00000404	Thiazolides: a new class of antiviral drugs. Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):667-74.
REF00000405	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
REF00000406	Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues. Eur J Med Chem. 2008 Aug;43(8):1621-31.
REF00000407	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
REF00000408	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
REF00000409	High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem. 2009 Feb 1;17(3):990-1005.
REF00000410	"Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin. J Nat Prod. 2009 Apr;72(4):725-31."
REF00000411	"Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammator... Bioorg Med Chem Lett. 2005 Apr 1;15(7):1793-7."
REF00000412	Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloprote... Bioorg Med Chem. 2009 Feb 1;17(3):1290-6.
REF00000413	"Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. J Med Chem. 2006 Oct 5;49(20):6111-9."
REF00000414	Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance. Genome Res. 2009 Jul;19(7):1214-23.
REF00000415	How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer. 2002 Sep;2(9):705-13.
REF00000416	Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage. Mol Cancer Ther. 2009 Apr;8(4):864-72.
REF00000417	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
REF00000418	"Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7."
REF00000419	Inhibition of eEF-2 kinase sensitizes human nasopharyngeal carcinoma cells to lapatinib-induced apoptosis through the Src and Erk pathways.BMC Cancer. 2016 Oct 19;16(1):813.
REF00000420	"Clinical pipeline report, company report or official report of GlaxoSmithKline (2009)."
REF00000421	"Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother. 2006 Jun;50(6):2156-66."
REF00000422	The glycylcyclines: a comparative review with the tetracyclines. Drugs. 2004;64(1):63-88.
REF00000423	"Repurposing of the epidermal growth factor. Journal of Commercial Biotechnology (2011) 17, 45-52."
REF00000424	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
REF00000425	Activities of antibiotics against methicillin-resistant Staphylococcus aureus with particular reference to synergetic effect between ticarcillin and fosfomycin on penicillinase non-producing methicillin-resistant S. aureus. Jpn J Antibiot. 1993 Jun;46(6):421-7.
REF00000426	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
REF00000427	Vitamin K3 disrupts the microtubule networks by binding to tubulin: a novel mechanism of its antiproliferative activity. Biochemistry. 2009 Jul 28;48(29):6963-74.
REF00000428	Mode of action of clotrimazole: implications for therapy. Am J Obstet Gynecol. 1985 Aug 1;152(7 Pt 2):939-44.
REF00000429	An examination of the differential sensitivity to ketolide antibiotics in ermB strains of Streptococcus pyogenes and Streptococcus pneumoniae. Curr Microbiol. 2004 Oct;49(4):239-47.
REF00000430	l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial. Br J Haematol. 2011 Apr;153(1):58-65.
REF00000431	Bacteriological characteristics of Staphylococcus aureus isolates from humans and bulk milk. J Dairy Sci. 2008 Feb;91(2):564-9.
REF00000432	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1948).
REF00000433	Photoluminescence of CdTe nanocrystals modulated by methylene blue and DNA. A label-free luminescent signaling nanohybrid platform. Phys Chem Chem Phys. 2009 Jul 7;11(25):5062-9.
REF00000434	Curcumin ameliorates high glucose-induced acute vascular endothelial dysfunction in rat thoracic aorta. Clin Exp Pharmacol Physiol. 2009 Dec;36(12):1177-82.
REF00000435	Methadone treatment and its dangers. Medicina (Kaunas). 2009;45(5):419-25.
REF00000436	Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol. 2008 Aug;64(8):753-67.
REF00000437	6-mercaptopurine (6-MP) induces p53-mediated apoptosis of neural progenitor cells in the developing fetal rodent brain. Neurotoxicol Teratol. 2009 Jul-Aug;31(4):198-202.
REF00000438	Diversity in enoyl-acyl carrier protein reductases. Cell Mol Life Sci. 2009 May;66(9):1507-17.
REF00000439	"Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72."
REF00000440	Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
REF00000441	Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only Curr HIV Res. 2009 May;7(3):320-6.
REF00000442	"In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect. 2007 Jun;13 Suppl 2:17-24."
REF00000443	Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009;48(5):281-302.
REF00000444	"Etoposide, topoisomerase II and cancer.Curr Med Chem Anticancer Agents.2005 Jul;5(4):363-72."
REF00000445	Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79.
REF00000446	"Clinical pipeline report, company report or official report of Genentech (2009)."
REF00000447	"Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem Biol Interact. 2000 Jan 3;124(1):61-76."
REF00000448	"Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases. Bioorg Med Chem. 2009 Mar 15;17(6):2276-81."
REF00000449	Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80.
REF00000450	"Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem. 2008 Mar 27;51(6):1706-18."
REF00000451	Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis. Zentralbl Gynakol. 2003 Jul-Aug;125(7-8):247-51.
REF00000452	"Clinical pipeline report, company report or official report of Roche (2009)."
REF00000453	"Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and ... Antimicrob Agents Chemother. 2007 Jul;51(7):2621-4."
REF00000454	Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success. Best Pract Res Clin Gastroenterol. 2008;22(6):1081-92.
REF00000455	Loperamide: evidence of interaction with mu and delta opioid receptors. Life Sci. 1983;33 Suppl 1:315-8.
REF00000456	O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int J Cancer. 1998 Sep 11;77(6):919-22.
REF00000457	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
REF00000458	Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
REF00000459	"Extended-spectrum cephalosporinases: structure, detection and epidemiology. Future Microbiol. 2007 Jun;2:297-307."
REF00000460	Aldosterone (mineralocorticoid) equivalent to prednisolone (glucocorticoid) in reversing hearing loss in MRL/MpJ-Fas1pr autoimmune mice. Laryngoscope. 2000 Nov;110(11):1902-6.
REF00000461	AMP-activated protein kinase-dependent and -independent mechanisms underlying in vitro antiglioma action of compound C. Biochem Pharmacol. 2009 Jun 1;77(11):1684-93.
REF00000462	"Molecular cloning, functional characterization and tissue distribution of rat H+/organic cation antiporter MATE1. Pharm Res. 2006 Aug;23(8):1696-701."
REF00000463	"The lactococcal secondary multidrug transporter LmrP confers resistance to lincosamides, macrolides, streptogramins and tetracyclines. Microbiology. 2001 Oct;147(Pt 10):2873-80."
REF00000464	Crystal structure of cefditoren complexed with Streptococcus pneumoniae penicillin-binding protein 2X: structural basis for its high antimicrobial ... Antimicrob Agents Chemother. 2007 Nov;51(11):3902-7.
REF00000465	Interaction between the ribosomal subunits: 16S rRNA suppressors of the lethal Delta A1916 mutation in the 23S rRNA of Escherichia coli. Mol Genet Genomics. 2007 Sep;278(3):307-15.
REF00000466	Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32.
REF00000467	Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci. 2014 Nov;35(11):604-20.
REF00000468	Purine nucleoside analogs in indolent non-Hodgkin's lymphoma. Oncology (Williston Park). 2000 Jun;14(6 Suppl 2):13-5.
REF00000469	Penicillin-binding protein PBP2 of Escherichia coli localizes preferentially in the lateral wall and at mid-cell in comparison with the old cell pole. Mol Microbiol. 2003 Jan;47(2):539-47.
REF00000470	"Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in ... J Antimicrob Chemother. 2009 Aug;64(2):398-410."
REF00000471	Sequence-dependent effects in drug-DNA interaction: the crystal structure of Hoechst 33258 bound to the d(CGCAAATTTGCG)2 duplex. Nucleic Acids Res. 1994 May 11;22(9):1607-12.
REF00000472	Bacillus subtilis tolerance of moderate concentrations of rifampin involves the sigma(B)-dependent general and multiple stress response. J Bacteriol. 2002 Jan;184(2):459-67.
REF00000473	Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1998 Jul;42(7):1853-7.
REF00000474	An ultrastructural study of the effects of mefloquine on malaria parasites. Am J Trop Med Hyg. 1987 Jan;36(1):9-14.
REF00000475	A comparative trial of imipenem versus ceftazidime in the release of endotoxin and cytokine generation in patients with gram-negative urosepsis. Urosepsis Study Group. J Endotoxin Res. 2000;6(1):25-31.
REF00000476	Treating HCV with ribavirin analogues and ribavirin-like molecules. J Antimicrob Chemother. 2006 Jan;57(1):8-13.
REF00000477	Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44.
REF00000478	Integration of panitumumab into the treatment of colorectal cancer. Crit Rev Oncol Hematol. 2010 Apr;74(1):16-26.
REF00000479	"Galangal pungent component, 1'-acetoxychavicol acetate, activates TRPA1. Biosci Biotechnol Biochem. 2010;74(8):1694-6."
REF00000480	Cytochromes P450 (CYP) in the Poeciliopsis lucida hepatocellular carcinoma cell line (PLHC-1): dose- and time-dependent glucocorticoid potentiation of CYP1A induction without induction of CYP3A. ArchBiochem Biophys. 1996 May 1;329(1):113-22.
REF00000481	Interaction between the glucocorticoid and erythropoietin receptors in human erythroid cells. Exp Hematol. 2009 May;37(5):559-72.
REF00000482	Detection of tetracycline resistance genes by PCR methods. Methods Mol Biol. 2004;268:3-13.
REF00000483	New dimension of statin action on ApoB atherogenicity. Clin Cardiol. 2003 Jan;26(1 Suppl 1):I7-10.
REF00000484	Beta3-tubulin is induced by estradiol in human breast carcinoma cells through an estrogen-receptor dependent pathway. Cell Motil Cytoskeleton. 2009 Jul;66(7):378-88.
REF00000485	MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6: 27.
REF00000486	"Clinical pipeline report, company report or official report of AstraZeneca (2009)."
REF00000487	"Genetic analyses of beta-lactamase negative ampicillin-resistant strains of Haemophilus influenzae isolated in Okinawa, Japan. Jpn J Infect Dis. 2006 Feb;59(1):36-41."
REF00000488	"Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma. Gan To Kagaku Ryoho. 2009 Jul;36(7):1076-9."
REF00000489	Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother. 1999 Sep;33(9):960-7.
REF00000490	Effect of hepatitis B virus reverse transcriptase variations on entecavir treatment response. J Infect Dis. 2014 Sep 1;210(5):701-7.
REF00000491	"From control to eradication of malaria: the end of being stuck in second gear . Asian Pacific Journal of Tropical Medicine Volume 3, Issue 5, May 2010, Pages 412-420."
REF00000492	Company report (Axcentua)
REF00000493	Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol. 2003;146:95-158.
REF00000494	Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Expert Opin Investig Drugs.2010 Aug;19(8):931-45.
REF00000495	Brain insulin impairs amyloid-beta(1-40) clearance from the brain. J Neurosci. 2004 Oct 27;24(43):9632-7.
REF00000496	Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015 Apr 30;372(18):1700-9.
REF00000497	The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem Biol. 2001 Aug;8(8):759-66.
REF00000498	Hypoxia-induced neutrophil survival is mediated by HIF-1alpha-dependent NF-kappaB activity. J Exp Med. 2005 Jan 3;201(1):105-15.
REF00000499	Novel anion liposome-encapsulated antisense oligonucleotide restores susceptibility of methicillin-resistant Staphylococcus aureus and rescues mice... Antimicrob Agents Chemother. 2009 Jul;53(7):2871-8.
REF00000500	Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol Cancer Ther. 2002 May;1(7):507-14.
REF00000501	"Histone deacetylase inhibitors induce apoptosis, histone hyperacetylation and up-regulation of gene transcription in Schistosoma mansoni. Mol Biochem Parasitol. 2009 Nov;168(1):7-15."
REF00000502	Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer. 2003 Feb 20;103(5):587-99.
REF00000503	HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism.Nat Struct Mol Biol.2012 Jan 22;19(2):253-9.
REF00000504	"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4(9):1046-61."
REF00000505	New and emerging treatment of Staphylococcus aureus infections in the hospital setting. Clin Microbiol Infect. 2008 Apr;14 Suppl 3:32-41.
REF00000506	"Specific inhibition of 50S ribosomal subunit formation in Staphylococcus aureus cells by 16-membered macrolide, lincosamide, and streptogramin B antibiotics. Curr Microbiol. 2000 Aug;41(2):126-35."
REF00000507	Transcriptional responses of Bacillus subtillis and thuringiensis to antibiotics and anti-tumour drugs. Int J Mol Med. 2009 Jan;23(1):33-9.
REF00000508	"Role of penicillin-binding protein 2 (PBP2) in the antibiotic susceptibility and cell wall cross-linking of Staphylococcus aureus: evidence for the cooperative functioning of PBP2, PBP4, and PBP2A. JBacteriol. 2005 Mar;187(5):1815-24."
REF00000509	Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007351.
REF00000510	The antibiotic viomycin traps the ribosome in an intermediate state of translocation.Nat Struct Mol Biol.2007 Jun;14(6):493-7.
REF00000511	Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cyst... Bioorg Med Chem. 2007 Jun 1;15(11):3635-48.
REF00000512	Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19936-41.
REF00000513	Mechanism of tissue-selective drug action in the cardiovascular system. Mol Interv. 2005 Apr;5(2):84-93.
REF00000514	Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001 Oct 25;413(6858):814-21.
REF00000515	Bacterial Resistance to Penicillin G by Decreased Affinity of Penicillin-Binding Proteins: A Mathematical Model
REF00000516	"Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):270-5."
REF00000517	"Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6."
REF00000518	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1213).
REF00000519	In vitro activities of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte CFUs. Antimicrob Agents Chemother. 1995 Apr;39(4):948-52.
REF00000520	DNA polymerase beta inhibitors from Tetracera boiviniana. J Nat Prod. 1999 Dec;62(12):1660-3.
REF00000521	The mode of action of clofazimine DNA binding studies. Int J Lepr Other Mycobact Dis. 1976 Jan-Jun;44(1-2):133-4.
REF00000522	A ribosomal ATPase is a target for hygromycin B inhibition on Escherichia coli ribosomes. Antimicrob Agents Chemother. 2001 Oct;45(10):2813-9.
REF00000523	Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin. J Med Chem. 1995 Apr 28;38(9):1511-22.
REF00000524	Increased activity of a novel low pH folate transporter associated with lipophilic antifolate resistance in chinese hamster ovary cells. J Biol Chem. 1998 Apr 3;273(14):8106-11.
REF00000525	Kaposi sarcoma is a therapeutic target for vitamin D(3) receptor agonist. Blood. 2000 Nov 1;96(9):3188-94.
REF00000526	Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81.
REF00000527	Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
REF00000528	"CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 2011 May 17;19(5):679-90."
REF00000529	Capsaicin receptor: TRPV1 a promiscuous TRP channel. Handb Exp Pharmacol. 2007;(179):155-71.
REF00000530	Company report (JMI Laboratories)
REF00000531	Cisplatin and DNA repair in cancer chemotherapy.Trends Biochem Sci.1995 Oct;20(10):435-9.
REF00000532	Efficacy of different thalidomide regimens for patients with multiple myeloma and its relationship with TNF-alpha level. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Dec;16(6):1312-5.
REF00000533	"Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. Invest New Drugs. 2015 Apr;33(2):423-31."
REF00000534	Quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cell lysate using liq... J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Feb 15;877(5-6):575-80.
REF00000535	Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with ... Blood. 2008 Jun 15;111(12):5663-71.
REF00000536	The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses. Neoplasia. 2012 Jan;14(1):34-43.
REF00000537	Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome. J Pediatr Endocrinol Metab. 2002;15 Suppl 3:945-8.
REF00000538	"Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40."
REF00000539	"Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16."
REF00000540	Amino acid substitutions in mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2006 Nov;50(11):3638-45. doi: 10.1128/AAC.00626-06. Epub 2006 Aug 28.
REF00000541	Stage specificity of Plasmodium falciparum telomerase and its inhibition by berberine. Parasitol Int. 2002 Mar;51(1):99-103.
REF00000542	Effect of the antitumor drug vinblastine on nuclear betaII-tubulin in cultured rat kidney mesangial cells. Invest New Drugs. 2003 Feb;21(1):15-20.
REF00000543	"PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study. J Med Virol. 2008 Dec;80(12):2053-63."
REF00000544	Decreased affinity of mosaic-structure recombinant penicillin-binding protein 2 for oral cephalosporins in Neisseria gonorrhoeae. J Antimicrob Chemother. 2007 Jul;60(1):54-60.
REF00000545	"The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome. J Mol Biol. 2003 Jul 25;330(5):1005-14."
REF00000546	Inhibition of peptide bond formation by pleuromutilins: the structure of the 50S ribosomal subunit from Deinococcus radiodurans in complex with tiamulin. Mol Microbiol. 2004 Dec;54(5):1287-94.
REF00000547	Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.Clin Cancer Res.2010 Oct 1;16(19):4899-905.
REF00000548	Penicillin-binding protein sensitive to cephalexin in sporulation of Bacillus cereus. Microbiol Res. 1997 Sep;152(3):227-32.
REF00000549	"Assessment of cell viability, lipid peroxidation and quantification of DNA fragmentation after the treatment of anticancerous drug mitomycin C and ... Exp Toxicol Pathol. 2010 Sep;62(5):503-8."
REF00000550	Cefuroxime resistance in non-beta-lactamase Haemophilus influenzae is linked to mutations in ftsI. J Antimicrob Chemother. 2003 Mar;51(3):523-30.
REF00000551	Structures of oxaliplatin-oligonucleotide adducts from DNA.J Mass Spectrom.2012 Oct;47(10):1282-93.
REF00000552	Bacterial resistance to aminoglycosides and beta-lactams: the Tn1331 transposon paradigm. Front Biosci. 2000 Jan 1;5:D20-9.
REF00000553	Molecular insights into 14-membered macrolides using the MM-PBSA method. J Chem Inf Model. 2009 Jun;49(6):1558-67.
REF00000554	Updated clinical information on multitargeted antifolates in lung cancer. Clin Lung Cancer. 2009 Mar;10 Suppl 1:S35-40.
REF00000555	Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mono... Melanoma Res. 2011 Dec;21(6):502-8.
REF00000556	"Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci. Antimicrob Agents Chemother. 2002 May;46(5):1273-80."
REF00000557	SsrA-mediated protein tagging in the presence of miscoding drugs and its physiological role in Escherichia coli. Genes Cells. 2002 Jul;7(7):629-38.
REF00000558	Microbiology and antimicrobial management of sinusitis. J Laryngol Otol. 2005 Apr;119(4):251-8.
REF00000559	Relationship between penicillin-binding protein patterns and beta-lactamases in clinical isolates of Bacteroides fragilis with different susceptibility to beta-lactam antibiotics. J Med Microbiol. 2004 Mar;53(Pt 3):213-21.
REF00000560	Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs. 2005 Apr;6(4):386-94.
REF00000561	Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs). Int J Biochem Cell Biol. 2004 Sep;36(9):1687-705.
REF00000562	Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones. J Med Chem. 1999 Mar 25;42(6):1018-26.
REF00000563	"Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5389-94."
REF00000564	"Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 2008 Jul;62(1):98-104."
REF00000565	Comparison of Antitumor Effects of Combined and Separate Treatment with NO Synthase Inhibitor T1023 and PDK1 Inhibitor Dichloroacetate. Bull Exp Biol Med. 2019 Nov;168(1):92-94.
REF00000566	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
REF00000567	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5687).
REF00000568	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
REF00000569	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5012).
REF00000570	Resistance to Beta-Lactams in Neisseria ssp Due to Chromosomally Encoded Penicillin-Binding Proteins. Antibiotics (Basel). 2016 Sep 28;5(4):35. doi: 10.3390/antibiotics5040035.
REF00000571	The motion/disparity aftereffect: a preliminary study. Vision Res. 1976;16(12):1507-9. doi: 10.1016/0042-6989(76)90172-3.
REF00000572	"Prodigious substrate specificity of AAC(6')-APH(2""), an aminoglycoside antibiotic resistance determinant in enterococci and staphylococci. Chem Biol. 1999 Feb;6(2):99-110. doi: 10.1016/S1074-5521(99)80006-4."
REF00000573	Functional analysis of the promoter of the yeast SNQ2 gene encoding a multidrug resistance transporter that confers the resistance to 4-nitroquinoline N-oxide. Biosci Biotechnol Biochem. 1999 Jan;63(1):162-7. doi: 10.1271/bbb.63.162.
REF00000574	rpoB mutations in multidrug-resistant strains of Mycobacterium tuberculosis isolated in Italy. J Clin Microbiol. 1999 Apr;37(4):1197-9. doi: 10.1128/JCM.37.4.1197-1199.1999.
REF00000575	"Structure of In31, a blaIMP-containing Pseudomonas aeruginosa integron phyletically related to In5, which carries an unusual array of gene cassettes. Antimicrob Agents Chemother. 1999 Apr;43(4):890-901. doi: 10.1128/AAC.43.4.890."
REF00000576	Identification and characterization of a new porin gene of Klebsiella pneumoniae: its role in beta-lactam antibiotic resistance. J Bacteriol. 1999 May;181(9):2726-32. doi: 10.1128/JB.181.9.2726-2732.1999.
REF00000577	Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal candidiasis in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 1999 Jul;43(7):1621-30. doi: 10.1128/AAC.43.7.1621.
REF00000578	Universal pattern of RpoB gene mutations among multidrug-resistant isolates of Mycobacterium tuberculosis complex from Africa. Int J Tuberc Lung Dis. 1999 Jul;3(7):620-6.
REF00000579	Multiple amino acid substitutions in lanosterol 14alpha-demethylase contribute to azole resistance in Candida albicans. Microbiology (Reading). 1999 Oct;145 ( Pt 10):2715-25. doi: 10.1099/00221287-145-10-2715.
REF00000580	Molecular characterization of rpoB mutations conferring cross-resistance to rifamycins on methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1999 Nov;43(11):2813-6. doi: 10.1128/AAC.43.11.2813.
REF00000581	Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res. 1999 Oct;16(10):1550-6. doi: 10.1023/a:1015000503629.
REF00000582	Automated thermal cycling is superior to traditional methods for nucleotide sequencing of bla(SHV) genes. Antimicrob Agents Chemother. 1999 Dec;43(12):2960-3. doi: 10.1128/AAC.43.12.2960.
REF00000583	Novel streptomycin and spectinomycin resistance gene as a gene cassette within a class 1 integron isolated from Escherichia coli. Antimicrob Agents Chemother. 1999 Dec;43(12):3036-8. doi: 10.1128/AAC.43.12.3036.
REF00000584	Mutant EF-Tu species reveal novel features of the enacyloxin IIa inhibition mechanism on the ribosome. J Mol Biol. 1999 Dec 3;294(3):627-37. doi: 10.1006/jmbi.1999.3296.
REF00000585	Substitutions in the eyelet region disrupt cefepime diffusion through the Escherichia coli OmpF channel. Antimicrob Agents Chemother. 2000 Feb;44(2):311-5. doi: 10.1128/AAC.44.2.311-315.2000.
REF00000586	Identification and characterization of the point mutation which affects the transcription level of the chromosomal 3-N-acetyltransferase gene of Streptomyces griseus SS-1198. Antimicrob Agents Chemother. 2000 Feb;44(2):437-40. doi: 10.1128/AAC.44.2.437-440.2000.
REF00000587	Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis. 1998;79(1):3-29. doi: 10.1054/tuld.1998.0002.
REF00000588	"Biochemical sequence analyses of GES-1, a novel class A extended-spectrum beta-lactamase, and the class 1 integron In52 from Klebsiella pneumoniae. Antimicrob Agents Chemother. 2000 Mar;44(3):622-32. doi: 10.1128/AAC.44.3.622-632.2000."
REF00000589	Occurrence of the new tetracycline resistance gene tet(W) in bacteria from the human gut. Antimicrob Agents Chemother. 2000 Mar;44(3):775-7. doi: 10.1128/AAC.44.3.775-777.2000.
REF00000590	"Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment. J Infect Dis. 2000 Mar;181(3):1180-4. doi: 10.1086/315312."
REF00000591	Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2000 Apr;44(4):1075-7. doi: 10.1128/AAC.44.4.1075-1077.2000.
REF00000592	"The 51,409-bp R-plasmid pTP10 from the multiresistant clinical isolate Corynebacterium striatum M82B is composed of DNA segments initially identified in soil bacteria and in plant, animal, and human pathogens. Mol Gen Genet. 2000 Feb;263(1):1-11. doi: 10.1007/pl00008668."
REF00000593	Glycosylation of macrolide antibiotics. Purification and kinetic studies of a macrolide glycosyltransferase from Streptomyces antibioticus. J Biol Chem. 2000 Apr 21;275(16):11713-20. doi: 10.1074/jbc.275.16.11713.
REF00000594	Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis isolates from Brazil. J Clin Microbiol. 2000 Aug;38(8):3119-22. doi: 10.1128/JCM.38.8.3119-3122.2000.
REF00000595	"Detection of the high-level aminoglycoside resistance gene aph(2"")-Ib in Enterococcus faecium. Antimicrob Agents Chemother. 2000 Oct;44(10):2876-9. doi: 10.1128/AAC.44.10.2876-2879.2000."
REF00000596	Cholesterol interaction with the daunorubicin binding site of P-glycoprotein. Biochem Biophys Res Commun. 2000 Oct 5;276(3):909-16. doi: 10.1006/bbrc.2000.3554.
REF00000597	ACI-1 from Acidaminococcus fermentans: characterization of the first beta-lactamase in Anaerobic cocci. Antimicrob Agents Chemother. 2000 Nov;44(11):3144-9. doi: 10.1128/AAC.44.11.3144-3149.2000.
REF00000598	"Disruption of an Enterococcus faecium species-specific gene, a homologue of acquired macrolide resistance genes of staphylococci, is associated with an increase in macrolide susceptibility. Antimicrob Agents Chemother. 2001 Jan;45(1):263-6. doi: 10.1128/AAC.45.1.263-266.2001."
REF00000599	GE2270A-resistant mutations in elongation factor Tu allow productive aminoacyl-tRNA binding to EF-Tu.GTP.GE2270A complexes. J Mol Biol. 2000 Dec 15;304(5):995-1005. doi: 10.1006/jmbi.2000.4260.
REF00000600	Frequency of rpoB mutations inside and outside the cluster I region in rifampin-resistant clinical Mycobacterium tuberculosis isolates. J Clin Microbiol. 2001 Jan;39(1):107-10. doi: 10.1128/JCM.39.1.107-110.2001.
REF00000601	"In70 of plasmid pAX22, a bla(VIM-1)-containing integron carrying a new aminoglycoside phosphotransferase gene cassette. Antimicrob Agents Chemother. 2001 Apr;45(4):1249-53. doi: 10.1128/AAC.45.4.1249-1253.2001."
REF00000602	Oxacillinase-mediated resistance to cefepime and susceptibility to ceftazidime in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2001 Jun;45(6):1615-20. doi: 10.1128/AAC.45.6.1615-1620.2001.
REF00000603	"Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev. 2001 Jun;65(2):232-60 ; second page, table of contents. doi: 10.1128/MMBR.65.2.232-260.2001."
REF00000604	Inducible macrolide resistance in Corynebacterium jeikeium. Antimicrob Agents Chemother. 2001 Jul;45(7):1982-9. doi: 10.1128/AAC.45.7.1982-1989.2001.
REF00000605	Plasmid-mediated extended-spectrum beta-lactamase (CTX-M-3 like) from India and gene association with insertion sequence ISEcp1. FEMS Microbiol Lett. 2001 Jul 24;201(2):237-41. doi: 10.1111/j.1574-6968.2001.tb10762.x.
REF00000606	Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis clinical isolates from India. J Clin Microbiol. 2001 Aug;39(8):2987-90. doi: 10.1128/JCM.39.8.2987-2990.2001.
REF00000607	"Aminoglycoside resistance genes aph(2"")-Ib and aac(6')-Im detected together in strains of both Escherichia coli and Enterococcus faecium. Antimicrob Agents Chemother. 2001 Oct;45(10):2691-4. doi: 10.1128/AAC.45.10.2691-2694.2001."
REF00000608	Molecular analysis of antibiotic resistance gene clusters in vibrio cholerae O139 and O1 SXT constins. Antimicrob Agents Chemother. 2001 Nov;45(11):2991-3000. doi: 10.1128/AAC.45.11.2991-3000.2001.
REF00000609	Sequence of the 50-kb conjugative multiresistance plasmid pRE25 from Enterococcus faecalis RE25. Plasmid. 2001 Nov;46(3):170-87. doi: 10.1006/plas.2001.1544.
REF00000610	Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. Br J Pharmacol. 2001 Dec;134(8):1601-8. doi: 10.1038/sj.bjp.0704399.
REF00000611	Molecular characterization of multidrug-resistant isolates of Mycobacterium tuberculosis from patients in North India. Antimicrob Agents Chemother. 2002 Feb;46(2):443-50. doi: 10.1128/AAC.46.2.443-450.2002.
REF00000612	Molecular characterization of a novel class 1 integron containing bla(GES-1) and a fused product of aac3-Ib/aac6'-Ib' gene cassettes in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2002 Mar;46(3):638-45. doi: 10.1128/AAC.46.3.638-645.2002.
REF00000613	"Mutations in ponA, the gene encoding penicillin-binding protein 1, and a novel locus, penC, are required for high-level chromosomally mediated penicillin resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2002 Mar;46(3):769-77. doi: 10.1128/AAC.46.3.769-777.2002."
REF00000614	BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet. 2002 Feb 9;359(9305):487-91. doi: 10.1016/S0140-6736(02)07679-1.
REF00000615	Genetic determinants of tetracycline resistance in Vibrio harveyi. Antimicrob Agents Chemother. 2002 Apr;46(4):1038-45. doi: 10.1128/AAC.46.4.1038-1045.2002.
REF00000616	Characterization of plasmids carrying CMY-2 from expanded-spectrum cephalosporin-resistant Salmonella strains isolated in the United States between 1996 and 1998. Antimicrob Agents Chemother. 2002 May;46(5):1269-72. doi: 10.1128/AAC.46.5.1269-1272.2002.
REF00000617	High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood. 2002 May 1;99(9):3472-5. doi: 10.1182/blood.v99.9.3472.
REF00000618	Studies on the antimicrobial mechanisms of capsaicin using yeast DNA microarray. Biosci Biotechnol Biochem. 2002 Mar;66(3):532-6. doi: 10.1271/bbb.66.532.
REF00000619	Activity of the ketolide telithromycin is refractory to Erm monomethylation of bacterial rRNA. Antimicrob Agents Chemother. 2002 Jun;46(6):1629-33. doi: 10.1128/AAC.46.6.1629-1633.2002.
REF00000620	Plasmid-borne macrolide resistance in Micrococcus luteus. Microbiology (Reading). 2002 Aug;148(Pt 8):2479-2487. doi: 10.1099/00221287-148-8-2479.
REF00000621	"Occurrence of antibiotic resistance gene cassettes aac(6')-Ib, dfrA5, dfrA12, and ereA2 in class I integrons in non-O1, non-O139 Vibrio cholerae strains in India. Antimicrob Agents Chemother. 2002 Sep;46(9):2948-55. doi: 10.1128/AAC.46.9.2948-2955.2002."
REF00000622	Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002 Aug;2(2):117-25. doi: 10.1016/s1535-6108(02)00096-x.
REF00000623	Inhibitory mechanisms of antibiotics targeting elongation factor Tu. Curr Protein Pept Sci. 2002 Feb;3(1):121-31. doi: 10.2174/1389203023380855.
REF00000624	The 27.8-kb R-plasmid pTET3 from Corynebacterium glutamicum encodes the aminoglycoside adenyltransferase gene cassette aadA9 and the regulated tetracycline efflux system Tet 33 flanked by active copies of the widespread insertion sequence IS6100. Plasmid. 2002 Sep;48(2):117-29. doi: 10.1016/s0147-619x(02)00120-8.
REF00000625	"Staphylococcus sciuri gene erm(33), encoding inducible resistance to macrolides, lincosamides, and streptogramin B antibiotics, is a product of recombination between erm(C) and erm(A). Antimicrob Agents Chemother. 2002 Nov;46(11):3621-3. doi: 10.1128/AAC.46.11.3621-3623.2002."
REF00000626	Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002 Nov;16(11):2190-6. doi: 10.1038/sj.leu.2402741.
REF00000627	Characterization of rpoB mutations in rifampin-resistant clinical isolates of Mycobacterium tuberculosis from Turkey by DNA sequencing and line probe assay. J Clin Microbiol. 2002 Dec;40(12):4435-8. doi: 10.1128/JCM.40.12.4435-4438.2002.
REF00000628	Biochemical analysis of the ceftazidime-hydrolysing extended-spectrum beta-lactamase CTX-M-15 and of its structurally related beta-lactamase CTX-M-3. J Antimicrob Chemother. 2002 Dec;50(6):1031-4. doi: 10.1093/jac/dkf240.
REF00000629	Relationship of XIST expression and responses of ovarian cancer to chemotherapy. Mol Cancer Ther. 2002 Aug;1(10):769-76.
REF00000630	Contributions of MexAB-OprM and an EmrE homolog to intrinsic resistance of Pseudomonas aeruginosa to aminoglycosides and dyes. Antimicrob Agents Chemother. 2003 Jan;47(1):27-33. doi: 10.1128/AAC.47.1.27-33.2003.
REF00000631	gyrA mutations in ciprofloxacin-resistant Bartonella bacilliformis strains obtained in vitro. Antimicrob Agents Chemother. 2003 Jan;47(1):383-6. doi: 10.1128/AAC.47.1.383-386.2003.
REF00000632	"Identification and characterization of a Cryptococcus neoformans ATP binding cassette (ABC) transporter-encoding gene, CnAFR1, involved in the resistance to fluconazole. Mol Microbiol. 2003 Jan;47(2):357-71. doi: 10.1046/j.1365-2958.2003.03281.x."
REF00000633	Analysis of the Pseudomonas aeruginosa oprD gene from clinical and environmental isolates. Environ Microbiol. 2002 Dec;4(12):872-82. doi: 10.1046/j.1462-2920.2002.00281.x.
REF00000634	Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase. Antimicrob Agents Chemother. 2003 Feb;47(2):577-81. doi: 10.1128/AAC.47.2.577-581.2003.
REF00000635	A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 2003 Mar;47(3):1120-4. doi: 10.1128/AAC.47.3.1120-1124.2003.
REF00000636	"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003 Jul 1;102(1):276-83. doi: 10.1182/blood-2002-09-2896. Epub 2003 Mar 6."
REF00000637	"Novel 3-N-aminoglycoside acetyltransferase gene, aac(3)-Ic, from a Pseudomonas aeruginosa integron. Antimicrob Agents Chemother. 2003 May;47(5):1746-8. doi: 10.1128/AAC.47.5.1746-1748.2003."
REF00000638	Evolution of antibiotic resistance in Salmonella enterica serovar typhimurium strains isolated in the Czech Republic between 1984 and 2002. Antimicrob Agents Chemother. 2003 Jun;47(6):2002-5. doi: 10.1128/AAC.47.6.2002-2005.2003.
REF00000639	Effect of D240G substitution in a novel ESBL CTX-M-27. J Antimicrob Chemother. 2003 Jul;52(1):29-35. doi: 10.1093/jac/dkg256. Epub 2003 May 29.
REF00000640	Effects of continuous exposure to digoxin on MDR1 function and expression in Caco-2 cells. J Pharm Pharmacol. 2003 May;55(5):675-81. doi: 10.1211/002235703765344595.
REF00000641	"Identification of a new ribosomal protection type of tetracycline resistance gene, tet(36), from swine manure pits. Appl Environ Microbiol. 2003 Jul;69(7):4151-8. doi: 10.1128/AEM.69.7.4151-4158.2003."
REF00000642	Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology. 2003 Sep;125(3):660-7. doi: 10.1016/s0016-5085(03)01046-1.
REF00000643	gyrB mutations which confer coumarin resistance also affect DNA supercoiling and ATP hydrolysis by Escherichia coli DNA gyrase. Mol Microbiol. 1992 Jun;6(12):1617-24. doi: 10.1111/j.1365-2958.1992.tb00886.x.
REF00000644	"Activation of a cryptic streptomycin-resistance gene in the Bacteroides erm transposon, Tn4551. Mol Microbiol. 1992 Aug;6(16):2287-97. doi: 10.1111/j.1365-2958.1992.tb01404.x."
REF00000645	Purification and characterization of macrolide 2'-phosphotransferase type II from a strain of Escherichia coli highly resistant to macrolide antibiotics. FEMS Microbiol Lett. 1992 Oct 1;76(1-2):89-94. doi: 10.1016/0378-1097(92)90369-y.
REF00000646	The plasmid-encoded chloramphenicol-resistance protein of Rhodococcus fascians is homologous to the transmembrane tetracycline efflux proteins. Mol Microbiol. 1992 Aug;6(16):2377-85. doi: 10.1111/j.1365-2958.1992.tb01412.x.
REF00000647	Cloning and nucleotide sequence analysis of a chloramphenicol acetyltransferase gene from Vibrio anguillarum. Microbiol Immunol. 1992;36(7):695-705. doi: 10.1111/j.1348-0421.1992.tb02072.x.
REF00000648	Cloning and DNA sequence analysis of an aac(3)-Vb gene from Serratia marcescens. Antimicrob Agents Chemother. 1992 Oct;36(10):2222-7. doi: 10.1128/AAC.36.10.2222.
REF00000649	"Functional reconstitution, gene isolation and topology modelling of porins from Burkholderia pseudomallei and Burkholderia thailandensis. Biochem J. 2004 Feb 1;377(Pt 3):579-87. doi: 10.1042/BJ20031118."
REF00000650	G484S amino acid substitution in lanosterol 14-alpha demethylase (ERG11) is related to fluconazole resistance in a recurrent Cryptococcus neoformans clinical isolate. Antimicrob Agents Chemother. 2003 Nov;47(11):3653-6. doi: 10.1128/AAC.47.11.3653-3656.2003.
REF00000651	Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers. Pharmacogenetics. 2003 Nov;13(11):651-60. doi: 10.1097/00008571-200311000-00001.
REF00000652	Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003 Dec 1;21(23):4342-9. doi: 10.1200/JCO.2003.04.190.
REF00000653	Acquisition of 16S rRNA methylase gene in Pseudomonas aeruginosa. Lancet. 2003 Dec 6;362(9399):1888-93. doi: 10.1016/S0140-6736(03)14959-8.
REF00000654	Beta-glucosylation as a part of self-resistance mechanism in methymycin/pikromycin producing strain Streptomyces venezuelae. Biochemistry. 2003 Dec 23;42(50):14794-804. doi: 10.1021/bi035501m.
REF00000655	"An H(+)-coupled multidrug efflux pump, PmpM, a member of the MATE family of transporters, from Pseudomonas aeruginosa. J Bacteriol. 2004 Jan;186(1):262-5. doi: 10.1128/JB.186.1.262-265.2004."
REF00000656	Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2004 Jan;48(1):15-22. doi: 10.1128/AAC.48.1.15-22.2004.
REF00000657	"FKS1 mutations responsible for selective resistance of Saccharomyces cerevisiae to the novel 1,3-beta-glucan synthase inhibitor arborcandin C. Antimicrob Agents Chemother. 2004 Jan;48(1):319-22. doi: 10.1128/AAC.48.1.319-322.2004."
REF00000658	Characterization of a new erm-related macrolide resistance gene present in probiotic strains of Bacillus clausii. Appl Environ Microbiol. 2004 Jan;70(1):280-4. doi: 10.1128/AEM.70.1.280-284.2004.
REF00000659	High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol J. 2004;5(1):55-60. doi: 10.1038/sj.thj.6200319.
REF00000660	Comparative sequence analysis of the catB gene from Clostridium butyricum. Antimicrob Agents Chemother. 1992 Nov;36(11):2548-51. doi: 10.1128/AAC.36.11.2548.
REF00000661	Effect of rpoB mutations conferring rifampin resistance on fitness of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2004 Apr;48(4):1289-94. doi: 10.1128/AAC.48.4.1289-1294.2004.
REF00000662	Mycobacterium tuberculosis isolate with a distinct genomic identity overexpresses a tap-like efflux pump. Infection. 2004 Apr;32(2):109-11. doi: 10.1007/s15010-004-3097-x.
REF00000663	"New aminoglycoside acetyltransferase gene, aac(3)-Id, in a class 1 integron from a multiresistant strain of Vibrio fluvialis isolated from an infant aged 6 months. J Antimicrob Chemother. 2004 Jun;53(6):947-51. doi: 10.1093/jac/dkh221. Epub 2004 Apr 29."
REF00000664	Biochemical characterization of the naturally occurring oxacillinase OXA-50 of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2004 Jun;48(6):2043-8. doi: 10.1128/AAC.48.6.2043-2048.2004.
REF00000665	Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles. Antimicrob Agents Chemother. 2004 Jun;48(6):2124-31. doi: 10.1128/AAC.48.6.2124-2131.2004.
REF00000666	Clade-specific flucytosine resistance is due to a single nucleotide change in the FUR1 gene of Candida albicans. Antimicrob Agents Chemother. 2004 Jun;48(6):2223-7. doi: 10.1128/AAC.48.6.2223-2227.2004.
REF00000667	The Vibrio cholerae ToxR-regulated porin OmpU confers resistance to antimicrobial peptides. Infect Immun. 2004 Jun;72(6):3577-83. doi: 10.1128/IAI.72.6.3577-3583.2004.
REF00000668	Molecular characterization of rifampin- and isoniazid-resistant Mycobacterium tuberculosis strains isolated in Poland. J Clin Microbiol. 2004 Jun;42(6):2425-31. doi: 10.1128/JCM.42.6.2425-2431.2004.
REF00000669	Efflux pump-mediated intrinsic drug resistance in Mycobacterium smegmatis. Antimicrob Agents Chemother. 2004 Jul;48(7):2415-23. doi: 10.1128/AAC.48.7.2415-2423.2004.
REF00000670	Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob Agents Chemother. 2004 Jul;48(7):2747-50. doi: 10.1128/AAC.48.7.2747-2750.2004.
REF00000671	The malaria parasite's chloroquine resistance transporter is a member of the drug/metabolite transporter superfamily. Mol Biol Evol. 2004 Oct;21(10):1938-49. doi: 10.1093/molbev/msh205. Epub 2004 Jul 7.
REF00000672	Molecular characterisation of streptomycin-resistant Mycobacterium tuberculosis strains isolated in Poland. Int J Tuberc Lung Dis. 2004 Aug;8(8):1032-5.
REF00000673	Evaluation of fluconazole resistance mechanisms in candida albicans clinical isolates from HIV-infected patients in Brazil. Diagn Microbiol Infect Dis. 2004 Sep;50(1):25-32. doi: 10.1016/j.diagmicrobio.2004.04.009.
REF00000674	Evidence of ABL-kinase domain mutations in highly purified primitive stem cell populations of patients with chronic myelogenous leukemia. Biochem Biophys Res Commun. 2004 Oct 22;323(3):728-30. doi: 10.1016/j.bbrc.2004.08.169.
REF00000675	"Mechanisms of resistance in multiple-antibiotic-resistant Escherichia coli strains of human, animal, and food origins. Antimicrob Agents Chemother. 2004 Oct;48(10):3996-4001. doi: 10.1128/AAC.48.10.3996-4001.2004."
REF00000676	Mutations of Pneumocystis jirovecii dihydrofolate reductase associated with failure of prophylaxis. Antimicrob Agents Chemother. 2004 Nov;48(11):4301-5. doi: 10.1128/AAC.48.11.4301-4305.2004.
REF00000677	Mutant sequences in the rpsL gene of Escherichia coli B/r: mechanistic implications for spontaneous and ultraviolet light mutagenesis. Mol Gen Genet. 1992 Mar;232(1):89-96. doi: 10.1007/BF00299141.
REF00000678	Molecular basis of intrinsic macrolide resistance in clinical isolates of Mycobacterium fortuitum. J Antimicrob Chemother. 2005 Feb;55(2):170-7. doi: 10.1093/jac/dkh523. Epub 2004 Dec 8.
REF00000679	Mutations in genes related to drug resistance in Mycobacterium leprae isolates from leprosy patients in Korea. J Infect. 2005 Jan;50(1):6-11. doi: 10.1016/j.jinf.2004.03.012.
REF00000680	"Rapid, high-throughput, multiplex, real-time PCR for identification of mutations in the cyp51A gene of Aspergillus fumigatus that confer resistance to itraconazole. J Clin Microbiol. 2005 Jan;43(1):214-22. doi: 10.1128/JCM.43.1.214-222.2005."
REF00000681	Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology. 2005 Feb;128(2):270-9. doi: 10.1053/j.gastro.2004.11.020.
REF00000682	Genetic analysis of the beta-lactamases of Mycobacterium tuberculosis and Mycobacterium smegmatis and susceptibility to beta-lactam antibiotics. Microbiology (Reading). 2005 Feb;151(Pt 2):521-532. doi: 10.1099/mic.0.27629-0.
REF00000683	Clonal evolution with inv(11)(p15q22) and NUP98/DDX10 fusion gene in imatinib-resistant chronic myelogenous leukemia. Cancer Genet Cytogenet. 2005 Mar;157(2):104-8. doi: 10.1016/j.cancergencyto.2004.06.014.
REF00000684	EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005 Feb 24;352(8):786-92. doi: 10.1056/NEJMoa044238.
REF00000685	Disequilibrium in distribution of resistance mutations among Mycobacterium tuberculosis Beijing and non-Beijing strains isolated from patients in Germany. Antimicrob Agents Chemother. 2005 Mar;49(3):1229-31. doi: 10.1128/AAC.49.3.1229-1231.2005.
REF00000686	An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS. 2005 Mar 4;19(4):371-80. doi: 10.1097/01.aids.0000161766.13782.2f.
REF00000687	Class 1 integron-associated gene cassettes in Salmonella enterica subsp. enterica serovar Agona isolated from pig carcasses in Brazil. J Antimicrob Chemother. 2005 May;55(5):776-9. doi: 10.1093/jac/dki081. Epub 2005 Mar 10.
REF00000688	"Identification of Tet 39, a novel class of tetracycline resistance determinant in Acinetobacter spp. of environmental and clinical origin. J Antimicrob Chemother. 2005 Apr;55(4):566-9. doi: 10.1093/jac/dki051. Epub 2005 Mar 10."
REF00000689	Effect of Walker A mutation (K86M) on oligomerization and surface targeting of the multidrug resistance transporter ABCG2. J Cell Sci. 2005 Apr 1;118(Pt 7):1417-26. doi: 10.1242/jcs.01729. Epub 2005 Mar 15.
REF00000690	MgrA is a multiple regulator of two new efflux pumps in Staphylococcus aureus. J Bacteriol. 2005 Apr;187(7):2395-405. doi: 10.1128/JB.187.7.2395-2405.2005.
REF00000691	Analysis of rpoB and pncA mutations in the published literature: an insight into the role of oxidative stress in Mycobacterium tuberculosis evolution . J Antimicrob Chemother. 2005 May;55(5):674-9. doi: 10.1093/jac/dki069. Epub 2005 Apr 6.
REF00000692	Update on acquired tetracycline resistance genes. FEMS Microbiol Lett. 2005 Apr 15;245(2):195-203. doi: 10.1016/j.femsle.2005.02.034.
REF00000693	YojI of Escherichia coli functions as a microcin J25 efflux pump. J Bacteriol. 2005 May;187(10):3465-70. doi: 10.1128/JB.187.10.3465-3470.2005.
REF00000694	High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood. 2005 Sep 15;106(6):2128-37. doi: 10.1182/blood-2005-03-1036. Epub 2005 May 24.
REF00000695	"PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol. 2005 Aug 10;23(23):5357-64. doi: 10.1200/JCO.2005.14.068. Epub 2005 May 31."
REF00000696	Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res. 2005 Jun 1;11(11):4182-90. doi: 10.1158/1078-0432.CCR-04-2245.
REF00000697	BcrC from Bacillus subtilis acts as an undecaprenyl pyrophosphate phosphatase in bacitracin resistance. J Biol Chem. 2005 Aug 12;280(32):28852-7. doi: 10.1074/jbc.M413750200. Epub 2005 Jun 9.
REF00000698	"Novel spectinomycin/streptomycin resistance gene, aadA14, from Pasteurella multocida. Antimicrob Agents Chemother. 2005 Jul;49(7):3046-9. doi: 10.1128/AAC.49.7.3046-3049.2005."
REF00000699	The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells. Lung Cancer. 2005 Sep;49(3):345-51. doi: 10.1016/j.lungcan.2005.05.003.
REF00000700	EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer. N Engl J Med. 2005 Jul 14;353(2):207-8. doi: 10.1056/NEJM200507143530217.
REF00000701	Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother. 2005 Aug;49(8):3264-73. doi: 10.1128/AAC.49.8.3264-3273.2005.
REF00000702	Reactive oxygen species-linked regulation of the multidrug resistance transporter P-glycoprotein in Nox-1 overexpressing prostate tumor spheroids. FEBS Lett. 2005 Aug 15;579(20):4541-4549. doi: 10.1016/j.febslet.2005.06.078.
REF00000703	The penC mutation conferring antibiotic resistance in Neisseria gonorrhoeae arises from a mutation in the PilQ secretin that interferes with multimer stability. Mol Microbiol. 2005 Sep;57(5):1238-51. doi: 10.1111/j.1365-2958.2005.04752.x.
REF00000704	Identification of intra- and intermolecular disulfide bridges in the multidrug resistance transporter ABCG2. J Biol Chem. 2005 Nov 4;280(44):36926-34. doi: 10.1074/jbc.M502937200. Epub 2005 Aug 17.
REF00000705	Mycobacterium smegmatis Erm(38) is a reluctant dimethyltransferase. Antimicrob Agents Chemother. 2005 Sep;49(9):3803-9. doi: 10.1128/AAC.49.9.3803-3809.2005.
REF00000706	Accumulation of mutations in both gyrB and parE genes is associated with high-level resistance to novobiocin in Staphylococcus aureus. Antimicrob Agents Chemother. 2005 Sep;49(9):3810-5. doi: 10.1128/AAC.49.9.3810-3815.2005.
REF00000707	Macrolide efflux in Streptococcus pneumoniae is mediated by a dual efflux pump (mel and mef) and is erythromycin inducible. Antimicrob Agents Chemother. 2005 Oct;49(10):4203-9. doi: 10.1128/AAC.49.10.4203-4209.2005.
REF00000708	"AbeM, an H+-coupled Acinetobacter baumannii multidrug efflux pump belonging to the MATE family of transporters. Antimicrob Agents Chemother. 2005 Oct;49(10):4362-4. doi: 10.1128/AAC.49.10.4362-4364.2005."
REF00000709	Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese. Lung Cancer. 2006 Jan;51(1):71-7. doi: 10.1016/j.lungcan.2005.08.006. Epub 2005 Sep 29.
REF00000710	Mechanisms of azole resistance in a clinical isolate of Candida tropicalis. Antimicrob Agents Chemother. 2005 Nov;49(11):4608-15. doi: 10.1128/AAC.49.11.4608-4615.2005.
REF00000711	Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers. Antimicrob Agents Chemother. 2005 Dec;49(12):4903-10. doi: 10.1128/AAC.49.12.4903-4910.2005.
REF00000712	Virulence and drug resistance roles of multidrug efflux systems of Salmonella enterica serovar Typhimurium. Mol Microbiol. 2006 Jan;59(1):126-41. doi: 10.1111/j.1365-2958.2005.04940.x.
REF00000713	Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob Agents Chemother. 2006 Jan;50(1):104-12. doi: 10.1128/AAC.50.1.104-112.2006.
REF00000714	[Expression and significance of GST-Pi and HIF-1alpha in bladder carcinoma]. Ai Zheng. 2006 Feb;25(2):190-3.
REF00000715	Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res. 2006 Mar 15;12(6):1743-9. doi: 10.1158/1078-0432.CCR-05-1211.
REF00000716	"Regulation of apoptosis by a prostate-specific and prostate cancer-associated noncoding gene, PCGEM1. DNA Cell Biol. 2006 Mar;25(3):135-41. doi: 10.1089/dna.2006.25.135."
REF00000717	Contribution of rpoB2 RNA polymerase beta subunit gene to rifampin resistance in Nocardia species. Antimicrob Agents Chemother. 2006 Apr;50(4):1342-6. doi: 10.1128/AAC.50.4.1342-1346.2006.
REF00000718	Resistance mechanisms in fluconazole-resistant Candida albicans isolates from vaginal candidiasis. Int J Antimicrob Agents. 2006 May;27(5):403-8. doi: 10.1016/j.ijantimicag.2005.12.005. Epub 2006 Apr 18.
REF00000719	Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole. J Antimicrob Chemother. 2006 Jun;57(6):1235-9. doi: 10.1093/jac/dkl133. Epub 2006 Apr 20.
REF00000720	Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother. 2006 Jun;50(6):2058-63. doi: 10.1128/AAC.01653-05.
REF00000721	Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob Agents Chemother. 2006 Jun;50(6):2137-45. doi: 10.1128/AAC.00039-06.
REF00000722	Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients. Oncogene. 2006 Oct 5;25(45):6140-6. doi: 10.1038/sj.onc.1209639. Epub 2006 Jun 5.
REF00000723	Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology. 2006 Jun;130(7):2113-29. doi: 10.1053/j.gastro.2006.02.057.
REF00000724	Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl). 2006 Sep;187(4):415-23. doi: 10.1007/s00213-006-0437-9. Epub 2006 Jun 30.
REF00000725	Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol. 2006 Oct 10;24(29):4764-74. doi: 10.1200/JCO.2006.06.2265. Epub 2006 Sep 5.
REF00000726	Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol. 2006 Sep 20;24(27):4517-20. doi: 10.1200/JCO.2006.06.6126.
REF00000727	A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib. Leukemia. 2006 Nov;20(11):2057-60. doi: 10.1038/sj.leu.2404400. Epub 2006 Sep 28.
REF00000728	Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res. 2006 Oct 1;12(19):5764-9. doi: 10.1158/1078-0432.CCR-06-0714.
REF00000729	Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res. 2006 Nov 1;12(21):6494-501. doi: 10.1158/1078-0432.CCR-06-1570.
REF00000730	"Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 2007 Jan;51(1):359-60. doi: 10.1128/AAC.00795-06. Epub 2006 Nov 6."
REF00000731	HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res. 2006;8(6):215. doi: 10.1186/bcr1612.
REF00000732	Detection of multidrug resistance in Mycobacterium tuberculosis. J Clin Microbiol. 2007 Jan;45(1):179-92. doi: 10.1128/JCM.00750-06. Epub 2006 Nov 15.
REF00000733	Cloning and sequence analysis of a plasmid-encoded chloramphenicol acetyltransferase gene from Staphylococcus intermedius. J Gen Microbiol. 1991 Apr;137(4):977-81. doi: 10.1099/00221287-137-4-977.
REF00000734	"Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin Cancer Res. 2006 Dec 1;12(23):7117-25. doi: 10.1158/1078-0432.CCR-06-0760."
REF00000735	"Mutations in transmembrane domains 1, 4 and 9 of the Plasmodium falciparum chloroquine resistance transporter alter susceptibility to chloroquine, quinine and quinidine. Mol Microbiol. 2007 Jan;63(1):270-82. doi: 10.1111/j.1365-2958.2006.05511.x. Epub 2006 Dec 5."
REF00000736	Resistance to gefitinib. Int J Clin Oncol. 2006 Dec;11(6):487-91. doi: 10.1007/s10147-006-0609-y. Epub 2006 Dec 25.
REF00000737	Loss of a conserved 7-methylguanosine modification in 16S rRNA confers low-level streptomycin resistance in bacteria. Mol Microbiol. 2007 Feb;63(4):1096-106. doi: 10.1111/j.1365-2958.2006.05585.x.
REF00000738	Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells. Oncogene. 2007 Jul 19;26(33):4877-81. doi: 10.1038/sj.onc.1210266. Epub 2007 Feb 5.
REF00000739	Resistance phenotypes conferred by macrolide phosphotransferases. FEMS Microbiol Lett. 2007 Apr;269(2):317-22. doi: 10.1111/j.1574-6968.2007.00643.x. Epub 2007 Feb 16.
REF00000740	Novel tetracycline resistance determinant isolated from an environmental strain of Serratia marcescens. Appl Environ Microbiol. 2007 Apr;73(7):2199-206. doi: 10.1128/AEM.02511-06. Epub 2007 Feb 16.
REF00000741	Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob Agents Chemother. 2007 May;51(5):1876-8. doi: 10.1128/AAC.00067-07. Epub 2007 Feb 26.
REF00000742	Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. Cancer Res. 2007 Mar 1;67(5):2046-53. doi: 10.1158/0008-5472.CAN-06-3339.
REF00000743	EGFR mutation status in pleural fluid predicts tumor responsiveness and resistance to gefitinib. Lung Cancer. 2007 Jun;56(3):445-8. doi: 10.1016/j.lungcan.2007.01.014. Epub 2007 Mar 1.
REF00000744	Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship. Cancer Chemother Pharmacol. 2007 Nov;60(6):789-97. doi: 10.1007/s00280-007-0426-7. Epub 2007 Mar 8.
REF00000745	Genetic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates in Hong Kong. J Antimicrob Chemother. 2007 May;59(5):866-73. doi: 10.1093/jac/dkm054. Epub 2007 Mar 14.
REF00000746	A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother. 2007 Jun;51(6):1897-904. doi: 10.1128/AAC.01092-06. Epub 2007 Mar 19.
REF00000747	Multiple antimicrobial resistance in plague: an emerging public health risk. PLoS One. 2007 Mar 21;2(3):e309. doi: 10.1371/journal.pone.0000309.
REF00000748	The crystal structure of two macrolide glycosyltransferases provides a blueprint for host cell antibiotic immunity. Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5336-41. doi: 10.1073/pnas.0607897104. Epub 2007 Mar 21.
REF00000749	"Antibiotic stress, genetic response and altered permeability of E. coli. PLoS One. 2007 Apr 11;2(4):e365. doi: 10.1371/journal.pone.0000365."
REF00000750	"The emergence of a novel ceftazidime-resistant CTX-M extended-spectrum beta-lactamase, CTX-M-55, in both community-onset and hospital-acquired infections in Thailand. Diagn Microbiol Infect Dis. 2007 Jul;58(3):349-55. doi: 10.1016/j.diagmicrobio.2007.02.005. Epub 2007 Apr 20."
REF00000751	"New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate. Antimicrob Agents Chemother. 2007 Sep;51(9):3354-60. doi: 10.1128/AAC.00339-07. Epub 2007 Jun 4."
REF00000752	"Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica. 2007 Sep;92(9):1242-5. doi: 10.3324/haematol.10720. Epub 2007 Aug 1."
REF00000753	"Cloning vectors, mutagenesis, and gene disruption (ermR) for the erythromycin-producing bacterium Aeromicrobium erythreum. Appl Environ Microbiol. 1991 Sep;57(9):2758-61. doi: 10.1128/aem.57.9.2758-2761.1991."
REF00000754	Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line. Cancer Res. 2007 Aug 15;67(16):7807-14. doi: 10.1158/0008-5472.CAN-07-0681.
REF00000755	Lack of correlation between embB mutation and ethambutol MIC in Mycobacterium tuberculosis clinical isolates from China. Antimicrob Agents Chemother. 2007 Dec;51(12):4515-7. doi: 10.1128/AAC.00416-07. Epub 2007 Sep 10.
REF00000756	"Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum. Antimicrob Agents Chemother. 2007 Nov;51(11):4133-40. doi: 10.1128/AAC.00669-07. Epub 2007 Sep 10."
REF00000757	Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5398-405. doi: 10.1158/1078-0432.CCR-06-0858.
REF00000758	A newly identified 191A/C mutation in the Rv2629 gene that was significantly associated with rifampin resistance in Mycobacterium tuberculosis. J Proteome Res. 2007 Dec;6(12):4564-71. doi: 10.1021/pr070242z. Epub 2007 Oct 31.
REF00000759	BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med. 2007 Oct;4(10):1669-79; discussion 1680. doi: 10.1371/journal.pmed.0040315.
REF00000760	Molecular survey of clindamycin and tetracycline resistance determinants in Bacteroides species. Antimicrob Agents Chemother. 1991 Nov;35(11):2415-8. doi: 10.1128/AAC.35.11.2415.
REF00000761	MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008 Jan 15;68(2):425-33. doi: 10.1158/0008-5472.CAN-07-2488.
REF00000762	Susceptibility of clinical isolates of Candida species to fluconazole and detection of Candida albicans ERG11 mutations. J Antimicrob Chemother. 2008 Apr;61(4):798-804. doi: 10.1093/jac/dkn015. Epub 2008 Jan 24.
REF00000763	MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene. 2008 Jun 19;27(27):3845-55. doi: 10.1038/onc.2008.6. Epub 2008 Feb 4.
REF00000764	A subcelluar proteomic investigation into vincristine-resistant gastric cancer cell line. J Cell Biochem. 2008 Jun 1;104(3):1010-21. doi: 10.1002/jcb.21687.
REF00000765	Peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based detection test for gefitinib-refractory T790M epidermal growth factor receptor mutation. Cancer Sci. 2008 Mar;99(3):595-600. doi: 10.1111/j.1349-7006.2007.00706.x.
REF00000766	Distribution of rpoB mutations among multidrug-resistant Mycobacterium tuberculosis (MDRTB) strains from Thailand and development of a rapid method for mutation detection. Clin Microbiol Infect. 2008 May;14(5):446-53. doi: 10.1111/j.1469-0691.2008.01951.x. Epub 2008 Feb 22.
REF00000767	Crystal structure and mechanism of the Staphylococcus cohnii virginiamycin B lyase (Vgb). Biochemistry. 2008 Apr 8;47(14):4257-65. doi: 10.1021/bi7015266. Epub 2008 Mar 15.
REF00000768	Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation. J Thorac Oncol. 2008 Apr;3(4):451-2. doi: 10.1097/JTO.0b013e318169e32a.
REF00000769	TTI-237: a novel microtubule-active compound with in vivo antitumor activity. Cancer Res. 2008 Apr 1;68(7):2292-300. doi: 10.1158/0008-5472.CAN-07-1420.
REF00000770	"Positive selection in penicillin-binding proteins 1a, 2b, and 2x from Streptococcus pneumoniae and its correlation with amoxicillin resistance development. Infect Genet Evol. 2008 May;8(3):331-9. doi: 10.1016/j.meegid.2008.02.001. Epub 2008 Feb 14."
REF00000771	Molecular mechanism of drug-dependent ribosome stalling. Mol Cell. 2008 Apr 25;30(2):190-202. doi: 10.1016/j.molcel.2008.02.026.
REF00000772	"A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother. 2008 Jul;52(7):2305-12. doi: 10.1128/AAC.00262-08. Epub 2008 Apr 28."
REF00000773	miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer. 2008 Jul 15;123(2):372-379. doi: 10.1002/ijc.23501.
REF00000774	Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs). J Surg Oncol. 2008 Jul 1;98(1):27-33. doi: 10.1002/jso.21065.
REF00000775	Beta-lactam and aminoglycoside resistance rates and mechanisms among Pseudomonas aeruginosa in French general practice (community and private healthcare centres). J Antimicrob Chemother. 2008 Aug;62(2):316-23. doi: 10.1093/jac/dkn174. Epub 2008 May 8.
REF00000776	Inhibition of efflux of quinolines as new therapeutic strategy in malaria. Curr Top Med Chem. 2008;8(7):563-78. doi: 10.2174/156802608783955593.
REF00000777	Evolution from heterozygous to homozygous KIT mutation in gastrointestinal stromal tumor correlates with the mechanism of mitotic nondisjunction and significant tumor progression. Mod Pathol. 2008 Jul;21(7):826-36. doi: 10.1038/modpathol.2008.46. Epub 2008 May 16.
REF00000778	Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol. 2008 Jun 1;26(16):2745-53. doi: 10.1200/JCO.2007.15.6695.
REF00000779	4-Quinolone resistance mutations in the DNA gyrase of Escherichia coli clinical isolates identified by using the polymerase chain reaction. Antimicrob Agents Chemother. 1991 Feb;35(2):387-9. doi: 10.1128/AAC.35.2.387.
REF00000780	Identification of rifampin-resistant genotypes in Mycobacterium tuberculosis by PCR-reverse dot blot hybridization. Mol Biotechnol. 2009 Jan;41(1):1-7. doi: 10.1007/s12033-008-9085-0. Epub 2008 Jul 4.
REF00000781	Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol. 2008 Sep;216(1):64-74. doi: 10.1002/path.2382.
REF00000782	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. Antimicrob Agents Chemother. 2008 Oct;52(10):3801-4. doi: 10.1128/AAC.00638-08. Epub 2008 Jul 21.
REF00000783	Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther. 2008 Jul;7(7):2152-9. doi: 10.1158/1535-7163.MCT-08-0021.
REF00000784	Homology between proteins controlling Streptomyces fradiae tylosin resistance and ATP-binding transport. Gene. 1991 Jun 15;102(1):27-32. doi: 10.1016/0378-1119(91)90533-h.
REF00000785	Genotypic analysis of isoniazid and rifampin resistance in drug-resistant clinical Mycobacterium tuberculosis complex isolates in southern Turkey. Jpn J Infect Dis. 2008 Jul;61(4):255-60.
REF00000786	Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res. 2008 Aug 1;14(15):4877-82. doi: 10.1158/1078-0432.CCR-07-5123.
REF00000787	A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Ann Oncol. 2009 Jan;20(1):175-81. doi: 10.1093/annonc/mdn548. Epub 2008 Aug 7.
REF00000788	MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem. 2008 Oct 31;283(44):29897-903. doi: 10.1074/jbc.M804612200. Epub 2008 Aug 15.
REF00000789	Increased expression of HSP27 linked to vincristine resistance in human gastric cancer cell line. J Cancer Res Clin Oncol. 2009 Feb;135(2):181-9. doi: 10.1007/s00432-008-0460-9. Epub 2008 Aug 29.
REF00000790	Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3. Apoptosis. 2008 Oct;13(10):1215-22. doi: 10.1007/s10495-008-0256-z.
REF00000791	Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood. 2008 Nov 15;112(10):4178-83. doi: 10.1182/blood-2008-06-165027. Epub 2008 Sep 2.
REF00000792	MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem. 2008 Nov 7;283(45):31079-86. doi: 10.1074/jbc.M806041200. Epub 2008 Sep 12.
REF00000793	Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer. 2008 Sep 21;8:266. doi: 10.1186/1471-2407-8-266.
REF00000794	Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol. 2008 Dec;111(3):478-86. doi: 10.1016/j.ygyno.2008.08.017. Epub 2008 Sep 26.
REF00000795	Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression. Am J Surg Pathol. 2009 Feb;33(2):218-26. doi: 10.1097/PAS.0b013e31817ec2e6.
REF00000796	Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55. doi: 10.1186/1479-5876-6-55.
REF00000797	Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun. 2008 Dec 5;377(1):114-9. doi: 10.1016/j.bbrc.2008.09.086. Epub 2008 Oct 1.
REF00000798	Unusual resistance patterns in macrolide-resistant Streptococcus pyogenes harbouring erm(A). J Antimicrob Chemother. 2009 Jan;63(1):42-6. doi: 10.1093/jac/dkn432. Epub 2008 Oct 24.
REF00000799	Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008 Nov 20;26(33):5352-9. doi: 10.1200/JCO.2007.15.7461. Epub 2008 Oct 27.
REF00000800	Crystal structures of penicillin-binding protein 2 from penicillin-susceptible and -resistant strains of Neisseria gonorrhoeae reveal an unexpectedly subtle mechanism for antibiotic resistance. J Biol Chem. 2009 Jan 9;284(2):1202-12. doi: 10.1074/jbc.M805761200. Epub 2008 Nov 4.
REF00000801	Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations. Lung Cancer. 2009 Jun;64(3):314-8. doi: 10.1016/j.lungcan.2008.09.010. Epub 2008 Nov 6.
REF00000802	"dfrA27, a new integron-associated trimethoprim resistance gene from Escherichia coli. J Antimicrob Chemother. 2009 Feb;63(2):405-6. doi: 10.1093/jac/dkn474. Epub 2008 Nov 13."
REF00000803	MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res. 2008 Dec 15;68(24):10307-14. doi: 10.1158/0008-5472.CAN-08-1954.
REF00000804	Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem . Cancer Chemother Pharmacol. 2009 Jun;64(1):195-7. doi: 10.1007/s00280-008-0905-5. Epub 2009 Jan 21.
REF00000805	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009 May;53(5):1766-71. doi: 10.1128/AAC.01410-08. Epub 2009 Mar 2.
REF00000806	Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia. Am J Hematol. 2009 Apr;84(4):256-7. doi: 10.1002/ajh.21366.
REF00000807	MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol. 2009 Jun;75(6):1374-9. doi: 10.1124/mol.108.054163. Epub 2009 Mar 6.
REF00000808	"A systems pathology model for predicting overall survival in patients with refractory, advanced non-small-cell lung cancer treated with gefitinib. Eur J Cancer. 2009 May;45(8):1518-26. doi: 10.1016/j.ejca.2009.02.004. Epub 2009 Mar 9."
REF00000809	microRNA-205 regulates HER3 in human breast cancer. Cancer Res. 2009 Mar 15;69(6):2195-200. doi: 10.1158/0008-5472.CAN-08-2920. Epub 2009 Mar 10.
REF00000810	Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer. Pathol Oncol Res. 2009 Dec;15(4):651-8. doi: 10.1007/s12253-009-9167-8. Epub 2009 Apr 21.
REF00000811	The role of p-glycoprotein in limiting brain penetration of the peripherally acting anticholinergic overactive bladder drug trospium chloride. Drug Metab Dispos. 2009 Jul;37(7):1371-4. doi: 10.1124/dmd.109.027144. Epub 2009 Apr 23.
REF00000812	Nucleotide sequence of dihydrofolate reductase type VI. J Med Microbiol. 1991 Oct;35(4):214-8. doi: 10.1099/00222615-35-4-214.
REF00000813	"MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol Cancer Ther. 2009 May;8(5):1067-74. doi: 10.1158/1535-7163.MCT-08-0592. Epub 2009 May 12."
REF00000814	MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther. 2009 May;8(5):1055-66. doi: 10.1158/1535-7163.MCT-08-1046. Epub 2009 May 12.
REF00000815	Horizontal transfer of the tetracycline resistance gene tetM mediated by pCF10 among Enterococcus faecalis in the house fly (Musca domestica L.) alimentary canal. Microb Ecol. 2009 Oct;58(3):509-18. doi: 10.1007/s00248-009-9533-9. Epub 2009 May 28.
REF00000816	Comparison of two commercial assays for the characterization of rpoB mutations in Mycobacterium tuberculosis and description of new mutations conferring weak resistance to rifampicin. J Antimicrob Chemother. 2009 Aug;64(2):259-62. doi: 10.1093/jac/dkp204. Epub 2009 Jun 11.
REF00000817	Global spread of mobile antimicrobial drug resistance determinants in human and animal Escherichia coli and Salmonella strains causing community-acquired infections. Clin Infect Dis. 2009 Aug 1;49(3):365-71. doi: 10.1086/600301.
REF00000818	"Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob Agents Chemother. 2009 Sep;53(9):3690-9. doi: 10.1128/AAC.00443-09. Epub 2009 Jun 22."
REF00000819	Mutations in rpoB and katG genes in Mycobacterium isolates from the Southeast of Mexico. Mem Inst Oswaldo Cruz. 2009 May;104(3):468-72. doi: 10.1590/s0074-02762009000300012.
REF00000820	MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. Brain Res. 2009 Aug 25;1286:13-8. doi: 10.1016/j.brainres.2009.06.053. Epub 2009 Jun 24.
REF00000821	Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood. 2009 Sep 3;114(10):2037-43. doi: 10.1182/blood-2009-01-197715. Epub 2009 Jun 30.
REF00000822	MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab Dispos. 2009 Oct;37(10):2112-7. doi: 10.1124/dmd.109.027680. Epub 2009 Jul 6.
REF00000823	MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 2009 Jul 15;69(14):5761-7. doi: 10.1158/0008-5472.CAN-08-4797. Epub 2009 Jul 7.
REF00000824	"Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer. 2010 May;68(2):198-203. doi: 10.1016/j.lungcan.2009.05.022. Epub 2009 Jul 8."
REF00000825	Determination of the target nucleosides for members of two families of 16S rRNA methyltransferases that confer resistance to partially overlapping groups of aminoglycoside antibiotics. Nucleic Acids Res. 2009 Sep;37(16):5420-31. doi: 10.1093/nar/gkp575. Epub 2009 Jul 9.
REF00000826	Efficacy of a lumbo-peritoneal shunt for meningeal carcinomatosis refractory to gefitinib treatment. Anticancer Res. 2009 Jul;29(7):2759-60.
REF00000827	Characterization of two aminoglycoside-(3)-N-acetyltransferase genes and assay as epidemiological probes. J Antimicrob Chemother. 1991 Sep;28(3):333-46. doi: 10.1093/jac/28.3.333.
REF00000828	Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis. 2009 Jul;15(7):1068-76. doi: 10.3201/eid1507.090043.
REF00000829	Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib. Blood. 2009 Sep 24;114(13):2598-605. doi: 10.1182/blood-2008-08-173674. Epub 2009 Jul 22.
REF00000830	Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 2009 Aug 15;69(16):6704-12. doi: 10.1158/0008-5472.CAN-09-1298. Epub 2009 Aug 4.
REF00000831	miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res. 2009 Aug 15;15(16):5060-72. doi: 10.1158/1078-0432.CCR-08-2245. Epub 2009 Aug 11.
REF00000832	Inhibition of human P-glycoprotein transport and substrate binding using a galantamine dimer. Biochem Biophys Res Commun. 2009 Oct 30;388(4):672-6. doi: 10.1016/j.bbrc.2009.08.056. Epub 2009 Aug 14.
REF00000833	Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol. 2009 Nov;4(11):1415-9. doi: 10.1097/JTO.0b013e3181b62572.
REF00000834	High-level rifampin resistance correlates with multiple mutations in the rpoB gene of pulmonary tuberculosis isolates from the Afghanistan border of Iran. J Clin Microbiol. 2009 Sep;47(9):2744-50. doi: 10.1128/JCM.r00548-09.
REF00000835	MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem. 2009 Nov 13;284(46):32015-27. doi: 10.1074/jbc.M109.016774. Epub 2009 Sep 2.
REF00000836	Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science. 2009 Oct 23;326(5952):572-4. doi: 10.1126/science.1179386. Epub 2009 Sep 2.
REF00000837	Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene. 2009 Nov 19;28(46):4065-74. doi: 10.1038/onc.2009.274. Epub 2009 Sep 7.
REF00000838	Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors. Hematol Oncol. 2010 Jun;28(2):82-8. doi: 10.1002/hon.918.
REF00000839	"Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii. Antimicrob Agents Chemother. 2009 Dec;53(12):5312-6. doi: 10.1128/AAC.00748-09. Epub 2009 Sep 21."
REF00000840	Chloroquine transport via the malaria parasite's chloroquine resistance transporter. Science. 2009 Sep 25;325(5948):1680-2. doi: 10.1126/science.1175667.
REF00000841	Regulation of antibiotic resistance in Staphylococcus aureus. Int J Med Microbiol. 2010 Feb;300(2-3):118-29. doi: 10.1016/j.ijmm.2009.08.015. Epub 2009 Oct 2.
REF00000842	E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int J Cancer. 2010 Jun 1;126(11):2575-83. doi: 10.1002/ijc.24972.
REF00000843	MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells. FEBS J. 2009 Nov;276(22):6689-700. doi: 10.1111/j.1742-4658.2009.07383.x. Epub 2009 Oct 16.
REF00000844	Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol. 2010 Mar 15;79(6):817-24. doi: 10.1016/j.bcp.2009.10.017. Epub 2009 Oct 31.
REF00000845	miR-138 might reverse multidrug resistance of leukemia cells. Leuk Res. 2010 Aug;34(8):1078-82. doi: 10.1016/j.leukres.2009.10.002. Epub 2009 Nov 6.
REF00000846	Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1). J Cell Mol Med. 2010 Jan;14(1-2):206-14. doi: 10.1111/j.1582-4934.2009.00964.x. Epub 2009 Nov 9.
REF00000847	The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion. PLoS Pathog. 2009 Nov;5(11):e1000660. doi: 10.1371/journal.ppat.1000660. Epub 2009 Nov 13.
REF00000848	Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions. Leuk Lymphoma. 2009 Dec;50(12):2092-5. doi: 10.3109/10428190903332486.
REF00000849	blaCMY-2-positive IncA/C plasmids from Escherichia coli and Salmonella enterica are a distinct component of a larger lineage of plasmids. Antimicrob Agents Chemother. 2010 Feb;54(2):590-6. doi: 10.1128/AAC.00055-09. Epub 2009 Nov 30.
REF00000850	Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig Dis Sci. 2010 Sep;55(9):2545-51. doi: 10.1007/s10620-009-1051-6. Epub 2009 Dec 4.
REF00000851	Involvement of annexin A1 in multidrug resistance of K562/ADR cells identified by the proteomic study. OMICS. 2009 Dec;13(6):467-76. doi: 10.1089/omi.2009.0046.
REF00000852	Identifying a resistance determinant for the antimitotic natural products disorazole C1 and A1. J Pharmacol Exp Ther. 2010 Mar;332(3):906-11. doi: 10.1124/jpet.109.162842. Epub 2009 Dec 15.
REF00000853	TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene. 2010 Mar 25;29(12):1787-97. doi: 10.1038/onc.2009.468. Epub 2009 Dec 21.
REF00000854	Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells. Cancer Res. 2010 Jan 1;70(1):150-9. doi: 10.1158/0008-5472.CAN-09-1449. Epub 2009 Dec 22.
REF00000855	Establishment and characterization of a human gastrointestinal stromal tumour (GIST) xenograft in athymic nude mice. Anticancer Res. 2009 Nov;29(11):4331-6.
REF00000856	Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors. J Cancer Res Clin Oncol. 2010 Jul;136(7):1065-71. doi: 10.1007/s00432-009-0753-7. Epub 2009 Dec 31.
REF00000857	Kinase domain mutations and responses to dose escalation in chronic myeloid leukemia resistant to standard dose imatinib mesylate. Leuk Lymphoma. 2010 Jan;51(1):79-84. doi: 10.3109/10428190903437629.
REF00000858	Quantitative proteome analysis of multidrug resistance in human ovarian cancer cell line. J Cell Biochem. 2010 Mar 1;109(4):625-33. doi: 10.1002/jcb.22413.
REF00000859	Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells. Technol Cancer Res Treat. 2010 Feb;9(1):77-86. doi: 10.1177/153303461000900109.
REF00000860	MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol. BMC Cancer. 2010 Jan 31;10:27. doi: 10.1186/1471-2407-10-27.
REF00000861	Nucleotide sequence analysis of a chloramphenicol-resistance determinant from Agrobacterium tumefaciens and identification of its gene product. Gene. 1991 Feb 1;98(1):113-6. doi: 10.1016/0378-1119(91)90112-o.
REF00000862	miRNA-21 regulates arsenic-induced anti-leukemia activity in myelogenous cell lines. Med Oncol. 2011 Mar;28(1):211-8. doi: 10.1007/s12032-009-9413-7. Epub 2010 Feb 9.
REF00000863	Anti-miR-21 oligonucleotide sensitizes leukemic K562 cells to arsenic trioxide by inducing apoptosis. Cancer Sci. 2010 Apr;101(4):948-54. doi: 10.1111/j.1349-7006.2010.01489.x. Epub 2010 Jan 7.
REF00000864	miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer. 2010 Dec 1;127(11):2520-9. doi: 10.1002/ijc.25260.
REF00000865	Structural basis for the methylation of G1405 in 16S rRNA by aminoglycoside resistance methyltransferase Sgm from an antibiotic producer: a diversity of active sites in m7G methyltransferases. Nucleic Acids Res. 2010 Jul;38(12):4120-32. doi: 10.1093/nar/gkq122. Epub 2010 Mar 1.
REF00000866	MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol. 2010 Apr;46(4):317-22. doi: 10.1016/j.oraloncology.2010.02.002. Epub 2010 Mar 9.
REF00000867	Mutations in ABL kinase domain are associated with inferior progression-free survival. Leuk Lymphoma. 2010 Jun;51(6):1072-8. doi: 10.3109/10428191003729741.
REF00000868	"MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem. 2010 Jun 4;285(23):17869-79. doi: 10.1074/jbc.M110.101055. Epub 2010 Apr 6."
REF00000869	miR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED. Cancer Res. 2010 May 1;70(9):3638-46. doi: 10.1158/0008-5472.CAN-09-3341. Epub 2010 Apr 13.
REF00000870	Relationship between the Clostridium perfringens catQ gene product and chloramphenicol acetyltransferases from other bacteria. Antimicrob Agents Chemother. 1991 Mar;35(3):471-6. doi: 10.1128/AAC.35.3.471.
REF00000871	"MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression. J Biol Chem. 2010 Jun 18;285(25):19076-84. doi: 10.1074/jbc.M109.079525. Epub 2010 Apr 20."
REF00000872	Signature gene expression profile of triclosan-resistant Escherichia coli. J Antimicrob Chemother. 2010 Jun;65(6):1171-7. doi: 10.1093/jac/dkq114. Epub 2010 Apr 21.
REF00000873	Natural evolution of TEM-1 Beta-lactamase: experimental reconstruction and clinical relevance. FEMS Microbiol Rev. 2010 Nov;34(6):1015-36. doi: 10.1111/j.1574-6976.2010.00222.x.
REF00000874	Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Mol Cancer. 2010 Apr 30;9:96. doi: 10.1186/1476-4598-9-96.
REF00000875	MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem. 2010 Jul 9;285(28):21496-507. doi: 10.1074/jbc.M109.083337. Epub 2010 May 11.
REF00000876	MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 2010 Jun 1;70(11):4528-38. doi: 10.1158/0008-5472.CAN-09-4467. Epub 2010 May 11.
REF00000877	"Two novel antibiotic resistance genes, tet(44) and ant(6)-Ib, are located within a transferable pathogenicity island in Campylobacter fetus subsp. fetus. Antimicrob Agents Chemother. 2010 Jul;54(7):3052-5. doi: 10.1128/AAC.00304-10. Epub 2010 May 17."
REF00000878	The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. Ann Surg. 2010 Jun;251(6):1056-63. doi: 10.1097/SLA.0b013e3181dd4ea9.
REF00000879	Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia. Mol Cancer. 2010 May 20;9:115. doi: 10.1186/1476-4598-9-115.
REF00000880	Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One. 2010 May 14;5(5):e10630. doi: 10.1371/journal.pone.0010630.
REF00000881	MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 2010 Jun 15;70(12):5184-93. doi: 10.1158/0008-5472.CAN-10-0145. Epub 2010 May 25.
REF00000882	"Reduced susceptibility to ceftriaxone in Neisseria gonorrhoeae is associated with mutations G542S, P551S and P551L in the gonococcal penicillin-binding protein 2. J Antimicrob Chemother. 2010 Aug;65(8):1615-8. doi: 10.1093/jac/dkq187. Epub 2010 May 28."
REF00000883	Rapid and sensitive allele-specific (AS)-RT-PCR assay for detection of T315I mutation in chronic myeloid leukemia patients treated with tyrosine-kinase inhibitors. Clin Exp Med. 2011 Mar;11(1):55-9. doi: 10.1007/s10238-010-0101-x. Epub 2010 May 29.
REF00000884	Novel florfenicol and chloramphenicol resistance gene discovered in Alaskan soil by using functional metagenomics. Appl Environ Microbiol. 2010 Aug;76(15):5321-6. doi: 10.1128/AEM.00323-10. Epub 2010 Jun 11.
REF00000885	Gastrointestinal stromal tumor with structures resembling intracytoplasmic lumina. Ultrastruct Pathol. 2010 Oct;34(5):301-6. doi: 10.3109/01913123.2010.487970.
REF00000886	"Molecular and functional characterization of a novel efflux pump, AmvA, mediating antimicrobial and disinfectant resistance in Acinetobacter baumannii. J Antimicrob Chemother. 2010 Sep;65(9):1919-25. doi: 10.1093/jac/dkq195. Epub 2010 Jun 23."
REF00000887	Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells. Acta Pharmacol Sin. 2010 Jul;31(7):867-73. doi: 10.1038/aps.2010.48. Epub 2010 Jun 28.
REF00000888	Characterisation of aminoglycoside acetyltransferase-encoding genes of neomycin-producing Micromonospora chalcea and Streptomyces fradiae. Gene. 1991 May 15;101(1):143-8. doi: 10.1016/0378-1119(91)90237-6.
REF00000889	Analysis of a Candida albicans gene that encodes a novel mechanism for resistance to benomyl and methotrexate. Mol Gen Genet. 1991 Jun;227(2):318-29. doi: 10.1007/BF00259685.
REF00000890	MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Gynecol Oncol. 2010 Oct;119(1):125-30. doi: 10.1016/j.ygyno.2010.06.004. Epub 2010 Jul 10.
REF00000891	Methylation patterns of genes coding for drug-metabolizing enzymes in tamoxifen-resistant breast cancer tissues. J Mol Med (Berl). 2010 Nov;88(11):1123-31. doi: 10.1007/s00109-010-0652-z. Epub 2010 Jul 14.
REF00000892	MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. Brain Res. 2010 Sep 17;1352:255-64. doi: 10.1016/j.brainres.2010.07.009. Epub 2010 Jul 13.
REF00000893	"Neocortical interneurons: from diversity, strength. Cell. 2010 Jul 23;142(2):189-93. doi: 10.1016/j.cell.2010.07.005."
REF00000894	Anti-miR-21 oligonucleotide enhances chemosensitivity of leukemic HL60 cells to arabinosylcytosine by inducing apoptosis. Hematology. 2010 Aug;15(4):215-21. doi: 10.1179/102453310X12647083620840.
REF00000895	Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients. Leuk Res. 2011 Jan;35(1):38-43. doi: 10.1016/j.leukres.2010.06.030. Epub 2010 Jul 29.
REF00000896	Chronic myeloid leukemia with e19a2 atypical transcript: early imatinib resistance and complete response to dasatinib. Cancer Genet Cytogenet. 2010 Sep;201(2):133-4. doi: 10.1016/j.cancergencyto.2010.05.012.
REF00000897	Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma. Anticancer Res. 2010 Jul;30(7):2513-7.
REF00000898	"Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial. J Thorac Oncol. 2010 Sep;5(9):1382-90. doi: 10.1097/JTO.0b013e3181eba657."
REF00000899	MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate. 2010 Oct 1;70(14):1501-12. doi: 10.1002/pros.21185.
REF00000900	"Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res. 2010 Sep;8(9):1207-16. doi: 10.1158/1541-7786.MCR-10-0052. Epub 2010 Aug 9."
REF00000901	Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients. Ann Hematol. 2011 Jan;90(1):47-52. doi: 10.1007/s00277-010-1039-5. Epub 2010 Aug 10.
REF00000902	"Metallo-Beta-lactamase expression confers an advantage to Pseudomonas aeruginosa isolates compared with other Beta-lactam resistance mechanisms, favoring the prevalence of metallo-Beta-lactamase producers in a clinical environment. Microb Drug Resist. 2010 Sep;16(3):223-30. doi: 10.1089/mdr.2010.0016."
REF00000903	Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother. 2010 Dec;54(12):4971-7. doi: 10.1128/AAC.00834-10. Epub 2010 Sep 20.
REF00000904	LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus. Antimicrob Agents Chemother. 2010 Dec;54(12):5406-12. doi: 10.1128/AAC.00580-10. Epub 2010 Sep 20.
REF00000905	Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. PLoS One. 2010 Sep 13;5(9):e12702. doi: 10.1371/journal.pone.0012702.
REF00000906	Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer. Br J Cancer. 2010 Oct 12;103(8):1284-91. doi: 10.1038/sj.bjc.6605884. Epub 2010 Sep 21.
REF00000907	Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer. J Thorac Oncol. 2010 Oct;5(10):1623-9. doi: 10.1097/JTO.0b013e3181ec1531.
REF00000908	Novel apramycin resistance gene apmA in bovine and porcine methicillin-resistant Staphylococcus aureus ST398 isolates. Antimicrob Agents Chemother. 2011 Jan;55(1):373-5. doi: 10.1128/AAC.01124-10. Epub 2010 Sep 27.
REF00000909	MicroRNA-21 induces resistance to the anti-tumour effect of interferon-Alpha/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer. 2010 Nov 9;103(10):1617-26. doi: 10.1038/sj.bjc.6605958. Epub 2010 Oct 26.
REF00000910	Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med. 2010 Oct 28;363(18):1704-14. doi: 10.1056/NEJMoa1008410. Epub 2010 Aug 29.
REF00000911	The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res. 2010 Dec 15;70(24):10038-43. doi: 10.1158/0008-5472.CAN-10-2956. Epub 2010 Oct 28.
REF00000912	Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2010 Dec 1;16(23):5873-82. doi: 10.1158/1078-0432.CCR-10-1588. Epub 2010 Oct 28.
REF00000913	Toward understanding the mechanism of action of the yeast multidrug resistance transporter Pdr5p: a molecular modeling study. J Struct Biol. 2011 Feb;173(2):333-44. doi: 10.1016/j.jsb.2010.10.012. Epub 2010 Oct 27.
REF00000914	miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines. Biochem Biophys Res Commun. 2010 Dec 3;403(1):120-5. doi: 10.1016/j.bbrc.2010.10.130. Epub 2010 Nov 3.
REF00000915	Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res. 2010 Nov 15;16(22):5489-98. doi: 10.1158/1078-0432.CCR-10-1371. Epub 2010 Nov 9.
REF00000916	Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer Lett. 2011 Jan 28;300(2):197-204. doi: 10.1016/j.canlet.2010.10.006. Epub 2010 Nov 9.
REF00000917	Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia. J Cell Mol Med. 2011 Oct;15(10):2164-75. doi: 10.1111/j.1582-4934.2010.01213.x.
REF00000918	MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci U S A. 2010 Dec 7;107(49):21098-103. doi: 10.1073/pnas.1015541107. Epub 2010 Nov 15.
REF00000919	COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010 Dec 16;468(7326):968-72. doi: 10.1038/nature09627. Epub 2010 Nov 24.
REF00000920	Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010 Dec 16;468(7326):973-7. doi: 10.1038/nature09626. Epub 2010 Nov 24.
REF00000921	Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res. 2011 Mar 15;17(6):1616-22. doi: 10.1158/1078-0432.CCR-10-2692. Epub 2010 Dec 6.
REF00000922	The ermC leader peptide: amino acid alterations leading to differential efficiency of induction by macrolide-lincosamide-streptogramin B antibiotics. J Bacteriol. 1990 Jul;172(7):3772-9. doi: 10.1128/jb.172.7.3772-3779.1990.
REF00000923	"Involvement, and dissemination, of the enterococcal small multidrug resistance transporter QacZ in resistance to quaternary ammonium compounds. J Antimicrob Chemother. 2011 Feb;66(2):283-6. doi: 10.1093/jac/dkq460. Epub 2010 Dec 8."
REF00000924	Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood. 2011 Mar 31;117(13):3641-7. doi: 10.1182/blood-2010-08-302679. Epub 2010 Dec 14.
REF00000925	Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Mol Cancer. 2010 Dec 20;9:317. doi: 10.1186/1476-4598-9-317.
REF00000926	miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro Oncol. 2011 Feb;13(2):165-75. doi: 10.1093/neuonc/noq179. Epub 2010 Dec 22.
REF00000927	Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line. FEBS Lett. 2011 Jan 21;585(2):402-8. doi: 10.1016/j.febslet.2010.12.027. Epub 2010 Dec 25.
REF00000928	In vitro activities of arylomycin natural-product antibiotics against Staphylococcus epidermidis and other coagulase-negative staphylococci. Antimicrob Agents Chemother. 2011 Mar;55(3):1130-4. doi: 10.1128/AAC.01459-10. Epub 2010 Dec 28.
REF00000929	miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell. 2011 Jan 21;41(2):210-20. doi: 10.1016/j.molcel.2010.12.005. Epub 2010 Dec 30.
REF00000930	miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS. Mol Cell Biochem. 2011 Apr;350(1-2):207-13. doi: 10.1007/s11010-010-0700-6. Epub 2011 Jan 1.
REF00000931	BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations . Med Oncol. 2012 Mar;29(1):219-26. doi: 10.1007/s12032-010-9781-z. Epub 2011 Jan 8.
REF00000932	MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance. J Cell Sci. 2011 Feb 1;124(Pt 3):359-68. doi: 10.1242/jcs.072223. Epub 2011 Jan 11.
REF00000933	BCR-ABL1 mutations in patients with imatinib-resistant Philadelphia chromosome-positive leukemia by use of the PCR-Invader assay. Leuk Res. 2011 May;35(5):598-603. doi: 10.1016/j.leukres.2010.12.006. Epub 2011 Jan 15.
REF00000934	miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines. Acta Biochim Biophys Sin (Shanghai). 2011 Mar;43(3):217-25. doi: 10.1093/abbs/gmq125. Epub 2011 Jan 17.
REF00000935	"Cross-resistance to lincosamides, streptogramins A, and pleuromutilins due to the lsa(C) gene in Streptococcus agalactiae UCN70. Antimicrob Agents Chemother. 2011 Apr;55(4):1470-4. doi: 10.1128/AAC.01068-10. Epub 2011 Jan 18."
REF00000936	Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells. J Gastrointest Surg. 2011 Mar;15(3):429-38. doi: 10.1007/s11605-011-1418-9. Epub 2011 Jan 19.
REF00000937	Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway. Clin Cancer Res. 2011 May 1;17(9):3029-38. doi: 10.1158/1078-0432.CCR-10-2532. Epub 2011 Jan 19.
REF00000938	Novel regulation of nuclear factor-YB by miR-485-3p affects the expression of DNA topoisomerase IIAlpha and drug responsiveness. Mol Pharmacol. 2011 Apr;79(4):735-41. doi: 10.1124/mol.110.069633. Epub 2011 Jan 20.
REF00000939	miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol. 2012 Mar;29(1):384-91. doi: 10.1007/s12032-010-9797-4. Epub 2011 Jan 22.
REF00000940	A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis. Int J Hematol. 2011 Feb;93(2):237-242. doi: 10.1007/s12185-011-0766-2. Epub 2011 Jan 25.
REF00000941	miR-153 sensitized the K562 cells to As2O3-induced apoptosis. Med Oncol. 2012 Mar;29(1):243-7. doi: 10.1007/s12032-010-9807-6. Epub 2011 Jan 26.
REF00000942	Prevalence of resistance associated polymorphisms in Plasmodium falciparum field isolates from southern Pakistan. Malar J. 2011 Jan 28;10:18. doi: 10.1186/1475-2875-10-18.
REF00000943	MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma. J Hum Genet. 2011 Apr;56(4):270-6. doi: 10.1038/jhg.2011.1. Epub 2011 Feb 3.
REF00000944	Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2011 May;55(5):2032-41. doi: 10.1128/AAC.01550-10. Epub 2011 Feb 7.
REF00000945	Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma. Lung Cancer. 2011 Sep;73(3):361-5. doi: 10.1016/j.lungcan.2011.01.008. Epub 2011 Feb 18.
REF00000946	Genome-wide screen identifies PVT1 as a regulator of Gemcitabine sensitivity in human pancreatic cancer cells. Biochem Biophys Res Commun. 2011 Apr 1;407(1):1-6. doi: 10.1016/j.bbrc.2011.02.027. Epub 2011 Feb 18.
REF00000947	Sequence and gene expression of chloroquine resistance transporter (pfcrt) in the association of in vitro drugs resistance of Plasmodium falciparum. Malar J. 2011 Feb 15;10:42. doi: 10.1186/1475-2875-10-42.
REF00000948	Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549). J Exp Clin Cancer Res. 2011 Feb 17;30(1):20. doi: 10.1186/1756-9966-30-20.
REF00000949	MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer. Ann Surg Oncol. 2011 Aug;18(8):2381-7. doi: 10.1245/s10434-011-1602-x. Epub 2011 Feb 23.
REF00000950	miR-203 reverses chemoresistance in p53-mutated colon cancer cells through downregulation of Akt2 expression. Cancer Lett. 2011 May 1;304(1):52-9. doi: 10.1016/j.canlet.2011.02.003. Epub 2011 Feb 26.
REF00000951	Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy. Haematologica. 2011 Jun;96(6):918-21. doi: 10.3324/haematol.2010.039321. Epub 2011 Feb 28.
REF00000952	Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis. 2010 Dec 9;1(12):e105. doi: 10.1038/cddis.2010.85.
REF00000953	Bcl-2 upregulation induced by miR-21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa-2 pancreatic cancer cells. Arch Med Res. 2011 Jan;42(1):8-14. doi: 10.1016/j.arcmed.2011.01.006.
REF00000954	"CMY-42, a novel plasmid-mediated CMY-2 variant AmpC beta-lactamase. Microb Drug Resist. 2011 Jun;17(2):165-9. doi: 10.1089/mdr.2010.0137. Epub 2011 Mar 9."
REF00000955	A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report. Neurosurgery. 2011 Jun;68(6):E1761-7; discussion E1767. doi: 10.1227/NEU.0b013e318217161a.
REF00000956	CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature. 2011 Mar 10;471(7337):235-9. doi: 10.1038/nature09727.
REF00000957	Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors. Int J Clin Oncol. 2011 Dec;16(6):741-5. doi: 10.1007/s10147-011-0208-4. Epub 2011 Mar 12.
REF00000958	miRNA-34a is associated with docetaxel resistance in human breast cancer cells. Breast Cancer Res Treat. 2012 Jan;131(2):445-54. doi: 10.1007/s10549-011-1424-3. Epub 2011 Mar 12.
REF00000959	"A novel gene cassette, aacA43, in a plasmid-borne class 1 integron. Antimicrob Agents Chemother. 2011 Jun;55(6):2979-82. doi: 10.1128/AAC.01582-10. Epub 2011 Mar 21."
REF00000960	Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011 Mar 23;3(75):75ra26. doi: 10.1126/scitranslmed.3002003.
REF00000961	microRNA-21 modulates cell proliferation and sensitivity to doxorubicin in bladder cancer cells. Oncol Rep. 2011 Jun;25(6):1721-9. doi: 10.3892/or.2011.1245. Epub 2011 Apr 4.
REF00000962	Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem. 2011 May 27;286(21):19127-37. doi: 10.1074/jbc.M110.216887. Epub 2011 Apr 6.
REF00000963	miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. Oncogene. 2011 Oct 27;30(43):4386-98. doi: 10.1038/onc.2011.148. Epub 2011 May 9.
REF00000964	Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells. J Exp Clin Cancer Res. 2011 May 13;30(1):55. doi: 10.1186/1756-9966-30-55.
REF00000965	Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells. Mol Cell Biochem. 2011 Nov;357(1-2):31-8. doi: 10.1007/s11010-011-0872-8. Epub 2011 May 19.
REF00000966	Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. Int J Cancer. 2012 Apr 15;130(8):1787-97. doi: 10.1002/ijc.26190. Epub 2011 Aug 16.
REF00000967	Do complex mutations of the epidermal growth factor receptor gene reflect intratumoral heterogeneity . J Thorac Oncol. 2011 Jun;6(6):1144-6. doi: 10.1097/JTO.0b013e31821b1194.
REF00000968	"Detection of staphylococcal cassette chromosome mec type XI carrying highly divergent mecA, mecI, mecR1, blaZ, and ccr genes in human clinical isolates of clonal complex 130 methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2011 Aug;55(8):3765-73. doi: 10.1128/AAC.00187-11. Epub 2011 Jun 2."
REF00000969	Clinical outcome of chronic myeloid leukemia imatinib-resistant patients: do BCR-ABL kinase domain mutations affect patient survival  First multicenter Argentinean study. Leuk Lymphoma. 2011 Sep;52(9):1720-6. doi: 10.3109/10428194.2011.578310. Epub 2011 Jun 12.
REF00000970	PCR cloning of a streptomycin phosphotransferase (aphE) gene from Streptomyces griseus ATCC 12475. Nucleic Acids Res. 1990 Aug 11;18(15):4615. doi: 10.1093/nar/18.15.4615.
REF00000971	Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother. 1990 Jun;34(6):1271-2. doi: 10.1128/AAC.34.6.1271.
REF00000972	MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status. Int J Cancer. 2012 Jun 1;130(11):2526-38. doi: 10.1002/ijc.26256. Epub 2011 Dec 2.
REF00000973	miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222. Oncogene. 2012 Feb 2;31(5):634-42. doi: 10.1038/onc.2011.260. Epub 2011 Jun 27.
REF00000974	MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene. 2012 Jan 26;31(4):432-45. doi: 10.1038/onc.2011.263. Epub 2011 Jul 4.
REF00000975	"Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones. J Bacteriol. 1990 Dec;172(12):6942-9. doi: 10.1128/jb.172.12.6942-6949.1990."
REF00000976	"Characterization of OXA-181, a carbapenem-hydrolyzing class D beta-lactamase from Klebsiella pneumoniae. Antimicrob Agents Chemother. 2011 Oct;55(10):4896-9. doi: 10.1128/AAC.00481-11. Epub 2011 Jul 18."
REF00000977	MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. Cancer Lett. 2011 Nov 28;310(2):160-9. doi: 10.1016/j.canlet.2011.06.027. Epub 2011 Jul 2.
REF00000978	MicroRNA miR-199a-3p regulates cell proliferation and survival by targeting caveolin-2. J Cell Sci. 2011 Aug 15;124(Pt 16):2826-36. doi: 10.1242/jcs.077529.
REF00000979	"MicroRNA-32 upregulation by 1,25-dihydroxyvitamin D3 in human myeloid leukemia cells leads to Bim targeting and inhibition of AraC-induced apoptosis. Cancer Res. 2011 Oct 1;71(19):6230-9. doi: 10.1158/0008-5472.CAN-11-1717. Epub 2011 Aug 4."
REF00000980	MicroRNA-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN. Arch Med Res. 2011 May;42(4):281-90. doi: 10.1016/j.arcmed.2011.06.008.
REF00000981	miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1. J Huazhong Univ Sci Technolog Med Sci. 2011 Aug;31(4):543. doi: 10.1007/s11596-011-0487-z. Epub 2011 Aug 7.
REF00000982	let-7 microRNAs induce tamoxifen sensitivity by downregulation of estrogen receptor Alpha signaling in breast cancer. Mol Med. 2011;17(11-12):1233-41. doi: 10.2119/molmed.2010.00225. Epub 2011 Jul 27.
REF00000983	Mutation in cytochrome P-450-dependent 14 alpha-demethylase results in decreased affinity for azole antifungals. Biochem Soc Trans. 1990 Feb;18(1):56-9. doi: 10.1042/bst0180056.
REF00000984	Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res. 2011 Oct 15;71(20):6320-6. doi: 10.1158/0008-5472.CAN-11-1021. Epub 2011 Aug 23.
REF00000985	Underexpression of miR-224 in methotrexate resistant human colon cancer cells. Biochem Pharmacol. 2011 Dec 1;82(11):1572-82. doi: 10.1016/j.bcp.2011.08.009. Epub 2011 Aug 16.
REF00000986	Contribution of efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex. Infect Genet Evol. 2012 Jun;12(4):695-700. doi: 10.1016/j.meegid.2011.08.009. Epub 2011 Aug 17.
REF00000987	"Interrogation of related clinical pan-azole-resistant Aspergillus fumigatus strains: G138C, Y431C, and G434C single nucleotide polymorphisms in cyp51A, upregulation of cyp51A, and integration and activation of transposon Atf1 in the cyp51A promoter. Antimicrob Agents Chemother. 2011 Nov;55(11):5113-21. doi: 10.1128/AAC.00517-11. Epub 2011 Aug 29."
REF00000988	MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis. Int J Oncol. 2012 Jan;40(1):119-29. doi: 10.3892/ijo.2011.1179. Epub 2011 Aug 29.
REF00000989	Upregulation of microRNA-125b contributes to leukemogenesis and increases drug resistance in pediatric acute promyelocytic leukemia. Mol Cancer. 2011 Sep 1;10:108. doi: 10.1186/1476-4598-10-108.
REF00000990	Use of direct sequencing for detection of mutations in the BCR-ABL kinase domain in Slovak patients with chronic myeloid leukemia. Neoplasma. 2011;58(6):548-53. doi: 10.4149/neo_2011_06_548.
REF00000991	Genetic basis for in vivo daptomycin resistance in enterococci. N Engl J Med. 2011 Sep 8;365(10):892-900. doi: 10.1056/NEJMoa1011138.
REF00000992	A noninvasive system for monitoring resistance to epidermal growth factor receptor tyrosine kinase inhibitors with plasma DNA. J Thorac Oncol. 2011 Oct;6(10):1639-48. doi: 10.1097/JTO.0b013e31822956e8.
REF00000993	"A novel variant, NDM-5, of the New Delhi metallo-Beta-lactamase in a multidrug-resistant Escherichia coli ST648 isolate recovered from a patient in the United Kingdom. Antimicrob Agents Chemother. 2011 Dec;55(12):5952-4. doi: 10.1128/AAC.05108-11. Epub 2011 Sep 19."
REF00000994	Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011 Dec 15;118(25):6521-8. doi: 10.1182/blood-2011-05-351403. Epub 2011 Sep 19.
REF00000995	Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells. J Hematol Oncol. 2011 Sep 22;4:37. doi: 10.1186/1756-8722-4-37.
REF00000996	miRNA-195 sensitizes human hepatocellular carcinoma cells to 5-FU by targeting BCL-w. Oncol Rep. 2012 Jan;27(1):250-7. doi: 10.3892/or.2011.1472. Epub 2011 Sep 22.
REF00000997	"MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells. Stem Cells. 2011 Nov;29(11):1661-71. doi: 10.1002/stem.741."
REF00000998	Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. Clin Cancer Res. 2011 Nov 15;17(22):7105-15. doi: 10.1158/1078-0432.CCR-11-0071. Epub 2011 Sep 27.
REF00000999	miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy. J Pathol. 2012 Apr;226(5):796-805. doi: 10.1002/path.3007.
REF00001000	[ABL domain kinase point mutations as a cause of resistance to therapy of patients with chronic myeloid leukemia with tyrosine kinase inhibitors. Single center experience]. Przegl Lek. 2011;68(5):253-7.
REF00001001	Role of Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes on in vitro chloroquine resistance in isolates of Plasmodium falciparum from Thailand. Am J Trop Med Hyg. 2011 Oct;85(4):606-11. doi: 10.4269/ajtmh.2011.11-0108.
REF00001002	miR-146a suppresses the sensitivity to interferon-Alpha in hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2011 Nov 4;414(4):675-80. doi: 10.1016/j.bbrc.2011.09.124. Epub 2011 Oct 1.
REF00001003	miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol. 2012 Mar;69(3):723-31. doi: 10.1007/s00280-011-1752-3. Epub 2011 Oct 13.
REF00001004	Topoisomerase mutations that are associated with high-level resistance to earlier fluoroquinolones in Staphylococcus aureus have less effect on the antibacterial activity of besifloxacin. Chemotherapy. 2011;57(5):363-71. doi: 10.1159/000330858. Epub 2011 Oct 12.
REF00001005	"ICEPmu1, an integrative conjugative element (ICE) of Pasteurella multocida: analysis of the regions that comprise 12 antimicrobial resistance genes. J Antimicrob Chemother. 2012 Jan;67(1):84-90. doi: 10.1093/jac/dkr406. Epub 2011 Oct 14."
REF00001006	Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1. Gynecol Oncol. 2012 Feb;124(2):325-34. doi: 10.1016/j.ygyno.2011.10.013. Epub 2011 Oct 15.
REF00001007	The interactions between MicroRNA-200c and BRD7 in endometrial carcinoma. Gynecol Oncol. 2012 Jan;124(1):125-33. doi: 10.1016/j.ygyno.2011.09.026. Epub 2011 Oct 19.
REF00001008	"Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan. Antimicrob Agents Chemother. 2012 Jan;56(1):584-7. doi: 10.1128/AAC.05394-11. Epub 2011 Oct 24."
REF00001009	MicroRNA 506 regulates expression of PPAR alpha in hydroxycamptothecin-resistant human colon cancer cells. FEBS Lett. 2011 Nov 16;585(22):3560-8. doi: 10.1016/j.febslet.2011.10.021. Epub 2011 Oct 22.
REF00001010	Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol. 2011 Dec;6(12):2011-7. doi: 10.1097/JTO.0b013e31823ab0dd.
REF00001011	Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4). Cancer Chemother Pharmacol. 2012 Apr;69(4):891-9. doi: 10.1007/s00280-011-1738-1. Epub 2011 Nov 10.
REF00001012	Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer. Med Oncol. 2012 Dec;29(4):2527-34. doi: 10.1007/s12032-011-0117-4. Epub 2011 Nov 19.
REF00001013	Spatial and temporal genetic heterogeneity of epidermal growth factor receptor gene status in a patient with non-small cell lung cancer: a case report. J Med Case Rep. 2011 Nov 22;5:553. doi: 10.1186/1752-1947-5-553.
REF00001014	The miRNA-17 92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. Leukemia. 2012 May;26(5):1064-72. doi: 10.1038/leu.2011.305. Epub 2011 Nov 25.
REF00001015	DNA methylation-regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via repression of SRSF2 expression. J Biol Chem. 2012 Feb 17;287(8):5639-49. doi: 10.1074/jbc.M111.291229. Epub 2011 Nov 23.
REF00001016	MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1. Cancer Lett. 2012 Apr 28;317(2):184-91. doi: 10.1016/j.canlet.2011.11.024. Epub 2011 Nov 25.
REF00001017	miR-1915 inhibits Bcl-2 to modulate multidrug resistance by increasing drug-sensitivity in human colorectal carcinoma cells. Mol Carcinog. 2013 Jan;52(1):70-8. doi: 10.1002/mc.21832. Epub 2011 Nov 28.
REF00001018	Regulation of deoxycytidine kinase expression and sensitivity to gemcitabine by micro-RNA 330 and promoter methylation in cancer cells. Nucleosides Nucleotides Nucleic Acids. 2011 Dec;30(12):1214-22. doi: 10.1080/15257770.2011.629271.
REF00001019	First report of mefA and msrA/msrB multidrug efflux pumps associated with blaTEM-1 Beta-lactamase in Enterococcus faecalis. Int J Infect Dis. 2012 Feb;16(2):e104-9. doi: 10.1016/j.ijid.2011.09.024. Epub 2011 Dec 1.
REF00001020	MicroRNA-200b reverses chemoresistance of docetaxel-resistant human lung adenocarcinoma cells by targeting E2F3. Cancer. 2012 Jul 1;118(13):3365-76. doi: 10.1002/cncr.26560. Epub 2011 Dec 2.
REF00001021	High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother. 2012 Mar;56(3):1273-80. doi: 10.1128/AAC.05760-11. Epub 2011 Dec 12.
REF00001022	Plasma miR-221 as a predictive biomarker for chemoresistance in breast cancer patients who previously received neoadjuvant chemotherapy. Onkologie. 2011;34(12):675-80. doi: 10.1159/000334552. Epub 2011 Nov 23.
REF00001023	MicroRNA-30a sensitizes tumor cells to cis-platinum via suppressing beclin 1-mediated autophagy. J Biol Chem. 2012 Feb 3;287(6):4148-56. doi: 10.1074/jbc.M111.307405. Epub 2011 Dec 8.
REF00001024	"Drug resistance associated genetic polymorphisms in Plasmodium falciparum and Plasmodium vivax collected in Honduras, Central America. Malar J. 2011 Dec 19;10:376. doi: 10.1186/1475-2875-10-376."
REF00001025	MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ. 2012 Jun;19(6):1038-48. doi: 10.1038/cdd.2011.190. Epub 2011 Dec 23.
REF00001026	A miR-200b/200c/429-binding site polymorphism in the 3' untranslated region of the AP-2Alpha gene is associated with cisplatin resistance. PLoS One. 2011;6(12):e29043. doi: 10.1371/journal.pone.0029043. Epub 2011 Dec 14.
REF00001027	Anti-miR-203 Upregulates SOCS3 Expression in Breast Cancer Cells and Enhances Cisplatin Chemosensitivity. Genes Cancer. 2011 Jul;2(7):720-7. doi: 10.1177/1947601911425832.
REF00001028	miR-181a sensitizes resistant leukaemia HL-60/Ara-C cells to Ara-C by inducing apoptosis. J Cancer Res Clin Oncol. 2012 Apr;138(4):595-602. doi: 10.1007/s00432-011-1137-3. Epub 2012 Jan 1.
REF00001029	Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol. 2012 Feb 1;30(4):433-40. doi: 10.1200/JCO.2011.38.3224. Epub 2012 Jan 3.
REF00001030	The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor. Mol Cancer Ther. 2012 Mar;11(3):784-91. doi: 10.1158/1535-7163.MCT-11-0750. Epub 2012 Jan 6.
REF00001031	MiRNA-21: a biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer. Cancer Biol Ther. 2012 Mar;13(5):330-40. doi: 10.4161/cbt.19073. Epub 2012 Mar 1.
REF00001032	Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus. PLoS One. 2012;7(1):e28316. doi: 10.1371/journal.pone.0028316. Epub 2012 Jan 6.
REF00001033	miR-21 inhibitor sensitizes human OSCC cells to cisplatin. Mol Biol Rep. 2012 May;39(5):5481-5. doi: 10.1007/s11033-011-1350-9. Epub 2012 Jan 15.
REF00001034	NDM-4 metallo-Beta-lactamase with increased carbapenemase activity from Escherichia coli. Antimicrob Agents Chemother. 2012 Apr;56(4):2184-6. doi: 10.1128/AAC.05961-11. Epub 2012 Jan 17.
REF00001035	"Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: preclinical and clinical evidences. Stem Cells. 2012 Mar;30(3):372-8. doi: 10.1002/stem.1035."
REF00001036	"Chloramphenicol resistance in Campylobacter coli: nucleotide sequence, expression, and cloning vector construction. Gene. 1990 Sep 28;94(1):23-8. doi: 10.1016/0378-1119(90)90463-2."
REF00001037	Alcohol septal ablation for obstructive hypertrophic cardiomyopathy: the perfect septal branch may originate from an atypical location. Can J Cardiol. 2012 Mar-Apr;28(2):245.e1-3. doi: 10.1016/j.cjca.2011.09.015. Epub 2012 Jan 25.
REF00001038	Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med. 2012 Feb 8;4(120):120ra17. doi: 10.1126/scitranslmed.3003316. Epub 2012 Jan 25.
REF00001039	miR-181a sensitizes a multidrug-resistant leukemia cell line K562/A02 to daunorubicin by targeting BCL-2. Acta Biochim Biophys Sin (Shanghai). 2012 Mar;44(3):269-77. doi: 10.1093/abbs/gmr128. Epub 2012 Jan 26.
REF00001040	Glucocorticoid regulation of a novel HPV-E6-p53-miR-145 pathway modulates invasion and therapy resistance of cervical cancer cells. J Pathol. 2012 Oct;228(2):148-57. doi: 10.1002/path.3997. Epub 2012 Apr 18.
REF00001041	"Genetic and biochemical characterization of a novel metallo-Beta-lactamase, TMB-1, from an Achromobacter xylosoxidans strain isolated in Tripoli, Libya. Antimicrob Agents Chemother. 2012 May;56(5):2241-5. doi: 10.1128/AAC.05640-11. Epub 2012 Jan 30."
REF00001042	Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study. Br J Haematol. 2012 May;157(4):507-10. doi: 10.1111/j.1365-2141.2012.09039.x. Epub 2012 Feb 2.
REF00001043	Loxapine P-glycoprotein interactions in vitro. Drug Metab Lett. 2012 Mar;6(1):26-32. doi: 10.2174/187231212800229255.
REF00001044	Mechanism and diversity of the erythromycin esterase family of enzymes. Biochemistry. 2012 Feb 28;51(8):1740-51. doi: 10.1021/bi201790u. Epub 2012 Feb 10.
REF00001045	The T788G mutation in the cyp51C gene confers voriconazole resistance in Aspergillus flavus causing aspergillosis. Antimicrob Agents Chemother. 2012 May;56(5):2598-603. doi: 10.1128/AAC.05477-11. Epub 2012 Feb 6.
REF00001046	MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells. Ann Surg Oncol. 2012 Sep;19(9):3065-71. doi: 10.1245/s10434-012-2246-1. Epub 2012 Feb 10.
REF00001047	Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. Leukemia. 2012 Jul;26(7):1462-70. doi: 10.1038/leu.2012.52. Epub 2012 Feb 22.
REF00001048	Saquinavir inhibits the malaria parasite's chloroquine resistance transporter. Antimicrob Agents Chemother. 2012 May;56(5):2283-9. doi: 10.1128/AAC.00166-12. Epub 2012 Feb 21.
REF00001049	Comparative analysis of the first complete Enterococcus faecium genome. J Bacteriol. 2012 May;194(9):2334-41. doi: 10.1128/JB.00259-12. Epub 2012 Feb 24.
REF00001050	Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. Blood. 2012 May 31;119(22):5133-43. doi: 10.1182/blood-2011-06-363960. Epub 2012 Feb 24.
REF00001051	miR-34c may protect lung cancer cells from paclitaxel-induced apoptosis. Oncogene. 2013 Jan 17;32(3):341-51. doi: 10.1038/onc.2012.51. Epub 2012 Feb 27.
REF00001052	Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer. 2012 May 15;118(10):2603-14. doi: 10.1002/cncr.26565. Epub 2011 Oct 5.
REF00001053	Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells. J Gastroenterol. 2012 Aug;47(8):883-95. doi: 10.1007/s00535-012-0547-6. Epub 2012 Mar 1.
REF00001054	Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells. Leukemia. 2012 Aug;26(8):1752-60. doi: 10.1038/leu.2012.65. Epub 2012 Mar 7.
REF00001055	ERK inhibition overcomes acquired resistance to MEK inhibitors. Mol Cancer Ther. 2012 May;11(5):1143-54. doi: 10.1158/1535-7163.MCT-11-1010. Epub 2012 Mar 8.
REF00001056	MicroRNA expression profiling identifies miR-328 regulates cancer stem cell-like SP cells in colorectal cancer. Br J Cancer. 2012 Mar 27;106(7):1320-30. doi: 10.1038/bjc.2012.88.
REF00001057	"Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Lett. 2012 May 7;586(9):1279-86. doi: 10.1016/j.febslet.2012.03.006. Epub 2012 Mar 27."
REF00001058	"Analysis of mutations in the BCR-ABL1 kinase domain, using direct sequencing: detection of the T315I mutation in bone marrow CD34+ cells of a patient with chronic myelogenous leukemia 6 months prior to its emergence in peripheral blood. Mol Diagn Ther. 2012 Jun 1;16(3):163-6. doi: 10.2165/11632420-000000000-00000."
REF00001059	MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells. FEBS J. 2012 Jun;279(11):2047-59. doi: 10.1111/j.1742-4658.2012.08589.x. Epub 2012 Apr 24.
REF00001060	MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines. Asian Pac J Cancer Prev. 2012;13(1):255-60. doi: 10.7314/apjcp.2012.13.1.255.
REF00001061	Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 2012 Apr 15;485(7397):260-3. doi: 10.1038/nature11016.
REF00001062	Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene. 2013 Feb 28;32(9):1173-82. doi: 10.1038/onc.2012.128. Epub 2012 Apr 16.
REF00001063	miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A. Acta Biochim Biophys Sin (Shanghai). 2012 Jun;44(6):519-26. doi: 10.1093/abbs/gms026. Epub 2012 Apr 16.
REF00001064	Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am J Pathol. 2012 Jun;180(6):2490-503. doi: 10.1016/j.ajpath.2012.02.024. Epub 2012 Apr 19.
REF00001065	Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS One. 2012;7(4):e34210. doi: 10.1371/journal.pone.0034210. Epub 2012 Apr 16.
REF00001066	The order Bacillales hosts functional homologs of the worrisome cfr antibiotic resistance gene. Antimicrob Agents Chemother. 2012 Jul;56(7):3563-7. doi: 10.1128/AAC.00673-12. Epub 2012 Apr 30.
REF00001067	Resistance to voriconazole due to a G448S substitution in Aspergillus fumigatus in a patient with cerebral aspergillosis. J Clin Microbiol. 2012 Jul;50(7):2531-4. doi: 10.1128/JCM.00329-12. Epub 2012 May 9.
REF00001068	Long non-coding RNA UCA1a(CUDR) promotes proliferation and tumorigenesis of bladder cancer. Int J Oncol. 2012 Jul;41(1):276-84. doi: 10.3892/ijo.2012.1443. Epub 2012 Apr 20.
REF00001069	miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. Carcinogenesis. 2012 Jul;33(7):1294-301. doi: 10.1093/carcin/bgs179. Epub 2012 May 18.
REF00001070	Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance. Oncol Rep. 2012 Aug;28(2):592-600. doi: 10.3892/or.2012.1823. Epub 2012 May 18.
REF00001071	microRNA 30A promotes autophagy in response to cancer therapy. Autophagy. 2012 May 1;8(5):853-5. doi: 10.4161/auto.20053. Epub 2012 May 1.
REF00001072	Mechanism of action of and mechanism of reduced susceptibility to the novel anti-Clostridium difficile compound LFF571. Antimicrob Agents Chemother. 2012 Aug;56(8):4463-5. doi: 10.1128/AAC.06354-11. Epub 2012 May 29.
REF00001073	Tetracycline resistance and presence of tetracycline resistance determinants tet(V) and tap in rapidly growing mycobacteria from agricultural soils and clinical isolates. Microbes Environ. 2012;27(4):413-22. doi: 10.1264/jsme2.me12028. Epub 2012 May 17.
REF00001074	miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2. Biochem J. 2012 Sep 1;446(2):291-300. doi: 10.1042/BJ20120386.
REF00001075	MiR-222 modulates multidrug resistance in human colorectal carcinoma by down-regulating ADAM-17. Exp Cell Res. 2012 Oct 15;318(17):2168-77. doi: 10.1016/j.yexcr.2012.04.014. Epub 2012 Jun 4.
REF00001076	"Nucleotide sequences of genes encoding the type II chloramphenicol acetyltransferases of Escherichia coli and Haemophilus influenzae, which are sensitive to inhibition by thiol-reactive reagents. Biochem J. 1990 Dec 1;272(2):505-10. doi: 10.1042/bj2720505."
REF00001077	Changes in the brain accumulation of glucocorticoids in abcb1a-deficient CF-1 mice. J Neuroendocrinol. 2012 Nov;24(11):1440-6. doi: 10.1111/j.1365-2826.2012.02353.x.
REF00001078	Characterization of mutations causing rifampicin and isoniazid resistance of Mycobacterium tuberculosis in Syria. Pol J Microbiol. 2012;61(1):23-32.
REF00001079	MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer. Oncogene. 2013 Apr 11;32(15):1910-20. doi: 10.1038/onc.2012.214. Epub 2012 Jun 18.
REF00001080	Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell. Biochem Biophys Res Commun. 2012 Jul 13;423(4):826-31. doi: 10.1016/j.bbrc.2012.06.048. Epub 2012 Jun 16.
REF00001081	Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Clin Cancer Res. 2012 Aug 15;18(16):4458-64. doi: 10.1158/1078-0432.CCR-11-3025. Epub 2012 Jun 20.
REF00001082	Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer. J Thorac Oncol. 2012 May;7(5):856-65. doi: 10.1097/JTO.0b013e31824c943f.
REF00001083	Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012 Jun 28;486(7404):532-6. doi: 10.1038/nature11156.
REF00001084	The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012 Jun 28;486(7404):537-40. doi: 10.1038/nature11219.
REF00001085	miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers. PLoS One. 2012;7(6):e39167. doi: 10.1371/journal.pone.0039167. Epub 2012 Jun 18.
REF00001086	miR-513a-3p sensitizes human lung adenocarcinoma cells to chemotherapy by targeting GSTP1. Lung Cancer. 2012 Sep;77(3):488-94. doi: 10.1016/j.lungcan.2012.05.107. Epub 2012 Jun 30.
REF00001087	Correlation between triazole treatment history and susceptibility in clinically isolated Aspergillus fumigatus. Antimicrob Agents Chemother. 2012 Sep;56(9):4870-5. doi: 10.1128/AAC.00514-12. Epub 2012 Jul 2.
REF00001088	Genetic variation that predicts platinum sensitivity reveals the role of miR-193b* in chemotherapeutic susceptibility. Mol Cancer Ther. 2012 Sep;11(9):2054-61. doi: 10.1158/1535-7163.MCT-12-0221. Epub 2012 Jun 29.
REF00001089	MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cells. Anticancer Res. 2012 Jul;32(7):2835-41.
REF00001090	MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition. Cancer Res. 2012 Aug 15;72(16):4037-46. doi: 10.1158/0008-5472.CAN-12-0103. Epub 2012 Jul 3.
REF00001091	HG-829 is a potent noncompetitive inhibitor of the ATP-binding cassette multidrug resistance transporter ABCB1. Cancer Res. 2012 Aug 15;72(16):4204-13. doi: 10.1158/0008-5472.CAN-12-0743. Epub 2012 Jul 3.
REF00001092	New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations. PLoS One. 2012;7(6):e39754. doi: 10.1371/journal.pone.0039754. Epub 2012 Jun 28.
REF00001093	"Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):E2127-33. doi: 10.1073/pnas.1203530109. Epub 2012 Jul 6."
REF00001094	In vivo emergence of Aspergillus terreus with reduced azole susceptibility and a Cyp51a M217I alteration. J Infect Dis. 2012 Sep 15;206(6):981-5. doi: 10.1093/infdis/jis442. Epub 2012 Jul 10.
REF00001095	Characterization of a rifampin-inactivating glycosyltransferase from a screen of environmental actinomycetes. Antimicrob Agents Chemother. 2012 Oct;56(10):5061-9. doi: 10.1128/AAC.01166-12. Epub 2012 Jul 16.
REF00001096	Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells. PLoS One. 2012;7(7):e41017. doi: 10.1371/journal.pone.0041017. Epub 2012 Jul 17.
REF00001097	gyrA and parC mutations in quinolone-resistant clinical isolates of Pseudomonas aeruginosa from Nini Hospital in north Lebanon. J Infect Chemother. 2013 Feb;19(1):77-81. doi: 10.1007/s10156-012-0455-y. Epub 2012 Jul 21.
REF00001098	"Molecular epidemiology of drug resistance markers of Plasmodium falciparum in Yunnan Province, China. Malar J. 2012 Jul 28;11:243. doi: 10.1186/1475-2875-11-243."
REF00001099	Myc induced miR-144/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562. Biochem Biophys Res Commun. 2012 Aug 24;425(2):368-73. doi: 10.1016/j.bbrc.2012.07.098. Epub 2012 Jul 27.
REF00001100	"Clonal analysis in recurrent astrocytic, oligoastrocytic and oligodendroglial tumors implicates IDH1- mutation as common tumor initiating event. PLoS One. 2012;7(7):e41298. doi: 10.1371/journal.pone.0041298. Epub 2012 Jul 23."
REF00001101	Upregulated miR-130a increases drug resistance by regulating RUNX3 and Wnt signaling in cisplatin-treated HCC cell. Biochem Biophys Res Commun. 2012 Aug 24;425(2):468-72. doi: 10.1016/j.bbrc.2012.07.127. Epub 2012 Jul 27.
REF00001102	Let-7 expression is a significant determinant of response to chemotherapy through the regulation of IL-6/STAT3 pathway in esophageal squamous cell carcinoma. Clin Cancer Res. 2012 Sep 15;18(18):5144-53. doi: 10.1158/1078-0432.CCR-12-0701. Epub 2012 Jul 30.
REF00001103	Mutation in the Plasmodium falciparum CRT protein determines the stereospecific activity of antimalarial cinchona alkaloids. Antimicrob Agents Chemother. 2012 Oct;56(10):5356-64. doi: 10.1128/AAC.05667-11. Epub 2012 Aug 6.
REF00001104	Early detection and quantification of mutations in the tyrosine kinase domain of chimerical BCR-ABL1 gene combining high-resolution melting analysis and mutant-allele specific quantitative polymerase chain reaction. Leuk Lymphoma. 2013 Mar;54(3):598-606. doi: 10.3109/10428194.2012.718767. Epub 2012 Aug 31.
REF00001105	Role of treatment in the appearance and selection of BCR-ABL1 kinase domain mutations. Mol Diagn Ther. 2012 Aug 1;16(4):251-9. doi: 10.1007/BF03262214.
REF00001106	MicroRNA-133b inhibits the growth of non-small-cell lung cancer by targeting the epidermal growth factor receptor. FEBS J. 2012 Oct;279(20):3800-12. doi: 10.1111/j.1742-4658.2012.08741.x. Epub 2012 Sep 11.
REF00001107	MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome. Br J Cancer. 2012 Sep 4;107(6):967-76. doi: 10.1038/bjc.2012.356. Epub 2012 Aug 14.
REF00001108	BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib. Br J Cancer. 2012 Sep 4;107(6):947-55. doi: 10.1038/bjc.2012.351. Epub 2012 Aug 14.
REF00001109	Decrease in blood miR-296 predicts chemotherapy resistance and poor clinical outcome in patients receiving systemic chemotherapy for metastatic colon cancer. Int J Colorectal Dis. 2013 Jun;28(6):887. doi: 10.1007/s00384-012-1560-1. Epub 2012 Aug 15.
REF00001110	LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin. Cancer Res. 2012 Aug 15;72(16):4060-73. doi: 10.1158/0008-5472.CAN-12-0203.
REF00001111	The deoxycholic acid targets miRNA-dependent CAC1 gene expression in multidrug resistance of human colorectal cancer. Int J Biochem Cell Biol. 2012 Dec;44(12):2321-32. doi: 10.1016/j.biocel.2012.08.006. Epub 2012 Aug 10.
REF00001112	Molecular cloning and functional characterization of an ATP-binding cassette transporter OtrC from Streptomyces rimosus. BMC Biotechnol. 2012 Aug 20;12:52. doi: 10.1186/1472-6750-12-52.
REF00001113	Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. Cancer Res. 2012 Nov 15;72(22):5945-55. doi: 10.1158/0008-5472.CAN-12-1400. Epub 2012 Aug 31.
REF00001114	"Drug resistance-conferring mutations in Mycobacterium tuberculosis from Madang, Papua New Guinea. BMC Microbiol. 2012 Sep 4;12:191. doi: 10.1186/1471-2180-12-191."
REF00001115	Genotypic and phenotypic evaluation of the evolution of high-level daptomycin nonsusceptibility in vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother. 2012 Nov;56(11):6051-3. doi: 10.1128/AAC.01318-12. Epub 2012 Sep 4.
REF00001116	"MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN. Mol Cell Biochem. 2013 Jan;372(1-2):35-45. doi: 10.1007/s11010-012-1443-3. Epub 2012 Sep 6."
REF00001117	Triptolide modulates the sensitivity of K562/A02 cells to adriamycin by regulating miR-21 expression. Pharm Biol. 2012 Oct;50(10):1233-40. doi: 10.3109/13880209.2012.665931.
REF00001118	Methylation mediated silencing of miR-23b expression and its role in glioma stem cells. Neurosci Lett. 2012 Oct 24;528(2):185-9. doi: 10.1016/j.neulet.2012.08.055. Epub 2012 Sep 5.
REF00001119	Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI. Anticancer Res. 2012 Sep;32(9):3785-90.
REF00001120	MiR-155 inhibits the sensitivity of lung cancer cells to cisplatin via negative regulation of Apaf-1 expression. Cancer Gene Ther. 2012 Nov;19(11):773-8. doi: 10.1038/cgt.2012.60. Epub 2012 Sep 21.
REF00001121	MiR-296-3p regulates cell growth and multi-drug resistance of human glioblastoma by targeting ether-a-go-go (EAG1). Eur J Cancer. 2013 Feb;49(3):710-24. doi: 10.1016/j.ejca.2012.08.020. Epub 2012 Sep 18.
REF00001122	Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance. Clin Microbiol Rev. 2012 Oct;25(4):661-81. doi: 10.1128/CMR.00043-12.
REF00001123	microRNA-34a sensitizes lung cancer cell lines to DDP treatment independent of p53 status. Cancer Biother Radiopharm. 2013 Feb;28(1):45-50. doi: 10.1089/cbr.2012.1218. Epub 2012 Oct 4.
REF00001124	Adrenaline promotes cell proliferation and increases chemoresistance in colon cancer HT29 cells through induction of miR-155. Biochem Biophys Res Commun. 2012 Nov 16;428(2):210-5. doi: 10.1016/j.bbrc.2012.09.126. Epub 2012 Oct 1.
REF00001125	Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am J Pathol. 2012 Dec;181(6):2188-201. doi: 10.1016/j.ajpath.2012.08.011. Epub 2012 Oct 3.
REF00001126	Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. Am J Hematol. 2012 Nov;87(11):E125-8. doi: 10.1002/ajh.23338. Epub 2012 Oct 9.
REF00001127	miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene. 2013 Sep 5;32(36):4284-93. doi: 10.1038/onc.2012.433. Epub 2012 Oct 8.
REF00001128	Genetic markers of widespread extensively drug-resistant Pseudomonas aeruginosa high-risk clones. Antimicrob Agents Chemother. 2012 Dec;56(12):6349-57. doi: 10.1128/AAC.01388-12. Epub 2012 Oct 8.
REF00001129	Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia. Ann Hematol. 2013 Jan;92(2):179-83. doi: 10.1007/s00277-012-1591-2. Epub 2012 Oct 10.
REF00001130	Impact of amino acid substitutions in B subunit of DNA gyrase in Mycobacterium leprae on fluoroquinolone resistance. PLoS Negl Trop Dis. 2012;6(10):e1838. doi: 10.1371/journal.pntd.0001838. Epub 2012 Oct 11.
REF00001131	miRNA profiling in pancreatic cancer and restoration of chemosensitivity. Cancer Lett. 2013 Jul 1;334(2):211-20. doi: 10.1016/j.canlet.2012.10.008. Epub 2012 Oct 13.
REF00001132	Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel. Mol Cancer Ther. 2012 Dec;11(12):2556-65. doi: 10.1158/1535-7163.MCT-12-0463. Epub 2012 Oct 16.
REF00001133	Micro-RNA-21 regulates the sensitivity to cisplatin in human neuroblastoma cells. J Pediatr Surg. 2012 Oct;47(10):1797-805. doi: 10.1016/j.jpedsurg.2012.05.013.
REF00001134	MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting Notch1. Arch Med Res. 2012 Oct;43(7):514-21. doi: 10.1016/j.arcmed.2012.09.007. Epub 2012 Oct 16.
REF00001135	"miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer. Oncogene. 2013 Sep 26;32(39):4694-701. doi: 10.1038/onc.2012.483. Epub 2012 Oct 22."
REF00001136	Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood. 2012 Oct 18;120(16):3382-3. doi: 10.1182/blood-2012-04-424192.
REF00001137	Comparative genomics of IncL/M-type plasmids: evolution by acquisition of resistance genes and insertion sequences. Antimicrob Agents Chemother. 2013 Jan;57(1):674-6. doi: 10.1128/AAC.01086-12. Epub 2012 Oct 31.
REF00001138	Biochemical characterization of cardiolipin synthase mutations associated with daptomycin resistance in enterococci. Antimicrob Agents Chemother. 2013 Jan;57(1):289-96. doi: 10.1128/AAC.01743-12. Epub 2012 Oct 31.
REF00001139	HBVdb: a knowledge database for Hepatitis B Virus. Nucleic Acids Res. 2013 Jan;41(Database issue):D566-70. doi: 10.1093/nar/gks1022. Epub 2012 Nov 3.
REF00001140	Novel aminoglycoside 2''-phosphotransferase identified in a gram-negative pathogen. Antimicrob Agents Chemother. 2013 Jan;57(1):452-7. doi: 10.1128/AAC.02049-12. Epub 2012 Nov 5.
REF00001141	CBDCA + Pemetrexed + Bevacizumab and Its Maintenance Chemotherapy in a Case of Solitary Breast Metastasis from a Lung Adenocarcinoma Resistant to Gefitinib. Case Rep Oncol. 2012 Sep;5(3):546-53. doi: 10.1159/000343678. Epub 2012 Oct 10.
REF00001142	MicroRNA-29c enhances the sensitivities of human nasopharyngeal carcinoma to cisplatin-based chemotherapy and radiotherapy. Cancer Lett. 2013 Feb 1;329(1):91-8. doi: 10.1016/j.canlet.2012.10.033. Epub 2012 Nov 8.
REF00001143	miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer. Cell Death Dis. 2012 Nov 15;3(11):e423. doi: 10.1038/cddis.2012.160.
REF00001144	Low prevalence of Pneumocystis pneumonia (PCP) but high prevalence of pneumocystis dihydropteroate synthase (dhps) gene mutations in HIV-infected persons in Uganda. PLoS One. 2012;7(11):e49991. doi: 10.1371/journal.pone.0049991. Epub 2012 Nov 16.
REF00001145	"The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL. Mol Oncol. 2013 Jun;7(3):334-45. doi: 10.1016/j.molonc.2012.10.011. Epub 2012 Nov 7."
REF00001146	miR-137 restoration sensitizes multidrug-resistant MCF-7/ADM cells to anticancer agents by targeting YB-1. Acta Biochim Biophys Sin (Shanghai). 2013 Feb;45(2):80-6. doi: 10.1093/abbs/gms099. Epub 2012 Nov 23.
REF00001147	Restriction endonuclease-mediated real-time digestion-PCR for somatic mutation detection. Int J Cancer. 2013 Jun 15;132(12):2858-66. doi: 10.1002/ijc.27968. Epub 2012 Dec 13.
REF00001148	Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012 Nov 29;367(22):2075-88. doi: 10.1056/NEJMoa1205127.
REF00001149	LysR family activator-regulated major facilitator superfamily transporters are involved in Vibrio cholerae antimicrobial compound resistance and intestinal colonisation. Int J Antimicrob Agents. 2013 Feb;41(2):188-92. doi: 10.1016/j.ijantimicag.2012.10.008. Epub 2012 Nov 30.
REF00001150	A possible role for microRNA-141 down-regulation in sunitinib resistant metastatic clear cell renal cell carcinoma through induction of epithelial-to-mesenchymal transition and hypoxia resistance. J Urol. 2013 May;189(5):1930-8. doi: 10.1016/j.juro.2012.11.133. Epub 2012 Nov 30.
REF00001151	miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression. PLoS One. 2012;7(11):e50469. doi: 10.1371/journal.pone.0050469. Epub 2012 Nov 29.
REF00001152	BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood. 2013 Jan 17;121(3):489-98. doi: 10.1182/blood-2012-05-431379. Epub 2012 Dec 5.
REF00001153	Discovery of a HapE mutation that causes azole resistance in Aspergillus fumigatus through whole genome sequencing and sexual crossing. PLoS One. 2012;7(11):e50034. doi: 10.1371/journal.pone.0050034. Epub 2012 Nov 30.
REF00001154	Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines. Oncol Rep. 2013 Feb;29(2):555-62. doi: 10.3892/or.2012.2155. Epub 2012 Nov 28.
REF00001155	Glutathione transport: a new role for PfCRT in chloroquine resistance. Antioxid Redox Signal. 2013 Sep 1;19(7):683-95. doi: 10.1089/ars.2012.4625. Epub 2012 Dec 20.
REF00001156	MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen. Int J Hematol. 2013 Feb;97(2):223-31. doi: 10.1007/s12185-012-1256-x. Epub 2012 Dec 30.
REF00001157	Increased anaerobic metabolism is a distinctive signature in a colorectal cancer cellular model of resistance to antiepidermal growth factor receptor antibody. Proteomics. 2013 Mar;13(5):866-77. doi: 10.1002/pmic.201200303. Epub 2013 Jan 24.
REF00001158	Up-regulated miR155 reverses the epithelial-mesenchymal transition induced by EGF and increases chemo-sensitivity to cisplatin in human Caski cervical cancer cells. PLoS One. 2012;7(12):e52310. doi: 10.1371/journal.pone.0052310. Epub 2012 Dec 20.
REF00001159	MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. Oncogene. 2014 Jan 16;33(3):378-86. doi: 10.1038/onc.2012.575. Epub 2013 Jan 14.
REF00001160	MiR-125a/b regulates the activation of cancer stem cells in paclitaxel-resistant colon cancer. Cancer Invest. 2013 Jan;31(1):17-23. doi: 10.3109/07357907.2012.743557.
REF00001161	MiR-214 reduces cell survival and enhances cisplatin-induced cytotoxicity via down-regulation of Bcl2l2 in cervical cancer cells. FEBS Lett. 2013 Mar 1;587(5):488-95. doi: 10.1016/j.febslet.2013.01.016. Epub 2013 Jan 18.
REF00001162	MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun. 2013;4:1393. doi: 10.1038/ncomms2393.
REF00001163	Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. J Thorac Oncol. 2013 Apr;8(4):415-22. doi: 10.1097/JTO.0b013e318283dcc0.
REF00001164	Dedifferentiation in gastrointestinal stromal tumor to an anaplastic KIT-negative phenotype: a diagnostic pitfall: morphologic and molecular characterization of 8 cases occurring either de novo or after imatinib therapy. Am J Surg Pathol. 2013 Mar;37(3):385-92. doi: 10.1097/PAS.0b013e31826c1761.
REF00001165	Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients. Hematol Rep. 2012 Nov 19;4(4):e23. doi: 10.4081/hr.2012.e23. Epub 2012 Nov 23.
REF00001166	MicroRNA-31 sensitizes human breast cells to apoptosis by direct targeting of protein kinase C epsilon (PKCepsilon). J Biol Chem. 2013 Mar 22;288(12):8750-8761. doi: 10.1074/jbc.M112.414128. Epub 2013 Jan 30.
REF00001167	MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. PLoS One. 2013;8(1):e53906. doi: 10.1371/journal.pone.0053906. Epub 2013 Jan 23.
REF00001168	Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat Genet. 2013 Mar;45(3):290-4. doi: 10.1038/ng.2558. Epub 2013 Feb 3.
REF00001169	"Rapid selection of Plasmodium falciparum chloroquine resistance transporter gene and multidrug resistance gene-1 haplotypes associated with past chloroquine and present artemether-lumefantrine use in Inhambane District, southern Mozambique. Am J Trop Med Hyg. 2013 Mar;88(3):536-41. doi: 10.4269/ajtmh.12-0525. Epub 2013 Feb 4."
REF00001170	"Detection of tripoli metallo-Beta-lactamase 2 (TMB-2), a variant of blaTMB-1, in clinical isolates of Acinetobacter spp. in Japan. J Antimicrob Chemother. 2013 Jun;68(6):1441-2. doi: 10.1093/jac/dkt031. Epub 2013 Feb 6."
REF00001171	The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013 Jun;27(6):1416-8. doi: 10.1038/leu.2013.14. Epub 2013 Jan 16.
REF00001172	Does T790M disappear  Successful gefitinib rechallenge after T790M disappearance in a patient with EGFR-mutant non-small-cell lung cancer. J Thorac Oncol. 2013 Mar;8(3):e27-9. doi: 10.1097/JTO.0b013e318282e047.
REF00001173	Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel. Cancer Chemother Pharmacol. 2013 May;71(5):1159-71. doi: 10.1007/s00280-013-2108-y. Epub 2013 Feb 20.
REF00001174	Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors. Med Clin (Barc). 2013 Aug 4;141(3):95-9. doi: 10.1016/j.medcli.2012.10.028. Epub 2013 Feb 22.
REF00001175	Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment. Genomics. 2013 Sep;102(3):157-62. doi: 10.1016/j.ygeno.2013.02.006. Epub 2013 Feb 20.
REF00001176	The overexpression of hypomethylated miR-663 induces chemotherapy resistance in human breast cancer cells by targeting heparin sulfate proteoglycan 2 (HSPG2). J Biol Chem. 2013 Apr 19;288(16):10973-85. doi: 10.1074/jbc.M112.434340. Epub 2013 Feb 22.
REF00001177	"MiR-138 and MiR-135 directly target focal adhesion kinase, inhibit cell invasion, and increase sensitivity to chemotherapy in cancer cells. Anticancer Agents Med Chem. 2014 Jan;14(1):18-28. doi: 10.2174/187152061401140108113435."
REF00001178	miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2. Oncol Rep. 2013 May;29(5):1769-76. doi: 10.3892/or.2013.2297. Epub 2013 Feb 21.
REF00001179	MiR-218 impairs tumor growth and increases chemo-sensitivity to cisplatin in cervical cancer. Int J Mol Sci. 2012 Nov 28;13(12):16053-64. doi: 10.3390/ijms131216053.
REF00001180	Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors. Med Oncol. 2013 Jun;30(2):522. doi: 10.1007/s12032-013-0522-y. Epub 2013 Mar 2.
REF00001181	Undecaprenyl pyrophosphate phosphatase confers low-level resistance to bacitracin in Enterococcus faecalis. J Antimicrob Chemother. 2013 Jul;68(7):1583-93. doi: 10.1093/jac/dkt048. Epub 2013 Mar 3.
REF00001182	miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN. Toxicology. 2013 Apr 5;306:162-8. doi: 10.1016/j.tox.2013.02.014. Epub 2013 Mar 4.
REF00001183	MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology. 2013 Aug;58(2):629-41. doi: 10.1002/hep.26369. Epub 2013 Jun 25.
REF00001184	Erg11 mutations associated with azole resistance in clinical isolates of Candida albicans. FEMS Yeast Res. 2013 Jun;13(4):386-93. doi: 10.1111/1567-1364.12042. Epub 2013 Apr 4.
REF00001185	"Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease. Br J Haematol. 2013 Jun;161(5):748-51. doi: 10.1111/bjh.12291. Epub 2013 Mar 11."
REF00001186	miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor. Cancer Cell Int. 2013 Mar 4;13(1):21. doi: 10.1186/1475-2867-13-21.
REF00001187	Alpha-Lipoic acid-induced inhibition of proliferation and met phosphorylation in human non-small cell lung cancer cells. Cancer Lett. 2013 Jul 28;335(2):472-8. doi: 10.1016/j.canlet.2013.03.008. Epub 2013 Mar 16.
REF00001188	Identification of the novel spectinomycin resistance gene spw in methicillin-resistant and methicillin-susceptible Staphylococcus aureus of human and animal origin. J Antimicrob Chemother. 2013 Jul;68(7):1679-80. doi: 10.1093/jac/dkt081. Epub 2013 Mar 19.
REF00001189	MicroRNA-195 chemosensitizes colon cancer cells to the chemotherapeutic drug doxorubicin by targeting the first binding site of BCL2L2 mRNA. J Cell Physiol. 2015 Mar;230(3):535-45. doi: 10.1002/jcp.24366.
REF00001190	Downregulation of miRNA-128 sensitises breast cancer cell to chemodrugs by targeting Bax. Cell Biol Int. 2013 Jul;37(7):653-8. doi: 10.1002/cbin.10100. Epub 2013 May 8.
REF00001191	cMyc/miR-125b-5p signalling determines sensitivity to bortezomib in preclinical model of cutaneous T-cell lymphomas. PLoS One. 2013;8(3):e59390. doi: 10.1371/journal.pone.0059390. Epub 2013 Mar 19.
REF00001192	Dual-functioning antimalarials that inhibit the chloroquine-resistance transporter. Future Microbiol. 2013 Apr;8(4):475-89. doi: 10.2217/fmb.13.18.
REF00001193	Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells. Cancer Res. 2013 May 15;73(10):3051-61. doi: 10.1158/0008-5472.CAN-12-4136. Epub 2013 Mar 29.
REF00001194	Correlation of MTDH/AEG-1 and HOTAIR Expression with Metastasis and Response to Treatment in Sarcoma Patients. J Cancer Sci Ther. 2011 Dec 29;S5(4):004.
REF00001195	miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling. Mol Med Rep. 2013 May;7(5):1579-84. doi: 10.3892/mmr.2013.1403. Epub 2013 Mar 28.
REF00001196	Identification of ovarian cancer metastatic miRNAs. PLoS One. 2013;8(3):e58226. doi: 10.1371/journal.pone.0058226. Epub 2013 Mar 12.
REF00001197	"Additional routes to Staphylococcus aureus daptomycin resistance as revealed by comparative genome sequencing, transcriptional profiling, and phenotypic studies. PLoS One. 2013;8(3):e58469. doi: 10.1371/journal.pone.0058469. Epub 2013 Mar 15."
REF00001198	Let-7c governs the acquisition of chemo- or radioresistance and epithelial-to-mesenchymal transition phenotypes in docetaxel-resistant lung adenocarcinoma. Mol Cancer Res. 2013 Jul;11(7):699-713. doi: 10.1158/1541-7786.MCR-13-0019-T. Epub 2013 Apr 5.
REF00001199	Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013 May 2;497(7447):108-12. doi: 10.1038/nature12065. Epub 2013 Apr 7.
REF00001200	MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers. Cell Cycle. 2013 May 1;12(9):1385-94. doi: 10.4161/cc.24477. Epub 2013 Apr 8.
REF00001201	Repeated favorable responses to epidermal growth factor receptor-tyrosine kinase inhibitors in a case of advanced lung adenocarcinoma. Tuberc Respir Dis (Seoul). 2013 Mar;74(3):129-33. doi: 10.4046/trd.2013.74.3.129. Epub 2013 Mar 29.
REF00001202	Evolution of high-level daptomycin resistance in Enterococcus faecium during daptomycin therapy is associated with limited mutations in the bacterial genome. J Antimicrob Chemother. 2013 Aug;68(8):1926-8. doi: 10.1093/jac/dkt117. Epub 2013 Apr 11.
REF00001203	Identification of amino acids conferring high-level resistance to expanded-spectrum cephalosporins in the penA gene from Neisseria gonorrhoeae strain H041. Antimicrob Agents Chemother. 2013 Jul;57(7):3029-36. doi: 10.1128/AAC.00093-13. Epub 2013 Apr 15.
REF00001204	MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun. 2013 May 10;434(3):688-94. doi: 10.1016/j.bbrc.2013.04.010. Epub 2013 Apr 16.
REF00001205	miR-125b regulates side population in breast cancer and confers a chemoresistant phenotype. J Cell Biochem. 2013 Oct;114(10):2248-57. doi: 10.1002/jcb.24574.
REF00001206	Inhibition of BCR/ABL protein expression by miR-203 sensitizes for imatinib mesylate. PLoS One. 2013 Apr 16;8(4):e61858. doi: 10.1371/journal.pone.0061858. Print 2013.
REF00001207	"MiR-142-3p functions as a tumor suppressor by targeting CD133, ABCG2, and Lgr5 in colon cancer cells. J Mol Med (Berl). 2013 Aug;91(8):989-1000. doi: 10.1007/s00109-013-1037-x. Epub 2013 Apr 26."
REF00001208	MicroRNA-302a sensitizes testicular embryonal carcinoma cells to cisplatin-induced cell death. J Cell Physiol. 2013 Dec;228(12):2294-304. doi: 10.1002/jcp.24394.
REF00001209	miR-135a/b modulate cisplatin resistance of human lung cancer cell line by targeting MCL1. Pathol Oncol Res. 2013 Oct;19(4):677-83. doi: 10.1007/s12253-013-9630-4. Epub 2013 May 3.
REF00001210	miR-181b modulates glioma cell sensitivity to temozolomide by targeting MEK1. Cancer Chemother Pharmacol. 2013 Jul;72(1):147-58. doi: 10.1007/s00280-013-2180-3. Epub 2013 May 5.
REF00001211	CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. J Clin Invest. 2013 Jun;123(6):2395-407. doi: 10.1172/JCI66553. Epub 2013 May 8.
REF00001212	Long non-coding RNA GAS5 regulates apoptosis in prostate cancer cell lines. Biochim Biophys Acta. 2013 Oct;1832(10):1613-23. doi: 10.1016/j.bbadis.2013.05.005. Epub 2013 May 12.
REF00001213	Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib. Hematology. 2013 Nov;18(6):328-33. doi: 10.1179/1607845413Y.0000000095. Epub 2013 May 8.
REF00001214	Small nucleolar RNA-derived microRNA hsa-miR-1291 modulates cellular drug disposition through direct targeting of ABC transporter ABCC1. Drug Metab Dispos. 2013 Oct;41(10):1744-51. doi: 10.1124/dmd.113.052092. Epub 2013 May 16.
REF00001215	Mir-375 enhances ruthenium-derived compound Rawq01 induced cell death in human ovarian cancer. Int J Clin Exp Pathol. 2013 May 15;6(6):1095-102. Print 2013.
REF00001216	Prediction value of miR-483 and miR-214 in prognosis and multidrug resistance of esophageal squamous cell carcinoma. Genet Test Mol Biomarkers. 2013 Jun;17(6):470-4. doi: 10.1089/gtmb.2012.0518. Epub 2013 May 13.
REF00001217	Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 2013 Jun;3(6):658-73. doi: 10.1158/2159-8290.CD-12-0558. Epub 2013 Jun 2.
REF00001218	The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in non-small-cell lung cancer cell. PLoS One. 2013 May 31;8(5):e65309. doi: 10.1371/journal.pone.0065309. Print 2013.
REF00001219	miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer. Cell Death Dis. 2013 Jun 6;4(6):e659. doi: 10.1038/cddis.2013.193.
REF00001220	Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer. Cancer Discov. 2013 Sep;3(9):1058-71. doi: 10.1158/2159-8290.CD-12-0569. Epub 2013 Jun 6.
REF00001221	MiR-26a inhibits proliferation and migration of breast cancer through repression of MCL-1. PLoS One. 2013 Jun 4;8(6):e65138. doi: 10.1371/journal.pone.0065138. Print 2013.
REF00001222	Distinction between the Cfr methyltransferase conferring antibiotic resistance and the housekeeping RlmN methyltransferase. Antimicrob Agents Chemother. 2013 Aug;57(8):4019-26. doi: 10.1128/AAC.00448-13. Epub 2013 Jun 10.
REF00001223	MicroRNA 223 is upregulated in the multistep progression of Barrett's esophagus and modulates sensitivity to chemotherapy by targeting PARP1. Clin Cancer Res. 2013 Aug 1;19(15):4067-78. doi: 10.1158/1078-0432.CCR-13-0601. Epub 2013 Jun 11.
REF00001224	Upregulation of miR-195 increases the sensitivity of breast cancer cells to Adriamycin treatment through inhibition of Raf-1. Oncol Rep. 2013 Aug;30(2):877-89. doi: 10.3892/or.2013.2532. Epub 2013 Jun 11.
REF00001225	MicroRNA-200a/b influenced the therapeutic effects of curcumin in hepatocellular carcinoma (HCC) cells. Tumour Biol. 2013 Oct;34(5):3209-18. doi: 10.1007/s13277-013-0891-z. Epub 2013 Jun 13.
REF00001226	miR-375 is upregulated in acquired paclitaxel resistance in cervical cancer. Br J Cancer. 2013 Jul 9;109(1):92-9. doi: 10.1038/bjc.2013.308. Epub 2013 Jun 18.
REF00001227	MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2). Breast Cancer Res Treat. 2013 Jun;139(3):717-30. doi: 10.1007/s10549-013-2607-x. Epub 2013 Jun 19.
REF00001228	"microRNA-17 regulates the expression of ATG7 and modulates the autophagy process, improving the sensitivity to temozolomide and low-dose ionizing radiation treatments in human glioblastoma cells. Cancer Biol Ther. 2013 Jul;14(7):574-86. doi: 10.4161/cbt.24597. Epub 2013 May 10."
REF00001229	BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance. Br J Cancer. 2013 Sep 17;109(6):1593-8. doi: 10.1038/bjc.2013.318. Epub 2013 Jun 25.
REF00001230	miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1. Br J Cancer. 2013 Jul 23;109(2):502-11. doi: 10.1038/bjc.2013.320. Epub 2013 Jun 25.
REF00001231	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013 Aug 8;122(6):872-84. doi: 10.1182/blood-2013-05-501569. Epub 2013 Jun 26.
REF00001232	Let-7b expression determines response to chemotherapy through the regulation of cyclin D1 in glioblastoma. J Exp Clin Cancer Res. 2013 Jun 27;32(1):41. doi: 10.1186/1756-9966-32-41.
REF00001233	Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer. Br J Cancer. 2013 Jul 23;109(2):452-61. doi: 10.1038/bjc.2013.305. Epub 2013 Jun 27.
REF00001234	"miR-381, a novel intrinsic WEE1 inhibitor, sensitizes renal cancer cells to 5-FU by up-regulation of Cdc2 activities in 786-O. J Chemother. 2013 Aug;25(4):229-38. doi: 10.1179/1973947813Y.0000000092. Epub 2013 May 7."
REF00001235	MicroRNA-200c regulates the sensitivity of chemotherapy of gastric cancer SGC7901/DDP cells by directly targeting RhoE. Pathol Oncol Res. 2014 Jan;20(1):93-8. doi: 10.1007/s12253-013-9664-7. Epub 2013 Jul 3.
REF00001236	"Genetic basis for in vitro and in vivo resistance to lincosamides, streptogramins A, and pleuromutilins (LSAP phenotype) in Enterococcus faecium. Antimicrob Agents Chemother. 2013 Sep;57(9):4463-9. doi: 10.1128/AAC.01030-13. Epub 2013 Jul 8."
REF00001237	Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013 Aug;10(8):472-84. doi: 10.1038/nrclinonc.2013.110. Epub 2013 Jul 9.
REF00001238	Circulating miR-200c levels significantly predict response to chemotherapy and prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer. Ann Surg Oncol. 2013 Dec;20 Suppl 3:S607-15. doi: 10.1245/s10434-013-3093-4. Epub 2013 Jul 10.
REF00001239	miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2. Int J Mol Med. 2013 Sep;32(3):593-8. doi: 10.3892/ijmm.2013.1439. Epub 2013 Jul 12.
REF00001240	miR-125b inhibitor may enhance the invasion-prevention activity of temozolomide in glioblastoma stem cells by targeting PIAS3. BioDrugs. 2014 Feb;28(1):41-54. doi: 10.1007/s40259-013-0053-2.
REF00001241	MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment. Technol Cancer Res Treat. 2014 Feb;13(1):77-86. doi: 10.7785/tcrt.2012.500364. Epub 2013 Jul 11.
REF00001242	Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia. Mol Cytogenet. 2013 Jul 16;6(1):27. doi: 10.1186/1755-8166-6-27.
REF00001243	MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2). Cancer Lett. 2013 Oct 1;339(1):107-15. doi: 10.1016/j.canlet.2013.07.016. Epub 2013 Jul 20.
REF00001244	Highly sensitive and noninvasive detection of epidermal growth factor receptor T790M mutation in non-small cell lung cancer. Clin Chim Acta. 2013 Oct 21;425:119-24. doi: 10.1016/j.cca.2013.07.012. Epub 2013 Jul 23.
REF00001245	"In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin. J Antimicrob Chemother. 2014 Jan;69(1):41-4. doi: 10.1093/jac/dkt302. Epub 2013 Jul 25."
REF00001246	Deregulated MIR335 that targets MAPK1 is implicated in poor outcome of paediatric acute lymphoblastic leukaemia. Br J Haematol. 2013 Oct;163(1):93-103. doi: 10.1111/bjh.12489. Epub 2013 Jul 25.
REF00001247	miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1. Oncogene. 2014 Jun 19;33(25):3267-76. doi: 10.1038/onc.2013.297. Epub 2013 Jul 29.
REF00001248	MicroRNA-29a induces resistance to gemcitabine through the Wnt/Beta-catenin signaling pathway in pancreatic cancer cells. Int J Oncol. 2013 Oct;43(4):1066-72. doi: 10.3892/ijo.2013.2037. Epub 2013 Jul 24.
REF00001249	Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells. Int J Cancer. 2014 Feb 1;134(3):542-51. doi: 10.1002/ijc.28399. Epub 2013 Aug 28.
REF00001250	MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells. J Huazhong Univ Sci Technolog Med Sci. 2013 Aug;33(4):567-572. doi: 10.1007/s11596-013-1160-5. Epub 2013 Aug 1.
REF00001251	"Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer. Int J Clin Oncol. 2014 Aug;19(4):594-600. doi: 10.1007/s10147-013-0602-1. Epub 2013 Aug 6."
REF00001252	"MiR-125b, miR-100 and miR-99a co-regulate vincristine resistance in childhood acute lymphoblastic leukemia. Leuk Res. 2013 Oct;37(10):1315-21. doi: 10.1016/j.leukres.2013.06.027. Epub 2013 Jul 31."
REF00001253	Involvement of miR-20a in promoting gastric cancer progression by targeting early growth response 2 (EGR2). Int J Mol Sci. 2013 Aug 6;14(8):16226-39. doi: 10.3390/ijms140816226.
REF00001254	MiR-223 modulates multidrug resistance via downregulation of ABCB1 in hepatocellular carcinoma cells. Exp Biol Med (Maywood). 2013 Sep;238(9):1024-32. doi: 10.1177/1535370213497321. Epub 2013 Aug 7.
REF00001255	MicroRNA-106a induces multidrug resistance in gastric cancer by targeting RUNX3. FEBS Lett. 2013 Sep 17;587(18):3069-75. doi: 10.1016/j.febslet.2013.06.058. Epub 2013 Aug 8.
REF00001256	miR-137 regulates the constitutive androstane receptor and modulates doxorubicin sensitivity in parental and doxorubicin-resistant neuroblastoma cells. Oncogene. 2014 Jul 10;33(28):3717-29. doi: 10.1038/onc.2013.330. Epub 2013 Aug 12.
REF00001257	Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing. J Antimicrob Chemother. 2014 Jan;69(1):12-20. doi: 10.1093/jac/dkt316. Epub 2013 Aug 9.
REF00001258	Genistein inhibits prostate cancer cell growth by targeting miR-34a and oncogenic HOTAIR. PLoS One. 2013 Aug 1;8(8):e70372. doi: 10.1371/journal.pone.0070372. Print 2013.
REF00001259	miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance. Cancer Res. 2013 Nov 1;73(21):6435-47. doi: 10.1158/0008-5472.CAN-12-3308. Epub 2013 Aug 15.
REF00001260	Identification and characterization of a novel aac(6')-Iag associated with the blaIMP-1-integron in a multidrug-resistant Pseudomonas aeruginosa. PLoS One. 2013 Aug 12;8(8):e70557. doi: 10.1371/journal.pone.0070557. eCollection 2013.
REF00001261	Adaptation of Enterococcus faecalis to daptomycin reveals an ordered progression to resistance. Antimicrob Agents Chemother. 2013 Nov;57(11):5373-83. doi: 10.1128/AAC.01473-13. Epub 2013 Aug 19.
REF00001262	Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia. Clin Cancer Res. 2013 Oct 15;19(20):5758-68. doi: 10.1158/1078-0432.CCR-13-1323. Epub 2013 Aug 22.
REF00001263	Iron metabolism disturbances in the MCF-7 human breast cancer cells with acquired resistance to doxorubicin and cisplatin. Int J Oncol. 2013 Nov;43(5):1481-6. doi: 10.3892/ijo.2013.2063. Epub 2013 Aug 20.
REF00001264	"[miR-126 inhibits colon cancer proliferation and invasion through targeting IRS1, SLC7A5 and TOM1 gene]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2013 Aug;38(8):809-17. doi: 10.3969/j.issn.1672-7347.2013.08.009."
REF00001265	MicroRNA-650 was a prognostic factor in human lung adenocarcinoma and confers the docetaxel chemoresistance of lung adenocarcinoma cells via regulating Bcl-2/Bax expression. PLoS One. 2013 Aug 21;8(8):e72615. doi: 10.1371/journal.pone.0072615. eCollection 2013.
REF00001266	MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells. Gene. 2013 Nov 15;531(1):8-14. doi: 10.1016/j.gene.2013.08.062. Epub 2013 Aug 29.
REF00001267	Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2013 Nov;57(11):5649-57. doi: 10.1128/AAC.01536-13. Epub 2013 Sep 3.
REF00001268	"Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness. Oncotarget. 2013 Sep;4(9):1399-415. doi: 10.18632/oncotarget.1202."
REF00001269	Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib. Mol Cancer Ther. 2013 Nov;12(11):2541-58. doi: 10.1158/1535-7163.MCT-13-0170. Epub 2013 Sep 11.
REF00001270	Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors. Lung Cancer. 2013 Nov;82(2):294-8. doi: 10.1016/j.lungcan.2013.08.023. Epub 2013 Sep 3.
REF00001271	miR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper-transporting P-type adenosine triphosphatase A (ATP7A). J Cell Biochem. 2014 Jul;115(7):1234-42. doi: 10.1002/jcb.24665.
REF00001272	Induction of the unfolded protein response drives enhanced metabolism and chemoresistance in glioma cells. PLoS One. 2013 Aug 15;8(8):e73267. doi: 10.1371/journal.pone.0073267. eCollection 2013.
REF00001273	A Bmi1-miRNAs cross-talk modulates chemotherapy response to 5-fluorouracil in breast cancer cells. PLoS One. 2013 Sep 9;8(9):e73268. doi: 10.1371/journal.pone.0073268. eCollection 2013.
REF00001274	Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 2013 Sep 26;4(6):1116-30. doi: 10.1016/j.celrep.2013.08.022. Epub 2013 Sep 19.
REF00001275	miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway. Tumour Biol. 2014 Feb;35(2):1287-95. doi: 10.1007/s13277-013-1171-7. Epub 2013 Sep 26.
REF00001276	Involvement of microRNA-181b in the gemcitabine resistance of pancreatic cancer cells. Pancreatology. 2013 Sep-Oct;13(5):517-23. doi: 10.1016/j.pan.2013.06.007. Epub 2013 Jun 28.
REF00001277	"miR-205 promotes the growth, metastasis and chemoresistance of NSCLC cells by targeting PTEN. Oncol Rep. 2013 Dec;30(6):2897-902. doi: 10.3892/or.2013.2755. Epub 2013 Sep 30."
REF00001278	Systematic screen identifies miRNAs that target RAD51 and RAD51D to enhance chemosensitivity. Mol Cancer Res. 2013 Dec;11(12):1564-73. doi: 10.1158/1541-7786.MCR-13-0292. Epub 2013 Oct 2.
REF00001279	"MiR-92b regulates the cell growth, cisplatin chemosensitivity of A549 non small cell lung cancer cell line and target PTEN. Biochem Biophys Res Commun. 2013 Nov 1;440(4):604-10. doi: 10.1016/j.bbrc.2013.09.111. Epub 2013 Oct 4."
REF00001280	MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9. Cancer Lett. 2014 Feb 28;343(2):249-57. doi: 10.1016/j.canlet.2013.09.034. Epub 2013 Oct 4.
REF00001281	Deregulation of let-7e in epithelial ovarian cancer promotes the development of resistance to cisplatin. Oncogenesis. 2013 Oct 7;2(10):e75. doi: 10.1038/oncsis.2013.39.
REF00001282	MiR-23a-mediated inhibition of topoisomerase 1 expression potentiates cell response to etoposide in human hepatocellular carcinoma. Mol Cancer. 2013 Oct 8;12(1):119. doi: 10.1186/1476-4598-12-119.
REF00001283	MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma. Leukemia. 2014 Apr;28(4):880-7. doi: 10.1038/leu.2013.291. Epub 2013 Oct 9.
REF00001284	Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations. Cancer. 2013 Dec 15;119(24):4325-32. doi: 10.1002/cncr.28364. Epub 2013 Sep 16.
REF00001285	miR-106a confers cisplatin resistance by regulating PTEN/Akt pathway in gastric cancer cells. Acta Biochim Biophys Sin (Shanghai). 2013 Nov;45(11):963-72. doi: 10.1093/abbs/gmt106. Epub 2013 Oct 9.
REF00001286	High miR-21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer. Int J Cancer. 2014 Apr 15;134(8):1926-34. doi: 10.1002/ijc.28522. Epub 2013 Nov 8.
REF00001287	The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression. Clin Cancer Res. 2013 Dec 1;19(23):6520-31. doi: 10.1158/1078-0432.CCR-13-0877. Epub 2013 Oct 18.
REF00001288	miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase. Mol Oncol. 2014 Feb;8(1):83-92. doi: 10.1016/j.molonc.2013.09.004. Epub 2013 Oct 8.
REF00001289	Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly. Acta Biochim Biophys Sin (Shanghai). 2013 Dec;45(12):995-1001. doi: 10.1093/abbs/gmt113. Epub 2013 Oct 20.
REF00001290	"miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells. PLoS One. 2013 Oct 17;8(10):e77623. doi: 10.1371/journal.pone.0077623. eCollection 2013."
REF00001291	MiR-370 sensitizes chronic myeloid leukemia K562 cells to homoharringtonine by targeting Forkhead box M1. J Transl Med. 2013 Oct 23;11:265. doi: 10.1186/1479-5876-11-265.
REF00001292	miR-181a-Twist1 pathway in the chemoresistance of tongue squamous cell carcinoma. Biochem Biophys Res Commun. 2013 Nov 15;441(2):364-70. doi: 10.1016/j.bbrc.2013.10.051. Epub 2013 Oct 19.
REF00001293	Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. Ann Oncol. 2013 Dec;24(12):3128-35. doi: 10.1093/annonc/mdt412. Epub 2013 Oct 22.
REF00001294	The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to trastuzumab. Ann Surg Oncol. 2014 Jan;21(1):343-50. doi: 10.1245/s10434-013-3325-7. Epub 2013 Oct 24.
REF00001295	The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregualtion of p21(WAF1/CIP1) expression. PLoS One. 2013 Oct 14;8(10):e77293. doi: 10.1371/journal.pone.0077293. eCollection 2013.
REF00001296	The long non-coding RNA ERIC is regulated by E2F and modulates the cellular response to DNA damage. Mol Cancer. 2013 Oct 29;12(1):131. doi: 10.1186/1476-4598-12-131.
REF00001297	miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition. J Natl Cancer Inst. 2013 Nov 20;105(22):1750-8. doi: 10.1093/jnci/djt302. Epub 2013 Oct 29.
REF00001298	Direct targeting of SUZ12/ROCK2 by miR-200b/c inhibits cholangiocarcinoma tumourigenesis and metastasis. Br J Cancer. 2013 Dec 10;109(12):3092-104. doi: 10.1038/bjc.2013.655. Epub 2013 Oct 29.
REF00001299	MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD. Exp Cell Res. 2014 Jan 1;320(1):12-20. doi: 10.1016/j.yexcr.2013.10.014. Epub 2013 Oct 31.
REF00001300	A novel long non-coding RNA-ARA: adriamycin resistance-associated. Biochem Pharmacol. 2014 Jan 15;87(2):254-83. doi: 10.1016/j.bcp.2013.10.020. Epub 2013 Oct 30.
REF00001301	Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013 Dec;45(12):1446-51. doi: 10.1038/ng.2823. Epub 2013 Nov 3.
REF00001302	ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013 Dec;45(12):1439-45. doi: 10.1038/ng.2822. Epub 2013 Nov 3.
REF00001303	Biological cost of different mechanisms of colistin resistance and their impact on virulence in Acinetobacter baumannii. Antimicrob Agents Chemother. 2014;58(1):518-26. doi: 10.1128/AAC.01597-13. Epub 2013 Nov 4.
REF00001304	Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs. J Hematol Oncol. 2013 Oct 7;6(1):77. doi: 10.1186/1756-8722-6-77.
REF00001305	MicroRNA-29a upregulates MMP2 in oral squamous cell carcinoma to promote cancer invasion and anti-apoptosis. Biomed Pharmacother. 2014 Feb;68(1):13-9. doi: 10.1016/j.biopha.2013.10.005. Epub 2013 Oct 18.
REF00001306	MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity. J Hepatol. 2014 Mar;60(3):590-8. doi: 10.1016/j.jhep.2013.10.028. Epub 2013 Nov 6.
REF00001307	MiR-365 induces gemcitabine resistance in pancreatic cancer cells by targeting the adaptor protein SHC1 and pro-apoptotic regulator BAX. Cell Signal. 2014 Feb;26(2):179-85. doi: 10.1016/j.cellsig.2013.11.003. Epub 2013 Nov 9.
REF00001308	D538G mutation in estrogen receptor-Alpha: A novel mechanism for acquired endocrine resistance in breast cancer. Cancer Res. 2013 Dec 1;73(23):6856-64. doi: 10.1158/0008-5472.CAN-13-1197. Epub 2013 Nov 11.
REF00001309	MiR-320a downregulation is associated with imatinib resistance in gastrointestinal stromal tumors. Acta Biochim Biophys Sin (Shanghai). 2014 Jan;46(1):72-5. doi: 10.1093/abbs/gmt118. Epub 2013 Nov 10.
REF00001310	Overexpression of miR-145 increases the sensitivity of vemurafenib in drug-resistant colo205 cell line. Tumour Biol. 2014 Apr;35(4):2983-8. doi: 10.1007/s13277-013-1383-x. Epub 2013 Nov 19.
REF00001311	MicroRNA-23a antisense enhances 5-fluorouracil chemosensitivity through APAF-1/caspase-9 apoptotic pathway in colorectal cancer cells. J Cell Biochem. 2014 Apr;115(4):772-84. doi: 10.1002/jcb.24721.
REF00001312	Survey of Plasmodium falciparum multidrug resistance-1 and chloroquine resistance transporter alleles in Haiti. Malar J. 2013 Nov 19;12:426. doi: 10.1186/1475-2875-12-426.
REF00001313	MiR-134/487b/655 cluster regulates TGF-Beta-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells. Mol Cancer Ther. 2014 Feb;13(2):444-53. doi: 10.1158/1535-7163.MCT-13-0448. Epub 2013 Nov 20.
REF00001314	The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 2014 Jan;4(1):94-109. doi: 10.1158/2159-8290.CD-13-0617. Epub 2013 Nov 21.
REF00001315	Fulvestrant increases gefitinib sensitivity in non-small cell lung cancer cells by upregulating let-7c expression. Biomed Pharmacother. 2014 Apr;68(3):307-13. doi: 10.1016/j.biopha.2013.10.007. Epub 2013 Nov 7.
REF00001316	Targeting miR-21 enhances the sensitivity of human colon cancer HT-29 cells to chemoradiotherapy in vitro. Biochem Biophys Res Commun. 2014 Jan 17;443(3):789-95. doi: 10.1016/j.bbrc.2013.11.064. Epub 2013 Nov 23.
REF00001317	MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN. BMB Rep. 2014 May;47(5):268-73. doi: 10.5483/bmbrep.2014.47.5.165.
REF00001318	Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014 Jan 17;343(6168):301-5. doi: 10.1126/science.1244851. Epub 2013 Nov 29.
REF00001319	Downregulation of histone deacetylase 1 by microRNA-520h contributes to the chemotherapeutic effect of doxorubicin. FEBS Lett. 2014 Jan 3;588(1):184-91. doi: 10.1016/j.febslet.2013.11.034. Epub 2013 Dec 6.
REF00001320	"miR-200b suppresses cell proliferation, migration and enhances chemosensitivity in prostate cancer by regulating Bmi-1. Oncol Rep. 2014 Feb;31(2):910-8. doi: 10.3892/or.2013.2897. Epub 2013 Dec 5."
REF00001321	p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma. Mol Cancer Res. 2014 Feb;12(2):203-16. doi: 10.1158/1541-7786.MCR-13-0312-T. Epub 2013 Dec 9.
REF00001322	MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer. Lung Cancer. 2014 Feb;83(2):146-53. doi: 10.1016/j.lungcan.2013.11.003. Epub 2013 Nov 13.
REF00001323	The function role of miR-181a in chemosensitivity to adriamycin by targeting Bcl-2 in low-invasive breast cancer cells. Cell Physiol Biochem. 2013;32(5):1225-37. doi: 10.1159/000354521. Epub 2013 Nov 14.
REF00001324	Regulation of autophagy by miR-30d impacts sensitivity of anaplastic thyroid carcinoma to cisplatin. Biochem Pharmacol. 2014 Feb 15;87(4):562-70. doi: 10.1016/j.bcp.2013.12.004. Epub 2013 Dec 15.
REF00001325	microRNA-106a modulates cisplatin sensitivity by targeting PDCD4 in human ovarian cancer cells. Oncol Lett. 2014 Jan;7(1):183-188. doi: 10.3892/ol.2013.1644. Epub 2013 Oct 29.
REF00001326	Downregulation of miR-217 correlates with resistance of Ph(+) leukemia cells to ABL tyrosine kinase inhibitors. Cancer Sci. 2014 Mar;105(3):297-307. doi: 10.1111/cas.12339. Epub 2014 Jan 30.
REF00001327	Quinine dimers are potent inhibitors of the Plasmodium falciparum chloroquine resistance transporter and are active against quinoline-resistant P. falciparum. ACS Chem Biol. 2014 Mar 21;9(3):722-30. doi: 10.1021/cb4008953. Epub 2014 Jan 6.
REF00001328	Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer. BMC Cancer. 2013 Dec 27;13:606. doi: 10.1186/1471-2407-13-606.
REF00001329	miR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells. Biochem Pharmacol. 2014 Feb 15;87(4):579-97. doi: 10.1016/j.bcp.2013.12.009. Epub 2013 Dec 24.
REF00001330	miR-126 Suppresses the proliferation of cervical cancer cells and alters cell sensitivity to the chemotherapeutic drug bleomycin. Asian Pac J Cancer Prev. 2014 Jan;14(11):6569-72. doi: 10.7314/apjcp.2013.14.11.6569.
REF00001331	microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nat Commun. 2014;5:2977. doi: 10.1038/ncomms3977.
REF00001332	Emergence of constitutively active estrogen receptor-Alpha mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res. 2014 Apr 1;20(7):1757-1767. doi: 10.1158/1078-0432.CCR-13-2332. Epub 2014 Jan 7.
REF00001333	[The reversing and molecular mechanisms of miR-503 on the drug-resistance to cisplatin in A549/DDP cells]. Zhongguo Fei Ai Za Zhi. 2014 Jan;17(1):1-7. doi: 10.3779/j.issn.1009-3419.2014.01.01.
REF00001334	miR-223 is a coordinator of breast cancer progression as revealed by bioinformatics predictions. PLoS One. 2014 Jan 6;9(1):e84859. doi: 10.1371/journal.pone.0084859. eCollection 2014.
REF00001335	Identification of a novel plasmid-associated spectinomycin adenyltransferase gene spd in methicillin-resistant Staphylococcus aureus ST398 isolated from animal and human sources. J Antimicrob Chemother. 2014 May;69(5):1193-6. doi: 10.1093/jac/dkt510. Epub 2014 Jan 8.
REF00001336	MicroRNA-137 down-regulates KIT and inhibits small cell lung cancer cell proliferation. Biomed Pharmacother. 2014 Feb;68(1):7-12. doi: 10.1016/j.biopha.2013.12.002. Epub 2013 Dec 24.
REF00001337	Cisplatin-induced epigenetic activation of miR-34a sensitizes bladder cancer cells to chemotherapy. Mol Cancer. 2014 Jan 15;13:8. doi: 10.1186/1476-4598-13-8.
REF00001338	Receptor-interacting protein 1 increases chemoresistance by maintaining inhibitor of apoptosis protein levels and reducing reactive oxygen species through a microRNA-146a-mediated catalase pathway. J Biol Chem. 2014 Feb 28;289(9):5654-63. doi: 10.1074/jbc.M113.526152. Epub 2014 Jan 14.
REF00001339	Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014;5:2997. doi: 10.1038/ncomms3997.
REF00001340	Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP1. Gene. 2014 Apr 1;538(2):342-7. doi: 10.1016/j.gene.2013.12.043. Epub 2014 Jan 19.
REF00001341	MicroRNA-147 induces a mesenchymal-to-epithelial transition (MET) and reverses EGFR inhibitor resistance. PLoS One. 2014 Jan 15;9(1):e84597. doi: 10.1371/journal.pone.0084597. eCollection 2014.
REF00001342	"BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome. Leuk Res. 2014 Apr;38(4):454-9. doi: 10.1016/j.leukres.2013.12.025. Epub 2014 Jan 6."
REF00001343	Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases. Asian Pac J Cancer Prev. 2013;14(12):7421-6. doi: 10.7314/apjcp.2013.14.12.7421.
REF00001344	MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells. Asian Pac J Cancer Prev. 2013;14(12):7529-36. doi: 10.7314/apjcp.2013.14.12.7529.
REF00001345	BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res. 2014 Apr 1;20(7):1965-77. doi: 10.1158/1078-0432.CCR-13-3122. Epub 2014 Jan 24.
REF00001346	miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST. J Exp Clin Cancer Res. 2014 Jan 27;33(1):12. doi: 10.1186/1756-9966-33-12.
REF00001347	Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma. Lung Cancer. 2014 Mar;83(3):374-82. doi: 10.1016/j.lungcan.2013.12.011. Epub 2014 Jan 3.
REF00001348	The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer. Gynecol Oncol. 2014 Mar;132(3):739-44. doi: 10.1016/j.ygyno.2014.01.034. Epub 2014 Jan 25.
REF00001349	"PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res. 2014 Mar 15;74(6):1651-60. doi: 10.1158/0008-5472.CAN-13-3159. Epub 2014 Jan 28."
REF00001350	Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma. PLoS One. 2014 Jan 24;9(1):e86263. doi: 10.1371/journal.pone.0086263. eCollection 2014.
REF00001351	Reversible dimers of the atypical antipsychotic quetiapine inhibit p-glycoprotein-mediated efflux in vitro with increased binding affinity and in situ at the blood-brain barrier. ACS Chem Neurosci. 2014 Apr 16;5(4):305-17. doi: 10.1021/cn4002329. Epub 2014 Feb 7.
REF00001352	Epigenetic silencing of MicroRNA-503 regulates FANCA expression in non-small cell lung cancer cell. Biochem Biophys Res Commun. 2014 Feb 21;444(4):611-6. doi: 10.1016/j.bbrc.2014.01.103. Epub 2014 Jan 31.
REF00001353	Long non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling. FEBS J. 2014 Apr;281(7):1750-8. doi: 10.1111/febs.12737. Epub 2014 Feb 20.
REF00001354	Regulation of expression of abcA and its response to environmental conditions. J Bacteriol. 2014 Apr;196(8):1532-9. doi: 10.1128/JB.01406-13. Epub 2014 Feb 7.
REF00001355	miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6. Int J Cancer. 2014 Sep 15;135(6):1286-96. doi: 10.1002/ijc.28774. Epub 2014 Apr 28.
REF00001356	Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11. Clin Cancer Res. 2014 Apr 1;20(7):1990-2000. doi: 10.1158/1078-0432.CCR-13-2805. Epub 2014 Feb 10.
REF00001357	Involvement of miR-30c in resistance to doxorubicin by regulating YWHAZ in breast cancer cells. Braz J Med Biol Res. 2014 Jan;47(1):60-9. doi: 10.1590/1414-431X20133324. Epub 2014 Jan 10.
REF00001358	Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110). J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):318-26. doi: 10.1097/QAI.0000000000000017.
REF00001359	In-depth analysis shows synergy between erlotinib and miR-34a. PLoS One. 2014 Feb 14;9(2):e89105. doi: 10.1371/journal.pone.0089105. eCollection 2014.
REF00001360	Brain metastasis effectively treated with erlotinib following the acquisition of resistance to gefitinib: a case report. J Med Case Rep. 2014 Feb 20;8:64. doi: 10.1186/1752-1947-8-64.
REF00001361	Downregulation of HOXA1 gene affects small cell lung cancer cell survival and chemoresistance under the regulation of miR-100. Eur J Cancer. 2014 May;50(8):1541-54. doi: 10.1016/j.ejca.2014.01.024. Epub 2014 Feb 19.
REF00001362	Regulation of the expression of the Beta-lactam antibiotic-resistance determinants in methicillin-resistant Staphylococcus aureus (MRSA). Biochemistry. 2014 Mar 18;53(10):1548-50. doi: 10.1021/bi500074w. Epub 2014 Mar 3.
REF00001363	MicroRNA-26b suppresses the NF-kB signaling and enhances the chemosensitivity of hepatocellular carcinoma cells by targeting TAK1 and TAB3. Mol Cancer. 2014 Feb 24;13:35. doi: 10.1186/1476-4598-13-35.
REF00001364	MicroRNA-100 resensitizes resistant chondrosarcoma cells to cisplatin through direct targeting of mTOR. Asian Pac J Cancer Prev. 2014;15(2):917-23. doi: 10.7314/apjcp.2014.15.2.917.
REF00001365	Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R. BMC Cancer. 2014 Feb 26;14:134. doi: 10.1186/1471-2407-14-134.
REF00001366	miR-181 subunits enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeleton remodeling in glioblastoma cells. Med Oncol. 2014 Apr;31(4):892. doi: 10.1007/s12032-014-0892-9. Epub 2014 Feb 27.
REF00001367	miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124. Biochem Biophys Res Commun. 2014 Mar 28;446(1):179-86. doi: 10.1016/j.bbrc.2014.02.073. Epub 2014 Feb 28.
REF00001368	microRNA 125b promotes leukemia cell resistance to daunorubicin by inhibiting apoptosis. Mol Med Rep. 2014 May;9(5):1909-16. doi: 10.3892/mmr.2014.2011. Epub 2014 Mar 6.
REF00001369	MiR-130a overcomes gefitinib resistance by targeting met in non-small cell lung cancer cell lines. Asian Pac J Cancer Prev. 2014;15(3):1391-6. doi: 10.7314/apjcp.2014.15.3.1391.
REF00001370	Hyaluronan-CD44 interaction promotes c-Jun signaling and miRNA21 expression leading to Bcl-2 expression and chemoresistance in breast cancer cells. Mol Cancer. 2014 Mar 8;13:52. doi: 10.1186/1476-4598-13-52.
REF00001371	MiR-21 modulates chemosensitivity of tongue squamous cell carcinoma cells to cisplatin by targeting PDCD4. Mol Cell Biochem. 2014 May;390(1-2):253-62. doi: 10.1007/s11010-014-1976-8. Epub 2014 Mar 11.
REF00001372	MiR-200c suppresses TGF-Beta signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer. Int J Cancer. 2014 Sep 15;135(6):1356-68. doi: 10.1002/ijc.28782. Epub 2014 Mar 3.
REF00001373	Helicobacter pylori modulates cisplatin sensitivity in gastric cancer by down-regulating miR-141 expression. Helicobacter. 2014 Jun;19(3):174-81. doi: 10.1111/hel.12120. Epub 2014 Mar 17.
REF00001374	miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer. Mol Cancer. 2014 Mar 24;13:71. doi: 10.1186/1476-4598-13-71.
REF00001375	Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer. Oncotarget. 2014 Feb 28;5(4):944-58. doi: 10.18632/oncotarget.1458.
REF00001376	Distribution of pfmdr1 polymorphisms in Plasmodium falciparum isolated from Southern Thailand. Malar J. 2014 Mar 27;13:117. doi: 10.1186/1475-2875-13-117.
REF00001377	The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014 Jun;4(6):662-673. doi: 10.1158/2159-8290.CD-13-0846. Epub 2014 Mar 27.
REF00001378	Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML patients. Gene. 2014 Jun 1;542(2):109-12. doi: 10.1016/j.gene.2014.03.049. Epub 2014 Mar 27.
REF00001379	MiR-489 modulates cisplatin resistance in human ovarian cancer cells by targeting Akt3. Anticancer Drugs. 2014 Aug;25(7):799-809. doi: 10.1097/CAD.0000000000000107.
REF00001380	"Characterization of sal(A), a novel gene responsible for lincosamide and streptogramin A resistance in Staphylococcus sciuri. Antimicrob Agents Chemother. 2014 Jun;58(6):3335-41. doi: 10.1128/AAC.02797-13. Epub 2014 Mar 31."
REF00001381	Role of GAS5 noncoding RNA in mediating the effects of rapamycin and its analogues on mantle cell lymphoma cells. Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):468-73. doi: 10.1016/j.clml.2014.02.011. Epub 2014 Mar 3.
REF00001382	Effect of microRNA-210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia. Cancer Sci. 2014 Apr;105(4):463-72. doi: 10.1111/cas.12370. Epub 2014 Mar 30.
REF00001383	MiRNA 17 family regulates cisplatin-resistant and metastasis by targeting TGFbetaR2 in NSCLC. PLoS One. 2014 Apr 10;9(4):e94639. doi: 10.1371/journal.pone.0094639. eCollection 2014.
REF00001384	Notch and NF-kB signaling pathways regulate miR-223/FBXW7 axis in T-cell acute lymphoblastic leukemia. Leukemia. 2014 Dec;28(12):2324-35. doi: 10.1038/leu.2014.133. Epub 2014 Apr 14.
REF00001385	Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients. Onco Targets Ther. 2014 Apr 3;7:513-24. doi: 10.2147/OTT.S60122. eCollection 2014.
REF00001386	Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J Thorac Oncol. 2014 Apr;9(4):549-53. doi: 10.1097/JTO.0000000000000094.
REF00001387	EGFR-Driven Behavior and Intrapatient T790M Mutation Heterogeneity of Non-Small-Cell Carcinoma With Squamous Histology. J Clin Oncol. 2015 Nov 1;33(31):e115-8. doi: 10.1200/JCO.2013.49.5697. Epub 2014 Apr 21.
REF00001388	"Polymorphisms in Pfmdr1, Pfcrt, and Pfnhe1 genes are associated with reduced in vitro activities of quinine in Plasmodium falciparum isolates from western Kenya. Antimicrob Agents Chemother. 2014 Jul;58(7):3737-43. doi: 10.1128/AAC.02472-14. Epub 2014 Apr 21."
REF00001389	MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer. J Pathol. 2014 Aug;233(4):368-79. doi: 10.1002/path.4363. Epub 2014 Jun 2.
REF00001390	miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin1 expression. PLoS One. 2014 Apr 22;9(4):e95716. doi: 10.1371/journal.pone.0095716. eCollection 2014.
REF00001391	miR-181b increases drug sensitivity in acute myeloid leukemia via targeting HMGB1 and Mcl-1. Int J Oncol. 2014 Jul;45(1):383-92. doi: 10.3892/ijo.2014.2390. Epub 2014 Apr 16.
REF00001392	MicroRNA-185 regulates chemotherapeutic sensitivity in gastric cancer by targeting apoptosis repressor with caspase recruitment domain. Cell Death Dis. 2014 Apr 24;5(4):e1197. doi: 10.1038/cddis.2014.148.
REF00001393	Involvement of miR-29b signaling in the sensitivity to chemotherapy in patients with ovarian carcinoma. Hum Pathol. 2014 Jun;45(6):1285-93. doi: 10.1016/j.humpath.2014.02.008. Epub 2014 Feb 28.
REF00001394	Zinc finger E-box-binding homeobox 2 (ZEB2) regulated by miR-200b contributes to multi-drug resistance of small cell lung cancer. Exp Mol Pathol. 2014 Jun;96(3):438-44. doi: 10.1016/j.yexmp.2014.04.008. Epub 2014 Apr 22.
REF00001395	A rifamycin inactivating phosphotransferase family shared by environmental and pathogenic bacteria. Proc Natl Acad Sci U S A. 2014 May 13;111(19):7102-7. doi: 10.1073/pnas.1402358111. Epub 2014 Apr 28.
REF00001396	MicroRNA-221 targeting PI3-K/Akt signaling axis induces cell proliferation and BCNU resistance in human glioblastoma. Neuropathology. 2014 Oct;34(5):455-64. doi: 10.1111/neup.12129. Epub 2014 Apr 30.
REF00001397	Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses. Clin Pharmacol Ther. 2014 Aug;96(2):182-91. doi: 10.1038/clpt.2014.93. Epub 2014 Apr 29.
REF00001398	MiR-489 regulates chemoresistance in breast cancer via epithelial mesenchymal transition pathway. FEBS Lett. 2014 May 29;588(11):2009-15. doi: 10.1016/j.febslet.2014.04.024. Epub 2014 Apr 29.
REF00001399	Porin involvement in cephalosporin and carbapenem resistance of Burkholderia pseudomallei. PLoS One. 2014 May 1;9(5):e95918. doi: 10.1371/journal.pone.0095918. eCollection 2014.
REF00001400	Let-7 g microRNA sensitizes fluorouracil-resistant human hepatoma cells. Pharmazie. 2014 Apr;69(4):287-92.
REF00001401	Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1. Cell Rep. 2014 May 22;7(4):999-1008. doi: 10.1016/j.celrep.2014.04.014. Epub 2014 May 9.
REF00001402	HDAC 1/4-mediated silencing of microRNA-200b promotes chemoresistance in human lung adenocarcinoma cells. Oncotarget. 2014 May 30;5(10):3333-49. doi: 10.18632/oncotarget.1948.
REF00001403	The TGFBeta-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors. Cancer Res. 2014 Jul 15;74(14):3995-4005. doi: 10.1158/0008-5472.CAN-14-0110. Epub 2014 May 15.
REF00001404	Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer. Cell Death Dis. 2014 May 15;5(5):e1227. doi: 10.1038/cddis.2014.186.
REF00001405	[MiR-192 confers cisplatin resistance by targeting Bim in lung cancer]. Zhongguo Fei Ai Za Zhi. 2014 May;17(5):384-90. doi: 10.3779/j.issn.1009-3419.2014.05.04.
REF00001406	The clonal evolution of leukemic stem cells in T-cell acute lymphoblastic leukemia. Curr Opin Hematol. 2014 Jul;21(4):320-5. doi: 10.1097/MOH.0000000000000058.
REF00001407	Characterization of the chloroquine resistance transporter homologue in Toxoplasma gondii. Eukaryot Cell. 2014 Nov;13(11):1360-70. doi: 10.1128/EC.00027-14. Epub 2014 May 23.
REF00001408	Upregulation of miR-21 in cisplatin resistant ovarian cancer via JNK-1/c-Jun pathway. PLoS One. 2014 May 27;9(5):e97094. doi: 10.1371/journal.pone.0097094. eCollection 2014.
REF00001409	Overexpression of microRNA-125b sensitizes human hepatocellular carcinoma cells to 5-fluorouracil through inhibition of glycolysis by targeting hexokinase II. Mol Med Rep. 2014 Aug;10(2):995-1002. doi: 10.3892/mmr.2014.2271. Epub 2014 May 26.
REF00001410	Involvement of extracellular vesicle long noncoding RNA (linc-VLDLR) in tumor cell responses to chemotherapy. Mol Cancer Res. 2014 Oct;12(10):1377-87. doi: 10.1158/1541-7786.MCR-13-0636. Epub 2014 May 29.
REF00001411	"miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2. Anticancer Agents Med Chem. 2014;14(6):884-91. doi: 10.2174/1871520614666140528161318."
REF00001412	Chlorpheniramine Analogues Reverse Chloroquine Resistance in Plasmodium falciparum by Inhibiting PfCRT. ACS Med Chem Lett. 2014 Mar 3;5(5):576-81. doi: 10.1021/ml5000228. eCollection 2014 May 8.
REF00001413	miR-125b controls apoptosis and temozolomide resistance by targeting TNFAIP3 and NKIRAS2 in glioblastomas. Cell Death Dis. 2014 Jun 5;5(6):e1279. doi: 10.1038/cddis.2014.245.
REF00001414	Downregulation of miR-21 increases cisplatin sensitivity of non-small-cell lung cancer. Cancer Genet. 2014 May;207(5):214-20. doi: 10.1016/j.cancergen.2014.04.003. Epub 2014 Apr 13.
REF00001415	MicroRNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression. Oncotarget. 2014 May 30;5(10):2974-87. doi: 10.18632/oncotarget.1614.
REF00001416	"A 2-amino quinoline, 5-(3-(2-(7-chloroquinolin-2-yl)ethenyl)phenyl)-8-dimethylcarbamyl-4,6-dithiaoctanoic acid, interacts with PfMDR1 and inhibits its drug transport in Plasmodium falciparum. Mol Biochem Parasitol. 2014 Jun;195(1):34-42. doi: 10.1016/j.molbiopara.2014.05.006. Epub 2014 Jun 8."
REF00001417	[Effect of miR-342-3p on chemotherapy sensitivity in triple-negative breast cancer]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2014 May;39(5):488-95. doi: 10.3969/j.issn.1672-7347.2014.05.009.
REF00001418	MiR-224 promotes the chemoresistance of human lung adenocarcinoma cells to cisplatin via regulating G /S transition and apoptosis by targeting p21(WAF1/CIP1). Br J Cancer. 2014 Jul 15;111(2):339-54. doi: 10.1038/bjc.2014.157. Epub 2014 Jun 12.
REF00001419	Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3. Cancer Gene Ther. 2014 Jul;21(7):290-6. doi: 10.1038/cgt.2014.29. Epub 2014 Jun 13.
REF00001420	Mono- and dimethylating activities and kinetic studies of the ermC 23 S rRNA methyltransferase. J Biol Chem. 1989 Feb 15;264(5):2615-24.
REF00001421	Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma. J Thorac Oncol. 2014 Jul;9(7):998-1007. doi: 10.1097/JTO.0000000000000202.
REF00001422	MiR-503 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R and BCL2. Chin Med J (Engl). 2014;127(12):2357-62.
REF00001423	miR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behavior of pancreatic cancer cells. Nucleosides Nucleotides Nucleic Acids. 2014;33(4-6):384-93. doi: 10.1080/15257770.2014.891741.
REF00001424	OmpU as a biomarker for rapid discrimination between toxigenic and epidemic Vibrio cholerae O1/O139 and non-epidemic Vibrio cholerae in a modified MALDI-TOF MS assay. BMC Microbiol. 2014 Jun 18;14:158. doi: 10.1186/1471-2180-14-158.
REF00001425	Molecular mechanism of fluoroquinolones resistance in Mycoplasma hominis clinical isolates. Braz J Microbiol. 2014 May 19;45(1):239-42. doi: 10.1590/s1517-83822014000100034. eCollection 2014.
REF00001426	Defining daptomycin resistance prevention exposures in vancomycin-resistant Enterococcus faecium and E. faecalis. Antimicrob Agents Chemother. 2014 Sep;58(9):5253-61. doi: 10.1128/AAC.00098-14. Epub 2014 Jun 23.
REF00001427	Long noncoding RNA MRUL promotes ABCB1 expression in multidrug-resistant gastric cancer cell sublines. Mol Cell Biol. 2014 Sep;34(17):3182-93. doi: 10.1128/MCB.01580-13. Epub 2014 Jun 23.
REF00001428	Expansion of the aminoglycoside-resistance 16S rRNA (m(1)A1408) methyltransferase family: expression and functional characterization of four hypothetical enzymes of diverse bacterial origin. Biochim Biophys Acta. 2014 Sep;1844(9):1648-55. doi: 10.1016/j.bbapap.2014.06.012. Epub 2014 Jun 22.
REF00001429	Hypoxia-induced miR-424 decreases tumor sensitivity to chemotherapy by inhibiting apoptosis. Cell Death Dis. 2014 Jun 26;5(6):e1301. doi: 10.1038/cddis.2014.240.
REF00001430	miR-942 decreases TRAIL-induced apoptosis through ISG12a downregulation and is regulated by AKT. Oncotarget. 2014 Jul 15;5(13):4959-71. doi: 10.18632/oncotarget.2067.
REF00001431	Isocitrate lyase mediates broad antibiotic tolerance in Mycobacterium tuberculosis. Nat Commun. 2014 Jun 30;5:4306. doi: 10.1038/ncomms5306.
REF00001432	Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol. 2014 Aug;11(8):473-81. doi: 10.1038/nrclinonc.2014.104. Epub 2014 Jul 1.
REF00001433	MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET. Cancer Lett. 2014 Sep 1;351(2):265-71. doi: 10.1016/j.canlet.2014.06.010. Epub 2014 Jun 28.
REF00001434	SS18-SSX-regulated miR-17 promotes tumor growth of synovial sarcoma by inhibiting p21WAF1/CIP1. Cancer Sci. 2014 Sep;105(9):1152-9. doi: 10.1111/cas.12479. Epub 2014 Sep 3.
REF00001435	Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance. Oncotarget. 2014 Jun 15;5(11):3770-84. doi: 10.18632/oncotarget.1994.
REF00001436	miR-155 mediates drug resistance in osteosarcoma cells via inducing autophagy. Exp Ther Med. 2014 Aug;8(2):527-532. doi: 10.3892/etm.2014.1752. Epub 2014 Jun 2.
REF00001437	MicroRNA-182 modulates chemosensitivity of human non-small cell lung cancer to cisplatin by targeting PDCD4. Diagn Pathol. 2014 Jul 10;9:143. doi: 10.1186/1746-1596-9-143.
REF00001438	Blocked autophagy by miR-101 enhances osteosarcoma cell chemosensitivity in vitro. ScientificWorldJournal. 2014;2014:794756. doi: 10.1155/2014/794756. Epub 2014 Jun 9.
REF00001439	miR-let-7f-1 regulates SPARC mediated cisplatin resistance in medulloblastoma cells. Cell Signal. 2014 Oct;26(10):2193-201. doi: 10.1016/j.cellsig.2014.06.014. Epub 2014 Jul 8.
REF00001440	Expression of miR-224-5p is associated with the original cisplatin resistance of ovarian papillary serous carcinoma. Oncol Rep. 2014 Sep;32(3):1003-12. doi: 10.3892/or.2014.3311. Epub 2014 Jul 7.
REF00001441	miR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma. Oncol Rep. 2014 Sep;32(3):957-64. doi: 10.3892/or.2014.3318. Epub 2014 Jul 10.
REF00001442	Decreased expression of miR-204 is associated with poor prognosis in patients with breast cancer. Int J Clin Exp Pathol. 2014 May 15;7(6):3287-92. eCollection 2014.
REF00001443	Restoration of miR-193b sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib. Cancer Lett. 2014 Oct 1;352(2):245-52. doi: 10.1016/j.canlet.2014.07.004. Epub 2014 Jul 14.
REF00001444	MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma. Liver Int. 2015 Mar;35(3):1077-86. doi: 10.1111/liv.12636. Epub 2014 Jul 21.
REF00001445	A pleiotropic drug resistance transporter is involved in reduced sensitivity to multiple fungicide classes in Sclerotinia homoeocarpa (F.T. Bennett). Mol Plant Pathol. 2015 Apr;16(3):251-61. doi: 10.1111/mpp.12174. Epub 2014 Aug 24.
REF00001446	Down-regulation of miRNA-452 is associated with adriamycin-resistance in breast cancer cells. Asian Pac J Cancer Prev. 2014;15(13):5137-42. doi: 10.7314/apjcp.2014.15.13.5137.
REF00001447	"Ex vivo activity of endoperoxide antimalarials, including artemisone and arterolane, against multidrug-resistant Plasmodium falciparum isolates from Cambodia. Antimicrob Agents Chemother. 2014 Oct;58(10):5831-40. doi: 10.1128/AAC.02462-14. Epub 2014 Jul 21."
REF00001448	miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression. Prostate. 2014 Sep;74(13):1320-34. doi: 10.1002/pros.22848. Epub 2014 Jul 22.
REF00001449	Alteration in Mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancer. PLoS One. 2014 Jul 24;9(7):e103305. doi: 10.1371/journal.pone.0103305. eCollection 2014.
REF00001450	MicroRNA-370 suppresses proliferation and promotes endometrioid ovarian cancer chemosensitivity to cDDP by negatively regulating ENG. Cancer Lett. 2014 Oct 28;353(2):201-10. doi: 10.1016/j.canlet.2014.07.026. Epub 2014 Jul 22.
REF00001451	A long non-coding RNA snaR contributes to 5-fluorouracil resistance in human colon cancer cells. Mol Cells. 2014 Jul;37(7):540-6. doi: 10.14348/molcells.2014.0151. Epub 2014 Jul 31.
REF00001452	Hypoxia-induced miR-497 decreases glioma cell sensitivity to TMZ by inhibiting apoptosis. FEBS Lett. 2014 Sep 17;588(18):3333-9. doi: 10.1016/j.febslet.2014.07.021. Epub 2014 Jul 29.
REF00001453	miR 222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma. Int J Oncol. 2014 Oct;45(4):1537-46. doi: 10.3892/ijo.2014.2577. Epub 2014 Aug 4.
REF00001454	Type II and type IV topoisomerase mutations in clinical isolates of Morganella morganii harbouring the qnrD gene. Ann Clin Microbiol Antimicrob. 2014 Aug 9;13:34. doi: 10.1186/s12941-014-0034-4.
REF00001455	Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma. Oncogene. 2015 Jun 4;34(23):2951-7. doi: 10.1038/onc.2014.249. Epub 2014 Aug 11.
REF00001456	Enforced expression of miR-101 enhances cisplatin sensitivity in human bladder cancer cells by modulating the cyclooxygenase-2 pathway. Mol Med Rep. 2014 Oct;10(4):2203-9. doi: 10.3892/mmr.2014.2455. Epub 2014 Aug 6.
REF00001457	MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer. Br J Cancer. 2014 Oct 14;111(8):1572-80. doi: 10.1038/bjc.2014.454. Epub 2014 Aug 12.
REF00001458	"Lung adenocarcinoma harboring L858R and T790M mutations in epidermal growth factor receptor, with poor response to gefitinib: A case report. Oncol Lett. 2014 Sep;8(3):1039-1042. doi: 10.3892/ol.2014.2321. Epub 2014 Jul 4."
REF00001459	Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations. Sci Rep. 2014 Aug 18;4:6104. doi: 10.1038/srep06104.
REF00001460	Modulation of chemotherapeutic drug resistance in neuroblastoma SK-N-AS cells by the neural apoptosis inhibitory protein and miR-520f. Int J Cancer. 2015 Apr 1;136(7):1579-88. doi: 10.1002/ijc.29144. Epub 2014 Sep 2.
REF00001461	miR-326-histone deacetylase-3 feedback loop regulates the invasion and tumorigenic and angiogenic response to anti-cancer drugs. J Biol Chem. 2014 Oct 3;289(40):28019-39. doi: 10.1074/jbc.M114.578229. Epub 2014 Aug 19.
REF00001462	MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis. Oncotarget. 2014 Aug 30;5(16):6983-93. doi: 10.18632/oncotarget.2184.
REF00001463	MiR-181b sensitizes glioma cells to teniposide by targeting MDM2. BMC Cancer. 2014 Aug 25;14:611. doi: 10.1186/1471-2407-14-611.
REF00001464	The contribution of antibiotic resistance mechanisms in clinical Burkholderia cepacia complex isolates: an emphasis on efflux pump activity. PLoS One. 2014 Aug 25;9(8):e104986. doi: 10.1371/journal.pone.0104986. eCollection 2014.
REF00001465	Methylation-regulated miR-149 modulates chemoresistance by targeting GlcNAc N-deacetylase/N-sulfotransferase-1 in human breast cancer. FEBS J. 2014 Oct;281(20):4718-30. doi: 10.1111/febs.13012. Epub 2014 Sep 30.
REF00001466	Expression levels of pvcrt-o and pvmdr-1 are associated with chloroquine resistance and severe Plasmodium vivax malaria in patients of the Brazilian Amazon. PLoS One. 2014 Aug 26;9(8):e105922. doi: 10.1371/journal.pone.0105922. eCollection 2014.
REF00001467	A methylation-based regulatory network for microRNA 320a in chemoresistant breast cancer. Mol Pharmacol. 2014 Nov;86(5):536-47. doi: 10.1124/mol.114.092759. Epub 2014 Aug 26.
REF00001468	The sensitivity of gastric cancer to trastuzumab is regulated by the miR-223/FBXW7 pathway. Int J Cancer. 2015 Apr 1;136(7):1537-45. doi: 10.1002/ijc.29168. Epub 2014 Sep 11.
REF00001469	MicroRNA-218 is upregulated in gastric cancer after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy and increases chemosensitivity to cisplatin. World J Gastroenterol. 2014 Aug 28;20(32):11347-55. doi: 10.3748/wjg.v20.i32.11347.
REF00001470	"MicroRNA-29b-1 impairs in vitro cell proliferation, self renewal and chemoresistance of human osteosarcoma 3AB-OS cancer stem cells. Int J Oncol. 2014 Nov;45(5):2013-23. doi: 10.3892/ijo.2014.2618. Epub 2014 Aug 22."
REF00001471	MicroRNA-449a reduces cell survival and enhances cisplatin-induced cytotoxicity via downregulation of NOTCH1 in ovarian cancer cells. Tumour Biol. 2014 Dec;35(12):12369-78. doi: 10.1007/s13277-014-2551-3. Epub 2014 Sep 2.
REF00001472	KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance. Gastric Cancer. 2015 Oct;18(4):796-802. doi: 10.1007/s10120-014-0414-7. Epub 2014 Aug 15.
REF00001473	The DNA methylation-regulated miR-193a-3p dictates the multi-chemoresistance of bladder cancer via repression of SRSF2/PLAU/HIC2 expression. Cell Death Dis. 2014 Sep 4;5(9):e1402. doi: 10.1038/cddis.2014.367.
REF00001474	Acquired resistance to the Hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma. J Am Acad Dermatol. 2014 Nov;71(5):1005-8. doi: 10.1016/j.jaad.2014.08.001. Epub 2014 Sep 4.
REF00001475	In Vitro selection of Neisseria gonorrhoeae mutants with elevated MIC values and increased resistance to cephalosporins. Antimicrob Agents Chemother. 2014 Nov;58(11):6986-9. doi: 10.1128/AAC.03082-14. Epub 2014 Sep 8.
REF00001476	Overexpression of secretagogin inhibits cell apoptosis and induces chemoresistance in small cell lung cancer under the regulation of miR-494. Oncotarget. 2014 Sep 15;5(17):7760-75. doi: 10.18632/oncotarget.2305.
REF00001477	miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer. Breast Cancer Res. 2014 Sep 17;16(5):435. doi: 10.1186/s13058-014-0435-5.
REF00001478	Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin Cancer Res. 2014 Nov 15;20(22):5686-96. doi: 10.1158/1078-0432.CCR-14-1511. Epub 2014 Sep 16.
REF00001479	MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma. Oncol Rep. 2014 Dec;32(6):2365-72. doi: 10.3892/or.2014.3481. Epub 2014 Sep 16.
REF00001480	MicroRNA-217 functions as a tumour suppressor gene and correlates with cell resistance to cisplatin in lung cancer. Mol Cells. 2014 Sep;37(9):664-71. doi: 10.14348/molcells.2014.0121. Epub 2014 Sep 18.
REF00001481	Deregulation of miR-128 in ovarian cancer promotes cisplatin resistance. Int J Gynecol Cancer. 2014 Oct;24(8):1381-8. doi: 10.1097/IGC.0000000000000252.
REF00001482	SNAI2 modulates colorectal cancer 5-fluorouracil sensitivity through miR145 repression. Mol Cancer Ther. 2014 Nov;13(11):2713-26. doi: 10.1158/1535-7163.MCT-14-0207. Epub 2014 Sep 23.
REF00001483	miR-101 regulates expression of EZH2 and contributes to progression of and cisplatin resistance in epithelial ovarian cancer. Tumour Biol. 2014 Dec;35(12):12619-26. doi: 10.1007/s13277-014-2585-6. Epub 2014 Sep 27.
REF00001484	"Mechanism-based cancer therapy: resistance to therapy, therapy for resistance. Oncogene. 2015 Jul;34(28):3617-26. doi: 10.1038/onc.2014.314. Epub 2014 Sep 29."
REF00001485	Role and mechanisms of microRNA 503 in drug resistance reversal in HepG2/ADM human hepatocellular carcinoma cells. Mol Med Rep. 2014 Dec;10(6):3268-74. doi: 10.3892/mmr.2014.2591. Epub 2014 Sep 22.
REF00001486	miR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type. Oncotarget. 2014 Sep 15;5(17):7902-16. doi: 10.18632/oncotarget.2302.
REF00001487	Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance. J Antimicrob Chemother. 2015 Feb;70(2):405-11. doi: 10.1093/jac/dku387. Epub 2014 Oct 3.
REF00001488	Increased genomic instability may contribute to the development of kinase domain mutations in chronic myeloid leukemia. Int J Hematol. 2014 Dec;100(6):567-74. doi: 10.1007/s12185-014-1685-9. Epub 2014 Oct 4.
REF00001489	Reduced miR-3127-5p expression promotes NSCLC proliferation/invasion and contributes to dasatinib sensitivity via the c-Abl/Ras/ERK pathway. Sci Rep. 2014 Oct 6;4:6527. doi: 10.1038/srep06527.
REF00001490	miR-150 modulates cisplatin chemosensitivity and invasiveness of muscle-invasive bladder cancer cells via targeting PDCD4 in vitro. Med Sci Monit. 2014 Oct 7;20:1850-7. doi: 10.12659/MSM.891340.
REF00001491	MicroRNA-7 sensitizes non-small cell lung cancer cells to paclitaxel. Oncol Lett. 2014 Nov;8(5):2193-2200. doi: 10.3892/ol.2014.2500. Epub 2014 Sep 4.
REF00001492	Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov. 2014 Nov;4(11):1269-80. doi: 10.1158/2159-8290.CD-14-0462. Epub 2014 Oct 7.
REF00001493	miR-204-5p inhibits proliferation and invasion and enhances chemotherapeutic sensitivity of colorectal cancer cells by downregulating RAB22A. Clin Cancer Res. 2014 Dec 1;20(23):6187-99. doi: 10.1158/1078-0432.CCR-14-1030. Epub 2014 Oct 7.
REF00001494	Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med. 2014 Oct 9;371(15):1426-33. doi: 10.1056/NEJMoa1403352.
REF00001495	A novel Pseudomonas aeruginosa strain with an oprD mutation in relation to a nosocomial respiratory infection outbreak in an intensive care unit. J Clin Microbiol. 2014 Dec;52(12):4388-90. doi: 10.1128/JCM.02782-14. Epub 2014 Oct 8.
REF00001496	microRNA 490-3P enhances the drug-resistance of human ovarian cancer cells. J Ovarian Res. 2014 Aug 31;7:84. doi: 10.1186/s13048-014-0084-4.
REF00001497	MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein. Cancer Lett. 2015 Jan 28;356(2 Pt B):597-605. doi: 10.1016/j.canlet.2014.10.006. Epub 2014 Oct 8.
REF00001498	Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma. Mol Oncol. 2015 Feb;9(2):389-97. doi: 10.1016/j.molonc.2014.09.003. Epub 2014 Sep 26.
REF00001499	MicroRNA-451 induces epithelial-mesenchymal transition in docetaxel-resistant lung adenocarcinoma cells by targeting proto-oncogene c-Myc. Eur J Cancer. 2014 Nov;50(17):3050-67. doi: 10.1016/j.ejca.2014.09.008. Epub 2014 Oct 10.
REF00001500	Mutation position within evolutionary subclonal architecture in AML. Semin Hematol. 2014 Oct;51(4):273-81. doi: 10.1053/j.seminhematol.2014.08.004. Epub 2014 Aug 7.
REF00001501	miR-193a-3p regulates the multi-drug resistance of bladder cancer by targeting the LOXL4 gene and the oxidative stress pathway. Mol Cancer. 2014 Oct 14;13:234. doi: 10.1186/1476-4598-13-234.
REF00001502	Regulation of BGC-823 cell sensitivity to adriamycin via miRNA-135a-5p. Oncol Rep. 2014 Dec;32(6):2549-56. doi: 10.3892/or.2014.3546. Epub 2014 Oct 14.
REF00001503	Effect of microRNA-21 on multidrug resistance reversal in A549/DDP human lung cancer cells. Mol Med Rep. 2015 Jan;11(1):682-90. doi: 10.3892/mmr.2014.2662. Epub 2014 Oct 15.
REF00001504	miR-375 mediated acquired chemo-resistance in cervical cancer by facilitating EMT. PLoS One. 2014 Oct 16;9(10):e109299. doi: 10.1371/journal.pone.0109299. eCollection 2014.
REF00001505	Inhibition of lactate dehydrogenase A by microRNA-34a resensitizes colon cancer cells to 5-fluorouracil. Mol Med Rep. 2015 Jan;11(1):577-82. doi: 10.3892/mmr.2014.2726. Epub 2014 Oct 21.
REF00001506	Let-7b binding site polymorphism in the B-cell lymphoma-extra large 3'UTR is associated with fluorouracil resistance of hepatocellular carcinoma. Mol Med Rep. 2015 Jan;11(1):677-81. doi: 10.3892/mmr.2014.2692. Epub 2014 Oct 17.
REF00001507	MicroRNA-106a confers cisplatin resistance in non-small cell lung cancer A549 cells by targeting adenosine triphosphatase-binding cassette A1. Mol Med Rep. 2015 Jan;11(1):625-32. doi: 10.3892/mmr.2014.2688. Epub 2014 Oct 17.
REF00001508	MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells. Mol Med Rep. 2015 Jan;11(1):333-40. doi: 10.3892/mmr.2014.2757. Epub 2014 Oct 23.
REF00001509	miR-382 inhibits tumor growth and enhance chemosensitivity in osteosarcoma. Oncotarget. 2014 Oct 15;5(19):9472-83. doi: 10.18632/oncotarget.2418.
REF00001510	Methylation of miR-129-5p CpG island modulates multi-drug resistance in gastric cancer by targeting ABC transporters. Oncotarget. 2014 Nov 30;5(22):11552-63. doi: 10.18632/oncotarget.2594.
REF00001511	microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer. 2014 Nov 25;111(11):2091-102. doi: 10.1038/bjc.2014.548. Epub 2014 Oct 30.
REF00001512	Targeting of miR34a-NOTCH1 axis reduced breast cancer stemness and chemoresistance. Cancer Res. 2014 Dec 15;74(24):7573-82. doi: 10.1158/0008-5472.CAN-14-1140. Epub 2014 Nov 3.
REF00001513	Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib. J Thorac Oncol. 2014 Dec;9(12):1821-5. doi: 10.1097/JTO.0000000000000368.
REF00001514	Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib. J Thorac Oncol. 2014 Dec;9(12):e86-7. doi: 10.1097/JTO.0000000000000358.
REF00001515	MiR-634 sensitizes nasopharyngeal carcinoma cells to paclitaxel and inhibits cell growth both in vitro and in vivo. Int J Clin Exp Pathol. 2014 Sep 15;7(10):6784-91. eCollection 2014.
REF00001516	miR-107 regulates cisplatin chemosensitivity of A549 non small cell lung cancer cell line by targeting cyclin dependent kinase 8. Int J Clin Exp Pathol. 2014 Sep 15;7(10):7236-41. eCollection 2014.
REF00001517	Structural effect of the Asp345a insertion in penicillin-binding protein 2 from penicillin-resistant strains of Neisseria gonorrhoeae. Biochemistry. 2014 Dec 9;53(48):7596-603. doi: 10.1021/bi5011317. Epub 2014 Dec 1.
REF00001518	Convergent loss of PTEN leads to clinical resistance to a PI(3)KAlpha inhibitor. Nature. 2015 Feb 12;518(7538):240-4. doi: 10.1038/nature13948. Epub 2014 Nov 17.
REF00001519	"Temporal and seasonal changes of genetic polymorphisms associated with altered drug susceptibility to chloroquine, lumefantrine, and quinine in Guinea-Bissau between 2003 and 2012. Antimicrob Agents Chemother. 2015 Feb;59(2):872-9. doi: 10.1128/AAC.03554-14. Epub 2014 Nov 24."
REF00001520	Novel mutation detection IN rpoB OF rifampicin-resistant Mycobacterium tuberculosis using pyrosequencing. Southeast Asian J Trop Med Public Health. 2014 Jul;45(4):843-52.
REF00001521	MiR-16 targets Bcl-2 in paclitaxel-resistant lung cancer cells and overexpression of miR-16 along with miR-17 causes unprecedented sensitivity by simultaneously modulating autophagy and apoptosis. Cell Signal. 2015 Feb;27(2):189-203. doi: 10.1016/j.cellsig.2014.11.023. Epub 2014 Nov 27.
REF00001522	MiR-193a-3p promotes the multi-chemoresistance of bladder cancer by targeting the HOXC9 gene. Cancer Lett. 2015 Feb 1;357(1):105-113. doi: 10.1016/j.canlet.2014.11.002. Epub 2014 Nov 11.
REF00001523	miR-320 enhances the sensitivity of human colon cancer cells to chemoradiotherapy in vitro by targeting FOXM1. Biochem Biophys Res Commun. 2015 Feb 6;457(2):125-32. doi: 10.1016/j.bbrc.2014.11.039. Epub 2014 Nov 21.
REF00001524	MiR-22 regulates 5-FU sensitivity by inhibiting autophagy and promoting apoptosis in colorectal cancer cells. Cancer Lett. 2015 Jan 28;356(2 Pt B):781-90. doi: 10.1016/j.canlet.2014.10.029. Epub 2014 Oct 29.
REF00001525	miRNA expression patterns in chemoresistant breast cancer tissues. Biomed Pharmacother. 2014 Oct;68(8):935-42. doi: 10.1016/j.biopha.2014.09.011. Epub 2014 Oct 5.
REF00001526	Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nat Commun. 2014 Dec 2;5:5694. doi: 10.1038/ncomms6694.
REF00001527	MiR-96 promotes proliferation and chemo- or radioresistance by down-regulating RECK in esophageal cancer. Biomed Pharmacother. 2014 Oct;68(8):951-8. doi: 10.1016/j.biopha.2014.10.023. Epub 2014 Oct 31.
REF00001528	MiR-222 targeted PUMA to improve sensitization of UM1 cells to cisplatin. Int J Mol Sci. 2014 Dec 2;15(12):22128-41. doi: 10.3390/ijms151222128.
REF00001529	Expression of miR-136 is associated with the primary cisplatin resistance of human epithelial ovarian cancer. Oncol Rep. 2015 Feb;33(2):591-8. doi: 10.3892/or.2014.3640. Epub 2014 Dec 2.
REF00001530	Cloning and characterization of a DNA gyrase A gene from Escherichia coli that confers clinical resistance to 4-quinolones. Antimicrob Agents Chemother. 1989 Jun;33(6):886-94. doi: 10.1128/AAC.33.6.886.
REF00001531	"On the evolution of Tn21-like multiresistance transposons: sequence analysis of the gene (aacC1) for gentamicin acetyltransferase-3-I(AAC(3)-I), another member of the Tn21-based expression cassette. Mol Gen Genet. 1989 Jun;217(2-3):202-8. doi: 10.1007/BF02464882."
REF00001532	LEIGC long non-coding RNA acts as a tumor suppressor in gastric carcinoma by inhibiting the epithelial-to-mesenchymal transition. BMC Cancer. 2014 Dec 11;14:932. doi: 10.1186/1471-2407-14-932.
REF00001533	miR-23a promotes cisplatin chemoresistance and protects against cisplatin-induced apoptosis in tongue squamous cell carcinoma cells through Twist. Oncol Rep. 2015 Feb;33(2):942-50. doi: 10.3892/or.2014.3664. Epub 2014 Dec 10.
REF00001534	Nucleotide sequence of the chromosomal gene coding for the aminoglycoside 6-adenylyltransferase from Bacillus subtilis Marburg 168. Gene. 1989 May 30;78(2):377-8. doi: 10.1016/0378-1119(89)90241-2.
REF00001535	MicroRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation. Carcinogenesis. 2015 Mar;36(3):338-45. doi: 10.1093/carcin/bgu242. Epub 2014 Dec 10.
REF00001536	"Nucleotide sequence of a novel kanamycin resistance gene, aphA-7, from Campylobacter jejuni and comparison to other kanamycin phosphotransferase genes. Plasmid. 1989 Jul;22(1):52-8. doi: 10.1016/0147-619x(89)90035-8."
REF00001537	Overexpression of miR-126 sensitizes osteosarcoma cells to apoptosis induced by epigallocatechin-3-gallate. World J Surg Oncol. 2014 Dec 16;12:383. doi: 10.1186/1477-7819-12-383.
REF00001538	The role of mutations in epigenetic regulators in myeloid malignancies. Immunol Rev. 2015 Jan;263(1):22-35. doi: 10.1111/imr.12246.
REF00001539	"AbuO, a TolC-like outer membrane protein of Acinetobacter baumannii, is involved in antimicrobial and oxidative stress resistance. Antimicrob Agents Chemother. 2015 Feb;59(2):1236-45. doi: 10.1128/AAC.03626-14. Epub 2014 Dec 15."
REF00001540	MiR-203 sensitizes glioma cells to temozolomide and inhibits glioma cell invasion by targeting E2F3. Mol Med Rep. 2015 Apr;11(4):2838-44. doi: 10.3892/mmr.2014.3101. Epub 2014 Dec 16.
REF00001541	Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib. Pigment Cell Melanoma Res. 2015 May;28(3):318-23. doi: 10.1111/pcmr.12347. Epub 2015 Jan 7.
REF00001542	MicroRNA-486 regulates normal erythropoiesis and enhances growth and modulates drug response in CML progenitors. Blood. 2015 Feb 19;125(8):1302-13. doi: 10.1182/blood-2014-06-581926. Epub 2014 Dec 16.
REF00001543	MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1Alpha. PLoS One. 2014 Dec 22;9(12):e115565. doi: 10.1371/journal.pone.0115565. eCollection 2014.
REF00001544	MicroRNA-7 inhibits multiple oncogenic pathways to suppress HER2 Delta 16 mediated breast tumorigenesis and reverse trastuzumab resistance. PLoS One. 2014 Dec 22;9(12):e114419. doi: 10.1371/journal.pone.0114419. eCollection 2014.
REF00001545	The miR-193a-3p regulated PSEN1 gene suppresses the multi-chemoresistance of bladder cancer. Biochim Biophys Acta. 2015 Mar;1852(3):520-8. doi: 10.1016/j.bbadis.2014.12.014. Epub 2014 Dec 24.
REF00001546	"Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase. J Virol. 2015 Mar;89(6):3163-75. doi: 10.1128/JVI.03353-14. Epub 2014 Dec 31."
REF00001547	miR-340 reverses cisplatin resistance of hepatocellular carcinoma cell lines by targeting Nrf2-dependent antioxidant pathway. Asian Pac J Cancer Prev. 2014;15(23):10439-44. doi: 10.7314/apjcp.2014.15.23.10439.
REF00001548	"MicroRNA-574-3p, identified by microRNA library-based functional screening, modulates tamoxifen response in breast cancer. Sci Rep. 2015 Jan 6;5:7641. doi: 10.1038/srep07641."
REF00001549	"Structural and molecular basis for resistance to aminoglycoside antibiotics by the adenylyltransferase ANT(2"")-Ia. mBio. 2015 Jan 6;6(1):e02180-14. doi: 10.1128/mBio.02180-14."
REF00001550	microRNA-143 is associated with the survival of ALDH1+CD133+ osteosarcoma cells and the chemoresistance of osteosarcoma. Exp Biol Med (Maywood). 2015 Jul;240(7):867-75. doi: 10.1177/1535370214563893. Epub 2015 Jan 8.
REF00001551	"The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells. Gynecol Oncol. 2015 Apr;137(1):143-51. doi: 10.1016/j.ygyno.2014.12.042. Epub 2015 Jan 8."
REF00001552	MiRNA 542 3p downregulation promotes trastuzumab resistance in breast cancer cells via AKT activation. Oncol Rep. 2015 Mar;33(3):1215-20. doi: 10.3892/or.2015.3713. Epub 2015 Jan 13.
REF00001553	MicroRNA-10a silencing reverses cisplatin resistance in the A549/cisplatin human lung cancer cell line via the transforming growth factor-Beta/Smad2/STAT3/STAT5 pathway. Mol Med Rep. 2015 May;11(5):3854-9. doi: 10.3892/mmr.2015.3181. Epub 2015 Jan 12.
REF00001554	Mutational spectrum of adult T-ALL. Oncotarget. 2015 Feb 20;6(5):2754-66. doi: 10.18632/oncotarget.2218.
REF00001555	Future options for ALK-positive non-small cell lung cancer. Lung Cancer. 2015 Mar;87(3):211-9. doi: 10.1016/j.lungcan.2014.12.017. Epub 2015 Jan 3.
REF00001556	[Inhibition of microRNA-23a increases cisplatin sensitivity of ovarian cancer cells: the possible molecular mechanisms]. Nan Fang Yi Ke Da Xue Xue Bao. 2015 Jan;35(1):125-8.
REF00001557	MicroRNA-520g confers drug resistance by regulating p21 expression in colorectal cancer. J Biol Chem. 2015 Mar 6;290(10):6215-25. doi: 10.1074/jbc.M114.620252. Epub 2015 Jan 23.
REF00001558	[miR-34a may regulate sensitivity of breast cancer cells to adriamycin via targeting Notch1]. Zhonghua Zhong Liu Za Zhi. 2014 Dec;36(12):892-6.
REF00001559	[miR-15a and miR-16 modulate drug resistance by targeting bcl-2 in human colon cancer cells]. Zhonghua Zhong Liu Za Zhi. 2014 Dec;36(12):897-902.
REF00001560	Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol. 2015 Apr;26(4):731-736. doi: 10.1093/annonc/mdv005. Epub 2015 Jan 26.
REF00001561	Anti-miR21 oligonucleotide enhances chemosensitivity of T98G cell line to doxorubicin by inducing apoptosis. Am J Cancer Res. 2014 Dec 15;5(1):231-42. eCollection 2015.
REF00001562	Characterisation of novel mutations involved in quinolone resistance in Escherichia coli isolated from imported shrimp. Int J Antimicrob Agents. 2015 May;45(5):471-6. doi: 10.1016/j.ijantimicag.2014.11.010. Epub 2015 Jan 13.
REF00001563	Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Oncotarget. 2015 Jan 30;6(3):1740-9. doi: 10.18632/oncotarget.2714.
REF00001564	[The expression and functional study of miR-181a in pediatric acute lymphoblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2015 Jan;36(1):53-7. doi: 10.3760/cma.j.issn.0253-2727.2015.01.013.
REF00001565	"In vitro activity of five quinolones and analysis of the quinolone resistance-determining regions of gyrA, gyrB, parC, and parE in Ureaplasma parvum and Ureaplasma urealyticum clinical isolates from perinatal patients in Japan. Antimicrob Agents Chemother. 2015 Apr;59(4):2358-64. doi: 10.1128/AAC.04262-14. Epub 2015 Feb 2."
REF00001566	Beta-Elemene inhibits the proliferation of esophageal squamous cell carcinoma by regulating long noncoding RNA-mediated inhibition of hTERT expression. Anticancer Drugs. 2015 Jun;26(5):531-9. doi: 10.1097/CAD.0000000000000216.
REF00001567	Reciprocal regulation of GAS5 lncRNA levels and mTOR inhibitor action in prostate cancer cells. Prostate. 2015 May;75(7):693-705. doi: 10.1002/pros.22952. Epub 2015 Feb 3.
REF00001568	Systematic analysis of gene expression pattern in has-miR-760 overexpressed resistance of the MCF-7 human breast cancer cell to doxorubicin. Biomed Pharmacother. 2015 Feb;69:162-9. doi: 10.1016/j.biopha.2014.11.028. Epub 2014 Nov 25.
REF00001569	Metabolic reprogramming of metastatic breast cancer and melanoma by let-7a microRNA. Oncotarget. 2015 Feb 10;6(4):2451-65. doi: 10.18632/oncotarget.3235.
REF00001570	The genomic landscape of acute lymphoblastic leukemia in children and young adults. Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):174-80. doi: 10.1182/asheducation-2014.1.174. Epub 2014 Nov 18.
REF00001571	miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res. 2015 Apr;25(4):477-95. doi: 10.1038/cr.2015.23. Epub 2015 Feb 20.
REF00001572	Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. J Clin Invest. 2015 Apr;125(4):1459-70. doi: 10.1172/JCI78954. Epub 2015 Feb 23.
REF00001573	Heteroresistance to colistin in Klebsiella pneumoniae associated with alterations in the PhoPQ regulatory system. Antimicrob Agents Chemother. 2015 May;59(5):2780-4. doi: 10.1128/AAC.05055-14. Epub 2015 Mar 2.
REF00001574	Detection of KIT and PDGFRA mutations in the plasma of patients with gastrointestinal stromal tumor. Target Oncol. 2015 Dec;10(4):597-601. doi: 10.1007/s11523-015-0361-1. Epub 2015 Mar 5.
REF00001575	Incidence and clinical importance of BCR-ABL1 mutations in Iranian patients with chronic myeloid leukemia on imatinib. J Hum Genet. 2015 May;60(5):253-8. doi: 10.1038/jhg.2015.11. Epub 2015 Mar 5.
REF00001576	MiR-1204 sensitizes nasopharyngeal carcinoma cells to paclitaxel both in vitro and in vivo. Cancer Biol Ther. 2015;16(2):261-7. doi: 10.1080/15384047.2014.1001287.
REF00001577	Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell. 2015 Mar 9;27(3):327-41. doi: 10.1016/j.ccell.2015.02.001.
REF00001578	Smoothened variants explain the majority of drug resistance in basal cell carcinoma. Cancer Cell. 2015 Mar 9;27(3):342-53. doi: 10.1016/j.ccell.2015.02.002.
REF00001579	Upregulation of microRNA-126-5p is associated with drug resistance to cytarabine and poor prognosis in AML patients. Oncol Rep. 2015 May;33(5):2176-82. doi: 10.3892/or.2015.3839. Epub 2015 Mar 6.
REF00001580	Notch 1 promotes cisplatin-resistant gastric cancer formation by upregulating lncRNA AK022798 expression. Anticancer Drugs. 2015 Jul;26(6):632-40. doi: 10.1097/CAD.0000000000000227.
REF00001581	MicroRNA-34a suppresses the breast cancer stem cell-like characteristics by downregulating Notch1 pathway. Cancer Sci. 2015 Jun;106(6):700-8. doi: 10.1111/cas.12656.
REF00001582	E255K and G250E mutation appearing in a patient with e19a2 chronic myeloid leukemia resistant to imatinib. Clin Lab. 2015;61(1-2):183-6. doi: 10.7754/clin.lab.2014.140818.
REF00001583	Long noncoding RNA MALAT-1 enhances stem cell-like phenotypes in pancreatic cancer cells. Int J Mol Sci. 2015 Mar 24;16(4):6677-93. doi: 10.3390/ijms16046677.
REF00001584	miR-141 confers docetaxel chemoresistance of breast cancer cells via regulation of EIF4E expression. Oncol Rep. 2015 May;33(5):2504-12. doi: 10.3892/or.2015.3866. Epub 2015 Mar 18.
REF00001585	HOTAIR is a potential target for the treatment of cisplatin resistant ovarian cancer. Mol Med Rep. 2015 Aug;12(2):2211-6. doi: 10.3892/mmr.2015.3562. Epub 2015 Mar 27.
REF00001586	Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of ovarian cancer stem cells. Proc Natl Acad Sci U S A. 2015 Apr 7;112(14):4411-6. doi: 10.1073/pnas.1421365112. Epub 2015 Mar 23.
REF00001587	miR-483-5p determines mitochondrial fission and cisplatin sensitivity in tongue squamous cell carcinoma by targeting FIS1. Cancer Lett. 2015 Jul 1;362(2):183-91. doi: 10.1016/j.canlet.2015.03.045. Epub 2015 Apr 2.
REF00001588	[The role of some individual amino acid substitutions in penicillin-binding protein (PBP2) of Neisseria gonorrhoeae in the emergence of resistance to ceftriaxone]. Mol Biol (Mosk). 2014 Nov-Dec;48(6):977-82.
REF00001589	p85Alpha is a microRNA target and affects chemosensitivity in pancreatic cancer. J Surg Res. 2015 Jun 15;196(2):285-293. doi: 10.1016/j.jss.2015.02.071. Epub 2015 Mar 6.
REF00001590	MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2. Oncotarget. 2015 Apr 20;6(11):8914-28. doi: 10.18632/oncotarget.3563.
REF00001591	LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer. Oncotarget. 2015 May 10;6(13):11652-63. doi: 10.18632/oncotarget.3457.
REF00001592	MicroRNA-494 sensitizes colon cancer cells to fluorouracil through regulation of DPYD. IUBMB Life. 2015 Mar;67(3):191-201. doi: 10.1002/iub.1361. Epub 2015 Apr 15.
REF00001593	Massively parallel sequencing fails to detect minor resistant subclones in tissue samples prior to tyrosine kinase inhibitor therapy. BMC Cancer. 2015 Apr 15;15:291. doi: 10.1186/s12885-015-1311-0.
REF00001594	Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance. BMC Cancer. 2015 Feb 18;15:61. doi: 10.1186/s12885-015-1029-z.
REF00001595	The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer. J Transl Med. 2015 Mar 12;13:84. doi: 10.1186/s12967-015-0442-z.
REF00001596	miRNA-196b inhibits cell proliferation and induces apoptosis in HepG2 cells by targeting IGF2BP1. Mol Cancer. 2015 Apr 8;14:79. doi: 10.1186/s12943-015-0349-6.
REF00001597	Identification of ABC transporter genes conferring combined pleuromutilin-lincosamide-streptogramin A resistance in bovine methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci. Vet Microbiol. 2015 Jun 12;177(3-4):353-8. doi: 10.1016/j.vetmic.2015.03.027. Epub 2015 Apr 8.
REF00001598	Dissecting Genomic Aberrations in Myeloproliferative Neoplasms by Multiplex-PCR and Next Generation Sequencing. PLoS One. 2015 Apr 20;10(4):e0123476. doi: 10.1371/journal.pone.0123476. eCollection 2015.
REF00001599	Balancing drug resistance and growth rates via compensatory mutations in the Plasmodium falciparum chloroquine resistance transporter. Mol Microbiol. 2015 Jul;97(2):381-95. doi: 10.1111/mmi.13035. Epub 2015 May 20.
REF00001600	MicroRNA-218 increases cellular sensitivity to Rapamycin via targeting Rictor in cervical cancer. APMIS. 2015 Jul;123(7):562-70. doi: 10.1111/apm.12387. Epub 2015 Apr 24.
REF00001601	MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms. Br J Cancer. 2015 Apr 28;112(9):1480-90. doi: 10.1038/bjc.2015.125.
REF00001602	miR-128 modulates chemosensitivity and invasion of prostate cancer cells through targeting ZEB1. Jpn J Clin Oncol. 2015 May;45(5):474-82. doi: 10.1093/jjco/hyv027. Epub 2015 Mar 25.
REF00001603	"The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression. J Hematol Oncol. 2015 Apr 29;8:43. doi: 10.1186/s13045-015-0140-6."
REF00001604	miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNA (cytosine-5)-methyltransferase 1(DNMT1) expression. J Transl Med. 2015 Apr 28;13:132. doi: 10.1186/s12967-015-0488-y.
REF00001605	miRNA-497 Enhances the Sensitivity of Colorectal Cancer Cells to Neoadjuvant Chemotherapeutic Drug. Curr Protein Pept Sci. 2015;16(4):310-5. doi: 10.2174/138920371604150429154142.
REF00001606	"Complete genome sequences for 59 burkholderia isolates, both pathogenic and near neighbor. Genome Announc. 2015 Apr 30;3(2):e00159-15. doi: 10.1128/genomeA.00159-15."
REF00001607	Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015 Jun;21(6):560-2. doi: 10.1038/nm.3854. Epub 2015 May 4.
REF00001608	Outer membrane proteomics of kanamycin-resistant Escherichia coli identified MipA as a novel antibiotic resistance-related protein. FEMS Microbiol Lett. 2015 Jun;362(11):fnv074. doi: 10.1093/femsle/fnv074. Epub 2015 May 3.
REF00001609	Let-7 Sensitizes KRAS Mutant Tumor Cells to Chemotherapy. PLoS One. 2015 May 6;10(5):e0126653. doi: 10.1371/journal.pone.0126653. eCollection 2015.
REF00001610	Overexpression of long non-coding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance. Biochem Biophys Res Commun. 2015 Jul 3;462(3):227-32. doi: 10.1016/j.bbrc.2015.04.121. Epub 2015 May 5.
REF00001611	Darunavir/cobicistat once daily for the treatment of HIV. Expert Rev Anti Infect Ther. 2015 Jun;13(6):691-704. doi: 10.1586/14787210.2015.1033400.
REF00001612	The diagnostic and clinical impact of genetics and epigenetics in acute myeloid leukemia. Int J Lab Hematol. 2015 May;37 Suppl 1:122-32. doi: 10.1111/ijlh.12367.
REF00001613	Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer. Clin Chem. 2015 Jul;61(7):974-82. doi: 10.1373/clinchem.2015.238717. Epub 2015 May 15.
REF00001614	miR-520h is crucial for DAPK2 regulation and breast cancer progression. Oncogene. 2016 Mar 3;35(9):1134-42. doi: 10.1038/onc.2015.168. Epub 2015 May 18.
REF00001615	Effect of Variants of Penicillin-Binding Protein 2 on Cephalosporin and Carbapenem Susceptibilities in Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2015 Aug;59(8):5003-6. doi: 10.1128/AAC.05143-14. Epub 2015 May 18.
REF00001616	Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer. Int J Cancer. 2015 Nov 15;137(10):2513-9. doi: 10.1002/ijc.29612. Epub 2015 Jun 11.
REF00001617	Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers. J Natl Cancer Inst. 2015 May 20;107(7):djv108. doi: 10.1093/jnci/djv108. Print 2015 Jul.
REF00001618	miR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2. Cell Death Dis. 2015 May 21;6(5):e1766. doi: 10.1038/cddis.2015.123.
REF00001619	miR-335 Targets SIAH2 and Confers Sensitivity to Anti-Cancer Drugs by Increasing the Expression of HDAC3. Mol Cells. 2015 Jun;38(6):562-72. doi: 10.14348/molcells.2015.0051. Epub 2015 May 22.
REF00001620	Implications of Glutathione Levels in the Plasmodium berghei Response to Chloroquine and Artemisinin. PLoS One. 2015 May 26;10(5):e0128212. doi: 10.1371/journal.pone.0128212. eCollection 2015.
REF00001621	Has miR 125a and 125b are induced by treatment with cisplatin in nasopharyngeal carcinoma and inhibit apoptosis in a p53 dependent manner by targeting p53 mRNA. Mol Med Rep. 2015 Sep;12(3):3569-3574. doi: 10.3892/mmr.2015.3863. Epub 2015 May 27.
REF00001622	Dynamic Proteome Response of Pseudomonas aeruginosa to Tobramycin Antibiotic Treatment. Mol Cell Proteomics. 2015 Aug;14(8):2126-37. doi: 10.1074/mcp.M115.050161. Epub 2015 May 27.
REF00001623	The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells. Mol Oncol. 2015 Oct;9(8):1678-93. doi: 10.1016/j.molonc.2015.04.015. Epub 2015 May 16.
REF00001624	miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts. Carcinogenesis. 2015 Aug;36(8):894-903. doi: 10.1093/carcin/bgv067. Epub 2015 May 30.
REF00001625	Proteomic Analysis of Drug-Resistant Mycobacteria: Co-Evolution of Copper and INH Resistance. PLoS One. 2015 Jun 2;10(6):e0127788. doi: 10.1371/journal.pone.0127788. eCollection 2015.
REF00001626	MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells. PLoS One. 2015 Jun 4;10(6):e0128886. doi: 10.1371/journal.pone.0128886. eCollection 2015.
REF00001627	MicroRNA-522 reverses drug resistance of doxorubicin-induced HT29 colon cancer cell by targeting ABCB5. Mol Med Rep. 2015 Sep;12(3):3930-3936. doi: 10.3892/mmr.2015.3890. Epub 2015 Jun 4.
REF00001628	Downregulation of Meg3 enhances cisplatin resistance of lung cancer cells through activation of the WNT/Beta-catenin signaling pathway. Mol Med Rep. 2015 Sep;12(3):4530-4537. doi: 10.3892/mmr.2015.3897. Epub 2015 Jun 8.
REF00001629	miR-130a activates apoptotic signaling through activation of caspase-8 in taxane-resistant prostate cancer cells. Prostate. 2015 Oct;75(14):1568-78. doi: 10.1002/pros.23031. Epub 2015 Jun 12.
REF00001630	CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcoma. Sci Rep. 2015 Jun 16;5:11365. doi: 10.1038/srep11365.
REF00001631	Carboplatin-docetaxel-induced activity against ovarian cancer is dependent on up-regulated lncRNA PVT1. Int J Clin Exp Pathol. 2015 Apr 1;8(4):3803-10. eCollection 2015.
REF00001632	Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanisms. Am J Cancer Res. 2015 Mar 15;5(4):1507-18. eCollection 2015.
REF00001633	MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. Expert Opin Ther Targets. 2015;19(8):1017-26. doi: 10.1517/14728222.2015.1057569. Epub 2015 Jun 24.
REF00001634	"The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation. Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8326-31. doi: 10.1073/pnas.1424220112. Epub 2015 Jun 25."
REF00001635	The Effect of MicroRNA-124 Overexpression on Anti-Tumor Drug Sensitivity. PLoS One. 2015 Jun 26;10(6):e0128472. doi: 10.1371/journal.pone.0128472. eCollection 2015.
REF00001636	Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat Genet. 2015 Aug;47(8):864-71. doi: 10.1038/ng.3333. Epub 2015 Jun 29.
REF00001637	Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors. Cancer Res Treat. 2016 Apr;48(2):546-52. doi: 10.4143/crt.2015.015. Epub 2015 Jun 22.
REF00001638	Identification of a Novel ALK G1123S Mutation in a Patient with ALK-rearranged Non-small-cell Lung Cancer Exhibiting Resistance to Ceritinib. J Thorac Oncol. 2015 Jul;10(7):e55-7. doi: 10.1097/JTO.0000000000000509.
REF00001639	LincHOTAIR epigenetically silences miR34a by binding to PRC2 to promote the epithelial-to-mesenchymal transition in human gastric cancer. Cell Death Dis. 2015 Jul 2;6(7):e1802. doi: 10.1038/cddis.2015.150.
REF00001640	Downregulation of miR-363 increases drug resistance in cisplatin-treated HepG2 by dysregulating Mcl-1. Gene. 2015 Nov 1;572(1):116-122. doi: 10.1016/j.gene.2015.07.002. Epub 2015 Jul 2.
REF00001641	MicroRNA-101 Suppresses Tumor Cell Proliferation by Acting as an Endogenous Proteasome Inhibitor via Targeting the Proteasome Assembly Factor POMP. Mol Cell. 2015 Jul 16;59(2):243-57. doi: 10.1016/j.molcel.2015.05.036. Epub 2015 Jul 2.
REF00001642	A cfr-like gene from Clostridium difficile confers multiple antibiotic resistance by the same mechanism as the cfr gene. Antimicrob Agents Chemother. 2015 Sep;59(9):5841-3. doi: 10.1128/AAC.01274-15. Epub 2015 Jul 6.
REF00001643	MicroRNA 197 reverses the drug resistance of fluorouracil induced SGC7901 cells by targeting mitogen activated protein kinase 1. Mol Med Rep. 2015 Oct;12(4):5019-25. doi: 10.3892/mmr.2015.4052. Epub 2015 Jul 7.
REF00001644	Multidrug-Resistance Transporter AbcA Secretes Staphylococcus aureus Cytolytic Toxins. J Infect Dis. 2016 Jan 15;213(2):295-304. doi: 10.1093/infdis/jiv376. Epub 2015 Jul 9.
REF00001645	"MicroRNA-200a Targets EGFR and c-Met to Inhibit Migration, Invasion, and Gefitinib Resistance in Non-Small Cell Lung Cancer. Cytogenet Genome Res. 2015;146(1):1-8. doi: 10.1159/000434741. Epub 2015 Jul 11."
REF00001646	Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4. BMC Cancer. 2015 Jul 24;15:540. doi: 10.1186/s12885-015-1561-x.
REF00001647	Reduced Let-7a Is Associated with Chemoresistance in Primary Breast Cancer. PLoS One. 2015 Jul 28;10(7):e0133643. doi: 10.1371/journal.pone.0133643. eCollection 2015.
REF00001648	Mutation of G234 amino acid residue in candida albicans drug-resistance-related protein Rta2p is associated with fluconazole resistance and dihydrosphingosine transport. Virulence. 2015;6(6):599-607. doi: 10.1080/21505594.2015.1051296.
REF00001649	p53-p66(shc)/miR-21-Sod2 signaling is critical for the inhibitory effect of betulinic acid on hepatocellular carcinoma. Toxicol Lett. 2015 Nov 4;238(3):1-10. doi: 10.1016/j.toxlet.2015.07.016. Epub 2015 Jul 26.
REF00001650	MiRNA-149 modulates chemosensitivity of ovarian cancer A2780 cells to paclitaxel by targeting MyD88. J Ovarian Res. 2015 Jul 30;8:48. doi: 10.1186/s13048-015-0178-7.
REF00001651	Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015 Oct 17;386(10003):1546-55. doi: 10.1016/S0140-6736(15)61412-X. Epub 2015 Jul 28.
REF00001652	miR-219-5p plays a tumor suppressive role in colon cancer by targeting oncogene Sall4. Oncol Rep. 2015 Oct;34(4):1923-32. doi: 10.3892/or.2015.4168. Epub 2015 Aug 4.
REF00001653	Substrate-bound structure of the E. coli multidrug resistance transporter MdfA. Cell Res. 2015 Sep;25(9):1060-73. doi: 10.1038/cr.2015.94. Epub 2015 Aug 4.
REF00001654	MicroRNA 133a and microRNA 326 co contribute to hepatocellular carcinoma 5 fluorouracil and cisplatin sensitivity by directly targeting B cell lymphoma extra large. Mol Med Rep. 2015 Oct;12(4):6235-40. doi: 10.3892/mmr.2015.4134. Epub 2015 Jul 29.
REF00001655	The R263K substitution in HIV-1 subtype C is more deleterious for integrase enzymatic function and viral replication than in subtype B. AIDS. 2015 Jul 31;29(12):1459-66. doi: 10.1097/QAD.0000000000000752.
REF00001656	MicroRNA-587 antagonizes 5-FU-induced apoptosis and confers drug resistance by regulating PPP2R1B expression in colorectal cancer. Cell Death Dis. 2015 Aug 6;6(8):e1845. doi: 10.1038/cddis.2015.200.
REF00001657	A Novel Y319H Substitution in CYP51C Associated with Azole Resistance in Aspergillus flavus. Antimicrob Agents Chemother. 2015 Oct;59(10):6615-9. doi: 10.1128/AAC.00637-15. Epub 2015 Jul 27.
REF00001658	"Detection of a New cfr-Like Gene, cfr(B), in Enterococcus faecium Isolates Recovered from Human Specimens in the United States as Part of the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother. 2015 Oct;59(10):6256-61. doi: 10.1128/AAC.01473-15. Epub 2015 Jul 27."
REF00001659	miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patients. Int J Mol Sci. 2015 Aug 5;16(8):18077-95. doi: 10.3390/ijms160818077.
REF00001660	Knockdown of microRNA-127 reverses adriamycin resistance via cell cycle arrest and apoptosis sensitization in adriamycin-resistant human glioma cells. Int J Clin Exp Pathol. 2015 Jun 1;8(6):6107-16. eCollection 2015.
REF00001661	MiR-218 inhibits multidrug resistance (MDR) of gastric cancer cells by targeting Hedgehog/smoothened. Int J Clin Exp Pathol. 2015 Jun 1;8(6):6397-406. eCollection 2015.
REF00001662	Bone Marrow MicroRNA-335 Level Predicts the Chemotherapy Response and Prognosis of Adult Acute Myeloid Leukemia. Medicine (Baltimore). 2015 Aug;94(33):e0986. doi: 10.1097/MD.0000000000000986.
REF00001663	Fentanyl inhibits the invasion and migration of colorectal cancer cells via inhibiting the negative regulation of Ets-1 on BANCR. Biochem Biophys Res Commun. 2015 Sep 25;465(3):594-600. doi: 10.1016/j.bbrc.2015.08.068. Epub 2015 Aug 18.
REF00001664	MiR-139-5p inhibits the biological function of breast cancer cells by targeting Notch1 and mediates chemosensitivity to docetaxel. Biochem Biophys Res Commun. 2015 Oct 2;465(4):702-13. doi: 10.1016/j.bbrc.2015.08.053. Epub 2015 Aug 20.
REF00001665	Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. PLoS One. 2015 Aug 24;10(8):e0136155. doi: 10.1371/journal.pone.0136155. eCollection 2015.
REF00001666	Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015 Dec 1;121(23):4158-64. doi: 10.1002/cncr.29646. Epub 2015 Aug 26.
REF00001667	Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K). Onco Targets Ther. 2015 Aug 18;8:1997-2003. doi: 10.2147/OTT.S81558. eCollection 2015.
REF00001668	Breast Cancer Anti-Estrogen Resistance 4 (BCAR4) Drives Proliferation of IPH-926 lobular Carcinoma Cells. PLoS One. 2015 Aug 28;10(8):e0136845. doi: 10.1371/journal.pone.0136845. eCollection 2015.
REF00001669	MiR-873 acts as a novel sensitizer of glioma cells to cisplatin by targeting Bcl-2. Int J Oncol. 2015 Oct;47(4):1603-11. doi: 10.3892/ijo.2015.3143. Epub 2015 Aug 31.
REF00001670	MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells. Int J Oncol. 2015 Oct;47(4):1379-92. doi: 10.3892/ijo.2015.3144. Epub 2015 Aug 31.
REF00001671	"A novel mitosis-associated lncRNA, MA-linc1, is required for cell cycle progression and sensitizes cancer cells to Paclitaxel. Oncotarget. 2015 Sep 29;6(29):27880-90. doi: 10.18632/oncotarget.4944."
REF00001672	Up-regulation of miR-125b reverses epithelial-mesenchymal transition in paclitaxel-resistant lung cancer cells. Biol Chem. 2015 Aug 20:/j/bchm.just-accepted/hsz-2015-0153/hsz-2015-0153.xml. doi: 10.1515/hsz-2015-0153. Online ahead of print.
REF00001673	LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer. Oncogene. 2016 May;35(21):2746-55. doi: 10.1038/onc.2015.340. Epub 2015 Sep 14.
REF00001674	Functional Characterization of Sirtuin-like Protein in Mycobacterium smegmatis. J Proteome Res. 2015 Nov 6;14(11):4441-9. doi: 10.1021/acs.jproteome.5b00359. Epub 2015 Sep 29.
REF00001675	MicroRNA-133b targets glutathione S-transferase Pi expression to increase ovarian cancer cell sensitivity to chemotherapy drugs. Drug Des Devel Ther. 2015 Sep 16;9:5225-35. doi: 10.2147/DDDT.S87526. eCollection 2015.
REF00001676	Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer. Sci Rep. 2015 Sep 24;5:14447. doi: 10.1038/srep14447.
REF00001677	"Characterizing of Four Common BCR-ABL Kinase Domain Mutations (T315I, Y253H, M351T and E255K) in Iranian Chronic Myelogenous Leukemia Patients With Imatinib Resistance. Iran J Cancer Prev. 2015 May;8(3):e2334. doi: 10.17795/ijcp2334. Epub 2015 May 27."
REF00001678	miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity. Oncotarget. 2015 Oct 20;6(32):32774-89. doi: 10.18632/oncotarget.5192.
REF00001679	[Drug resistance of colon cancer cells to 5-fluorouracil mediated by microRNA-21]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2015 Oct;32(5):620-4. doi: 10.3760/cma.j.issn.1003-9406.2015.05.003.
REF00001680	"Mutations in the Plasmodium falciparum chloroquine resistance transporter, PfCRT, enlarge the parasite's food vacuole and alter drug sensitivities. Sci Rep. 2015 Sep 30;5:14552. doi: 10.1038/srep14552."
REF00001681	Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens. Transl Res. 2015 Dec;166(6):540-553.e2. doi: 10.1016/j.trsl.2015.09.003. Epub 2015 Sep 14.
REF00001682	MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. Oncotarget. 2015 Nov 10;6(35):37269-80. doi: 10.18632/oncotarget.5495.
REF00001683	Emergence of daptomycin non-susceptibility in colonizing vancomycin-resistant Enterococcus faecium isolates during daptomycin therapy. Int J Med Microbiol. 2015 Dec;305(8):902-9. doi: 10.1016/j.ijmm.2015.09.005. Epub 2015 Sep 12.
REF00001684	MiR-26a enhances the sensitivity of gastric cancer cells to cisplatin by targeting NRAS and E2F2. Saudi J Gastroenterol. 2015 Sep-Oct;21(5):313-9. doi: 10.4103/1319-3767.166206.
REF00001685	WT1-AS promotes cell apoptosis in hepatocellular carcinoma through down-regulating of WT1. J Exp Clin Cancer Res. 2015 Oct 13;34:119. doi: 10.1186/s13046-015-0233-7.
REF00001686	ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression. Lung Cancer. 2016 Jan;91:70-2. doi: 10.1016/j.lungcan.2015.09.006. Epub 2015 Sep 12.
REF00001687	"Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor. J Thorac Oncol. 2015 Dec;10(12):1736-44. doi: 10.1097/JTO.0000000000000688."
REF00001688	Decreased MicroRNA-26a expression causes cisplatin resistance in human non-small cell lung cancer. Cancer Biol Ther. 2016 May 3;17(5):515-25. doi: 10.1080/15384047.2015.1095405. Epub 2015 Oct 22.
REF00001689	Functional studies of miR-130a on the inhibitory pathways of apoptosis in patients with chronic myeloid leukemia. Cancer Gene Ther. 2015 Dec;22(12):573-80. doi: 10.1038/cgt.2015.50. Epub 2015 Oct 23.
REF00001690	MicroRNA-17-5p induces drug resistance and invasion of ovarian carcinoma cells by targeting PTEN signaling. J Biol Res (Thessalon). 2015 Oct 22;22:12. doi: 10.1186/s40709-015-0035-2. eCollection 2015 Dec.
REF00001691	Verapamil-Sensitive Transport of Quinacrine and Methylene Blue via the Plasmodium falciparum Chloroquine Resistance Transporter Reduces the Parasite's Susceptibility to these Tricyclic Drugs. J Infect Dis. 2016 Mar 1;213(5):800-10. doi: 10.1093/infdis/jiv509. Epub 2015 Oct 26.
REF00001692	Propofol promotes cell apoptosis via inhibiting HOTAIR mediated mTOR pathway in cervical cancer. Biochem Biophys Res Commun. 2015 Dec 25;468(4):561-7. doi: 10.1016/j.bbrc.2015.10.129. Epub 2015 Oct 31.
REF00001693	Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget. 2015 Dec 8;6(39):42008-18. doi: 10.18632/oncotarget.5788.
REF00001694	miR-193b Modulates Resistance to Doxorubicin in Human Breast Cancer Cells by Downregulating MCL-1. Biomed Res Int. 2015;2015:373574. doi: 10.1155/2015/373574. Epub 2015 Oct 7.
REF00001695	A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells. Clin Cancer Res. 2016 Mar 1;22(5):1222-33. doi: 10.1158/1078-0432.CCR-15-0489. Epub 2015 Nov 2.
REF00001696	MiR-143 enhances the antitumor activity of shikonin by targeting BAG3 expression in human glioblastoma stem cells. Biochem Biophys Res Commun. 2015 Dec 4-11;468(1-2):105-12. doi: 10.1016/j.bbrc.2015.10.153. Epub 2015 Nov 2.
REF00001697	miR-146b-5p promotes invasion and metastasis contributing to chemoresistance in osteosarcoma by targeting zinc and ring finger 3. Oncol Rep. 2016 Jan;35(1):275-83. doi: 10.3892/or.2015.4393. Epub 2015 Nov 4.
REF00001698	Molecular mechanism of increased sensitivity of cisplatin to ovarian cancer by inhibition of microRNA-23a expression. Int J Clin Exp Med. 2015 Aug 15;8(8):13329-34. eCollection 2015.
REF00001699	[Effects of miRNA-21 on paclitaxel-resistance in human breast cancer cells]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2015 Jul;44(4):400-9. doi: 10.3785/j.issn.1008-9292.2015.07.09.
REF00001700	Four Amino Acid Changes in HIV-2 Protease Confer Class-Wide Sensitivity to Protease Inhibitors. J Virol. 2015 Nov 11;90(2):1062-9. doi: 10.1128/JVI.01772-15. Print 2016 Jan 15.
REF00001701	Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. 2015 Nov 26;527(7579):472-6. doi: 10.1038/nature15748. Epub 2015 Nov 11.
REF00001702	Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway. Oncotarget. 2015 Dec 29;6(42):44466-79. doi: 10.18632/oncotarget.6298.
REF00001703	[miR-29b Reduces Cisplatin Resistance of Gastric Cancer Cell by Targeting PI3K/Akt Pathway]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2015 Oct;37(5):514-9. doi: 10.3881/j.issn.1000-503X.2015.05.005.
REF00001704	MiR-181b promotes chemoresistance in breast cancer by regulating Bim expression. Oncol Rep. 2016 Feb;35(2):683-90. doi: 10.3892/or.2015.4417. Epub 2015 Nov 13.
REF00001705	MicroRNA-101 induces apoptosis in cisplatin-resistant gastric cancer cells by targeting VEGF-C. Mol Med Rep. 2016 Jan;13(1):572-8. doi: 10.3892/mmr.2015.4560. Epub 2015 Nov 12.
REF00001706	MiR-106b~25 cluster regulates multidrug resistance in an ABC transporter-independent manner via downregulation of EP300. Oncol Rep. 2016 Feb;35(2):1170-8. doi: 10.3892/or.2015.4412. Epub 2015 Nov 12.
REF00001707	miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway. Mol Cancer. 2015 Nov 17;14:196. doi: 10.1186/s12943-015-0464-4.
REF00001708	MiR-181a suppresses autophagy and sensitizes gastric cancer cells to cisplatin. Gene. 2016 Feb 1;576(2 Pt 2):828-33. doi: 10.1016/j.gene.2015.11.013. Epub 2015 Nov 14.
REF00001709	MicroRNA-203 Is a Prognostic Indicator in Bladder Cancer and Enhances Chemosensitivity to Cisplatin via Apoptosis by Targeting Bcl-w and Survivin. PLoS One. 2015 Nov 23;10(11):e0143441. doi: 10.1371/journal.pone.0143441. eCollection 2015.
REF00001710	[Expression of microRNA-100 and its correlation with drug resistance in human ovarian cancer SKOV3/DDP cells]. Nan Fang Yi Ke Da Xue Xue Bao. 2015 Nov;35(11):1624-7.
REF00001711	Rapid clearance of circulating tumor DNA during treatment with AZD9291 of a lung cancer patient presenting the resistance EGFR T790M mutation. Lung Cancer. 2016 Jan;91:73-4. doi: 10.1016/j.lungcan.2015.11.008. Epub 2015 Nov 7.
REF00001712	MicroRNA-299-3p promotes the sensibility of lung cancer to doxorubicin through directly targeting ABCE1. Int J Clin Exp Pathol. 2015 Sep 1;8(9):10072-81. eCollection 2015.
REF00001713	MiR-181b regulates cisplatin chemosensitivity and metastasis by targeting TGFBetaR1/Smad signaling pathway in NSCLC. Sci Rep. 2015 Dec 1;5:17618. doi: 10.1038/srep17618.
REF00001714	miR-302b enhances breast cancer cell sensitivity to cisplatin by regulating E2F1 and the cellular DNA damage response. Oncotarget. 2016 Jan 5;7(1):786-97. doi: 10.18632/oncotarget.6381.
REF00001715	MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1. J Ovarian Res. 2015 Dec 2;8:80. doi: 10.1186/s13048-015-0207-6.
REF00001716	"Overexpression of Lin28 Decreases the Chemosensitivity of Gastric Cancer Cells to Oxaliplatin, Paclitaxel, Doxorubicin, and Fluorouracil in Part via microRNA-107. PLoS One. 2015 Dec 4;10(12):e0143716. doi: 10.1371/journal.pone.0143716. eCollection 2015."
REF00001717	miR-302a/b/c/d cooperatively inhibit BCRP expression to increase drug sensitivity in breast cancer cells. Gynecol Oncol. 2016 Jun;141(3):592-601. doi: 10.1016/j.ygyno.2015.11.034. Epub 2015 Nov 28.
REF00001718	MicroRNA-425-5p regulates chemoresistance in colorectal cancer cells via regulation of Programmed Cell Death 10. J Cell Mol Med. 2016 Feb;20(2):360-9. doi: 10.1111/jcmm.12742. Epub 2015 Dec 9.
REF00001719	Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients. Onco Targets Ther. 2015 Nov 11;8:3323-8. doi: 10.2147/OTT.S92443. eCollection 2015.
REF00001720	BAG3-mediated miRNA let-7g and let-7i inhibit proliferation and enhance apoptosis of human esophageal carcinoma cells by targeting the drug transporter ABCC10. Cancer Lett. 2016 Feb 1;371(1):125-33. doi: 10.1016/j.canlet.2015.11.031. Epub 2015 Dec 3.
REF00001721	MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways. Cancer Lett. 2016 Feb 28;371(2):171-81. doi: 10.1016/j.canlet.2015.11.034. Epub 2015 Dec 3.
REF00001722	MiR-214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagy. Mol Cancer. 2015 Dec 15;14:208. doi: 10.1186/s12943-015-0480-4.
REF00001723	MicroRNA-497 inhibits tumor growth and increases chemosensitivity to 5-fluorouracil treatment by targeting KSR1. Oncotarget. 2016 Jan 19;7(3):2660-71. doi: 10.18632/oncotarget.6545.
REF00001724	miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma. Oncotarget. 2016 Jan 26;7(4):4009-23. doi: 10.18632/oncotarget.6546.
REF00001725	"Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b. Oncotarget. 2016 Jan 26;7(4):4428-41. doi: 10.18632/oncotarget.6599."
REF00001726	Metformin Induces Cell Cycle Arrest and Apoptosis in Drug-Resistant Leukemia Cells. Leuk Res Treatment. 2015;2015:516460. doi: 10.1155/2015/516460. Epub 2015 Nov 25.
REF00001727	Study on the Association Between miRNA-202 Expression and Drug Sensitivity in Multiple Myeloma Cells. Pathol Oncol Res. 2016 Jul;22(3):531-9. doi: 10.1007/s12253-015-0035-4. Epub 2015 Dec 21.
REF00001728	MiRNA-155 mediates TAM resistance by modulating SOCS6-STAT3 signalling pathway in breast cancer. Am J Transl Res. 2015 Oct 15;7(10):2115-26. eCollection 2015.
REF00001729	Increased fucosylation has a pivotal role in multidrug resistance of breast cancer cells through miR-224-3p targeting FUT4. Gene. 2016 Mar 10;578(2):232-41. doi: 10.1016/j.gene.2015.12.028. Epub 2015 Dec 14.
REF00001730	MicroRNA-30a downregulation contributes to chemoresistance of osteosarcoma cells through activating Beclin-1-mediated autophagy. Oncol Rep. 2016 Mar;35(3):1757-63. doi: 10.3892/or.2015.4497. Epub 2015 Dec 18.
REF00001731	MicroRNA-101 sensitizes hepatocellular carcinoma cells to doxorubicin-induced apoptosis via targeting Mcl-1. Mol Med Rep. 2016 Feb;13(2):1923-9. doi: 10.3892/mmr.2015.4727. Epub 2015 Dec 28.
REF00001732	MiR-16 modulate temozolomide resistance by regulating BCL-2 in human glioma cells. Int J Clin Exp Pathol. 2015 Oct 1;8(10):12698-707. eCollection 2015.
REF00001733	miR-193a-3p regulation of chemoradiation resistance in oesophageal cancer cells via the PSEN1 gene. Gene. 2016 Apr 1;579(2):139-45. doi: 10.1016/j.gene.2015.12.060. Epub 2015 Dec 29.
REF00001734	MiR-125b Functions as a Tumor Suppressor and Enhances Chemosensitivity to Cisplatin in Osteosarcoma. Technol Cancer Res Treat. 2016 Dec;15(6):NP105-NP112. doi: 10.1177/1533034615618849. Epub 2016 Jan 6.
REF00001735	MicroRNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR. Oncotarget. 2016 Feb 2;7(5):5702-14. doi: 10.18632/oncotarget.6790.
REF00001736	"Squamous Cell Carcinoma ""Transformation"" Concurrent with Secondary T790M Mutation in Resistant EGFR-Mutated Adenocarcinomas. J Thorac Oncol. 2016 Apr;11(4):e49-51. doi: 10.1016/j.jtho.2015.12.096. Epub 2015 Dec 30."
REF00001737	Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer. J Thorac Oncol. 2016 Apr;11(4):e45-7. doi: 10.1016/j.jtho.2015.12.093. Epub 2015 Dec 31.
REF00001738	MiR-125a regulates chemo-sensitivity to gemcitabine in human pancreatic cancer cells through targeting A20. Acta Biochim Biophys Sin (Shanghai). 2016 Feb;48(2):202-8. doi: 10.1093/abbs/gmv129. Epub 2016 Jan 11.
REF00001739	miR-1182 inhibits growth and mediates the chemosensitivity of bladder cancer by targeting hTERT. Biochem Biophys Res Commun. 2016 Feb 5;470(2):445-452. doi: 10.1016/j.bbrc.2016.01.014. Epub 2016 Jan 7.
REF00001740	Detecting Secondary C-KIT Mutations in the Peripheral Blood of Patients with Imatinib-Resistant Gastrointestinal Stromal Tumor. Oncology. 2016;90(2):112-7. doi: 10.1159/000442948. Epub 2016 Jan 19.
REF00001741	miRNA-378 reverses chemoresistance to cisplatin in lung adenocarcinoma cells by targeting secreted clusterin. Sci Rep. 2016 Jan 19;6:19455. doi: 10.1038/srep19455.
REF00001742	miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells. Int J Oncol. 2016 Mar;48(3):937-44. doi: 10.3892/ijo.2016.3331. Epub 2016 Jan 11.
REF00001743	MicroRNA-509-3p increases the sensitivity of epithelial ovarian cancer cells to cisplatin-induced apoptosis. Pharmacogenomics. 2016 Feb;17(3):187-97. doi: 10.2217/pgs.15.166. Epub 2016 Jan 20.
REF00001744	Novel Genes Related to Ceftriaxone Resistance Found among Ceftriaxone-Resistant Neisseria gonorrhoeae Strains Selected In Vitro. Antimicrob Agents Chemother. 2016 Mar 25;60(4):2043-51. doi: 10.1128/AAC.00149-15. Print 2016 Apr.
REF00001745	Silencing of MicroRNA-21 confers the sensitivity to tamoxifen and fulvestrant by enhancing autophagic cell death through inhibition of the PI3K-AKT-mTOR pathway in breast cancer cells. Biomed Pharmacother. 2016 Feb;77:37-44. doi: 10.1016/j.biopha.2015.11.005. Epub 2015 Dec 12.
REF00001746	"miR-493 mediated DKK1 down-regulation confers proliferation, invasion and chemo-resistance in gastric cancer cells. Oncotarget. 2016 Feb 9;7(6):7044-54. doi: 10.18632/oncotarget.6951."
REF00001747	Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism. Cancer Lett. 2016 Apr 1;373(1):36-44. doi: 10.1016/j.canlet.2016.01.009. Epub 2016 Jan 19.
REF00001748	miR-143 or miR-145 overexpression increases cetuximab-mediated antibody-dependent cellular cytotoxicity in human colon cancer cells. Oncotarget. 2016 Feb 23;7(8):9368-87. doi: 10.18632/oncotarget.7010.
REF00001749	MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer. Cancer Lett. 2016 Apr 1;373(1):130-137. doi: 10.1016/j.canlet.2016.01.038. Epub 2016 Jan 28.
REF00001750	MiR-302a/b/c/d cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein(P-gp) by targeting MAP/ERK kinase kinase 1 (MEKK1). J Exp Clin Cancer Res. 2016 Feb 3;35:25. doi: 10.1186/s13046-016-0300-8.
REF00001751	miR-137 Suppresses the Phosphorylation of AKT and Improves the Dexamethasone Sensitivity in Multiple Myeloma Cells Via Targeting MITF. Curr Cancer Drug Targets. 2016;16(9):807-817. doi: 10.2174/1568009616666160203114140.
REF00001752	miR-450b-5p Suppresses Stemness and the Development of Chemoresistance by Targeting SOX2 in Colorectal Cancer. DNA Cell Biol. 2016 May;35(5):249-56. doi: 10.1089/dna.2015.3120. Epub 2016 Feb 4.
REF00001753	"Longitudinal copy number, whole exome and targeted deep sequencing of 'good risk' IGHV-mutated CLL patients with progressive disease. Leukemia. 2016 Jun;30(6):1301-10. doi: 10.1038/leu.2016.10. Epub 2016 Feb 5."
REF00001754	The Plasmodium falciparum chloroquine resistance transporter is associated with the ex vivo P. falciparum African parasite response to pyronaridine. Parasit Vectors. 2016 Feb 9;9:77. doi: 10.1186/s13071-016-1358-z.
REF00001755	The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. Oncotarget. 2016 Mar 15;7(11):12404-13. doi: 10.18632/oncotarget.7189.
REF00001756	MicroRNA-21 induces 5-fluorouracil resistance in human pancreatic cancer cells by regulating PTEN and PDCD4. Cancer Med. 2016 Apr;5(4):693-702. doi: 10.1002/cam4.626. Epub 2016 Feb 10.
REF00001757	Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition. Blood. 2016 Apr 28;127(17):2155-7. doi: 10.1182/blood-2015-12-686782. Epub 2016 Feb 16.
REF00001758	Overexpression of long non-coding RNA PVT1 in ovarian cancer cells promotes cisplatin resistance by regulating apoptotic pathways. Int J Clin Exp Med. 2015 Nov 15;8(11):20565-72. eCollection 2015.
REF00001759	MicroRNA-138 promotes acquired alkylator resistance in glioblastoma by targeting the Bcl-2-interacting mediator BIM. Oncotarget. 2016 Mar 15;7(11):12937-50. doi: 10.18632/oncotarget.7346.
REF00001760	miR-17-92 plays an oncogenic role and conveys chemo-resistance to cisplatin in human prostate cancer cells. Int J Oncol. 2016 Apr;48(4):1737-48. doi: 10.3892/ijo.2016.3392. Epub 2016 Feb 15.
REF00001761	MicroRNA-205 increases the sensitivity of docetaxel in breast cancer. Oncol Lett. 2016 Feb;11(2):1105-1109. doi: 10.3892/ol.2015.4030. Epub 2015 Dec 11.
REF00001762	Effect of miR-155 knockdown on the reversal of doxorubicin resistance in human lung cancer A549/dox cells. Oncol Lett. 2016 Feb;11(2):1161-1166. doi: 10.3892/ol.2015.3995. Epub 2015 Dec 3.
REF00001763	"Over-expression of miR-451a can enhance the sensitivity of breast cancer cells to tamoxifen by regulating 14-3-3 Zeta, estrogen receptor Alpha, and autophagy. Life Sci. 2016 Mar 15;149:104-13. doi: 10.1016/j.lfs.2016.02.059. Epub 2016 Feb 17."
REF00001764	The ancient small mobilizable plasmid pALWED1.8 harboring a new variant of the non-cassette streptomycin/spectinomycin resistance gene aadA27. Plasmid. 2016 Mar-May;84-85:36-43. doi: 10.1016/j.plasmid.2016.02.005. Epub 2016 Feb 16.
REF00001765	"miR-194 inhibits the proliferation, invasion, migration, and enhances the chemosensitivity of non-small cell lung cancer cells by targeting forkhead box A1 protein. Oncotarget. 2016 Mar 15;7(11):13139-52. doi: 10.18632/oncotarget.7545."
REF00001766	miR-409-3p sensitizes colon cancer cells to oxaliplatin by inhibiting Beclin-1-mediated autophagy. Int J Mol Med. 2016 Apr;37(4):1030-8. doi: 10.3892/ijmm.2016.2492. Epub 2016 Feb 18.
REF00001767	Downregulation of microRNA-196a enhances the sensitivity of non-small cell lung cancer cells to cisplatin treatment. Int J Mol Med. 2016 Apr;37(4):1067-74. doi: 10.3892/ijmm.2016.2513. Epub 2016 Mar 1.
REF00001768	"MicroRNA-141 and its associated gene FUS modulate proliferation, migration and cisplatin chemosensitivity in neuroblastoma cell lines. Oncol Rep. 2016 May;35(5):2943-51. doi: 10.3892/or.2016.4640. Epub 2016 Feb 26."
REF00001769	MiR-1284 modulates multidrug resistance of gastric cancer cells by targeting EIF4A1. Oncol Rep. 2016 May;35(5):2583-91. doi: 10.3892/or.2016.4643. Epub 2016 Feb 29.
REF00001770	Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse. Cancer Res. 2016 Apr 15;76(8):2197-205. doi: 10.1158/0008-5472.CAN-15-1015. Epub 2016 Mar 3.
REF00001771	miR-203 inhibits cell proliferation and promotes cisplatin induced cell death in tongue squamous cancer. Biochem Biophys Res Commun. 2016 Apr 29;473(2):382-7. doi: 10.1016/j.bbrc.2016.02.105. Epub 2016 Mar 3.
REF00001772	miR-125b acts as a tumor suppressor in chondrosarcoma cells by the sensitization to doxorubicin through direct targeting the ErbB2-regulated glucose metabolism. Drug Des Devel Ther. 2016 Feb 24;10:571-83. doi: 10.2147/DDDT.S90530. eCollection 2016.
REF00001773	Genetic progression of malignant melanoma. Cancer Metastasis Rev. 2016 Mar;35(1):93-107. doi: 10.1007/s10555-016-9613-5.
REF00001774	MicroRNA-137 inhibits tumor growth and sensitizes chemosensitivity to paclitaxel and cisplatin in lung cancer. Oncotarget. 2016 Apr 12;7(15):20728-42. doi: 10.18632/oncotarget.8011.
REF00001775	MicroRNA-16 sensitizes breast cancer cells to paclitaxel through suppression of IKBKB expression. Oncotarget. 2016 Apr 26;7(17):23668-83. doi: 10.18632/oncotarget.8056.
REF00001776	Clonal origin and spread of metastatic prostate cancer. Endocr Relat Cancer. 2016 Apr;23(4):R207-17. doi: 10.1530/ERC-16-0049. Epub 2016 Mar 21.
REF00001777	"Q148N, a Novel Integrase Inhibitor Resistance Mutation Associated with Low-Level Reduction in Elvitegravir Susceptibility. AIDS Res Hum Retroviruses. 2016 Jul;32(7):702-4. doi: 10.1089/AID.2016.0038. Epub 2016 Apr 19."
REF00001778	MiR-424 and miR-27a increase TRAIL sensitivity of acute myeloid leukemia by targeting PLAG1. Oncotarget. 2016 May 3;7(18):25276-90. doi: 10.18632/oncotarget.8252.
REF00001779	miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET. Oncotarget. 2016 Apr 26;7(17):24510-26. doi: 10.18632/oncotarget.8229.
REF00001780	Nrf2 inhibition sensitizes cholangiocarcinoma cells to cytotoxic and antiproliferative activities of chemotherapeutic agents. Tumour Biol. 2016 Aug;37(8):11495-507. doi: 10.1007/s13277-016-5015-0. Epub 2016 Mar 25.
REF00001781	"MicroRNA-421 regulated by HIF-1Alpha promotes metastasis, inhibits apoptosis, and induces cisplatin resistance by targeting E-cadherin and caspase-3 in gastric cancer. Oncotarget. 2016 Apr 26;7(17):24466-82. doi: 10.18632/oncotarget.8228."
REF00001782	MiR-138 Acts as a Tumor Suppressor by Targeting EZH2 and Enhances Cisplatin-Induced Apoptosis in Osteosarcoma Cells. PLoS One. 2016 Mar 28;11(3):e0150026. doi: 10.1371/journal.pone.0150026. eCollection 2016.
REF00001783	Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat Commun. 2016 Mar 29;7:11150. doi: 10.1038/ncomms11150.
REF00001784	Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer. Oncotarget. 2016 May 10;7(19):27778-86. doi: 10.18632/oncotarget.8413.
REF00001785	Plasmodium falciparum chloroquine resistance transporter (PfCRT) isoforms PH1 and PH2 perturb vacuolar physiology. Malar J. 2016 Mar 31;15:186. doi: 10.1186/s12936-016-1238-1.
REF00001786	Relation of the Allelic Variants of Multidrug Resistance Gene to Agranulocytosis Associated With Clozapine. J Clin Psychopharmacol. 2016 Jun;36(3):257-61. doi: 10.1097/JCP.0000000000000495.
REF00001787	MicroRNA-3646 Contributes to Docetaxel Resistance in Human Breast Cancer Cells by GSK-3Beta/Beta-Catenin Signaling Pathway. PLoS One. 2016 Apr 5;11(4):e0153194. doi: 10.1371/journal.pone.0153194. eCollection 2016.
REF00001788	Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing. PLoS One. 2016 Apr 5;11(4):e0153065. doi: 10.1371/journal.pone.0153065. eCollection 2016.
REF00001789	LncRNA-UCA1 enhances cell proliferation and 5-fluorouracil resistance in colorectal cancer by inhibiting miR-204-5p. Sci Rep. 2016 Apr 5;6:23892. doi: 10.1038/srep23892.
REF00001790	MicroRNA-138 regulates chemoresistance in human non-small cell lung cancer via epithelial mesenchymal transition. Eur Rev Med Pharmacol Sci. 2016;20(6):1080-6.
REF00001791	MicroRNA-520g promotes epithelial ovarian cancer progression and chemoresistance via DAPK2 repression. Oncotarget. 2016 May 3;7(18):26516-34. doi: 10.18632/oncotarget.8530.
REF00001792	MicroRNA-31 functions as a tumor suppressor and increases sensitivity to mitomycin-C in urothelial bladder cancer by targeting integrin Alpha5. Oncotarget. 2016 May 10;7(19):27445-57. doi: 10.18632/oncotarget.8479.
REF00001793	MiR-34a-5p promotes the multi-drug resistance of osteosarcoma by targeting the CD117 gene. Oncotarget. 2016 May 10;7(19):28420-34. doi: 10.18632/oncotarget.8546.
REF00001794	[Expression of MiR-130a in Serum Samples of Patients with Epithelial Ovarian Cancer and Its Association with Platinum Resistance]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2016 Jan;47(1):60-3.
REF00001795	An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer. J Thorac Oncol. 2016 Aug;11(8):1273-1281. doi: 10.1016/j.jtho.2016.04.001. Epub 2016 Apr 9.
REF00001796	"Mutational prevalence of chloroquine resistance transporter gene among Plasmodium falciparum field isolates in Assam and Arunachal Pradesh, India. Indian J Med Microbiol. 2016 Apr-Jun;34(2):193-7. doi: 10.4103/0255-0857.180298."
REF00001797	Inhibition of c-FLIPL expression by miRNA-708 increases the sensitivity of renal cancer cells to anti-cancer drugs. Oncotarget. 2016 May 31;7(22):31832-46. doi: 10.18632/oncotarget.7149.
REF00001798	miR-3188 regulates nasopharyngeal carcinoma proliferation and chemosensitivity through a FOXO1-modulated positive feedback loop with mTOR-p-PI3K/AKT-c-JUN. Nat Commun. 2016 Apr 20;7:11309. doi: 10.1038/ncomms11309.
REF00001799	Targeting the MIR34C-5p-ATG4B-autophagy axis enhances the sensitivity of cervical cancer cells to pirarubicin. Autophagy. 2016 Jul 2;12(7):1105-17. doi: 10.1080/15548627.2016.1173798. Epub 2016 Apr 20.
REF00001800	miR-487b-5p Regulates Temozolomide Resistance of Lung Cancer Cells Through LAMP2-Medicated Autophagy. DNA Cell Biol. 2016 Aug;35(8):385-92. doi: 10.1089/dna.2016.3259. Epub 2016 Apr 20.
REF00001801	Rifampin phosphotransferase is an unusual antibiotic resistance kinase. Nat Commun. 2016 Apr 22;7:11343. doi: 10.1038/ncomms11343.
REF00001802	The importance of DNA methylation in prostate cancer development. J Steroid Biochem Mol Biol. 2017 Feb;166:1-15. doi: 10.1016/j.jsbmb.2016.04.009. Epub 2016 Apr 24.
REF00001803	Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA. Cancer Cell. 2016 May 9;29(5):653-668. doi: 10.1016/j.ccell.2016.03.004. Epub 2016 Apr 21.
REF00001804	miR-133a enhances the sensitivity of Hep-2 cells and vincristine-resistant Hep-2v cells to cisplatin by downregulating ATP7B expression. Int J Mol Med. 2016 Jun;37(6):1636-42. doi: 10.3892/ijmm.2016.2569. Epub 2016 Apr 20.
REF00001805	Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review. Clin Lung Cancer. 2016 Sep;17(5):e77-e94. doi: 10.1016/j.cllc.2016.03.005. Epub 2016 Mar 30.
REF00001806	miR-146a Inhibits Proliferation and Enhances Chemosensitivity in Epithelial Ovarian Cancer via Reduction of SOD2. Oncol Res. 2016;23(6):275-82. doi: 10.3727/096504016X14562725373798.
REF00001807	MiR-122 Reverses the Doxorubicin-Resistance in Hepatocellular Carcinoma Cells through Regulating the Tumor Metabolism. PLoS One. 2016 May 3;11(5):e0152090. doi: 10.1371/journal.pone.0152090. eCollection 2016.
REF00001808	miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint. Nat Commun. 2016 May 5;7:11406. doi: 10.1038/ncomms11406.
REF00001809	Proposal for a unified nomenclature for target-site mutations associated with resistance to fungicides. Pest Manag Sci. 2016 Aug;72(8):1449-59. doi: 10.1002/ps.4301. Epub 2016 Jun 16.
REF00001810	"The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 2016 May 10;7:11479. doi: 10.1038/ncomms11479."
REF00001811	Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes. Cancer Lett. 2016 Aug 10;378(2):69-79. doi: 10.1016/j.canlet.2016.05.004. Epub 2016 May 6.
REF00001812	miR-363 promotes proliferation and chemo-resistance of human gastric cancer via targeting of FBW7 ubiquitin ligase expression. Oncotarget. 2016 Jun 7;7(23):35284-92. doi: 10.18632/oncotarget.9169.
REF00001813	Suppression of SPIN1-mediated PI3K-Akt pathway by miR-489 increases chemosensitivity in breast cancer. J Pathol. 2016 Aug;239(4):459-72. doi: 10.1002/path.4743. Epub 2016 Jul 1.
REF00001814	miR-139-5p sensitizes colorectal cancer cells to 5-fluorouracil by targeting NOTCH-1. Pathol Res Pract. 2016 Jul;212(7):643-9. doi: 10.1016/j.prp.2016.04.011. Epub 2016 May 3.
REF00001815	[Investigation of fluoroquinolone resistance mechanisms in clinical Acinetobacter baumannii isolates]. Mikrobiyol Bul. 2016 Apr;50(2):278-86. doi: 10.5578/mb.24126.
REF00001816	miR-223 enhances the sensitivity of non-small cell lung cancer cells to erlotinib by targeting the insulin-like growth factor-1 receptor. Int J Mol Med. 2016 Jul;38(1):183-91. doi: 10.3892/ijmm.2016.2588. Epub 2016 May 13.
REF00001817	miRNA-296-3p modulates chemosensitivity of lung cancer cells by targeting CX3CR1. Am J Transl Res. 2016 Apr 15;8(4):1848-56. eCollection 2016.
REF00001818	Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies. Nat Commun. 2016 May 18;7:11553. doi: 10.1038/ncomms11553.
REF00001819	The Essential Role of H19 Contributing to Cisplatin Resistance by Regulating Glutathione Metabolism in High-Grade Serous Ovarian Cancer. Sci Rep. 2016 May 19;6:26093. doi: 10.1038/srep26093.
REF00001820	MiR-30a increases cisplatin sensitivity of gastric cancer cells through suppressing epithelial-to-mesenchymal transition (EMT). Eur Rev Med Pharmacol Sci. 2016 May;20(9):1733-9.
REF00001821	"MicroRNA-874 inhibits growth, induces apoptosis and reverses chemoresistance in colorectal cancer by targeting X-linked inhibitor of apoptosis protein. Oncol Rep. 2016 Jul;36(1):542-50. doi: 10.3892/or.2016.4810. Epub 2016 May 16."
REF00001822	MicroRNA-27b reverses docetaxel resistance of non-small cell lung carcinoma cells via targeting epithelial growth factor receptor. Mol Med Rep. 2016 Jul;14(1):949-54. doi: 10.3892/mmr.2016.5332. Epub 2016 May 24.
REF00001823	MicroRNA-184 Modulates Doxorubicin Resistance in Osteosarcoma Cells by Targeting BCL2L1. Med Sci Monit. 2016 May 25;22:1761-5. doi: 10.12659/msm.896451.
REF00001824	Sequence analysis of pfcrt and pfmdr1 genes and its association with chloroquine resistance in Southeast Indian Plasmodium falciparum isolates. Genom Data. 2016 Apr 18;8:85-90. doi: 10.1016/j.gdata.2016.04.010. eCollection 2016 Jun.
REF00001825	Metabolic Enzymes of Cocaine Metabolite Benzoylecgonine. ACS Chem Biol. 2016 Aug 19;11(8):2186-94. doi: 10.1021/acschembio.6b00277. Epub 2016 Jun 9.
REF00001826	Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations. Oncotarget. 2016 Jun 21;7(25):38180-38190. doi: 10.18632/oncotarget.9500.
REF00001827	MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells. PLoS One. 2016 May 26;11(5):e0156260. doi: 10.1371/journal.pone.0156260. eCollection 2016.
REF00001828	Evidence for the role of microRNA 374b in acquired cisplatin resistance in pancreatic cancer cells. Cancer Gene Ther. 2016 Aug;23(8):241-5. doi: 10.1038/cgt.2016.23. Epub 2016 May 27.
REF00001829	Downregulation of miR-101 contributes to epithelial-mesenchymal transition in cisplatin resistance of NSCLC cells by targeting ROCK2. Oncotarget. 2016 Jun 21;7(25):37524-37535. doi: 10.18632/oncotarget.6852.
REF00001830	The lncRNA PVT1 Contributes to the Cervical Cancer Phenotype and Associates with Poor Patient Prognosis. PLoS One. 2016 May 27;11(5):e0156274. doi: 10.1371/journal.pone.0156274. eCollection 2016.
REF00001831	miR-139-5p Inhibits the Epithelial-Mesenchymal Transition and Enhances the Chemotherapeutic Sensitivity of Colorectal Cancer Cells by Downregulating BCL2. Sci Rep. 2016 May 31;6:27157. doi: 10.1038/srep27157.
REF00001832	Silencing of ABCG2 by MicroRNA-3163 Inhibits Multidrug Resistance in Retinoblastoma Cancer Stem Cells. J Korean Med Sci. 2016 Jun;31(6):836-42. doi: 10.3346/jkms.2016.31.6.836. Epub 2016 Apr 20.
REF00001833	MiR-181a upregulation is associated with epithelial-to-mesenchymal transition (EMT) and multidrug resistance (MDR) of ovarian cancer cells. Eur Rev Med Pharmacol Sci. 2016 May;20(10):2004-10.
REF00001834	MiR-183 modulates multi-drug resistance in hepatocellular cancer (HCC) cells via miR-183-IDH2/SOCS6-HIF-1Alpha feedback loop. Eur Rev Med Pharmacol Sci. 2016 May;20(10):2020-7.
REF00001835	Low miR-187 expression promotes resistance to chemoradiation therapy in vitro and correlates with treatment failure in patients with esophageal adenocarcinoma. Mol Med. 2016 May 23;22:388-97. doi: 10.2119/molmed.2016.00020.
REF00001836	[The effect and mechanism of microRNA-21 on cis-dichlorodiamineplatinum resistance in lung cancer cell strain]. Zhonghua Yi Xue Za Zhi. 2016 May 17;96(18):1454-8. doi: 10.3760/cma.j.issn.0376-2491.2016.18.014.
REF00001837	Long noncoding RNA RP11-838N2.4 enhances the cytotoxic effects of temozolomide by inhibiting the functions of miR-10a in glioblastoma cell lines. Oncotarget. 2016 Jul 12;7(28):43835-43851. doi: 10.18632/oncotarget.9699.
REF00001838	NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells. Oncotarget. 2016 Jul 12;7(28):43337-43351. doi: 10.18632/oncotarget.9712.
REF00001839	TP53 mutations are early events in chronic lymphocytic leukemia disease progression and precede evolution to complex karyotypes. Int J Cancer. 2016 Oct 15;139(8):1759-63. doi: 10.1002/ijc.30222. Epub 2016 Jun 24.
REF00001840	Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Nature. 2016 Jun 9;534(7606):272-6. doi: 10.1038/nature17963. Epub 2016 May 18.
REF00001841	MicroRNA-320a promotes 5-FU resistance in human pancreatic cancer cells. Sci Rep. 2016 Jun 9;6:27641. doi: 10.1038/srep27641.
REF00001842	Targeted Silencing of S100A8 Gene by miR-24 to Increase Chemotherapy Sensitivity of Endometrial Carcinoma Cells to Paclitaxel. Med Sci Monit. 2016 Jun 9;22:1953-8. doi: 10.12659/msm.899179.
REF00001843	miR-222 confers the resistance of breast cancer cells to Adriamycin through suppression of p27(kip1) expression. Gene. 2016 Sep 15;590(1):44-50. doi: 10.1016/j.gene.2016.06.013. Epub 2016 Jun 6.
REF00001844	Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun. 2016 Jun 10;7:11815. doi: 10.1038/ncomms11815.
REF00001845	miR-26a desensitizes non-small cell lung cancer cells to tyrosine kinase inhibitors by targeting PTPN13. Oncotarget. 2016 Jul 19;7(29):45687-45701. doi: 10.18632/oncotarget.9920.
REF00001846	Heterogeneity of resistance mutations detectable by nextgeneration sequencing in TKI-treated lung adenocarcinoma. Oncotarget. 2016 Jul 19;7(29):45237-45248. doi: 10.18632/oncotarget.9931.
REF00001847	MiR-18a upregulation decreases Dicer expression and confers paclitaxel resistance in triple negative breast cancer. Eur Rev Med Pharmacol Sci. 2016 Jun;20(11):2201-8.
REF00001848	GAS5 modulated autophagy is a mechanism modulating cisplatin sensitivity in NSCLC cells. Eur Rev Med Pharmacol Sci. 2016 Jun;20(11):2271-7.
REF00001849	Androgen-induced Long Noncoding RNA (lncRNA) SOCS2-AS1 Promotes Cell Growth and Inhibits Apoptosis in Prostate Cancer Cells. J Biol Chem. 2016 Aug 19;291(34):17861-80. doi: 10.1074/jbc.M116.718536. Epub 2016 Jun 24.
REF00001850	Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping. J Thorac Oncol. 2016 Aug;11(8):1242-1245. doi: 10.1016/j.jtho.2016.06.013. Epub 2016 Jun 22.
REF00001851	The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nat Genet. 2016 Aug;48(8):848-55. doi: 10.1038/ng.3602. Epub 2016 Jun 27.
REF00001852	miR-20a induces cisplatin resistance of a human gastric cancer cell line via targeting CYLD. Mol Med Rep. 2016 Aug;14(2):1742-50. doi: 10.3892/mmr.2016.5413. Epub 2016 Jun 21.
REF00001853	miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer. Cell Death Dis. 2016 Jun 30;7(6):e2291. doi: 10.1038/cddis.2016.194.
REF00001854	MiR-27b is epigenetically downregulated in tamoxifen resistant breast cancer cells due to promoter methylation and regulates tamoxifen sensitivity by targeting HMGB3. Biochem Biophys Res Commun. 2016 Sep 2;477(4):768-773. doi: 10.1016/j.bbrc.2016.06.133. Epub 2016 Jun 27.
REF00001855	Knockdown of long noncoding RNA H19 sensitizes human glioma cells to temozolomide therapy. Onco Targets Ther. 2016 Jun 13;9:3501-9. doi: 10.2147/OTT.S96278. eCollection 2016.
REF00001856	MicroRNA-106a targets autophagy and enhances sensitivity of lung cancer cells to Src inhibitors. Lung Cancer. 2017 May;107:73-83. doi: 10.1016/j.lungcan.2016.06.004. Epub 2016 Jun 14.
REF00001857	Inhibition of miR-141 reverses cisplatin resistance in non-small cell lung cancer cells via upregulation of programmed cell death protein 4. Eur Rev Med Pharmacol Sci. 2016 Jun;20(12):2565-72.
REF00001858	miR-29c contribute to glioma cells temozolomide sensitivity by targeting O6-methylguanine-DNA methyltransferases indirectely. Oncotarget. 2016 Aug 2;7(31):50229-50238. doi: 10.18632/oncotarget.10357.
REF00001859	miR-181a induces sorafenib resistance of hepatocellular carcinoma cells through downregulation of RASSF1 expression. Cancer Sci. 2016 Sep;107(9):1256-62. doi: 10.1111/cas.13006. Epub 2016 Sep 2.
REF00001860	The miR-644a/CTBP1/p53 axis suppresses drug resistance by simultaneous inhibition of cell survival and epithelial-mesenchymal transition in breast cancer. Oncotarget. 2016 Aug 2;7(31):49859-49877. doi: 10.18632/oncotarget.10489.
REF00001861	Species Distribution and In Vitro Azole Susceptibility of Aspergillus Section Nigri Isolates from Clinical and Environmental Settings. J Clin Microbiol. 2016 Sep;54(9):2365-72. doi: 10.1128/JCM.01075-16. Epub 2016 Jul 13.
REF00001862	MicroRNA-149 Increases the Sensitivity of Colorectal Cancer Cells to 5-Fluorouracil by Targeting Forkhead Box Transcription Factor FOXM1. Cell Physiol Biochem. 2016;39(2):617-29. doi: 10.1159/000445653. Epub 2016 Jul 15.
REF00001863	miR-214 promotes apoptosis and sensitizes breast cancer cells to doxorubicin by targeting the RFWD2-p53 cascade. Biochem Biophys Res Commun. 2016 Sep 9;478(1):337-342. doi: 10.1016/j.bbrc.2016.07.054. Epub 2016 Jul 12.
REF00001864	Epidemiology and Molecular Characterizations of Azole Resistance in Clinical and Environmental Aspergillus fumigatus Isolates from China. Antimicrob Agents Chemother. 2016 Sep 23;60(10):5878-84. doi: 10.1128/AAC.01005-16. Print 2016 Oct.
REF00001865	Over expression of miR-200c suppresses invasion and restores methotrexate sensitivity in lung cancer A549 cells. Gene. 2016 Nov 30;593(2):265-71. doi: 10.1016/j.gene.2016.07.038. Epub 2016 Jul 16.
REF00001866	miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways. Oncotarget. 2016 Aug 16;7(33):53558-53570. doi: 10.18632/oncotarget.10669.
REF00001867	MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2. Oncotarget. 2016 Aug 16;7(33):53254-53268. doi: 10.18632/oncotarget.10736.
REF00001868	A Salmonella nanoparticle mimic overcomes multidrug resistance in tumours. Nat Commun. 2016 Jul 25;7:12225. doi: 10.1038/ncomms12225.
REF00001869	MiR-375 is epigenetically downregulated due to promoter methylation and modulates multi-drug resistance in breast cancer cells via targeting YBX1. Eur Rev Med Pharmacol Sci. 2016 Jul;20(15):3223-9.
REF00001870	miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas. Neuro Oncol. 2017 Jan;19(1):55-65. doi: 10.1093/neuonc/now129. Epub 2016 Jul 28.
REF00001871	miR-145 sensitizes breast cancer to doxorubicin by targeting multidrug resistance-associated protein-1. Oncotarget. 2016 Sep 13;7(37):59714-59726. doi: 10.18632/oncotarget.10845.
REF00001872	Characterisation of class 3 integrons with oxacillinase gene cassettes in hospital sewage and sludge samples from France and Luxembourg. Int J Antimicrob Agents. 2016 Oct;48(4):431-4. doi: 10.1016/j.ijantimicag.2016.06.018. Epub 2016 Jul 28.
REF00001873	"Loss of MiR-424-3p, not miR-424-5p, confers chemoresistance through targeting YAP1 in non-small cell lung cancer. Mol Carcinog. 2017 Mar;56(3):821-832. doi: 10.1002/mc.22536. Epub 2016 Aug 26."
REF00001874	miR-221 Mediates Chemoresistance of Esophageal Adenocarcinoma by Direct Targeting of DKK2 Expression. Ann Surg. 2016 Nov;264(5):804-814. doi: 10.1097/SLA.0000000000001928.
REF00001875	"Molecular epidemiology of drug-resistant Neisseria gonorrhoeae in Russia (Current Status, 2015). BMC Infect Dis. 2016 Aug 9;16:389. doi: 10.1186/s12879-016-1688-7."
REF00001876	MiR-30c-2* negative regulated MTA-1 expression involved in metastasis and drug resistance of HPV-infected non-small cell lung cancer. Surgery. 2016 Dec;160(6):1591-1598. doi: 10.1016/j.surg.2016.06.025. Epub 2016 Aug 6.
REF00001877	miRNA-24-3p promotes cell proliferation and regulates chemosensitivity in head and neck squamous cell carcinoma by targeting CHD5. Future Oncol. 2016 Dec;12(23):2701-2712. doi: 10.2217/fon-2016-0179. Epub 2016 Aug 11.
REF00001878	MicroRNA-21 Increases Proliferation and Cisplatin Sensitivity of Osteosarcoma-Derived Cells. PLoS One. 2016 Aug 11;11(8):e0161023. doi: 10.1371/journal.pone.0161023. eCollection 2016.
REF00001879	Upregulation of microRNA-34a enhances the DDP sensitivity of gastric cancer cells by modulating proliferation and apoptosis via targeting MET. Oncol Rep. 2016 Oct;36(4):2391-7. doi: 10.3892/or.2016.5016. Epub 2016 Aug 11.
REF00001880	Clonal rat parathyroid cell line expresses a parathyroid hormone-related peptide but not parathyroid hormone itself. Biochem Biophys Res Commun. 1989 Jul 14;162(1):108-15. doi: 10.1016/0006-291x(89)91969-4.
REF00001881	Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood. 2016 Sep 29;128(13):1735-44. doi: 10.1182/blood-2016-06-723007. Epub 2016 Aug 11.
REF00001882	MicroRNA-29a contributes to drug-resistance of breast cancer cells to adriamycin through PTEN/AKT/GSK3Beta signaling pathway. Gene. 2016 Nov 15;593(1):84-90. doi: 10.1016/j.gene.2016.08.016. Epub 2016 Aug 11.
REF00001883	miR-625-3p regulates oxaliplatin resistance by targeting MAP2K6-p38 signalling in human colorectal adenocarcinoma cells. Nat Commun. 2016 Aug 16;7:12436. doi: 10.1038/ncomms12436.
REF00001884	Upregulation of miR-181c inhibits chemoresistance by targeting ST8SIA4 in chronic myelocytic leukemia. Oncotarget. 2016 Sep 13;7(37):60074-60086. doi: 10.18632/oncotarget.11054.
REF00001885	Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing. Oncotarget. 2016 Sep 20;7(38):61755-61763. doi: 10.18632/oncotarget.11237.
REF00001886	"The long non-coding RNA, SNHG6-003, functions as a competing endogenous RNA to promote the progression of hepatocellular carcinoma. Oncogene. 2017 Feb 23;36(8):1112-1122. doi: 10.1038/onc.2016.278. Epub 2016 Aug 15."
REF00001887	The role of long non-coding RNA HOTAIR in the progression and development of laryngeal squamous cell carcinoma interacting with EZH2. Acta Otolaryngol. 2017 Jan;137(1):90-98. doi: 10.1080/00016489.2016.1214982. Epub 2016 Aug 19.
REF00001888	Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital. Oncologist. 2016 Sep;21(9):1035-40. doi: 10.1634/theoncologist.2016-0240. Epub 2016 Aug 22.
REF00001889	"Decreased expression of LncRNA SLC25A25-AS1 promotes proliferation, chemoresistance, and EMT in colorectal cancer cells. Tumour Biol. 2016 Oct;37(10):14205-14215. doi: 10.1007/s13277-016-5254-0. Epub 2016 Aug 23."
REF00001890	"Prevalence of gyrA Mutations in Nalidixic Acid-Resistant Strains of Salmonella Enteritidis Isolated from Humans, Food, Chickens, and the Farm Environment in Brazil. Microb Drug Resist. 2017 Jun;23(4):421-428. doi: 10.1089/mdr.2016.0024. Epub 2016 Aug 25."
REF00001891	DNA damage responsive miR-33b-3p promoted lung cancer cells survival and cisplatin resistance by targeting p21(WAF1/CIP1). Cell Cycle. 2016 Nov;15(21):2920-2930. doi: 10.1080/15384101.2016.1224043. Epub 2016 Aug 25.
REF00001892	Diversity of the Tetracycline Mobilome within a Chinese Pig Manure Sample. Appl Environ Microbiol. 2016 Oct 14;82(21):6454-6462. doi: 10.1128/AEM.01754-16. Print 2016 Nov 1.
REF00001893	Long noncoding RNA CCAT1 acts as an oncogene and promotes chemoresistance in docetaxel-resistant lung adenocarcinoma cells. Oncotarget. 2016 Sep 20;7(38):62474-62489. doi: 10.18632/oncotarget.11518.
REF00001894	Evolution of resistance to thyroid cancer therapy. Aging (Albany NY). 2016 Aug;8(8):1576-7. doi: 10.18632/aging.101030.
REF00001895	miR-223 increases gallbladder cancer cell sensitivity to docetaxel by downregulating STMN1. Oncotarget. 2016 Sep 20;7(38):62364-62376. doi: 10.18632/oncotarget.11634.
REF00001896	A directly negative interaction of miR-203 and ZEB2 modulates tumor stemness and chemotherapy resistance in nasopharyngeal carcinoma. Oncotarget. 2016 Oct 11;7(41):67288-67301. doi: 10.18632/oncotarget.11691.
REF00001897	MiroRNA-127-3p targets XRCC3 to enhance the chemosensitivity of esophageal cancer cells to a novel phenanthroline-dione derivative. Int J Biochem Cell Biol. 2016 Oct;79:158-167. doi: 10.1016/j.biocel.2016.08.026. Epub 2016 Aug 30.
REF00001898	Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells. Cancer Lett. 2016 Nov 1;382(1):64-76. doi: 10.1016/j.canlet.2016.08.015. Epub 2016 Aug 31.
REF00001899	Up-regulation of miR-370-3p restores glioblastoma multiforme sensitivity to temozolomide by influencing MGMT expression. Sci Rep. 2016 Sep 6;6:32972. doi: 10.1038/srep32972.
REF00001900	Noninvasive monitoring of the genetic evolution of EGFR-mutant non-small-cell lung cancer by analyzing circulating tumor DNA during combination chemotherapy with gefitinib and pemetrexed or S-1. Onco Targets Ther. 2016 Aug 24;9:5287-95. doi: 10.2147/OTT.S105976. eCollection 2016.
REF00001901	Expression of microRNA-30a-5p in drug-resistant and drug-sensitive ovarian cancer cell lines. Oncol Lett. 2016 Sep;12(3):2065-2070. doi: 10.3892/ol.2016.4831. Epub 2016 Jul 8.
REF00001902	Long non-coding RNA LINC00161 sensitises osteosarcoma cells to cisplatin-induced apoptosis by regulating the miR-645-IFIT2 axis. Cancer Lett. 2016 Nov 28;382(2):137-146. doi: 10.1016/j.canlet.2016.08.024. Epub 2016 Sep 5.
REF00001903	Low expression of miR-381 is a favorite prognosis factor and enhances the chemosensitivity of osteosarcoma. Oncotarget. 2016 Oct 18;7(42):68585-68596. doi: 10.18632/oncotarget.11861.
REF00001904	MicroRNA-223 Increases the Sensitivity of Triple-Negative Breast Cancer Stem Cells to TRAIL-Induced Apoptosis by Targeting HAX-1. PLoS One. 2016 Sep 12;11(9):e0162754. doi: 10.1371/journal.pone.0162754. eCollection 2016.
REF00001905	"Novel mutations in quinolone resistance-determining regions of gyrA, gyrB, parC and parE in Shigella flexneri clinical isolates from eastern Chinese populations between 2001 and 2011. Eur J Clin Microbiol Infect Dis. 2016 Dec;35(12):2037-2045. doi: 10.1007/s10096-016-2761-2. Epub 2016 Sep 12."
REF00001906	MicroRNA-126 increases chemosensitivity in drug-resistant gastric cancer cells by targeting EZH2. Biochem Biophys Res Commun. 2016 Oct 7;479(1):91-6. doi: 10.1016/j.bbrc.2016.09.040. Epub 2016 Sep 10.
REF00001907	Long non-coding RNA UCA1 enhances tamoxifen resistance in breast cancer cells through a miR-18a-HIF1Alpha feedback regulatory loop. Tumour Biol. 2016 Nov;37(11):14733-14743. doi: 10.1007/s13277-016-5348-8. Epub 2016 Sep 15.
REF00001908	GyrA ser83 and ParC trp106 Mutations in Salmonella enterica Serovar Typhi Isolated from Typhoid Fever Patients in Tertiary Care Hospital. J Clin Diagn Res. 2016 Jul;10(7):DC14-8. doi: 10.7860/JCDR/2016/17677.8153. Epub 2016 Jul 1.
REF00001909	miR-17-5p down-regulation contributes to erlotinib resistance in non-small cell lung cancer cells. J Drug Target. 2017 Feb;25(2):125-131. doi: 10.1080/1061186X.2016.1207647. Epub 2016 Sep 16.
REF00001910	Linc00152 Functions as a Competing Endogenous RNA to Confer Oxaliplatin Resistance and Holds Prognostic Values in Colon Cancer. Mol Ther. 2016 Dec;24(12):2064-2077. doi: 10.1038/mt.2016.180. Epub 2016 Sep 16.
REF00001911	miR-135b reverses chemoresistance of non-small cell lung cancer cells by downregulation of FZD1. Biomed Pharmacother. 2016 Dec;84:123-129. doi: 10.1016/j.biopha.2016.09.027. Epub 2016 Sep 16.
REF00001912	Involvement of microRNA-141-3p in 5-fluorouracil and oxaliplatin chemo-resistance in esophageal cancer cells via regulation of PTEN. Mol Cell Biochem. 2016 Nov;422(1-2):161-170. doi: 10.1007/s11010-016-2816-9. Epub 2016 Sep 19.
REF00001913	"Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile. Antimicrob Agents Chemother. 2016 Nov 21;60(12):7086-7097. doi: 10.1128/AAC.01474-16. Print 2016 Dec."
REF00001914	Targeting PCDH20 gene by microRNA-122 confers 5-FU resistance in hepatic carcinoma. Am J Cancer Res. 2016 Aug 1;6(8):1681-94. eCollection 2016.
REF00001915	miRNA-21 sensitizes gastrointestinal stromal tumors (GISTs) cells to Imatinib via targeting B-cell lymphoma 2 (Bcl-2). Eur Rev Med Pharmacol Sci. 2016 Sep;20(17):3574-81.
REF00001916	"Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2016 Oct 4;113(40):11306-11311. doi: 10.1073/pnas.1608420113. Epub 2016 Sep 21."
REF00001917	miR-200c regulates crizotinib-resistant ALK-positive lung cancer cells by reversing epithelial-mesenchymal transition via targeting ZEB1. Mol Med Rep. 2016 Nov;14(5):4135-4143. doi: 10.3892/mmr.2016.5770. Epub 2016 Sep 23.
REF00001918	Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping. J Thorac Oncol. 2017 Jan;12(1):137-140. doi: 10.1016/j.jtho.2016.09.119. Epub 2016 Sep 22.
REF00001919	miR-135a promotes gastric cancer progression and resistance to oxaliplatin. Oncotarget. 2016 Oct 25;7(43):70699-70714. doi: 10.18632/oncotarget.12208.
REF00001920	The UCA1/miR-204/Sirt1 axis modulates docetaxel sensitivity of prostate cancer cells. Cancer Chemother Pharmacol. 2016 Nov;78(5):1025-1031. doi: 10.1007/s00280-016-3158-8. Epub 2016 Sep 29.
REF00001921	MicroRNA-451 sensitizes lung cancer cells to cisplatin through regulation of Mcl-1. Mol Cell Biochem. 2016 Dec;423(1-2):85-91. doi: 10.1007/s11010-016-2827-6. Epub 2016 Sep 30.
REF00001922	The miR-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis through Altering the Androgen Receptor Signals. EBioMedicine. 2016 Oct;12:55-67. doi: 10.1016/j.ebiom.2016.07.013. Epub 2016 Jul 14.
REF00001923	MiR-128 reverses the gefitinib resistance of the lung cancer stem cells by inhibiting the c-met/PI3K/AKT pathway. Oncotarget. 2016 Nov 8;7(45):73188-73199. doi: 10.18632/oncotarget.12283.
REF00001924	Enforced expression of hsa-miR-125a-3p in breast cancer cells potentiates docetaxel sensitivity via modulation of BRCA1 signaling. Biochem Biophys Res Commun. 2016 Oct 28;479(4):893-900. doi: 10.1016/j.bbrc.2016.09.087. Epub 2016 Sep 28.
REF00001925	Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer. Cancer Discov. 2016 Dec;6(12):1334-1341. doi: 10.1158/2159-8290.CD-16-0686. Epub 2016 Sep 30.
REF00001926	Long Non-Coding RNA (LncRNA) Urothelial Carcinoma Associated 1 (UCA1) Increases Multi-Drug Resistance of Gastric Cancer via Downregulating miR-27b. Med Sci Monit. 2016 Oct 1;22:3506-3513. doi: 10.12659/msm.900688.
REF00001927	MicroRNA-494 Activation Suppresses Bone Marrow Stromal Cell-Mediated Drug Resistance in Acute Myeloid Leukemia Cells. J Cell Physiol. 2017 Jun;232(6):1387-1395. doi: 10.1002/jcp.25628. Epub 2016 Oct 19.
REF00001928	Aldo-keto reductase 1C1 induced by interleukin-1Beta mediates the invasive potential and drug resistance of metastatic bladder cancer cells. Sci Rep. 2016 Oct 4;6:34625. doi: 10.1038/srep34625.
REF00001929	miR-222 induces Adriamycin resistance in breast cancer through PTEN/Akt/p27(kip1) pathway. Tumour Biol. 2016 Nov;37(11):15315-15324. doi: 10.1007/s13277-016-5341-2. Epub 2016 Oct 4.
REF00001930	miR-186 regulates chemo-sensitivity to paclitaxel via targeting MAPT in non-small cell lung cancer (NSCLC). Mol Biosyst. 2016 Oct 18;12(11):3417-3424. doi: 10.1039/c6mb00576d.
REF00001931	microRNA-539 suppresses tumor growth and tumorigenesis and overcomes arsenic trioxide resistance in hepatocellular carcinoma. Life Sci. 2016 Dec 1;166:34-40. doi: 10.1016/j.lfs.2016.10.002. Epub 2016 Oct 4.
REF00001932	MiRNA-221-3p desensitizes pancreatic cancer cells to 5-fluorouracil by targeting RB1. Tumour Biol. 2016 Oct 10. doi: 10.1007/s13277-016-5445-8. Online ahead of print.
REF00001933	Direct interaction between miR-203 and ZEB2 suppresses epithelial-mesenchymal transition signaling and reduces lung adenocarcinoma chemoresistance. Acta Biochim Biophys Sin (Shanghai). 2016 Nov;48(11):1042-1049. doi: 10.1093/abbs/gmw099. Epub 2016 Oct 12.
REF00001934	MiR-139-5p reverses CD44+/CD133+-associated multidrug resistance by downregulating NOTCH1 in colorectal carcinoma cells. Oncotarget. 2016 Nov 15;7(46):75118-75129. doi: 10.18632/oncotarget.12611.
REF00001935	"Downregulation of Foxo3 and TRIM31 by miR-551b in side population promotes cell proliferation, invasion, and drug resistance of ovarian cancer. Med Oncol. 2016 Nov;33(11):126. doi: 10.1007/s12032-016-0842-9. Epub 2016 Oct 14."
REF00001936	MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway. Gene. 2017 Jan 5;596:110-118. doi: 10.1016/j.gene.2016.10.016. Epub 2016 Oct 13.
REF00001937	miR-100 resensitizes resistant epithelial ovarian cancer to cisplatin. Oncol Rep. 2016 Dec;36(6):3552-3558. doi: 10.3892/or.2016.5140. Epub 2016 Oct 3.
REF00001938	miR-590-5p regulates gastric cancer cell growth and chemosensitivity through RECK and the AKT/ERK pathway. Onco Targets Ther. 2016 Oct 3;9:6009-6019. doi: 10.2147/OTT.S110923. eCollection 2016.
REF00001939	MiRNA-145 increases therapeutic sensibility to gemcitabine treatment of pancreatic adenocarcinoma cells. Oncotarget. 2016 Oct 25;7(43):70857-70868. doi: 10.18632/oncotarget.12268.
REF00001940	Long Non-Coding RNA (lncRNA) Urothelial Carcinoma-Associated 1 (UCA1) Enhances Tamoxifen Resistance in Breast Cancer Cells via Inhibiting mTOR Signaling Pathway. Med Sci Monit. 2016 Oct 21;22:3860-3867. doi: 10.12659/msm.900689.
REF00001941	"Overexpression of miR-422a inhibits cell proliferation and invasion, and enhances chemosensitivity in osteosarcoma cells. Oncol Rep. 2016 Dec;36(6):3371-3378. doi: 10.3892/or.2016.5182. Epub 2016 Oct 19."
REF00001942	Downregulation of YEATS4 by miR-218 sensitizes colorectal cancer cells to L-OHP-induced cell apoptosis by inhibiting cytoprotective autophagy. Oncol Rep. 2016 Dec;36(6):3682-3690. doi: 10.3892/or.2016.5195. Epub 2016 Oct 21.
REF00001943	Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2017 May 15;23(10):2414-2422. doi: 10.1158/1078-0432.CCR-16-1863. Epub 2016 Oct 25.
REF00001944	"A variant c-KIT mutation, D816H, fundamental to the sequential development of an ovarian mixed germ cell tumor and systemic mastocytosis with chronic myelomonocytic leukemia. Pediatr Blood Cancer. 2017 Apr;64(4). doi: 10.1002/pbc.26282. Epub 2016 Oct 26."
REF00001945	The mutational signature of chronic lymphocytic leukemia. Biochem J. 2016 Nov 1;473(21):3725-3740. doi: 10.1042/BCJ20160256.
REF00001946	MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3Beta in glioblastoma. Oncotarget. 2016 Nov 29;7(48):79584-79595. doi: 10.18632/oncotarget.12861.
REF00001947	Screening and Characterization of a Non-cyp51A Mutation in an Aspergillus fumigatus cox10 Strain Conferring Azole Resistance. Antimicrob Agents Chemother. 2016 Dec 27;61(1):e02101-16. doi: 10.1128/AAC.02101-16. Print 2017 Jan.
REF00001948	Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression. Cell Death Dis. 2016 Nov 3;7(11):e2454. doi: 10.1038/cddis.2016.361.
REF00001949	MicroRNA-326 sensitizes human glioblastoma cells to curcumin via the SHH/GLI1 signaling pathway. Cancer Biol Ther. 2018 Apr 3;19(4):260-270. doi: 10.1080/15384047.2016.1250981. Epub 2018 Feb 22.
REF00001950	Epigenetic inactivation of the p53-induced long noncoding RNA TP53 target 1 in human cancer. Proc Natl Acad Sci U S A. 2016 Nov 22;113(47):E7535-E7544. doi: 10.1073/pnas.1608585113. Epub 2016 Nov 7.
REF00001951	MiR-31 regulates the cisplatin resistance by targeting Src in gallbladder cancer. Oncotarget. 2016 Dec 13;7(50):83060-83070. doi: 10.18632/oncotarget.13067.
REF00001952	Decreased expression of microRNA-17 and microRNA-20b promotes breast cancer resistance to taxol therapy by upregulation of NCOA3. Cell Death Dis. 2016 Nov 10;7(11):e2463. doi: 10.1038/cddis.2016.367.
REF00001953	MiR-129-5p is downregulated in breast cancer cells partly due to promoter H3K27m3 modification and regulates epithelial-mesenchymal transition and multi-drug resistance. Eur Rev Med Pharmacol Sci. 2016 Oct;20(20):4257-4265.
REF00001954	miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1. Mol Cancer. 2016 Nov 10;15(1):70. doi: 10.1186/s12943-016-0556-9.
REF00001955	miR-34a sensitizes lung cancer cells to cisplatin via p53/miR-34a/MYCN axis. Biochem Biophys Res Commun. 2017 Jan 1;482(1):22-27. doi: 10.1016/j.bbrc.2016.11.037. Epub 2016 Nov 9.
REF00001956	Susceptibility of Rhodobacter sphaeroides to beta-lactam antibiotics: isolation and characterization of a periplasmic beta-lactamase (cephalosporinase). J Bacteriol. 1989 Jan;171(1):308-13. doi: 10.1128/jb.171.1.308-313.1989.
REF00001957	Exosomal miR-221 targets DNM3 to induce tumor progression and temozolomide resistance in glioma. J Neurooncol. 2017 Jan;131(2):255-265. doi: 10.1007/s11060-016-2308-5. Epub 2016 Nov 11.
REF00001958	miR-141 regulation of EIF4E expression affects docetaxel chemoresistance of non-small cell lung cancer. Oncol Rep. 2017 Jan;37(1):608-616. doi: 10.3892/or.2016.5214. Epub 2016 Nov 2.
REF00001959	miR-503 inhibits proliferation making human hepatocellular carcinoma cells susceptible to 5 fluorouracil by targeting EIF4E. Oncol Rep. 2017 Jan;37(1):563-570. doi: 10.3892/or.2016.5220. Epub 2016 Nov 7.
REF00001960	MicroRNA-302a enhances 5-fluorouracil-induced cell death in human colon cancer cells. Oncol Rep. 2017 Jan;37(1):631-639. doi: 10.3892/or.2016.5237. Epub 2016 Nov 8.
REF00001961	Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal cell carcinoma. Oncogene. 2017 Apr 6;36(14):1965-1977. doi: 10.1038/onc.2016.356. Epub 2016 Nov 14.
REF00001962	Mechanisms of resistance to EGFR-targeted drugs: lung cancer. ESMO Open. 2016 May 11;1(3):e000060. doi: 10.1136/esmoopen-2016-000060. eCollection 2016.
REF00001963	LncRNA H19 confers chemoresistance in ERAlpha-positive breast cancer through epigenetic silencing of the pro-apoptotic gene BIK. Oncotarget. 2016 Dec 6;7(49):81452-81462. doi: 10.18632/oncotarget.13263.
REF00001964	FGFR-TACC gene fusions in human glioma. Neuro Oncol. 2017 Apr 1;19(4):475-483. doi: 10.1093/neuonc/now240.
REF00001965	lncRNA UCA1 Contributes to Imatinib Resistance by Acting as a ceRNA Against miR-16 in Chronic Myeloid Leukemia Cells. DNA Cell Biol. 2017 Jan;36(1):18-25. doi: 10.1089/dna.2016.3533. Epub 2016 Nov 17.
REF00001966	Expression of MicroRNA-301a and its Functional Roles in Malignant Melanoma. Cell Physiol Biochem. 2016;40(1-2):230-244. doi: 10.1159/000452540. Epub 2016 Nov 18.
REF00001967	Epigenetic silencing of miR-137 induces drug resistance and chromosomal instability by targeting AURKA in multiple myeloma. Leukemia. 2017 May;31(5):1123-1135. doi: 10.1038/leu.2016.325. Epub 2016 Nov 18.
REF00001968	Surgical resection of recurrent gastrointestinal stromal tumor after interruption of long-term nilotinib therapy. Surg Case Rep. 2016 Dec;2(1):137. doi: 10.1186/s40792-016-0266-y. Epub 2016 Nov 19.
REF00001969	MiR-335 regulates the chemo-radioresistance of small cell lung cancer cells by targeting PARP-1. Gene. 2017 Feb 5;600:9-15. doi: 10.1016/j.gene.2016.11.031. Epub 2016 Nov 19.
REF00001970	The role of long noncoding RNA HOTAIR in the acquired multidrug resistance to imatinib in chronic myeloid leukemia cells. Hematology. 2017 May;22(4):208-216. doi: 10.1080/10245332.2016.1258152. Epub 2016 Nov 22.
REF00001971	MiR-30a Decreases Multidrug Resistance (MDR) of Gastric Cancer Cells. Med Sci Monit. 2016 Nov 23;0:0.
REF00001972	miR-20b reduces 5-FU resistance by suppressing the ADAM9/EGFR signaling pathway in colon cancer. Oncol Rep. 2017 Jan;37(1):123-130. doi: 10.3892/or.2016.5259. Epub 2016 Nov 18.
REF00001973	Long non-coding RNA TUC338 is functionally involved in sorafenib-sensitized hepatocarcinoma cells by targeting RASAL1. Oncol Rep. 2017 Jan;37(1):273-280. doi: 10.3892/or.2016.5248. Epub 2016 Nov 15.
REF00001974	Long noncoding RNA GAS5 inhibits malignant proliferation and chemotherapy resistance to doxorubicin in bladder transitional cell carcinoma. Cancer Chemother Pharmacol. 2017 Jan;79(1):49-55. doi: 10.1007/s00280-016-3194-4. Epub 2016 Nov 22.
REF00001975	Inhibition of HAX-1 by miR-125a reverses cisplatin resistance in laryngeal cancer stem cells. Oncotarget. 2016 Dec 27;7(52):86446-86456. doi: 10.18632/oncotarget.13424.
REF00001976	Upregulation of microRNA-524-5p enhances the cisplatin sensitivity of gastric cancer cells by modulating proliferation and metastasis via targeting SOX9. Oncotarget. 2017 Jan 3;8(1):574-582. doi: 10.18632/oncotarget.13479.
REF00001977	Analysis of mutations in DNA gyrase and topoisomerase IV of Ureaplasma urealyticum and Ureaplasma parvum serovars resistant to fluoroquinolones. Infect Genet Evol. 2017 Jan;47:64-67. doi: 10.1016/j.meegid.2016.11.019. Epub 2016 Nov 21.
REF00001978	MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3. Cancer Lett. 2017 Feb 1;386:168-178. doi: 10.1016/j.canlet.2016.11.017. Epub 2016 Nov 22.
REF00001979	Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse. Oncotarget. 2016 Dec 27;7(52):87301-87311. doi: 10.18632/oncotarget.13541.
REF00001980	MicroRNA-595 sensitizes ovarian cancer cells to cisplatin by targeting ABCB1. Oncotarget. 2016 Dec 27;7(52):87091-87099. doi: 10.18632/oncotarget.13526.
REF00001981	MiR-30a-5p Overexpression May Overcome EGFR-Inhibitor Resistance through Regulating PI3K/AKT Signaling Pathway in Non-small Cell Lung Cancer Cell Lines. Front Genet. 2016 Nov 15;7:197. doi: 10.3389/fgene.2016.00197. eCollection 2016.
REF00001982	Overexpression of microRNA-24 increases the sensitivity to paclitaxel in drug-resistant breast carcinoma cell lines via targeting ABCB9. Oncol Lett. 2016 Nov;12(5):3905-3911. doi: 10.3892/ol.2016.5139. Epub 2016 Sep 15.
REF00001983	Small cell lung cancer transformation and the T790M mutation: A case report of two acquired mechanisms of TKI resistance detected in a tumor rebiopsy and plasma sample of EGFR-mutant lung adenocarcinoma. Oncol Lett. 2016 Nov;12(5):4009-4012. doi: 10.3892/ol.2016.5193. Epub 2016 Sep 26.
REF00001984	MicroRNA-199a-5p inhibits cisplatin-induced drug resistance via inhibition of autophagy in osteosarcoma cells. Oncol Lett. 2016 Nov;12(5):4203-4208. doi: 10.3892/ol.2016.5172. Epub 2016 Sep 22.
REF00001985	LncRNA HOTAIR promotes cisplatin resistance in gastric cancer by targeting miR-126 to activate the PI3K/AKT/MRP1 genes. Tumour Biol. 2016 Nov 30. doi: 10.1007/s13277-016-5448-5. Online ahead of print.
REF00001986	MicroRNA-185-5p modulates chemosensitivity of human non-small cell lung cancer to cisplatin via targeting ABCC1. Eur Rev Med Pharmacol Sci. 2016 Nov;20(22):4697-4704.
REF00001987	MiR-346 promotes the biological function of breast cancer cells by targeting SRCIN1 and reduces chemosensitivity to docetaxel. Gene. 2017 Feb 5;600:21-28. doi: 10.1016/j.gene.2016.11.037. Epub 2016 Nov 29.
REF00001988	MiR-193b Mediates CEBPD-Induced Cisplatin Sensitization Through Targeting ETS1 and Cyclin D1 in Human Urothelial Carcinoma Cells. J Cell Biochem. 2017 Jun;118(6):1563-1573. doi: 10.1002/jcb.25818. Epub 2016 Dec 20.
REF00001989	H19 mediates methotrexate resistance in colorectal cancer through activating Wnt/Beta-catenin pathway. Exp Cell Res. 2017 Jan 15;350(2):312-317. doi: 10.1016/j.yexcr.2016.12.003. Epub 2016 Dec 2.
REF00001990	miR-124 modulates gefitinib resistance through SNAI2 and STAT3 in non-small cell lung cancer. J Huazhong Univ Sci Technolog Med Sci. 2016 Dec;36(6):839-845. doi: 10.1007/s11596-016-1672-x. Epub 2016 Dec 7.
REF00001991	MiR-433-3p suppresses cell growth and enhances chemosensitivity by targeting CREB in human glioma. Oncotarget. 2017 Jan 17;8(3):5057-5068. doi: 10.18632/oncotarget.13789.
REF00001992	Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. Nat Commun. 2016 Dec 8;7:13665. doi: 10.1038/ncomms13665.
REF00001993	A diverse intrinsic antibiotic resistome from a cave bacterium. Nat Commun. 2016 Dec 8;7:13803. doi: 10.1038/ncomms13803.
REF00001994	miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1. Biomed Pharmacother. 2017 Jan;85:113-119. doi: 10.1016/j.biopha.2016.11.100. Epub 2016 Dec 5.
REF00001995	Let-7a enhances the sensitivity of hepatocellular carcinoma cells to cetuximab by regulating STAT3 expression. Onco Targets Ther. 2016 Nov 28;9:7253-7261. doi: 10.2147/OTT.S116127. eCollection 2016.
REF00001996	microRNA-210 overexpression inhibits tumor growth and potentially reverses gemcitabine resistance in pancreatic cancer. Cancer Lett. 2017 Mar 1;388:107-117. doi: 10.1016/j.canlet.2016.11.035. Epub 2016 Dec 7.
REF00001997	"mir-218-2 promotes glioblastomas growth, invasion and drug resistance by targeting CDC27. Oncotarget. 2017 Jan 24;8(4):6304-6318. doi: 10.18632/oncotarget.13850."
REF00001998	miR-760 mediates chemoresistance through inhibition of epithelial mesenchymal transition in breast cancer cells. Eur Rev Med Pharmacol Sci. 2016 Dec;20(23):5002-5008.
REF00001999	Response and acquired resistance to crizotinib in Chinese patients with lung adenocarcinomas harboring MET Exon 14 splicing alternations. Lung Cancer. 2016 Dec;102:118-121. doi: 10.1016/j.lungcan.2016.11.006. Epub 2016 Nov 9.
REF00002000	micorRNA-101 silences DNA-PKcs and sensitizes pancreatic cancer cells to gemcitabine. Biochem Biophys Res Commun. 2017 Jan 29;483(1):725-731. doi: 10.1016/j.bbrc.2016.12.074. Epub 2016 Dec 14.
REF00002001	Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses. Clin Infect Dis. 2017 Jan 15;64(2):134-140. doi: 10.1093/cid/ciw691. Epub 2016 Oct 20.
REF00002002	MicroRNA-30e reduces cell growth and enhances drug sensitivity to gefitinib in lung carcinoma. Oncotarget. 2017 Jan 17;8(3):4572-4581. doi: 10.18632/oncotarget.13944.
REF00002003	MiR-99a and MiR-491 Regulate Cisplatin Resistance in Human Gastric Cancer Cells by Targeting CAPNS1. Int J Biol Sci. 2016 Nov 5;12(12):1437-1447. doi: 10.7150/ijbs.16529. eCollection 2016.
REF00002004	[miR-202 contributes to sensitizing MM cells to drug significantly via activing JNK/SAPK signaling pathway]. Zhonghua Xue Ye Xue Za Zhi. 2016 Nov 14;37(11):987-992. doi: 10.3760/cma.j.issn.0253-2727.2016.11.012.
REF00002005	Genomic and transcriptomic analysis of imatinib resistance in gastrointestinal stromal tumors. Genes Chromosomes Cancer. 2017 Apr;56(4):303-313. doi: 10.1002/gcc.22438. Epub 2017 Jan 23.
REF00002006	hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10. Oncol Rep. 2017 Feb;37(2):961-968. doi: 10.3892/or.2016.5318. Epub 2016 Dec 14.
REF00002007	miR-20a-directed regulation of BID is associated with the TRAIL sensitivity in colorectal cancer. Oncol Rep. 2017 Jan;37(1):571-578. doi: 10.3892/or.2016.5278. Epub 2016 Nov 28.
REF00002008	MicroRNA-335-5p and -3p synergize to inhibit estrogen receptor alpha expression and promote tamoxifen resistance. FEBS Lett. 2017 Jan;591(2):382-392. doi: 10.1002/1873-3468.12538. Epub 2017 Jan 12.
REF00002009	MiR-129 regulates cisplatin-resistance in human gastric cancer cells by targeting P-gp. Biomed Pharmacother. 2017 Feb;86:450-456. doi: 10.1016/j.biopha.2016.11.139. Epub 2016 Dec 23.
REF00002010	Long noncoding RNA HULC modulates the phosphorylation of YB-1 through serving as a scaffold of extracellular signal-regulated kinase and YB-1 to enhance hepatocarcinogenesis. Hepatology. 2017 May;65(5):1612-1627. doi: 10.1002/hep.29010. Epub 2017 Mar 22.
REF00002011	MicroRNA-137 chemosensitizes colon cancer cells to the chemotherapeutic drug oxaliplatin (OXA) by targeting YBX1. Cancer Biomark. 2017;18(1):1-9. doi: 10.3233/CBM-160650.
REF00002012	"Novel lnu(G) gene conferring resistance to lincomycin by nucleotidylation, located on Tn6260 from Enterococcus faecalis E531. J Antimicrob Chemother. 2017 Apr 1;72(4):993-997. doi: 10.1093/jac/dkw549."
REF00002013	Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood. 2017 Mar 16;129(11):1469-1479. doi: 10.1182/blood-2016-06-719294. Epub 2017 Jan 3.
REF00002014	Bioinformatic identification of IGF1 as a hub gene in hepatocellular carcinoma (HCC) and in-vitro analysis of the chemosensitizing effect of miR-379 via suppressing the IGF1/IGF1R signaling pathway. Eur Rev Med Pharmacol Sci. 2016 Dec;20(24):5098-5106.
REF00002015	MicroRNA-218 inhibits tumor growth and increases chemosensitivity to CDDP treatment by targeting BCAT1 in prostate cancer. Mol Carcinog. 2017 Jun;56(6):1570-1577. doi: 10.1002/mc.22612. Epub 2017 Jan 18.
REF00002016	MiR-24 induces chemotherapy resistance and hypoxic advantage in breast cancer. Oncotarget. 2017 Mar 21;8(12):19507-19521. doi: 10.18632/oncotarget.14470.
REF00002017	Effects of long noncoding RNA-ROR on tamoxifen resistance of breast cancer cells by regulating microRNA-205. Cancer Chemother Pharmacol. 2017 Feb;79(2):327-337. doi: 10.1007/s00280-016-3208-2. Epub 2017 Jan 6.
REF00002018	MiR-148a and miR-152 reduce tamoxifen resistance in ER+ breast cancer via downregulating ALCAM. Biochem Biophys Res Commun. 2017 Feb 5;483(2):840-846. doi: 10.1016/j.bbrc.2017.01.012. Epub 2017 Jan 4.
REF00002019	Up-regulation of miR-497 confers resistance to temozolomide in human glioma cells by targeting mTOR/Bcl-2. Cancer Med. 2017 Feb;6(2):452-462. doi: 10.1002/cam4.987. Epub 2017 Jan 8.
REF00002020	Elevated HOTAIR expression associated with cisplatin resistance in non-small cell lung cancer patients. J Thorac Dis. 2016 Nov;8(11):3314-3322. doi: 10.21037/jtd.2016.11.75.
REF00002021	Long noncoding RNA HULC promotes cell proliferation by regulating PI3K/AKT signaling pathway in chronic myeloid leukemia. Gene. 2017 Apr 5;607:41-46. doi: 10.1016/j.gene.2017.01.004. Epub 2017 Jan 6.
REF00002022	MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2. Mol Cancer Ther. 2017 Apr;16(4):739-751. doi: 10.1158/1535-7163.MCT-16-0591. Epub 2017 Jan 9.
REF00002023	The miR-34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene. BMC Cancer. 2017 Jan 10;17(1):45. doi: 10.1186/s12885-016-3002-x.
REF00002024	MiR-488 inhibits proliferation and cisplatin sensibility in non-small-cell lung cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling pathway. Sci Rep. 2017 Jan 11;7:40384. doi: 10.1038/srep40384.
REF00002025	miR-375 inhibits cancer stem cell phenotype and tamoxifen resistance by degrading HOXB3 in human ER-positive breast cancer. Oncol Rep. 2017 Feb;37(2):1093-1099. doi: 10.3892/or.2017.5360. Epub 2017 Jan 9.
REF00002026	Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers. Pharmacol Res. 2017 Mar;117:343-356. doi: 10.1016/j.phrs.2017.01.007. Epub 2017 Jan 8.
REF00002027	MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy. Cell Death Dis. 2017 Jan 12;8(1):e2540. doi: 10.1038/cddis.2016.461.
REF00002028	Inhibition of Src by microRNA-23b increases the cisplatin sensitivity of chondrosarcoma cells. Cancer Biomark. 2017;18(3):231-239. doi: 10.3233/CBM-160102.
REF00002029	LncRNA-SLC6A9-5:2: A potent sensitizer in 131I-resistant papillary thyroid carcinoma with PARP-1 induction. Oncotarget. 2017 Apr 4;8(14):22954-22967. doi: 10.18632/oncotarget.14578.
REF00002030	MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression. J Ovarian Res. 2017 Jan 11;10(1):1. doi: 10.1186/s13048-016-0301-4.
REF00002031	Regulation of Docetaxel Sensitivity in Prostate Cancer Cells by hsa-miR-125a-3p via Modulation of Metastasis-Associated Protein 1 Signaling. Urology. 2017 Jul;105:208.e11-208.e17. doi: 10.1016/j.urology.2017.01.001. Epub 2017 Jan 11.
REF00002032	In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3-Mediated Apoptosis. Clin Cancer Res. 2017 Jul 15;23(14):3953-3965. doi: 10.1158/1078-0432.CCR-16-1464. Epub 2017 Jan 17.
REF00002033	miR-148a increases the sensitivity to cisplatin by targeting Rab14 in renal cancer cells. Int J Oncol. 2017 Mar;50(3):984-992. doi: 10.3892/ijo.2017.3851. Epub 2017 Jan 17.
REF00002034	Cisplatin induces HepG2 cell cycle arrest through targeting specific long noncoding RNAs and the p53 signaling pathway. Oncol Lett. 2016 Dec;12(6):4605-4612. doi: 10.3892/ol.2016.5288. Epub 2016 Oct 18.
REF00002035	MicroRNA-141 inhibits tumor growth and minimizes therapy resistance in colorectal cancer. Mol Med Rep. 2017 Mar;15(3):1037-1042. doi: 10.3892/mmr.2017.6135. Epub 2017 Jan 23.
REF00002036	Decreased expression of miR-939 contributes to chemoresistance and metastasis of gastric cancer via dysregulation of SLC34A2 and Raf/MEK/ERK pathway. Mol Cancer. 2017 Jan 23;16(1):18. doi: 10.1186/s12943-017-0586-y.
REF00002037	Perturbations of Phosphatidate Cytidylyltransferase (CdsA) Mediate Daptomycin Resistance in Streptococcus mitis/oralis by a Novel Mechanism. Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02435-16. doi: 10.1128/AAC.02435-16. Print 2017 Apr.
REF00002038	Suppression of EIF4G2 by miR-379 potentiates the cisplatin chemosensitivity in nonsmall cell lung cancer cells. FEBS Lett. 2017 Feb;591(4):636-645. doi: 10.1002/1873-3468.12566. Epub 2017 Feb 20.
REF00002039	Downregulation of lncRNA ANRIL represses tumorigenicity and enhances cisplatin-induced cytotoxicity via regulating microRNA let-7a in nasopharyngeal carcinoma. J Biochem Mol Toxicol. 2017 Jul;31(7). doi: 10.1002/jbt.21904. Epub 2017 Jan 24.
REF00002040	LncRNA CASC2 Interacts With miR-181a to Modulate Glioma Growth and Resistance to TMZ Through PTEN Pathway. J Cell Biochem. 2017 Jul;118(7):1889-1899. doi: 10.1002/jcb.25910. Epub 2017 Feb 13.
REF00002041	The long noncoding RNA PVT1 functions as a competing endogenous RNA by sponging miR-186 in gastric cancer. Biomed Pharmacother. 2017 Apr;88:302-308. doi: 10.1016/j.biopha.2017.01.049. Epub 2017 Feb 24.
REF00002042	miR-143 inhibits bladder cancer cell proliferation and enhances their sensitivity to gemcitabine by repressing IGF-1R signaling. Oncol Lett. 2017 Jan;13(1):435-440. doi: 10.3892/ol.2016.5388. Epub 2016 Nov 16.
REF00002043	MiR-199a-3p enhances breast cancer cell sensitivity to cisplatin by downregulating TFAM (TFAM). Biomed Pharmacother. 2017 Apr;88:507-514. doi: 10.1016/j.biopha.2017.01.058. Epub 2017 Jan 23.
REF00002044	Long noncoding RNAs and sulforaphane: a target for chemoprevention and suppression of prostate cancer. J Nutr Biochem. 2017 Apr;42:72-83. doi: 10.1016/j.jnutbio.2017.01.001. Epub 2017 Jan 12.
REF00002045	The TLR3 Agonist Inhibit Drug Efflux and Sequentially Consolidates Low-Dose Cisplatin-Based Chemoimmunotherapy while Reducing Side Effects. Mol Cancer Ther. 2017 Jun;16(6):1068-1079. doi: 10.1158/1535-7163.MCT-16-0454. Epub 2017 Jan 30.
REF00002046	MicroRNA-410 regulates autophagy-related gene ATG16L1 expression and enhances chemosensitivity via autophagy inhibition in osteosarcoma. Mol Med Rep. 2017 Mar;15(3):1326-1334. doi: 10.3892/mmr.2017.6149. Epub 2017 Jan 26.
REF00002047	The Moment that KRAS Mutation Started to Evolve into Precision Medicine in Metastatic Colorectal Cancer. Cancer Res. 2016 Nov 15;76(22):6443-6444. doi: 10.1158/0008-5472.CAN-16-2867.
REF00002048	microRNA-577 suppresses tumor growth and enhances chemosensitivity in colorectal cancer. J Biochem Mol Toxicol. 2017 Jun;31(6). doi: 10.1002/jbt.21888. Epub 2017 Feb 2.
REF00002049	Longitudinal analysis of treatment-induced genomic alterations in gliomas. Genome Med. 2017 Feb 2;9(1):12. doi: 10.1186/s13073-017-0401-9.
REF00002050	MicroRNA-130b targets PTEN to mediate drug resistance and proliferation of breast cancer cells via the PI3K/Akt signaling pathway. Sci Rep. 2017 Feb 6;7:41942. doi: 10.1038/srep41942.
REF00002051	LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells. Oncogene. 2017 Jun 22;36(25):3528-3540. doi: 10.1038/onc.2016.521. Epub 2017 Feb 6.
REF00002052	Capturing tumor heterogeneity and clonal evolution in solid cancers using circulating tumor DNA analysis. Pharmacol Ther. 2017 Jun;174:22-26. doi: 10.1016/j.pharmthera.2017.02.003. Epub 2017 Feb 3.
REF00002053	Curcumin suppresses cisplatin resistance development partly via modulating extracellular vesicle-mediated transfer of MEG3 and miR-214 in ovarian cancer. Cancer Chemother Pharmacol. 2017 Mar;79(3):479-487. doi: 10.1007/s00280-017-3238-4. Epub 2017 Feb 8.
REF00002054	CXCL12/CXCR4 axis induced miR-125b promotes invasion and confers 5-fluorouracil resistance through enhancing autophagy in colorectal cancer. Sci Rep. 2017 Feb 8;7:42226. doi: 10.1038/srep42226.
REF00002055	STAT3 is required for MiR-17-5p-mediated sensitization to chemotherapy-induced apoptosis in breast cancer cells. Oncotarget. 2017 Feb 28;8(9):15763-15774. doi: 10.18632/oncotarget.15000.
REF00002056	MED12 is recurrently mutated in Middle Eastern colorectal cancer. Gut. 2018 Apr;67(4):663-671. doi: 10.1136/gutjnl-2016-313334. Epub 2017 Feb 9.
REF00002057	MicroRNA hsa-miR-29b potentiates etoposide toxicity in HeLa cells via down-regulation of Mcl-1. Toxicol In Vitro. 2017 Apr;40:289-296. doi: 10.1016/j.tiv.2017.02.005. Epub 2017 Feb 6.
REF00002058	MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression. Oncotarget. 2017 Apr 4;8(14):22783-22799. doi: 10.18632/oncotarget.15199.
REF00002059	"H19 Overexpression Induces Resistance to 1,25(OH)2D3 by Targeting VDR Through miR-675-5p in Colon Cancer Cells. Neoplasia. 2017 Mar;19(3):226-236. doi: 10.1016/j.neo.2016.10.007. Epub 2017 Feb 8."
REF00002060	LncRNA MEG3 Regulates Imatinib Resistance in Chronic Myeloid Leukemia via Suppressing MicroRNA-21. Biomol Ther (Seoul). 2017 Sep 1;25(5):490-496. doi: 10.4062/biomolther.2016.162.
REF00002061	MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. Sci Rep. 2017 Feb 15;7:42339. doi: 10.1038/srep42339.
REF00002062	Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J. BMC Cancer. 2017 Feb 15;17(1):138. doi: 10.1186/s12885-017-3132-9.
REF00002063	miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression. Cell Prolif. 2017 Jun;50(3):e12341. doi: 10.1111/cpr.12341. Epub 2017 Feb 19.
REF00002064	[Targeting miR155 restores chemotherapy sensitivity in drug-resistant myeloma cell-line RPMI8226/DOX cells]. Zhonghua Xue Ye Xue Za Zhi. 2017 Jan 14;38(1):55-59. doi: 10.3760/cma.j.issn.0253-2727.2017.01.012.
REF00002065	MicroRNA-218 Increases the Sensitivity of Bladder Cancer to Cisplatin by Targeting Glut1. Cell Physiol Biochem. 2017;41(3):921-932. doi: 10.1159/000460505. Epub 2017 Feb 20.
REF00002066	A Feedback Loop Between miR-30a/c-5p and DNMT1 Mediates Cisplatin Resistance in Ovarian Cancer Cells. Cell Physiol Biochem. 2017;41(3):973-986. doi: 10.1159/000460618. Epub 2017 Feb 21.
REF00002067	Circulating-free DNA Mutation Associated with Response of Targeted Therapy in Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer. Chin Med J (Engl). 2017 Mar 5;130(5):522-529. doi: 10.4103/0366-6999.200542.
REF00002068	Long non-coding RNA LINC00672 contributes to p53 protein-mediated gene suppression and promotes endometrial cancer chemosensitivity. J Biol Chem. 2017 Apr 7;292(14):5801-5813. doi: 10.1074/jbc.M116.758508. Epub 2017 Feb 23.
REF00002069	Precise insertion of antibiotic resistance determinants into Tn21-like transposons: nucleotide sequence of the OXA-1 beta-lactamase gene. Proc Natl Acad Sci U S A. 1987 Nov;84(21):7378-82. doi: 10.1073/pnas.84.21.7378.
REF00002070	miR-124 suppresses glioblastoma growth and potentiates chemosensitivity by inhibiting AURKA. Biochem Biophys Res Commun. 2017 Apr 22;486(1):43-48. doi: 10.1016/j.bbrc.2017.02.120. Epub 2017 Feb 24.
REF00002071	"2-O-Methylmagnolol upregulates the long non-coding RNA, GAS5, and enhances apoptosis in skin cancer cells. Cell Death Dis. 2017 Mar 2;8(3):e2638. doi: 10.1038/cddis.2017.66."
REF00002072	Mutational profiling of acute lymphoblastic leukemia with testicular relapse. J Hematol Oncol. 2017 Mar 2;10(1):65. doi: 10.1186/s13045-017-0434-y.
REF00002073	miR-125b-5p enhances chemotherapy sensitivity to cisplatin by down-regulating Bcl2 in gallbladder cancer. Sci Rep. 2017 Mar 3;7:43109. doi: 10.1038/srep43109.
REF00002074	microRNA-125b reverses the multidrug resistance of nasopharyngeal carcinoma cells via targeting of Bcl-2. Mol Med Rep. 2017 Apr;15(4):2223-2228. doi: 10.3892/mmr.2017.6233. Epub 2017 Feb 22.
REF00002075	miR-9 regulates the multidrug resistance of chronic myelogenous leukemia by targeting ABCB1. Oncol Rep. 2017 Apr;37(4):2193-2200. doi: 10.3892/or.2017.5464. Epub 2017 Feb 17.
REF00002076	Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy. Respir Med Case Rep. 2017 Feb 17;20:160-163. doi: 10.1016/j.rmcr.2017.02.009. eCollection 2017.
REF00002077	Novel methicillin resistance gene mecD in clinical Macrococcus caseolyticus strains from bovine and canine sources. Sci Rep. 2017 Mar 8;7:43797. doi: 10.1038/srep43797.
REF00002078	MiR-216b increases cisplatin sensitivity in ovarian cancer cells by targeting PARP1. Cancer Gene Ther. 2017 May;24(5):208-214. doi: 10.1038/cgt.2017.6. Epub 2017 Mar 10.
REF00002079	MiR-34a-5p promotes multi-chemoresistance of osteosarcoma through down-regulation of the DLL1 gene. Sci Rep. 2017 Mar 10;7:44218. doi: 10.1038/srep44218.
REF00002080	Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients. Eur J Cancer. 2017 May;76:76-83. doi: 10.1016/j.ejca.2017.02.007. Epub 2017 Mar 8.
REF00002081	Downregulation of miR-33a-5p in Hepatocellular Carcinoma: A Possible Mechanism for Chemotherapy Resistance. Med Sci Monit. 2017 Mar 14;23:1295-1304. doi: 10.12659/msm.902692.
REF00002082	LncRNA PVT1 epigenetically silences miR-195 and modulates EMT and chemoresistance in cervical cancer cells. J Drug Target. 2017 Aug;25(7):637-644. doi: 10.1080/1061186X.2017.1307379. Epub 2017 Apr 3.
REF00002083	TSPAN12 promotes chemoresistance and proliferation of SCLC under the regulation of miR-495. Biochem Biophys Res Commun. 2017 Apr 29;486(2):349-356. doi: 10.1016/j.bbrc.2017.03.044. Epub 2017 Mar 14.
REF00002084	TUG1 mediates methotrexate resistance in colorectal cancer via miR-186/CPEB2 axis. Biochem Biophys Res Commun. 2017 Sep 16;491(2):552-557. doi: 10.1016/j.bbrc.2017.03.042. Epub 2017 Mar 14.
REF00002085	Antisense lncRNA FOXC2-AS1 promotes doxorubicin resistance in osteosarcoma by increasing the expression of FOXC2. Cancer Lett. 2017 Jun 28;396:66-75. doi: 10.1016/j.canlet.2017.03.018. Epub 2017 Mar 16.
REF00002086	A piRNA-like Small RNA Induces Chemoresistance to Cisplatin-Based Therapy by Inhibiting Apoptosis in Lung Squamous Cell Carcinoma. Mol Ther Nucleic Acids. 2017 Mar 17;6:269-278. doi: 10.1016/j.omtn.2017.01.003. Epub 2017 Jan 24.
REF00002087	MicroRNA-488-3p sensitizes malignant melanoma cells to cisplatin by targeting PRKDC. Cell Biol Int. 2017 Jun;41(6):622-629. doi: 10.1002/cbin.10765. Epub 2017 Apr 7.
REF00002088	Nucleotide sequence of the kanamycin resistance determinant of plasmid RP4: homology to other aminoglycoside 3'-phosphotransferases. Plasmid. 1987 Nov;18(3):193-204. doi: 10.1016/0147-619x(87)90062-x.
REF00002089	MiR-223/PAX6 Axis Regulates Glioblastoma Stem Cell Proliferation and the Chemo Resistance to TMZ via Regulating PI3K/Akt Pathway. J Cell Biochem. 2017 Oct;118(10):3452-3461. doi: 10.1002/jcb.26003. Epub 2017 Jun 6.
REF00002090	The aacA-aphD gentamicin and kanamycin resistance determinant of Tn4001 from Staphylococcus aureus: expression and nucleotide sequence analysis. J Gen Microbiol. 1987 Nov;133(11):3039-52. doi: 10.1099/00221287-133-11-3039.
REF00002091	MicroRNA-140-5p regulates osteosarcoma chemoresistance by targeting HMGN5 and autophagy. Sci Rep. 2017 Mar 24;7(1):416. doi: 10.1038/s41598-017-00405-3.
REF00002092	Overexpression of miR-203 increases the sensitivity of NSCLC A549/H460 cell lines to cisplatin by targeting Dickkopf-1. Oncol Rep. 2017 Apr;37(4):2129-2136. doi: 10.3892/or.2017.5505. Epub 2017 Mar 13.
REF00002093	miR-15b inhibits cancer-initiating cell phenotypes and chemoresistance of cisplatin by targeting TRIM14 in oral tongue squamous cell cancer. Oncol Rep. 2017 May;37(5):2720-2726. doi: 10.3892/or.2017.5532. Epub 2017 Mar 27.
REF00002094	Upregulation of miR-137 reverses sorafenib resistance and cancer-initiating cell phenotypes by degrading ANT2 in hepatocellular carcinoma. Oncol Rep. 2017 Apr;37(4):2071-2078. doi: 10.3892/or.2017.5498. Epub 2017 Mar 10.
REF00002095	Suppression of microRNA-629 enhances sensitivity of cervical cancer cells to 1'S-1'-acetoxychavicol acetate via regulating RSU1. Onco Targets Ther. 2017 Mar 20;10:1695-1705. doi: 10.2147/OTT.S117492. eCollection 2017.
REF00002096	Silencing of LncRNA HULC Enhances Chemotherapy Induced Apoptosis in Human Gastric Cancer. J Med Biochem. 2016 Apr;35(2):137-143. doi: 10.1515/jomb-2015-0016. Epub 2016 May 9.
REF00002097	LncRNA CCAT1 modulates the sensitivity of paclitaxel in nasopharynx cancers cells via miR-181a/CPEB2 axis. Cell Cycle. 2017 Apr 18;16(8):795-801. doi: 10.1080/15384101.2017.1301334. Epub 2017 Mar 30.
REF00002098	Blocking MIR155HG/miR-155 axis inhibits mesenchymal transition in glioma. Neuro Oncol. 2017 Sep 1;19(9):1195-1205. doi: 10.1093/neuonc/nox017.
REF00002099	miR-216b promotes cell growth and enhances chemosensitivity of colorectal cancer by suppressing PDZ-binding kinase. Biochem Biophys Res Commun. 2017 Jun 24;488(2):247-252. doi: 10.1016/j.bbrc.2017.03.162. Epub 2017 Mar 31.
REF00002100	Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair. J Ovarian Res. 2017 Apr 4;10(1):24. doi: 10.1186/s13048-017-0321-8.
REF00002101	[Role of miR-206/CDK4 in modulating the growth and chemotlerapy sensitivity of ovarian cancer cells]. Nan Fang Yi Ke Da Xue Xue Bao. 2017 Mar 20;37(3):393-397. doi: 10.3969/j.issn.1673-4254.2017.03.20.
REF00002102	miR-423-5p knockdown enhances the sensitivity of glioma stem cells to apigenin through the mitochondrial pathway. Tumour Biol. 2017 Apr;39(4):1010428317695526. doi: 10.1177/1010428317695526.
REF00002103	Involvement of miR-125a in resistance to daunorubicin by inhibiting apoptosis in leukemia cell lines. Tumour Biol. 2017 Apr;39(4):1010428317695964. doi: 10.1177/1010428317695964.
REF00002104	Upregulated miR-132 in Lgr5(+) gastric cancer stem cell-like cells contributes to cisplatin-resistance via SIRT1/CREB/ABCG2 signaling pathway. Mol Carcinog. 2017 Sep;56(9):2022-2034. doi: 10.1002/mc.22656. Epub 2017 May 2.
REF00002105	MiR-490-3p sensitizes ovarian cancer cells to cisplatin by directly targeting ABCC2. Am J Transl Res. 2017 Mar 15;9(3):1127-1138. eCollection 2017.
REF00002106	Downregulation of miR-429 contributes to the development of drug resistance in epithelial ovarian cancer by targeting ZEB1. Am J Transl Res. 2017 Mar 15;9(3):1357-1368. eCollection 2017.
REF00002107	Long noncoding RNA ROR regulates chemoresistance in docetaxel-resistant lung adenocarcinoma cells via epithelial mesenchymal transition pathway. Oncotarget. 2017 May 16;8(20):33144-33158. doi: 10.18632/oncotarget.16562.
REF00002108	Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression. Sci Rep. 2017 Apr 10;7(1):781. doi: 10.1038/s41598-017-00901-6.
REF00002109	miR-495 promotes the chemoresistance of SCLC through the epithelial-mesenchymal transition via Etk/BMX. Am J Cancer Res. 2017 Mar 1;7(3):628-646. eCollection 2017.
REF00002110	Silence of Long Noncoding RNA NEAT1 Inhibits Malignant Biological Behaviors and Chemotherapy Resistance in Gastric Cancer. Pathol Oncol Res. 2018 Jan;24(1):109-113. doi: 10.1007/s12253-017-0233-3. Epub 2017 Apr 11.
REF00002111	The long noncoding RNA ANRIL acts as an oncogene and contributes to paclitaxel resistance of lung adenocarcinoma A549 cells. Oncotarget. 2017 Jun 13;8(24):39177-39184. doi: 10.18632/oncotarget.16640.
REF00002112	Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells. J Exp Clin Cancer Res. 2017 Apr 13;36(1):53. doi: 10.1186/s13046-017-0528-y.
REF00002113	Yeast response and tolerance to benzoic acid involves the Gcn4- and Stp1-regulated multidrug/multixenobiotic resistance transporter Tpo1. Appl Microbiol Biotechnol. 2017 Jun;101(12):5005-5018. doi: 10.1007/s00253-017-8277-6. Epub 2017 Apr 13.
REF00002114	The Effect of miR-200c Inhibition on Chemosensitivity (5- FluoroUracil) in Colorectal Cancer. Pathol Oncol Res. 2018 Jan;24(1):145-151. doi: 10.1007/s12253-017-0222-6. Epub 2017 Apr 14.
REF00002115	miR-495 sensitizes MDR cancer cells to the combination of doxorubicin and taxol by inhibiting MDR1 expression. J Cell Mol Med. 2017 Sep;21(9):1929-1943. doi: 10.1111/jcmm.13114. Epub 2017 Apr 14.
REF00002116	Potentiation of docetaxel sensitivity by miR-638 via regulation of STARD10 pathway in human breast cancer cells. Biochem Biophys Res Commun. 2017 May 27;487(2):255-261. doi: 10.1016/j.bbrc.2017.04.045. Epub 2017 Apr 12.
REF00002117	Expression of Long Noncoding RNA Urothelial Cancer Associated 1 Promotes Cisplatin Resistance in Cervical Cancer. Cancer Biother Radiopharm. 2017 Apr;32(3):101-110. doi: 10.1089/cbr.2016.2156.
REF00002118	Long non-coding RNA CTA sensitizes osteosarcoma cells to doxorubicin through inhibition of autophagy. Oncotarget. 2017 May 9;8(19):31465-31477. doi: 10.18632/oncotarget.16356.
REF00002119	MicroRNA-100 suppresses human osteosarcoma cell proliferation and chemo-resistance via ZNRF2. Oncotarget. 2017 May 23;8(21):34678-34686. doi: 10.18632/oncotarget.16149.
REF00002120	[Urothelial carcinoma-associated 1 enhances tamoxifen resistance in breast cancer cells through competitively inhibiting miR-18a]. Beijing Da Xue Xue Bao Yi Xue Ban. 2017 Apr 18;49(2):295-302.
REF00002121	Therapeutic targeting using tumor specific peptides inhibits long non-coding RNA HOTAIR activity in ovarian and breast cancer. Sci Rep. 2017 Apr 18;7(1):894. doi: 10.1038/s41598-017-00966-3.
REF00002122	MiR-199a-3p enhances cisplatin sensitivity of cholangiocarcinoma cells by inhibiting mTOR signaling pathway and expression of MDR1. Oncotarget. 2017 May 16;8(20):33621-33630. doi: 10.18632/oncotarget.16834.
REF00002123	Knockdown of miR-27a sensitizes colorectal cancer stem cells to TRAIL by promoting the formation of Apaf-1-caspase-9 complex. Oncotarget. 2017 Jul 11;8(28):45213-45223. doi: 10.18632/oncotarget.16779.
REF00002124	miR-503-5p confers drug resistance by targeting PUMA in colorectal carcinoma. Oncotarget. 2017 Mar 28;8(13):21719-21732. doi: 10.18632/oncotarget.15559.
REF00002125	MiR-519d impedes cisplatin-resistance in breast cancer stem cells by down-regulating the expression of MCL-1. Oncotarget. 2017 Mar 28;8(13):22003-22013. doi: 10.18632/oncotarget.15781.
REF00002126	MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT. J Neurooncol. 2017 May;133(1):59-68. doi: 10.1007/s11060-017-2425-9. Epub 2017 Apr 19.
REF00002127	MiR-142-3p Overexpression Increases Chemo-Sensitivity of NSCLC by Inhibiting HMGB1-Mediated Autophagy. Cell Physiol Biochem. 2017;41(4):1370-1382. doi: 10.1159/000467896. Epub 2017 Mar 16.
REF00002128	Down-regulation of long non-coding RNA RP11-708H21.4 is associated with poor prognosis for colorectal cancer and promotes tumorigenesis through regulating AKT/mTOR pathway. Oncotarget. 2017 Apr 25;8(17):27929-27942. doi: 10.18632/oncotarget.15846.
REF00002129	MicroRNA-145 exerts tumor-suppressive and chemo-resistance lowering effects by targeting CD44 in gastric cancer. World J Gastroenterol. 2017 Apr 7;23(13):2337-2345. doi: 10.3748/wjg.v23.i13.2337.
REF00002130	MicroRNA-451 regulates chemoresistance in renal cell carcinoma by targeting ATF-2 gene. Exp Biol Med (Maywood). 2017 Jun;242(12):1299-1305. doi: 10.1177/1535370217701625. Epub 2017 Apr 21.
REF00002131	MiR-33b-5p sensitizes gastric cancer cells to chemotherapy drugs via inhibiting HMGA2 expression. J Drug Target. 2017 Aug;25(7):653-660. doi: 10.1080/1061186X.2017.1323220. Epub 2017 May 11.
REF00002132	MicroRNA-340-5p modulates cisplatin resistance by targeting LPAATBeta in osteosarcoma. Braz J Med Biol Res. 2017 Apr 20;50(5):e6359. doi: 10.1590/1414-431X20176359.
REF00002133	miR-21 inhibitor suppresses cell proliferation and colony formation through regulating the PTEN/AKT pathway and improves paclitaxel sensitivity in cervical cancer cells. Mol Med Rep. 2017 May;15(5):2713-2719. doi: 10.3892/mmr.2017.6340. Epub 2017 Mar 16.
REF00002134	miRNA-34c-5p inhibits amphiregulin-induced ovarian cancer stemness and drug resistance via downregulation of the AREG-EGFR-ERK pathway. Oncogenesis. 2017 May 1;6(5):e326. doi: 10.1038/oncsis.2017.25.
REF00002135	miR-153 enhances the therapeutic effect of gemcitabine by targeting Snail in pancreatic cancer. Acta Biochim Biophys Sin (Shanghai). 2017 Jun 1;49(6):520-529. doi: 10.1093/abbs/gmx039.
REF00002136	Long Noncoding RNA lncARSR Promotes Doxorubicin Resistance in Hepatocellular Carcinoma via Modulating PTEN-PI3K/Akt Pathway. J Cell Biochem. 2017 Dec;118(12):4498-4507. doi: 10.1002/jcb.26107. Epub 2017 Jun 9.
REF00002137	"Nucleotide sequence of Acinetobacter baumannii aphA-6 gene: evolutionary and functional implications of sequence homologies with nucleotide-binding proteins, kinases and other aminoglycoside-modifying enzymes. Mol Microbiol. 1988 Sep;2(5):615-25. doi: 10.1111/j.1365-2958.1988.tb00070.x."
REF00002138	"Long Noncoding RNA GAS5, Which Acts as a Tumor Suppressor via microRNA 21, Regulates Cisplatin Resistance Expression in Cervical Cancer. Int J Gynecol Cancer. 2017 Jul;27(6):1096-1108. doi: 10.1097/IGC.0000000000001028."
REF00002139	The long non-coding RNA HOTAIR enhances pancreatic cancer resistance to TNF-related apoptosis-inducing ligand. J Biol Chem. 2017 Jun 23;292(25):10390-10397. doi: 10.1074/jbc.M117.786830. Epub 2017 May 5.
REF00002140	Micro-RNA-21 Regulates Cancer-Associated Fibroblast-Mediated Drug Resistance in Pancreatic Cancer. Oncol Res. 2018 Jul 5;26(6):827-835. doi: 10.3727/096504017X14934840662335. Epub 2017 May 5.
REF00002141	"Isolation, characterization, and cloning of a plasmid-borne gene encoding a phosphotransferase that confers high-level amikacin resistance in enteric bacilli. Antimicrob Agents Chemother. 1988 Sep;32(9):1379-84. doi: 10.1128/AAC.32.9.1379."
REF00002142	MicroRNA-181a promotes docetaxel resistance in prostate cancer cells. Prostate. 2017 Jun;77(9):1020-1028. doi: 10.1002/pros.23358.
REF00002143	A Variant PfCRT Isoform Can Contribute to Plasmodium falciparum Resistance to the First-Line Partner Drug Piperaquine. mBio. 2017 May 9;8(3):e00303-17. doi: 10.1128/mBio.00303-17.
REF00002144	miR-30a-5p enhances paclitaxel sensitivity in non-small cell lung cancer through targeting BCL-2 expression. J Mol Med (Berl). 2017 Aug;95(8):861-871. doi: 10.1007/s00109-017-1539-z. Epub 2017 May 9.
REF00002145	miR-218-5p restores sensitivity to gemcitabine through PRKCE/MDR1 axis in gallbladder cancer. Cell Death Dis. 2017 May 11;8(5):e2770. doi: 10.1038/cddis.2017.178.
REF00002146	Modulation of CASC2/miR-21/PTEN pathway sensitizes cervical cancer to cisplatin. Arch Biochem Biophys. 2017 Jun 1;623-624:20-30. doi: 10.1016/j.abb.2017.05.001. Epub 2017 May 8.
REF00002147	microRNA-200a-3p increases 5-fluorouracil resistance by regulating dual specificity phosphatase 6 expression. Exp Mol Med. 2017 May 12;49(5):e327. doi: 10.1038/emm.2017.33.
REF00002148	Effect of miR-1244 on cisplatin-treated non-small cell lung cancer via MEF2D expression. Oncol Rep. 2017 Jun;37(6):3475-3483. doi: 10.3892/or.2017.5624. Epub 2017 May 4.
REF00002149	Long non-coding RNA AC023115.3 suppresses chemoresistance of glioblastoma by reducing autophagy. Biochim Biophys Acta Mol Cell Res. 2017 Aug;1864(8):1393-1404. doi: 10.1016/j.bbamcr.2017.05.008. Epub 2017 May 9.
REF00002150	MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor. J Neurooncol. 2017 Jul;133(3):477-485. doi: 10.1007/s11060-017-2463-3. Epub 2017 May 13.
REF00002151	Sensitivity of non-small cell lung cancer to erlotinib is regulated by the Notch/miR-223/FBXW7 pathway. Biosci Rep. 2017 Jun 21;37(3):BSR20160478. doi: 10.1042/BSR20160478. Print 2017 Jun 30.
REF00002152	Attenuation of deregulated miR-369-3p expression sensitizes non-small cell lung cancer cells to cisplatin via modulation of the nucleotide sugar transporter SLC35F5. Biochem Biophys Res Commun. 2017 Jul 1;488(3):501-508. doi: 10.1016/j.bbrc.2017.05.075. Epub 2017 May 13.
REF00002153	Downregulation of miR-224 and let-7i contribute to cell survival and chemoresistance in chronic myeloid leukemia cells by regulating ST3GAL IV expression. Gene. 2017 Aug 30;626:106-118. doi: 10.1016/j.gene.2017.05.030. Epub 2017 May 13.
REF00002154	Nucleotide sequence of the ribostamycin phosphotransferase gene and of its control region in Streptomyces ribosidificus. Gene. 1988 Sep 7;68(2):285-96. doi: 10.1016/0378-1119(88)90031-5.
REF00002155	Increased MIR31HG lncRNA expression increases gefitinib resistance in non-small cell lung cancer cell lines through the EGFR/PI3K/AKT signaling pathway. Oncol Lett. 2017 May;13(5):3494-3500. doi: 10.3892/ol.2017.5878. Epub 2017 Mar 20.
REF00002156	"Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells. Oncotarget. 2017 Jul 25;8(30):49451-49469. doi: 10.18632/oncotarget.17706."
REF00002157	[MiR-145 inhibits drug resistance to Oxaliplatin in colorectal cancer cells through regulating G protein coupled receptor 98]. Zhonghua Wei Chang Wai Ke Za Zhi. 2017 May 25;20(5):566-570.
REF00002158	"The relationship between miR-17-5p, miR-92a, and let-7b expression with non-small cell lung cancer targeted drug resistance. J BUON. 2017 Mar-Apr;22(2):454-461."
REF00002159	MicroRNA-200c regulates cisplatin resistance by targeting ZEB2 in human gastric cancer cells. Oncol Rep. 2017 Jul;38(1):151-158. doi: 10.3892/or.2017.5659. Epub 2017 May 22.
REF00002160	hsa-miR-485-5p reverses epithelial to mesenchymal transition and promotes cisplatin-induced cell death by targeting PAK1 in oral tongue squamous cell carcinoma. Int J Mol Med. 2017 Jul;40(1):83-89. doi: 10.3892/ijmm.2017.2992. Epub 2017 May 16.
REF00002161	Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205. Cancer Lett. 2017 Aug 28;402:1-8. doi: 10.1016/j.canlet.2017.05.007. Epub 2017 May 20.
REF00002162	Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner. Int J Nanomedicine. 2017 May 15;12:3721-3733. doi: 10.2147/IJN.S131516. eCollection 2017.
REF00002163	Upregulation of miR-101 enhances the cytotoxic effect of anticancer drugs through inhibition of colon cancer cell proliferation. Oncol Rep. 2017 Jul;38(1):100-108. doi: 10.3892/or.2017.5666. Epub 2017 May 24.
REF00002164	MicroRNA 146a 5p enhances cisplatin induced apoptosis in ovarian cancer cells by targeting multiple anti apoptotic genes. Int J Oncol. 2017 Jul;51(1):327-335. doi: 10.3892/ijo.2017.4023. Epub 2017 May 29.
REF00002165	Micro-RNA-130a-3p Regulates Gemcitabine Resistance via PPARG in Cholangiocarcinoma. Ann Surg Oncol. 2017 Aug;24(8):2344-2352. doi: 10.1245/s10434-017-5871-x. Epub 2017 May 30.
REF00002166	FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions. Mol Cancer Ther. 2017 Jun;16(6):991-1001. doi: 10.1158/1535-7163.MCT-16-0876.
REF00002167	"MiR-124 contributes to glucocorticoid resistance in acute lymphoblastic leukemia by promoting proliferation, inhibiting apoptosis and targeting the glucocorticoid receptor. J Steroid Biochem Mol Biol. 2017 Sep;172:62-68. doi: 10.1016/j.jsbmb.2017.05.014. Epub 2017 May 31."
REF00002168	Upregulation of microRNA-143 reverses drug resistance in human breast cancer cells via inhibition of cytokine-induced apoptosis inhibitor 1. Oncol Lett. 2017 Jun;13(6):4695-4700. doi: 10.3892/ol.2017.6078. Epub 2017 Apr 24.
REF00002169	Maintenance of cancer stemness by miR-196b-5p contributes to chemoresistance of colorectal cancer cells via activating STAT3 signaling pathway. Oncotarget. 2017 Jul 25;8(30):49807-49823. doi: 10.18632/oncotarget.17971.
REF00002170	miR-19a contributes to gefitinib resistance and epithelial mesenchymal transition in non-small cell lung cancer cells by targeting c-Met. Sci Rep. 2017 Jun 7;7(1):2939. doi: 10.1038/s41598-017-01153-0.
REF00002171	Sensitization of melanoma cells to temozolomide by overexpression of microRNA 203 through direct targeting of glutaminase-mediated glutamine metabolism. Clin Exp Dermatol. 2017 Aug;42(6):614-621. doi: 10.1111/ced.13119. Epub 2017 Jun 9.
REF00002172	Downregulation of eIF4G by microRNA-503 enhances drug sensitivity of MCF-7/ADR cells through suppressing the expression of ABC transport proteins. Oncol Lett. 2017 Jun;13(6):4785-4793. doi: 10.3892/ol.2017.6049. Epub 2017 Apr 19.
REF00002173	MicroRNA 217 inhibits cell proliferation and enhances chemosensitivity to doxorubicin in acute myeloid leukemia by targeting KRAS. Oncol Lett. 2017 Jun;13(6):4986-4994. doi: 10.3892/ol.2017.6076. Epub 2017 Apr 24.
REF00002174	miR-101 alleviates chemoresistance of gastric cancer cells by targeting ANXA2. Biomed Pharmacother. 2017 Aug;92:1030-1037. doi: 10.1016/j.biopha.2017.06.011. Epub 2017 Jun 10.
REF00002175	Prognostic Significance of microRNA-7 and its Roles in the Regulation of Cisplatin Resistance in Lung Adenocarcinoma. Cell Physiol Biochem. 2017;42(2):660-672. doi: 10.1159/000477884. Epub 2017 Jun 15.
REF00002176	MiR-129-5p inhibits non-small cell lung cancer cell stemness and chemoresistance through targeting DLK1. Biochem Biophys Res Commun. 2017 Aug 19;490(2):309-316. doi: 10.1016/j.bbrc.2017.06.041. Epub 2017 Jun 12.
REF00002177	MiR-183 overexpression inhibits tumorigenesis and enhances DDP-induced cytotoxicity by targeting MTA1 in nasopharyngeal carcinoma. Tumour Biol. 2017 Jun;39(6):1010428317703825. doi: 10.1177/1010428317703825.
REF00002178	Antagonizing miR-455-3p inhibits chemoresistance and aggressiveness in esophageal squamous cell carcinoma. Mol Cancer. 2017 Jun 21;16(1):106. doi: 10.1186/s12943-017-0669-9.
REF00002179	Inhibition of long non-coding RNA ROR reverses resistance to Tamoxifen by inducing autophagy in breast cancer. Tumour Biol. 2017 Jun;39(6):1010428317705790. doi: 10.1177/1010428317705790.
REF00002180	Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells. J Biol Chem. 2017 Aug 18;292(33):13551-13564. doi: 10.1074/jbc.M117.780973. Epub 2017 Jun 21.
REF00002181	miR-509-5p and miR-1243 increase the sensitivity to gemcitabine by inhibiting epithelial-mesenchymal transition in pancreatic cancer. Sci Rep. 2017 Jun 21;7(1):4002. doi: 10.1038/s41598-017-04191-w.
REF00002182	MicroRNA-138 enhances TRAIL-induced apoptosis through interferon-stimulated gene 15 downregulation in hepatocellular carcinoma cells. Tumour Biol. 2017 Jun;39(6):1010428317710410. doi: 10.1177/1010428317710410.
REF00002183	Upregulation of miR-199a/b contributes to cisplatin resistance via Wnt/Beta-catenin-ABCG2 signaling pathway in ALDHA1(+) colorectal cancer stem cells. Tumour Biol. 2017 Jun;39(6):1010428317715155. doi: 10.1177/1010428317715155.
REF00002184	[MiR-133b Affect the Proliferation and Drug Sensitivity in A549 Lung Cancer Stem Cells by Targeting PKM2]. Zhongguo Fei Ai Za Zhi. 2017 Jun 20;20(6):376-381. doi: 10.3779/j.issn.1009-3419.2017.06.02.
REF00002185	LncRNA-SARCC suppresses renal cell carcinoma (RCC) progression via altering the androgen receptor(AR)/miRNA-143-3p signals. Cell Death Differ. 2017 Sep;24(9):1502-1517. doi: 10.1038/cdd.2017.74. Epub 2017 Jun 23.
REF00002186	miR-15b-5p resensitizes colon cancer cells to 5-fluorouracil by promoting apoptosis via the NF-kB/XIAP axis. Sci Rep. 2017 Jun 23;7(1):4194. doi: 10.1038/s41598-017-04172-z.
REF00002187	miR-491 Inhibits Osteosarcoma Lung Metastasis and Chemoresistance by Targeting AlphaB-crystallin. Mol Ther. 2017 Sep 6;25(9):2140-2149. doi: 10.1016/j.ymthe.2017.05.018. Epub 2017 Jun 23.
REF00002188	Long non-coding RNA tumor suppressor candidate 7 advances chemotherapy sensitivity of endometrial carcinoma through targeted silencing of miR-23b. Tumour Biol. 2017 Jun;39(6):1010428317707883. doi: 10.1177/1010428317707883.
REF00002189	A Novel Environmental Azole Resistance Mutation in Aspergillus fumigatus and a Possible Role of Sexual Reproduction in Its Emergence. mBio. 2017 Jun 27;8(3):e00791-17. doi: 10.1128/mBio.00791-17.
REF00002190	Down-regulation of PARP1 by miR-891b sensitizes human breast cancer cells to alkylating chemotherapeutic drugs. Arch Gynecol Obstet. 2017 Sep;296(3):543-549. doi: 10.1007/s00404-017-4444-3. Epub 2017 Jun 28.
REF00002191	Extreme low dose of 5-fluorouracil reverses MDR in cancer by sensitizing cancer associated fibroblasts and down-regulating P-gp. PLoS One. 2017 Jun 29;12(6):e0180023. doi: 10.1371/journal.pone.0180023. eCollection 2017.
REF00002192	A cfr-like gene cfr(C) conferring linezolid resistance is common in Clostridium difficile. Int J Antimicrob Agents. 2017 Sep;50(3):496-500. doi: 10.1016/j.ijantimicag.2017.03.013. Epub 2017 Jun 27.
REF00002193	Different levels of let-7d expression modulate response of FaDu cells to irradiation and chemotherapeutics. PLoS One. 2017 Jun 30;12(6):e0180265. doi: 10.1371/journal.pone.0180265. eCollection 2017.
REF00002194	MiR-16-1 Targeted Silences Far Upstream Element Binding Protein 1 to Advance the Chemosensitivity to Adriamycin in Gastric Cancer. Pathol Oncol Res. 2018 Jul;24(3):483-488. doi: 10.1007/s12253-017-0263-x. Epub 2017 Jun 30.
REF00002195	Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide. Cell Physiol Biochem. 2017;42(3):1192-1201. doi: 10.1159/000478917. Epub 2017 Jul 3.
REF00002196	MiR-126 reverses drug resistance to TRAIL through inhibiting the expression of c-FLIP in cervical cancer. Gene. 2017 Sep 5;627:420-427. doi: 10.1016/j.gene.2017.06.055. Epub 2017 Jun 29.
REF00002197	Long non coding RNA MEG3 contributes to cisplatin induced apoptosis via inhibition of autophagy in human glioma cells. Mol Med Rep. 2017 Sep;16(3):2946-2952. doi: 10.3892/mmr.2017.6897. Epub 2017 Jun 30.
REF00002198	Oral squamous cell carcinoma cells are resistant to doxorubicin through upregulation of miR 221. Mol Med Rep. 2017 Sep;16(3):2659-2667. doi: 10.3892/mmr.2017.6915. Epub 2017 Jul 4.
REF00002199	MiR-146a-5p level in serum exosomes predicts therapeutic effect of cisplatin in non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 2017 Jun;21(11):2650-2658.
REF00002200	Downregulated long non-coding RNA TRPM2-AS inhibits cisplatin resistance of non-small cell lung cancer cells via activation of p53- p66shc pathway. Eur Rev Med Pharmacol Sci. 2017 Jun;21(11):2626-2634.
REF00002201	miR-340 suppresses tumor growth and enhances chemosensitivity of colorectal cancer by targeting RLIP76. Eur Rev Med Pharmacol Sci. 2017 Jun;21(12):2875-2886.
REF00002202	Restoration of microRNA-708 sensitizes ovarian cancer cells to cisplatin via IGF2BP1/Akt pathway. Cell Biol Int. 2017 Oct;41(10):1110-1118. doi: 10.1002/cbin.10819. Epub 2017 Aug 17.
REF00002203	GAS5 knockdown reduces the chemo-sensitivity of non-small cell lung cancer (NSCLC) cell to cisplatin (DDP) through regulating miR-21/PTEN axis. Biomed Pharmacother. 2017 Sep;93:570-579. doi: 10.1016/j.biopha.2017.06.089. Epub 2017 Jul 4.
REF00002204	[MiR-503 sensitizes human hepatocellular carcinoma cells to cisplatin by targeting bcl-2]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2017 Jun 28;42(6):605-610. doi: 10.11817/j.issn.1672-7347.2017.06.001.
REF00002205	Targeting miR-21 decreases expression of multi-drug resistant genes and promotes chemosensitivity of renal carcinoma. Tumour Biol. 2017 Jul;39(7):1010428317707372. doi: 10.1177/1010428317707372.
REF00002206	The lncRNA NEAT1 facilitates cell growth and invasion via the miR-211/HMGA2 axis in breast cancer. Int J Biol Macromol. 2017 Dec;105(Pt 1):346-353. doi: 10.1016/j.ijbiomac.2017.07.053. Epub 2017 Jul 16.
REF00002207	Targeted regulation of MiR-98 on E2F1 increases chemosensitivity of leukemia cells K562/A02. Onco Targets Ther. 2017 Jun 29;10:3233-3239. doi: 10.2147/OTT.S126819. eCollection 2017.
REF00002208	Autophagy regulated by lncRNA HOTAIR contributes to the cisplatin-induced resistance in endometrial cancer cells. Biotechnol Lett. 2017 Oct;39(10):1477-1484. doi: 10.1007/s10529-017-2392-4. Epub 2017 Jul 18.
REF00002209	miR-34a attenuates glioma cells progression and chemoresistance via targeting PD-L1. Biotechnol Lett. 2017 Oct;39(10):1485-1492. doi: 10.1007/s10529-017-2397-z. Epub 2017 Jul 18.
REF00002210	MicroRNA-106b-5p regulates cisplatin chemosensitivity by targeting polycystic kidney disease-2 in non-small-cell lung cancer. Anticancer Drugs. 2017 Sep;28(8):852-860. doi: 10.1097/CAD.0000000000000524.
REF00002211	Tumor Evolution as a Therapeutic Target. Cancer Discov. 2017 Jul 20. doi: 10.1158/2159-8290.CD-17-0343. Online ahead of print.
REF00002212	A novel interplay between HOTAIR and DNA methylation in osteosarcoma cells indicates a new therapeutic strategy. J Cancer Res Clin Oncol. 2017 Nov;143(11):2189-2200. doi: 10.1007/s00432-017-2478-3. Epub 2017 Jul 20.
REF00002213	Suppressing miR-199a-3p by promoter methylation contributes to tumor aggressiveness and cisplatin resistance of ovarian cancer through promoting DDR1 expression. J Ovarian Res. 2017 Jul 25;10(1):50. doi: 10.1186/s13048-017-0333-4.
REF00002214	LncRNA ODRUL Contributes to Osteosarcoma Progression through the miR-3182/MMP2 Axis. Mol Ther. 2017 Oct 4;25(10):2383-2393. doi: 10.1016/j.ymthe.2017.06.027. Epub 2017 Jul 5.
REF00002215	A polymorphism in ABCC4 is related to efficacy of 5-FU/capecitabine-based chemotherapy in colorectal cancer patients. Sci Rep. 2017 Aug 1;7(1):7059. doi: 10.1038/s41598-017-07491-3.
REF00002216	miR-93 and PTEN: Key regulators of doxorubicin-resistance and EMT in breast cancer. Oncol Rep. 2017 Oct;38(4):2401-2407. doi: 10.3892/or.2017.5859. Epub 2017 Jul 31.
REF00002217	Upregulation of microRNA-135b and microRNA-182 promotes chemoresistance of colorectal cancer by targeting ST6GALNAC2 via PI3K/AKT pathway. Mol Carcinog. 2017 Dec;56(12):2669-2680. doi: 10.1002/mc.22710. Epub 2017 Aug 21.
REF00002218	miRNA-21 enhances chemoresistance to cisplatin in epithelial ovarian cancer by negatively regulating PTEN. Oncol Lett. 2017 Aug;14(2):1807-1810. doi: 10.3892/ol.2017.6324. Epub 2017 Jun 7.
REF00002219	Knockdown of Hotair suppresses proliferation and cell cycle progression in hepatocellular carcinoma cell by downregulating CCND1 expression. Mol Med Rep. 2017 Oct;16(4):4980-4986. doi: 10.3892/mmr.2017.7162. Epub 2017 Aug 3.
REF00002220	Up-regulation of miR-21 decreases chemotherapeutic effect of dendrosomal curcumin in breast cancer cells. Iran J Basic Med Sci. 2017 Apr;20(4):350-359. doi: 10.22038/IJBMS.2017.8574.
REF00002221	LncRNA-XIST interacts with miR-29c to modulate the chemoresistance of glioma cell to TMZ through DNA mismatch repair pathway. Biosci Rep. 2017 Sep 7;37(5):BSR20170696. doi: 10.1042/BSR20170696. Print 2017 Oct 31.
REF00002222	MicroRNA-31 inhibits RhoA-mediated tumor invasion and chemotherapy resistance in MKN-45 gastric adenocarcinoma cells. Exp Biol Med (Maywood). 2017 Dec;242(18):1842-1847. doi: 10.1177/1535370217728460. Epub 2017 Aug 24.
REF00002223	Chromosome-Mediated mcr-3 Variants in Aeromonas veronii from Chicken Meat. Antimicrob Agents Chemother. 2017 Oct 24;61(11):e01272-17. doi: 10.1128/AAC.01272-17. Print 2017 Nov.
REF00002224	Long Noncoding RNA H19/miR-675 Axis Promotes Gastric Cancer via FADD/Caspase 8/Caspase 3 Signaling Pathway. Cell Physiol Biochem. 2017;42(6):2364-2376. doi: 10.1159/000480028. Epub 2017 Aug 18.
REF00002225	MicroRNA-218 promotes cisplatin resistance in oral cancer via the PPP2R5A/Wnt signaling pathway. Oncol Rep. 2017 Oct;38(4):2051-2061. doi: 10.3892/or.2017.5899. Epub 2017 Aug 11.
REF00002226	Epigenetic silencing of miR-493 increases the resistance to cisplatin in lung cancer by targeting tongue cancer resistance-related protein 1(TCRP1). J Exp Clin Cancer Res. 2017 Aug 31;36(1):114. doi: 10.1186/s13046-017-0582-5.
REF00002227	"MiR-214 inhibits cell migration, invasion and promotes the drug sensitivity in human cervical cancer by targeting FOXM1. Am J Transl Res. 2017 Aug 15;9(8):3541-3557. eCollection 2017."
REF00002228	microRNA-204 modulates chemosensitivity and apoptosis of prostate cancer cells by targeting zinc-finger E-box-binding homeobox 1 (ZEB1). Am J Transl Res. 2017 Aug 15;9(8):3599-3610. eCollection 2017.
REF00002229	LncRNA SNHG5 regulates imatinib resistance in chronic myeloid leukemia via acting as a CeRNA against MiR-205-5p. Am J Cancer Res. 2017 Aug 1;7(8):1704-1713. eCollection 2017.
REF00002230	Development and Validation of a High-Resolution Melting Assay To Detect Azole Resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 2017 Nov 22;61(12):e01083-17. doi: 10.1128/AAC.01083-17. Print 2017 Dec.
REF00002231	Analysis of Plasmodium vivax Chloroquine Resistance Transporter Mutant Isoforms. Biochemistry. 2017 Oct 17;56(41):5615-5622. doi: 10.1021/acs.biochem.7b00749. Epub 2017 Sep 26.
REF00002232	MiR-26b reverses temozolomide resistance via targeting Wee1 in glioma cells. Cell Cycle. 2017 Oct 18;16(20):1954-1964. doi: 10.1080/15384101.2017.1367071. Epub 2017 Sep 12.
REF00002233	"The Vibrio cholerae var regulon encodes a metallo-Beta-lactamase and an antibiotic efflux pump, which are regulated by VarR, a LysR-type transcription factor. PLoS One. 2017 Sep 12;12(9):e0184255. doi: 10.1371/journal.pone.0184255. eCollection 2017."
REF00002234	MicroRNA-132 induces temozolomide resistance and promotes the formation of cancer stem cell phenotypes by targeting tumor suppressor candidate 3 in glioblastoma. Int J Mol Med. 2017 Nov;40(5):1307-1314. doi: 10.3892/ijmm.2017.3124. Epub 2017 Sep 7.
REF00002235	Inhibition of miR-23a increases the sensitivity of lung cancer stem cells to erlotinib through PTEN/PI3K/Akt pathway. Oncol Rep. 2017 Nov;38(5):3064-3070. doi: 10.3892/or.2017.5938. Epub 2017 Sep 4.
REF00002236	Mutations in rpoB and katG genes of multidrug resistant mycobacterium tuberculosis undetectable using genotyping diagnostic methods. Pan Afr Med J. 2017 Jun 28;27:145. doi: 10.11604/pamj.2017.27.145.10883. eCollection 2017.
REF00002237	"MicroRNA-324-5p regulates stemness, pathogenesis and sensitivity to bortezomib in multiple myeloma cells by targeting hedgehog signaling. Int J Cancer. 2018 Jan 1;142(1):109-120. doi: 10.1002/ijc.31041. Epub 2017 Sep 30."
REF00002238	lncRNA HOTAIR Contributes to 5FU Resistance through Suppressing miR-218 and Activating NF-kB/TS Signaling in Colorectal Cancer. Mol Ther Nucleic Acids. 2017 Sep 15;8:356-369. doi: 10.1016/j.omtn.2017.07.007. Epub 2017 Jul 8.
REF00002239	Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma. Nat Med. 2017 Oct;23(10):1167-1175. doi: 10.1038/nm.4401. Epub 2017 Sep 18.
REF00002240	Emergence of Echinocandin Resistance Due to a Point Mutation in the fks1 Gene of Aspergillus fumigatus in a Patient with Chronic Pulmonary Aspergillosis. Antimicrob Agents Chemother. 2017 Nov 22;61(12):e01277-17. doi: 10.1128/AAC.01277-17. Print 2017 Dec.
REF00002241	miR-338-3p confers 5-fluorouracil resistance in p53 mutant colon cancer cells by targeting the mammalian target of rapamycin. Exp Cell Res. 2017 Nov 15;360(2):328-336. doi: 10.1016/j.yexcr.2017.09.023. Epub 2017 Sep 18.
REF00002242	Association of a Novel Mutation in the Plasmodium falciparum Chloroquine Resistance Transporter With Decreased Piperaquine Sensitivity. J Infect Dis. 2017 Aug 15;216(4):468-476. doi: 10.1093/infdis/jix334.
REF00002243	miR-19b-3p promotes colon cancer proliferation and oxaliplatin-based chemoresistance by targeting SMAD4: validation by bioinformatics and experimental analyses. J Exp Clin Cancer Res. 2017 Sep 22;36(1):131. doi: 10.1186/s13046-017-0602-5.
REF00002244	miR-155 mediates arsenic trioxide resistance by activating Nrf2 and suppressing apoptosis in lung cancer cells. Sci Rep. 2017 Sep 22;7(1):12155. doi: 10.1038/s41598-017-06061-x.
REF00002245	ZBTB7A Enhances Osteosarcoma Chemoresistance by Transcriptionally Repressing lncRNALINC00473-IL24 Activity. Neoplasia. 2017 Nov;19(11):908-918. doi: 10.1016/j.neo.2017.08.008. Epub 2017 Sep 21.
REF00002246	Downregulation of MicroRNA-147 Inhibits Cell Proliferation and Increases the Chemosensitivity of Gastric Cancer Cells to 5-Fluorouracil by Directly Targeting PTEN. Oncol Res. 2018 Jul 5;26(6):901-911. doi: 10.3727/096504017X15061902533715. Epub 2017 Sep 26.
REF00002247	CXCR4/Let-7a Axis Regulates Metastasis and Chemoresistance of Pancreatic Cancer Cells Through Targeting HMGA2. Cell Physiol Biochem. 2017;43(2):840-851. doi: 10.1159/000481610. Epub 2017 Sep 28.
REF00002248	miR-181c contributes to cisplatin resistance in non-small cell lung cancer cells by targeting Wnt inhibition factor 1. Cancer Chemother Pharmacol. 2017 Nov;80(5):973-984. doi: 10.1007/s00280-017-3435-1. Epub 2017 Sep 27.
REF00002249	LncRNA XIST promotes human lung adenocarcinoma cells to cisplatin resistance via let-7i/BAG-1 axis. Cell Cycle. 2017;16(21):2100-2107. doi: 10.1080/15384101.2017.1361071. Epub 2017 Sep 29.
REF00002250	MicroRNA-148a-3p enhances cisplatin cytotoxicity in gastric cancer through mitochondrial fission induction and cyto-protective autophagy suppression. Cancer Lett. 2017 Dec 1;410:212-227. doi: 10.1016/j.canlet.2017.09.035. Epub 2017 Sep 28.
REF00002251	HOX transcript antisense intergenic RNA represses E-cadherin expression by binding to EZH2 in gastric cancer. World J Gastroenterol. 2017 Sep 7;23(33):6100-6110. doi: 10.3748/wjg.v23.i33.6100.
REF00002252	Intensified Beclin-1 Mediated by Low Expression of Mir-30a-5p Promotes Chemoresistance in Human Small Cell Lung Cancer. Cell Physiol Biochem. 2017;43(3):1126-1139. doi: 10.1159/000481754. Epub 2017 Oct 5.
REF00002253	MiRNA-107 enhances chemosensitivity to paclitaxel by targeting antiapoptotic factor Bcl-w in non small cell lung cancer. Am J Cancer Res. 2017 Sep 1;7(9):1863-1873. eCollection 2017.
REF00002254	Involvement of miR-451 in resistance to paclitaxel by regulating YWHAZ in breast cancer. Cell Death Dis. 2017 Oct 5;8(10):e3071. doi: 10.1038/cddis.2017.460.
REF00002255	"miR-216b enhances the efficacy of vemurafenib by targeting Beclin-1, UVRAG and ATG5 in melanoma. Cell Signal. 2018 Jan;42:30-43. doi: 10.1016/j.cellsig.2017.09.024. Epub 2017 Oct 2."
REF00002256	MicroRNA-7 inhibits cell proliferation of chronic myeloid leukemia and sensitizes it to imatinib in vitro. Biochem Biophys Res Commun. 2017 Dec 9;494(1-2):372-378. doi: 10.1016/j.bbrc.2017.10.001. Epub 2017 Oct 3.
REF00002257	Distribution of Mutations Associated with Antifolate and Chloroquine Resistance among Imported Plasmodium vivax in the State of Qatar. Am J Trop Med Hyg. 2017 Dec;97(6):1797-1803. doi: 10.4269/ajtmh.17-0436. Epub 2017 Sep 28.
REF00002258	LncRNA CCAT1/miR-130a-3p axis increases cisplatin resistance in non-small-cell lung cancer cell line by targeting SOX4. Cancer Biol Ther. 2017 Dec 2;18(12):974-983. doi: 10.1080/15384047.2017.1385679. Epub 2017 Oct 11.
REF00002259	lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/Beta-catenin signaling. Nat Med. 2017 Nov;23(11):1331-1341. doi: 10.1038/nm.4424. Epub 2017 Oct 16.
REF00002260	High expression of HOXA13 correlates with poorly differentiated hepatocellular carcinomas and modulates sorafenib response in in vitro models. Lab Invest. 2018 Jan;98(1):95-105. doi: 10.1038/labinvest.2017.107. Epub 2017 Oct 16.
REF00002261	Global DNA methylation analysis reveals miR-214-3p contributes to cisplatin resistance in pediatric intracranial nongerminomatous malignant germ cell tumors. Neuro Oncol. 2018 Mar 27;20(4):519-530. doi: 10.1093/neuonc/nox186.
REF00002262	Downregulation of miR-874-3p promotes chemotherapeutic resistance in colorectal cancer via inactivation of the Hippo signaling pathway. Oncol Rep. 2017 Dec;38(6):3376-3386. doi: 10.3892/or.2017.6041. Epub 2017 Oct 17.
REF00002263	Linc-RoR promotes MAPK/ERK signaling and confers estrogen-independent growth of breast cancer. Mol Cancer. 2017 Oct 17;16(1):161. doi: 10.1186/s12943-017-0727-3.
REF00002264	miR-3656 expression enhances the chemosensitivity of pancreatic cancer to gemcitabine through modulation of the RHOF/EMT axis. Cell Death Dis. 2017 Oct 19;8(10):e3129. doi: 10.1038/cddis.2017.530.
REF00002265	"Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression. Carcinogenesis. 2017 Oct 1;38(10):1036-1046. doi: 10.1093/carcin/bgx065."
REF00002266	miR 146b 5p suppresses glioblastoma cell resistance to temozolomide through targeting TRAF6. Oncol Rep. 2017 Nov;38(5):2941-2950. doi: 10.3892/or.2017.5970. Epub 2017 Sep 19.
REF00002267	MiR-200c regulates tumor growth and chemosensitivity to cisplatin in osteosarcoma by targeting AKT2. Sci Rep. 2017 Oct 19;7(1):13598. doi: 10.1038/s41598-017-14088-3.
REF00002268	"MiR-34a, as a suppressor, enhance the susceptibility of gastric cancer cell to luteolin by directly targeting HK1. Gene. 2018 Feb 20;644:56-65. doi: 10.1016/j.gene.2017.10.046. Epub 2017 Oct 18."
REF00002269	LncRNA HANR Promotes Tumorigenesis and Increase of Chemoresistance in Hepatocellular Carcinoma. Cell Physiol Biochem. 2017;43(5):1926-1938. doi: 10.1159/000484116. Epub 2017 Oct 20.
REF00002270	miR-34a increases cisplatin sensitivity of osteosarcoma cells in vitro through up-regulation of c-Myc and Bim signal. Cancer Biomark. 2017 Dec 12;21(1):135-144. doi: 10.3233/CBM-170452.
REF00002271	Long non coding RNA AK001796 contributes to cisplatin resistance of non small cell lung cancer. Mol Med Rep. 2017 Oct;16(4):4107-4112. doi: 10.3892/mmr.2017.7081. Epub 2017 Jul 24.
REF00002272	Matrix metallopeptidase 9 targeted by hsa-miR-494 promotes silybin-inhibited osteosarcoma. Mol Carcinog. 2018 Feb;57(2):262-271. doi: 10.1002/mc.22753. Epub 2017 Nov 2.
REF00002273	LncRNA FENDRR sensitizes doxorubicin-resistance of osteosarcoma cells through down-regulating ABCB1 and ABCC1. Oncotarget. 2017 May 18;8(42):71881-71893. doi: 10.18632/oncotarget.17985. eCollection 2017 Sep 22.
REF00002274	"Mir-144-3p Promotes Cell Proliferation, Metastasis, Sunitinib Resistance in Clear Cell Renal Cell Carcinoma by Downregulating ARID1A. Cell Physiol Biochem. 2017;43(6):2420-2433. doi: 10.1159/000484395. Epub 2017 Oct 27."
REF00002275	MicroRNA-195 desensitizes HCT116 human colon cancer cells to 5-fluorouracil. Cancer Lett. 2018 Jan 1;412:264-271. doi: 10.1016/j.canlet.2017.10.022. Epub 2017 Nov 5.
REF00002276	Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/Beta-catenin signaling pathways by up-regulating miR-34a. Int J Biol Macromol. 2018 Feb;107(Pt B):2620-2629. doi: 10.1016/j.ijbiomac.2017.10.154. Epub 2017 Oct 26.
REF00002277	microRNA-323 upregulation promotes prostate cancer growth and docetaxel resistance by repressing p73. Biomed Pharmacother. 2018 Jan;97:528-534. doi: 10.1016/j.biopha.2017.10.040. Epub 2017 Nov 6.
REF00002278	Calycosin inhibits the in vitro and in vivo growth of breast cancer cells through WDR7-7-GPR30 Signaling. J Exp Clin Cancer Res. 2017 Nov 2;36(1):153. doi: 10.1186/s13046-017-0625-y.
REF00002279	miR-27b and miR-34a enhance docetaxel sensitivity of prostate cancer cells through inhibiting epithelial-to-mesenchymal transition by targeting ZEB1. Biomed Pharmacother. 2018 Jan;97:736-744. doi: 10.1016/j.biopha.2017.10.163. Epub 2017 Nov 6.
REF00002280	Overexpression of miR-26b decreases the cisplatin-resistance in laryngeal cancer by targeting ATF2. Oncotarget. 2017 Sep 8;8(45):79023-79033. doi: 10.18632/oncotarget.20784. eCollection 2017 Oct 3.
REF00002281	Long non-coding RNA GAS5 antagonizes the chemoresistance of pancreatic cancer cells through down-regulation of miR-181c-5p. Biomed Pharmacother. 2018 Jan;97:809-817. doi: 10.1016/j.biopha.2017.10.157. Epub 2017 Nov 6.
REF00002282	MicroRNA-25 contributes to cisplatin resistance in gastric cancer cells by inhibiting forkhead box O3a. Oncol Lett. 2017 Nov;14(5):6097-6102. doi: 10.3892/ol.2017.6982. Epub 2017 Sep 18.
REF00002283	Long non-coding RNA profile in mantle cell lymphoma identifies a functional lncRNA ROR1-AS1 associated with EZH2/PRC2 complex. Oncotarget. 2017 May 17;8(46):80223-80234. doi: 10.18632/oncotarget.17956. eCollection 2017 Oct 6.
REF00002284	"MicroRNA-375 as a potential serum biomarker for the diagnosis, prognosis, and chemosensitivity prediction of osteosarcoma. J Int Med Res. 2018 Mar;46(3):975-983. doi: 10.1177/0300060517734114. Epub 2017 Nov 8."
REF00002285	The long non-coding RNA ENST00000547547 reduces 5-fluorouracil resistance of colorectal cancer cells via competitive binding to microRNA-31. Oncol Rep. 2018 Jan;39(1):217-226. doi: 10.3892/or.2017.6082. Epub 2017 Nov 7.
REF00002286	MiR-20a-5p represses the multi-drug resistance of osteosarcoma by targeting the SDC2 gene. Cancer Cell Int. 2017 Nov 2;17:100. doi: 10.1186/s12935-017-0470-2. eCollection 2017.
REF00002287	LncRNA MEG3 enhances cisplatin sensitivity in non-small cell lung cancer by regulating miR-21-5p/SOX7 axis. Onco Targets Ther. 2017 Oct 25;10:5137-5149. doi: 10.2147/OTT.S146423. eCollection 2017.
REF00002288	LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression. Cancer Med. 2017 Dec;6(12):2897-2908. doi: 10.1002/cam4.1253. Epub 2017 Nov 10.
REF00002289	Knockdown of lncRNA-XIST enhances the chemosensitivity of NSCLC cells via suppression of autophagy. Oncol Rep. 2017 Dec;38(6):3347-3354. doi: 10.3892/or.2017.6056. Epub 2017 Oct 24.
REF00002290	Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR expression. Biomed Pharmacother. 2018 Jan;97:844-850. doi: 10.1016/j.biopha.2017.10.146. Epub 2017 Nov 7.
REF00002291	Identification and validation of cetuximab resistance associated long noncoding RNA biomarkers in metastatic colorectal cancer. Biomed Pharmacother. 2018 Jan;97:1138-1146. doi: 10.1016/j.biopha.2017.11.031. Epub 2017 Nov 10.
REF00002292	MiR-5100 increases the cisplatin resistance of the lung cancer stem cells by inhibiting the Rab6. Mol Carcinog. 2018 Mar;57(3):419-428. doi: 10.1002/mc.22765. Epub 2017 Dec 1.
REF00002293	Huaier Extract Inhibits Breast Cancer Progression Through a LncRNA-H19/MiR-675-5p Pathway. Cell Physiol Biochem. 2017;44(2):581-593. doi: 10.1159/000485093. Epub 2017 Nov 17.
REF00002294	The prototypical proton-coupled oligopeptide transporter YdgR from Escherichia coli facilitates chloramphenicol uptake into bacterial cells. J Biol Chem. 2018 Jan 19;293(3):1007-1017. doi: 10.1074/jbc.M117.805960. Epub 2017 Nov 17.
REF00002295	miR-320a modulates cell growth and chemosensitivity via regulating ADAM10 in gastric cancer. Mol Med Rep. 2017 Dec;16(6):9664-9670. doi: 10.3892/mmr.2017.7819. Epub 2017 Oct 19.
REF00002296	Long noncoding RNA MALAT1 regulates autophagy associated chemoresistance via miR-23b-3p sequestration in gastric cancer. Mol Cancer. 2017 Nov 21;16(1):174. doi: 10.1186/s12943-017-0743-3.
REF00002297	MiR-30e inhibits tumor growth and chemoresistance via targeting IRS1 in Breast Cancer. Sci Rep. 2017 Nov 21;7(1):15929. doi: 10.1038/s41598-017-16175-x.
REF00002298	MiR-1268b confers chemosensitivity in breast cancer by targeting ERBB2-mediated PI3K-AKT pathway. Oncotarget. 2017 Aug 9;8(52):89631-89642. doi: 10.18632/oncotarget.20099. eCollection 2017 Oct 27.
REF00002299	The effect of miR-224 down-regulation on SW80 cell proliferation and apoptosis and weakening of ADM drug resistance. Eur Rev Med Pharmacol Sci. 2017 Nov;21(21):5008-5016.
REF00002300	Long non-coding RNA LUCAT1 modulates methotrexate resistance in osteosarcoma via miR-200c/ABCB1 axis. Biochem Biophys Res Commun. 2018 Jan 1;495(1):947-953. doi: 10.1016/j.bbrc.2017.11.121. Epub 2017 Nov 21.
REF00002301	miR-509-3p promotes cisplatin-induced apoptosis in ovarian cancer cells through the regulation of anti-apoptotic genes. Pharmacogenomics. 2017 Dec;18(18):1671-1682. doi: 10.2217/pgs-2017-0115. Epub 2017 Nov 27.
REF00002302	Baicalein inhibits cervical cancer progression via downregulating long noncoding RNA BDLNR and its downstream PI3K/Akt pathway. Int J Biochem Cell Biol. 2018 Jan;94:107-118. doi: 10.1016/j.biocel.2017.11.009. Epub 2017 Nov 23.
REF00002303	Midkine derived from cancer-associated fibroblasts promotes cisplatin-resistance via up-regulation of the expression of lncRNA ANRIL in tumour cells. Sci Rep. 2017 Nov 24;7(1):16231. doi: 10.1038/s41598-017-13431-y.
REF00002304	Shikonin reduces tamoxifen resistance through long non-coding RNA uc.57. Oncotarget. 2017 Sep 11;8(51):88658-88669. doi: 10.18632/oncotarget.20809. eCollection 2017 Oct 24.
REF00002305	"Long non-coding RNA LINC00152 promotes cell proliferation, metastasis, and confers 5-FU resistance in colorectal cancer by inhibiting miR-139-5p. Oncogenesis. 2017 Nov 28;6(11):395. doi: 10.1038/s41389-017-0008-4."
REF00002306	LncRNA NEAT1 contributes to paclitaxel resistance of ovarian cancer cells by regulating ZEB1 expression via miR-194. Onco Targets Ther. 2017 Nov 10;10:5377-5390. doi: 10.2147/OTT.S147586. eCollection 2017.
REF00002307	Overexpressed miR-128a enhances chemoradiotherapy to laryngeal cancer cells and its correlation with BMI1. Future Oncol. 2018 Mar;14(7):611-620. doi: 10.2217/fon-2017-0542. Epub 2017 Nov 30.
REF00002308	Decoding the role of hypothetical protein All3255 of Anabaena PCC7120 in heavy metal stress management in Escherichia coli. Arch Microbiol. 2018 Apr;200(3):463-471. doi: 10.1007/s00203-017-1462-2. Epub 2017 Nov 30.
REF00002309	LncRNA H19 is a major mediator of doxorubicin chemoresistance in breast cancer cells through a cullin4A-MDR1 pathway. Oncotarget. 2017 Sep 21;8(54):91990-92003. doi: 10.18632/oncotarget.21121. eCollection 2017 Nov 3.
REF00002310	Extracellular vesicle-encapsulated microRNA-761 enhances pazopanib resistance in synovial sarcoma. Biochem Biophys Res Commun. 2018 Jan 1;495(1):1322-1327. doi: 10.1016/j.bbrc.2017.11.164. Epub 2017 Nov 27.
REF00002311	Maintenance of stemness by miR-589-5p in hepatocellular carcinoma cells promotes chemoresistance via STAT3 signaling. Cancer Lett. 2018 Jun 1;423:113-126. doi: 10.1016/j.canlet.2017.11.031. Epub 2017 Nov 28.
REF00002312	Gemcitabine treatment causes resistance and malignancy of pancreatic cancer stem-like cells via induction of lncRNA HOTAIR. Exp Ther Med. 2017 Nov;14(5):4773-4780. doi: 10.3892/etm.2017.5151. Epub 2017 Sep 20.
REF00002313	Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide. Nucleic Acids Res. 2018 Feb 16;46(3):1424-1440. doi: 10.1093/nar/gkx1221.
REF00002314	MiR-199a suppresses prostate cancer paclitaxel resistance by targeting YES1. World J Urol. 2018 Mar;36(3):357-365. doi: 10.1007/s00345-017-2143-0. Epub 2017 Dec 4.
REF00002315	LncRNA NEAT1 promotes dexamethasone resistance in multiple myeloma by targeting miR-193a/MCL1 pathway. J Biochem Mol Toxicol. 2018 Jan;32(1). doi: 10.1002/jbt.22008. Epub 2017 Dec 4.
REF00002316	Reciprocal regulation of DGCR5 and miR-320a affects the cellular malignant phenotype and 5-FU response in pancreatic ductal adenocarcinoma. Oncotarget. 2017 Jun 6;8(53):90868-90878. doi: 10.18632/oncotarget.18377. eCollection 2017 Oct 31.
REF00002317	"Exosomal MicroRNA MiR-1246 Promotes Cell Proliferation, Invasion and Drug Resistance by Targeting CCNG2 in Breast Cancer. Cell Physiol Biochem. 2017;44(5):1741-1748. doi: 10.1159/000485780. Epub 2017 Dec 6."
REF00002318	Silencing of miR-193a-5p increases the chemosensitivity of prostate cancer cells to docetaxel. J Exp Clin Cancer Res. 2017 Dec 8;36(1):178. doi: 10.1186/s13046-017-0649-3.
REF00002319	MicroRNA-429 sensitizes pancreatic cancer cells to gemcitabine through regulation of PDCD4. Am J Transl Res. 2017 Nov 15;9(11):5048-5055. eCollection 2017.
REF00002320	A miRNA-200c/cathepsin L feedback loop determines paclitaxel resistance in human lung cancer A549 cells in vitro through regulating epithelial-mesenchymal transition. Acta Pharmacol Sin. 2018 Jun;39(6):1034-1047. doi: 10.1038/aps.2017.164. Epub 2017 Dec 7.
REF00002321	MiR-21 enhanced glioma cells resistance to carmustine via decreasing Spry2 expression. Eur Rev Med Pharmacol Sci. 2017 Nov;21(22):5065-5071. doi: 10.26355/eurrev_201711_13819.
REF00002322	Long noncoding RNA SFTA1P promoted apoptosis and increased cisplatin chemosensitivity via regulating the hnRNP-U-GADD45A axis in lung squamous cell carcinoma. Oncotarget. 2017 Oct 27;8(57):97476-97489. doi: 10.18632/oncotarget.22138. eCollection 2017 Nov 14.
REF00002323	miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma. Cancer Res. 2018 Feb 15;78(4):1017-1030. doi: 10.1158/0008-5472.CAN-17-1318. Epub 2017 Dec 11.
REF00002324	Effect and mechanism of long noncoding RNAs HOTAIR on occurrence and development of gastric cancer. J Cell Biochem. 2017 Dec 13. doi: 10.1002/jcb.26594. Online ahead of print.
REF00002325	Linc-ROR promotes esophageal squamous cell carcinoma progression through the derepression of SOX9. J Exp Clin Cancer Res. 2017 Dec 13;36(1):182. doi: 10.1186/s13046-017-0658-2.
REF00002326	MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma. Blood Cancer J. 2017 Dec 15;7(12):654. doi: 10.1038/s41408-017-0033-8.
REF00002327	Knockdown of long non-coding RNA HOTAIR sensitizes hepatocellular carcinoma cell to cisplatin by suppressing the STAT3/ABCB1 signaling pathway. Oncol Lett. 2017 Dec;14(6):7986-7992. doi: 10.3892/ol.2017.7237. Epub 2017 Oct 20.
REF00002328	[Effects of lncRNA RP11-770J1.3 and TMEM25 expression on paclitaxel resistance in human breast cancer cells]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2017 Jul 25;46(4):364-370. doi: 10.3785/j.issn.1008-9292.2017.08.04.
REF00002329	MiR-129-5p Sensitizes the Response of Her-2 Positive Breast Cancer to Trastuzumab by Reducing Rps6. Cell Physiol Biochem. 2017;44(6):2346-2356. doi: 10.1159/000486122. Epub 2017 Dec 15.
REF00002330	miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer. Breast Cancer Res. 2017 Dec 19;19(1):133. doi: 10.1186/s13058-017-0918-2.
REF00002331	The complex resistomes of Paenibacillaceae reflect diverse antibiotic chemical ecologies. ISME J. 2018 Mar;12(3):885-897. doi: 10.1038/s41396-017-0017-5. Epub 2017 Dec 19.
REF00002332	Micro-RNA149 confers taxane resistance to malignant mesothelioma cells via regulation of P-glycoprotein expression. Cancer Biol Ther. 2018 Mar 4;19(3):181-187. doi: 10.1080/15384047.2017.1415677. Epub 2018 Jan 15.
REF00002333	Overexpression of miR-216b sensitizes NSCLC cells to cisplatin-induced apoptosis by targeting c-Jun. Oncotarget. 2017 Oct 27;8(61):104206-104215. doi: 10.18632/oncotarget.22171. eCollection 2017 Nov 28.
REF00002334	Long non-coding RNA LINC00261 sensitizes human colon cancer cells to cisplatin therapy. Braz J Med Biol Res. 2017 Dec 11;51(2):e6793. doi: 10.1590/1414-431X20176793.
REF00002335	MiR-181a contributes gefitinib resistance in non-small cell lung cancer cells by targeting GAS7. Biochem Biophys Res Commun. 2018 Jan 22;495(4):2482-2489. doi: 10.1016/j.bbrc.2017.12.096. Epub 2017 Dec 18.
REF00002336	Overexpression of HOTTIP promotes proliferation and drug resistance of lung adenocarcinoma by regulating AKT signaling pathway. Eur Rev Med Pharmacol Sci. 2017 Dec;21(24):5683-5690. doi: 10.26355/eurrev_201712_14013.
REF00002337	microRNA-381 suppresses the growth and increases cisplatin sensitivity in non-small cell lung cancer cells through inhibition of nuclear factor-kB signaling. Biomed Pharmacother. 2018 Feb;98:538-544. doi: 10.1016/j.biopha.2017.12.092. Epub 2017 Dec 27.
REF00002338	Long noncoding RNA LINP1 acts as an oncogene and promotes chemoresistance in breast cancer. Cancer Biol Ther. 2018 Feb 1;19(2):120-131. doi: 10.1080/15384047.2017.1394543. Epub 2018 Jan 2.
REF00002339	Downregulation of MicroRNA-135 Promotes Sensitivity of Non-Small Cell Lung Cancer to Gefitinib by Targeting TRIM16. Oncol Res. 2018 Aug 23;26(7):1005-1014. doi: 10.3727/096504017X15144755633680. Epub 2018 Jan 2.
REF00002340	MicroRNA-128 suppresses paclitaxel-resistant lung cancer by inhibiting MUC1-C and BMI-1 in cancer stem cells. Oncotarget. 2017 Nov 30;8(66):110540-110551. doi: 10.18632/oncotarget.22818. eCollection 2017 Dec 15.
REF00002341	The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma. Cell Death Dis. 2018 Jan 5;9(1):4. doi: 10.1038/s41419-017-0076-6.
REF00002342	"Activity of CD101, a long-acting echinocandin, against clinical isolates of Candida auris. Diagn Microbiol Infect Dis. 2018 Mar;90(3):196-197. doi: 10.1016/j.diagmicrobio.2017.10.021. Epub 2017 Nov 7."
REF00002343	LncRNA PCAT-1 promotes tumour growth and chemoresistance of oesophageal cancer to cisplatin. Cell Biochem Funct. 2018 Jan;36(1):27-33. doi: 10.1002/cbf.3314. Epub 2018 Jan 7.
REF00002344	The evolution of substrate discrimination in macrolide antibiotic resistance enzymes. Nat Commun. 2018 Jan 9;9(1):112. doi: 10.1038/s41467-017-02680-0.
REF00002345	MiR-770 suppresses the chemo-resistance and metastasis of triple negative breast cancer via direct targeting of STMN1. Cell Death Dis. 2018 Jan 11;9(1):14. doi: 10.1038/s41419-017-0030-7.
REF00002346	A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009-17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance. J Antimicrob Chemother. 2018 Apr 1;73(4):891-899. doi: 10.1093/jac/dkx480.
REF00002347	Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85. Arch Gynecol Obstet. 2018 Mar;297(3):699-707. doi: 10.1007/s00404-018-4649-0. Epub 2018 Jan 11.
REF00002348	"miR 378a enhances the sensitivity of liver cancer to sorafenib by targeting VEGFR, PDGFRBeta and c Raf. Mol Med Rep. 2018 Mar;17(3):4581-4588. doi: 10.3892/mmr.2018.8390. Epub 2018 Jan 8."
REF00002349	Long non-coding RNA MEG3 functions as a tumour suppressor and has prognostic predictive value in human pancreatic cancer. Oncol Rep. 2018 Mar;39(3):1132-1140. doi: 10.3892/or.2018.6178. Epub 2018 Jan 2.
REF00002350	Chronic oxymatrine treatment induces resistance and epithelial mesenchymal transition through targeting the long non-coding RNA MALAT1 in colorectal cancer cells. Oncol Rep. 2018 Mar;39(3):967-976. doi: 10.3892/or.2018.6204. Epub 2018 Jan 10.
REF00002351	miR-133b reverses cisplatin resistance by targeting GSTP1 in cisplatin-resistant lung cancer cells. Int J Mol Med. 2018 Apr;41(4):2050-2058. doi: 10.3892/ijmm.2018.3382. Epub 2018 Jan 11.
REF00002352	Regulation of drug resistance and metastasis of gastric cancer cells via the microRNA647-ANK2 axis. Int J Mol Med. 2018 Apr;41(4):1958-1966. doi: 10.3892/ijmm.2018.3381. Epub 2018 Jan 11.
REF00002353	miR 214 reduces cisplatin resistance by targeting netrin 1 in bladder cancer cells. Int J Mol Med. 2018 Mar;41(3):1765-1773. doi: 10.3892/ijmm.2018.3374. Epub 2018 Jan 10.
REF00002354	MicroRNA-200a confers chemoresistance by antagonizing TP53INP1 and YAP1 in human breast cancer. BMC Cancer. 2018 Jan 12;18(1):74. doi: 10.1186/s12885-017-3930-0.
REF00002355	Characteristics of ARG-carrying plasmidome in the cultivable microbial community from wastewater treatment system under high oxytetracycline concentration. Appl Microbiol Biotechnol. 2018 Feb;102(4):1847-1858. doi: 10.1007/s00253-018-8738-6. Epub 2018 Jan 13.
REF00002356	Exosome-mediated breast cancer chemoresistance via miR-155 transfer. Sci Rep. 2018 Jan 16;8(1):829. doi: 10.1038/s41598-018-19339-5.
REF00002357	miR-204 inhibits angiogenesis and promotes sensitivity to cetuximab in head and neck squamous cell carcinoma cells by blocking JAK2-STAT3 signaling. Biomed Pharmacother. 2018 Mar;99:278-285. doi: 10.1016/j.biopha.2018.01.055.
REF00002358	miR-34 increases in vitro PANC-1 cell sensitivity to gemcitabine via targeting Slug/PUMA. Cancer Biomark. 2018;21(4):755-762. doi: 10.3233/CBM-170289.
REF00002359	"miR-654-5p Targets GRAP to Promote Proliferation, Metastasis, and Chemoresistance of Oral Squamous Cell Carcinoma Through Ras/MAPK Signaling. DNA Cell Biol. 2018 Apr;37(4):381-388. doi: 10.1089/dna.2017.4095. Epub 2018 Jan 24."
REF00002360	Long non-coding RNA HOTTIP promotes BCL-2 expression and induces chemoresistance in small cell lung cancer by sponging miR-216a. Cell Death Dis. 2018 Jan 24;9(2):85. doi: 10.1038/s41419-017-0113-5.
REF00002361	Possible Role of microRNA-122 in Modulating Multidrug Resistance of Hepatocellular Carcinoma. Indian J Clin Biochem. 2018 Jan;33(1):21-30. doi: 10.1007/s12291-017-0651-8. Epub 2017 Apr 21.
REF00002362	Long non-coding RNA CASC2 regulates Sprouty2 via functioning as a competing endogenous RNA for miR-183 to modulate the sensitivity of prostate cancer cells to docetaxel. Arch Biochem Biophys. 2019 Apr 15;665:69-78. doi: 10.1016/j.abb.2018.01.013. Epub 2018 Jan 31.
REF00002363	miR-30 decreases multidrug resistance in human gastric cancer cells by modulating cell autophagy. Exp Ther Med. 2018 Jan;15(1):599-605. doi: 10.3892/etm.2017.5354. Epub 2017 Oct 23.
REF00002364	miR-135a Confers Resistance to Gefitinib in Non-Small Cell Lung Cancer Cells by Upregulation of RAC1. Oncol Res. 2018 Sep 14;26(8):1191-1200. doi: 10.3727/096504018X15166204902353. Epub 2018 Jan 31.
REF00002365	The silencing of LncRNA-H19 decreases chemoresistance of human glioma cells to temozolomide by suppressing epithelial-mesenchymal transition via the Wnt/Beta-Catenin pathway. Onco Targets Ther. 2018 Jan 11;11:313-321. doi: 10.2147/OTT.S154339. eCollection 2018.
REF00002366	miR 21 5p confers doxorubicin resistance in gastric cancer cells by targeting PTEN and TIMP3. Int J Mol Med. 2018 Apr;41(4):1855-1866. doi: 10.3892/ijmm.2018.3405. Epub 2018 Jan 18.
REF00002367	miR 149 5p promotes chemotherapeutic resistance in ovarian cancer via the inactivation of the Hippo signaling pathway. Int J Oncol. 2018 Mar;52(3):815-827. doi: 10.3892/ijo.2018.4252. Epub 2018 Jan 24.
REF00002368	Regulating BMI1 expression via miRNAs promote Mesenchymal to Epithelial Transition (MET) and sensitizes breast cancer cell to chemotherapeutic drug. PLoS One. 2018 Feb 2;13(2):e0190245. doi: 10.1371/journal.pone.0190245. eCollection 2018.
REF00002369	Long non-coding RNA TUSC7 inhibits temozolomide resistance by targeting miR-10a in glioblastoma. Cancer Chemother Pharmacol. 2018 Apr;81(4):671-678. doi: 10.1007/s00280-018-3522-y. Epub 2018 Feb 3.
REF00002370	MicroRNA-1 inhibits tumorigenicity of esophageal squamous cell carcinoma and enhances sensitivity to gefitinib. Oncol Lett. 2018 Jan;15(1):963-971. doi: 10.3892/ol.2017.7378. Epub 2017 Nov 9.
REF00002371	Long non-coding RNA UCA1 desensitizes breast cancer cells to trastuzumab by impeding miR-18a repression of Yes-associated protein 1. Biochem Biophys Res Commun. 2018 Feb 19;496(4):1308-1313. doi: 10.1016/j.bbrc.2018.02.006. Epub 2018 Feb 7.
REF00002372	miR-27b-3p inhibits proliferation and potentially reverses multi-chemoresistance by targeting CBLB/GRB2 in breast cancer cells. Cell Death Dis. 2018 Feb 7;9(2):188. doi: 10.1038/s41419-017-0211-4.
REF00002373	MicroRNA-761 promotes the sensitivity of colorectal cancer cells to 5-Fluorouracil through targeting FOXM1. Oncotarget. 2017 Aug 10;9(1):321-331. doi: 10.18632/oncotarget.20109. eCollection 2018 Jan 2.
REF00002374	The functional mechanism of miR-125b in gastric cancer and its effect on the chemosensitivity of cisplatin. Oncotarget. 2017 Dec 14;9(2):2105-2119. doi: 10.18632/oncotarget.23249. eCollection 2018 Jan 5.
REF00002375	Silencing long noncoding RNA PVT1 inhibits tumorigenesis and cisplatin resistance of colorectal cancer. Am J Transl Res. 2018 Jan 15;10(1):138-149. eCollection 2018.
REF00002376	CCDC26 knockdown enhances resistance of gastrointestinal stromal tumor cells to imatinib by interacting with c-KIT. Am J Transl Res. 2018 Jan 15;10(1):274-282. eCollection 2018.
REF00002377	Silencing of lncRNA ZFAS1 inhibits malignancies by blocking Wnt/Beta-catenin signaling in gastric cancer cells. Biosci Biotechnol Biochem. 2018 Mar;82(3):456-465. doi: 10.1080/09168451.2018.1431518. Epub 2018 Feb 9.
REF00002378	MicroRNA-139-5p affects cisplatin sensitivity in human nasopharyngeal carcinoma cells by regulating the epithelial-to-mesenchymal transition. Gene. 2018 Apr 30;652:48-58. doi: 10.1016/j.gene.2018.02.003. Epub 2018 Feb 8.
REF00002379	miR-223/Hsp70/JNK/JUN/miR-223 feedback loop modulates the chemoresistance of osteosarcoma to cisplatin. Biochem Biophys Res Commun. 2018 Mar 11;497(3):827-834. doi: 10.1016/j.bbrc.2018.02.091. Epub 2018 Feb 9.
REF00002380	miR-125b regulates the drug-resistance of breast cancer cells to doxorubicin by targeting HAX-1. Oncol Lett. 2018 Feb;15(2):1621-1629. doi: 10.3892/ol.2017.7476. Epub 2017 Nov 23.
REF00002381	miR-199a-3p enhances cisplatin sensitivity of ovarian cancer cells by targeting ITGB8. Oncol Rep. 2018 Apr;39(4):1649-1657. doi: 10.3892/or.2018.6259. Epub 2018 Feb 12.
REF00002382	miR-149 reverses cisplatin resistance of gastric cancer SGC7901/DDP cells by targeting FoxM1. Pharmazie. 2016 Nov 2;71(11):640-643. doi: 10.1691/ph.2016.6696.
REF00002383	MicroRNA-132 sensitizes nasopharyngeal carcinoma cells to cisplatin through regulation of forkhead box A1 protein. Pharmazie. 2016 Dec 1;71(12):715-718. doi: 10.1691/ph.2016.6764.
REF00002384	Downregulation of leucine-rich repeats and immunoglobulin-like domains 1 by microRNA-20a modulates gastric cancer multidrug resistance. Cancer Sci. 2018 Apr;109(4):1044-1054. doi: 10.1111/cas.13538. Epub 2018 Mar 23.
REF00002385	MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis. Biochem Biophys Res Commun. 2018 Mar 4;497(2):513-520. doi: 10.1016/j.bbrc.2018.02.062. Epub 2018 Feb 13.
REF00002386	Silencing of LncRNA-HOTAIR decreases drug resistance of Non-Small Cell Lung Cancer cells by inactivating autophagy via suppressing the phosphorylation of ULK1. Biochem Biophys Res Commun. 2018 Mar 18;497(4):1003-1010. doi: 10.1016/j.bbrc.2018.02.141. Epub 2018 Feb 19.
REF00002387	MiR-634 sensitizes glioma cells to temozolomide by targeting CYR61 through Raf-ERK signaling pathway. Cancer Med. 2018 Mar;7(3):913-921. doi: 10.1002/cam4.1351. Epub 2018 Feb 23.
REF00002388	miR-519b-3p promotes responsiveness to preoperative chemoradiotherapy in rectal cancer patients by targeting ARID4B. Gene. 2018 May 20;655:84-90. doi: 10.1016/j.gene.2018.02.056. Epub 2018 Mar 22.
REF00002389	Long noncoding RNA MALAT1 knockdown reverses chemoresistance to temozolomide via promoting microRNA-101 in glioblastoma. Cancer Med. 2018 Apr;7(4):1404-1415. doi: 10.1002/cam4.1384. Epub 2018 Feb 26.
REF00002390	Long noncoding RNA NKILA enhances the anti-cancer effects of baicalein in hepatocellular carcinoma via the regulation of NF-kB signaling. Chem Biol Interact. 2018 Apr 1;285:48-58. doi: 10.1016/j.cbi.2018.02.027. Epub 2018 Feb 23.
REF00002391	miR-33a-5p enhances the sensitivity of lung adenocarcinoma cells to celastrol by regulating mTOR signaling. Int J Oncol. 2018 Apr;52(4):1328-1338. doi: 10.3892/ijo.2018.4276. Epub 2018 Feb 14.
REF00002392	miR-181 regulates cisplatin-resistant non-small cell lung cancer via downregulation of autophagy through the PTEN/PI3K/AKT pathway. Oncol Rep. 2018 Apr;39(4):1631-1639. doi: 10.3892/or.2018.6268. Epub 2018 Feb 13.
REF00002393	miR-340 alleviates chemoresistance of osteosarcoma cells by targeting ZEB1. Anticancer Drugs. 2018 Jun;29(5):440-448. doi: 10.1097/CAD.0000000000000614.
REF00002394	MicroRNA-29a Functions as a Tumor Suppressor and Increases Cisplatin Sensitivity by Targeting NRAS in Lung Cancer. Technol Cancer Res Treat. 2018 Jan 1;17:1533033818758905. doi: 10.1177/1533033818758905.
REF00002395	MicroRNA-623 Targets Cyclin D1 to Inhibit Cell Proliferation and Enhance the Chemosensitivity of Cells to 5-Fluorouracil in Gastric Cancer. Oncol Res. 2018 Dec 27;27(1):19-27. doi: 10.3727/096504018X15193469240508. Epub 2018 Mar 1.
REF00002396	A Conformationally Gated Model of Methadone and Loperamide Transport by P-Glycoprotein. J Pharm Sci. 2018 Jul;107(7):1937-1947. doi: 10.1016/j.xphs.2018.02.019. Epub 2018 Feb 28.
REF00002397	Downregulation of MicroRNA-455-3p Links to Proliferation and Drug Resistance of Pancreatic Cancer Cells via Targeting TAZ. Mol Ther Nucleic Acids. 2018 Mar 2;10:215-226. doi: 10.1016/j.omtn.2017.12.002. Epub 2017 Dec 9.
REF00002398	LncRNA PDIA3P interacts with c-Myc to regulate cell proliferation via induction of pentose phosphate pathway in multiple myeloma. Biochem Biophys Res Commun. 2018 Mar 25;498(1):207-213. doi: 10.1016/j.bbrc.2018.02.211. Epub 2018 Mar 1.
REF00002399	Effects of miR-144 on the sensitivity of human anaplastic thyroid carcinoma cells to cisplatin by autophagy regulation. Cancer Biol Ther. 2018 Jun 3;19(6):484-496. doi: 10.1080/15384047.2018.1433502. Epub 2018 Mar 26.
REF00002400	LncRNA-MALAT1 contributes to the cisplatin-resistance of lung cancer by upregulating MRP1 and MDR1 via STAT3 activation. Biomed Pharmacother. 2018 May;101:536-542. doi: 10.1016/j.biopha.2018.02.130. Epub 2018 Mar 22.
REF00002401	A low microRNA-630 expression confers resistance to tyrosine kinase inhibitors in EGFR-mutated lung adenocarcinomas via miR-630/YAP1/ERK feedback loop. Theranostics. 2018 Feb 2;8(5):1256-1269. doi: 10.7150/thno.22048. eCollection 2018.
REF00002402	MicroRNA-223-3p regulates cell chemo-sensitivity by targeting FOXO3 in prostatic cancer. Gene. 2018 Jun 5;658:152-158. doi: 10.1016/j.gene.2018.03.013. Epub 2018 Mar 5.
REF00002403	Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway. J Exp Clin Cancer Res. 2018 Mar 12;37(1):52. doi: 10.1186/s13046-018-0677-7.
REF00002404	LncRNA-TUSC7/miR-224 affected chemotherapy resistance of esophageal squamous cell carcinoma by competitively regulating DESC1. J Exp Clin Cancer Res. 2018 Mar 12;37(1):56. doi: 10.1186/s13046-018-0724-4.
REF00002405	Downregulation of microRNA-17-5p inhibits drug resistance of gastric cancer cells partially through targeting p21. Oncol Lett. 2018 Apr;15(4):4585-4591. doi: 10.3892/ol.2018.7822. Epub 2018 Jan 19.
REF00002406	miR-19b-3p inhibits breast cancer cell proliferation and reverses saracatinib-resistance by regulating PI3K/Akt pathway. Arch Biochem Biophys. 2018 May 1;645:54-60. doi: 10.1016/j.abb.2018.03.015. Epub 2018 Mar 14.
REF00002407	MicroRNA-155 increases colon cancer chemoresistance to cisplatin by targeting forkhead box O3. Oncol Lett. 2018 Apr;15(4):4781-4788. doi: 10.3892/ol.2018.7976. Epub 2018 Feb 7.
REF00002408	Overexpression of miR-202 resensitizes imatinib resistant chronic myeloid leukemia cells through targetting Hexokinase 2. Biosci Rep. 2018 May 8;38(3):BSR20171383. doi: 10.1042/BSR20171383. Print 2018 Jun 29.
REF00002409	"Overexpressed circPVT1, a potential new circular RNA biomarker, contributes to doxorubicin and cisplatin resistance of osteosarcoma cells by regulating ABCB1. Int J Biol Sci. 2018 Feb 12;14(3):321-330. doi: 10.7150/ijbs.24360. eCollection 2018."
REF00002410	miRNA-34a decreases ovarian cancer cell proliferation and chemoresistance by targeting HDAC1. Biochem Cell Biol. 2018 Oct;96(5):663-671. doi: 10.1139/bcb-2018-0031. Epub 2018 Mar 21.
REF00002411	LncRNA PTCSC3 affects drug resistance of anaplastic thyroid cancer through STAT3/INO80 pathway. Cancer Biol Ther. 2018 Jul 3;19(7):590-597. doi: 10.1080/15384047.2018.1449610. Epub 2018 May 3.
REF00002412	Down-regulation of miR-377 contributes to cisplatin resistance by targeting XIAP in osteosarcoma. Eur Rev Med Pharmacol Sci. 2018 Mar;22(5):1249-1257. doi: 10.26355/eurrev_201803_14465.
REF00002413	MicroRNA-574 enhances doxorubicin resistance through down-regulating SMAD4 in breast cancer cells. Eur Rev Med Pharmacol Sci. 2018 Mar;22(5):1342-1350. doi: 10.26355/eurrev_201803_14476.
REF00002414	LncRNA NEAT1/let-7a-5p axis regulates the cisplatin resistance in nasopharyngeal carcinoma by targeting Rsf-1 and modulating the Ras-MAPK pathway. Cancer Biol Ther. 2018 Jun 3;19(6):534-542. doi: 10.1080/15384047.2018.1450119. Epub 2018 Apr 9.
REF00002415	MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-kB signaling pathway in breast cancer. Biomed Pharmacother. 2018 Jun;102:286-294. doi: 10.1016/j.biopha.2018.03.088. Epub 2018 Mar 22.
REF00002416	MicroRNA-630 may confer favorable cisplatin-based chemotherapy and clinical outcomes in non-small cell lung cancer by targeting Bcl-2. Oncotarget. 2018 Feb 9;9(17):13758-13767. doi: 10.18632/oncotarget.24474. eCollection 2018 Mar 2.
REF00002417	"MicroRNA 22 inhibits the proliferation and migration, and increases the cisplatin sensitivity, of osteosarcoma cells. Mol Med Rep. 2018 May;17(5):7209-7217. doi: 10.3892/mmr.2018.8790. Epub 2018 Mar 20."
REF00002418	Sanguinarine inhibits epithelial ovarian cancer development via regulating long non-coding RNA CASC2-EIF4A3 axis and/or inhibiting NF-kB signaling or PI3K/AKT/mTOR pathway. Biomed Pharmacother. 2018 Jun;102:302-308. doi: 10.1016/j.biopha.2018.03.071. Epub 2018 Mar 22.
REF00002419	MiR-192 and miR-662 enhance chemoresistance and invasiveness of squamous cell lung carcinoma. Lung Cancer. 2018 Apr;118:111-118. doi: 10.1016/j.lungcan.2018.02.002. Epub 2018 Feb 6.
REF00002420	MicroRNA-708-3p mediates metastasis and chemoresistance through inhibition of epithelial-to-mesenchymal transition in breast cancer. Cancer Sci. 2018 May;109(5):1404-1413. doi: 10.1111/cas.13588. Epub 2018 Apr 29.
REF00002421	Let-7c restores radiosensitivity and chemosensitivity and impairs stemness in oral cancer cells through inhibiting interleukin-8. J Oral Pathol Med. 2018 Jul;47(6):590-597. doi: 10.1111/jop.12711. Epub 2018 Apr 17.
REF00002422	TP53TG1 enhances cisplatin sensitivity of non-small cell lung cancer cells through regulating miR-18a/PTEN axis. Cell Biosci. 2018 Mar 22;8:23. doi: 10.1186/s13578-018-0221-7. eCollection 2018.
REF00002423	The long non-coding RNA SNHG5 regulates gefitinib resistance in lung adenocarcinoma cells by targetting miR-377/CASP1 axis. Biosci Rep. 2018 Aug 29;38(4):BSR20180400. doi: 10.1042/BSR20180400. Print 2018 Aug 31.
REF00002424	Genomic epidemiology of the UK outbreak of the emerging human fungal pathogen Candida auris. Emerg Microbes Infect. 2018 Mar 29;7(1):43. doi: 10.1038/s41426-018-0045-x.
REF00002425	MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B. Cancer Chemother Pharmacol. 2018 May;81(5):935-947. doi: 10.1007/s00280-018-3548-1. Epub 2018 Mar 28.
REF00002426	LncRNA NR2F1-AS1 regulates hepatocellular carcinoma oxaliplatin resistance by targeting ABCC1 via miR-363. J Cell Mol Med. 2018 Jun;22(6):3238-3245. doi: 10.1111/jcmm.13605. Epub 2018 Mar 30.
REF00002427	MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma. J Exp Clin Cancer Res. 2018 Apr 3;37(1):76. doi: 10.1186/s13046-018-0739-x.
REF00002428	miR 22 3p enhances multi chemoresistance by targeting NET1 in bladder cancer cells. Oncol Rep. 2018 Jun;39(6):2731-2740. doi: 10.3892/or.2018.6355. Epub 2018 Apr 4.
REF00002429	Substrate Recognition by a Colistin Resistance Enzyme from Moraxella catarrhalis. ACS Chem Biol. 2018 May 18;13(5):1322-1332. doi: 10.1021/acschembio.8b00116. Epub 2018 Apr 19.
REF00002430	Long noncoding RNA MALAT1 enhances the docetaxel resistance of prostate cancer cells via miR-145-5p-mediated regulation of AKAP12. J Cell Mol Med. 2018 Jun;22(6):3223-3237. doi: 10.1111/jcmm.13604. Epub 2018 Apr 6.
REF00002431	"Characterization of poxtA, a novel phenicol-oxazolidinone-tetracycline resistance gene from an MRSA of clinical origin. J Antimicrob Chemother. 2018 Jul 1;73(7):1763-1769. doi: 10.1093/jac/dky088."
REF00002432	miR-206 regulates 5-FU resistance by targeting Bcl-2 in colon cancer cells. Onco Targets Ther. 2018 Mar 29;11:1757-1765. doi: 10.2147/OTT.S159093. eCollection 2018.
REF00002433	MiR-30a-5p confers cisplatin resistance by regulating IGF1R expression in melanoma cells. BMC Cancer. 2018 Apr 11;18(1):404. doi: 10.1186/s12885-018-4233-9.
REF00002434	MicroRNA-130b targets PTEN to induce resistance to cisplatin in lung cancer cells by activating Wnt/Beta-catenin pathway. Cell Biochem Funct. 2018 Jun;36(4):194-202. doi: 10.1002/cbf.3331. Epub 2018 Apr 13.
REF00002435	Knockdown of the oncogene lncRNA NEAT1 restores the availability of miR-34c and improves the sensitivity to cisplatin in osteosarcoma. Biosci Rep. 2018 May 31;38(3):BSR20180375. doi: 10.1042/BSR20180375. Print 2018 Jun 29.
REF00002436	Trends in hepatitis B virus resistance to nucleoside/nucleotide analogues in North China from 2009-2016: A retrospective study. Int J Antimicrob Agents. 2018 Aug;52(2):201-209. doi: 10.1016/j.ijantimicag.2018.04.002. Epub 2018 Apr 12.
REF00002437	Knockdown of LncRNA-UCA1 suppresses chemoresistance of pediatric AML by inhibiting glycolysis through the microRNA-125a/hexokinase 2 pathway. J Cell Biochem. 2018 Jul;119(7):6296-6308. doi: 10.1002/jcb.26899. Epub 2018 Apr 16.
REF00002438	MicroRNA-195 regulates docetaxel resistance by targeting clusterin in prostate cancer. Biomed Pharmacother. 2018 Mar;99:445-450. doi: 10.1016/j.biopha.2018.01.088. Epub 2018 Feb 20.
REF00002439	miR-485-5p suppresses breast cancer progression and chemosensitivity by targeting survivin. Biochem Biophys Res Commun. 2018 Jun 18;501(1):48-54. doi: 10.1016/j.bbrc.2018.04.129. Epub 2018 Apr 22.
REF00002440	Knockdown of long non coding RNA PVT1 reverses multidrug resistance in colorectal cancer cells. Mol Med Rep. 2018 Jun;17(6):8309-8315. doi: 10.3892/mmr.2018.8907. Epub 2018 Apr 20.
REF00002441	Mir-1307 regulates cisplatin resistance by targeting Mdm4 in breast cancer expressing wild type P53. Thorac Cancer. 2018 Jun;9(6):676-683. doi: 10.1111/1759-7714.12607. Epub 2018 Apr 26.
REF00002442	Chemotherapy-Induced Long Non-coding RNA 1 Promotes Metastasis and Chemo-Resistance of TSCC via the Wnt/Beta-Catenin Signaling Pathway. Mol Ther. 2018 Jun 6;26(6):1494-1508. doi: 10.1016/j.ymthe.2018.04.002. Epub 2018 Apr 5.
REF00002443	MiR-223 promotes the doxorubicin resistance of colorectal cancer cells via regulating epithelial-mesenchymal transition by targeting FBXW7. Acta Biochim Biophys Sin (Shanghai). 2018 Jun 1;50(6):597-604. doi: 10.1093/abbs/gmy040.
REF00002444	Inhibition of MALAT1 sensitizes liver cancer cells to 5-flurouracil by regulating apoptosis through IKKAlpha/NF-kB pathway. Biochem Biophys Res Commun. 2018 Jun 18;501(1):33-40. doi: 10.1016/j.bbrc.2018.04.116. Epub 2018 May 7.
REF00002445	miRNA 146a promotes chemotherapy resistance in lung cancer cells by targeting DNA damage inducible transcript 3 (CHOP). Cancer Lett. 2018 Aug 1;428:55-68. doi: 10.1016/j.canlet.2018.04.028. Epub 2018 Apr 24.
REF00002446	Tumor suppressive microRNA-124a inhibits stemness and enhances gefitinib sensitivity of non-small cell lung cancer cells by targeting ubiquitin-specific protease 14. Cancer Lett. 2018 Jul 28;427:74-84. doi: 10.1016/j.canlet.2018.04.022. Epub 2018 Apr 24.
REF00002447	"Metformin, a first-line drug for type 2 diabetes mellitus, disrupts the MALAT1/miR-142-3p sponge to decrease invasion and migration in cervical cancer cells. Eur J Pharmacol. 2018 Jul 5;830:59-67. doi: 10.1016/j.ejphar.2018.04.027. Epub 2018 Apr 25."
REF00002448	Long noncoding RNA BLACAT1 modulates ABCB1 to promote oxaliplatin resistance of gastric cancer via sponging miR-361. Biomed Pharmacother. 2018 Mar;99:832-838. doi: 10.1016/j.biopha.2018.01.130. Epub 2018 Feb 20.
REF00002449	Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin Beta3. Oncogene. 2018 Aug;37(31):4300-4312. doi: 10.1038/s41388-018-0276-2. Epub 2018 May 2.
REF00002450	Reversal of cisplatin resistance by microRNA-139-5p-independent RNF2 downregulation and MAPK inhibition in ovarian cancer. Am J Physiol Cell Physiol. 2018 Aug 1;315(2):C225-C235. doi: 10.1152/ajpcell.00283.2017. Epub 2018 May 2.
REF00002451	MiR-505 mediates methotrexate resistance in colorectal cancer by targeting RASSF8. J Pharm Pharmacol. 2018 Jul;70(7):937-951. doi: 10.1111/jphp.12913. Epub 2018 May 3.
REF00002452	A novel long non-coding RNA-PRLB acts as a tumor promoter through regulating miR-4766-5p/SIRT1 axis in breast cancer. Cell Death Dis. 2018 May 1;9(5):563. doi: 10.1038/s41419-018-0582-1.
REF00002453	MiR-514 attenuates proliferation and increases chemoresistance by targeting ATP binding cassette subfamily in ovarian cancer. Mol Genet Genomics. 2018 Oct;293(5):1159-1167. doi: 10.1007/s00438-018-1447-0. Epub 2018 May 11.
REF00002454	"Defining ICR-Mo, an intrinsic colistin resistance determinant from Moraxella osloensis. PLoS Genet. 2018 May 14;14(5):e1007389. doi: 10.1371/journal.pgen.1007389. eCollection 2018 May."
REF00002455	Phenotypic and genotypic characterization of Thai isolates of Plasmodium falciparum after an artemisinin resistance containment project. Malar J. 2018 May 15;17(1):197. doi: 10.1186/s12936-018-2347-9.
REF00002456	MicroRNA-125a-5p enhances the sensitivity of esophageal squamous cell carcinoma cells to cisplatin by suppressing the activation of the STAT3 signaling pathway. Int J Oncol. 2018 Aug;53(2):644-658. doi: 10.3892/ijo.2018.4409. Epub 2018 May 16.
REF00002457	miR-301a plays a pivotal role in hypoxia-induced gemcitabine resistance in pancreatic cancer. Exp Cell Res. 2018 Aug 1;369(1):120-128. doi: 10.1016/j.yexcr.2018.05.013. Epub 2018 May 23.
REF00002458	UCA1 confers paclitaxel resistance to ovarian cancer through miR-129/ABCB1 axis. Biochem Biophys Res Commun. 2018 Jul 2;501(4):1034-1040. doi: 10.1016/j.bbrc.2018.05.104. Epub 2018 May 19.
REF00002459	"Autophagy, Cell Viability, and Chemoresistance Are Regulated By miR-489 in Breast Cancer. Mol Cancer Res. 2018 Sep;16(9):1348-1360. doi: 10.1158/1541-7786.MCR-17-0634. Epub 2018 May 21."
REF00002460	miR 494 inhibits cancer initiating cell phenotypes and reverses resistance to lapatinib by downregulating FGFR2 in HER2 positive gastric cancer. Int J Mol Med. 2018 Aug;42(2):998-1007. doi: 10.3892/ijmm.2018.3680. Epub 2018 May 16.
REF00002461	microRNA-129-5p suppresses Adriamycin resistance in breast cancer by targeting SOX2. Arch Biochem Biophys. 2018 Aug 1;651:52-60. doi: 10.1016/j.abb.2018.05.018. Epub 2018 May 23.
REF00002462	The action mechanism of lncRNA-HOTAIR on the drug resistance of non-small cell lung cancer by regulating Wnt signaling pathway. Exp Ther Med. 2018 Jun;15(6):4885-4889. doi: 10.3892/etm.2018.6052. Epub 2018 Apr 11.
REF00002463	MicroRNA-29c Increases the Chemosensitivity of Pancreatic Cancer Cells by Inhibiting USP22 Mediated Autophagy. Cell Physiol Biochem. 2018;47(2):747-758. doi: 10.1159/000490027. Epub 2018 May 22.
REF00002464	Exosome-mediated transfer of lncRNA RP11 838N2.4 promotes erlotinib resistance in non-small cell lung cancer. Int J Oncol. 2018 Aug;53(2):527-538. doi: 10.3892/ijo.2018.4412. Epub 2018 May 17.
REF00002465	MicroRNA 663b mediates TAM resistance in breast cancer by modulating TP73 expression. Mol Med Rep. 2018 Jul;18(1):1120-1126. doi: 10.3892/mmr.2018.9064. Epub 2018 May 23.
REF00002466	MicroRNA-1 overexpression increases chemosensitivity of non-small cell lung cancer cells by inhibiting autophagy related 3-mediated autophagy. Cell Biol Int. 2018 Sep;42(9):1240-1249. doi: 10.1002/cbin.10995. Epub 2018 Jun 15.
REF00002467	Overcoming stemness and chemoresistance in colorectal cancer through miR-195-5p-modulated inhibition of notch signaling. Int J Biol Macromol. 2018 Oct 1;117:445-453. doi: 10.1016/j.ijbiomac.2018.05.151. Epub 2018 May 28.
REF00002468	Nucleotide sequence analysis of a gene encoding a streptomycin/spectinomycin adenylyltransferase. Plasmid. 1985 Jan;13(1):17-30. doi: 10.1016/0147-619x(85)90052-6.
REF00002469	miR-129 inhibits tumor growth and potentiates chemosensitivity of neuroblastoma by targeting MYO10. Biomed Pharmacother. 2018 Jul;103:1312-1318. doi: 10.1016/j.biopha.2018.04.153. Epub 2018 May 7.
REF00002470	MiR-199a-3p affects the multi-chemoresistance of osteosarcoma through targeting AK4. BMC Cancer. 2018 Jun 4;18(1):631. doi: 10.1186/s12885-018-4460-0.
REF00002471	Negative Regulation of PTEN by MicroRNA-221 and Its Association with Drug Resistance and Cellular Senescence in Lung Cancer Cells. Biomed Res Int. 2018 Jan 30;2018:7908950. doi: 10.1155/2018/7908950. eCollection 2018.
REF00002472	Nucleotide sequences encoding and promoting expression of three antibiotic resistance genes indigenous to Streptomyces. Mol Gen Genet. 1985;199(1):26-36. doi: 10.1007/BF00327505.
REF00002473	miR-1268a regulates ABCC1 expression to mediate temozolomide resistance in glioblastoma. J Neurooncol. 2018 Jul;138(3):499-508. doi: 10.1007/s11060-018-2835-3. Epub 2018 Jun 6.
REF00002474	microRNA-199a/b-5p enhance imatinib efficacy via repressing WNT2 signaling-mediated protective autophagy in imatinib-resistant chronic myeloid leukemia cells. Chem Biol Interact. 2018 Aug 1;291:144-151. doi: 10.1016/j.cbi.2018.06.006. Epub 2018 Jun 8.
REF00002475	HOXD-AS1 Exerts Oncogenic Functions and Promotes Chemoresistance in Cisplatin-Resistant Cervical Cancer Cells. Hum Gene Ther. 2018 Dec;29(12):1438-1448. doi: 10.1089/hum.2017.256. Epub 2018 Sep 5.
REF00002476	Targeted regulationof STAT3 by miR-29a in mediating Taxol resistance of nasopharyngeal carcinoma cell line CNE-1. Cancer Biomark. 2018;22(4):641-648. doi: 10.3233/CBM-170964.
REF00002477	miR-27b-3p is Involved in Doxorubicin Resistance of Human Anaplastic Thyroid Cancer Cells via Targeting Peroxisome Proliferator-Activated Receptor Gamma. Basic Clin Pharmacol Toxicol. 2018 Dec;123(6):670-677. doi: 10.1111/bcpt.13076. Epub 2018 Aug 5.
REF00002478	miR-182 regulates trastuzumab resistance by targeting MET in breast cancer cells. Cancer Gene Ther. 2019 Feb;26(1-2):1-10. doi: 10.1038/s41417-018-0031-4. Epub 2018 Jun 21.
REF00002479	Inhibition of microRNA-16 facilitates the paclitaxel resistance by targeting IKBKB via NF-kB signaling pathway in hepatocellular carcinoma. Biochem Biophys Res Commun. 2018 Sep 5;503(2):1035-1041. doi: 10.1016/j.bbrc.2018.06.113. Epub 2018 Aug 2.
REF00002480	"Nucleotide sequence of a spectinomycin adenyltransferase AAD(9) determinant from Staphylococcus aureus and its relationship to AAD(3"") (9). Mol Gen Genet. 1985;200(1):33-9. doi: 10.1007/BF00383309."
REF00002481	Sensitization of Gastric Cancer Cells to 5-FU by MicroRNA-204 Through Targeting the TGFBR2-Mediated Epithelial to Mesenchymal Transition. Cell Physiol Biochem. 2018;47(4):1533-1545. doi: 10.1159/000490871. Epub 2018 Jun 21.
REF00002482	Knockdown of MiR-20a Enhances Sensitivity of Colorectal Cancer Cells to Cisplatin by Increasing ASK1 Expression. Cell Physiol Biochem. 2018;47(4):1432-1441. doi: 10.1159/000490834. Epub 2018 Jun 19.
REF00002483	MicroRNA-17 inhibition overcomes chemoresistance and suppresses epithelial-mesenchymal transition through a DEDD-dependent mechanism in gastric cancer. Int J Biochem Cell Biol. 2018 Sep;102:59-70. doi: 10.1016/j.biocel.2018.06.007. Epub 2018 Jun 25.
REF00002484	miR 195 5p regulates multi drug resistance of gastric cancer cells via targeting ZNF139. Oncol Rep. 2018 Sep;40(3):1370-1378. doi: 10.3892/or.2018.6524. Epub 2018 Jun 25.
REF00002485	LncRNA THOR attenuates cisplatin sensitivity of nasopharyngeal carcinoma cells via enhancing cells stemness. Biochimie. 2018 Sep;152:63-72. doi: 10.1016/j.biochi.2018.06.015. Epub 2018 Jun 26.
REF00002486	LncRNA TUG1 promoted viability and associated with gemcitabine resistant in pancreatic ductal adenocarcinoma. J Pharmacol Sci. 2018 Jun;137(2):116-121. doi: 10.1016/j.jphs.2018.06.002. Epub 2018 Jun 7.
REF00002487	Long non-coding RNA KCNQ1OT1 modulates oxaliplatin resistance in hepatocellular carcinoma through miR-7-5p/ ABCC1 axis. Biochem Biophys Res Commun. 2018 Sep 18;503(4):2400-2406. doi: 10.1016/j.bbrc.2018.06.168. Epub 2018 Jul 4.
REF00002488	Down-regulated miR-148b increases resistance to CHOP in diffuse large B-cell lymphoma cells by rescuing Ezrin. Biomed Pharmacother. 2018 Oct;106:267-274. doi: 10.1016/j.biopha.2018.06.093. Epub 2018 Jun 28.
REF00002489	Calycosin inhibits nasopharyngeal carcinoma cells by influencing EWSAT1 expression to regulate the TRAF6-related pathways. Biomed Pharmacother. 2018 Oct;106:342-348. doi: 10.1016/j.biopha.2018.06.143. Epub 2018 Jul 11.
REF00002490	MicroRNA-760 Inhibits Doxorubicin Resistance in Hepatocellular Carcinoma through Regulating Notch1/Hes1-PTEN/Akt Signaling Pathway. J Biochem Mol Toxicol. 2018 Aug;32(8):e22167. doi: 10.1002/jbt.22167. Epub 2018 Jul 3.
REF00002491	The miR-31-SOX10 axis regulates tumor growth and chemotherapy resistance of melanoma via PI3K/AKT pathway. Biochem Biophys Res Commun. 2018 Sep 18;503(4):2451-2458. doi: 10.1016/j.bbrc.2018.06.175. Epub 2018 Jul 3.
REF00002492	LncRNA KCNQ1OT1 regulates proliferation and cisplatin resistance in tongue cancer via miR-211-5p mediated Ezrin/Fak/Src signaling. Cell Death Dis. 2018 Jul 3;9(7):742. doi: 10.1038/s41419-018-0793-5.
REF00002493	MiR-92a Inhibits the Progress of Osteosarcoma Cells and Increases the Cisplatin Sensitivity by Targeting Notch1. Biomed Res Int. 2018 Jun 7;2018:9870693. doi: 10.1155/2018/9870693. eCollection 2018.
REF00002494	Helicobacter pylori-induced miR-135b-5p promotes cisplatin resistance in gastric cancer. FASEB J. 2019 Jan;33(1):264-274. doi: 10.1096/fj.201701456RR. Epub 2018 Jul 9.
REF00002495	miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn. Biomed Pharmacother. 2018 Oct;106:523-531. doi: 10.1016/j.biopha.2018.06.114. Epub 2018 Jul 11.
REF00002496	Small Molecule Inhibition of MicroRNA miR-21 Rescues Chemosensitivity of Renal-Cell Carcinoma to Topotecan. J Med Chem. 2018 Jul 26;61(14):5900-5909. doi: 10.1021/acs.jmedchem.7b01891. Epub 2018 Jul 11.
REF00002497	Linc00518 Contributes to Multidrug Resistance Through Regulating the MiR-199a/MRP1 Axis in Breast Cancer. Cell Physiol Biochem. 2018;48(1):16-28. doi: 10.1159/000491659. Epub 2018 Jul 12.
REF00002498	MicroRNA-34a Attenuates Metastasis and Chemoresistance of Bladder Cancer Cells by Targeting the TCF1/LEF1 Axis. Cell Physiol Biochem. 2018;48(1):87-98. doi: 10.1159/000491665. Epub 2018 Jul 12.
REF00002499	Overexpression of miR-4443 promotes the resistance of non-small cell lung cancer cells to epirubicin by targeting INPP4A and regulating the activation of JAK2/STAT3 pathway. Pharmazie. 2018 Jul 1;73(7):386-392. doi: 10.1691/ph.2018.8313.
REF00002500	Curcumin inhibits proliferation and enhances apoptosis in A549 cells by downregulating lncRNA UCA1. Pharmazie. 2018 Jul 1;73(7):402-407. doi: 10.1691/ph.2018.8402.
REF00002501	miR-106a Reduces 5-Fluorouracil (5-FU) Sensitivity of Colorectal Cancer by Targeting Dual-Specificity Phosphatases 2 (DUSP2). Med Sci Monit. 2018 Jul 16;24:4944-4951. doi: 10.12659/MSM.910016.
REF00002502	ACI-1 beta-lactamase is widespread across human gut microbiomes in Negativicutes due to transposons harboured by tailed prophages. Environ Microbiol. 2018 Jun;20(6):2288-2300. doi: 10.1111/1462-2920.14276. Epub 2018 Aug 7.
REF00002503	Exosome-mediated transfer of lncRNA SNHG14 promotes trastuzumab chemoresistance in breast cancer. Int J Oncol. 2018 Sep;53(3):1013-1026. doi: 10.3892/ijo.2018.4467. Epub 2018 Jul 3.
REF00002504	Circular RNA MTO1 suppresses breast cancer cell viability and reverses monastrol resistance through regulating the TRAF4/Eg5 axis. Int J Oncol. 2018 Oct;53(4):1752-1762. doi: 10.3892/ijo.2018.4485. Epub 2018 Jul 17.
REF00002505	microRNA-19a-3p promotes tumor metastasis and chemoresistance through the PTEN/Akt pathway in hepatocellular carcinoma. Biomed Pharmacother. 2018 Sep;105:1147-1154. doi: 10.1016/j.biopha.2018.06.097. Epub 2018 Jun 21.
REF00002506	LncRNA MEG3 enhances (131)I sensitivity in thyroid carcinoma via sponging miR-182. Biomed Pharmacother. 2018 Sep;105:1232-1239. doi: 10.1016/j.biopha.2018.06.087. Epub 2018 Jun 22.
REF00002507	MiR-373-3p enhances the chemosensitivity of gemcitabine through cell cycle pathway by targeting CCND2 in pancreatic carcinoma cells. Biomed Pharmacother. 2018 Sep;105:887-898. doi: 10.1016/j.biopha.2018.05.091. Epub 2018 Jun 19.
REF00002508	NRAL mediates cisplatin resistance in hepatocellular carcinoma via miR-340-5p/Nrf2 axis. J Cell Commun Signal. 2019 Mar;13(1):99-112. doi: 10.1007/s12079-018-0479-x. Epub 2018 Jul 20.
REF00002509	MiR-363 inhibits cisplatin chemoresistance of epithelial ovarian cancer by regulating snail-induced epithelial-mesenchymal transition. BMB Rep. 2018 Sep;51(9):456-461. doi: 10.5483/BMBRep.2018.51.9.104.
REF00002510	"HOTAIR, a long noncoding RNA, is a marker of abnormal cell cycle regulation in lung cancer. Cancer Sci. 2018 Sep;109(9):2717-2733. doi: 10.1111/cas.13745."
REF00002511	Exosome-mediated transfer of lncRNA PART1 induces gefitinib resistance in esophageal squamous cell carcinoma via functioning as a competing endogenous RNA. J Exp Clin Cancer Res. 2018 Jul 27;37(1):171. doi: 10.1186/s13046-018-0845-9.
REF00002512	Transposon Tn554: complete nucleotide sequence and isolation of transposition-defective and antibiotic-sensitive mutants. EMBO J. 1985 Dec 1;4(12):3357-65.
REF00002513	RNA interference of long noncoding RNA HOTAIR suppresses autophagy and promotes apoptosis and sensitivity to cisplatin in oral squamous cell carcinoma. J Oral Pathol Med. 2018 Nov;47(10):930-937. doi: 10.1111/jop.12769. Epub 2018 Aug 27.
REF00002514	STAT3 regulated miR-216a promotes ovarian cancer proliferation and cisplatin resistance. Biosci Rep. 2018 Aug 29;38(4):BSR20180547. doi: 10.1042/BSR20180547. Print 2018 Aug 31.
REF00002515	Inhibition of microRNA-299-5p sensitizes glioblastoma cells to temozolomide via the MAPK/ERK signaling pathway. Biosci Rep. 2018 Sep 12;38(5):BSR20181051. doi: 10.1042/BSR20181051. Print 2018 Oct 31.
REF00002516	Long non-coding RNA SNHG14 induces trastuzumab resistance of breast cancer via regulating PABPC1 expression through H3K27 acetylation. J Cell Mol Med. 2018 Oct;22(10):4935-4947. doi: 10.1111/jcmm.13758. Epub 2018 Jul 31.
REF00002517	Sequence and interspecies transfer of an aminoglycoside phosphotransferase gene (APH) of Bacillus circulans. Self-defence mechanism in antibiotic-producing organisms. Biochem J. 1986 Jan 15;233(2):383-93. doi: 10.1042/bj2330383.
REF00002518	Ultrasound targeted microbubble destruction mediated miR 205 enhances cisplatin cytotoxicity in prostate cancer cells. Mol Med Rep. 2018 Sep;18(3):3242-3250. doi: 10.3892/mmr.2018.9316. Epub 2018 Jul 24.
REF00002519	A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer. Int J Oncol. 2018 Oct;53(4):1601-1612. doi: 10.3892/ijo.2018.4492. Epub 2018 Jul 19.
REF00002520	Knockdown of miR 935 increases paclitaxel sensitivity via regulation of SOX7 in non small cell lung cancer. Mol Med Rep. 2018 Sep;18(3):3397-3402. doi: 10.3892/mmr.2018.9330. Epub 2018 Jul 27.
REF00002521	LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway. Eur Rev Med Pharmacol Sci. 2018 Aug;22(15):4879-4887. doi: 10.26355/eurrev_201808_15624.
REF00002522	Knockdown of Mir-135b Sensitizes Colorectal Cancer Cells to Oxaliplatin-Induced Apoptosis Through Increase of FOXO1. Cell Physiol Biochem. 2018;48(4):1628-1637. doi: 10.1159/000492284. Epub 2018 Aug 2.
REF00002523	Polyphyllin I modulates MALAT1/STAT3 signaling to induce apoptosis in gefitinib-resistant non-small cell lung cancer. Toxicol Appl Pharmacol. 2018 Oct 1;356:1-7. doi: 10.1016/j.taap.2018.07.031. Epub 2018 Aug 1.
REF00002524	Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal lncRNA H19. Theranostics. 2018 Jun 24;8(14):3932-3948. doi: 10.7150/thno.25541. eCollection 2018.
REF00002525	LncRNA GACAT3 acts as a competing endogenous RNA of HMGA1 and alleviates cucurbitacin B-induced apoptosis of gastric cancer cells. Gene. 2018 Dec 15;678:164-171. doi: 10.1016/j.gene.2018.08.037. Epub 2018 Aug 8.
REF00002526	Long non-coding RNA TUG1 sponges miR-197 to enhance cisplatin sensitivity in triple negative breast cancer. Biomed Pharmacother. 2018 Nov;107:338-346. doi: 10.1016/j.biopha.2018.07.076. Epub 2018 Aug 8.
REF00002527	LncRNA HOXA11-AS drives cisplatin resistance of human LUAD cells via modulating miR-454-3p/Stat3. Cancer Sci. 2018 Oct;109(10):3068-3079. doi: 10.1111/cas.13764. Epub 2018 Sep 2.
REF00002528	Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma. Cancer Lett. 2018 Nov 1;436:10-21. doi: 10.1016/j.canlet.2018.08.004. Epub 2018 Aug 10.
REF00002529	Long noncoding RNA cancer susceptibility candidate 9 promotes doxorubicin resistant breast cancer by binding to enhancer of zeste homolog 2. Int J Mol Med. 2018 Nov;42(5):2801-2810. doi: 10.3892/ijmm.2018.3812. Epub 2018 Aug 7.
REF00002530	miR-590-5p suppresses hepatocellular carcinoma chemoresistance by targeting YAP1 expression. EBioMedicine. 2018 Sep;35:142-154. doi: 10.1016/j.ebiom.2018.08.010. Epub 2018 Aug 13.
REF00002531	Emerging Southeast Asian PfCRT mutations confer Plasmodium falciparum resistance to the first-line antimalarial piperaquine. Nat Commun. 2018 Aug 17;9(1):3314. doi: 10.1038/s41467-018-05652-0.
REF00002532	miR-129-5p inhibits gemcitabine resistance and promotes cell apoptosis of bladder cancer cells by targeting Wnt5a. Int Urol Nephrol. 2018 Oct;50(10):1811-1819. doi: 10.1007/s11255-018-1959-x. Epub 2018 Aug 16.
REF00002533	miR-539 enhances chemosensitivity to cisplatin in non-small cell lung cancer by targeting DCLK1. Biomed Pharmacother. 2018 Oct;106:1072-1081. doi: 10.1016/j.biopha.2018.07.024. Epub 2018 Jul 17.
REF00002534	MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R. Biomed Pharmacother. 2018 Oct;106:1357-1363. doi: 10.1016/j.biopha.2018.07.059. Epub 2018 Jul 23.
REF00002535	Overexpression of MEG3 sensitizes colorectal cancer cells to oxaliplatin through regulation of miR-141/PDCD4 axis. Biomed Pharmacother. 2018 Oct;106:1607-1615. doi: 10.1016/j.biopha.2018.07.131. Epub 2018 Jul 29.
REF00002536	Long noncoding RNA SNHG12 mediates doxorubicin resistance of osteosarcoma via miR-320a/MCL1 axis. Biomed Pharmacother. 2018 Oct;106:850-857. doi: 10.1016/j.biopha.2018.07.003. Epub 2018 Jul 11.
REF00002537	lncRNA KRAL reverses 5-fluorouracil resistance in hepatocellular carcinoma cells by acting as a ceRNA against miR-141. Cell Commun Signal. 2018 Aug 17;16(1):47. doi: 10.1186/s12964-018-0260-z.
REF00002538	Knockdown of Linc00515 Inhibits Multiple Myeloma Autophagy and Chemoresistance by Upregulating miR-140-5p and Downregulating ATG14. Cell Physiol Biochem. 2018;48(6):2517-2527. doi: 10.1159/000492690. Epub 2018 Aug 17.
REF00002539	MiR-873 inhibition enhances gefitinib resistance in non-small cell lung cancer cells by targeting glioma-associated oncogene homolog 1. Thorac Cancer. 2018 Oct;9(10):1262-1270. doi: 10.1111/1759-7714.12830. Epub 2018 Aug 20.
REF00002540	LINC00473 promotes the Taxol resistance via miR-15a in colorectal cancer. Biosci Rep. 2018 Sep 20;38(5):BSR20180790. doi: 10.1042/BSR20180790. Print 2018 Oct 31.
REF00002541	Application of Intestinal Epithelial Cells Differentiated from Human Induced Pluripotent Stem Cells for Studies of Prodrug Hydrolysis and Drug Absorption in the Small Intestine. Drug Metab Dispos. 2018 Nov;46(11):1497-1506. doi: 10.1124/dmd.118.083246. Epub 2018 Aug 22.
REF00002542	MicroRNA-495 Confers Increased Sensitivity to Chemotherapeutic Agents in Gastric Cancer via the Mammalian Target of Rapamycin (mTOR) Signaling Pathway by Interacting with Human Epidermal Growth Factor Receptor 2 (ERBB2). Med Sci Monit. 2018 Aug 27;24:5960-5972. doi: 10.12659/MSM.909458.
REF00002543	The c-Myc-regulated lncRNA NEAT1 and paraspeckles modulate imatinib-induced apoptosis in CML cells. Mol Cancer. 2018 Aug 28;17(1):130. doi: 10.1186/s12943-018-0884-z.
REF00002544	SP1-induced lncRNA AGAP2-AS1 expression promotes chemoresistance of breast cancer by epigenetic regulation of MyD88. J Exp Clin Cancer Res. 2018 Aug 29;37(1):202. doi: 10.1186/s13046-018-0875-3.
REF00002545	miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer. Oncogene. 2019 Jan;38(4):564-580. doi: 10.1038/s41388-018-0459-x. Epub 2018 Aug 30.
REF00002546	Long non-coding RNA 00607 as a tumor suppressor by modulating NF-kB p65/p53 signaling axis in hepatocellular carcinoma. Carcinogenesis. 2018 Dec 31;39(12):1438-1446. doi: 10.1093/carcin/bgy113.
REF00002547	Paclitaxel promotes lung cancer cell apoptosis via MEG3-P53 pathway activation. Biochem Biophys Res Commun. 2018 Sep 26;504(1):123-128. doi: 10.1016/j.bbrc.2018.08.142. Epub 2018 Aug 31.
REF00002548	MicroRNA-9 Enhanced Cisplatin Sensitivity in Nonsmall Cell Lung Cancer Cells by Regulating Eukaryotic Translation Initiation Factor 5A2. Biomed Res Int. 2018 Aug 5;2018:1769040. doi: 10.1155/2018/1769040. eCollection 2018.
REF00002549	miR-34a Regulates Multidrug Resistance via Positively Modulating OAZ2 Signaling in Colon Cancer Cells. J Immunol Res. 2018 Aug 2;2018:7498514. doi: 10.1155/2018/7498514. eCollection 2018.
REF00002550	miR-217 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitors by targeting pro-oncogenic anterior gradient 2. Exp Hematol. 2018 Dec;68:80-88.e2. doi: 10.1016/j.exphem.2018.09.001. Epub 2018 Sep 5.
REF00002551	The Long Noncoding RNA D63785 Regulates Chemotherapy Sensitivity in Human Gastric Cancer by Targeting miR-422a. Mol Ther Nucleic Acids. 2018 Sep 7;12:405-419. doi: 10.1016/j.omtn.2018.05.024. Epub 2018 Jul 5.
REF00002552	HOXA4-regulated miR-138 suppresses proliferation and gefitinib resistance in non-small cell lung cancer. Mol Genet Genomics. 2019 Feb;294(1):85-93. doi: 10.1007/s00438-018-1489-3. Epub 2018 Sep 8.
REF00002553	Upregulation of long non-coding RNA XIST has anticancer effects on epithelial ovarian cancer cells through inverse downregulation of hsa-miR-214-3p. J Gynecol Oncol. 2018 Nov;29(6):e99. doi: 10.3802/jgo.2018.29.e99.
REF00002554	Exosome-derived miRNAs as predictive biomarkers for diffuse large B-cell lymphoma chemotherapy resistance. Epigenomics. 2019 Jan;11(1):35-51. doi: 10.2217/epi-2018-0123. Epub 2018 Sep 13.
REF00002555	The long noncoding RNA HIF1A-AS2 facilitates cisplatin resistance in bladder cancer. J Cell Biochem. 2019 Jan;120(1):243-252. doi: 10.1002/jcb.27327. Epub 2018 Sep 14.
REF00002556	MicroRNA-7-5p Promotes Cisplatin Resistance of Cervical Cancer Cells and Modulation of Cellular Energy Homeostasis by Regulating the Expression of the PARP-1 and BCL2 Genes. Med Sci Monit. 2018 Sep 16;24:6506-6516. doi: 10.12659/MSM.910969.
REF00002557	Suppression of long noncoding RNA NCK1-AS1 increases chemosensitivity to cisplatin in cervical cancer. J Cell Physiol. 2019 Apr;234(4):4302-4313. doi: 10.1002/jcp.27198. Epub 2018 Sep 17.
REF00002558	miR 501 3p sensitizes glioma cells to cisplatin by targeting MYCN. Mol Med Rep. 2018 Nov;18(5):4747-4752. doi: 10.3892/mmr.2018.9458. Epub 2018 Sep 5.
REF00002559	miRNA 328 overexpression confers cisplatin resistance in non small cell lung cancer via targeting of PTEN. Mol Med Rep. 2018 Nov;18(5):4563-4570. doi: 10.3892/mmr.2018.9478. Epub 2018 Sep 12.
REF00002560	"Long non-coding RNAs in esophageal cancer: molecular mechanisms, functions, and potential applications. J Hematol Oncol. 2018 Sep 17;11(1):118. doi: 10.1186/s13045-018-0663-8."
REF00002561	CircBA9.3 supports the survival of leukaemic cells by up-regulating c-ABL1 or BCR-ABL1 protein levels. Blood Cells Mol Dis. 2018 Nov;73:38-44. doi: 10.1016/j.bcmd.2018.09.002. Epub 2018 Sep 14.
REF00002562	Long noncoding RNA LINC00261 induces chemosensitization to 5-fluorouracil by mediating methylation-dependent repression of DPYD in human esophageal cancer. FASEB J. 2019 Feb;33(2):1972-1988. doi: 10.1096/fj.201800759R. Epub 2018 Sep 18.
REF00002563	MicroRNA-19b Promotes Nasopharyngeal Carcinoma More Sensitive to Cisplatin by Suppressing KRAS. Technol Cancer Res Treat. 2018 Jan 1;17:1533033818793652. doi: 10.1177/1533033818793652.
REF00002564	Nucleotide sequence of the AAD(2'') aminoglycoside adenylyltransferase determinant aadB. Evolutionary relationship of this region with those surrounding aadA in R538-1 and dhfrII in R388. Nucleic Acids Res. 1986 Nov 11;14(21):8625-35. doi: 10.1093/nar/14.21.8625.
REF00002565	Knockdown of lncRNA H19 restores chemo-sensitivity in paclitaxel-resistant triple-negative breast cancer through triggering apoptosis and regulating Akt signaling pathway. Toxicol Appl Pharmacol. 2018 Nov 15;359:55-61. doi: 10.1016/j.taap.2018.09.018. Epub 2018 Sep 20.
REF00002566	Chemo-resistance of A172 glioblastoma cells is controlled by miR-1271-regulated Bcl-2. Biomed Pharmacother. 2018 Dec;108:734-740. doi: 10.1016/j.biopha.2018.08.102. Epub 2018 Sep 21.
REF00002567	"Cloning and analysis of ermG, a new macrolide-lincosamide-streptogramin B resistance element from Bacillus sphaericus. J Bacteriol. 1987 Jan;169(1):340-50. doi: 10.1128/jb.169.1.340-350.1987."
REF00002568	miR-378a-3p sensitizes ovarian cancer cells to cisplatin through targeting MAPK1/GRB2. Biomed Pharmacother. 2018 Nov;107:1410-1417. doi: 10.1016/j.biopha.2018.08.132. Epub 2018 Aug 31.
REF00002569	MiR-1284 enhances sensitivity of cervical cancer cells to cisplatin via downregulating HMGB1. Biomed Pharmacother. 2018 Nov;107:997-1003. doi: 10.1016/j.biopha.2018.08.059. Epub 2018 Aug 23.
REF00002570	miR-381 induces sensitivity of breast cancer cells to doxorubicin by inactivation of MAPK signaling via FYN. Eur J Pharmacol. 2018 Nov 15;839:66-75. doi: 10.1016/j.ejphar.2018.09.024. Epub 2018 Sep 26.
REF00002571	Long non-coding RNA CUDR promotes malignant phenotypes in pancreatic ductal adenocarcinoma via activating AKT and ERK signaling pathways. Int J Oncol. 2018 Dec;53(6):2671-2682. doi: 10.3892/ijo.2018.4574. Epub 2018 Sep 27.
REF00002572	Downregulation of miR 200c 3p contributes to the resistance of breast cancer cells to paclitaxel by targeting SOX2. Oncol Rep. 2018 Dec;40(6):3821-3829. doi: 10.3892/or.2018.6735. Epub 2018 Sep 26.
REF00002573	MicroRNA-195 reverses the resistance to temozolomide through targeting cyclin E1 in glioma cells. Anticancer Drugs. 2019 Jan;30(1):81-88. doi: 10.1097/CAD.0000000000000700.
REF00002574	miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22. Cell Physiol Biochem. 2018;50(1):136-149. doi: 10.1159/000493964. Epub 2018 Oct 2.
REF00002575	ANRIL promotes chemoresistance via disturbing expression of ABCC1 by regulating the expression of Let-7a in colorectal cancer. Biosci Rep. 2018 Nov 20;38(6):BSR20180620. doi: 10.1042/BSR20180620. Print 2018 Dec 21.
REF00002576	MicroRNA-34a Attenuates Paclitaxel Resistance in Prostate Cancer Cells via Direct Suppression of JAG1/Notch1 Axis. Cell Physiol Biochem. 2018;50(1):261-276. doi: 10.1159/000494004. Epub 2018 Oct 3.
REF00002577	LGR5 acts as a target of miR-340-5p in the suppression of cell progression and drug resistance in breast cancer via Wnt/Beta-catenin pathway. Gene. 2019 Jan 30;683:47-53. doi: 10.1016/j.gene.2018.10.014. Epub 2018 Oct 6.
REF00002578	In silico modeling of Plasmodium falciparum chloroquine resistance transporter protein and biochemical studies suggest its key contribution to chloroquine resistance. Acta Trop. 2019 Jan;189:84-93. doi: 10.1016/j.actatropica.2018.10.001. Epub 2018 Oct 9.
REF00002579	miR-874 regulates multiple-drug resistance in gastric cancer by targeting ATG16L1. Int J Oncol. 2018 Dec;53(6):2769-2779. doi: 10.3892/ijo.2018.4593. Epub 2018 Oct 11.
REF00002580	Gemcitabine exhibits a suppressive effect on pancreatic cancer cell growth by regulating processing of PVT1 to miR1207. Mol Oncol. 2018 Dec;12(12):2147-2164. doi: 10.1002/1878-0261.12393. Epub 2018 Oct 30.
REF00002581	Inhibitory Effects of Commonly Used Excipients on P-Glycoprotein in Vitro. Mol Pharm. 2018 Nov 5;15(11):4835-4842. doi: 10.1021/acs.molpharmaceut.8b00482. Epub 2018 Oct 23.
REF00002582	Growth arrest-specific 5 attenuates cisplatin-induced apoptosis in cervical cancer by regulating STAT3 signaling via miR-21. J Cell Physiol. 2019 Jun;234(6):9605-9615. doi: 10.1002/jcp.27647. Epub 2018 Oct 23.
REF00002583	Paclitaxel resistant gastric cancer MGC 803 cells promote epithelial to mesenchymal transition and chemoresistance in paclitaxel sensitive cells via exosomal delivery of miR 155 5p. Int J Oncol. 2019 Jan;54(1):326-338. doi: 10.3892/ijo.2018.4601. Epub 2018 Oct 22.
REF00002584	miR-186 reverses cisplatin resistance and inhibits the formation of the glioblastoma-initiating cell phenotype by degrading Yin Yang 1 in glioblastoma. Int J Mol Med. 2019 Jan;43(1):517-524. doi: 10.3892/ijmm.2018.3940. Epub 2018 Oct 18.
REF00002585	LncRNA MALAT1 potentiates autophagy associated cisplatin resistance by regulating the microRNA 30b/autophagy related gene 5 axis in gastric cancer. Int J Oncol. 2019 Jan;54(1):239-248. doi: 10.3892/ijo.2018.4609. Epub 2018 Oct 26.
REF00002586	LncRNA MALAT1 promotes cell proliferation and imatinib resistance by sponging miR-328 in chronic myelogenous leukemia. Biochem Biophys Res Commun. 2018 Dec 9;507(1-4):1-8. doi: 10.1016/j.bbrc.2018.09.034. Epub 2018 Oct 23.
REF00002587	Down-regulation of CASC2 contributes to cisplatin resistance in gastric cancer by sponging miR-19a. Biomed Pharmacother. 2018 Dec;108:1775-1782. doi: 10.1016/j.biopha.2018.09.181. Epub 2018 Oct 16.
REF00002588	Predictive role of UCA1-containing exosomes in cetuximab-resistant colorectal cancer. Cancer Cell Int. 2018 Oct 22;18:164. doi: 10.1186/s12935-018-0660-6. eCollection 2018.
REF00002589	MicroRNA-22 Suppresses Breast Cancer Cell Growth and Increases Paclitaxel Sensitivity by Targeting NRAS. Technol Cancer Res Treat. 2018 Jan 1;17:1533033818809997. doi: 10.1177/1533033818809997.
REF00002590	LncRNA BLACAT1 is involved in chemoresistance of non small cell lung cancer cells by regulating autophagy. Int J Oncol. 2019 Jan;54(1):339-347. doi: 10.3892/ijo.2018.4614. Epub 2018 Oct 31.
REF00002591	miR 34a regulates the chemosensitivity of retinoblastoma cells via modulation of MAGE A/p53 signaling. Int J Oncol. 2019 Jan;54(1):177-187. doi: 10.3892/ijo.2018.4613. Epub 2018 Oct 31.
REF00002592	lncRNA GAS5 Reverses EMT and Tumor Stem Cell-Mediated Gemcitabine Resistance and Metastasis by Targeting miR-221/SOCS3 in Pancreatic Cancer. Mol Ther Nucleic Acids. 2018 Dec 7;13:472-482. doi: 10.1016/j.omtn.2018.09.026. Epub 2018 Oct 6.
REF00002593	lncARSR promotes liver cancer stem cells expansion via STAT3 pathway. Gene. 2019 Mar 1;687:73-81. doi: 10.1016/j.gene.2018.10.087. Epub 2018 Oct 31.
REF00002594	CircPAN3 mediates drug resistance in acute myeloid leukemia through the miR-153-5p/miR-183-5p-XIAP axis. Exp Hematol. 2019 Feb;70:42-54.e3. doi: 10.1016/j.exphem.2018.10.011. Epub 2018 Nov 3.
REF00002595	MicroRNA-107 Targets IKBKG and Sensitizes A549 Cells to Parthenolide. Anticancer Res. 2018 Nov;38(11):6309-6316. doi: 10.21873/anticanres.12987.
REF00002596	Up-regulation of miR-383-5p suppresses proliferation and enhances chemosensitivity in ovarian cancer cells by targeting TRIM27. Biomed Pharmacother. 2019 Jan;109:595-601. doi: 10.1016/j.biopha.2018.10.148. Epub 2018 Nov 3.
REF00002597	miR-509-3p enhances platinum drug sensitivity in ovarian cancer. Gene. 2019 Feb 20;686:63-67. doi: 10.1016/j.gene.2018.11.011. Epub 2018 Nov 5.
REF00002598	MiRNA-27a sensitizes breast cancer cells to treatment with Selective Estrogen Receptor Modulators. Breast. 2019 Feb;43:31-38. doi: 10.1016/j.breast.2018.10.007. Epub 2018 Oct 18.
REF00002599	Long non-coding RNA H19 promotes TDRG1 expression and cisplatin resistance by sequestering miRNA-106b-5p in seminoma. Cancer Med. 2018 Dec;7(12):6247-6257. doi: 10.1002/cam4.1871. Epub 2018 Nov 14.
REF00002600	Overexpression of lncRNA EGFR AS1 is associated with a poor prognosis and promotes chemotherapy resistance in non small cell lung cancer. Int J Oncol. 2019 Jan;54(1):295-305. doi: 10.3892/ijo.2018.4629. Epub 2018 Nov 9.
REF00002601	Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun. Cell Physiol Biochem. 2018;51(1):129-141. doi: 10.1159/000495169. Epub 2018 Nov 15.
REF00002602	[Mechanism of miR-221 contributes to gefitinib resistance in PC-9 cells]. Zhonghua Yi Xue Za Zhi. 2018 Nov 13;98(42):3447-3452. doi: 10.3760/cma.j.issn.0376-2491.2018.42.014.
REF00002603	miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1. Cell Biol Int. 2019 Jan;43(1):12-21. doi: 10.1002/cbin.11071.
REF00002604	Investigations on the mechanism of progesterone in inhibiting endometrial cancer cell cycle and viability via regulation of long noncoding RNA NEAT1/microRNA-146b-5p mediated Wnt/Beta-catenin signaling. IUBMB Life. 2019 Feb;71(2):223-234. doi: 10.1002/iub.1959. Epub 2018 Nov 19.
REF00002605	Exosomal transfer of miR-214 mediates gefitinib resistance in non-small cell lung cancer. Biochem Biophys Res Commun. 2018 Dec 9;507(1-4):457-464. doi: 10.1016/j.bbrc.2018.11.061. Epub 2018 Nov 17.
REF00002606	Long non-coding RNA Linc00518 promotes paclitaxel resistance of the human prostate cancer by sequestering miR-216b-5p. Biol Cell. 2019 Feb;111(2):39-50. doi: 10.1111/boc.201800054. Epub 2018 Dec 7.
REF00002607	MicroRNA-98 promotes drug resistance and regulates mitochondrial dynamics by targeting LASS2 in bladder cancer cells. Exp Cell Res. 2018 Dec 15;373(1-2):188-197. doi: 10.1016/j.yexcr.2018.10.013. Epub 2018 Oct 25.
REF00002608	Knockdown of Long Noncoding RNA HOXA-AS2 Suppresses Chemoresistance of Acute Myeloid Leukemia via the miR-520c-3p/S100A4 Axis. Cell Physiol Biochem. 2018;51(2):886-896. doi: 10.1159/000495387. Epub 2018 Nov 22.
REF00002609	miR-181b/Notch2 overcome chemoresistance by regulating cancer stem cell-like properties in NSCLC. Stem Cell Res Ther. 2018 Nov 23;9(1):327. doi: 10.1186/s13287-018-1072-1.
REF00002610	LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis. Cancer Biol Ther. 2019;20(3):261-271. doi: 10.1080/15384047.2018.1529091. Epub 2018 Nov 27.
REF00002611	Long Non-Coding RNA XLOC_006753 Promotes the Development of Multidrug Resistance in Gastric Cancer Cells Through the PI3K/AKT/mTOR Signaling Pathway. Cell Physiol Biochem. 2018;51(3):1221-1236. doi: 10.1159/000495499. Epub 2018 Nov 27.
REF00002612	Nucleotide sequence analysis and overexpression of the gene encoding a type III chloramphenicol acetyltransferase. Biochem J. 1988 May 15;252(1):173-9. doi: 10.1042/bj2520173.
REF00002613	Upregulated microRNA-193a-3p is responsible for cisplatin resistance in CD44(+) gastric cancer cells. Cancer Sci. 2019 Feb;110(2):662-673. doi: 10.1111/cas.13894. Epub 2018 Dec 26.
REF00002614	Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells. Cell Physiol Biochem. 2018;51(4):1518-1532. doi: 10.1159/000495643. Epub 2018 Nov 29.
REF00002615	Mapping and sequencing of mutations in the Escherichia coli rpoB gene that lead to rifampicin resistance. J Mol Biol. 1988 Jul 5;202(1):45-58. doi: 10.1016/0022-2836(88)90517-7.
REF00002616	"Circular RNA hsa_circ_0004015 regulates the proliferation, invasion, and TKI drug resistance of non-small cell lung cancer by miR-1183/PDPK1 signaling pathway. Biochem Biophys Res Commun. 2019 Jan 8;508(2):527-535. doi: 10.1016/j.bbrc.2018.11.157. Epub 2018 Nov 30."
REF00002617	Complex role of miR-130a-3p and miR-148a-3p balance on drug resistance and tumor biology in esophageal squamous cell carcinoma. Sci Rep. 2018 Dec 3;8(1):17553. doi: 10.1038/s41598-018-35799-1.
REF00002618	miR-29 Family Inhibits Resistance to Methotrexate and Promotes Cell Apoptosis by Targeting COL3A1 and MCL1 in Osteosarcoma. Med Sci Monit. 2018 Dec 6;24:8812-8821. doi: 10.12659/MSM.911972.
REF00002619	Long noncoding RNA H19 mediated the chemosensitivity of breast cancer cells via Wnt pathway and EMT process. Onco Targets Ther. 2018 Nov 9;11:8001-8012. doi: 10.2147/OTT.S172379. eCollection 2018.
REF00002620	LINC01118 Modulates Paclitaxel Resistance of Epithelial Ovarian Cancer by Regulating miR-134/ABCC1. Med Sci Monit. 2018 Dec 6;24:8831-8839. doi: 10.12659/MSM.910932.
REF00002621	miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway. Cell Physiol Biochem. 2018;51(5):2160-2171. doi: 10.1159/000495835. Epub 2018 Dec 6.
REF00002622	miR-122 Targets X-Linked Inhibitor of Apoptosis Protein to Sensitize Oxaliplatin-Resistant Colorectal Cancer Cells to Oxaliplatin-Mediated Cytotoxicity. Cell Physiol Biochem. 2018;51(5):2148-2159. doi: 10.1159/000495832. Epub 2018 Dec 6.
REF00002623	MicroRNA 29a enhances cisplatin sensitivity in non small cell lung cancer through the regulation of REV3L. Mol Med Rep. 2019 Feb;19(2):831-840. doi: 10.3892/mmr.2018.9723. Epub 2018 Dec 4.
REF00002624	MicroRNA-497 inhibits multiple myeloma growth and increases susceptibility to bortezomib by targeting Bcl-2. Int J Mol Med. 2019 Feb;43(2):1058-1066. doi: 10.3892/ijmm.2018.4019. Epub 2018 Dec 7.
REF00002625	"miR 138 5p modulates the expression of excision repair cross complementing proteins ERCC1 and ERCC4, and regulates the sensitivity of gastric cancer cells to cisplatin. Oncol Rep. 2019 Feb;41(2):1131-1139. doi: 10.3892/or.2018.6907. Epub 2018 Dec 6."
REF00002626	MicroRNA 506 3p reverses gefitinib resistance in non small cell lung cancer by targeting Yes associated protein 1. Mol Med Rep. 2019 Feb;19(2):1331-1339. doi: 10.3892/mmr.2018.9710. Epub 2018 Nov 29.
REF00002627	The microRNA miR-181c enhances chemosensitivity and reduces chemoresistance in breast cancer cells via down-regulating osteopontin. Int J Biol Macromol. 2019 Mar 15;125:544-556. doi: 10.1016/j.ijbiomac.2018.12.075. Epub 2018 Dec 8.
REF00002628	miR-494 Sensitizes Gastric Cancer Cells to TRAIL Treatment Through Downregulation of Survivin. Cell Physiol Biochem. 2018;51(5):2212-2223. doi: 10.1159/000495867. Epub 2018 Dec 7.
REF00002629	miR-122 enhances sensitivity of hepatocellular carcinoma to oxaliplatin via inhibiting MDR1 by targeting Wnt/Beta-catenin pathway. Exp Mol Pathol. 2019 Feb;106:34-43. doi: 10.1016/j.yexmp.2018.10.009. Epub 2018 Oct 26.
REF00002630	miR 144 3p regulates the resistance of lung cancer to cisplatin by targeting Nrf2. Oncol Rep. 2018 Dec;40(6):3479-3488. doi: 10.3892/or.2018.6772. Epub 2018 Oct 8.
REF00002631	Tumor released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non small cell lung cancer. Oncol Rep. 2018 Dec;40(6):3438-3446. doi: 10.3892/or.2018.6762. Epub 2018 Oct 3.
REF00002632	Long noncoding RNA OIP5-AS1 causes cisplatin resistance in osteosarcoma through inducing the LPAATBeta/PI3K/AKT/mTOR signaling pathway by sponging the miR-340-5p. J Cell Biochem. 2019 Jun;120(6):9656-9666. doi: 10.1002/jcb.28244. Epub 2018 Dec 11.
REF00002633	TCF7L2 activated HOXA-AS2 decreased the glucocorticoid sensitivity in acute lymphoblastic leukemia through regulating HOXA3/EGFR/Ras/Raf/MEK/ERK pathway. Biomed Pharmacother. 2019 Jan;109:1640-1649. doi: 10.1016/j.biopha.2018.10.046. Epub 2018 Nov 16.
REF00002634	TUG1 confers Adriamycin resistance in acute myeloid leukemia by epigenetically suppressing miR-34a expression via EZH2. Biomed Pharmacother. 2019 Jan;109:1793-1801. doi: 10.1016/j.biopha.2018.11.003. Epub 2018 Nov 26.
REF00002635	MiR-181b-5p modulates chemosensitivity of glioma cells to temozolomide by targeting Bcl-2. Biomed Pharmacother. 2019 Jan;109:2192-2202. doi: 10.1016/j.biopha.2018.11.074. Epub 2018 Nov 27.
REF00002636	MiR-148a suppressed cell invasion and migration via targeting WNT10b and modulating Beta-catenin signaling in cisplatin-resistant colorectal cancer cells. Biomed Pharmacother. 2019 Jan;109:902-909. doi: 10.1016/j.biopha.2018.10.080. Epub 2018 Nov 5.
REF00002637	PIWI-interacting RNA-54265 is oncogenic and a potential therapeutic target in colorectal adenocarcinoma. Theranostics. 2018 Oct 6;8(19):5213-5230. doi: 10.7150/thno.28001. eCollection 2018.
REF00002638	MEG3 affects the progression and chemoresistance of T-cell lymphoblastic lymphoma by suppressing epithelial-mesenchymal transition via the PI3K/mTOR pathway. J Cell Biochem. 2018 Dec 16. doi: 10.1002/jcb.28093. Online ahead of print.
REF00002639	Linc00161 regulated the drug resistance of ovarian cancer by sponging microRNA-128 and modulating MAPK1. Mol Carcinog. 2019 Apr;58(4):577-587. doi: 10.1002/mc.22952. Epub 2019 Jan 22.
REF00002640	"miRNA-106a Promotes Breast Cancer Cell Proliferation, Clonogenicity, Migration, and Invasion Through Inhibiting Apoptosis and Chemosensitivity. DNA Cell Biol. 2019 Feb;38(2):198-207. doi: 10.1089/dna.2018.4282. Epub 2018 Dec 20."
REF00002641	MiR-7-5p suppresses stemness and enhances temozolomide sensitivity of drug-resistant glioblastoma cells by targeting Yin Yang 1. Exp Cell Res. 2019 Feb 1;375(1):73-81. doi: 10.1016/j.yexcr.2018.12.016. Epub 2018 Dec 23.
REF00002642	H3K27me3 induces multidrug resistance in small cell lung cancer by affecting HOXA1 DNA methylation via regulation of the lncRNA HOTAIR. Ann Transl Med. 2018 Nov;6(22):440. doi: 10.21037/atm.2018.10.21.
REF00002643	Long Noncoding RNA LINC00460 Promotes the Gefitinib Resistance of Nonsmall Cell Lung Cancer Through Epidermal Growth Factor Receptor by Sponging miR-769-5p. DNA Cell Biol. 2019 Feb;38(2):176-183. doi: 10.1089/dna.2018.4462. Epub 2019 Jan 2.
REF00002644	Targeting EphA2 with miR-124 mediates Erlotinib resistance in K-RAS mutated pancreatic cancer. J Pharm Pharmacol. 2019 Feb;71(2):196-205. doi: 10.1111/jphp.12941. Epub 2019 Jan 2.
REF00002645	Effects of long noncoding RNA (linc-VLDLR) existing in extracellular vesicles on the occurrence and multidrug resistance of esophageal cancer cells. Pathol Res Pract. 2019 Mar;215(3):470-477. doi: 10.1016/j.prp.2018.12.033. Epub 2018 Dec 31.
REF00002646	Downregulation of miR-196b Promotes Glioma Cell Sensitivity to Temozolomide Chemotherapy and Radiotherapy. Ann Clin Lab Sci. 2018 Nov;48(6):719-725.
REF00002647	Activation of LncRNA TINCR by H3K27 acetylation promotes Trastuzumab resistance and epithelial-mesenchymal transition by targeting MicroRNA-125b in breast Cancer. Mol Cancer. 2019 Jan 8;18(1):3. doi: 10.1186/s12943-018-0931-9.
REF00002648	Foxo3a-dependent miR-633 regulates chemotherapeutic sensitivity in gastric cancer by targeting Fas-associated death domain. RNA Biol. 2019 Feb;16(2):233-248. doi: 10.1080/15476286.2019.1565665. Epub 2019 Jan 22.
REF00002649	Long non coding RNA UCA1 confers tamoxifen resistance in breast cancer endocrinotherapy through regulation of the EZH2/p21 axis and the PI3K/AKT signaling pathway. Int J Oncol. 2019 Mar;54(3):1033-1042. doi: 10.3892/ijo.2019.4679. Epub 2019 Jan 8.
REF00002650	MicroRNA-200b and -301 are associated with gemcitabine response as biomarkers in pancreatic carcinoma cells. Int J Oncol. 2019 Mar;54(3):991-1000. doi: 10.3892/ijo.2019.4676. Epub 2019 Jan 7.
REF00002651	"Ginsenoside Rg3 inhibits cell growth, migration and invasion in Caco-2 cells by downregulation of lncRNA CCAT1. Exp Mol Pathol. 2019 Feb;106:131-138. doi: 10.1016/j.yexmp.2019.01.003. Epub 2019 Jan 8."
REF00002652	PIWI-interacting RNA-36712 restrains breast cancer progression and chemoresistance by interaction with SEPW1 pseudogene SEPW1P RNA. Mol Cancer. 2019 Jan 12;18(1):9. doi: 10.1186/s12943-019-0940-3.
REF00002653	Long non-coding RNA FAM84B-AS promotes resistance of gastric cancer to platinum drugs through inhibition of FAM84B expression. Biochem Biophys Res Commun. 2019 Feb 12;509(3):753-762. doi: 10.1016/j.bbrc.2018.12.177. Epub 2019 Jan 9.
REF00002654	miR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes. Biochem Pharmacol. 2019 Mar;161:98-112. doi: 10.1016/j.bcp.2019.01.009. Epub 2019 Jan 11.
REF00002655	Exosomal miR-196a derived from cancer-associated fibroblasts confers cisplatin resistance in head and neck cancer through targeting CDKN1B and ING5. Genome Biol. 2019 Jan 14;20(1):12. doi: 10.1186/s13059-018-1604-0.
REF00002656	Silence of  lncRNA UCA1 rescues drug resistance of cisplatin to non-small-cell lung cancer cells. J Cell Biochem. 2019 Jun;120(6):9243-9249. doi: 10.1002/jcb.28200. Epub 2019 Jan 16.
REF00002657	miR-1207-5p regulates the sensitivity of triple-negative breast cancer cells to Taxol treatment via the suppression of LZTS1 expression. Oncol Lett. 2019 Jan;17(1):990-998. doi: 10.3892/ol.2018.9687. Epub 2018 Nov 12.
REF00002658	MicroRNA-206 facilitates gastric cancer cell apoptosis and suppresses cisplatin resistance by targeting MAPK2 signaling pathway. Eur Rev Med Pharmacol Sci. 2019 Jan;23(1):171-180. doi: 10.26355/eurrev_201901_16761.
REF00002659	Investigation of the potential theranostic role of KDM5B/miR-29c signaling axis in paclitaxel resistant endometrial carcinoma. Gene. 2019 Apr 30;694:76-82. doi: 10.1016/j.gene.2018.12.076. Epub 2019 Jan 16.
REF00002660	lncRNAPVT1 targets miR-152 to enhance chemoresistance of osteosarcoma to gemcitabine through activating c-MET/PI3K/AKT pathway. Pathol Res Pract. 2019 Mar;215(3):555-563. doi: 10.1016/j.prp.2018.12.013. Epub 2018 Dec 12.
REF00002661	miR-135b-5p enhances doxorubicin-sensitivity of breast cancer cells through targeting anterior gradient 2. J Exp Clin Cancer Res. 2019 Jan 21;38(1):26. doi: 10.1186/s13046-019-1024-3.
REF00002662	Long noncoding RNA UCA1 targets miR-582-5p and contributes to the progression and drug resistance of bladder cancer cells through ATG7-mediated autophagy inhibition. Onco Targets Ther. 2019 Jan 9;12:495-508. doi: 10.2147/OTT.S183940. eCollection 2019.
REF00002663	"Resveratrol mediated cancer cell apoptosis, and modulation of multidrug resistance proteins and metabolic enzymes. Phytomedicine. 2019 Mar 1;55:269-281. doi: 10.1016/j.phymed.2018.06.046. Epub 2018 Jun 28."
REF00002664	MicroRNA 494 increases chemosensitivity to doxorubicin in gastric cancer cells by targeting phosphodiesterases 4D. Cell Mol Biol (Noisy-le-grand). 2018 Dec 31;64(15):62-66.
REF00002665	miR-200b and miR-200c co-contribute to the cisplatin sensitivity of ovarian cancer cells by targeting DNA methyltransferases. Oncol Lett. 2019 Feb;17(2):1453-1460. doi: 10.3892/ol.2018.9745. Epub 2018 Nov 22.
REF00002666	Long non-coding RNA highly up-regulated in liver cancer promotes epithelial-to-mesenchymal transition process in oral squamous cell carcinoma. J Cell Mol Med. 2019 Apr;23(4):2645-2655. doi: 10.1111/jcmm.14160. Epub 2019 Jan 24.
REF00002667	"MicroRNA-31 triggers G(2)/M cell cycle arrest, enhances the chemosensitivity and inhibits migration and invasion of human gastric cancer cells by downregulating the expression of zeste homolog 2 (ZH2). Arch Biochem Biophys. 2019 Mar 15;663:269-275. doi: 10.1016/j.abb.2019.01.023. Epub 2019 Jan 21."
REF00002668	Berberine Promotes Apoptosis of Colorectal Cancer via Regulation of the Long Non-Coding RNA (lncRNA) Cancer Susceptibility Candidate 2 (CASC2)/AU-Binding Factor 1 (AUF1)/B-Cell CLL/Lymphoma 2 (Bcl-2) Axis. Med Sci Monit. 2019 Jan 25;25:730-738. doi: 10.12659/MSM.912082.
REF00002669	Induction of miR-31 causes increased sensitivity to 5-FU and decreased migration and cell invasion in gastric adenocarcinoma. Bratisl Lek Listy. 2019;120(1):35-39. doi: 10.4149/BLL_2019_005.
REF00002670	MiR-122 Targets SerpinB3 and Is Involved in Sorafenib Resistance in Hepatocellular Carcinoma. J Clin Med. 2019 Feb 1;8(2):171. doi: 10.3390/jcm8020171.
REF00002671	Long non coding RNA linc00239 promotes malignant behaviors and chemoresistance against doxorubicin partially via activation of the PI3K/Akt/mTOR pathway in acute myeloid leukaemia cells. Oncol Rep. 2019 Apr;41(4):2311-2320. doi: 10.3892/or.2019.6991. Epub 2019 Jan 31.
REF00002672	Long non-coding RNA LINC00346 promotes pancreatic cancer growth and gemcitabine resistance by sponging miR-188-3p to derepress BRD4 expression. J Exp Clin Cancer Res. 2019 Feb 6;38(1):60. doi: 10.1186/s13046-019-1055-9.
REF00002673	LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p. Cell Death Dis. 2019 Feb 6;10(2):106. doi: 10.1038/s41419-018-1219-0.
REF00002674	MSC-regulated lncRNA MACC1-AS1 promotes stemness and chemoresistance through fatty acid oxidation in gastric cancer. Oncogene. 2019 Jun;38(23):4637-4654. doi: 10.1038/s41388-019-0747-0. Epub 2019 Feb 11.
REF00002675	miR-9 Enhances the Chemosensitivity of AML Cells to Daunorubicin by Targeting the EIF5A2/MCL-1 Axis. Int J Biol Sci. 2019 Jan 1;15(3):579-586. doi: 10.7150/ijbs.29775. eCollection 2019.
REF00002676	Macrophages derived exosomes deliver miR-223 to epithelial ovarian cancer cells to elicit a chemoresistant phenotype. J Exp Clin Cancer Res. 2019 Feb 15;38(1):81. doi: 10.1186/s13046-019-1095-1.
REF00002677	MiR-30a regulates cancer cell response to chemotherapy through SNAI1/IRS1/AKT pathway. Cell Death Dis. 2019 Feb 15;10(3):153. doi: 10.1038/s41419-019-1326-6.
REF00002678	Downregulation of miR-194-5p induces paclitaxel resistance in ovarian cancer cells by altering MDM2 expression. Oncotarget. 2019 Jan 18;10(6):673-683. doi: 10.18632/oncotarget.26586. eCollection 2019 Jan 18.
REF00002679	Effect of lncRNA ANRIL knockdown on proliferation and cisplatin chemoresistance of osteosarcoma cells in vitro. Pathol Res Pract. 2019 May;215(5):931-938. doi: 10.1016/j.prp.2019.01.042. Epub 2019 Jan 30.
REF00002680	MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy. Biosci Rep. 2019 May 7;39(5):BSR20181374. doi: 10.1042/BSR20181374. Print 2019 May 31.
REF00002681	MiR-34b-3p Represses the Multidrug-Chemoresistance of Bladder Cancer Cells by Regulating the CCND2 and P2RY1 Genes. Med Sci Monit. 2019 Feb 19;25:1323-1335. doi: 10.12659/MSM.913746.
REF00002682	miR-29c regulates resistance to paclitaxel in nasopharyngeal cancer by targeting ITGB1. Exp Cell Res. 2019 May 1;378(1):1-10. doi: 10.1016/j.yexcr.2019.02.012. Epub 2019 Feb 16.
REF00002683	NEAT1 mediates paclitaxel-resistance of non-small cell of lung cancer through activation of Akt/mTOR signalling pathway. J Drug Target. 2019 Dec;27(10):1061-1067. doi: 10.1080/1061186X.2019.1585437. Epub 2019 Mar 20.
REF00002684	"A novel miR-365-3p/EHF/keratin 16 axis promotes oral squamous cell carcinoma metastasis, cancer stemness and drug resistance via enhancing Beta5-integrin/c-met signaling pathway. J Exp Clin Cancer Res. 2019 Feb 19;38(1):89. doi: 10.1186/s13046-019-1091-5."
REF00002685	"Knockdown of lncRNA HOXD-AS1 suppresses proliferation, migration and invasion and enhances cisplatin sensitivity of glioma cells by sponging miR-204. Biomed Pharmacother. 2019 Apr;112:108633. doi: 10.1016/j.biopha.2019.108633. Epub 2019 Feb 20."
REF00002686	Gemcitabine enhances OSI-027 cytotoxicity by upregulation of miR-663a in pancreatic ductal adenocarcinoma cells. Am J Transl Res. 2019 Jan 15;11(1):473-485. eCollection 2019.
REF00002687	"Genetic, Biochemical, and Structural Characterization of CMY-136 Beta-Lactamase, a Peculiar CMY-2 Variant. ACS Infect Dis. 2019 Apr 12;5(4):528-538. doi: 10.1021/acsinfecdis.8b00240. Epub 2019 Mar 7."
REF00002688	"Identification of a novel metallo-Beta-lactamase, CAM-1, in clinical Pseudomonas aeruginosa isolates from Canada. J Antimicrob Chemother. 2019 Jun 1;74(6):1563-1567. doi: 10.1093/jac/dkz066."
REF00002689	Long non-coding RNA LINC00968 attenuates drug resistance of breast cancer cells through inhibiting the Wnt2/Beta-catenin signaling pathway by regulating WNT2. J Exp Clin Cancer Res. 2019 Feb 21;38(1):94. doi: 10.1186/s13046-019-1100-8.
REF00002690	miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC. Biochem Biophys Res Commun. 2019 Apr 2;511(2):260-265. doi: 10.1016/j.bbrc.2019.02.016. Epub 2019 Feb 18.
REF00002691	Long noncoding RNA GIHCG induces cancer progression and chemoresistance and indicates poor prognosis in colorectal cancer. Onco Targets Ther. 2019 Feb 7;12:1059-1070. doi: 10.2147/OTT.S192290. eCollection 2019.
REF00002692	MicroRNA-383 inhibits doxorubicin resistance in hepatocellular carcinoma by targeting eukaryotic translation initiation factor 5A2. J Cell Mol Med. 2019 Nov;23(11):7190-7199. doi: 10.1111/jcmm.14197. Epub 2019 Feb 23.
REF00002693	microRNA-1236-3p Regulates DDP Resistance in Lung Cancer Cells. Open Med (Wars). 2019 Jan 16;14:41-51. doi: 10.1515/med-2019-0007. eCollection 2018.
REF00002694	Dual-Targeting of miR-124-3p and ABCC4 Promotes Sensitivity to Adriamycin in Breast Cancer Cells. Genet Test Mol Biomarkers. 2019 Mar;23(3):156-165. doi: 10.1089/gtmb.2018.0259. Epub 2019 Feb 26.
REF00002695	Methylation-Mediated Silencing of MicroRNA-211 Decreases the Sensitivity of Melanoma Cells to Cisplatin. Med Sci Monit. 2019 Mar 1;25:1590-1599. doi: 10.12659/MSM.911862.
REF00002696	Downregulated lncRNA ADAMTS9-AS2 in breast cancer enhances tamoxifen resistance by activating microRNA-130a-5p. Eur Rev Med Pharmacol Sci. 2019 Feb;23(4):1563-1573. doi: 10.26355/eurrev_201902_17115.
REF00002697	LncRNA MALAT1 Depressed Chemo-Sensitivity of NSCLC Cells through Directly Functioning on miR-197-3p/p120 Catenin Axis. Mol Cells. 2019 Mar 31;42(3):270-283. doi: 10.14348/molcells.2019.2364. Epub 2019 Feb 19.
REF00002698	Down-regulation of miR-543 expression increases the sensitivity of colorectal cancer cells to 5-Fluorouracil through the PTEN/PI3K/AKT pathway. Biosci Rep. 2019 Mar 22;39(3):BSR20190249. doi: 10.1042/BSR20190249. Print 2019 Mar 29.
REF00002699	MiR-876-3p regulates cisplatin resistance and stem cell-like properties of gastric cancer cells by targeting TMED3. J Gastroenterol Hepatol. 2019 Oct;34(10):1711-1719. doi: 10.1111/jgh.14649. Epub 2019 Apr 2.
REF00002700	Solamargine inhibits gastric cancer progression by regulating the expression of lncNEAT1_2 via the MAPK signaling pathway. Int J Oncol. 2019 May;54(5):1545-1554. doi: 10.3892/ijo.2019.4744. Epub 2019 Mar 12.
REF00002701	MiR-155-3p acts as a tumor suppressor and reverses paclitaxel resistance via negative regulation of MYD88 in human breast cancer. Gene. 2019 Jun 5;700:85-95. doi: 10.1016/j.gene.2019.02.066. Epub 2019 Mar 13.
REF00002702	LINC00665 Induces Acquired Resistance to Gefitinib through Recruiting EZH2 and Activating PI3K/AKT Pathway in NSCLC. Mol Ther Nucleic Acids. 2019 Jun 7;16:155-161. doi: 10.1016/j.omtn.2019.02.010. Epub 2019 Feb 21.
REF00002703	MicroRNA-613 induces the sensitivity of gastric cancer cells to cisplatin through targeting SOX9 expression. Am J Transl Res. 2019 Feb 15;11(2):885-894. eCollection 2019.
REF00002704	miR3609 sensitizes breast cancer cells to adriamycin by blocking the programmed death-ligand 1 immune checkpoint. Exp Cell Res. 2019 Jul 1;380(1):20-28. doi: 10.1016/j.yexcr.2019.03.025. Epub 2019 Mar 20.
REF00002705	Over-expression of miR-206 decreases the Euthyrox-resistance by targeting MAP4K3 in papillary thyroid carcinoma. Biomed Pharmacother. 2019 Jun;114:108605. doi: 10.1016/j.biopha.2019.108605. Epub 2019 Mar 21.
REF00002706	Increased Expression of Exosomal AGAP2-AS1 (AGAP2 Antisense RNA 1) In Breast Cancer Cells Inhibits Trastuzumab-Induced Cell Cytotoxicity. Med Sci Monit. 2019 Mar 26;25:2211-2220. doi: 10.12659/MSM.915419.
REF00002707	MiR-214 sensitizes human colon cancer cells to 5-FU by targeting Hsp27. Cell Mol Biol Lett. 2019 Mar 14;24:22. doi: 10.1186/s11658-019-0143-3. eCollection 2019.
REF00002708	MicroRNA-574-3p regulates epithelial mesenchymal transition and cisplatin resistance via targeting ZEB1 in human gastric carcinoma cells. Gene. 2019 Jun 5;700:110-119. doi: 10.1016/j.gene.2019.03.043. Epub 2019 Mar 24.
REF00002709	microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma. Oncologist. 2019 Jun;24(6):e241-e250. doi: 10.1634/theoncologist.2018-0849. Epub 2019 Mar 27.
REF00002710	Circular RNA AKT3 upregulates PIK3R1 to enhance cisplatin resistance in gastric cancer via miR-198 suppression. Mol Cancer. 2019 Mar 30;18(1):71. doi: 10.1186/s12943-019-0969-3.
REF00002711	Long noncoding RNA NEAT1 suppresses sorafenib sensitivity of hepatocellular carcinoma cells via regulating miR-335-c-Met. J Cell Physiol. 2019 Apr 1. doi: 10.1002/jcp.27567. Online ahead of print.
REF00002712	Long non-coding RNA GBCDRlnc1 induces chemoresistance of gallbladder cancer cells by activating autophagy. Mol Cancer. 2019 Apr 5;18(1):82. doi: 10.1186/s12943-019-1016-0.
REF00002713	miR 210 3p regulates cell growth and affects cisplatin sensitivity in human ovarian cancer cells via targeting E2F3. Mol Med Rep. 2019 Jun;19(6):4946-4954. doi: 10.3892/mmr.2019.10129. Epub 2019 Apr 4.
REF00002714	gyrA and parC mutations in fluoroquinolone-resistant Neisseria gonorrhoeae isolates from Kenya. BMC Microbiol. 2019 Apr 8;19(1):76. doi: 10.1186/s12866-019-1439-1.
REF00002715	MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma. Blood Adv. 2019 Apr 9;3(7):1185-1196. doi: 10.1182/bloodadvances.2018029660.
REF00002716	miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/Beta-catenin signaling via targeting SOX2. Life Sci. 2019 Jun 1;226:98-106. doi: 10.1016/j.lfs.2019.04.023. Epub 2019 Apr 10.
REF00002717	MicroRNA-204 Potentiates the Sensitivity of Acute Myeloid Leukemia Cells to Arsenic Trioxide. Oncol Res. 2019 Sep 23;27(9):1035-1042. doi: 10.3727/096504019X15528367532612. Epub 2019 Apr 8.
REF00002718	Exosomal transfer of long non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastoma. J Exp Clin Cancer Res. 2019 Apr 16;38(1):166. doi: 10.1186/s13046-019-1139-6.
REF00002719	MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9. Biomed Pharmacother. 2019 Jun;114:108662. doi: 10.1016/j.biopha.2019.108662. Epub 2019 Apr 15.
REF00002720	Ai-lncRNA EGOT enhancing autophagy sensitizes paclitaxel cytotoxicity via upregulation of ITPR1 expression by RNA-RNA and RNA-protein interactions in human cancer. Mol Cancer. 2019 Apr 18;18(1):89. doi: 10.1186/s12943-019-1017-z.
REF00002721	Involvement of miR-770-5p in trastuzumab response in HER2 positive breast cancer cells. PLoS One. 2019 Apr 22;14(4):e0215894. doi: 10.1371/journal.pone.0215894. eCollection 2019.
REF00002722	"SNHG15 is a bifunctional MYC-regulated noncoding locus encoding a lncRNA that promotes cell proliferation, invasion and drug resistance in colorectal cancer by interacting with AIF. J Exp Clin Cancer Res. 2019 Apr 24;38(1):172. doi: 10.1186/s13046-019-1169-0."
REF00002723	Hsa_circ_0005379 regulates malignant behavior of oral squamous cell carcinoma through the EGFR pathway. BMC Cancer. 2019 Apr 29;19(1):400. doi: 10.1186/s12885-019-5593-5.
REF00002724	"MicroRNA-27a regulates the proliferation, chemosensitivity and invasion of human ovarian cancer cell lines by targeting Cullin 5. Arch Biochem Biophys. 2019 Jun 15;668:9-15. doi: 10.1016/j.abb.2019.04.009. Epub 2019 Apr 29."
REF00002725	LINC00511 knockdown enhances paclitaxel cytotoxicity in breast cancer via regulating miR-29c/CDK6 axis. Life Sci. 2019 Jul 1;228:135-144. doi: 10.1016/j.lfs.2019.04.063. Epub 2019 May 7.
REF00002726	LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells. J Exp Clin Cancer Res. 2019 May 3;38(1):183. doi: 10.1186/s13046-019-1177-0.
REF00002727	Lnc-TALC promotes O(6)-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun. 2019 May 3;10(1):2045. doi: 10.1038/s41467-019-10025-2.
REF00002728	Nucleotide sequence of the streptothricin acetyltransferase gene from Streptomyces lavendulae and its expression in heterologous hosts. J Bacteriol. 1987 May;169(5):1929-37. doi: 10.1128/jb.169.5.1929-1937.1987.
REF00002729	"Identification of Novel Mobilized Colistin Resistance Gene mcr-9 in a Multidrug-Resistant, Colistin-Susceptible Salmonella enterica Serotype Typhimurium Isolate. mBio. 2019 May 7;10(3):e00853-19. doi: 10.1128/mBio.00853-19."
REF00002730	[Long non-coding RNA XIST modulates cisplatin resistance by altering PDCD4 and Fas-Lexpressions in human nasopharyngeal carcinoma HNE1 cells in vitro]. Nan Fang Yi Ke Da Xue Xue Bao. 2019 Mar 30;39(3):357-363. doi: 10.12122/j.issn.1673-4254.2019.03.15.
REF00002731	Long non-coding RNA TPTEP1 inhibits hepatocellular carcinoma progression by suppressing STAT3 phosphorylation. J Exp Clin Cancer Res. 2019 May 9;38(1):189. doi: 10.1186/s13046-019-1193-0.
REF00002732	miR-613 inhibits liver cancer stem cell expansion by regulating SOX9 pathway. Gene. 2019 Jul 30;707:78-85. doi: 10.1016/j.gene.2019.05.015. Epub 2019 May 7.
REF00002733	miR-1271 enhances the sensitivity of colorectal cancer cells to cisplatin. Exp Ther Med. 2019 Jun;17(6):4363-4370. doi: 10.3892/etm.2019.7501. Epub 2019 Apr 18.
REF00002734	MiR-144 overexpression as a promising therapeutic strategy to overcome glioblastoma cell invasiveness and resistance to chemotherapy. Hum Mol Genet. 2019 Aug 15;28(16):2738-2751. doi: 10.1093/hmg/ddz099.
REF00002735	The microRNA-141-3p/ CDK8 pathway regulates the chemosensitivity of breast cancer cells to trastuzumab. J Cell Biochem. 2019 Aug;120(8):14095-14106. doi: 10.1002/jcb.28685. Epub 2019 May 14.
REF00002736	A panel of serum exosomal microRNAs as predictive markers for chemoresistance in advanced colorectal cancer. Cancer Chemother Pharmacol. 2019 Aug;84(2):315-325. doi: 10.1007/s00280-019-03867-6. Epub 2019 May 14.
REF00002737	First genetic characterisation of multidrug-resistant Mycobacterium tuberculosis isolates from Algeria. J Glob Antimicrob Resist. 2019 Dec;19:301-307. doi: 10.1016/j.jgar.2019.05.010. Epub 2019 May 14.
REF00002738	MiR-374b re-sensitizes hepatocellular carcinoma cells to sorafenib therapy by antagonizing PKM2-mediated glycolysis pathway. Am J Cancer Res. 2019 Apr 1;9(4):765-778. eCollection 2019.
REF00002739	Deregulation of lncRNA-AC078883.3 and microRNA-19a is involved in the development of chemoresistance to cisplatin via modulating signaling pathway of PTEN/AKT. J Cell Physiol. 2019 Dec;234(12):22657-22665. doi: 10.1002/jcp.28832. Epub 2019 May 20.
REF00002740	Matrine induces apoptosis and autophagy of glioma cell line U251 by regulation of circRNA-104075/BCL-9. Chem Biol Interact. 2019 Aug 1;308:198-205. doi: 10.1016/j.cbi.2019.05.030. Epub 2019 May 18.
REF00002741	microRNA-301b-3p downregulation underlies a novel inhibitory role of long non-coding RNA MBNL1-AS1 in non-small cell lung cancer. Stem Cell Res Ther. 2019 May 21;10(1):144. doi: 10.1186/s13287-019-1235-8.
REF00002742	Long noncoding RNA LINC-PINT regulates laryngeal carcinoma cell stemness and chemoresistance through miR-425-5p/PTCH1/SHH axis. J Cell Physiol. 2019 Dec;234(12):23111-23122. doi: 10.1002/jcp.28874. Epub 2019 May 26.
REF00002743	LncRNA MALAT1 Promotes Lung Cancer Proliferation and Gefitinib Resistance by Acting as a miR-200a Sponge. Arch Bronconeumol (Engl Ed). 2019 Dec;55(12):627-633. doi: 10.1016/j.arbres.2019.03.026. Epub 2019 May 24.
REF00002744	Emergence of plasmid-mediated high-level tigecycline resistance genes in animals and humans. Nat Microbiol. 2019 Sep;4(9):1450-1456. doi: 10.1038/s41564-019-0445-2. Epub 2019 May 27.
REF00002745	circRNA_0025202 Regulates Tamoxifen Sensitivity and Tumor Progression via Regulating the miR-182-5p/FOXO3a Axis in Breast Cancer. Mol Ther. 2019 Sep 4;27(9):1638-1652. doi: 10.1016/j.ymthe.2019.05.011. Epub 2019 May 17.
REF00002746	Induced miR-31 by 5-fluorouracil exposure contributes to the resistance in colorectal tumors. Cancer Sci. 2019 Aug;110(8):2540-2548. doi: 10.1111/cas.14090. Epub 2019 Jul 23.
REF00002747	Downregulation of lncRNA CCDC26 contributes to imatinib resistance in human gastrointestinal stromal tumors through IGF-1R upregulation. Braz J Med Biol Res. 2019;52(6):e8399. doi: 10.1590/1414-431x20198399. Epub 2019 Jun 3.
REF00002748	LncRNA SNHG5 promotes cisplatin resistance in gastric cancer via inhibiting cell apoptosis. Eur Rev Med Pharmacol Sci. 2019 May;23(10):4185-4191. doi: 10.26355/eurrev_201905_17921.
REF00002749	"Expression of the macrolide-lincosamide-streptogramin-B-resistance methylase gene, ermE, from Streptomyces erythraeus in Escherichia coli results in N6-monomethylation and N6,N6-dimethylation of ribosomal RNA. Gene. 1987;55(2-3):319-25. doi: 10.1016/0378-1119(87)90291-5."
REF00002750	LINC00511 knockdown prevents cervical cancer cell proliferation and reduces resistance to paclitaxel. J Biosci. 2019 Jun;44(2):44.
REF00002751	Overexpression of CASC11 in ovarian squamous cell carcinoma mediates the development of cancer cell resistance to chemotherapy. Gene. 2019 Aug 20;710:363-366. doi: 10.1016/j.gene.2019.06.011. Epub 2019 Jun 7.
REF00002752	LncRNA LOXL1-AS1/miR-let-7a-5p/EGFR-related pathway regulates the doxorubicin resistance of prostate cancer DU-145 cells. IUBMB Life. 2019 Oct;71(10):1537-1551. doi: 10.1002/iub.2075. Epub 2019 Jun 12.
REF00002753	miR-130b Promotes Sunitinib Resistance through Regulation of PTEN in Renal Cell Carcinoma. Oncology. 2019;97(3):164-172. doi: 10.1159/000500605. Epub 2019 Jun 13.
REF00002754	LncRNA PVT1 Mediates Antiapoptosis and 5-Fluorouracil Resistance via Increasing Bcl2 Expression in Gastric Cancer. J Oncol. 2019 May 8;2019:9325407. doi: 10.1155/2019/9325407. eCollection 2019.
REF00002755	miR-107 Enhances the Sensitivity of Breast Cancer Cells to Paclitaxel. Open Med (Wars). 2019 Jun 1;14:456-466. doi: 10.1515/med-2019-0049. eCollection 2019.
REF00002756	MicroRNA-33b regulates sensitivity to daunorubicin in acute myelocytic leukemia by regulating eukaryotic translation initiation factor 5A-2. J Cell Biochem. 2020 Jan;121(1):385-393. doi: 10.1002/jcb.29192. Epub 2019 Jun 21.
REF00002757	miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A. J Exp Clin Cancer Res. 2019 Jun 21;38(1):272. doi: 10.1186/s13046-019-1238-4.
REF00002758	Hsa_circ_0001946 Inhibits Lung Cancer Progression and Mediates Cisplatin Sensitivity in Non-small Cell Lung Cancer via the Nucleotide Excision Repair Signaling Pathway. Front Oncol. 2019 Jun 12;9:508. doi: 10.3389/fonc.2019.00508. eCollection 2019.
REF00002759	Overexpression of microRNA-620 facilitates the resistance of triple negative breast cancer cells to gemcitabine treatment by targeting DCTD. Exp Ther Med. 2019 Jul;18(1):550-558. doi: 10.3892/etm.2019.7601. Epub 2019 May 23.
REF00002760	Long noncoding RNA UCA1 enhances sensitivity to oncolytic vaccinia virus by sponging miR-18a/miR-182 and modulating the Cdc42/filopodia axis in colorectal cancer. Biochem Biophys Res Commun. 2019 Aug 27;516(3):831-838. doi: 10.1016/j.bbrc.2019.06.125. Epub 2019 Jun 28.
REF00002761	miR 1 reverses multidrug resistance in gastric cancer cells via downregulation of sorcin through promoting the accumulation of intracellular drugs and apoptosis of cells. Int J Oncol. 2019 Aug;55(2):451-461. doi: 10.3892/ijo.2019.4831. Epub 2019 Jun 25.
REF00002762	MicroRNA-222 promotes drug resistance to doxorubicin in breast cancer via regulation of miR-222/bim pathway. Biosci Rep. 2019 Jul 15;39(7):BSR20190650. doi: 10.1042/BSR20190650. Print 2019 Jul 31.
REF00002763	MicroRNA-214 targets PTK6 to inhibit tumorigenic potential and increase drug sensitivity of prostate cancer cells. Sci Rep. 2019 Jul 5;9(1):9776. doi: 10.1038/s41598-019-46170-3.
REF00002764	"MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC, WNT and AKT pathways. Oncogene. 2019 Aug;38(32):6035-6050. doi: 10.1038/s41388-019-0860-0. Epub 2019 Jul 5."
REF00002765	Knockdown of lncRNA-HOTAIR downregulates the drug-resistance of breast cancer cells to doxorubicin via the PI3K/AKT/mTOR signaling pathway. Exp Ther Med. 2019 Jul;18(1):435-442. doi: 10.3892/etm.2019.7629. Epub 2019 May 29.
REF00002766	Phosphomimetic substitution at Ser-33 of the chloroquine resistance transporter PfCRT reconstitutes drug responses in Plasmodium falciparum. J Biol Chem. 2019 Aug 23;294(34):12766-12778. doi: 10.1074/jbc.RA119.009464. Epub 2019 Jul 8.
REF00002767	MiR-124 reversed the doxorubicin resistance of breast cancer stem cells through STAT3/HIF-1 signaling pathways. Cell Cycle. 2019 Sep;18(18):2215-2227. doi: 10.1080/15384101.2019.1638182. Epub 2019 Jul 29.
REF00002768	LncRNA TUG1 promotes cisplatin resistance in esophageal squamous cell carcinoma cells by regulating Nrf2. Acta Biochim Biophys Sin (Shanghai). 2019 Aug 5;51(8):826-833. doi: 10.1093/abbs/gmz069.
REF00002769	MicroRNA-200c reverses drug resistance of human gastric cancer cells by targeting regulation of the NER-ERCC3/4 pathway. Oncol Lett. 2019 Jul;18(1):145-152. doi: 10.3892/ol.2019.10304. Epub 2019 May 2.
REF00002770	Effect of microRNA-27b on cisplatin chemotherapy sensitivity of oral squamous cell carcinoma via FZD7 signaling pathway. Oncol Lett. 2019 Jul;18(1):667-673. doi: 10.3892/ol.2019.10347. Epub 2019 May 13.
REF00002771	"Effects of long non-coding RNA (lncRNA) cancer susceptibility candidate 2c (CASC2c) on proliferation, metastasis and drug resistance of non-small cell lung cancer (NSCLC) cells through ERK1/2 and Beta-catenin signaling pathways. Pathol Res Pract. 2019 Sep;215(9):152522. doi: 10.1016/j.prp.2019.152522. Epub 2019 Jun 27."
REF00002772	Knockdown of lncRNA BLACAT1 reverses the resistance of afatinib to non-small cell lung cancer via modulating STAT3 signalling. J Drug Target. 2020 Mar;28(3):300-306. doi: 10.1080/1061186X.2019.1650368. Epub 2019 Aug 5.
REF00002773	Long noncoding RNA CCAL transferred from fibroblasts by exosomes promotes chemoresistance of colorectal cancer cells. Int J Cancer. 2020 Mar 15;146(6):1700-1716. doi: 10.1002/ijc.32608. Epub 2019 Aug 27.
REF00002774	Role of Toxoplasma gondii Chloroquine Resistance Transporter in Bradyzoite Viability and Digestive Vacuole Maintenance. mBio. 2019 Aug 6;10(4):e01324-19. doi: 10.1128/mBio.01324-19.
REF00002775	Antiviral activity of HIV-1 integrase strand-transfer inhibitors against mutants with integrase resistance-associated mutations and their frequency in treatment-na ve individuals. J Med Virol. 2019 Dec;91(12):2188-2194. doi: 10.1002/jmv.25564. Epub 2019 Aug 20.
REF00002776	Long non-coding RNA GAS5 inhibits DDP-resistance and tumor progression of epithelial ovarian cancer via GAS5-E2F4-PARP1-MAPK axis. J Exp Clin Cancer Res. 2019 Aug 7;38(1):345. doi: 10.1186/s13046-019-1329-2.
REF00002777	Downregulation of long noncoding RNA CRNDE suppresses drug resistance of liver cancer cells by increasing microRNA-33a expression and decreasing HMGA2 expression. Cell Cycle. 2019 Oct;18(19):2524-2537. doi: 10.1080/15384101.2019.1652035. Epub 2019 Aug 15.
REF00002778	"Long non-coding RNA bladder cancer-associated transcript 2 contributes to disease progression, chemoresistance and poor survival of patients with colorectal cancer. Oncol Lett. 2019 Aug;18(2):2050-2058. doi: 10.3892/ol.2019.10487. Epub 2019 Jun 18."
REF00002779	Correlation between long non-coding RNAs (lncRNAs) H19 expression and trastuzumab resistance in breast cancer. J Cancer Res Ther. 2019;15(4):933-940. doi: 10.4103/jcrt.JCRT_208_19.
REF00002780	"Long non-coding RNA NONHSAT101069 promotes epirubicin resistance, migration, and invasion of breast cancer cells through NONHSAT101069/miR-129-5p/Twist1 axis. Oncogene. 2019 Nov;38(47):7216-7233. doi: 10.1038/s41388-019-0904-5. Epub 2019 Aug 23."
REF00002781	PIWI-interacting RNA 39980 promotes tumor progression and reduces drug sensitivity in neuroblastoma cells. J Cell Physiol. 2020 Mar;235(3):2286-2299. doi: 10.1002/jcp.29136. Epub 2019 Sep 3.
REF00002782	Comparable In Vitro Activities of Second-Generation HIV-1 Integrase Strand Transfer Inhibitors (INSTIs) on HIV-1 Clinical Isolates with INSTI Resistance Mutations. Antimicrob Agents Chemother. 2019 Dec 20;64(1):e01717-19. doi: 10.1128/AAC.01717-19. Print 2019 Dec 20.
REF00002783	Structure and drug resistance of the Plasmodium falciparum transporter PfCRT. Nature. 2019 Dec;576(7786):315-320. doi: 10.1038/s41586-019-1795-x. Epub 2019 Nov 27.
REF00002784	"En-route to the 'elimination' of genotypic chloroquine resistance in Western and Southern Zambia, 14 years after chloroquine withdrawal. Malar J. 2019 Dec 3;18(1):391. doi: 10.1186/s12936-019-3031-4."
REF00002785	Interplay of MKP-1 and Nrf2 drives tumor growth and drug resistance in non-small cell lung cancer. Aging (Albany NY). 2019 Dec 6;11(23):11329-11346. doi: 10.18632/aging.102531. Epub 2019 Dec 6.
REF00002786	Functional relevance of the multi-drug transporter abcg2 on teriflunomide therapy in an animal model of multiple sclerosis. J Neuroinflammation. 2020 Jan 8;17(1):9. doi: 10.1186/s12974-019-1677-z.
REF00002787	Antibiotic resistance by high-level intrinsic suppression of a frameshift mutation in an essential gene. Proc Natl Acad Sci U S A. 2020 Feb 11;117(6):3185-3191. doi: 10.1073/pnas.1919390117. Epub 2020 Jan 28.
REF00002788	DJ-1 protects retinal pericytes against high glucose-induced oxidative stress through the Nrf2 signaling pathway. Sci Rep. 2020 Feb 12;10(1):2477. doi: 10.1038/s41598-020-59408-2.
REF00002789	Structural and evolutionary analyses of the Plasmodium falciparum chloroquine resistance transporter. Sci Rep. 2020 Mar 16;10(1):4842. doi: 10.1038/s41598-020-61181-1.
REF00002790	"LINC00963 Promotes Cancer Stemness, Metastasis, and Drug Resistance in Head and Neck Carcinomas via ABCB5 Regulation. Cancers (Basel). 2020 Apr 26;12(5):1073. doi: 10.3390/cancers12051073."
REF00002791	Prevalence of chloroquine and antifolate drug resistance alleles in Plasmodium falciparum clinical isolates from three areas in Ghana. AAS Open Res. 2018 Dec 3;1:1. doi: 10.12688/aasopenres.12825.2. eCollection 2018.
REF00002792	ABC Transporter DerAB of Lactobacillus casei Mediates Resistance against Insect-Derived Defensins. Appl Environ Microbiol. 2020 Jul 2;86(14):e00818-20. doi: 10.1128/AEM.00818-20. Print 2020 Jul 2.
REF00002793	"Prevalence of mutations in the Plasmodium falciparum chloroquine resistance transporter, PfCRT, and association with ex vivo susceptibility to common anti-malarial drugs against African Plasmodium falciparum isolates. Malar J. 2020 Jun 5;19(1):201. doi: 10.1186/s12936-020-03281-x."
REF00002794	Ex vivo susceptibilities of Plasmodium vivax isolates from the China-Myanmar border to antimalarial drugs and association with polymorphisms in Pvmdr1 and Pvcrt-o genes. PLoS Negl Trop Dis. 2020 Jun 12;14(6):e0008255. doi: 10.1371/journal.pntd.0008255. eCollection 2020 Jun.
REF00002795	Altered Drug Transport by Plasmodium falciparum Chloroquine Resistance Transporter Isoforms Harboring Mutations Associated with Piperaquine Resistance. Biochemistry. 2020 Jul 14;59(27):2484-2493. doi: 10.1021/acs.biochem.0c00247. Epub 2020 Jul 1.
REF00002796	Piperaquine resistant Cambodian Plasmodium falciparum clinical isolates: in vitro genotypic and phenotypic characterization. Malar J. 2020 Jul 25;19(1):269. doi: 10.1186/s12936-020-03339-w.
REF00002797	"The carotenoid fucoxanthin can sensitize multidrug resistant cancer cells to doxorubicin via induction of apoptosis, inhibition of multidrug resistance proteins and metabolic enzymes. Phytomedicine. 2020 Oct;77:153280. doi: 10.1016/j.phymed.2020.153280. Epub 2020 Jul 8."
REF00002798	The natural function of the malaria parasite's chloroquine resistance transporter. Nat Commun. 2020 Aug 6;11(1):3922. doi: 10.1038/s41467-020-17781-6.
REF00002799	Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer. Cell Biochem Funct. 2021 Mar;39(2):277-286. doi: 10.1002/cbf.3577. Epub 2020 Aug 20.
REF00002800	Molecular Mechanisms of Drug Resistance in Plasmodium falciparum Malaria. Annu Rev Microbiol. 2020 Sep 8;74:431-454. doi: 10.1146/annurev-micro-020518-115546.
REF00002801	Characterization of the Human Intestinal Drug Transport with Ussing Chamber System Incorporating Freshly Isolated Human Jejunum. Drug Metab Dispos. 2021 Jan;49(1):84-93. doi: 10.1124/dmd.120.000138. Epub 2020 Oct 21.
REF00002802	"Evidence for linkage of pfmdr1, pfcrt, and pfk13 polymorphisms to lumefantrine and mefloquine susceptibilities in a Plasmodium falciparum cross. Int J Parasitol Drugs Drug Resist. 2020 Dec;14:208-217. doi: 10.1016/j.ijpddr.2020.10.009. Epub 2020 Oct 27."
REF00002803	Energy-dependent efflux mediated by class L (tetL) tetracycline resistance determinant from streptococci. Antimicrob Agents Chemother. 1987 Oct;31(10):1648-50. doi: 10.1128/AAC.31.10.1648.
REF00002804	Identifying novel Beta-lactamase substrate activity through in silico prediction of antimicrobial resistance. Microb Genom. 2021 Jan;7(1):mgen000500. doi: 10.1099/mgen.0.000500.
REF00002805	Distribution and Temporal Dynamics of Plasmodium falciparum Chloroquine Resistance Transporter Mutations Associated With Piperaquine Resistance in Northern Cambodia. J Infect Dis. 2021 Sep 17;224(6):1077-1085. doi: 10.1093/infdis/jiab055.
REF00002806	Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers. Cancers (Basel). 2021 Feb 25;13(5):966. doi: 10.3390/cancers13050966.
REF00002807	The oncogene AAMDC links PI3K-AKT-mTOR signaling with metabolic reprograming in estrogen receptor-positive breast cancer. Nat Commun. 2021 Mar 26;12(1):1920. doi: 10.1038/s41467-021-22101-7.
REF00002808	Pleiotropic effects of probenecid on three-dimensional cultures of prostate cancer cells. Life Sci. 2021 Aug 1;278:119554. doi: 10.1016/j.lfs.2021.119554. Epub 2021 Apr 28.
REF00002809	"Molecular Characterization and Antimicrobial Resistance in Neisseria gonorrhoeae, Nunavut Region of Inuit Nunangat, Canada, 2018-2019. Emerg Infect Dis. 2021 Jun;27(6):1718-1722. doi: 10.3201/eid2706.204407."
REF00002810	Elevation of Chemosensitivity of Lung Adenocarcinoma A549 Spheroid Cells by Claudin-2 Knockdown through Activation of Glucose Transport and Inhibition of Nrf2 Signal. Int J Mol Sci. 2021 Jun 19;22(12):6582. doi: 10.3390/ijms22126582.
REF00002811	MiR-200c-based metabolic modulation in glioblastoma cells as a strategy to overcome tumor chemoresistance. Hum Mol Genet. 2021 Nov 16;30(23):2315-2331. doi: 10.1093/hmg/ddab193.
REF00002812	Metabolic reprograming confers tamoxifen resistance in breast cancer. Chem Biol Interact. 2021 Sep 25;347:109602. doi: 10.1016/j.cbi.2021.109602. Epub 2021 Jul 28.
REF00002813	Chebulagic acid attenuates HFD/streptozotocin induced impaired glucose metabolism and insulin resistance via up regulations of PPAR Gamma and GLUT 4 in type 2 diabetic rats. Toxicol Mech Methods. 2022 Mar;32(3):159-170. doi: 10.1080/15376516.2021.1976333. Epub 2021 Sep 22.
REF00002814	Evolution of Multidrug Resistance in Plasmodium falciparum: a Longitudinal Study of Genetic Resistance Markers in the Greater Mekong Subregion. Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0112121. doi: 10.1128/AAC.01121-21. Epub 2021 Sep 13.
REF00002815	Drug susceptibility of Plasmodium falciparum in eastern Uganda: a longitudinal phenotypic and genotypic study. Lancet Microbe. 2021 Sep;2(9):e441-e449. doi: 10.1016/s2666-5247(21)00085-9. Epub 2021 Jun 18.
REF00002816	Assessment of Transporter-Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients With Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. J Clin Pharmacol. 2022 Apr;62(4):494-504. doi: 10.1002/jcph.1979. Epub 2021 Oct 27.
REF00002817	[Establishment of Cytarabine-resistant Acute Lymphoblastic Leukemia Cell Lines and Its Resistance Mechanism]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021 Oct;29(5):1403-1410. doi: 10.19746/j.cnki.issn.1009-2137.2021.05.006.
REF00002818	Counteracting Action of Curcumin on High Glucose-Induced Chemoresistance in Hepatic Carcinoma Cells. Front Oncol. 2021 Oct 6;11:738961. doi: 10.3389/fonc.2021.738961. eCollection 2021.
REF00002819	Nucleotide sequence of the ampicillin resistance gene of Escherichia coli plasmid pBR322. Proc Natl Acad Sci U S A. 1978 Aug;75(8):3737-41. doi: 10.1073/pnas.75.8.3737.
REF00002820	Genes for gentamicin-(3)-N-acetyl-transferases III and IV. II. Nucleotide sequences of three AAC(3)-III genes and evolutionary aspects. Mol Gen Genet. 1985;198(3):514-20. doi: 10.1007/BF00332949.
REF00002821	Nucleotide sequence analysis of the cat gene of Proteus mirabilis: comparison with the type I (Tn9) cat gene. J Bacteriol. 1985 Oct;164(1):123-9. doi: 10.1128/jb.164.1.123-129.1985.
REF00002822	Penicillinase synthesis controlled by infectious R factors in Enterobacteriaceae. Nature. 1965 Oct 16;208(5007):239-41. doi: 10.1038/208239a0.
REF00002823	"Nucleotide sequence of the Streptococcus faecalis plasmid gene encoding the 3'5""-aminoglycoside phosphotransferase type III. Gene. 1983 Sep;23(3):331-41. doi: 10.1016/0378-1119(83)90022-7."
REF00002824	Analysis of a bacterial hygromycin B resistance gene by transcriptional and translational fusions and by DNA sequencing. Nucleic Acids Res. 1983 Oct 11;11(19):6895-911. doi: 10.1093/nar/11.19.6895.
REF00002825	Nucleotide sequence of a Bacillus pumilus gene specifying chloramphenicol acetyltransferase. Gene. 1983 Oct;24(2-3):163-9. doi: 10.1016/0378-1119(83)90076-8.
REF00002826	Improved purification and characterization of the OXA-2 beta-lactamase. Biochem J. 1984 Dec 15;224(3):1009-13. doi: 10.1042/bj2241009.
REF00002827	Role of porin proteins OmpF and OmpC in the permeation of beta-lactams. Antimicrob Agents Chemother. 1982 Dec;22(6):942-8. doi: 10.1128/AAC.22.6.942.
REF00002828	Characterization of a plasmid-specified ribosome methylase associated with macrolide resistance. Nucleic Acids Res. 1981 Jun 11;9(11):2549-62. doi: 10.1093/nar/9.11.2549.
REF00002829	Bacillus licheniformis bacitracin-resistance ABC transporter: relationship to mammalian multidrug resistance. Mol Microbiol. 1995 Jun;16(5):969-76. doi: 10.1111/j.1365-2958.1995.tb02322.x.
REF00002830	The structural and functional basis for the kirromycin resistance of mutant EF-Tu species in Escherichia coli. EMBO J. 1994 Oct 17;13(20):4877-85.
REF00002831	The thiostrepton-resistance-encoding gene in Streptomyces laurentii is located within a cluster of ribosomal protein operons. Gene. 1995 Oct 16;164(1):137-42. doi: 10.1016/0378-1119(95)00442-9.
REF00002832	"Inactivation of chloramphenicol by O-phosphorylation. A novel resistance mechanism in Streptomyces venezuelae ISP5230, a chloramphenicol producer. J Biol Chem. 1995 Nov 10;270(45):27000-6. doi: 10.1074/jbc.270.45.27000."
REF00002833	Characterization of a novel Schizosaccharomyces pombe multidrug resistance transporter conferring brefeldin A resistance. Biochem Biophys Res Commun. 1995 Aug 15;213(2):410-8. doi: 10.1006/bbrc.1995.2147.
REF00002834	"TmrB protein, which confers resistance to tunicamycin on Bacillus subtilis, binds tunicamycin. Biosci Biotechnol Biochem. 1995 Feb;59(2):321-2. doi: 10.1271/bbb.59.321."
REF00002835	Presence of the Listeria tetracycline resistance gene tet(S) in Enterococcus faecalis. Antimicrob Agents Chemother. 1994 Oct;38(10):2330-5. doi: 10.1128/AAC.38.10.2330.
REF00002836	Characterization of rifampin-resistance in pathogenic mycobacteria. Antimicrob Agents Chemother. 1994 Oct;38(10):2380-6. doi: 10.1128/AAC.38.10.2380.
REF00002837	Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs. Antimicrob Agents Chemother. 1994 Oct;38(10):2477-9. doi: 10.1128/AAC.38.10.2477.
REF00002838	Implications of multidrug resistance for the future of short-course chemotherapy of tuberculosis: a molecular study. Lancet. 1994 Jul 30;344(8918):293-8. doi: 10.1016/s0140-6736(94)91338-2.
REF00002839	Phosphorylative inactivation of rifampicin by Nocardia otitidiscaviarum. J Antimicrob Chemother. 1994 Jun;33(6):1127-35. doi: 10.1093/jac/33.6.1127.
REF00002840	Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: alterations of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNA pseudoknot. Mol Microbiol. 1993 Sep;9(6):1239-46. doi: 10.1111/j.1365-2958.1993.tb01253.x.
REF00002841	Pulvomycin-resistant mutants of E.coli elongation factor Tu. EMBO J. 1994 Nov 1;13(21):5113-20.
REF00002842	Domain V of 23S rRNA contains all the structural elements necessary for recognition by the ErmE methyltransferase. J Bacteriol. 1994 Nov;176(22):6999-7004. doi: 10.1128/jb.176.22.6999-7004.1994.
REF00002843	The rpsL gene and streptomycin resistance in single and multiple drug-resistant strains of Mycobacterium tuberculosis. Mol Microbiol. 1993 Nov;10(3):521-7. doi: 10.1111/j.1365-2958.1993.tb00924.x.
REF00002844	Differential susceptibilities of enterococcal species to elfamycin antibiotics. J Clin Microbiol. 1994 Aug;32(8):2016-8. doi: 10.1128/jcm.32.8.2016-2018.1994.
REF00002845	Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase beta subunit in rifampin-resistant Mycobacterium tuberculosis strains from New York City and Texas. J Clin Microbiol. 1994 Apr;32(4):1095-8. doi: 10.1128/jcm.32.4.1095-1098.1994.
REF00002846	Analysis of a carbapenem-hydrolyzing class A beta-lactamase from Enterobacter cloacae and of its LysR-type regulatory protein. Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7693-7. doi: 10.1073/pnas.91.16.7693.
REF00002847	Characterization of the sat4 gene encoding a streptothricin acetyltransferase in Campylobacter coli BE/G4. FEMS Microbiol Lett. 1994 Jul 1;120(1-2):13-7. doi: 10.1111/j.1574-6968.1994.tb07000.x.
REF00002848	"Transcription and expression analysis, using lacZ and phoA gene fusions, of Mycobacterium fortuitum beta-lactamase genes cloned from a natural isolate and a high-level beta-lactamase producer. Mol Microbiol. 1994 May;12(3):491-504. doi: 10.1111/j.1365-2958.1994.tb01037.x."
REF00002849	"Cloning and sequence analysis of ermQ, the predominant macrolide-lincosamide-streptogramin B resistance gene in Clostridium perfringens. Antimicrob Agents Chemother. 1994 May;38(5):1041-6. doi: 10.1128/AAC.38.5.1041."
REF00002850	Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet. 1993 Mar 13;341(8846):647-50. doi: 10.1016/0140-6736(93)90417-f.
REF00002851	Study of heterogeneity of chloramphenicol acetyltransferase (CAT) genes in streptococci and enterococci by polymerase chain reaction: characterization of a new CAT determinant. Antimicrob Agents Chemother. 1993 Dec;37(12):2593-8. doi: 10.1128/AAC.37.12.2593.
REF00002852	A spontaneous point mutation in the aac(6')-Ib' gene results in altered substrate specificity of aminoglycoside 6'-N-acetyltransferase of a Pseudomonas fluorescens strain. FEMS Microbiol Lett. 1994 Jan 15;115(2-3):297-304. doi: 10.1111/j.1574-6968.1994.tb06654.x.
REF00002853	Characterization of a Streptomyces antibioticus gene cluster encoding a glycosyltransferase involved in oleandomycin inactivation. Gene. 1993 Nov 30;134(1):139-40. doi: 10.1016/0378-1119(93)90189-a.
REF00002854	Analysis of the aac(3)-VIa gene encoding a novel 3-N-acetyltransferase. Antimicrob Agents Chemother. 1993 Oct;37(10):2074-9. doi: 10.1128/AAC.37.10.2074.
REF00002855	Genetic mapping in Bacillus subtilis 168 of the aadK gene which encodes aminoglycoside 6-adenylyltransferase. FEMS Microbiol Lett. 1993 Nov 15;114(1):47-52. doi: 10.1016/0378-1097(93)90140-w.
REF00002856	"Streptomyces antibioticus contains at least three oleandomycin-resistance determinants, one of which shows similarity with proteins of the ABC-transporter superfamily. Mol Microbiol. 1993 May;8(3):571-82. doi: 10.1111/j.1365-2958.1993.tb01601.x."
REF00002857	Characterization of a new class of tetracycline-resistance gene tet(S) in Listeria monocytogenes BM4210. Gene. 1993 Sep 6;131(1):27-34. doi: 10.1016/0378-1119(93)90665-p.
REF00002858	Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol Rev. 1993 Mar;57(1):138-63. doi: 10.1128/mr.57.1.138-163.1993.
REF00002859	Mutations in the gyrA gene of a highly fluoroquinolone-resistant clinical isolate of Escherichia coli. Antimicrob Agents Chemother. 1993 Apr;37(4):696-701. doi: 10.1128/AAC.37.4.696.
REF00002860	Characterization and transcriptional regulation of the 2'-N-acetyltransferase gene from Providencia stuartii. J Bacteriol. 1993 Oct;175(20):6492-8. doi: 10.1128/jb.175.20.6492-6498.1993.
REF00002861	Genetic and biochemical analysis of a novel Ambler class A beta-lactamase responsible for cefoxitin resistance in Bacteroides species. Antimicrob Agents Chemother. 1993 May;37(5):1028-36. doi: 10.1128/AAC.37.5.1028.
REF00002862	A self-defense gene homologous to tetracycline effluxing gene essential for antibiotic production in Streptomyces aureofaciens. Biosci Biotechnol Biochem. 1995 Oct;59(10):1835-41. doi: 10.1271/bbb.59.1835.
REF00002863	DNA gyrase gyrA mutations in quinolone-resistant clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1995 Sep;39(9):1970-2. doi: 10.1128/AAC.39.9.1970.
REF00002864	Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother. 1995 Nov;39(11):2378-86. doi: 10.1128/AAC.39.11.2378.
REF00002865	H19 gene overexpression in atypical multidrug-resistant cells associated with expression of a 95-kilodalton membrane glycoprotein. Cancer Res. 1996 Jul 1;56(13):2904-7.
REF00002866	"A novel tetracycline-resistant determinant, tet(U), is encoded on the plasmid pKq10 in Enterococcus faecium. Plasmid. 1996 Mar;35(2):71-80. doi: 10.1006/plas.1996.0009."
REF00002867	"Characterization of the plasmidic beta-lactamase CMY-2, which is responsible for cephamycin resistance. Antimicrob Agents Chemother. 1996 Jan;40(1):221-4. doi: 10.1128/AAC.40.1.221."
REF00002868	Purification of the Tn10-specified tetracycline efflux antiporter TetA in a native state as a polyhistidine fusion protein. Mol Microbiol. 1996 Jan;19(1):187-95. doi: 10.1046/j.1365-2958.1996.359886.x.
REF00002869	"Multifocal outbreaks of metallo-beta-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum beta-lactams, including carbapenems. Antimicrob Agents Chemother. 1996 Feb;40(2):349-53. doi: 10.1128/AAC.40.2.349."
REF00002870	Characterization of rpsL and rrs mutations in streptomycin-resistant Mycobacterium tuberculosis isolates from diverse geographic localities. Antimicrob Agents Chemother. 1996 Apr;40(4):1024-6. doi: 10.1128/AAC.40.4.1024.
REF00002871	Rifampicin resistance and mutation of the rpoB gene in Mycobacterium tuberculosis. FEMS Microbiol Lett. 1996 Oct 15;144(1):103-8. doi: 10.1111/j.1574-6968.1996.tb08515.x.
REF00002872	Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob Agents Chemother. 1996 Oct;40(10):2300-5. doi: 10.1128/AAC.40.10.2300.
REF00002873	Characterization of the chromosomal aminoglycoside 2'-N-acetyltransferase gene from Mycobacterium fortuitum. Antimicrob Agents Chemother. 1996 Oct;40(10):2350-5. doi: 10.1128/AAC.40.10.2350.
REF00002874	Cloning and nucleotide sequence of the mphB gene for macrolide 2'-phosphotransferase II in Escherichia coli. FEMS Microbiol Lett. 1996 Nov 1;144(2-3):197-202. doi: 10.1111/j.1574-6968.1996.tb08530.x.
REF00002875	A TEM-derived extended-spectrum beta-lactamase in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1996 Nov;40(11):2488-93. doi: 10.1128/AAC.40.11.2488.
REF00002876	Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob Agents Chemother. 1996 Nov;40(11):2505-10. doi: 10.1128/AAC.40.11.2505.
REF00002877	Molecular characterization of a plasmid-borne (pTC82) chloramphenicol resistance determinant (cat-TC) from Lactobacillus reuteri G4. Plasmid. 1996 Sep;36(2):116-24. doi: 10.1006/plas.1996.0039.
REF00002878	New tetracycline resistance determinants coding for ribosomal protection in streptococci and nucleotide sequence of tet(T) isolated from Streptococcus pyogenes A498. Antimicrob Agents Chemother. 1997 Jan;41(1):112-6. doi: 10.1128/AAC.41.1.112.
REF00002879	Monooxygenase-like sequence of a Rhodococcus equi gene conferring increased resistance to rifampin by inactivating this antibiotic. Antimicrob Agents Chemother. 1997 Jan;41(1):218-21. doi: 10.1128/AAC.41.1.218.
REF00002880	"Interaction between ATP, oleandomycin and the OleB ATP-binding cassette transporter of Streptomyces antibioticus involved in oleandomycin secretion. Biochem J. 1997 Jan 1;321 ( Pt 1)(Pt 1):139-44. doi: 10.1042/bj3210139."
REF00002881	Mutations in the rpoB gene of Mycobacterium tuberculosis that interfere with PCR-single-strand conformation polymorphism analysis for rifampin susceptibility testing. J Clin Microbiol. 1997 Feb;35(2):492-4. doi: 10.1128/jcm.35.2.492-494.1997.
REF00002882	Mycobacterium tuberculosis efpA encodes an efflux protein of the QacA transporter family. Clin Diagn Lab Immunol. 1997 Jan;4(1):23-32. doi: 10.1128/cdli.4.1.23-32.1997.
REF00002883	Natural kirromycin resistance of elongation factor Tu from the kirrothricin producer Streptomyces cinnamoneus. Microbiology (Reading). 1997 Feb;143 ( Pt 2):617-624. doi: 10.1099/00221287-143-2-617.
REF00002884	Purification and properties of the Mycobacterium smegmatis mc(2)155 beta-lactamase. FEMS Microbiol Lett. 1997 Apr 1;149(1):11-5. doi: 10.1016/s0378-1097(97)00041-4.
REF00002885	"Survey and molecular genetics of SHV beta-lactamases in Enterobacteriaceae in Switzerland: two novel enzymes, SHV-11 and SHV-12. Antimicrob Agents Chemother. 1997 May;41(5):943-9. doi: 10.1128/AAC.41.5.943."
REF00002886	Aminoglycoside 2'-N-acetyltransferase genes are universally present in mycobacteria: characterization of the aac(2')-Ic gene from Mycobacterium tuberculosis and the aac(2')-Id gene from Mycobacterium smegmatis. Mol Microbiol. 1997 Apr;24(2):431-41. doi: 10.1046/j.1365-2958.1997.3471717.x.
REF00002887	Transposition of the IS21-related element IS1415 in Rhodococcus erythropolis. J Bacteriol. 1997 Jul;179(14):4635-8. doi: 10.1128/jb.179.14.4635-4638.1997.
REF00002888	Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains. FEMS Microbiol Lett. 1997 Jun 15;151(2):263-8. doi: 10.1111/j.1574-6968.1997.tb12580.x.
REF00002889	Characterization of mutations contributing to sulfathiazole resistance in Escherichia coli. Antimicrob Agents Chemother. 1998 Jan;42(1):88-93. doi: 10.1128/AAC.42.1.88.
REF00002890	Expression of the mphB gene for macrolide 2'-phosphotransferase II from Escherichia coli in Staphylococcus aureus. FEMS Microbiol Lett. 1998 Feb 15;159(2):337-42. doi: 10.1111/j.1574-6968.1998.tb12880.x.
REF00002891	Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother. 1998 Feb;42(2):241-53. doi: 10.1128/AAC.42.2.241.
REF00002892	"Cefotaxime-resistant Enterobacteriaceae isolates from a hospital in Warsaw, Poland: identification of a new CTX-M-3 cefotaxime-hydrolyzing beta-lactamase that is closely related to the CTX-M-1/MEN-1 enzyme. Antimicrob Agents Chemother. 1998 Apr;42(4):827-32. doi: 10.1128/AAC.42.4.827."
REF00002893	Sulfonamide resistance in Streptococcus pyogenes is associated with differences in the amino acid sequence of its chromosomal dihydropteroate synthase. Antimicrob Agents Chemother. 1998 May;42(5):1062-7. doi: 10.1128/AAC.42.5.1062.
REF00002894	"Molecular cloning and functional analysis of a novel tetracycline resistance determinant, tet(V), from Mycobacterium smegmatis. Antimicrob Agents Chemother. 1998 Aug;42(8):1931-7. doi: 10.1128/AAC.42.8.1931."
REF00002895	ErmE methyltransferase recognition elements in RNA substrates. J Mol Biol. 1998 Sep 18;282(2):255-64. doi: 10.1006/jmbi.1998.2024.
REF00002896	Corynebacterium striatum chloramphenicol resistance transposon Tn5564: genetic organization and transposition in Corynebacterium glutamicum. Plasmid. 1998 Sep;40(2):126-39. doi: 10.1006/plas.1998.1362.
REF00002897	"Characterization of In40 of Enterobacter aerogenes BM2688, a class 1 integron with two new gene cassettes, cmlA2 and qacF. Antimicrob Agents Chemother. 1998 Oct;42(10):2557-63. doi: 10.1128/AAC.42.10.2557."
REF00002898	"Characterization of a glycosyl transferase inactivating macrolides, encoded by gimA from Streptomyces ambofaciens. Antimicrob Agents Chemother. 1998 Oct;42(10):2612-9. doi: 10.1128/AAC.42.10.2612."
REF00002899	A gene cluster for macrolide antibiotic biosynthesis in Streptomyces venezuelae: architecture of metabolic diversity. Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12111-6. doi: 10.1073/pnas.95.21.12111.
REF00002900	Mutations in Bartonella bacilliformis gyrB confer resistance to coumermycin A1. Antimicrob Agents Chemother. 1998 Nov;42(11):2906-13. doi: 10.1128/AAC.42.11.2906.
REF00002901	Distinct patterns of gene expression associated with development of fluconazole resistance in serial candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother. 1998 Nov;42(11):2932-7. doi: 10.1128/AAC.42.11.2932.
REF00002902	"Molecular cloning and characterization of Tap, a putative multidrug efflux pump present in Mycobacterium fortuitum and Mycobacterium tuberculosis. J Bacteriol. 1998 Nov;180(22):5836-43. doi: 10.1128/JB.180.22.5836-5843.1998."
REF00002903	The Escherichia coli cmlA gene encodes the multidrug efflux pump Cmr/MdfA and is responsible for isopropyl-beta-D-thiogalactopyranoside exclusion and spectinomycin sensitivity. J Bacteriol. 1998 Nov;180(22):6072-5. doi: 10.1128/JB.180.22.6072-6075.1998.
REF00002904	A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15665-70. doi: 10.1073/pnas.95.26.15665.
REF00002905	Revised sequence of OtrB (tet347) tetracycline efflux protein from Streptomyces rimosus. Antimicrob Agents Chemother. 1998 Nov;42(11):3050. doi: 10.1128/AAC.42.11.3050.
REF00002906	Cloning and characterization of a tetracycline resistance determinant present in Agrobacterium tumefaciens C58. J Bacteriol. 1999 Jan;181(2):618-26. doi: 10.1128/JB.181.2.618-626.1999.
REF00002907	Cloning and characterization of arylamine N-acetyltransferase genes from Mycobacterium smegmatis and Mycobacterium tuberculosis: increased expression results in isoniazid resistance. J Bacteriol. 1999 Feb;181(4):1343-7. doi: 10.1128/JB.181.4.1343-1347.1999.
REF00002908	ErmE methyltransferase recognizes features of the primary and secondary structure in a motif within domain V of 23 S rRNA. J Mol Biol. 1999 Feb 19;286(2):365-74. doi: 10.1006/jmbi.1998.2504.
REF00002909	Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study Ann Rheum Dis. 2020 Oct;79(10):1277-1285. doi: 10.1136/annrheumdis-2020-218122. Epub 2020 Jul 3.
REF00002910	Baricitinib restrains the immune dysregulation in patients with severe COVID-19 J Clin Invest. 2020 Dec 1;130(12):6409-6416. doi: 10.1172/JCI141772.
REF00002911	Anakinra for severe forms of COVID-19: a cohort study Lancet Rheumatol. 2020 Jul;2(7):e393-e400. doi: 10.1016/S2665-9913(20)30164-8. Epub 2020 May 29.
REF00002912	Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study Int J Infect Dis. 2021 Mar;104:433-440. doi: 10.1016/j.ijid.2020.12.073. Epub 2020 Dec 29.
REF00002913	Mechanism of SARS-CoV-2 polymerase stalling by remdesivir Nat Commun. 2021 Jan 12;12(1):279. doi: 10.1038/s41467-020-20542-0.
REF00002914	Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia N Engl J Med. 2021 Apr 22;384(16):1503-1516. doi: 10.1056/NEJMoa2028700. Epub 2021 Feb 25.
REF00002915	Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies Nat Med. 2021 Apr;27(4):717-726. doi: 10.1038/s41591-021-01294-w. Epub 2021 Mar 4.
REF00002916	Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 Nature. 2021 May;593(7857):130-135. doi: 10.1038/s41586-021-03398-2. Epub 2021 Mar 8.
REF00002917	Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia Nature. 2021 Jun;594(7861):88-93. doi: 10.1038/s41586-021-03491-6. Epub 2021 Apr 7.
REF00002918	Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis Curr Med Res Opin. 2021 Jul;37(7):1085-1097. doi: 10.1080/03007995.2021.1920900. Epub 2021 May 19.
REF00002919	The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials Sci Rep. 2021 May 26;11(1):11022. doi: 10.1038/s41598-021-90551-6.
REF00002920	Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19 EClinicalMedicine. 2021 Oct;40:101102. doi: 10.1016/j.eclinm.2021.101102. Epub 2021 Aug 30.
REF00002921	In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2 PLoS Pathog. 2021 Sep 17;17(9):e1009929. doi: 10.1371/journal.ppat.1009929. eCollection 2021 Sep.
REF00002922	Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial Lancet Rheumatol. 2022 Jan;4(1):e24-e32. doi: 10.1016/S2665-9913(21)00315-5. Epub 2021 Nov 17.
REF00002923	Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients N Engl J Med. 2022 Feb 10;386(6):509-520. doi: 10.1056/NEJMoa2116044. Epub 2021 Dec 16.
REF00002924	Tixagevimab and Cilgavimab (Evusheld) for Pre-Exposure Prophylaxis of COVID-19 JAMA. 2022 Jan 25;327(4):384-385. doi: 10.1001/jama.2021.24931.
REF00002925	"Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern Antiviral Res. 2022 Feb;198:105252. doi: 10.1016/j.antiviral.2022.105252. Epub 2022 Jan 24."
REF00002926	"Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16."
REF00002927	Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use N Engl J Med. 2022 Apr 14;386(15):1477-1479. doi: 10.1056/NEJMc2120219. Epub 2022 Mar 9.
REF00002928	Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial JAMA. 2022 Apr 5;327(13):1236-1246. doi: 10.1001/jama.2022.2832.
REF00002929	De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report Nat Commun. 2022 Mar 17;13(1):1547. doi: 10.1038/s41467-022-29104-y.
REF00002930	AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin PLoS One. 2013;8(1):e53518. doi: 10.1371/journal.pone.0053518. Epub 2013 Jan 8.
REF00002931	LincHOTAIR epigenetically silences miR34a by binding to PRC2 to promote the epithelial-to-mesenchymal transition in human gastric cancer Cell Death Dis. 2015 Jul 2;6(7):e1802. doi: 10.1038/cddis.2015.150.
REF00002932	Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin LymphomaClin Cancer Res. 2020 Mar 1;26(5):1034-1044. doi: 10.1158/1078-0432.CCR-19-1768. Epub 2019 Dec 6.
REF00002933	Inotuzumab ozogamicin resistance associated with a novel CD22 truncating mutation in a case of B-acute lymphoblastic leukaemiaBr J Haematol. 2020 Oct;191(1):123-126. doi: 10.1111/bjh.16949. Epub 2020 Jul 9.
REF00002934	Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia Leukemia. 2019 Apr;33(4):884-892. doi: 10.1038/s41375-018-0265-z. Epub 2018 Sep 28.
REF00002935	Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma Clin Cancer Res. 2020 Mar 1;26(5):1034-1044. doi: 10.1158/1078-0432.CCR-19-1768. Epub 2019 Dec 6.
REF00002936	Inotuzumab ozogamicin resistance associated with a novel CD22 truncating mutation in a case of B-acute lymphoblastic leukaemia Br J Haematol. 2020 Oct;191(1):123-126. doi: 10.1111/bjh.16949. Epub 2020 Jul 9.
REF00002937	Resistance to PI3Kappa Delta inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis Haematologica. 2022 Apr 28. doi: 10.3324/haematol.2021.279957. Online ahead of print.
REF00002938	Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial .JAMA. 2018 Sep 11;320(10):984-994. doi: 10.1001/jama.2018.12163. 10.1001/jama.2018.12163
REF00002939	Diagnosis and Treatment of Parkinson Disease: A Review .JAMA. 2020 Feb 11;323(6):548-560. doi: 10.1001/jama.2019.22360. 10.1001/jama.2019.22360
REF00002940	"Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal Beta-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial .JAMA. 2020 Feb 11;323(6):527-537. doi: 10.1001/jama.2020.0103. 10.1001/jama.2020.0103"
REF00002941	Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial .JAMA Neurol. 2020 Mar 1;77(3):300-308. doi: 10.1001/jamaneurol.2019.4113. 10.1001/jamaneurol.2019.4113
REF00002942	Interventions for idiopathic steroid-resistant nephrotic syndrome in children .Cochrane Database Syst Rev. 2019 Nov 21;2019(11):CD003594. doi: 10.1002/14651858.CD003594.pub6. 10.1002/14651858.CD003594.pub6
REF00002943	Exercise for dysmenorrhoea .Cochrane Database Syst Rev. 2019 Sep 20;9(9):CD004142. doi: 10.1002/14651858.CD004142.pub4. 10.1002/14651858.CD004142.pub4
REF00002944	Antibiotics for preventing meningococcal infections .Cochrane Database Syst Rev. 2013 Oct 25;2013(10):CD004785. doi: 10.1002/14651858.CD004785.pub5. 10.1002/14651858.CD004785.pub5
REF00002945	Interventions for sexual dysfunction following stroke .Cochrane Database Syst Rev. 2020 May 1;5(5):CD011189. doi: 10.1002/14651858.CD011189.pub2. 10.1002/14651858.CD011189.pub2
REF00002946	Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder .Cochrane Database Syst Rev. 2021 Sep 12;9(9):CD011612. doi: 10.1002/14651858.CD011612.pub3. 10.1002/14651858.CD011612.pub3
REF00002947	Tocopherol biosynthesis in Leishmania (L.) amazonensis promastigotes .FEBS Open Bio. 2019 Mar 5;9(4):743-754. doi: 10.1002/2211-5463.12613. eCollection 2019 Apr. 10.1002/2211-5463.12613
REF00002948	Trifluoperazine induces cellular apoptosis by inhibiting autophagy and targeting NUPR1 in multiple myeloma .FEBS Open Bio. 2020 Oct;10(10):2097-2106. doi: 10.1002/2211-5463.12960. Epub 2020 Aug 31. 10.1002/2211-5463.12960
REF00002949	Donepezil increases resistance to induced seizures in a mouse model of Dravet syndrome .Ann Clin Transl Neurol. 2019 Aug;6(8):1566-1571. doi: 10.1002/acn3.50848. Epub 2019 Jul 23. 10.1002/acn3.50848
REF00002950	Diclofenac Resensitizes Methicillin-Resistant Staphylococcus aureus to Beta-Lactams and Prevents Implant Infections .Adv Sci (Weinh). 2021 May 3;8(13):2100681. doi: 10.1002/advs.202100681. eCollection 2021 Jul. 10.1002/advs.202100681
REF00002951	"Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment .Am J Hematol. 2019 Nov;94(11):1266-1287. doi: 10.1002/ajh.25595. Epub 2019 Oct 4. 10.1002/ajh.25595"
REF00002952	"Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring .Am J Hematol. 2020 Jun;95(6):691-709. doi: 10.1002/ajh.25792. Epub 2020 Apr 10. 10.1002/ajh.25792"
REF00002953	"Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management .Am J Hematol. 2021 Jan;96(1):145-162. doi: 10.1002/ajh.26050. Epub 2020 Dec 2. 10.1002/ajh.26050"
REF00002954	"Glycogen synthase kinase-3Beta inactivation promotes cervical cancer progression, invasion, and drug resistance .Biotechnol Appl Biochem. 2021 Sep 23. doi: 10.1002/bab.2258. Online ahead of print. 10.1002/bab.2258"
REF00002955	BRD2 induces drug resistance through activation of the RasGRP1/Ras/ERK signaling pathway in adult T-cell lymphoblastic lymphoma .Cancer Commun (Lond). 2020 Jun;40(6):245-259. doi: 10.1002/cac2.12039. Epub 2020 May 27. 10.1002/cac2.12039
REF00002956	EMT-associated microRNAs and their roles in cancer stemness and drug resistance .Cancer Commun (Lond). 2021 Mar;41(3):199-217. doi: 10.1002/cac2.12138. Epub 2021 Jan 27. 10.1002/cac2.12138
REF00002957	Trifluridine/tipiracil plus bevacizumab as a first-line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial .Cancer Med. 2021 Jan;10(2):454-461. doi: 10.1002/cam4.3618. Epub 2020 Nov 29. 10.1002/cam4.3618
REF00002958	Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors .Cancer Med. 2021 Feb;10(3):843-856. doi: 10.1002/cam4.3658. Epub 2021 Jan 20. 10.1002/cam4.3658
REF00002959	Esomeprazole overcomes paclitaxel-resistance and enhances anticancer effects of paclitaxel by inducing autophagy in A549/Taxol cells .Cell Biol Int. 2021 Jan;45(1):177-187. doi: 10.1002/cbin.11481. Epub 2020 Oct 20. 10.1002/cbin.11481
REF00002960	Novel HER2-targeted therapies for HER2-positive metastatic breast cancer .Cancer. 2020 Oct 1;126(19):4278-4288. doi: 10.1002/cncr.33102. Epub 2020 Jul 28. 10.1002/cncr.33102
REF00002961	Assessment of Bezlotoxumab Immunogenicity .Clin Pharmacol Drug Dev. 2020 Apr;9(3):330-340. doi: 10.1002/cpdd.729. Epub 2019 Aug 14. 10.1002/cpdd.729
REF00002962	Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects .Clin Pharmacol Drug Dev. 2021 Nov;10(11):1335-1344. doi: 10.1002/cpdd.957. Epub 2021 Jun 9. 10.1002/cpdd.957
REF00002963	CD13 promotes hepatocellular carcinogenesis and sorafenib resistance by activating HDAC5-LSD1-NF-kB oncogenic signaling .Clin Transl Med. 2020 Dec;10(8):e233. doi: 10.1002/ctm2.233. 10.1002/ctm2.233
REF00002964	"Glycine and N-acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition: Results of a pilot clinical trial .Clin Transl Med. 2021 Mar;11(3):e372. doi: 10.1002/ctm2.372. 10.1002/ctm2.372"
REF00002965	"Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients .Endocrinol Diabetes Metab. 2021 Feb 2;4(2):e00217. doi: 10.1002/edm2.217. eCollection 2021 Apr. 10.1002/edm2.217"
REF00002966	Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance .Eur J Heart Fail. 2019 Nov;21(11):1415-1422. doi: 10.1002/ejhf.1478. Epub 2019 May 9. 10.1002/ejhf.1478
REF00002967	Open-label long-term treatment of add-on triheptanoin in adults with drug-resistant epilepsy .Epilepsia Open. 2020 Apr 12;5(2):230-239. doi: 10.1002/epi4.12391. eCollection 2020 Jun. 10.1002/epi4.12391
REF00002968	"Vitamin D Receptor Activation in Liver Macrophages Ameliorates Hepatic Inflammation, Steatosis, and Insulin Resistance in Mice .Hepatology. 2020 May;71(5):1559-1574. doi: 10.1002/hep.30937. Epub 2020 Feb 23. 10.1002/hep.30937"
REF00002969	Mast Cells Regulate Ductular Reaction and Intestinal Inflammation in Cholestasis Through Farnesoid X Receptor Signaling .Hepatology. 2021 Nov;74(5):2684-2698. doi: 10.1002/hep.32028. Epub 2021 Sep 9. 10.1002/hep.32028
REF00002970	"Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer .Int J Cancer. 2009 Dec 1;125(11):2721-7. doi: 10.1002/ijc.24654. 10.1002/ijc.24654"
REF00002971	Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review .Int J Cancer. 2019 Sep 1;145(5):1179-1188. doi: 10.1002/ijc.32020. Epub 2019 Jan 7. 10.1002/ijc.32020
REF00002972	miR-34a is upregulated in AIP-mutated somatotropinomas and promotes octreotide resistance .Int J Cancer. 2020 Dec 15;147(12):3523-3538. doi: 10.1002/ijc.33268. Epub 2020 Sep 10. 10.1002/ijc.33268
REF00002973	m6A methyltransferase Wilms' tumor 1-associated protein facilitates cell proliferation and cisplatin resistance in NK/T cell lymphoma by regulating dual-specificity phosphatases 6 expression via m6A RNA methylation .IUBMB Life. 2021 Jan;73(1):108-117. doi: 10.1002/iub.2410. Epub 2020 Nov 17. 10.1002/iub.2410
REF00002974	Shc inhibitor idebenone ameliorates liver injury and fibrosis in dietary NASH in mice .J Biochem Mol Toxicol. 2021 Oct;35(10):e22876. doi: 10.1002/jbt.22876. Epub 2021 Aug 8. 10.1002/jbt.22876
REF00002975	"Overexpression of interleukin-2 receptor alpha in a human squamous cell carcinoma of the head and neck cell line is associated with increased proliferation, drug resistance, and transforming ability .J Cell Biochem. 2003 Jul 1;89(4):824-36. doi: 10.1002/jcb.10557. 10.1002/jcb.10557"
REF00002976	Exploring the functional impact of mutational drift in LRRK2 gene and identification of specific inhibitors for the treatment of Parkinson disease .J Cell Biochem. 2018 Jun;119(6):4878-4889. doi: 10.1002/jcb.26703. Epub 2018 Mar 9. 10.1002/jcb.26703
REF00002977	Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy .J Cell Physiol. 2020 Apr;235(4):3142-3156. doi: 10.1002/jcp.29216. Epub 2019 Sep 30. 10.1002/jcp.29216
REF00002978	Talazoparib nanoparticles for overcoming multidrug resistance in triple-negative breast cancer .J Cell Physiol. 2020 Sep;235(9):6230-6245. doi: 10.1002/jcp.29552. Epub 2020 Feb 3. 10.1002/jcp.29552
REF00002979	l-lactic acidosis confers insensitivity to PKC inhibitors by competing for uptake via monocarboxylate transporters .J Cell Physiol. 2022 Jan;237(1):934-948. doi: 10.1002/jcp.30570. Epub 2021 Sep 1. 10.1002/jcp.30570
REF00002980	"Osteosarcopenia: epidemiology, diagnosis, and treatment-facts and numbers .J Cachexia Sarcopenia Muscle. 2020 Jun;11(3):609-618. doi: 10.1002/jcsm.12567. Epub 2020 Mar 22. 10.1002/jcsm.12567"
REF00002981	Persistent pulmonary hypertension of the newborn .Pediatr Pulmonol. 2021 Mar;56(3):661-669. doi: 10.1002/ppul.25073. 10.1002/ppul.25073
REF00002982	NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer .Prostate. 2019 Jan;79(1):44-53. doi: 10.1002/pros.23709. Epub 2018 Sep 3. 10.1002/pros.23709
REF00002983	Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients .Prostate. 2019 Feb;79(2):234-242. doi: 10.1002/pros.23728. Epub 2018 Oct 16. 10.1002/pros.23728
REF00002984	Permethrin resistance associated with inherited genes in a near-isogenic line of Musca domestica .Pest Manag Sci. 2021 Feb;77(2):963-969. doi: 10.1002/ps.6108. Epub 2020 Oct 7. 10.1002/ps.6108
REF00002985	Molecular innovations underlying resistance to nicotine and neonicotinoids in the aphid Myzus persicae .Pest Manag Sci. 2021 Dec;77(12):5311-5320. doi: 10.1002/ps.6558. Epub 2021 Jul 29. 10.1002/ps.6558
REF00002986	"Spinosad resistance in field populations of melon fly, Zeugodacus cucurbitae (Coquillett), in Hawaii .Pest Manag Sci. 2021 Dec;77(12):5439-5444. doi: 10.1002/ps.6583. Epub 2021 Aug 13. 10.1002/ps.6583"
REF00002987	Hesperidin ameliorates insulin resistance by regulating the IRS1-GLUT2 pathway via TLR4 in HepG2 cells .Phytother Res. 2019 Jun;33(6):1697-1705. doi: 10.1002/ptr.6358. Epub 2019 May 10. 10.1002/ptr.6358
REF00002988	Free ammonia resistance of nitrite-oxidizing bacteria developed in aerobic granular sludge cultivated in continuous upflow airlift reactors performing partial nitritation .Water Environ Res. 2021 Mar;93(3):421-432. doi: 10.1002/wer.1440. Epub 2020 Sep 14. 10.1002/wer.1440
REF00002989	Testing Albendazole Resistance in Fasciola hepatica .Methods Mol Biol. 2020;2137:213-220. doi: 10.1007/978-1-0716-0475-5_16. 10.1007/978-1-0716-0475-5_16
REF00002990	Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus .Methods Mol Biol. 2019;1911:3-32. doi: 10.1007/978-1-4939-8976-8_1. 10.1007/978-1-4939-8976-8_1
REF00002991	CAR T-Cells .Adv Exp Med Biol. 2020;1244:215-233. doi: 10.1007/978-3-030-41008-7_10. 10.1007/978-3-030-41008-7_10
REF00002992	In-vitro antibacterial activities of cefpiramide and other broad-spectrum antibiotics against 440 clinical isolates in China .J Infect Chemother. 2000 Jun;6(2):81-5. doi: 10.1007/pl00012156. 10.1007/pl00012156
REF00002993	ABCB1 in dermatology: roles in skin diseases and their treatment .J Mol Med (Berl). 2021 Nov;99(11):1527-1538. doi: 10.1007/s00109-021-02105-y. Epub 2021 Aug 9. 10.1007/s00109-021-02105-y
REF00002994	An innovative role for tenoxicam as a quorum sensing inhibitor in Pseudomonas aeruginosa .Arch Microbiol. 2020 Apr;202(3):555-565. doi: 10.1007/s00203-019-01771-4. Epub 2019 Nov 15. 10.1007/s00203-019-01771-4
REF00002995	Catabolism of aromatic Beta-glucosides by bacteria can lead to antibiotics resistance .Arch Microbiol. 2020 Aug;202(6):1301-1315. doi: 10.1007/s00203-020-01836-9. Epub 2020 Mar 4. 10.1007/s00203-020-01836-9
REF00002996	"Toxicities of opioid analgesics: respiratory depression, histamine release, hemodynamic changes, hypersensitivity, serotonin toxicity .Arch Toxicol. 2021 Aug;95(8):2627-2642. doi: 10.1007/s00204-021-03068-2. Epub 2021 May 11. 10.1007/s00204-021-03068-2"
REF00002997	Non-response to maprotiline caused by ultra-rapid metabolism that is different from CYP2D6  .Eur J Clin Pharmacol. 1997;52(5):387-90. doi: 10.1007/s002280050306. 10.1007/s002280050306
REF00002998	"Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects .Eur J Clin Pharmacol. 2021 Apr;77(4):527-537. doi: 10.1007/s00228-020-03023-7. Epub 2020 Oct 30. 10.1007/s00228-020-03023-7"
REF00002999	"Teicoplanin biosynthesis: unraveling the interplay of structural, regulatory, and resistance genes .Appl Microbiol Biotechnol. 2020 Apr;104(8):3279-3291. doi: 10.1007/s00253-020-10436-y. Epub 2020 Feb 19. 10.1007/s00253-020-10436-y"
REF00003000	Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis .Ann Hematol. 2019 Jun;98(6):1421-1426. doi: 10.1007/s00277-019-03654-6. Epub 2019 Mar 27. 10.1007/s00277-019-03654-6
REF00003001	Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIalpha and beta .Cancer Chemother Pharmacol. 1999;44(4):275-82. doi: 10.1007/s002800050978. 10.1007/s002800050978
REF00003002	"Mannitol-1-phosphate dehydrogenase, MpdA, is required for mannitol production in vegetative cells and involved in hyphal branching, heat resistance of conidia and sexual development in Aspergillus nidulans .Curr Genet. 2021 Aug;67(4):613-630. doi: 10.1007/s00294-021-01163-6. Epub 2021 Mar 8. 10.1007/s00294-021-01163-6"
REF00003003	Antiplatelet drug resistance is associated with early neurological deterioration in acute minor ischemic stroke in the Chinese population .J Neurol. 2016 Aug;263(8):1612-9. doi: 10.1007/s00415-016-8181-5. Epub 2016 Jun 3. 10.1007/s00415-016-8181-5
REF00003004	"Phenotypic and genetic characterization of varicella-zoster virus mutants resistant to acyclovir, brivudine and/or foscarnet .Med Microbiol Immunol. 2011 Aug;200(3):193-202. doi: 10.1007/s00430-011-0191-4. Epub 2011 Mar 4. 10.1007/s00430-011-0191-4"
REF00003005	The forkhead box M1 (FOXM1) expression and antitumor effect of FOXM1 inhibition in malignant rhabdoid tumor .J Cancer Res Clin Oncol. 2021 May;147(5):1499-1518. doi: 10.1007/s00432-020-03438-w. Epub 2020 Nov 21. 10.1007/s00432-020-03438-w
REF00003006	Susceptibility or resistance of praziquantel in human schistosomiasis: a review .Parasitol Res. 2012 Nov;111(5):1871-7. doi: 10.1007/s00436-012-3151-z. Epub 2012 Oct 7. 10.1007/s00436-012-3151-z
REF00003007	[Myofascial chronic pelvic pain in women : A retrospective evaluation of the effects of specific diagnostics and therapy] .Schmerz. 2020 Oct;34(5):388-399. doi: 10.1007/s00482-020-00488-4. 10.1007/s00482-020-00488-4
REF00003008	European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment .Eur Child Adolesc Psychiatry. 2022 Mar;31(3):425-441. doi: 10.1007/s00787-021-01899-z. Epub 2021 Nov 10. 10.1007/s00787-021-01899-z
REF00003009	Efficient photodynamic therapy against drug-resistant prostate cancer using replication-deficient virus particles and talaporfin sodium .Lasers Med Sci. 2021 Jun;36(4):743-750. doi: 10.1007/s10103-020-03076-1. Epub 2020 Jun 27. 10.1007/s10103-020-03076-1
REF00003010	Diabetes mellitus contributes to carbamazepine resistance in patient with trigeminal neuralgia .Neurosurg Rev. 2021 Apr;44(2):1119-1125. doi: 10.1007/s10143-020-01304-4. Epub 2020 Apr 24. 10.1007/s10143-020-01304-4
REF00003011	Assessment of the Chemosensitivity of Uveal Melanoma Cells Ex Vivo .Bull Exp Biol Med. 2020 Nov;170(1):142-147. doi: 10.1007/s10517-020-05020-3. Epub 2020 Nov 24. 10.1007/s10517-020-05020-3
REF00003012	Cilostazol: a Review of Basic Mechanisms and Clinical Uses .Cardiovasc Drugs Ther. 2021 Apr 16. doi: 10.1007/s10557-021-07187-x. Online ahead of print. 10.1007/s10557-021-07187-x
REF00003013	Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer .Invest New Drugs. 2020 Apr;38(2):360-368. doi: 10.1007/s10637-019-00795-3. Epub 2019 May 24. 10.1007/s10637-019-00795-3
REF00003014	Whole-genome resequencing of Trichophyton rubrum provides insights into population differentiation and drug resistance .Mycopathologia. 2020 Feb;185(1):103-112. doi: 10.1007/s11046-019-00384-1. Epub 2019 Sep 19. 10.1007/s11046-019-00384-1
REF00003015	Current concepts of the diagnosis of adult growth hormone deficiency .Rev Endocr Metab Disord. 2021 Mar;22(1):109-116. doi: 10.1007/s11154-020-09594-1. Epub 2020 Sep 22. 10.1007/s11154-020-09594-1
REF00003016	Gene polymorphisms in dual antiplatelet therapy and the presence of hypo-attenuated leaflet thickening after transcatheter aortic valve replacement .J Thromb Thrombolysis. 2018 Apr;45(3):463-465. doi: 10.1007/s11239-018-1636-z. 10.1007/s11239-018-1636-z
REF00003017	AcidoCEST MRI Evaluates the Bone Microenvironment in Multiple Myeloma .Mol Imaging Biol. 2021 Dec;23(6):865-873. doi: 10.1007/s11307-021-01611-2. Epub 2021 May 3. 10.1007/s11307-021-01611-2
REF00003018	"Occurrence of antibiotics and antibiotic resistance genes and their correlations in river-type drinking water source, China .Environ Sci Pollut Res Int. 2021 Aug;28(31):42339-42352. doi: 10.1007/s11356-021-13637-8. Epub 2021 Apr 4. 10.1007/s11356-021-13637-8"
REF00003019	Marginal Zone Lymphoma: State-of-the-Art Treatment .Curr Treat Options Oncol. 2019 Dec 5;20(12):90. doi: 10.1007/s11864-019-0687-5. 10.1007/s11864-019-0687-5
REF00003020	Targeting BTK in CLL: Beyond Ibrutinib .Curr Hematol Malig Rep. 2019 Jun;14(3):197-205. doi: 10.1007/s11899-019-00512-0. 10.1007/s11899-019-00512-0
REF00003021	Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy .Curr Hematol Malig Rep. 2020 Apr;15(2):90-102. doi: 10.1007/s11899-020-00557-6. 10.1007/s11899-020-00557-6
REF00003022	Considerations and Current Trends in the Management of the Geriatric Patient on a Consultation-Liaison Service .Curr Psychiatry Rep. 2020 Apr 13;22(5):21. doi: 10.1007/s11920-020-01147-2. 10.1007/s11920-020-01147-2
REF00003023	Antimicrobial Mechanism of Hydroquinone .Appl Biochem Biotechnol. 2019 Dec;189(4):1291-1303. doi: 10.1007/s12010-019-03067-1. Epub 2019 Jun 28. 10.1007/s12010-019-03067-1
REF00003024	Dexmedetomidine alleviates insulin resistance in hepatocytes by reducing endoplasmic reticulum stress .Endocrine. 2020 Jan;67(1):87-94. doi: 10.1007/s12020-019-02118-1. Epub 2019 Nov 2. 10.1007/s12020-019-02118-1
REF00003025	Could the kinetin riboside be used to inhibit human prostate cell epithelial-mesenchymal transition  .Med Oncol. 2020 Feb 6;37(3):17. doi: 10.1007/s12032-020-1338-1. 10.1007/s12032-020-1338-1
REF00003026	Invasive meningococcal infection: analysis of 110 cases from a tertiary care centre in North East India .Indian J Pediatr. 2013 May;80(5):359-64. doi: 10.1007/s12098-012-0855-0. Epub 2012 Jul 22. 10.1007/s12098-012-0855-0
REF00003027	Effectiveness and Safety of Nitrazepam in Children with Resistant West Syndrome .Indian J Pediatr. 2022 Jan;89(1):37-44. doi: 10.1007/s12098-021-03823-4. Epub 2021 Jun 24. 10.1007/s12098-021-03823-4
REF00003028	miR-370 Sensitizes TMZ Response Dependent of MGMT Status in Primary Central Nervous System Lymphoma .Pathol Oncol Res. 2020 Apr;26(2):707-714. doi: 10.1007/s12253-019-00605-4. Epub 2019 Feb 2. 10.1007/s12253-019-00605-4
REF00003029	Sevoflurane-induced hyperglycemia is attenuated by salsalate in obese insulin-resistant mice .Can J Anaesth. 2021 Jul;68(7):972-979. doi: 10.1007/s12630-021-01935-1. Epub 2021 Feb 12. 10.1007/s12630-021-01935-1
REF00003030	Rabeprazole has efficacy per se and reduces resistance to temozolomide in glioma via EMT inhibition .Cell Oncol (Dordr). 2021 Aug;44(4):889-905. doi: 10.1007/s13402-021-00609-w. Epub 2021 May 4. 10.1007/s13402-021-00609-w
REF00003031	New Acne Therapies and Updates on Use of Spironolactone and Isotretinoin: A Narrative Review .Dermatol Ther (Heidelb). 2021 Feb;11(1):79-91. doi: 10.1007/s13555-020-00481-w. Epub 2021 Jan 6. 10.1007/s13555-020-00481-w
REF00003032	Management of Difficult-to-Treat Warts: Traditional and New Approaches .Am J Clin Dermatol. 2021 May;22(3):379-394. doi: 10.1007/s40257-020-00582-4. Epub 2021 Jan 11. 10.1007/s40257-020-00582-4
REF00003033	Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use .Drugs. 2017 Jul;77(10):1043-1055. doi: 10.1007/s40265-017-0753-x. 10.1007/s40265-017-0753-x
REF00003034	Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli .Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2. 10.1007/s40265-019-1055-2
REF00003035	Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent .Drugs. 2020 Feb;80(3):285-313. doi: 10.1007/s40265-020-01257-4. 10.1007/s40265-020-01257-4
REF00003036	An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis .Pharmacoeconomics. 2021 Feb;39(2):181-209. doi: 10.1007/s40273-020-00965-9. Epub 2020 Oct 7. 10.1007/s40273-020-00965-9
REF00003037	Beclomethasone/Formoterol in Extra-Fine Formulation Improves Small Airway Dysfunction in COPD Patients .Pulm Ther. 2021 Jun;7(1):133-143. doi: 10.1007/s41030-021-00144-x. Epub 2021 Feb 4. 10.1007/s41030-021-00144-x
REF00003038	Serum cortisone and glucocorticoid receptor gene (NR3C1) polymorphism in human dysglycemia .Hormones (Athens). 2020 Sep;19(3):385-393. doi: 10.1007/s42000-020-00196-9. Epub 2020 Apr 17. 10.1007/s42000-020-00196-9
REF00003039	"Pharmacokinetics of lorcainide, a new antiarrhythmic drug, in patients with cardiac rhythm disorders .Am J Cardiol. 1981 Jul;48(1):157-63. doi: 10.1016/0002-9149(81)90585-3. 10.1016/0002-9149(81)90585-3"
REF00003040	"Efficacy of troleandomycin in outpatients with severe, corticosteroid-dependent asthma .J Allergy Clin Immunol. 1980 Dec;66(6):438-46. doi: 10.1016/0091-6749(80)90003-2. 10.1016/0091-6749(80)90003-2"
REF00003041	Further in vitro studies with oxiconazole nitrate .Diagn Microbiol Infect Dis. 1988 Apr;9(4):231-7. doi: 10.1016/0732-8893(88)90114-9. 10.1016/0732-8893(88)90114-9
REF00003042	Rapid-acting antidepressants .Adv Pharmacol. 2019;86:47-96. doi: 10.1016/bs.apha.2019.03.002. Epub 2019 Apr 24. 10.1016/bs.apha.2019.03.002
REF00003043	A Case of Diabetic Hemichorea Hemiballismus Exacerbated by Hypoglycemia .AACE Clin Case Rep. 2021 Apr 24;7(5):327-329. doi: 10.1016/j.aace.2021.04.004. eCollection 2021 Sep-Oct. 10.1016/j.aace.2021.04.004
REF00003044	Impact of NSAID etoricoxib on side effects of orthodontic tooth movement .Ann Anat. 2020 Nov;232:151585. doi: 10.1016/j.aanat.2020.151585. Epub 2020 Aug 18. 10.1016/j.aanat.2020.151585
REF00003045	Mapping benznidazole resistance in trypanosomatids and exploring evolutionary histories of nitroreductases and ABCG transporter protein sequences .Acta Trop. 2019 Dec;200:105161. doi: 10.1016/j.actatropica.2019.105161. Epub 2019 Sep 5. 10.1016/j.actatropica.2019.105161
REF00003046	Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC) .Actas Urol Esp (Engl Ed). 2021 Mar;45(2):93-102. doi: 10.1016/j.acuro.2020.08.003. Epub 2020 Oct 2. 10.1016/j.acuro.2020.08.003
REF00003047	Nicardipine: When high dose nitrates fail in treating heart failure .Am J Emerg Med. 2021 Jul;45:681.e3-681.e5. doi: 10.1016/j.ajem.2020.12.016. Epub 2020 Dec 13. 10.1016/j.ajem.2020.12.016
REF00003048	Recurrent vulvovaginal candidiasis .Am J Obstet Gynecol. 2016 Jan;214(1):15-21. doi: 10.1016/j.ajog.2015.06.067. Epub 2015 Jul 9. 10.1016/j.ajog.2015.06.067
REF00003049	"Nonsteroidal antiinflammatory drug resistance in dysmenorrhea: epidemiology, causes, and treatment .Am J Obstet Gynecol. 2018 Apr;218(4):390-400. doi: 10.1016/j.ajog.2017.08.108. Epub 2017 Sep 6. 10.1016/j.ajog.2017.08.108"
REF00003050	Cardiogenic Pulmonary Edema .Am J Med Sci. 2019 Dec;358(6):389-397. doi: 10.1016/j.amjms.2019.09.011. Epub 2019 Oct 1. 10.1016/j.amjms.2019.09.011
REF00003051	New treatments for chronic urticaria .Ann Allergy Asthma Immunol. 2020 Jan;124(1):2-12. doi: 10.1016/j.anai.2019.08.014. Epub 2019 Aug 23. 10.1016/j.anai.2019.08.014
REF00003052	Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations .Ann Oncol. 2021 Feb;32(2):261-268. doi: 10.1016/j.annonc.2020.10.599. Epub 2020 Nov 5. 10.1016/j.annonc.2020.10.599
REF00003053	Resistance of human cytomegalovirus to ganciclovir/valganciclovir: a comprehensive review of putative resistance pathways .Antiviral Res. 2014 Jan;101:12-25. doi: 10.1016/j.antiviral.2013.10.011. Epub 2013 Oct 31. 10.1016/j.antiviral.2013.10.011
REF00003054	Efficacy of a ML336 derivative against Venezuelan and eastern equine encephalitis viruses .Antiviral Res. 2019 Jul;167:25-34. doi: 10.1016/j.antiviral.2019.04.004. Epub 2019 Apr 7. 10.1016/j.antiviral.2019.04.004
REF00003055	The influence of the gut microbiota on the bioavailability of oral drugs .Acta Pharm Sin B. 2021 Jul;11(7):1789-1812. doi: 10.1016/j.apsb.2020.09.013. Epub 2020 Sep 28. 10.1016/j.apsb.2020.09.013
REF00003056	ER Stress Amelioration by Saxagliptin Protects the Liver Against Fructose-induced Insulin Resistance .Arch Med Res. 2020 May;51(4):303-309. doi: 10.1016/j.arcmed.2020.03.007. Epub 2020 Mar 26. 10.1016/j.arcmed.2020.03.007
REF00003057	Bioactive Lipids in COVID-19-Further Evidence .Arch Med Res. 2021 Jan;52(1):107-120. doi: 10.1016/j.arcmed.2020.09.006. Epub 2020 Sep 9. 10.1016/j.arcmed.2020.09.006
REF00003058	ABC transporter Pdr5 is required for cantharidin resistance in Saccharomyces cerevisiae .Biochem Biophys Res Commun. 2021 May 14;553:141-147. doi: 10.1016/j.bbrc.2021.03.074. Epub 2021 Mar 24. 10.1016/j.bbrc.2021.03.074
REF00003059	Valdecoxib improves lipid-induced skeletal muscle insulin resistance via simultaneous suppression of inflammation and endoplasmic reticulum stress .Biochem Pharmacol. 2021 Jun;188:114557. doi: 10.1016/j.bcp.2021.114557. Epub 2021 Apr 18. 10.1016/j.bcp.2021.114557
REF00003060	Resistance to thyrotropin .Best Pract Res Clin Endocrinol Metab. 2017 Mar;31(2):183-194. doi: 10.1016/j.beem.2017.03.004. Epub 2017 Mar 30. 10.1016/j.beem.2017.03.004
REF00003061	Venetoclax-based therapies for acute myeloid leukemia .Best Pract Res Clin Haematol. 2019 Jun;32(2):145-153. doi: 10.1016/j.beha.2019.05.008. Epub 2019 May 24. 10.1016/j.beha.2019.05.008
REF00003062	Cross-talk between EPAS-1/HIF-2Alpha and PXR signaling pathway regulates multi-drug resistance of stomach cancer cell .Int J Biochem Cell Biol. 2016 Mar;72:73-88. doi: 10.1016/j.biocel.2016.01.006. Epub 2016 Jan 16. 10.1016/j.biocel.2016.01.006
REF00003063	Multidrug resistance-1 (MDR-1) in autoimmune disorders IV. P-glycoprotein overfunction in lymphocytes from myasthenia gravis patients .Biomed Pharmacother. 2004 Jun;58(5):320-4. doi: 10.1016/j.biopha.2004.04.008. 10.1016/j.biopha.2004.04.008
REF00003064	High glucose inhibits myogenesis and induces insulin resistance by down-regulating AKT signaling .Biomed Pharmacother. 2019 Dec;120:109498. doi: 10.1016/j.biopha.2019.109498. Epub 2019 Oct 18. 10.1016/j.biopha.2019.109498
REF00003065	Long noncoding RNA LINC00461 mediates cisplatin resistance of rectal cancer via miR-593-5p/CCND1 axis .Biomed Pharmacother. 2020 Apr;124:109740. doi: 10.1016/j.biopha.2019.109740. Epub 2020 Jan 20. 10.1016/j.biopha.2019.109740
REF00003066	Diets and drugs for weight loss and health in obesity - An update .Biomed Pharmacother. 2021 Aug;140:111789. doi: 10.1016/j.biopha.2021.111789. Epub 2021 May 31. 10.1016/j.biopha.2021.111789
REF00003067	JNK downregulation improves olanzapine-induced insulin resistance by suppressing IRS1(Ser307) phosphorylation and reducing inflammation .Biomed Pharmacother. 2021 Oct;142:112071. doi: 10.1016/j.biopha.2021.112071. Epub 2021 Aug 26. 10.1016/j.biopha.2021.112071
REF00003068	Repurposing of antipsychotics perphenazine for the treatment of endometrial cancer .Bioorg Med Chem Lett. 2020 Jul 15;30(14):127239. doi: 10.1016/j.bmcl.2020.127239. Epub 2020 May 4. 10.1016/j.bmcl.2020.127239
REF00003069	The optimization and characterization of functionalized sulfonamides derived from sulfaphenazole against Mycobacterium tuberculosis with reduced CYP 2C9 inhibition .Bioorg Med Chem Lett. 2021 May 15;40:127924. doi: 10.1016/j.bmcl.2021.127924. Epub 2021 Mar 9. 10.1016/j.bmcl.2021.127924
REF00003070	Progesterone and endometrial cancer .Best Pract Res Clin Obstet Gynaecol. 2020 Nov;69:95-107. doi: 10.1016/j.bpobgyn.2020.05.003. Epub 2020 Jun 9. 10.1016/j.bpobgyn.2020.05.003
REF00003071	Role of TGF-Beta1/Smad3-mediated fibrosis in drug resistance mechanism of prolactinoma .Brain Res. 2018 Nov 1;1698:204-212. doi: 10.1016/j.brainres.2018.07.024. Epub 2018 Jul 27. 10.1016/j.brainres.2018.07.024
REF00003072	Isoflurane aggravates peripheral and central insulin resistance in high-fat diet/streptozocin-induced type 2 diabetic mice .Brain Res. 2020 Jan 15;1727:146511. doi: 10.1016/j.brainres.2019.146511. Epub 2019 Oct 28. 10.1016/j.brainres.2019.146511
REF00003073	miR-191 promotes radiation resistance of prostate cancer through interaction with RXRA .Cancer Lett. 2020 Mar 31;473:107-117. doi: 10.1016/j.canlet.2019.12.025. Epub 2019 Dec 23. 10.1016/j.canlet.2019.12.025
REF00003074	"Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity .Clin Chim Acta. 2020 Mar;502:214-221. doi: 10.1016/j.cca.2019.11.003. Epub 2019 Nov 13. 10.1016/j.cca.2019.11.003"
REF00003075	Targeting Ferroptosis to Iron Out Cancer .Cancer Cell. 2019 Jun 10;35(6):830-849. doi: 10.1016/j.ccell.2019.04.002. Epub 2019 May 16. 10.1016/j.ccell.2019.04.002
REF00003076	The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance .Cancer Cell. 2021 Jul 12;39(7):999-1014.e8. doi: 10.1016/j.ccell.2021.06.003. Epub 2021 Jun 24. 10.1016/j.ccell.2021.06.003
REF00003077	Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms .Cancer Cell. 2021 Nov 8;39(11):1531-1547.e10. doi: 10.1016/j.ccell.2021.09.003. Epub 2021 Oct 7. 10.1016/j.ccell.2021.09.003
REF00003078	"The Hyaluronidase, TMEM2, Promotes ER Homeostasis and Longevity Independent of the UPR(ER) .Cell. 2019 Nov 27;179(6):1306-1318.e18. doi: 10.1016/j.cell.2019.10.018. Epub 2019 Nov 21. 10.1016/j.cell.2019.10.018"
REF00003079	Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies .Cell. 2020 Mar 5;180(5):895-914.e27. doi: 10.1016/j.cell.2020.02.019. 10.1016/j.cell.2020.02.019
REF00003080	Bacterial community change and antibiotic resistance promotion after exposure to sulfadiazine and the role of UV/H(2)O(2)-GAC treatment .Chemosphere. 2021 Nov;283:131214. doi: 10.1016/j.chemosphere.2021.131214. Epub 2021 Jun 15. 10.1016/j.chemosphere.2021.131214
REF00003081	Pitolisant for Residual Excessive Daytime Sleepiness in OSA Patients Adhering to CPAP: A Randomized Trial .Chest. 2021 Apr;159(4):1598-1609. doi: 10.1016/j.chest.2020.09.281. Epub 2020 Oct 26. 10.1016/j.chest.2020.09.281
REF00003082	Investigation and analysis of the characteristics and drug sensitivity of bacteria in skin ulcer infections .Chin J Traumatol. 2017 Aug;20(4):194-197. doi: 10.1016/j.cjtee.2016.09.005. Epub 2017 May 24. 10.1016/j.cjtee.2016.09.005
REF00003083	Pharmacologic Management of Portal Hypertension .Clin Liver Dis. 2019 Nov;23(4):713-736. doi: 10.1016/j.cld.2019.06.004. Epub 2019 Aug 7. 10.1016/j.cld.2019.06.004
REF00003084	NAD(+) in Brain Aging and Neurodegenerative Disorders .Cell Metab. 2019 Oct 1;30(4):630-655. doi: 10.1016/j.cmet.2019.09.001. 10.1016/j.cmet.2019.09.001
REF00003085	Detection of novel mutations associated with independent resistance and cross-resistance to isoniazid and prothionamide in Mycobacterium tuberculosis clinical isolates .Clin Microbiol Infect. 2019 Aug;25(8):1041.e1-1041.e7. doi: 10.1016/j.cmi.2018.12.008. Epub 2018 Dec 22. 10.1016/j.cmi.2018.12.008
REF00003086	"Oral amoxicillin and amoxicillin-clavulanic acid: properties, indications and usage .Clin Microbiol Infect. 2020 Jul;26(7):871-879. doi: 10.1016/j.cmi.2019.11.028. Epub 2019 Dec 4. 10.1016/j.cmi.2019.11.028"
REF00003087	Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis .Clin Microbiol Infect. 2021 Jan;27(1):19-27. doi: 10.1016/j.cmi.2020.08.022. Epub 2020 Aug 26. 10.1016/j.cmi.2020.08.022
REF00003088	"An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-Beta-1a and hydroxychloroquine in hospitalized patients with COVID-19 .Clin Microbiol Infect. 2021 Dec;27(12):1826-1837. doi: 10.1016/j.cmi.2021.05.020. Epub 2021 May 26. 10.1016/j.cmi.2021.05.020"
REF00003089	Bone interface modulates drug resistance in breast cancer bone metastasis .Colloids Surf B Biointerfaces. 2020 Nov;195:111224. doi: 10.1016/j.colsurfb.2020.111224. Epub 2020 Jun 26. 10.1016/j.colsurfb.2020.111224
REF00003090	Doxifluridine-based pharmacosomes delivering miR-122 as tumor microenvironments-activated nanoplatforms for synergistic treatment of hepatocellular carcinoma .Colloids Surf B Biointerfaces. 2021 Jan;197:111367. doi: 10.1016/j.colsurfb.2020.111367. Epub 2020 Sep 23. 10.1016/j.colsurfb.2020.111367
REF00003091	"Lactobacillus species isolated from the vagina: identification, hydrogen peroxide production and nonoxynol-9 resistance .Contraception. 2006 Jan;73(1):78-81. doi: 10.1016/j.contraception.2005.06.066. Epub 2005 Nov 16. 10.1016/j.contraception.2005.06.066"
REF00003092	Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters .Contraception. 2020 Dec;102(6):396-402. doi: 10.1016/j.contraception.2020.08.015. Epub 2020 Sep 19. 10.1016/j.contraception.2020.08.015
REF00003093	Drug resistance in inflammatory bowel diseases .Curr Opin Pharmacol. 2015 Dec;25:56-61. doi: 10.1016/j.coph.2015.11.003. Epub 2015 Nov 29. 10.1016/j.coph.2015.11.003
REF00003094	"Drug-resistance in rheumatoid arthritis: the role of p53 gene mutations, ABC family transporters and personal factors .Curr Opin Pharmacol. 2020 Oct;54:59-71. doi: 10.1016/j.coph.2020.08.002. Epub 2020 Sep 14. 10.1016/j.coph.2020.08.002"
REF00003095	Hepatitis B antivirals and resistance .Curr Opin Virol. 2013 Oct;3(5):495-500. doi: 10.1016/j.coviro.2013.08.006. Epub 2013 Sep 7. 10.1016/j.coviro.2013.08.006
REF00003096	Association of Monoamine Oxidase A with Tumor Burden and Castration Resistance in Prostate Cancer .Curr Ther Res Clin Exp. 2020 Oct 28;93:100610. doi: 10.1016/j.curtheres.2020.100610. eCollection 2020. 10.1016/j.curtheres.2020.100610
REF00003097	Gemcitabine resistance in pancreatic ductal adenocarcinoma .Drug Resist Updat. 2015 Nov;23:55-68. doi: 10.1016/j.drup.2015.10.002. Epub 2015 Nov 3. 10.1016/j.drup.2015.10.002
REF00003098	Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance .Drug Resist Updat. 2020 Jan;48:100663. doi: 10.1016/j.drup.2019.100663. Epub 2019 Nov 11. 10.1016/j.drup.2019.100663
REF00003099	Surmounting cancer drug resistance: New insights from the perspective of N(6)-methyladenosine RNA modification .Drug Resist Updat. 2020 Dec;53:100720. doi: 10.1016/j.drup.2020.100720. Epub 2020 Aug 20. 10.1016/j.drup.2020.100720
REF00003100	"Recent advances of podophyllotoxin/epipodophyllotoxin hybrids in anticancer activity, mode of action, and structure-activity relationship: An update (2010-2020) .Eur J Med Chem. 2020 Dec 15;208:112830. doi: 10.1016/j.ejmech.2020.112830. Epub 2020 Sep 12. 10.1016/j.ejmech.2020.112830"
REF00003101	Hesperetin ameliorates DSS-induced colitis by maintaining the epithelial barrier via blocking RIPK3/MLKL necroptosis signaling .Eur J Pharmacol. 2020 Apr 15;873:172992. doi: 10.1016/j.ejphar.2020.172992. Epub 2020 Feb 6. 10.1016/j.ejphar.2020.172992
REF00003102	Revisit ligand-receptor interaction at the human vasopressin V(2) receptor: A kinetic perspective .Eur J Pharmacol. 2020 Aug 5;880:173157. doi: 10.1016/j.ejphar.2020.173157. Epub 2020 Apr 30. 10.1016/j.ejphar.2020.173157
REF00003103	Alogliptin reversed hippocampal insulin resistance in an amyloid-beta fibrils induced animal model of Alzheimer's disease .Eur J Pharmacol. 2020 Dec 15;889:173522. doi: 10.1016/j.ejphar.2020.173522. Epub 2020 Aug 29. 10.1016/j.ejphar.2020.173522
REF00003104	A review of potential suggested drugs for coronavirus disease (COVID-19) treatment .Eur J Pharmacol. 2021 Mar 15;895:173890. doi: 10.1016/j.ejphar.2021.173890. Epub 2021 Jan 20. 10.1016/j.ejphar.2021.173890
REF00003105	Gliquidone ameliorates hepatic insulin resistance in streptozotocin-induced diabetic Sur1(-/-) rats .Eur J Pharmacol. 2021 Sep 5;906:174221. doi: 10.1016/j.ejphar.2021.174221. Epub 2021 Jun 1. 10.1016/j.ejphar.2021.174221
REF00003106	Verapamil and riluzole cocktail liposomes overcome pharmacoresistance by inhibiting P-glycoprotein in brain endothelial and astrocyte cells: A potent approach to treat amyotrophic lateral sclerosis .Eur J Pharm Sci. 2018 Jul 30;120:30-39. doi: 10.1016/j.ejps.2018.04.026. Epub 2018 Apr 26. 10.1016/j.ejps.2018.04.026
REF00003107	CYP2C19 Polymorphism is Associated With Amputation Rates in Patients Taking Clopidogrel After Endovascular Intervention for Critical Limb Ischaemia .Eur J Vasc Endovasc Surg. 2019 Sep;58(3):373-382. doi: 10.1016/j.ejvs.2019.02.011. Epub 2019 Aug 5. 10.1016/j.ejvs.2019.02.011
REF00003108	An Overview of Rickets in Children .Kidney Int Rep. 2020 Apr 11;5(7):980-990. doi: 10.1016/j.ekir.2020.03.025. eCollection 2020 Jul. 10.1016/j.ekir.2020.03.025
REF00003109	Antibiotic resistance genes are increased by combined exposure to sulfamethoxazole and naproxen but relieved by low-salinity .Environ Int. 2020 Jun;139:105742. doi: 10.1016/j.envint.2020.105742. Epub 2020 Apr 18. 10.1016/j.envint.2020.105742
REF00003110	Association of ABCB1 polymorphisms with carbamazepine metabolism and resistance in epilepsy: A meta-analysis .Epilepsy Res. 2021 Nov;177:106785. doi: 10.1016/j.eplepsyres.2021.106785. Epub 2021 Oct 7. 10.1016/j.eplepsyres.2021.106785
REF00003111	"The effect of tibolone treatment on fasting blood sugar, insulin, insulin resistance and endothelial function in postmenopausal women: A meta-analysis of randomized controlled trials .Exp Gerontol. 2021 Nov;155:111586. doi: 10.1016/j.exger.2021.111586. Epub 2021 Oct 8. 10.1016/j.exger.2021.111586"
REF00003112	Quantitative molecular diagnosis of levamisole resistance in populations of Haemonchus contortus .Exp Parasitol. 2019 Oct;205:107734. doi: 10.1016/j.exppara.2019.107734. Epub 2019 Aug 5. 10.1016/j.exppara.2019.107734
REF00003113	Oral exposure of rats to dienestrol during gestation and lactation: Effects on the reproductive system of male offspring .Food Chem Toxicol. 2019 Jun;128:193-201. doi: 10.1016/j.fct.2019.04.013. Epub 2019 Apr 12. 10.1016/j.fct.2019.04.013
REF00003114	Imatinib interferes with survival of multi drug resistant Kaposi's sarcoma cells .FEBS Lett. 2007 Dec 22;581(30):5897-903. doi: 10.1016/j.febslet.2007.11.069. Epub 2007 Dec 3. 10.1016/j.febslet.2007.11.069
REF00003115	Multi-drug resistance-1 gene polymorphisms in nephrotic syndrome: impact on susceptibility and response to steroids .Gene. 2013 Nov 10;530(2):201-7. doi: 10.1016/j.gene.2013.08.045. Epub 2013 Aug 27. 10.1016/j.gene.2013.08.045
REF00003116	Molecular principles behind Boceprevir resistance due to mutations in hepatitis C NS3/4A protease .Gene. 2015 Oct 1;570(1):115-21. doi: 10.1016/j.gene.2015.06.008. Epub 2015 Jun 6. 10.1016/j.gene.2015.06.008
REF00003117	"Drug-resistant cytomegalovirus infection after lung transplantation: Incidence, characteristics, and clinical outcomes .J Heart Lung Transplant. 2019 Dec;38(12):1268-1274. doi: 10.1016/j.healun.2019.09.005. Epub 2019 Sep 10. 10.1016/j.healun.2019.09.005"
REF00003118	Is pulmonary vascular resistance index better than pulmonary vascular resistance in predicting outcomes in pulmonary arterial hypertension  .J Heart Lung Transplant. 2021 Jul;40(7):614-622. doi: 10.1016/j.healun.2021.03.022. Epub 2021 Apr 2. 10.1016/j.healun.2021.03.022
REF00003119	The evolution of the pilocarpine animal model of status epilepticus .Heliyon. 2020 Jul 28;6(7):e04557. doi: 10.1016/j.heliyon.2020.e04557. eCollection 2020 Jul. 10.1016/j.heliyon.2020.e04557
REF00003120	Enhanced expression of membrane transporter and drug resistance in keloid fibroblasts .Hum Pathol. 2012 Nov;43(11):2024-32. doi: 10.1016/j.humpath.2011.12.026. Epub 2012 May 21. 10.1016/j.humpath.2011.12.026
REF00003121	Resistance of the Burkholderia cepacia complex to fosmidomycin and fosmidomycin derivatives .Int J Antimicrob Agents. 2011 Sep;38(3):261-4. doi: 10.1016/j.ijantimicag.2011.04.020. Epub 2011 Jul 2. 10.1016/j.ijantimicag.2011.04.020
REF00003122	Ivermectin: From theory to clinical application .Int J Antimicrob Agents. 2019 Aug;54(2):134-142. doi: 10.1016/j.ijantimicag.2019.05.003. Epub 2019 May 7. 10.1016/j.ijantimicag.2019.05.003
REF00003123	Faropenem resistance causes in vitro cross-resistance to carbapenems in ESBL-producing Escherichia coli .Int J Antimicrob Agents. 2020 Mar;55(3):105902. doi: 10.1016/j.ijantimicag.2020.105902. Epub 2020 Jan 17. 10.1016/j.ijantimicag.2020.105902
REF00003124	Acid-responsive dextran-based therapeutic nanoplatforms for photodynamic-chemotherapy against multidrug resistance .Int J Biol Macromol. 2020 Jul 15;155:233-240. doi: 10.1016/j.ijbiomac.2020.03.197. Epub 2020 Mar 26. 10.1016/j.ijbiomac.2020.03.197
REF00003125	"Prevalence, genetic diversity, and antibiotic resistance patterns of Campylobacter jejuni from retail raw chickens in Korea .Int J Food Microbiol. 2007 Feb 28;114(1):50-9. doi: 10.1016/j.ijfoodmicro.2006.10.042. Epub 2007 Jan 4. 10.1016/j.ijfoodmicro.2006.10.042"
REF00003126	Characterizing the gene mutations associated with resistance to gatifloxacin in Mycobacterium tuberculosis through whole-genome sequencing .Int J Infect Dis. 2021 Nov;112:189-194. doi: 10.1016/j.ijid.2021.09.028. Epub 2021 Sep 20. 10.1016/j.ijid.2021.09.028
REF00003127	Resistance of Leishmania infantum to allopurinol is associated with chromosome and gene copy number variations including decrease in the S-adenosylmethionine synthetase (METK) gene copy number .Int J Parasitol Drugs Drug Resist. 2018 Dec;8(3):403-410. doi: 10.1016/j.ijpddr.2018.08.002. Epub 2018 Aug 23. 10.1016/j.ijpddr.2018.08.002
REF00003128	Using droplet digital PCR for the detection of hco-acr-8b levamisole resistance marker in H. contortus .Int J Parasitol Drugs Drug Resist. 2021 Apr;15:168-176. doi: 10.1016/j.ijpddr.2021.03.002. Epub 2021 Mar 26. 10.1016/j.ijpddr.2021.03.002
REF00003129	"Everolimus and pancreatic neuroendocrine tumors (PNETs): Activity, resistance and how to overcome it .Int J Surg. 2015 Sep;21 Suppl 1:S89-94. doi: 10.1016/j.ijsu.2015.06.064. Epub 2015 Jun 27. 10.1016/j.ijsu.2015.06.064"
REF00003130	Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients .J Am Acad Dermatol. 2020 Jan;82(1):161-201. doi: 10.1016/j.jaad.2019.08.049. Epub 2019 Nov 5. 10.1016/j.jaad.2019.08.049
REF00003131	Abatacept as a Long-Term Targeted Therapy for LRBA Deficiency .J Allergy Clin Immunol Pract. 2019 Nov-Dec;7(8):2790-2800.e15. doi: 10.1016/j.jaip.2019.06.011. Epub 2019 Jun 22. 10.1016/j.jaip.2019.06.011
REF00003132	c-Met expression in renal cell carcinoma with bone metastases .J Bone Oncol. 2020 Sep 16;25:100315. doi: 10.1016/j.jbo.2020.100315. eCollection 2020 Dec. 10.1016/j.jbo.2020.100315
REF00003133	Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis .Joint Bone Spine. 2021 Oct;88(5):105219. doi: 10.1016/j.jbspin.2021.105219. Epub 2021 May 19. 10.1016/j.jbspin.2021.105219
REF00003134	Midodrine Improves the Tolerability of Diuretics in Patients with Acute-on-Chronic Liver Failure-A Pilot Study .J Clin Exp Hepatol. 2021 Sep-Oct;11(5):573-578. doi: 10.1016/j.jceh.2020.12.002. Epub 2020 Dec 17. 10.1016/j.jceh.2020.12.002
REF00003135	Diuretic Strategies for Loop Diuretic Resistance in Acute Heart Failure: The 3T Trial .JACC Heart Fail. 2020 Mar;8(3):157-168. doi: 10.1016/j.jchf.2019.09.012. Epub 2019 Dec 11. 10.1016/j.jchf.2019.09.012
REF00003136	Besifloxacin in the management of bacterial infections of the ocular surface .Can J Ophthalmol. 2015 Jun;50(3):184-91. doi: 10.1016/j.jcjo.2014.12.013. 10.1016/j.jcjo.2014.12.013
REF00003137	Current uses of chlorhexidine for management of oral disease: a narrative review .J Dent. 2020 Dec;103:103497. doi: 10.1016/j.jdent.2020.103497. Epub 2020 Oct 17. 10.1016/j.jdent.2020.103497
REF00003138	The Effect of Ground Poles and Elastic Resistance Bands on Longissimus Dorsi and Rectus Abdominus Muscle Activity During Equine Walk and Trot .J Equine Vet Sci. 2021 Dec;107:103772. doi: 10.1016/j.jevs.2021.103772. Epub 2021 Sep 17. 10.1016/j.jevs.2021.103772
REF00003139	Eye amputation following lifitegrast treatment for ocular graft-versus-host disease: First case report .J Fr Ophtalmol. 2021 May;44(5):652-657. doi: 10.1016/j.jfo.2020.12.004. Epub 2021 Apr 12. 10.1016/j.jfo.2020.12.004
REF00003140	Novel dihydropteroate synthase gene mutation in Pneumocystis jirovecii among HIV-infected patients in India: Putative association with drug resistance and mortality .J Glob Antimicrob Resist. 2019 Jun;17:236-239. doi: 10.1016/j.jgar.2019.01.007. Epub 2019 Jan 15. 10.1016/j.jgar.2019.01.007
REF00003141	Mupirocin resistance in Staphylococcus aureus: A systematic review and meta-analysis .J Glob Antimicrob Resist. 2020 Mar;20:238-247. doi: 10.1016/j.jgar.2019.07.032. Epub 2019 Aug 20. 10.1016/j.jgar.2019.07.032
REF00003142	Prevalence of biocide resistance genes and chlorhexidine and mupirocin non-susceptibility in Portuguese hospitals during a 31-year period (1985-2016) .J Glob Antimicrob Resist. 2021 Mar;24:169-174. doi: 10.1016/j.jgar.2020.12.010. Epub 2020 Dec 26. 10.1016/j.jgar.2020.12.010
REF00003143	Full spectrum driven SCR removal of NO over hierarchical CeVO(4)/attapulgite nanocomposite with high resistance to SO(2) and H(2)O .J Hazard Mater. 2020 Mar 15;386:121977. doi: 10.1016/j.jhazmat.2019.121977. Epub 2019 Dec 26. 10.1016/j.jhazmat.2019.121977
REF00003144	"In-feed antibiotic use changed the behaviors of oxytetracycline, sulfamerazine, and ciprofloxacin and related antibiotic resistance genes during swine manure composting .J Hazard Mater. 2021 Jan 15;402:123710. doi: 10.1016/j.jhazmat.2020.123710. Epub 2020 Aug 22. 10.1016/j.jhazmat.2020.123710"
REF00003145	Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir .J Hepatol. 2017 Apr;66(4):703-710. doi: 10.1016/j.jhep.2016.11.022. Epub 2016 Dec 5. 10.1016/j.jhep.2016.11.022
REF00003146	ABCB5-Targeted Chemoresistance Reversal Inhibits Merkel Cell Carcinoma Growth .J Invest Dermatol. 2016 Apr;136(4):838-846. doi: 10.1016/j.jid.2015.12.038. Epub 2016 Jan 29. 10.1016/j.jid.2015.12.038
REF00003147	Cancer-Associated Fibroblasts in Mycosis Fungoides Promote Tumor Cell Migration and Drug Resistance through CXCL12/CXCR4 .J Invest Dermatol. 2021 Mar;141(3):619-627.e2. doi: 10.1016/j.jid.2020.06.034. Epub 2020 Aug 11. 10.1016/j.jid.2020.06.034
REF00003148	Jak-STAT Inhibition Mediates Romidepsin and Mechlorethamine Synergism in Cutaneous T-Cell Lymphoma .J Invest Dermatol. 2021 Dec;141(12):2908-2920.e7. doi: 10.1016/j.jid.2021.04.023. Epub 2021 Jun 3. 10.1016/j.jid.2021.04.023
REF00003149	Combined Cyclin-Dependent Kinase Inhibition Overcomes MAPK/Extracellular Signal-Regulated Kinase Kinase Inhibitor Resistance in Plexiform Neurofibroma of Neurofibromatosis Type I .J Invest Dermatol. 2022 Mar;142(3 Pt A):613-623.e7. doi: 10.1016/j.jid.2021.07.164. Epub 2021 Sep 15. 10.1016/j.jid.2021.07.164
REF00003150	Probing the mechanisms of inhibition for various inhibitors of metallo-Beta-lactamases VIM-2 and NDM-1 .J Inorg Biochem. 2020 Sep;210:111123. doi: 10.1016/j.jinorgbio.2020.111123. Epub 2020 Jun 15. 10.1016/j.jinorgbio.2020.111123
REF00003151	"Overview of hepatitis C infection, molecular biology, and new treatment .J Infect Public Health. 2020 May;13(5):773-783. doi: 10.1016/j.jiph.2019.11.015. Epub 2019 Dec 20. 10.1016/j.jiph.2019.11.015"
REF00003152	Downregulation of Na(+)-NQR complex is essential for Vibrio alginolyticus in resistance to balofloxacin .J Proteomics. 2012 May 17;75(9):2638-48. doi: 10.1016/j.jprot.2012.03.006. Epub 2012 Mar 17. 10.1016/j.jprot.2012.03.006
REF00003153	Onabotulinum toxin-A versus extended release tolterodine in the management of idiopathic overactive bladder in children: A pilot randomised controlled trial (OVERT trial) .J Pediatr Urol. 2021 Feb;17(1):77.e1-77.e12. doi: 10.1016/j.jpurol.2020.10.012. Epub 2020 Oct 19. 10.1016/j.jpurol.2020.10.012
REF00003154	Gamma-Tocotrienol reverses multidrug resistance of breast cancer cells through the regulation of the Gamma-Tocotrienol-NF-kB-P-gp axis .J Steroid Biochem Mol Biol. 2021 May;209:105835. doi: 10.1016/j.jsbmb.2021.105835. Epub 2021 Feb 5. 10.1016/j.jsbmb.2021.105835
REF00003155	Pharmacological torpor prolongs rat survival in lethal normobaric hypoxia .J Therm Biol. 2021 May;98:102906. doi: 10.1016/j.jtherbio.2021.102906. Epub 2021 Mar 18. 10.1016/j.jtherbio.2021.102906
REF00003156	Erdafitinib Overcomes FGFR3-TACC3-Mediated Resistance to Osimertinib .J Thorac Oncol. 2020 Sep;15(9):e154-e156. doi: 10.1016/j.jtho.2019.12.132. 10.1016/j.jtho.2019.12.132
REF00003157	A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor .J Thorac Oncol. 2021 May;16(5):850-859. doi: 10.1016/j.jtho.2021.01.1605. Epub 2021 Feb 3. 10.1016/j.jtho.2021.01.1605
REF00003158	"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial .Kidney Int. 2020 Jan;97(1):202-212. doi: 10.1016/j.kint.2019.09.013. Epub 2019 Oct 10. 10.1016/j.kint.2019.09.013"
REF00003159	Synthetic peptides against Trichophyton mentagrophytes and T. rubrum: Mechanisms of action and efficiency compared to griseofulvin and itraconazole .Life Sci. 2021 Jan 15;265:118803. doi: 10.1016/j.lfs.2020.118803. Epub 2020 Nov 23. 10.1016/j.lfs.2020.118803
REF00003160	"Propranolol and low-dose isoproterenol ameliorate insulin resistance, enhance Beta-arrestin2 signaling, and reduce cardiac remodeling in high-fructose, high-fat diet-fed mice: Comparative study with metformin .Life Sci. 2021 Dec 1;286:120055. doi: 10.1016/j.lfs.2021.120055. Epub 2021 Oct 15. 10.1016/j.lfs.2021.120055"
REF00003161	"Occurrence and antibacterial resistance of culturable antibiotic-resistant bacteria in the Fildes Peninsula, Antarctica .Mar Pollut Bull. 2021 Jan;162:111829. doi: 10.1016/j.marpolbul.2020.111829. Epub 2020 Nov 23. 10.1016/j.marpolbul.2020.111829"
REF00003162	MicroRNA expression profile of bromocriptine-resistant prolactinomas .Mol Cell Endocrinol. 2014 Sep;395(1-2):10-8. doi: 10.1016/j.mce.2014.07.014. Epub 2014 Jul 23. 10.1016/j.mce.2014.07.014
REF00003163	Treatment of Graves' ophthalmopathy .Med Clin (Barc). 2021 Feb 26;156(4):180-186. doi: 10.1016/j.medcli.2020.07.031. Epub 2020 Oct 14. 10.1016/j.medcli.2020.07.031
REF00003164	Cefoperazone/sulbactam: New composites against multiresistant gram negative bacteria  .Infect Genet Evol. 2021 Mar;88:104707. doi: 10.1016/j.meegid.2021.104707. Epub 2021 Jan 5. 10.1016/j.meegid.2021.104707
REF00003165	"Fenofibrate, a PPARAlpha agonist, reduces hepatic fat accumulation through the upregulation of TFEB-mediated lipophagy .Metabolism. 2021 Jul;120:154798. doi: 10.1016/j.metabol.2021.154798. Epub 2021 May 11. 10.1016/j.metabol.2021.154798"
REF00003166	"Amantadine resistance markers among low pathogenic avian influenza H9N2 viruses isolated from poultry in India, during 2009-2017 .Microb Pathog. 2019 Dec;137:103779. doi: 10.1016/j.micpath.2019.103779. Epub 2019 Oct 7. 10.1016/j.micpath.2019.103779"
REF00003167	Oncogene-dependent sloppiness in mRNA translation .Mol Cell. 2021 Nov 18;81(22):4709-4721.e9. doi: 10.1016/j.molcel.2021.09.002. Epub 2021 Sep 24. 10.1016/j.molcel.2021.09.002
REF00003168	Cloning and immunobiochemical analyses on recombinant chymopapain allergen Cari p 2 showing pollen-fruit cross-reaction .Mol Immunol. 2021 Sep;137:42-51. doi: 10.1016/j.molimm.2021.06.010. Epub 2021 Jun 29. 10.1016/j.molimm.2021.06.010
REF00003169	In vitro evaluation of anti-fungal activity of tropicamide against strains of Candida spp. resistant to fluconazole in planktonic and biofilm form .J Mycol Med. 2021 Mar;31(1):101080. doi: 10.1016/j.mycmed.2020.101080. Epub 2020 Nov 11. 10.1016/j.mycmed.2020.101080
REF00003170	Side effects of continuous intra-arterial infusion of nimodipine for management of resistant cerebral vasospasm in subarachnoid hemorrhage patients: A systematic review .Neurochirurgie. 2021 Sep;67(5):461-469. doi: 10.1016/j.neuchi.2021.02.005. Epub 2021 Feb 27. 10.1016/j.neuchi.2021.02.005
REF00003171	"Linagliptin, a DPP-4 inhibitor, ameliorates ABeta (1-42) peptides induced neurodegeneration and brain insulin resistance (BIR) via insulin receptor substrate-1 (IRS-1) in rat model of Alzheimer's disease .Neuropharmacology. 2021 Sep 1;195:108662. doi: 10.1016/j.neuropharm.2021.108662. Epub 2021 Jun 11. 10.1016/j.neuropharm.2021.108662"
REF00003172	Assessment of drug transporters involved in the urinary secretion of [(99m)Tc]dimercaptosuccinic acid .Nucl Med Biol. 2021 Mar-Apr;94-95:92-97. doi: 10.1016/j.nucmedbio.2021.01.004. Epub 2021 Feb 5. 10.1016/j.nucmedbio.2021.01.004
REF00003173	UDP-glycosyltransferases contribute to spirotetramat resistance in Aphis gossypii Glover .Pestic Biochem Physiol. 2020 Jun;166:104565. doi: 10.1016/j.pestbp.2020.104565. Epub 2020 Mar 23. 10.1016/j.pestbp.2020.104565
REF00003174	Identification of up- and down-regulated proteins in doxorubicin-resistant uterine cancer cells: reticulocalbin-1 plays a key role in the development of doxorubicin-associated resistance .Pharmacol Res. 2014 Dec;90:1-17. doi: 10.1016/j.phrs.2014.08.007. Epub 2014 Sep 19. 10.1016/j.phrs.2014.08.007
REF00003175	Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update .Pharmacol Res. 2020 Feb;152:104609. doi: 10.1016/j.phrs.2019.104609. Epub 2019 Dec 17. 10.1016/j.phrs.2019.104609
REF00003176	Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2 .Pharmacol Res. 2020 Sep;159:105007. doi: 10.1016/j.phrs.2020.105007. Epub 2020 Jun 17. 10.1016/j.phrs.2020.105007
REF00003177	"Epimagnolin A, a tetrahydrofurofuranoid lignan from Magnolia fargesii, reverses ABCB1-mediated drug resistance .Phytomedicine. 2018 Dec 1;51:112-119. doi: 10.1016/j.phymed.2018.06.030. Epub 2018 Jun 20. 10.1016/j.phymed.2018.06.030"
REF00003178	"Clonal dissemination of Salmonella enterica serovar albany with concurrent resistance to ampicillin, chloramphenicol, streptomycin, sulfisoxazole, tetracycline, and nalidixic acid in broiler chicken in Korea .Poult Sci. 2021 Jul;100(7):101141. doi: 10.1016/j.psj.2021.101141. Epub 2021 Mar 22. 10.1016/j.psj.2021.101141"
REF00003179	A ganglionic blocker and adrenoceptor ligands modify clozapine-induced insulin resistance .Psychoneuroendocrinology. 2021 Jul;129:105257. doi: 10.1016/j.psyneuen.2021.105257. Epub 2021 May 12. 10.1016/j.psyneuen.2021.105257
REF00003180	Drug resistance in African trypanosomiasis: the melarsoprol and pentamidine story .Trends Parasitol. 2013 Mar;29(3):110-8. doi: 10.1016/j.pt.2012.12.005. Epub 2013 Jan 30. 10.1016/j.pt.2012.12.005
REF00003181	Melarsoprol Resistance in African Trypanosomiasis .Trends Parasitol. 2018 Jun;34(6):481-492. doi: 10.1016/j.pt.2018.04.002. Epub 2018 Apr 25. 10.1016/j.pt.2018.04.002
REF00003182	Pathogen characteristics reveal novel antibacterial approaches for interstitial lung disease .Pulm Pharmacol Ther. 2014 Dec;29(2):250-4. doi: 10.1016/j.pupt.2014.03.005. Epub 2014 Apr 1. 10.1016/j.pupt.2014.03.005
REF00003183	Oxidative stress-based therapeutics in COPD .Redox Biol. 2020 Jun;33:101544. doi: 10.1016/j.redox.2020.101544. Epub 2020 Apr 20. 10.1016/j.redox.2020.101544
REF00003184	The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies .Semin Cancer Biol. 2020 Oct;65:176-188. doi: 10.1016/j.semcancer.2019.12.007. Epub 2019 Dec 23. 10.1016/j.semcancer.2019.12.007
REF00003185	Radiopharmaceuticals for Bone Metastases .Semin Radiat Oncol. 2021 Jan;31(1):45-59. doi: 10.1016/j.semradonc.2020.07.005. 10.1016/j.semradonc.2020.07.005
REF00003186	Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells .Cell Stem Cell. 2020 Nov 5;27(5):748-764.e4. doi: 10.1016/j.stem.2020.07.021. Epub 2020 Aug 20. 10.1016/j.stem.2020.07.021
REF00003187	Nandrolone combined with strenuous resistance training impairs myocardial proteome profile of rats .Steroids. 2021 Nov;175:108916. doi: 10.1016/j.steroids.2021.108916. Epub 2021 Sep 4. 10.1016/j.steroids.2021.108916
REF00003188	"Diosmin ameliorates inflammation, insulin resistance, and fibrosis in an experimental model of non-alcoholic steatohepatitis in rats .Toxicol Appl Pharmacol. 2020 Aug 15;401:115101. doi: 10.1016/j.taap.2020.115101. Epub 2020 Jun 6. 10.1016/j.taap.2020.115101"
REF00003189	RANKL-induced osteoclastogenesis in bone marrow-derived macrophages is suppressed by cisapride .Toxicology. 2019 Jun 15;422:95-101. doi: 10.1016/j.tox.2019.05.010. Epub 2019 May 28. 10.1016/j.tox.2019.05.010
REF00003190	Dual TBK1/IKK Epsilon inhibitor amlexanox mitigates palmitic acid-induced hepatotoxicity and lipoapoptosis in vitro .Toxicology. 2020 Nov;444:152579. doi: 10.1016/j.tox.2020.152579. Epub 2020 Sep 6. 10.1016/j.tox.2020.152579
REF00003191	Evaluation of intramuscular sodium nitroprusside injection to improve oxygenation in white-tailed deer (Odocoileus virginianus) anesthetized with medetomidine-alfaxalone-azaperone .Vet Anaesth Analg. 2021 Jan;48(1):65-73. doi: 10.1016/j.vaa.2020.10.006. Epub 2020 Nov 6. 10.1016/j.vaa.2020.10.006
REF00003192	Use of intravenous lidocaine to treat dexmedetomidine-induced bradycardia in sedated and anesthetized dogs .Vet Anaesth Analg. 2021 Mar;48(2):174-186. doi: 10.1016/j.vaa.2020.11.005. Epub 2020 Dec 23. 10.1016/j.vaa.2020.11.005
REF00003193	Prediction of ligands to universally conserved binding sites of the influenza a virus nuclear export protein .Virology. 2019 Nov;537:97-103. doi: 10.1016/j.virol.2019.08.013. Epub 2019 Aug 14. 10.1016/j.virol.2019.08.013
REF00003194	Understanding triclabendazole resistance .Exp Mol Pathol. 2007 Apr;82(2):104-9. doi: 10.1016/j.yexmp.2007.01.009. Epub 2007 Feb 15. 10.1016/j.yexmp.2007.01.009
REF00003195	Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines .FEBS Lett. 2002 Nov 20;531(3):415-20. doi: 10.1016/s0014-5793(02)03575-5. 10.1016/s0014-5793(02)03575-5
REF00003196	Tetracyclines .Zentralbl Bakteriol Parasitenkd Infektionskr Hyg. 1973;128(1):51-60. doi: 10.1016/s0044-4057(73)80038-3. 10.1016/s0044-4057(73)80038-3
REF00003197	MDR1 expression is associated with adverse survival in melanoma of the uveal tract .Hum Pathol. 1998 Jun;29(6):594-8. doi: 10.1016/s0046-8177(98)80008-7. 10.1016/s0046-8177(98)80008-7
REF00003198	"Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial .Lancet. 2019 May 25;393(10186):2125-2134. doi: 10.1016/S0140-6736(19)30724-X. Epub 2019 Apr 17. 10.1016/S0140-6736(19)30724-X"
REF00003199	Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis .Lancet. 2019 Sep 14;394(10202):939-951. doi: 10.1016/S0140-6736(19)31135-3. Epub 2019 Jul 11. 10.1016/S0140-6736(19)31135-3
REF00003200	"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study .Lancet Oncol. 2020 Jun;21(6):796-807. doi: 10.1016/S1470-2045(20)30157-1. Epub 2020 May 13. 10.1016/S1470-2045(20)30157-1"
REF00003201	"Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial .Lancet Oncol. 2020 Jul;21(7):923-934. doi: 10.1016/S1470-2045(20)30168-6. Epub 2020 Jun 5. 10.1016/S1470-2045(20)30168-6"
REF00003202	"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study .Lancet Oncol. 2020 Jul;21(7):978-988. doi: 10.1016/S1470-2045(20)30225-4. Epub 2020 Jun 5. 10.1016/S1470-2045(20)30225-4"
REF00003203	"Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial .Lancet Oncol. 2021 Jun;22(6):848-857. doi: 10.1016/S1470-2045(21)00126-1. Epub 2021 May 14. 10.1016/S1470-2045(21)00126-1"
REF00003204	Cephalosporin resistance in Malawi .Lancet Infect Dis. 2020 Mar;20(3):285-286. doi: 10.1016/S1473-3099(20)30047-5. 10.1016/S1473-3099(20)30047-5
REF00003205	"Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial .Lancet Respir Med. 2020 Nov;8(11):1132-1143. doi: 10.1016/S2213-2600(20)30154-5. Epub 2020 May 29. 10.1016/S2213-2600(20)30154-5"
REF00003206	Pharmacotherapy for pulmonary arterial hypertension .Lancet Respir Med. 2020 Nov;8(11):e81. doi: 10.1016/S2213-2600(20)30394-5. Epub 2020 Aug 25. 10.1016/S2213-2600(20)30394-5
REF00003207	Insecticide resistance and ITNs in India .Lancet Glob Health. 2021 Oct;9(10):e1370. doi: 10.1016/S2214-109X(21)00369-7. 10.1016/S2214-109X(21)00369-7
REF00003208	"Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis .Lancet Psychiatry. 2020 Jul;7(7):581-601. doi: 10.1016/S2215-0366(20)30137-1. 10.1016/S2215-0366(20)30137-1"
REF00003209	Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study .Lancet Haematol. 2020 Mar;7(3):e226-e237. doi: 10.1016/S2352-3026(19)30207-8. Epub 2020 Jan 23. 10.1016/S2352-3026(19)30207-8
REF00003210	Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation .Lancet Haematol. 2020 Feb;7(2):e157-e167. doi: 10.1016/S2352-3026(19)30256-X. 10.1016/S2352-3026(19)30256-X
REF00003211	WHO global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017-18: a retrospective observational study .Lancet Microbe. 2021 Nov;2(11):e627-e636. doi: 10.1016/S2666-5247(21)00171-3. Epub 2021 Sep 2. 10.1016/S2666-5247(21)00171-3
REF00003212	Anti-Wolbachia drug discovery and development: safe macrofilaricides for onchocerciasis and lymphatic filariasis .Parasitology. 2014 Jan;141(1):119-27. doi: 10.1017/S0031182013001108. Epub 2013 Jul 18. 10.1017/S0031182013001108
REF00003213	Leishmaniasis and various immunotherapeutic approaches .Parasitology. 2018 Apr;145(4):497-507. doi: 10.1017/S003118201600216X. Epub 2016 Dec 15. 10.1017/S003118201600216X
REF00003214	Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity .CNS Spectr. 2019 Oct;24(5):461-466. doi: 10.1017/S1092852919001470. 10.1017/S1092852919001470
REF00003215	Hairpin-Structured Magnetic SERS Sensor for Tetracycline Resistance Gene tetA Detection .Anal Chem. 2020 Dec 15;92(24):16229-16235. doi: 10.1021/acs.analchem.0c04085. Epub 2020 Nov 20. 10.1021/acs.analchem.0c04085
REF00003216	Interactions between Quinolones and Bacillus anthracis Gyrase and the Basis of Drug Resistance .Biochemistry. 2017 Aug 15;56(32):4191-4200. doi: 10.1021/acs.biochem.7b00203. Epub 2017 Aug 1. 10.1021/acs.biochem.7b00203
REF00003217	Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond .Chem Rev. 2021 Mar 24;121(6):3390-3411. doi: 10.1021/acs.chemrev.0c00199. Epub 2020 May 22. 10.1021/acs.chemrev.0c00199
REF00003218	Beta-Sitosterol Reverses Multidrug Resistance via BCRP Suppression by Inhibiting the p53-MDM2 Interaction in Colorectal Cancer .J Agric Food Chem. 2020 Mar 25;68(12):3850-3858. doi: 10.1021/acs.jafc.0c00107. Epub 2020 Mar 13. 10.1021/acs.jafc.0c00107
REF00003219	Procainamide-SAHA Fused Inhibitors of hHDAC6 Tackle Multidrug-Resistant Malaria Parasites .J Med Chem. 2021 Jul 22;64(14):10403-10417. doi: 10.1021/acs.jmedchem.1c00821. Epub 2021 Jun 29. 10.1021/acs.jmedchem.1c00821
REF00003220	"Retraction of ""Collateral Sensitivity of Multidrug-Resistant Cells to the Orphan Drug Tiopronin"" .J Med Chem. 2020 Feb 13;63(3):1443. doi: 10.1021/acs.jmedchem.9b01794. Epub 2020 Feb 4. 10.1021/acs.jmedchem.9b01794"
REF00003221	The Permeation of Acamprosate Is Predominantly Caused by Paracellular Diffusion across Caco-2 Cell Monolayers: A Paracellular Modeling Approach .Mol Pharm. 2019 Nov 4;16(11):4636-4650. doi: 10.1021/acs.molpharmaceut.9b00733. Epub 2019 Oct 17. 10.1021/acs.molpharmaceut.9b00733
REF00003222	"Water-Templated, Polysaccharide-rich Bioartificial 3D Microarchitectures as Extra-Cellular Matrix Bioautomatons .ACS Appl Mater Interfaces. 2020 May 6;12(18):20912-20921. doi: 10.1021/acsami.0c01012. Epub 2020 Apr 22. 10.1021/acsami.0c01012"
REF00003223	GTP Cyclohydrolase 1/Tetrahydrobiopterin Counteract Ferroptosis through Lipid Remodeling .ACS Cent Sci. 2020 Jan 22;6(1):41-53. doi: 10.1021/acscentsci.9b01063. Epub 2019 Dec 27. 10.1021/acscentsci.9b01063
REF00003224	Doxofylline Protects Gram-Negative Pathogens against Antibiotic-Mediated Killing .ACS Infect Dis. 2021 Dec 10;7(12):3241-3253. doi: 10.1021/acsinfecdis.1c00417. Epub 2021 Dec 1. 10.1021/acsinfecdis.1c00417
REF00003225	Ring Distortion of Vincamine Leads to the Identification of Re-Engineered Antiplasmodial Agents .ACS Omega. 2021 Jul 28;6(31):20455-20470. doi: 10.1021/acsomega.1c02480. eCollection 2021 Aug 10. 10.1021/acsomega.1c02480
REF00003226	Improved Synthesis and Isolation of Bedaquiline .ACS Omega. 2020 Feb 17;5(7):3607-3611. doi: 10.1021/acsomega.9b04037. eCollection 2020 Feb 25. 10.1021/acsomega.9b04037
REF00003227	Pre-clinical activity of taxol in non-seminomatous germ cell tumor cell lines and nude mouse xenografts .Invest New Drugs. 1997;15(2):91-8. doi: 10.1023/a:1005852521656. 10.1023/a:1005852521656
REF00003228	Tumour exosomes from cells harbouring PTPRZ1-MET fusion contribute to a malignant phenotype and temozolomide chemoresistance in glioblastoma .Oncogene. 2017 Sep 21;36(38):5369-5381. doi: 10.1038/onc.2017.134. Epub 2017 May 15. 10.1038/onc.2017.134
REF00003229	Pirfenidone prevents and reverses hepatic insulin resistance and steatohepatitis by polarizing M2 macrophages .Lab Invest. 2019 Sep;99(9):1335-1348. doi: 10.1038/s41374-019-0255-4. Epub 2019 Apr 24. 10.1038/s41374-019-0255-4
REF00003230	FOXK2 transcriptionally activating VEGFA induces apatinib resistance in anaplastic thyroid cancer through VEGFA/VEGFR1 pathway .Oncogene. 2021 Oct;40(42):6115-6129. doi: 10.1038/s41388-021-01830-5. Epub 2021 Sep 6. 10.1038/s41388-021-01830-5
REF00003231	"Increased expression of glutamine transporter SNAT2/SLC38A2 promotes glutamine dependence and oxidative stress resistance, and is associated with worse prognosis in triple-negative breast cancer .Br J Cancer. 2021 Jan;124(2):494-505. doi: 10.1038/s41416-020-01113-y. Epub 2020 Oct 8. 10.1038/s41416-020-01113-y"
REF00003232	"Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance .Br J Cancer. 2021 Mar;124(5):880-892. doi: 10.1038/s41416-020-01157-0. Epub 2020 Dec 3. 10.1038/s41416-020-01157-0"
REF00003233	PI3K activation promotes resistance to eribulin in HER2-negative breast cancer .Br J Cancer. 2021 Apr;124(9):1581-1591. doi: 10.1038/s41416-021-01293-1. Epub 2021 Mar 15. 10.1038/s41416-021-01293-1
REF00003234	MicroRNA-375 represses tumor angiogenesis and reverses resistance to sorafenib in hepatocarcinoma .Cancer Gene Ther. 2021 Feb;28(1-2):126-140. doi: 10.1038/s41417-020-0191-x. Epub 2020 Jul 3. 10.1038/s41417-020-0191-x
REF00003235	"TNFAIP8 regulates autophagy, cell steatosis, and promotes hepatocellular carcinoma cell proliferation .Cell Death Dis. 2020 Mar 9;11(3):178. doi: 10.1038/s41419-020-2369-4. 10.1038/s41419-020-2369-4"
REF00003236	Everolimus and plicamycin specifically target chemoresistant colorectal cancer cells of the CMS4 subtype .Cell Death Dis. 2021 Oct 21;12(11):978. doi: 10.1038/s41419-021-04270-x. 10.1038/s41419-021-04270-x
REF00003237	Genome-scale CRISPR-Cas9 knockout screening in hepatocellular carcinoma with lenvatinib resistance .Cell Death Discov. 2021 Nov 18;7(1):359. doi: 10.1038/s41420-021-00747-y. 10.1038/s41420-021-00747-y
REF00003238	Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling .Cell Res. 2021 Oct;31(10):1072-1087. doi: 10.1038/s41422-021-00528-3. Epub 2021 Jul 8. 10.1038/s41422-021-00528-3
REF00003239	Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany .Gene Ther. 2021 Sep;28(9):513-527. doi: 10.1038/s41434-021-00246-w. Epub 2021 Mar 22. 10.1038/s41434-021-00246-w
REF00003240	Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC .Nat Commun. 2019 Oct 15;10(1):4681. doi: 10.1038/s41467-019-12606-7. 10.1038/s41467-019-12606-7
REF00003241	Gut microbiota mediates intermittent-fasting alleviation of diabetes-induced cognitive impairment .Nat Commun. 2020 Feb 18;11(1):855. doi: 10.1038/s41467-020-14676-4. 10.1038/s41467-020-14676-4
REF00003242	Caspase-11 promotes allergic airway inflammation .Nat Commun. 2020 Feb 26;11(1):1055. doi: 10.1038/s41467-020-14945-2. 10.1038/s41467-020-14945-2
REF00003243	The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer .Nat Commun. 2020 Jun 1;11(1):2689. doi: 10.1038/s41467-020-15396-5. 10.1038/s41467-020-15396-5
REF00003244	CryoEM structure of the type IVa pilus secretin required for natural competence in Vibrio cholerae .Nat Commun. 2020 Oct 8;11(1):5080. doi: 10.1038/s41467-020-18866-y. 10.1038/s41467-020-18866-y
REF00003245	Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2) .Nat Commun. 2021 May 3;12(1):2487. doi: 10.1038/s41467-021-22582-6. 10.1038/s41467-021-22582-6
REF00003246	Hypoxia-induced SETX links replication stress with the unfolded protein response .Nat Commun. 2021 Jun 17;12(1):3686. doi: 10.1038/s41467-021-24066-z. 10.1038/s41467-021-24066-z
REF00003247	FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth .Nat Commun. 2021 Oct 11;12(1):5919. doi: 10.1038/s41467-021-26222-x. 10.1038/s41467-021-26222-x
REF00003248	Lifestyle interventions for the prevention and treatment of hypertension .Nat Rev Cardiol. 2021 Apr;18(4):251-275. doi: 10.1038/s41569-020-00437-9. Epub 2020 Oct 9. 10.1038/s41569-020-00437-9
REF00003249	HER2-targeted therapies - a role beyond breast cancer .Nat Rev Clin Oncol. 2020 Jan;17(1):33-48. doi: 10.1038/s41571-019-0268-3. Epub 2019 Sep 23. 10.1038/s41571-019-0268-3
REF00003250	Diabetes insipidus .Nat Rev Dis Primers. 2019 Aug 8;5(1):54. doi: 10.1038/s41572-019-0103-2. 10.1038/s41572-019-0103-2
REF00003251	Gastrointestinal stromal tumours .Nat Rev Dis Primers. 2021 Mar 18;7(1):22. doi: 10.1038/s41572-021-00254-5. 10.1038/s41572-021-00254-5
REF00003252	The human microbiome encodes resistance to the antidiabetic drug acarbose .Nature. 2021 Dec;600(7887):110-115. doi: 10.1038/s41586-021-04091-0. Epub 2021 Nov 24. 10.1038/s41586-021-04091-0
REF00003253	Platelet GPIbAlpha is a mediator and potential interventional target for NASH and subsequent liver cancer .Nat Med. 2019 Apr;25(4):641-655. doi: 10.1038/s41591-019-0379-5. Epub 2019 Apr 1. 10.1038/s41591-019-0379-5
REF00003254	Targeted deubiquitination rescues distinct trafficking-deficient ion channelopathies .Nat Methods. 2020 Dec;17(12):1245-1253. doi: 10.1038/s41592-020-00992-6. Epub 2020 Nov 9. 10.1038/s41592-020-00992-6
REF00003255	Penfluridol overcomes paclitaxel resistance in metastatic breast cancer .Sci Rep. 2019 Mar 25;9(1):5066. doi: 10.1038/s41598-019-41632-0. 10.1038/s41598-019-41632-0
REF00003256	"A role for ABCB1 in prognosis, invasion and drug resistance in ependymoma .Sci Rep. 2019 Jul 16;9(1):10290. doi: 10.1038/s41598-019-46700-z. 10.1038/s41598-019-46700-z"
REF00003257	The PPAR Alpha/Gamma Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease .Sci Rep. 2020 Jun 9;10(1):9330. doi: 10.1038/s41598-020-66458-z. 10.1038/s41598-020-66458-z
REF00003258	"Tianeptine, but not fluoxetine, decreases avoidant behavior in a mouse model of early developmental exposure to fluoxetine .Sci Rep. 2021 Nov 24;11(1):22852. doi: 10.1038/s41598-021-02074-9. 10.1038/s41598-021-02074-9"
REF00003259	Histamine H1 receptor antagonists selectively kill cisplatin-resistant human cancer cells .Sci Rep. 2021 Jan 15;11(1):1492. doi: 10.1038/s41598-021-81077-y. 10.1038/s41598-021-81077-y
REF00003260	Electronic cigarette aerosols alter the expression of cisplatin transporters and increase drug resistance in oral cancer cells .Sci Rep. 2021 Jan 19;11(1):1821. doi: 10.1038/s41598-021-81148-0. 10.1038/s41598-021-81148-0
REF00003261	Sulodexide reduces glucose induced senescence in human retinal endothelial cells .Sci Rep. 2021 Jun 1;11(1):11532. doi: 10.1038/s41598-021-90987-w. 10.1038/s41598-021-90987-w
REF00003262	Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia .Commun Biol. 2021 Jun 25;4(1):799. doi: 10.1038/s42003-021-02215-w. 10.1038/s42003-021-02215-w
REF00003263	Reserpine improves Enterobacteriaceae resistance in chicken intestine via neuro-immunometabolic signaling and MEK1/2 activation .Commun Biol. 2021 Dec 3;4(1):1359. doi: 10.1038/s42003-021-02888-3. 10.1038/s42003-021-02888-3
REF00003264	Genome-scale in vivo CRISPR screen identifies RNLS as a target for beta cell protection in type 1 diabetes .Nat Metab. 2020 Sep;2(9):934-945. doi: 10.1038/s42255-020-0254-1. Epub 2020 Jul 27. 10.1038/s42255-020-0254-1
REF00003265	Authenticity and drug resistance in a panel of acute lymphoblastic leukaemia cell lines .Br J Cancer. 2006 Dec 4;95(11):1537-44. doi: 10.1038/sj.bjc.6603447. Epub 2006 Nov 21. 10.1038/sj.bjc.6603447
REF00003266	Isolation of tumour stem-like cells from benign tumours .Br J Cancer. 2009 Jul 21;101(2):303-11. doi: 10.1038/sj.bjc.6605142. Epub 2009 Jun 30. 10.1038/sj.bjc.6605142
REF00003267	Penfluridol suppresses pancreatic tumor growth by autophagy-mediated apoptosis .Sci Rep. 2016 May 18;6:26165. doi: 10.1038/srep26165. 10.1038/srep26165
REF00003268	"Revealing the binding and drug resistance mechanism of amprenavir, indinavir, ritonavir, and nelfinavir complexed with HIV-1 protease due to double mutations G48T/L89M by molecular dynamics simulations and free energy analyses .Phys Chem Chem Phys. 2020 Feb 26;22(8):4464-4480. doi: 10.1039/c9cp06657h. 10.1039/c9cp06657h"
REF00003269	Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from Mycobacterium tuberculosis to overcome kanamycin resistance .RSC Med Chem. 2021 Oct 5;12(11):1894-1909. doi: 10.1039/d1md00239b. eCollection 2021 Nov 17. 10.1039/d1md00239b
REF00003270	Insights into drug resistance mechanisms in Clostridium difficile .Essays Biochem. 2017 Mar 3;61(1):81-88. doi: 10.1042/EBC20160062. Print 2017 Feb 28. 10.1042/EBC20160062
REF00003271	Diuretic Resistance .Am J Kidney Dis. 2017 Jan;69(1):136-142. doi: 10.1053/j.ajkd.2016.08.027. Epub 2016 Nov 1. 10.1053/j.ajkd.2016.08.027
REF00003272	Treatment options for other hepatic malignancies .Liver Transpl. 2000 Nov;6(6 Suppl 2):S23-9. doi: 10.1053/jlts.2000.18687. 10.1053/jlts.2000.18687
REF00003273	Escalation of antimicrobial resistance among Streptococcus pneumoniae: implications for therapy .Semin Respir Crit Care Med. 2005 Dec;26(6):575-616. doi: 10.1055/s-2005-925524. 10.1055/s-2005-925524
REF00003274	Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection .N Engl J Med. 2020 Mar 26;382(13):1232-1243. doi: 10.1056/NEJMoa1902493. 10.1056/NEJMoa1902493
REF00003275	Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus .N Engl J Med. 2019 Nov 28;381(22):2103-2113. doi: 10.1056/NEJMoa1905795. 10.1056/NEJMoa1905795
REF00003276	Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma .N Engl J Med. 2020 Sep 24;383(13):1218-1230. doi: 10.1056/NEJMoa2002788. Epub 2020 Sep 18. 10.1056/NEJMoa2002788
REF00003277	Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer .N Engl J Med. 2021 Apr 22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485. 10.1056/NEJMoa2028485
REF00003278	Evinacumab in Patients with Refractory Hypercholesterolemia .N Engl J Med. 2020 Dec 10;383(24):2307-2319. doi: 10.1056/NEJMoa2031049. Epub 2020 Nov 15. 10.1056/NEJMoa2031049
REF00003279	Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma .N Engl J Med. 2021 Mar 25;384(12):1125-1135. doi: 10.1056/NEJMoa2035807. Epub 2021 Feb 12. 10.1056/NEJMoa2035807
REF00003280	Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women .N Engl J Med. 2021 Aug 12;385(7):595-608. doi: 10.1056/NEJMoa2101016. 10.1056/NEJMoa2101016
REF00003281	A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes .Proc Natl Acad Sci U S A. 2008 Apr 1;105(13):5022-7. doi: 10.1073/pnas.0711014105. Epub 2008 Mar 26. 10.1073/pnas.0711014105
REF00003282	Mechanism of drug inhibition and drug resistance of influenza A M2 channel .Proc Natl Acad Sci U S A. 2009 May 5;106(18):7379-84. doi: 10.1073/pnas.0902548106. Epub 2009 Apr 21. 10.1073/pnas.0902548106
REF00003283	Ferroptosis is controlled by the coordinated transcriptional regulation of glutathione and labile iron metabolism by the transcription factor BACH1 .J Biol Chem. 2020 Jan 3;295(1):69-82. doi: 10.1074/jbc.RA119.009548. Epub 2019 Nov 18. 10.1074/jbc.RA119.009548
REF00003284	Low-dose naltrexone rescues inflammation and insulin resistance associated with hyperinsulinemia .J Biol Chem. 2020 Nov 27;295(48):16359-16369. doi: 10.1074/jbc.RA120.013484. Epub 2020 Sep 17. 10.1074/jbc.RA120.013484
REF00003285	Repolarization of glioblastoma macrophage cells using non-agonistic Dectin-1 ligand encapsulating TLR-9 agonist: plausible role in regenerative medicine against brain tumor .Int J Neurosci. 2021 Jun;131(6):591-598. doi: 10.1080/00207454.2020.1750393. Epub 2020 Apr 19. 10.1080/00207454.2020.1750393
REF00003286	Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents .Postgrad Med. 2020 Apr;132(3):234-250. doi: 10.1080/00325481.2019.1680052. Epub 2019 Oct 24. 10.1080/00325481.2019.1680052
REF00003287	Effects of the multidrug resistance-1 gene on drug resistance in primary immune thrombocytopenia .Autoimmunity. 2016 Nov;49(7):486-495. doi: 10.1080/08916934.2016.1191476. Epub 2016 Jun 3. 10.1080/08916934.2016.1191476
REF00003288	Antifungal resistance in Superficial mycoses .J Dermatolog Treat. 2021 Jun 16:1-25. doi: 10.1080/09546634.2021.1942421. Online ahead of print. 10.1080/09546634.2021.1942421
REF00003289	Fructose and hepatic insulin resistance .Crit Rev Clin Lab Sci. 2020 Aug;57(5):308-322. doi: 10.1080/10408363.2019.1711360. Epub 2020 Jan 14. 10.1080/10408363.2019.1711360
REF00003290	Pharmacological basis for cladribine resistance .Leuk Lymphoma. 2003 Oct;44(10):1705-12. doi: 10.1080/1042819031000099698. 10.1080/1042819031000099698
REF00003291	Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention .Leuk Lymphoma. 2009 Jun;50(6):873-85. doi: 10.1080/10428190902878471. 10.1080/10428190902878471
REF00003292	Hairy cell leukemia: present and future directions .Leuk Lymphoma. 2019 Dec;60(12):2869-2879. doi: 10.1080/10428194.2019.1608536. Epub 2019 May 9. 10.1080/10428194.2019.1608536
REF00003293	Mycobacterial ethambutol responsive genes and implications in antibiotics resistance .J Drug Target. 2021 Mar;29(3):284-293. doi: 10.1080/1061186X.2020.1853733. Epub 2020 Dec 3. 10.1080/1061186X.2020.1853733
REF00003294	Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC) .Expert Opin Investig Drugs. 2020 Dec;29(12):1355-1364. doi: 10.1080/13543784.2020.1833857. Epub 2020 Oct 21. 10.1080/13543784.2020.1833857
REF00003295	Perspectives on the current pharmacotherapeutic strategies for management of functional neuroendocrine tumor syndromes .Expert Opin Pharmacother. 2021 Apr;22(6):685-693. doi: 10.1080/14656566.2020.1845651. Epub 2020 Nov 11. 10.1080/14656566.2020.1845651
REF00003296	Emerging antibiotics for community-acquired pneumonia .Expert Opin Emerg Drugs. 2019 Dec;24(4):221-231. doi: 10.1080/14728214.2019.1685494. Epub 2019 Nov 1. 10.1080/14728214.2019.1685494
REF00003297	Capmatinib for the treatment of non-small cell lung cancer .Expert Rev Anticancer Ther. 2019 Aug;19(8):659-671. doi: 10.1080/14737140.2019.1643239. Epub 2019 Aug 1. 10.1080/14737140.2019.1643239
REF00003298	Atezolizumab for the treatment of breast cancer .Expert Rev Anticancer Ther. 2020 Mar;20(3):151-158. doi: 10.1080/14737140.2020.1732211. Epub 2020 Feb 27. 10.1080/14737140.2020.1732211
REF00003299	Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm .Expert Rev Anticancer Ther. 2020 Jul;20(7):543-550. doi: 10.1080/14737140.2020.1776120. Epub 2020 Jun 24. 10.1080/14737140.2020.1776120
REF00003300	Biologics in the treatment of pustular psoriasis .Expert Opin Drug Saf. 2020 Aug;19(8):969-980. doi: 10.1080/14740338.2020.1785427. Epub 2020 Jul 2. 10.1080/14740338.2020.1785427
REF00003301	Anti-Helicobacter pylori activity of ethoxzolamide .J Enzyme Inhib Med Chem. 2019 Dec;34(1):1660-1667. doi: 10.1080/14756366.2019.1663416. 10.1080/14756366.2019.1663416
REF00003302	Nc886 promotes renal cancer cell drug-resistance by enhancing EMT through Rock2 phosphorylation-mediated Beta-catenin nuclear translocation .Cell Cycle. 2022 Feb;21(4):340-351. doi: 10.1080/15384101.2021.2020431. Epub 2022 Jan 2. 10.1080/15384101.2021.2020431
REF00003303	Azacitidine resistance caused by LAMP2 deficiency: a therapeutic window for the use of autophagy inhibitors in MDS/AML patients  .Autophagy. 2019 May;15(5):927-929. doi: 10.1080/15548627.2019.1586259. Epub 2019 Mar 1. 10.1080/15548627.2019.1586259
REF00003304	Mitochondrial DNA stress triggers autophagy-dependent ferroptotic death .Autophagy. 2021 Apr;17(4):948-960. doi: 10.1080/15548627.2020.1739447. Epub 2020 Mar 18. 10.1080/15548627.2020.1739447
REF00003305	The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma .Expert Opin Drug Discov. 2016 Sep;11(9):907-16. doi: 10.1080/17460441.2016.1201057. Epub 2016 Jun 23. 10.1080/17460441.2016.1201057
REF00003306	Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia .Expert Rev Hematol. 2020 Dec;13(12):1319-1332. doi: 10.1080/17474086.2020.1850253. Epub 2020 Nov 30. 10.1080/17474086.2020.1850253
REF00003307	Recent developments in geriatric psychopharmacology .Expert Rev Clin Pharmacol. 2021 Mar;14(3):341-355. doi: 10.1080/17512433.2021.1882848. Epub 2021 Feb 5. 10.1080/17512433.2021.1882848
REF00003308	Resistance mechanism and proteins in Aspergillus species against antifungal agents .Mycology. 2019 Feb 6;10(3):151-165. doi: 10.1080/21501203.2019.1574927. eCollection 2019. 10.1080/21501203.2019.1574927
REF00003309	"Identification of biomarkers, pathways and potential therapeutic agents for white adipocyte insulin resistance using bioinformatics analysis .Adipocyte. 2019 Dec;8(1):318-329. doi: 10.1080/21623945.2019.1649578. 10.1080/21623945.2019.1649578"
REF00003310	Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis .J Infect Dis. 2003 Mar 1;187(5):777-84. doi: 10.1086/368385. Epub 2003 Feb 24. 10.1086/368385
REF00003311	Drug Repurposing Approach for Developing Novel Therapy Against Mupirocin-Resistant Staphylococcus aureus .Assay Drug Dev Technol. 2019 Oct;17(7):298-309. doi: 10.1089/adt.2019.944. 10.1089/adt.2019.944
REF00003312	"A Novel Identified Circular RNA, mmu_mmu_circRNA_0000309, Involves in Germacrone-Mediated Improvement of Diabetic Nephropathy Through Regulating Ferroptosis by Targeting miR-188-3p/GPX4 Signaling Axis .Antioxid Redox Signal. 2022 Apr;36(10-12):740-759. doi: 10.1089/ars.2021.0063. 10.1089/ars.2021.0063"
REF00003313	Association of ACE and MDR1 Gene Polymorphisms with Steroid Resistance in Children with Idiopathic Nephrotic Syndrome .Genet Test Mol Biomarkers. 2015 Aug;19(8):454-6. doi: 10.1089/gtmb.2015.0077. Epub 2015 Jul 8. 10.1089/gtmb.2015.0077
REF00003314	Expression of multidrug resistance associated protein 5 (MRP5) on cornea and its role in drug efflux .J Ocul Pharmacol Ther. 2009 Apr;25(2):121-32. doi: 10.1089/jop.2008.0084. 10.1089/jop.2008.0084
REF00003315	Characterization and Treatment of Recurrent Bacterial Vaginosis .J Womens Health (Larchmt). 2019 Sep;28(9):1218-1226. doi: 10.1089/jwh.2018.7383. Epub 2019 Aug 12. 10.1089/jwh.2018.7383
REF00003316	Solithromycin Can Specifically Induce Macrolide-Lincosamide-Streptogramin B Resistance .Microb Drug Resist. 2020 Sep;26(9):1046-1049. doi: 10.1089/mdr.2019.0293. Epub 2020 Mar 26. 10.1089/mdr.2019.0293
REF00003317	The dual cyclooxygenase/5-lipoxygenase inhibitor licofelone attenuates p-glycoprotein-mediated drug resistance in the injured spinal cord .J Neurotrauma. 2013 Feb 1;30(3):211-26. doi: 10.1089/neu.2012.2587. Epub 2013 Jan 23. 10.1089/neu.2012.2587
REF00003318	What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC) .Ann Oncol. 2016 May;27(5):920-6. doi: 10.1093/annonc/mdw042. Epub 2016 Feb 15. 10.1093/annonc/mdw042
REF00003319	Effect of maternal betamethasone administration on feto-placental vascular resistance in the mouse  .Biol Reprod. 2019 Oct 25;101(4):823-831. doi: 10.1093/biolre/ioz128. 10.1093/biolre/ioz128
REF00003320	Succinylcholine resistance .Br J Anaesth. 2015 Dec;115(6):818-21. doi: 10.1093/bja/aev228. Epub 2015 Jul 16. 10.1093/bja/aev228
REF00003321	Clinical and In Vitro Resistance of Plasmodium falciparum to Artesunate-Amodiaquine in Cambodia .Clin Infect Dis. 2021 Aug 2;73(3):406-413. doi: 10.1093/cid/ciaa628. 10.1093/cid/ciaa628
REF00003322	Delamanid Resistance: Update and Clinical Management .Clin Infect Dis. 2020 Dec 15;71(12):3252-3259. doi: 10.1093/cid/ciaa755. 10.1093/cid/ciaa755
REF00003323	Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results from a Phase 3 Randomized Clinical Trial .Clin Infect Dis. 2021 Dec 2:ciab988. doi: 10.1093/cid/ciab988. Online ahead of print. 10.1093/cid/ciab988
REF00003324	Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections .Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S565-S575. doi: 10.1093/cid/ciz830. 10.1093/cid/ciz830
REF00003325	Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction .Eur Heart J. 2021 Sep 21;42(36):3741-3752. doi: 10.1093/eurheartj/ehab499. 10.1093/eurheartj/ehab499
REF00003326	Pyrazinamide resistance in Mycobacterium tuberculosis fails to bite  .Pathog Dis. 2015 Aug;73(6):ftv037. doi: 10.1093/femspd/ftv037. Epub 2015 May 19. 10.1093/femspd/ftv037
REF00003327	The JAK-Inhibitor Tofacitinib Rescues Human Intestinal Epithelial Cells and Colonoids from Cytokine-Induced Barrier Dysfunction .Inflamm Bowel Dis. 2020 Feb 11;26(3):407-422. doi: 10.1093/ibd/izz266. 10.1093/ibd/izz266
REF00003328	Tropisetron Facilitates Footshock Suppression of Compulsive Cocaine Seeking .Int J Neuropsychopharmacol. 2019 Sep 1;22(9):574-584. doi: 10.1093/ijnp/pyz023. 10.1093/ijnp/pyz023
REF00003329	Spatial modelling of tumour drug resistance: the case of GIST liver metastases .Math Med Biol. 2017 Jun 1;34(2):151-176. doi: 10.1093/imammb/dqw002. 10.1093/imammb/dqw002
REF00003330	Immune cell mediated cabozantinib resistance for patients with renal cell carcinoma .Integr Biol (Camb). 2021 Dec 30;13(11):259-268. doi: 10.1093/intbio/zyab018. 10.1093/intbio/zyab018
REF00003331	"Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid .J Antimicrob Chemother. 2020 Aug 1;75(8):2031-2043. doi: 10.1093/jac/dkaa136. 10.1093/jac/dkaa136"
REF00003332	Emergence of vancomycin- and teicoplanin-resistant Enterococcus faecium via vanD5-harbouring large genomic island .J Antimicrob Chemother. 2020 Sep 1;75(9):2411-2415. doi: 10.1093/jac/dkaa220. 10.1093/jac/dkaa220
REF00003333	Carprofen elicits pleiotropic mechanisms of bactericidal action with the potential to reverse antimicrobial drug resistance in tuberculosis .J Antimicrob Chemother. 2020 Nov 1;75(11):3194-3201. doi: 10.1093/jac/dkaa307. 10.1093/jac/dkaa307
REF00003334	Identification of a novel tedizolid resistance mutation in rpoB of MRSA after in vitro serial passage .J Antimicrob Chemother. 2021 Jan 19;76(2):292-296. doi: 10.1093/jac/dkaa422. 10.1093/jac/dkaa422
REF00003335	Mechanisms and physiological effects of protamine resistance in Salmonella enterica serovar Typhimurium LT2 .J Antimicrob Chemother. 2010 May;65(5):876-87. doi: 10.1093/jac/dkq059. Epub 2010 Mar 16. 10.1093/jac/dkq059
REF00003336	Identification of novel mutations associated with cycloserine resistance in Mycobacterium tuberculosis .J Antimicrob Chemother. 2017 Dec 1;72(12):3272-3276. doi: 10.1093/jac/dkx316. 10.1093/jac/dkx316
REF00003337	Daptomycin .J Antimicrob Chemother. 2018 Jan 1;73(1):1-11. doi: 10.1093/jac/dkx349. 10.1093/jac/dkx349
REF00003338	"Metronidazole: an update on metabolism, structure-cytotoxicity and resistance mechanisms .J Antimicrob Chemother. 2018 Feb 1;73(2):265-279. doi: 10.1093/jac/dkx351. 10.1093/jac/dkx351"
REF00003339	Canadian Association of Gastroenterology Position Statement on the Impact of Simethicone on Endoscope Reprocessing .J Can Assoc Gastroenterol. 2018 Mar 30;1(1):40-42. doi: 10.1093/jcag/gwx002. eCollection 2018 Apr. 10.1093/jcag/gwx002
REF00003340	Glucosamine attenuates drug resistance in Mitoxantrone-resistance breast cancer cells .J Pharm Pharmacol. 2021 Jun 8;73(7):922-927. doi: 10.1093/jpp/rgaa032. 10.1093/jpp/rgaa032
REF00003341	Activation and activity of STOP1 in aluminium resistance .J Exp Bot. 2021 Mar 29;72(7):2269-2272. doi: 10.1093/jxb/erab015. 10.1093/jxb/erab015
REF00003342	"Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure; links to inflammation and oxidative stress .Nephrol Dial Transplant. 2002;17 Suppl 5:32-7. doi: 10.1093/ndt/17.suppl_5.32. 10.1093/ndt/17.suppl_5.32"
REF00003343	"Iron sucrose ('RBT-3') activates the hepatic and renal HAMP1 gene, evoking renal hepcidin loading and resistance to cisplatin nephrotoxicity .Nephrol Dial Transplant. 2021 Feb 20;36(3):465-474. doi: 10.1093/ndt/gfaa348. 10.1093/ndt/gfaa348"
REF00003344	Role of Opioids in Fibromyalgia and Its Resistance to Therapy .Pain Med. 2020 Oct 1;21(10):2059-2060. doi: 10.1093/pm/pnaa231. 10.1093/pm/pnaa231
REF00003345	Nitrosative Stress and Lipid Homeostasis as a Mechanism for Zileuton Hepatotoxicity and Resistance in Genetically Sensitive Mice .Toxicol Sci. 2020 Jun 1;175(2):220-235. doi: 10.1093/toxsci/kfaa037. 10.1093/toxsci/kfaa037
REF00003346	Fungicide Resistance Profiles of Botrytis cinerea Isolates From Michigan Vineyards and Development of a TaqMan Assay for Detection of Fenhexamid Resistance .Plant Dis. 2021 Feb;105(2):285-294. doi: 10.1094/PDIS-05-20-1087-RE. Epub 2021 Jan 4. 10.1094/PDIS-05-20-1087-RE
REF00003347	"Baseline Sensitivities of Major Citrus, Pome, and Stone Fruits Postharvest Pathogens to Natamycin and Estimation of the Resistance Potential in Penicillium digitatum .Plant Dis. 2021 Aug;105(8):2114-2121. doi: 10.1094/PDIS-07-20-1421-RE. Epub 2021 Sep 7. 10.1094/PDIS-07-20-1421-RE"
REF00003348	Rocuronium-induced neuromuscular block is affected by chronic carbamazepine therapy .Anesthesiology. 1999 Jan;90(1):109-12. doi: 10.1097/00000542-199901000-00016. 10.1097/00000542-199901000-00016
REF00003349	"Schistosomiasis: challenges for control, treatment and drug resistance .Curr Opin Infect Dis. 2006 Dec;19(6):577-82. doi: 10.1097/01.qco.0000247591.13671.6a. 10.1097/01.qco.0000247591.13671.6a"
REF00003350	Enhanced anticancer activity by the combination of vinpocetine and sorafenib via PI3K/AKT/GSK-3Beta signaling axis in hepatocellular carcinoma cells .Anticancer Drugs. 2021 Aug 1;32(7):727-733. doi: 10.1097/CAD.0000000000001056. 10.1097/CAD.0000000000001056
REF00003351	Resistance towards nondepolarising muscle relaxants: prolonged onset time: A systematic review .Eur J Anaesthesiol. 2019 Jul;36(7):477-485. doi: 10.1097/EJA.0000000000000991. 10.1097/EJA.0000000000000991
REF00003352	Subanesthetic ketamine with an AMPAkine attenuates motor impulsivity in rats .Behav Pharmacol. 2021 Jun 1;32(4):335-344. doi: 10.1097/FBP.0000000000000623. 10.1097/FBP.0000000000000623
REF00003353	Selective Estrogen Receptor Modulators in Gynecology Practice .Clin Obstet Gynecol. 2021 Dec 1;64(4):803-812. doi: 10.1097/GRF.0000000000000647. 10.1097/GRF.0000000000000647
REF00003354	Herpes Simplex Virus-Related Conjunctivitis Resistant to Aciclovir: A Case Report and Review of the Literature .Cornea. 2021 Aug 1;40(8):1055-1058. doi: 10.1097/ICO.0000000000002613. 10.1097/ICO.0000000000002613
REF00003355	Clinical Features and Drug-Resistance Profile of Urinary Tuberculosis in South-Western China: A Cross-sectional Study .Medicine (Baltimore). 2016 May;95(19):e3537. doi: 10.1097/MD.0000000000003537. 10.1097/MD.0000000000003537
REF00003356	"Antimicrobial resistance patterns, clinical features, and risk factors for septic shock and death of nosocomial E coli bacteremia in adult patients with hematological disease: A monocenter retrospective study in China .Medicine (Baltimore). 2017 May;96(21):e6959. doi: 10.1097/MD.0000000000006959. 10.1097/MD.0000000000006959"
REF00003357	The comparison of the effectiveness and safety of drospirone ethinyl estradiol and ethinyl estradiol cyproterone in the treatment of polycystic ovarian syndrome: A protocol for systematic review and meta-analysis .Medicine (Baltimore). 2020 Dec 18;99(51):e23811. doi: 10.1097/MD.0000000000023811. 10.1097/MD.0000000000023811
REF00003358	Analysis of antibiotic sensitivity and resistance genes of Bordetella pertussis in Chinese children .Medicine (Baltimore). 2021 Jan 15;100(2):e24090. doi: 10.1097/MD.0000000000024090. 10.1097/MD.0000000000024090
REF00003359	Serious bronchospasm induced by cisatracurium besylate: A case report .Medicine (Baltimore). 2021 Apr 16;100(15):e25516. doi: 10.1097/MD.0000000000025516. 10.1097/MD.0000000000025516
REF00003360	Effects of atorvastatin on the insulin resistance in women of polycystic ovary syndrome: A systematic review and meta-analysis .Medicine (Baltimore). 2021 Jun 18;100(24):e26289. doi: 10.1097/MD.0000000000026289. 10.1097/MD.0000000000026289
REF00003361	"Obesity, insulin resistance, and type 1 diabetes mellitus .Curr Opin Endocrinol Diabetes Obes. 2015 Aug;22(4):277-82. doi: 10.1097/MED.0000000000000170. 10.1097/MED.0000000000000170"
REF00003362	MiR-124-3p alleviates the dezocine tolerance against pain by regulating TRAF6 in a rat model .Neuroreport. 2021 Jan 6;32(1):44-51. doi: 10.1097/WNR.0000000000001559. 10.1097/WNR.0000000000001559
REF00003363	A novel substitution in NS5A enhances the resistance of hepatitis C virus genotype 3 to daclatasvir .J Gen Virol. 2021 Jan;102(1):jgv001496. doi: 10.1099/jgv.0.001496. Epub 2020 Nov 3. 10.1099/jgv.0.001496
REF00003364	Resistance to nitrofurantoin is an indicator of extensive drug-resistant (XDR) Enterobacteriaceae .J Med Microbiol. 2021 Apr;70(4). doi: 10.1099/jmm.0.001347. 10.1099/jmm.0.001347
REF00003365	Multivalent designed proteins protect against SARS-CoV-2 variants of concern .bioRxiv. 2021 Jul 7:2021.07.07.451375. doi: 10.1101/2021.07.07.451375. Preprint. 10.1101/2021.07.07.451375
REF00003366	Fosfomycin: Mechanism and Resistance .Cold Spring Harb Perspect Med. 2017 Feb 1;7(2):a025262. doi: 10.1101/cshperspect.a025262. 10.1101/cshperspect.a025262
REF00003367	Magnetic Resistance Sensory System for the Quantitative Measurement of Morphine .IEEE Trans Biomed Circuits Syst. 2021 Feb;15(1):171-176. doi: 10.1109/TBCAS.2021.3060181. Epub 2021 Mar 30. 10.1109/TBCAS.2021.3060181
REF00003368	Nafamostat mesilate inhibits linezolid metabolism via its antioxidant effects .Ther Apher Dial. 2020 Oct;24(5):499-502. doi: 10.1111/1744-9987.13545. Epub 2020 Aug 4. 10.1111/1744-9987.13545
REF00003369	Successful management of treatment resistant nail psoriasis with tildrakizumab .Australas J Dermatol. 2021 Aug;62(3):390-393. doi: 10.1111/ajd.13642. Epub 2021 Jun 11. 10.1111/ajd.13642
REF00003370	Adoptive T cell immunotherapy for treatment of ganciclovir-resistant cytomegalovirus disease in a renal transplant recipient .Am J Transplant. 2015 Mar;15(3):827-32. doi: 10.1111/ajt.13023. Epub 2015 Feb 3. 10.1111/ajt.13023
REF00003371	Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease .Aliment Pharmacol Ther. 2020 Jun;51(11):1031-1038. doi: 10.1111/apt.15719. Epub 2020 Apr 24. 10.1111/apt.15719
REF00003372	"Efflux transport of nicotine, cotinine and trans-3'-hydroxycotinine glucuronides by human hepatic transporters .Basic Clin Pharmacol Toxicol. 2019 Dec;125(6):490-498. doi: 10.1111/bcpt.13281. Epub 2019 Jul 19. 10.1111/bcpt.13281"
REF00003373	Oncogenic role of microRNA-155 in mycosis fungoides: an in vitro and xenograft mouse model study .Br J Dermatol. 2017 Sep;177(3):791-800. doi: 10.1111/bjd.15422. Epub 2017 May 7. 10.1111/bjd.15422
REF00003374	Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma .Br J Haematol. 2015 Aug;170(4):445-56. doi: 10.1111/bjh.13427. Epub 2015 Apr 9. 10.1111/bjh.13427
REF00003375	"Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects .Br J Haematol. 2018 May;181(3):306-319. doi: 10.1111/bjh.15108. Epub 2018 Jan 23. 10.1111/bjh.15108"
REF00003376	Drug resistance profiles of mutations in the RET kinase domain .Br J Pharmacol. 2018 Sep;175(17):3504-3515. doi: 10.1111/bph.14395. Epub 2018 Jul 19. 10.1111/bph.14395
REF00003377	Y-box binding protein-1 promotes tumorigenesis and progression via the epidermal growth factor receptor/AKT pathway in spinal chordoma .Cancer Sci. 2019 Jan;110(1):166-179. doi: 10.1111/cas.13875. Epub 2018 Dec 19. 10.1111/cas.13875
REF00003378	PDK2 leads to cisplatin resistance through suppression of mitochondrial function in ovarian clear cell carcinoma .Cancer Sci. 2021 Nov;112(11):4627-4640. doi: 10.1111/cas.15125. Epub 2021 Sep 13. 10.1111/cas.15125
REF00003379	Successful dacomitinib treatment after osimertinib resistance in a patient with lung adenocarcinoma .Clin Respir J. 2021 Jul;15(7):851-852. doi: 10.1111/crj.13360. Epub 2021 Mar 25. 10.1111/crj.13360
REF00003380	Dactinomycin in acute myeloid leukemia with NPM1 mutations .Eur J Haematol. 2020 Sep;105(3):302-307. doi: 10.1111/ejh.13438. Epub 2020 May 25. 10.1111/ejh.13438
REF00003381	Current status on minimal access cavity preparations: a critical analysis and a proposal for a universal nomenclature .Int Endod J. 2020 Dec;53(12):1618-1635. doi: 10.1111/iej.13391. Epub 2020 Sep 18. 10.1111/iej.13391
REF00003382	"Association of CYP2C19, CYP3A5 and GPIIb/IIIa gene polymorphisms with Aspirin and Clopidogrel Resistance in a cohort of Indian patients with Coronary Artery Disease .Int J Lab Hematol. 2015 Dec;37(6):809-18. doi: 10.1111/ijlh.12416. Epub 2015 Aug 12. 10.1111/ijlh.12416"
REF00003383	A case of a markedly elevated dabigatran concentration resistant to the approved dose of idarucizumab .Intern Med J. 2021 Apr;51(4):616-617. doi: 10.1111/imj.15278. 10.1111/imj.15278
REF00003384	A prospective and comparative cohort study on efficacy and drug resistance during long-term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis .J Gastroenterol Hepatol. 2008 May;23(5):794-803. doi: 10.1111/j.1440-1746.2007.05240.x. Epub 2007 Dec 14. 10.1111/j.1440-1746.2007.05240.x
REF00003385	Management of metastatic gastrointestinal stromal tumour in the Glivec era: a practical case-based approach .Intern Med J. 2006 Jun;36(6):367-77. doi: 10.1111/j.1445-5994.2006.01077.x. 10.1111/j.1445-5994.2006.01077.x
REF00003386	Mechanisms of drug resistance in status epilepticus .Epilepsia. 2007;48 Suppl 8:74-7. doi: 10.1111/j.1528-1167.2007.01357.x. 10.1111/j.1528-1167.2007.01357.x
REF00003387	High incidence of anticytomegalovirus drug resistance among D+R- kidney transplant recipients receiving preemptive therapy .Am J Transplant. 2012 Jan;12(1):202-9. doi: 10.1111/j.1600-6143.2011.03766.x. Epub 2011 Oct 3. 10.1111/j.1600-6143.2011.03766.x
REF00003388	Enhancement of vancomycin activity by phenothiazines against vancomycin-resistant Enterococcus faecium in vitro .Basic Clin Pharmacol Toxicol. 2010 Aug;107(2):676-9. doi: 10.1111/j.1742-7843.2010.00558.x. Epub 2010 Mar 28. 10.1111/j.1742-7843.2010.00558.x
REF00003389	Adverse effects of brimonidine eye drop in children: A case series .J Clin Pharm Ther. 2021 Oct;46(5):1469-1472. doi: 10.1111/jcpt.13401. Epub 2021 Feb 24. 10.1111/jcpt.13401
REF00003390	Can hair re-growth be considered an early clinical marker of treatment resistance to Hedgehog inhibitors in patients with advanced basal cell carcinoma  A report of two cases .J Eur Acad Dermatol Venereol. 2016 Oct;30(10):1726-1729. doi: 10.1111/jdv.13754. Epub 2016 Jul 27. 10.1111/jdv.13754
REF00003391	Efficacy of ixekizumab in patients with resistance or incomplete response to secukinumab .J Eur Acad Dermatol Venereol. 2019 Sep;33(9):e338-e341. doi: 10.1111/jdv.15630. Epub 2019 Apr 29. 10.1111/jdv.15630
REF00003392	Combined bivalent human papillomavirus vaccine and Candida antigen versus Candida antigen alone in the treatment of recalcitrant warts .J Cosmet Dermatol. 2020 Mar;19(3):758-762. doi: 10.1111/jocd.13077. Epub 2019 Jul 22. 10.1111/jocd.13077
REF00003393	Defibrotide in the COVID-19 coagulopathy: What is the timing  .J Thromb Haemost. 2020 Nov;18(11):3113-3115. doi: 10.1111/jth.15100. 10.1111/jth.15100
REF00003394	Effect of spironolactone and benazepril on furosemide-induced diuresis and renin-angiotensin-aldosterone system activation in normal dogs .J Vet Intern Med. 2021 May;35(3):1245-1254. doi: 10.1111/jvim.16097. Epub 2021 Mar 13. 10.1111/jvim.16097
REF00003395	Therapeutic efficacy of topically used luliconazole vs. terbinafine 1% creams .Mycoses. 2021 Aug;64(8):967-975. doi: 10.1111/myc.13289. Epub 2021 Apr 30. 10.1111/myc.13289
REF00003396	"Codeine induces increased resistance at the esophagogastric junction but has no effect on motility and bolus flow in the pharynx and upper esophageal sphincter in healthy volunteers: A randomized, double-blind, placebo-controlled, cross-over trial .Neurogastroenterol Motil. 2021 May;33(5):e14041. doi: 10.1111/nmo.14041. Epub 2020 Nov 24. 10.1111/nmo.14041"
REF00003397	Enhancing the sweat resistance of sunscreens .Skin Res Technol. 2022 Mar;28(2):225-235. doi: 10.1111/srt.13115. Epub 2021 Nov 9. 10.1111/srt.13115
REF00003398	Malathion insecticide resistance in Aedes aegypti: laboratory conditions and in situ experimental approach through adult entomological surveillance .Trop Med Int Health. 2020 Oct;25(10):1271-1282. doi: 10.1111/tmi.13474. Epub 2020 Sep 6. 10.1111/tmi.13474
REF00003399	"Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options .Pharmacol Rev. 2020 Jul;72(3):606-638. doi: 10.1124/pr.120.019539. 10.1124/pr.120.019539"
REF00003400	Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients .Science. 2021 Feb 5;371(6529):595-602. doi: 10.1126/science.abf3363. 10.1126/science.abf3363
REF00003401	Targeting AKR1B1 inhibits glutathione de novo synthesis to overcome acquired resistance to EGFR-targeted therapy in lung cancer .Sci Transl Med. 2021 Oct 6;13(614):eabg6428. doi: 10.1126/scitranslmed.abg6428. Epub 2021 Oct 6. 10.1126/scitranslmed.abg6428
REF00003402	Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus .Antimicrob Agents Chemother. 2012 Jun;56(6):3359-68. doi: 10.1128/AAC.00054-12. Epub 2012 Mar 19. 10.1128/AAC.00054-12
REF00003403	"Ciclopirox and Efinaconazole Transungual Permeation, Antifungal Activity, and Proficiency To Induce Resistance in Trichophyton rubrum .Antimicrob Agents Chemother. 2019 Sep 23;63(10):e00442-19. doi: 10.1128/AAC.00442-19. Print 2019 Oct. 10.1128/AAC.00442-19"
REF00003404	Kanglemycin A Can Overcome Rifamycin Resistance Caused by ADP-Ribosylation by Arr Protein .Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0086421. doi: 10.1128/AAC.00864-21. Epub 2021 Oct 4. 10.1128/AAC.00864-21
REF00003405	"In Vitro Drug Susceptibility of Bedaquiline, Delamanid, Linezolid, Clofazimine, Moxifloxacin, and Gatifloxacin against Extensively Drug-Resistant Tuberculosis in Beijing, China .Antimicrob Agents Chemother. 2017 Sep 22;61(10):e00900-17. doi: 10.1128/AAC.00900-17. Print 2017 Oct. 10.1128/AAC.00900-17"
REF00003406	"Cefiderocol Resistance in Acinetobacter baumannii: Roles of Beta-Lactamases, Siderophore Receptors, and Penicillin Binding Protein 3 .Antimicrob Agents Chemother. 2020 Oct 20;64(11):e01221-20. doi: 10.1128/AAC.01221-20. Print 2020 Oct 20. 10.1128/AAC.01221-20"
REF00003407	MIC and Upper Limit of Wild-Type Distribution for 13 Antifungal Agents against a Trichophyton mentagrophytes-Trichophyton interdigitale Complex of Indian Origin .Antimicrob Agents Chemother. 2020 Mar 24;64(4):e01964-19. doi: 10.1128/AAC.01964-19. Print 2020 Mar 24. 10.1128/AAC.01964-19
REF00003408	Structure of Dirithromycin Bound to the Bacterial Ribosome Suggests New Ways for Rational Improvement of Macrolides .Antimicrob Agents Chemother. 2019 May 24;63(6):e02266-18. doi: 10.1128/AAC.02266-18. Print 2019 Jun. 10.1128/AAC.02266-18
REF00003409	A Conserved Inhibitory Mechanism of a Lycorine Derivative against Enterovirus and Hepatitis C Virus .Antimicrob Agents Chemother. 2015 Nov 23;60(2):913-24. doi: 10.1128/AAC.02274-15. Print 2016 Feb. 10.1128/AAC.02274-15
REF00003410	In Vitro Resistance and Evolution of Resistance to Tavaborole in Trichophyton rubrum .Antimicrob Agents Chemother. 2021 Mar 18;65(4):e02324-20. doi: 10.1128/AAC.02324-20. Print 2021 Mar 18. 10.1128/AAC.02324-20
REF00003411	Resistance to Thiacetazone Derivatives Active against Mycobacterium abscessus Involves Mutations in the MmpL5 Transcriptional Repressor MAB_4384 .Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02509-16. doi: 10.1128/AAC.02509-16. Print 2017 Apr. 10.1128/AAC.02509-16
REF00003412	Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks .Antimicrob Agents Chemother. 2019 Apr 25;63(5):e02533-18. doi: 10.1128/AAC.02533-18. Print 2019 May. 10.1128/AAC.02533-18
REF00003413	"In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways .Antimicrob Agents Chemother. 2015 Jan;59(1):590-8. doi: 10.1128/AAC.04201-14. Epub 2014 Nov 10. 10.1128/AAC.04201-14"
REF00003414	Influenza viral load and peramivir kinetics after single administration and proposal of regimens for peramivir administration against resistant variants .Antimicrob Agents Chemother. 2015 Mar;59(3):1643-9. doi: 10.1128/AAC.04263-14. Epub 2014 Dec 29. 10.1128/AAC.04263-14
REF00003415	Amdinocillin (Mecillinam) resistance mutations in clinical isolates and laboratory-selected mutants of Escherichia coli .Antimicrob Agents Chemother. 2015 Mar;59(3):1718-27. doi: 10.1128/AAC.04819-14. Epub 2015 Jan 12. 10.1128/AAC.04819-14
REF00003416	"Susceptibility of Haemophilus influenzae type b to cefatrizine, ampicillin, and chloramphenicol .Antimicrob Agents Chemother. 1976 Aug;10(2):322-4. doi: 10.1128/AAC.10.2.322. 10.1128/AAC.10.2.322"
REF00003417	Therapy of staphylococcal infections with cefamandole or vancomycin alone or with a combination of cefamandole and tobramycin .Antimicrob Agents Chemother. 1983 Jan;23(1):36-41. doi: 10.1128/AAC.23.1.36. 10.1128/AAC.23.1.36
REF00003418	"In vitro and in vivo antibacterial activities of carumonam (AMA-1080), a new N-sulfonated monocyclic beta-lactam antibiotic .Antimicrob Agents Chemother. 1985 May;27(5):821-7. doi: 10.1128/AAC.27.5.821. 10.1128/AAC.27.5.821"
REF00003419	Clinical evaluation of rosoxacin for the treatment of chancroid .Antimicrob Agents Chemother. 1986 Jul;30(1):39-41. doi: 10.1128/AAC.30.1.39. 10.1128/AAC.30.1.39
REF00003420	Mechanism of action of cephalosporins and resistance caused by decreased affinity for penicillin-binding proteins in Bacteroides fragilis .Antimicrob Agents Chemother. 1988 Dec;32(12):1848-53. doi: 10.1128/AAC.32.12.1848. 10.1128/AAC.32.12.1848
REF00003421	"Inactivation of the macrolide antibiotics erythromycin, midecamycin, and rokitamycin by pathogenic Nocardia species .Antimicrob Agents Chemother. 1994 Sep;38(9):2197-9. doi: 10.1128/AAC.38.9.2197. 10.1128/AAC.38.9.2197"
REF00003422	"Bactericidal activities of cefprozil, penicillin, cefaclor, cefixime, and loracarbef against penicillin-susceptible and -resistant Streptococcus pneumoniae in an in vitro pharmacodynamic infection model .Antimicrob Agents Chemother. 1996 May;40(5):1148-52. doi: 10.1128/AAC.40.5.1148. 10.1128/AAC.40.5.1148"
REF00003423	"Outbreak of cefozopran (penicillin, oral cephems, and aztreonam)-resistant Neisseria gonorrhoeae in Japan .Antimicrob Agents Chemother. 2001 Dec;45(12):3603-6. doi: 10.1128/AAC.45.12.3603-3606.2001. 10.1128/AAC.45.12.3603-3606.2001"
REF00003424	"Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model .Antimicrob Agents Chemother. 2001 Mar;45(3):673-8. doi: 10.1128/AAC.45.3.673-678.2001. 10.1128/AAC.45.3.673-678.2001"
REF00003425	"Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin .Antimicrob Agents Chemother. 2001 Mar;45(3):883-92. doi: 10.1128/AAC.45.3.883-892.2001. 10.1128/AAC.45.3.883-892.2001"
REF00003426	Antifungal Azoles as Tetracycline Resistance Modifiers in Staphylococcus aureus .Appl Environ Microbiol. 2021 Jul 13;87(15):e0015521. doi: 10.1128/AEM.00155-21. Epub 2021 Jul 13. 10.1128/AEM.00155-21
REF00003427	Improving Acetic Acid and Furfural Resistance of Xylose-Fermenting Saccharomyces cerevisiae Strains by Regulating Novel Transcription Factors Revealed via Comparative Transcriptomic Analysis .Appl Environ Microbiol. 2021 Apr 27;87(10):e00158-21. doi: 10.1128/AEM.00158-21. Print 2021 Apr 27. 10.1128/AEM.00158-21
REF00003428	Nitroreductase Increases Menadione-Mediated Oxidative Stress in Aspergillus nidulans .Appl Environ Microbiol. 2021 Nov 24;87(24):e0175821. doi: 10.1128/AEM.01758-21. Epub 2021 Oct 6. 10.1128/AEM.01758-21
REF00003429	In vitro antimicrobial activity and human pharmacology of cephaloglycin .Appl Microbiol. 1968 Jul;16(7):1006-10. doi: 10.1128/am.16.7.1006-1010.1968. 10.1128/am.16.7.1006-1010.1968
REF00003430	Comparative inhibition of methicillin-resistant strains of Staphylococcus aureus by lysostaphin and other antibiotics .Appl Microbiol. 1968 Aug;16(8):1174-8. doi: 10.1128/am.16.8.1174-1178.1968. 10.1128/am.16.8.1174-1178.1968
REF00003431	Effects of Immunomodulatory Drug Fingolimod (FTY720) on Chlamydia Dissemination and Pathogenesis .Infect Immun. 2020 Oct 19;88(11):e00281-20. doi: 10.1128/IAI.00281-20. Print 2020 Oct 19. 10.1128/IAI.00281-20
REF00003432	Enhancement of neonatal innate defense: effects of adding an N-terminal recombinant fragment of bactericidal/permeability-increasing protein on growth and tumor necrosis factor-inducing activity of gram-negative bacteria tested in neonatal cord blood ex vivo .Infect Immun. 2000 Sep;68(9):5120-5. doi: 10.1128/IAI.68.9.5120-5125.2000. 10.1128/IAI.68.9.5120-5125.2000
REF00003433	"Use of polymyxin B, levallorphan, and tetracaine to isolate novel envelope mutants of Escherichia coli .J Bacteriol. 1976 Aug;127(2):961-72. doi: 10.1128/jb.127.2.961-972.1976. 10.1128/jb.127.2.961-972.1976"
REF00003434	Identification of oseltamivir resistance among pandemic and seasonal influenza A (H1N1) viruses by an His275Tyr genotyping assay using the cycling probe method .J Clin Microbiol. 2011 Jan;49(1):125-30. doi: 10.1128/JCM.01401-10. Epub 2010 Nov 17. 10.1128/JCM.01401-10
REF00003435	"A Panton-Valentine leucocidin (PVL)-positive community-acquired methicillin-resistant Staphylococcus aureus (MRSA) strain, another such strain carrying a multiple-drug resistance plasmid, and other more-typical PVL-negative MRSA strains found in Japan .J Clin Microbiol. 2005 Jul;43(7):3356-63. doi: 10.1128/JCM.43.7.3356-3363.2005. 10.1128/JCM.43.7.3356-3363.2005"
REF00003436	An E460D Substitution in the NS5 Protein of Tick-Borne Encephalitis Virus Confers Resistance to the Inhibitor Galidesivir (BCX4430) and Also Attenuates the Virus for Mice .J Virol. 2019 Jul 30;93(16):e00367-19. doi: 10.1128/JVI.00367-19. Print 2019 Aug 15. 10.1128/JVI.00367-19
REF00003437	Mutations in the Fusion Protein of Measles Virus That Confer Resistance to the Membrane Fusion Inhibitors Carbobenzoxy-d-Phe-l-Phe-Gly and 4-Nitro-2-Phenylacetyl Amino-Benzamide .J Virol. 2017 Nov 14;91(23):e01026-17. doi: 10.1128/JVI.01026-17. Print 2017 Dec 1. 10.1128/JVI.01026-17
REF00003438	The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells .J Virol. 2020 Dec 9;95(1):e01648-20. doi: 10.1128/JVI.01648-20. Print 2020 Dec 9. 10.1128/JVI.01648-20
REF00003439	Homologs of the Acinetobacter baumannii AceI transporter represent a new family of bacterial multidrug efflux systems .mBio. 2015 Feb 10;6(1):e01982-14. doi: 10.1128/mBio.01982-14. 10.1128/mBio.01982-14
REF00003440	Na(+)-NQR Confers Aminoglycoside Resistance via the Regulation of l-Alanine Metabolism .mBio. 2020 Nov 17;11(6):e02086-20. doi: 10.1128/mBio.02086-20. 10.1128/mBio.02086-20
REF00003441	Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa .mSphere. 2021 Jan 27;6(1):e01026-20. doi: 10.1128/mSphere.01026-20. 10.1128/mSphere.01026-20
REF00003442	In Vitro Activity of Delafloxacin and Finafloxacin against Mycoplasma hominis and Ureaplasma Species .Microbiol Spectr. 2022 May 9:e0009922. doi: 10.1128/spectrum.00099-22. Online ahead of print. 10.1128/spectrum.00099-22
REF00003443	Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet .BMJ Open Diabetes Res Care. 2019 Oct 25;7(1):e000783. doi: 10.1136/bmjdrc-2019-000783. eCollection 2019. 10.1136/bmjdrc-2019-000783
REF00003444	Nicorandil attenuates high glucose-induced insulin resistance by suppressing oxidative stress-mediated ER stress PERK signaling pathway .BMJ Open Diabetes Res Care. 2021 Apr;9(1):e001884. doi: 10.1136/bmjdrc-2020-001884. 10.1136/bmjdrc-2020-001884
REF00003445	Residual homing of Alpha4Beta7-expressing Beta1(+)PI16(+) regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab .Gut. 2021 Aug 30:gutjnl-2021-324868. doi: 10.1136/gutjnl-2021-324868. Online ahead of print. 10.1136/gutjnl-2021-324868
REF00003446	Treosulfan in platinum-resistant ovarian cancer .Int J Gynecol Cancer. 2021 Jul;31(7):1045-1051. doi: 10.1136/ijgc-2021-002395. Epub 2021 May 18. 10.1136/ijgc-2021-002395
REF00003447	Carbimazole--resistant thyrotoxicosis .Postgrad Med J. 1997 Oct;73(864):686. doi: 10.1136/pgmj.73.864.686. 10.1136/pgmj.73.864.686
REF00003448	YAP confers resistance to vandetanib in medullary thyroid cancer .Biochem Cell Biol. 2020 Jun;98(3):443-448. doi: 10.1139/bcb-2019-0354. Epub 2020 May 25. 10.1139/bcb-2019-0354
REF00003449	Nitrofurazone-reducing enzymes in E. coli and their role in drug activation in vivo .Can J Microbiol. 1975 Oct;21(10):1484-91. doi: 10.1139/m75-220. 10.1139/m75-220
REF00003450	The Spectrum of Helicobacter-Mediated Diseases .Annu Rev Pathol. 2021 Jan 24;16:123-144. doi: 10.1146/annurev-pathol-032520-024949. Epub 2020 Nov 16. 10.1146/annurev-pathol-032520-024949
REF00003451	Stimulus-specific functional remodeling of the left ventricle in endurance and resistance-trained men .Am J Physiol Heart Circ Physiol. 2020 Sep 1;319(3):H632-H641. doi: 10.1152/ajpheart.00233.2020. Epub 2020 Aug 9. 10.1152/ajpheart.00233.2020
REF00003452	"Cold acclimation increases depolarization resistance and tolerance in muscle fibers from a chill-susceptible insect, Locusta migratoria .Am J Physiol Regul Integr Comp Physiol. 2020 Oct 1;319(4):R439-R447. doi: 10.1152/ajpregu.00068.2020. Epub 2020 Aug 26. 10.1152/ajpregu.00068.2020"
REF00003453	Beta(2)-Adrenergic agonist salbutamol augments hypertrophy in MHCIIa fibers and sprint mean power output but not muscle force during 11 weeks of resistance training in young men .J Appl Physiol (1985). 2021 Mar 1;130(3):617-626. doi: 10.1152/japplphysiol.00553.2020. Epub 2020 Dec 24. 10.1152/japplphysiol.00553.2020
REF00003454	Drug resistance in visceral leishmaniasis .J Biomed Biotechnol. 2010;2010:617521. doi: 10.1155/2010/617521. Epub 2009 Nov 1. 10.1155/2010/617521
REF00003455	"Serological Analysis and Drug Resistance of Chlamydia pneumoniae and Mycoplasma pneumoniae in 4500 Healthy Subjects in Shenzhen, China .Biomed Res Int. 2017;2017:3120138. doi: 10.1155/2017/3120138. Epub 2017 Sep 19. 10.1155/2017/3120138"
REF00003456	Physical Training Is a Potential Modifier of Risk for Contrast-Induced Acute Kidney Injury in Diabetes Mellitus .Biomed Res Int. 2020 Nov 17;2020:1830934. doi: 10.1155/2020/1830934. eCollection 2020. 10.1155/2020/1830934
REF00003457	Calorie Restriction Protects against Contrast-Induced Nephropathy via SIRT1/GPX4 Activation .Oxid Med Cell Longev. 2021 Oct 19;2021:2999296. doi: 10.1155/2021/2999296. eCollection 2021. 10.1155/2021/2999296
REF00003458	Simplified Assessment of the Index of Microvascular Resistance .J Interv Cardiol. 2021 Jun 2;2021:9971874. doi: 10.1155/2021/9971874. eCollection 2021. 10.1155/2021/9971874
REF00003459	Tegaserod Maleate Inhibits Breast Cancer Progression and Enhances the Sensitivity of Immunotherapy .J Oncol. 2022 Feb 3;2022:5320421. doi: 10.1155/2022/5320421. eCollection 2022. 10.1155/2022/5320421
REF00003460	PCPH/ENTPD5 expression confers to prostate cancer cells resistance against cisplatin-induced apoptosis through protein kinase Calpha-mediated Bcl-2 stabilization .Cancer Res. 2009 Jan 1;69(1):102-10. doi: 10.1158/0008-5472.CAN-08-2922. 10.1158/0008-5472.CAN-08-2922
REF00003461	YAP1 and COX2 Coordinately Regulate Urothelial Cancer Stem-like Cells .Cancer Res. 2018 Jan 1;78(1):168-181. doi: 10.1158/0008-5472.CAN-17-0836. Epub 2017 Nov 27. 10.1158/0008-5472.CAN-17-0836
REF00003462	Inhibition of NF-kB-Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma .Cancer Res. 2019 May 1;79(9):2415-2425. doi: 10.1158/0008-5472.CAN-18-3177. Epub 2019 Mar 18. 10.1158/0008-5472.CAN-18-3177
REF00003463	In vitro drug response and molecular markers associated with drug resistance in malignant gliomas .Clin Cancer Res. 2006 Aug 1;12(15):4523-32. doi: 10.1158/1078-0432.CCR-05-1830. 10.1158/1078-0432.CCR-05-1830
REF00003464	Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas .Clin Cancer Res. 2021 Apr 15;27(8):2326-2339. doi: 10.1158/1078-0432.CCR-19-4179. Epub 2021 Feb 5. 10.1158/1078-0432.CCR-19-4179
REF00003465	Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma .Mol Cancer Res. 2015 Apr;13(4):775-83. doi: 10.1158/1541-7786.MCR-14-0157. Epub 2014 Nov 24. 10.1158/1541-7786.MCR-14-0157
REF00003466	Targeting NAD(+) Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma Resistance .Mol Cancer Res. 2020 Jul;18(7):1004-1017. doi: 10.1158/1541-7786.MCR-19-0669. Epub 2020 Apr 1. 10.1158/1541-7786.MCR-19-0669
REF00003467	The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial .Cancer Discov. 2018 Nov;8(11):1390-1403. doi: 10.1158/2159-8290.CD-18-0264. Epub 2018 Sep 11. 10.1158/2159-8290.CD-18-0264
REF00003468	EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer .Cancer Discov. 2019 Feb;9(2):199-209. doi: 10.1158/2159-8290.CD-18-0598. Epub 2018 Nov 21. 10.1158/2159-8290.CD-18-0598
REF00003469	TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma .Cancer Discov. 2019 Aug;9(8):1064-1079. doi: 10.1158/2159-8290.CD-19-0182. Epub 2019 May 20. 10.1158/2159-8290.CD-19-0182
REF00003470	Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain .Cancer Discov. 2021 Jan;11(1):108-125. doi: 10.1158/2159-8290.CD-20-0487. Epub 2020 Sep 24. 10.1158/2159-8290.CD-20-0487
REF00003471	Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib .Cancer Discov. 2021 Feb;11(2):326-339. doi: 10.1158/2159-8290.CD-20-0766. Epub 2020 Nov 20. 10.1158/2159-8290.CD-20-0766
REF00003472	Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown .Cancer Discov. 2021 Nov;11(11):2828-2845. doi: 10.1158/2159-8290.CD-20-1543. Epub 2021 Jul 6. 10.1158/2159-8290.CD-20-1543
REF00003473	Liver cirrhosis with ascites: pathogenesis of resistance to diuretics and long-term efficacy and safety of torasemide .Cardiology. 1994;84 Suppl 2:87-98. doi: 10.1159/000176461. 10.1159/000176461
REF00003474	Enhanced expression of the multidrug resistance gene in vindesine-resistant human esophageal cancer cells .Oncology. 1994 Sep-Oct;51(5):440-5. doi: 10.1159/000227380. 10.1159/000227380
REF00003475	"Comparative activities of ampicillin, epicillin and amoxycillin in vitro and in vivo .Chemotherapy. 1979;25(3):170-80. doi: 10.1159/000237837. 10.1159/000237837"
REF00003476	Reversal of multidrug resistance by guggulsterone in drug-resistant MCF-7 cell lines .Chemotherapy. 2011;57(1):62-70. doi: 10.1159/000321484. Epub 2011 Feb 1. 10.1159/000321484
REF00003477	Sensitivity to lovastatin of Saccharomyces cerevisiae strains deleted for pleiotropic drug resistance (PDR) genes .J Mol Microbiol Biotechnol. 2011;20(4):191-5. doi: 10.1159/000329068. Epub 2011 Jul 12. 10.1159/000329068
REF00003478	"Acute bacterial prostatitis in humans: current microbiological spectrum, sensitivity to antibiotics and clinical findings .Urol Int. 2012;89(4):445-50. doi: 10.1159/000342653. Epub 2012 Oct 18. 10.1159/000342653"
REF00003479	Estradiol Protects Neuropeptide Y/Agouti-Related Peptide Neurons against Insulin Resistance in Females .Neuroendocrinology. 2020;110(1-2):105-118. doi: 10.1159/000501560. Epub 2019 Jun 19. 10.1159/000501560
REF00003480	Lubiprostone Induces Claudin-1 and Protects Intestinal Barrier Function .Pharmacology. 2020;105(1-2):102-108. doi: 10.1159/000503054. Epub 2019 Sep 19. 10.1159/000503054
REF00003481	Genotype-Guided Hydralazine Therapy .Am J Nephrol. 2020;51(10):764-776. doi: 10.1159/000510433. Epub 2020 Sep 14. 10.1159/000510433
REF00003482	"Glomerular and vascular atrial natriuretic factor receptors in saralasin-sensitive and -resistant two-kidney, one-clip hypertensive rats .Circ Res. 1988 Sep;63(3):563-71. doi: 10.1161/01.res.63.3.563. 10.1161/01.res.63.3.563"
REF00003483	Treatment of Resistant and Refractory Hypertension .Circ Res. 2019 Mar 29;124(7):1061-1070. doi: 10.1161/CIRCRESAHA.118.312156. 10.1161/CIRCRESAHA.118.312156
REF00003484	Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin .Circulation. 2013 Jan 22;127(3):377-85. doi: 10.1161/CIRCULATIONAHA.112.117283. Epub 2012 Dec 4. 10.1161/CIRCULATIONAHA.112.117283
REF00003485	Results of the FUEL Trial .Circulation. 2020 Feb 25;141(8):641-651. doi: 10.1161/CIRCULATIONAHA.119.044352. Epub 2019 Nov 17. 10.1161/CIRCULATIONAHA.119.044352
REF00003486	Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial .Circulation. 2021 May 4;143(18):1735-1749. doi: 10.1161/CIRCULATIONAHA.120.048740. Epub 2021 Feb 8. 10.1161/CIRCULATIONAHA.120.048740
REF00003487	Pathophysiology of Diuretic Resistance and Its Implications for the Management of Chronic Heart Failure .Hypertension. 2020 Oct;76(4):1045-1054. doi: 10.1161/HYPERTENSIONAHA.120.15205. Epub 2020 Aug 24. 10.1161/HYPERTENSIONAHA.120.15205
REF00003488	Effect of Increased Potassium Intake on Adrenal Cortical and Cardiovascular Responses to Angiotensin II: A Randomized Crossover Study .J Am Heart Assoc. 2021 May 4;10(9):e018716. doi: 10.1161/JAHA.120.018716. Epub 2021 Apr 19. 10.1161/JAHA.120.018716
REF00003489	Benzalkonium Chloride Resistance in Staphylococcus epidermidis on the Ocular Surface of Glaucoma Patients Under Long-Term Administration of Eye Drops .Transl Vis Sci Technol. 2020 Jul 7;9(8):9. doi: 10.1167/tvst.9.8.9. eCollection 2020 Jul. 10.1167/tvst.9.8.9
REF00003490	The antifibrotic drug pirfenidone promotes pulmonary cavitation and drug resistance in a mouse model of chronic tuberculosis .JCI Insight. 2016 Sep 8;1(14):e86017. doi: 10.1172/jci.insight.86017. 10.1172/jci.insight.86017
REF00003491	DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance .J Clin Invest. 2019 Nov 1;129(11):5005-5019. doi: 10.1172/JCI128571. 10.1172/JCI128571
REF00003492	The Beta3-adrenergic receptor agonist mirabegron improves glucose homeostasis in obese humans .J Clin Invest. 2020 May 1;130(5):2319-2331. doi: 10.1172/JCI134892. 10.1172/JCI134892
REF00003493	Monocyte metabolic transcriptional programs associate with resistance to tuberculin skin test/interferon-Gamma release assay conversion .J Clin Invest. 2021 Jul 15;131(14):e140073. doi: 10.1172/JCI140073. 10.1172/JCI140073
REF00003494	HIF-2Alpha activation potentiates oxidative cell death in colorectal cancers by increasing cellular iron .J Clin Invest. 2021 Jun 15;131(12):e143691. doi: 10.1172/JCI143691. 10.1172/JCI143691
REF00003495	Psychedelics and Psychedelic-Assisted Psychotherapy .Am J Psychiatry. 2020 May 1;177(5):391-410. doi: 10.1176/appi.ajp.2019.19010035. Epub 2020 Feb 26. 10.1176/appi.ajp.2019.19010035
REF00003496	Cevimeline co-treatment attenuates olanzapine-induced metabolic disorders via modulating hepatic M3 muscarinic receptor: AMPKAlpha signalling pathway in female rats .J Psychopharmacol. 2022 Feb;36(2):202-213. doi: 10.1177/02698811211050549. Epub 2021 Oct 25. 10.1177/02698811211050549
REF00003497	Very rare case of Graves' disease with resistance to methimazole: a case report and literature review .J Int Med Res. 2021 Mar;49(3):300060521996192. doi: 10.1177/0300060521996192. 10.1177/0300060521996192
REF00003498	Abnormal cardiovascular response to nitroglycerin in migraine .Cephalalgia. 2020 Mar;40(3):266-277. doi: 10.1177/0333102419881657. Epub 2019 Oct 9. 10.1177/0333102419881657
REF00003499	Chemosensitizing micelles self-assembled from amphiphilic TPGS-indomethacin twin drug for significantly synergetic multidrug resistance reversal .J Biomater Appl. 2021 Mar;35(8):994-1004. doi: 10.1177/0885328220975177. Epub 2020 Dec 6. 10.1177/0885328220975177
REF00003500	Early Identification of Argatroban Resistance and the Consideration of Factor VIII .J Pharm Pract. 2021 Apr;34(2):329-331. doi: 10.1177/0897190019885232. Epub 2019 Nov 6. 10.1177/0897190019885232
REF00003501	Abametapir for the Treatment of Head Lice: A Drug Review .Ann Pharmacother. 2022 Mar;56(3):352-357. doi: 10.1177/10600280211027968. Epub 2021 Jun 22. 10.1177/10600280211027968
REF00003502	Adjunctive Phenobarbital for Alcohol Withdrawal Syndrome: A Focused Literature Review .Ann Pharmacother. 2021 Dec;55(12):1515-1524. doi: 10.1177/1060028021999821. Epub 2021 Mar 7. 10.1177/1060028021999821
REF00003503	Cefsulodin .Drug Intell Clin Pharm. 1986 Nov;20(11):845-9. doi: 10.1177/106002808602001104. 10.1177/106002808602001104
REF00003504	Assessment of Risk Factors for Drug Resistance of Dual Anti Platelet Therapy After PCI .Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221083674. doi: 10.1177/10760296221083674. 10.1177/10760296221083674
REF00003505	"Lomustine, methotrexate and cytarabine chemotherapy as a rescue treatment for feline lymphoma .J Feline Med Surg. 2021 Aug;23(8):722-729. doi: 10.1177/1098612X20972066. Epub 2020 Nov 12. 10.1177/1098612X20972066"
REF00003506	Amiloride: A review .J Renin Angiotensin Aldosterone Syst. 2020 Oct-Dec;21(4):1470320320975893. doi: 10.1177/1470320320975893. 10.1177/1470320320975893
REF00003507	Non-Hodgkin's B-cell lymphoma: advances in molecular strategies targeting drug resistance .Exp Biol Med (Maywood). 2013 Sep;238(9):971-90. doi: 10.1177/1535370213498985. Epub 2013 Aug 28. 10.1177/1535370213498985
REF00003508	Advances in hepatitis B therapeutics .Ther Adv Infect Dis. 2020 Oct 15;7:2049936120965027. doi: 10.1177/2049936120965027. eCollection 2020 Jan-Dec. 10.1177/2049936120965027
REF00003509	A review: Mechanism of action of antiviral drugs .Int J Immunopathol Pharmacol. 2021 Jan-Dec;35:20587384211002621. doi: 10.1177/20587384211002621. 10.1177/20587384211002621
REF00003510	Rokitamycin: bacterial resistance to a 16-membered ring macrolide differs from that to 14- and 15-membered ring macrolides .J Chemother. 2002 Apr;14(2):115-31. doi: 10.1179/joc.2002.14.2.115. 10.1179/joc.2002.14.2.115
REF00003511	Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma .Blood. 2021 Jan 14;137(2):232-237. doi: 10.1182/blood.2020007081. 10.1182/blood.2020007081
REF00003512	How I treat chronic lymphocytic leukemia after venetoclax .Blood. 2021 Aug 5;138(5):361-369. doi: 10.1182/blood.2020008502. 10.1182/blood.2020008502
REF00003513	Cereblon enhancer methylation and IMiD resistance in multiple myeloma .Blood. 2021 Nov 4;138(18):1721-1726. doi: 10.1182/blood.2020010452. 10.1182/blood.2020010452
REF00003514	Resistance to mogamulizumab is associated with loss of CCR4 in Cutaneous T-cell Lymphoma .Blood. 2022 Apr 18:blood.2021014468. doi: 10.1182/blood.2021014468. Online ahead of print. 10.1182/blood.2021014468
REF00003515	"The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma .Blood. 2014 Oct 2;124(14):2190-5. doi: 10.1182/blood-2014-03-559963. Epub 2014 Jul 29. 10.1182/blood-2014-03-559963"
REF00003516	Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib .Blood Adv. 2019 May 14;3(9):1553-1562. doi: 10.1182/bloodadvances.2018030007. 10.1182/bloodadvances.2018030007
REF00003517	ERS guidelines on the diagnosis and treatment of chronic cough in adults and children .Eur Respir J. 2020 Jan 2;55(1):1901136. doi: 10.1183/13993003.01136-2019. Print 2020 Jan. 10.1183/13993003.01136-2019
REF00003518	Selexipag for the treatment of chronic thromboembolic pulmonary hypertension .Eur Respir J. 2021 Nov 25:2101694. doi: 10.1183/13993003.01694-2021. Online ahead of print. 10.1183/13993003.01694-2021
REF00003519	Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients .Eur Respir J. 2020 Jun 4;55(6):1902383. doi: 10.1183/13993003.02383-2019. Print 2020 Jun. 10.1183/13993003.02383-2019
REF00003520	"Colistin, mechanisms and prevalence of resistance .Curr Med Res Opin. 2015 Apr;31(4):707-21. doi: 10.1185/03007995.2015.1018989. Epub 2015 Mar 19. 10.1185/03007995.2015.1018989"
REF00003521	Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors .Mol Cancer. 2004 May 18;3:16. doi: 10.1186/1476-4598-3-16. 10.1186/1476-4598-3-16
REF00003522	Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors .J Transl Med. 2013 Sep 17;11:213. doi: 10.1186/1479-5876-11-213. 10.1186/1479-5876-11-213
REF00003523	The expression of V-ATPase is associated with drug resistance and pathology of non-small-cell lung cancer .Diagn Pathol. 2013 Aug 28;8:145. doi: 10.1186/1746-1596-8-145. 10.1186/1746-1596-8-145
REF00003524	Lysosomal drug sequestration as a mechanism of drug resistance in vascular sarcoma cells marked by high CSF-1R expression .Vasc Cell. 2014 Oct 1;6:20. doi: 10.1186/2045-824X-6-20. eCollection 2014. 10.1186/2045-824X-6-20
REF00003525	Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial .BMC Infect Dis. 2020 Dec 14;20(1):954. doi: 10.1186/s12879-020-05698-w. 10.1186/s12879-020-05698-w
REF00003526	Increased resistance of gram-negative urinary pathogens after kidney transplantation .BMC Nephrol. 2017 May 19;18(1):164. doi: 10.1186/s12882-017-0580-z. 10.1186/s12882-017-0580-z
REF00003527	Regulation of cellular sphingosine-1-phosphate by sphingosine kinase 1 and sphingosine-1-phopshate lyase determines chemotherapy resistance in gastroesophageal cancer .BMC Cancer. 2015 Oct 22;15:762. doi: 10.1186/s12885-015-1718-7. 10.1186/s12885-015-1718-7
REF00003528	Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer .BMC Cancer. 2018 Jan 6;18(1):46. doi: 10.1186/s12885-017-3907-z. 10.1186/s12885-017-3907-z
REF00003529	Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma .BMC Cancer. 2019 Oct 10;19(1):936. doi: 10.1186/s12885-019-6057-7. 10.1186/s12885-019-6057-7
REF00003530	Gene signature associated with resistance to fluvastatin chemoprevention for breast cancer .BMC Cancer. 2022 Mar 17;22(1):282. doi: 10.1186/s12885-022-09353-2. 10.1186/s12885-022-09353-2
REF00003531	Cefaclor as a first-line treatment for acute uncomplicated cystitis: a retrospective single-center study .BMC Urol. 2020 Apr 6;20(1):38. doi: 10.1186/s12894-020-00605-6. 10.1186/s12894-020-00605-6
REF00003532	Dasatinib reverses drug resistance by downregulating MDR1 and Survivin in Burkitt lymphoma cells .BMC Complement Med Ther. 2020 Mar 14;20(1):84. doi: 10.1186/s12906-020-2879-8. 10.1186/s12906-020-2879-8
REF00003533	Pyrvinium pamoate can overcome artemisinin's resistance in anaplastic thyroid cancer .BMC Complement Med Ther. 2021 May 28;21(1):156. doi: 10.1186/s12906-021-03332-z. 10.1186/s12906-021-03332-z
REF00003534	Modulation of doxorubicin-induced expression of the multidrug resistance gene in breast cancer cells by diltiazem and protection against cardiotoxicity in experimental animals .Cancer Cell Int. 2019 Jul 24;19:191. doi: 10.1186/s12935-019-0912-0. eCollection 2019. 10.1186/s12935-019-0912-0
REF00003535	Hypoxia-induced Tie1 drives stemness and cisplatin resistance in non-small cell lung carcinoma cells .Cancer Cell Int. 2021 Jan 18;21(1):57. doi: 10.1186/s12935-020-01729-3. 10.1186/s12935-020-01729-3
REF00003536	Identification and characterization of a subpopulation of CD133(+) cancer stem-like cells derived from SK-UT-1 cells .Cancer Cell Int. 2021 Mar 8;21(1):157. doi: 10.1186/s12935-021-01817-y. 10.1186/s12935-021-01817-y
REF00003537	Combating drug resistance in acute myeloid leukaemia by drug rotations: the effects of quizartinib and pexidartinib .Cancer Cell Int. 2021 Apr 8;21(1):198. doi: 10.1186/s12935-021-01856-5. 10.1186/s12935-021-01856-5
REF00003538	Multigenerational endometriosis : consequence of fetal exposure to diethylstilbestrol   .Environ Health. 2021 Aug 27;20(1):96. doi: 10.1186/s12940-021-00780-5. 10.1186/s12940-021-00780-5
REF00003539	Comprehensive bioinformatics analysis of acquired progesterone resistance in endometrial cancer cell line .J Transl Med. 2019 Feb 27;17(1):58. doi: 10.1186/s12967-019-1814-6. 10.1186/s12967-019-1814-6
REF00003540	Diabetogenic effect of pravastatin is associated with insulin resistance and myotoxicity in hypercholesterolemic mice .J Transl Med. 2019 Aug 27;17(1):285. doi: 10.1186/s12967-019-2045-6. 10.1186/s12967-019-2045-6
REF00003541	Anthelmintic resistance of horse strongyle nematodes to ivermectin and pyrantel in Lithuania .Acta Vet Scand. 2021 Jan 25;63(1):5. doi: 10.1186/s13028-021-00569-z. 10.1186/s13028-021-00569-z
REF00003542	Risk factors for liposomal bupivacaine resistance after total hip or knee arthroplasties: a retrospective observational cohort in 237 patients .Patient Saf Surg. 2020 Jan 30;14:6. doi: 10.1186/s13037-020-0230-4. eCollection 2020. 10.1186/s13037-020-0230-4
REF00003543	EZH2: a novel target for cancer treatment .J Hematol Oncol. 2020 Jul 28;13(1):104. doi: 10.1186/s13045-020-00937-8. 10.1186/s13045-020-00937-8
REF00003544	Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target .J Hematol Oncol. 2021 Sep 15;14(1):147. doi: 10.1186/s13045-021-01161-8. 10.1186/s13045-021-01161-8
REF00003545	m(6)A regulators as predictive biomarkers for chemotherapy benefit and potential therapeutic targets for overcoming chemotherapy resistance in small-cell lung cancer .J Hematol Oncol. 2021 Nov 10;14(1):190. doi: 10.1186/s13045-021-01173-4. 10.1186/s13045-021-01173-4
REF00003546	Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling .J Exp Clin Cancer Res. 2020 Jul 25;39(1):142. doi: 10.1186/s13046-020-01623-w. 10.1186/s13046-020-01623-w
REF00003547	Cancer-associated fibroblasts promote the survival of irradiated nasopharyngeal carcinoma cells via the NF-kB pathway .J Exp Clin Cancer Res. 2021 Mar 1;40(1):87. doi: 10.1186/s13046-021-01878-x. 10.1186/s13046-021-01878-x
REF00003548	Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies .J Exp Clin Cancer Res. 2021 Oct 18;40(1):328. doi: 10.1186/s13046-021-02130-2. 10.1186/s13046-021-02130-2
REF00003549	Vasoplegic syndrome following cardiothoracic surgery-review of pathophysiology and update of treatment options .Crit Care. 2020 Feb 4;24(1):36. doi: 10.1186/s13054-020-2743-8. 10.1186/s13054-020-2743-8
REF00003550	Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer .Breast Cancer Res. 2021 May 12;23(1):54. doi: 10.1186/s13058-021-01431-w. 10.1186/s13058-021-01431-w
REF00003551	Drug transporter and oxidative stress gene expression in human macrophages infected with benznidazole-sensitive and naturally benznidazole-resistant Trypanosoma cruzi parasites treated with benznidazole .Parasit Vectors. 2019 May 24;12(1):262. doi: 10.1186/s13071-019-3485-9. 10.1186/s13071-019-3485-9
REF00003552	Determination of azithromycin heteroresistant Campylobacter jejuni in traveler's diarrhea .Gut Pathog. 2019 May 6;11:19. doi: 10.1186/s13099-019-0301-1. eCollection 2019. 10.1186/s13099-019-0301-1
REF00003553	Antibacterial activity of ethoxzolamide against Helicobacter pylori strains SS1 and 26695 .Gut Pathog. 2020 Apr 15;12:20. doi: 10.1186/s13099-020-00358-5. eCollection 2020. 10.1186/s13099-020-00358-5
REF00003554	Urodynamic effectiveness of a beta-3 adrenoreceptor agonist (vibegron) for a pediatric patient with anticholinergic-resistant neurogenic detrusor overactivity: a case report .J Med Case Rep. 2021 Feb 18;15(1):86. doi: 10.1186/s13256-020-02564-w. 10.1186/s13256-020-02564-w
REF00003555	"Freezing of gait in Parkinson's disease: pathophysiology, risk factors and treatments .Transl Neurodegener. 2020 Apr 15;9:12. doi: 10.1186/s40035-020-00191-5. eCollection 2020. 10.1186/s40035-020-00191-5"
REF00003556	"Effect of carvedilol versus nebivolol on insulin resistance among non-diabetic, non-ischemic cardiomyopathy with heart failure .Egypt Heart J. 2020 Sep 29;72(1):63. doi: 10.1186/s43044-020-00099-5. 10.1186/s43044-020-00099-5"
REF00003557	Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine .Br J Psychiatry. 1995 Jan;166(1):80-6. doi: 10.1192/bjp.166.1.80. 10.1192/bjp.166.1.80
REF00003558	A Review of Immune Checkpoint Blockade Therapy in Endometrial Cancer .Am Soc Clin Oncol Educ Book. 2020 Mar;40:1-7. doi: 10.1200/EDBK_280503. 10.1200/EDBK_280503
REF00003559	Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer .J Clin Oncol. 1995 Oct;13(10):2613-9. doi: 10.1200/JCO.1995.13.10.2613. 10.1200/JCO.1995.13.10.2613
REF00003560	Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451 .J Clin Oncol. 2021 Apr 20;39(12):1349-1359. doi: 10.1200/JCO.20.02212. Epub 2021 Mar 8. 10.1200/JCO.20.02212
REF00003561	Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma .J Clin Oncol. 2021 Mar 1;39(7):757-767. doi: 10.1200/JCO.20.02259. Epub 2020 Dec 9. 10.1200/JCO.20.02259
REF00003562	Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia .J Clin Oncol. 2021 Sep 1;39(25):2768-2778. doi: 10.1200/JCO.20.03736. Epub 2021 May 27. 10.1200/JCO.20.03736
REF00003563	"Genomics, Signaling, and Treatment of Waldenstr m Macroglobulinemia .J Clin Oncol. 2017 Mar 20;35(9):994-1001. doi: 10.1200/JCO.2016.71.0814. Epub 2017 Feb 13. 10.1200/JCO.2016.71.0814"
REF00003564	Response and mechanisms of resistance to larotrectinib and selitrectinib in metastatic undifferentiated sarcoma harboring oncogenic fusion of NTRK1 .JCO Precis Oncol. 2020;4:79-90. doi: 10.1200/po.19.00287. Epub 2020 Feb 14. 10.1200/po.19.00287
REF00003565	Use of Drug Release Testing to Evaluate the Retention of Abuse-Deterrent Properties of Polyethylene Oxide Matrix Tablets .AAPS PharmSciTech. 2020 Oct 6;21(7):270. doi: 10.1208/s12249-020-01804-y. 10.1208/s12249-020-01804-y
REF00003566	Individualized Therapy for Hypothyroidism: Is T4 Enough for Everyone  .J Clin Endocrinol Metab. 2020 Sep 1;105(9):e3090-104. doi: 10.1210/clinem/dgaa430. 10.1210/clinem/dgaa430
REF00003567	Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease .J Clin Endocrinol Metab. 2021 Jan 23;106(2):e520-e533. doi: 10.1210/clinem/dgaa792. 10.1210/clinem/dgaa792
REF00003568	Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes .J Clin Endocrinol Metab. 2021 Jan 23;106(2):388-396. doi: 10.1210/clinem/dgaa863. 10.1210/clinem/dgaa863
REF00003569	"Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome .J Clin Endocrinol Metab. 2021 Sep 27;106(10):3019-3033. doi: 10.1210/clinem/dgab408. 10.1210/clinem/dgab408"
REF00003570	Characterization of multidrug-resistant pituitary tumor cells .Endocrinology. 1992 Jun;130(6):3246-56. doi: 10.1210/endo.130.6.1350759. 10.1210/endo.130.6.1350759
REF00003571	DPP-4 Inhibition with Anagliptin Reduces Lipotoxicity-Induced Insulin Resistance and Steatohepatitis in Male Mice .Endocrinology. 2020 Oct 1;161(10):bqaa139. doi: 10.1210/endocr/bqaa139. 10.1210/endocr/bqaa139
REF00003572	Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents .Endocr Rev. 2019 Dec 1;40(6):1447-1467. doi: 10.1210/er.2018-00141. 10.1210/er.2018-00141
REF00003573	Resistance to antiestrogen arzoxifene is mediated by overexpression of cyclin D1 .Mol Endocrinol. 2009 Sep;23(9):1335-45. doi: 10.1210/me.2008-0268. Epub 2009 May 28. 10.1210/me.2008-0268
REF00003574	Antiepileptic Drug Treatment of Epilepsy in Children .Continuum (Minneap Minn). 2019 Apr;25(2):381-407. doi: 10.1212/CON.0000000000000712. 10.1212/CON.0000000000000712
REF00003575	Involvement of Renal Efflux Transporter MATE1 in Renal Excretion of Flecainide .Biol Pharm Bull. 2019;42(7):1226-1229. doi: 10.1248/bpb.b19-00031. 10.1248/bpb.b19-00031
REF00003576	Regular Resistance Training Enhances Fibrinolytic Potential but Does Not Affect Coagulation .Med Sci Sports Exerc. 2021 Nov 1;53(11):2318-2323. doi: 10.1249/MSS.0000000000002724. 10.1249/MSS.0000000000002724
REF00003577	"[Pharmacological and clinical profile of linaclotide (Linzess( )), a novel therapeutic agent for irritable bowel syndrome with constipation and chronic constipation] .Nihon Yakurigaku Zasshi. 2019;153(6):289-298. doi: 10.1254/fpj.153.289. 10.1254/fpj.153.289"
REF00003578	Oxycodone Resistance Due to Rifampin Use in an Osteosarcoma Patient with Tuberculosis .Am J Case Rep. 2017 Oct 24;18:1130-1134. doi: 10.12659/ajcr.905637. 10.12659/ajcr.905637
REF00003579	"Molecular characterization and drug resistance of Escherichia coli strains isolated from urine from long-term care facility residents in Cracow, Poland .Med Sci Monit. 2013 May 1;19:317-26. doi: 10.12659/MSM.883898. 10.12659/MSM.883898"
REF00003580	Asiaticoside Antagonizes Proliferation and Chemotherapeutic Drug Resistance in Hepatocellular Carcinoma (HCC) Cells .Med Sci Monit. 2020 Aug 30;26:e924435. doi: 10.12659/MSM.924435. 10.12659/MSM.924435
REF00003581	"Retracted: Naturally Occurring Sesquiterpene Lactone-Santonin, Exerts Anticancer Effects in Multi-Drug Resistant Breast Cancer Cells by Inducing Mitochondrial Mediated Apoptosis, Caspase Activation, Cell Cycle Arrest, and by Targeting Ras/Raf/MEK/ERK Signaling Pathway .Med Sci Monit. 2020 Dec 30;26:e930755. doi: 10.12659/MSM.930755. 10.12659/MSM.930755"
REF00003582	Emerging therapies in the management of macular edema: a review .F1000Res. 2019 Aug 12;8:F1000 Faculty Rev-1413. doi: 10.12688/f1000research.19198.1. eCollection 2019. 10.12688/f1000research.19198.1
REF00003583	Localization of cerebral hypoperfusion in dogs with refractory and non-refractory epilepsy using [99mTc] ethyl cysteinate dimer and single photon emission computed tomography .J Vet Med Sci. 2020 May 15;82(5):553-558. doi: 10.1292/jvms.19-0372. Epub 2020 Mar 19. 10.1292/jvms.19-0372
REF00003584	Relationship between anti-insulin antibody production and severe insulin resistance in a diabetic cat .J Vet Med Sci. 2021 Mar 5. doi: 10.1292/jvms.2-0345. Online ahead of print. 10.1292/jvms.2-0345
REF00003585	Does oral care with chlorhexidine reduce ventilator-associated pneumonia in mechanically ventilated adults  .Br J Nurs. 2019 Jun 13;28(11):682-689. doi: 10.12968/bjon.2019.28.11.682. 10.12968/bjon.2019.28.11.682
REF00003586	Lurbinectedin for the treatment of small cell lung cancer .Drugs Today (Barc). 2021 Jun;57(6):377-385. doi: 10.1358/dot.2021.57.6.3294559. 10.1358/dot.2021.57.6.3294559
REF00003587	Urolithin A exerts antiobesity effects through enhancing adipose tissue thermogenesis in mice .PLoS Biol. 2020 Mar 27;18(3):e3000688. doi: 10.1371/journal.pbio.3000688. eCollection 2020 Mar. 10.1371/journal.pbio.3000688
REF00003588	Scabies in the age of increasing drug resistance .PLoS Negl Trop Dis. 2017 Nov 30;11(11):e0005920. doi: 10.1371/journal.pntd.0005920. eCollection 2017 Nov. 10.1371/journal.pntd.0005920
REF00003589	Drug resistance and treatment failure in leishmaniasis: A 21st century challenge .PLoS Negl Trop Dis. 2017 Dec 14;11(12):e0006052. doi: 10.1371/journal.pntd.0006052. eCollection 2017 Dec. 10.1371/journal.pntd.0006052
REF00003590	The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter .PLoS One. 2011 Apr 28;6(4):e19329. doi: 10.1371/journal.pone.0019329. 10.1371/journal.pone.0019329
REF00003591	"Aldehyde dehydrogenase 1, a potential marker for cancer stem cells in human sarcoma .PLoS One. 2012;7(8):e43664. doi: 10.1371/journal.pone.0043664. Epub 2012 Aug 23. 10.1371/journal.pone.0043664"
REF00003592	Genetic aberrations in imatinib-resistant dermatofibrosarcoma protuberans revealed by whole genome sequencing .PLoS One. 2013 Jul 29;8(7):e69752. doi: 10.1371/journal.pone.0069752. Print 2013. 10.1371/journal.pone.0069752
REF00003593	Common variants of KCNJ10 are associated with susceptibility and anti-epileptic drug resistance in Chinese genetic generalized epilepsies .PLoS One. 2015 Apr 13;10(4):e0124896. doi: 10.1371/journal.pone.0124896. eCollection 2015. 10.1371/journal.pone.0124896
REF00003594	"Effects of azilsartan compared with telmisartan on insulin resistance in patients with essential hypertension and type 2 diabetes mellitus: An open-label, randomized clinical trial .PLoS One. 2019 Apr 3;14(4):e0214727. doi: 10.1371/journal.pone.0214727. eCollection 2019. 10.1371/journal.pone.0214727"
REF00003595	Levosimendan reduces segmental pulmonary vascular resistance in isolated perfused rat lungs and relaxes human pulmonary vessels .PLoS One. 2020 May 18;15(5):e0233176. doi: 10.1371/journal.pone.0233176. eCollection 2020. 10.1371/journal.pone.0233176
REF00003596	Flow resistance characteristics of the stem and root from conifer (Sabina chinensis) xylem tracheid .PLoS One. 2021 Oct 28;16(10):e0259117. doi: 10.1371/journal.pone.0259117. eCollection 2021. 10.1371/journal.pone.0259117
REF00003597	Rifampicin and isoniazid drug resistance among patients diagnosed with pulmonary tuberculosis in southwestern Uganda .PLoS One. 2021 Oct 29;16(10):e0259221. doi: 10.1371/journal.pone.0259221. eCollection 2021. 10.1371/journal.pone.0259221
REF00003598	Oxamniquine resistance alleles are widespread in Old World Schistosoma mansoni and predate drug deployment .PLoS Pathog. 2019 Oct 25;15(10):e1007881. doi: 10.1371/journal.ppat.1007881. eCollection 2019 Oct. 10.1371/journal.ppat.1007881
REF00003599	Aldosterone Resistance Due to Tacrolimus: A Case Report .Sisli Etfal Hastan Tip Bul. 2018 Mar 21;52(4):310-312. doi: 10.14744/SEMB.2017.75436. eCollection 2018. 10.14744/SEMB.2017.75436
REF00003600	The differential influence of glimepiride and glibenclamide on insulin resistance and adiponectin levels in patients with type 2 diabetes .Endocr J. 2019 Oct 28;66(10):915-921. doi: 10.1507/endocrj.EJ18-0493. Epub 2019 Jul 11. 10.1507/endocrj.EJ18-0493
REF00003601	Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance .EMBO Mol Med. 2019 Jul;11(7):e9982. doi: 10.15252/emmm.201809982. Epub 2019 May 24. 10.15252/emmm.201809982
REF00003602	The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide .Endocrinol Diabetes Metab Case Rep. 2020 Mar 25;2020:19-0139. doi: 10.1530/EDM-19-0139. Online ahead of print. 10.1530/EDM-19-0139
REF00003603	Perioperative control of paroxysmal hypertension using esmolol with alpha-blockade in a child with a germline mutated paraganglioma .Endocrinol Diabetes Metab Case Rep. 2021 Jul 19;2021(20-0101):20-0101. doi: 10.1530/EDM-20-0101. 10.1530/EDM-20-0101
REF00003604	Apomorphine induces mitochondrial-dysfunction-dependent apoptosis in choriocarcinoma .Reproduction. 2020 Sep;160(3):367-377. doi: 10.1530/REP-20-0230. 10.1530/REP-20-0230
REF00003605	Nebulized Versus Dry Powder Long-Acting Muscarinic Antagonist Bronchodilators in Patients With COPD and Suboptimal Peak Inspiratory Flow Rate .Chronic Obstr Pulm Dis. 2019 Oct 23;6(4):321-31. doi: 10.15326/jcopdf.6.4.2019.0137. 10.15326/jcopdf.6.4.2019.0137
REF00003606	Etanercept With IVIg for Acute Kawasaki Disease: A Randomized Controlled Trial .Pediatrics. 2019 Jun;143(6):e20183675. doi: 10.1542/peds.2018-3675. Epub 2019 May 2. 10.1542/peds.2018-3675
REF00003607	Current Issues in the Treatment of Acne Vulgaris .Pediatrics. 2020 May;145(Suppl 2):S225-S230. doi: 10.1542/peds.2019-2056L. 10.1542/peds.2019-2056L
REF00003608	Invasive Diagnosis of Coronary Functional Disorders Causing Angina Pectoris .Eur Cardiol. 2021 Jul 5;16:e27. doi: 10.15420/ecr.2021.06. eCollection 2021 Feb. 10.15420/ecr.2021.06
REF00003609	The emerging threat of artemisinin resistance in malaria: focus on artemether-lumefantrine .Expert Rev Anti Infect Ther. 2015 Aug;13(8):1031-45. doi: 10.1586/14787210.2015.1052793. Epub 2015 Jun 16. 10.1586/14787210.2015.1052793
REF00003610	Prospects for the control of neglected tropical diseases by mass drug administration .Expert Rev Anti Infect Ther. 2009 Feb;7(1):37-56. doi: 10.1586/14787210.7.1.37. 10.1586/14787210.7.1.37
REF00003611	"Detection of cfxA2, cfxA3, and cfxA6 genes in beta-lactamase producing oral anaerobes .J Appl Oral Sci. 2016 Apr;24(2):142-7. doi: 10.1590/1678-775720150469. 10.1590/1678-775720150469"
REF00003612	Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC) .Oncologist. 2019 Sep;24(9):1188-1194. doi: 10.1634/theoncologist.2018-0621. Epub 2019 Apr 5. 10.1634/theoncologist.2018-0621
REF00003613	Epilepsy and cannabidiol: a guide to treatment .Epileptic Disord. 2020 Feb 1;22(1):1-14. doi: 10.1684/epd.2020.1141. 10.1684/epd.2020.1141
REF00003614	Celecoxib reverses the glioblastoma chemo-resistance to temozolomide through mitochondrial metabolism .Aging (Albany NY). 2021 Sep 8;13(17):21268-21282. doi: 10.18632/aging.203443. Epub 2021 Sep 8. 10.18632/aging.203443
REF00003615	Reduced argininosuccinate synthetase expression in refractory sarcomas: Impacts on therapeutic potential and drug resistance .Oncotarget. 2016 Oct 25;7(43):70832-70844. doi: 10.18632/oncotarget.12225. 10.18632/oncotarget.12225
REF00003616	Disruption of the association between drug transporter and actin cytoskeleton abolishes drug resistance in hypertrophic scar .Oncotarget. 2017 Jan 10;8(2):2617-2627. doi: 10.18632/oncotarget.13734. 10.18632/oncotarget.13734
REF00003617	Hyperactive ERK and persistent mTOR signaling characterize vemurafenib resistance in papillary thyroid cancer cells .Oncotarget. 2016 Feb 23;7(8):8676-87. doi: 10.18632/oncotarget.6779. 10.18632/oncotarget.6779
REF00003618	[Network pharmacology study of Tibetan medicine Corydalis Herba against acute myocardial ischemia] .Zhongguo Zhong Yao Za Zhi. 2021 Jun;46(12):3058-3065. doi: 10.19540/j.cnki.cjcmm.20210129.401. 10.19540/j.cnki.cjcmm.20210129.401
REF00003619	Tumour suppressor microRNAs contribute to drug resistance in malignant pleural mesothelioma by targeting anti-apoptotic pathways .Cancer Drug Resist. 2019 Dec 19;2(4):1193-1206. doi: 10.20517/cdr.2019.41. eCollection 2019. 10.20517/cdr.2019.41
REF00003620	Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia .Cancer Drug Resist. 2021;4(1):125-142. doi: 10.20517/cdr.2020.95. Epub 2021 Mar 19. 10.20517/cdr.2020.95
REF00003621	Inhaled pulmonary vasodilators: a narrative review .Ann Transl Med. 2021 Apr;9(7):597. doi: 10.21037/atm-20-4895. 10.21037/atm-20-4895
REF00003622	A potentially effective drug for patients with recurrent glioma: sermorelin .Ann Transl Med. 2021 Mar;9(5):406. doi: 10.21037/atm-20-6561. 10.21037/atm-20-6561
REF00003623	[Rotavirus genomics. Public health impact] .Salud Publica Mex. 2020 Jan-Feb;62(1):36-41. doi: 10.21149/9965. 10.21149/9965
REF00003624	Andrographolide is an Alternative Treatment to Overcome Resistance in ER-Positive Breast Cancer via Cholesterol Biosynthesis Pathway .Malays J Med Sci. 2019 Sep;26(5):6-20. doi: 10.21315/mjms2019.26.5.2. Epub 2019 Nov 4. 10.21315/mjms2019.26.5.2
REF00003625	Non-coding RNA NEAT1/miR-214-3p contribute to doxorubicin resistance of urothelial bladder cancer preliminary through the Wnt/Beta-catenin pathway .Cancer Manag Res. 2018 Oct 11;10:4371-4380. doi: 10.2147/CMAR.S171126. eCollection 2018. 10.2147/CMAR.S171126
REF00003626	"Eupatilin inhibits glioma proliferation, migration, and invasion by arresting cell cycle at G1/S phase and disrupting the cytoskeletal structure .Cancer Manag Res. 2019 May 24;11:4781-4796. doi: 10.2147/CMAR.S207257. eCollection 2019. 10.2147/CMAR.S207257"
REF00003627	Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer .Cancer Manag Res. 2021 Jul 1;13:5223-5237. doi: 10.2147/CMAR.S310649. eCollection 2021. 10.2147/CMAR.S310649
REF00003628	"TRONARTO: A Randomized, Placebo-Controlled Study of Tiotropium/Olodaterol Delivered via Soft Mist Inhaler in COPD Patients Stratified by Peak Inspiratory Flow .Int J Chron Obstruct Pulmon Dis. 2021 Aug 28;16:2455-2465. doi: 10.2147/COPD.S324467. eCollection 2021. 10.2147/COPD.S324467"
REF00003629	Ketamine and depression: a narrative review .Drug Des Devel Ther. 2019 Aug 27;13:3051-3067. doi: 10.2147/DDDT.S221437. eCollection 2019. 10.2147/DDDT.S221437
REF00003630	Ketorolac-fluconazole: A New Combination Reverting Resistance in Candida albicans from Acute Myeloid Leukemia Patients on Induction Chemotherapy: In vitro Study .J Blood Med. 2021 Jun 15;12:465-474. doi: 10.2147/JBM.S302158. eCollection 2021. 10.2147/JBM.S302158
REF00003631	Investigational and Experimental Drugs to Treat Obsessive-Compulsive Disorder .J Exp Pharmacol. 2021 Jan 5;12:695-706. doi: 10.2147/JEP.S255375. eCollection 2020. 10.2147/JEP.S255375
REF00003632	Butorphanol Inhibits the Malignant Biological Behaviors of Ovarian Cancer Cells via Down-Regulating the Expression of TMEFF1 .Onco Targets Ther. 2020 Oct 28;13:10973-10981. doi: 10.2147/OTT.S244928. eCollection 2020. 10.2147/OTT.S244928
REF00003633	Efficacy and Resistance of ALK Inhibitors in Two Inflammatory Myofibroblastic Tumor Patients with ALK Fusions Assessed by Whole Exome and RNA Sequencing .Onco Targets Ther. 2020 Oct 13;13:10335-10342. doi: 10.2147/OTT.S270481. eCollection 2020. 10.2147/OTT.S270481
REF00003634	Refractory Sarcoidosis: A Review .Ther Clin Risk Manag. 2020 Apr 17;16:323-345. doi: 10.2147/TCRM.S192922. eCollection 2020. 10.2147/TCRM.S192922
REF00003635	Staphylococcus aureus bacteremias following liver transplantation: a clinical analysis of 20 cases .Ther Clin Risk Manag. 2015 Jun 12;11:933-7. doi: 10.2147/TCRM.S84579. eCollection 2015. 10.2147/TCRM.S84579
REF00003636	"Miocamycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential .Drugs. 1993 Oct;46(4):720-45. doi: 10.2165/00003495-199346040-00008. 10.2165/00003495-199346040-00008"
REF00003637	Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection .Drugs. 1997 Jun;53(6):1054-80. doi: 10.2165/00003495-199753060-00009. 10.2165/00003495-199753060-00009
REF00003638	Efficacy of Vonoprazan for Helicobacter pylori Eradication .Intern Med. 2020 Jan 15;59(2):153-161. doi: 10.2169/internalmedicine.2521-18. Epub 2019 Jun 27. 10.2169/internalmedicine.2521-18
REF00003639	The Biological Impact of Ulipristal Acetate on Cellular Networks Regulating Uterine Leiomyoma Growth .Curr Pharm Des. 2020;26(3):310-317. doi: 10.2174/1381612826666200121141533. 10.2174/1381612826666200121141533
REF00003640	Evaluation of Insulin Resistance Induced Brain Tissue Dysfunction in Obese Dams and their Neonates: Role of Ipriflavone Amelioration .Comb Chem High Throughput Screen. 2021;24(6):767-780. doi: 10.2174/1386207323666200808181148. 10.2174/1386207323666200808181148
REF00003641	Multi-Target Drug Design of Anti-Alzheimer's Disease based on Tacrine .Mini Rev Med Chem. 2021;21(15):2039-2064. doi: 10.2174/1389557521666210212151127. 10.2174/1389557521666210212151127
REF00003642	"Guanabenz and Clonidine, Alpha2-Adrenergic Receptor Agonists, Inhibit Choroidal Neovascularization .Curr Neurovasc Res. 2021;18(1):85-92. doi: 10.2174/1567202618666210518133634. 10.2174/1567202618666210518133634"
REF00003643	Accumulation of HIV-1 Drug Resistance Mutations and Methamphetamine Use .Curr HIV Res. 2021;19(6):497-503. doi: 10.2174/1570162X19666210625103902. 10.2174/1570162X19666210625103902
REF00003644	Repurposing Disulfiram as An Anti-Cancer Agent: Updated Review on Literature and Patents .Recent Pat Anticancer Drug Discov. 2019;14(2):113-132. doi: 10.2174/1574892814666190514104035. 10.2174/1574892814666190514104035
REF00003645	Giardiasis: An Overview .Recent Pat Inflamm Allergy Drug Discov. 2019;13(2):134-143. doi: 10.2174/1872213X13666190618124901. 10.2174/1872213X13666190618124901
REF00003646	Dantrolene Potentiates the Antineoplastic Effect of Sorafenib in Hepatocellular Carcinoma via Targeting Ca(+2)/PI3K Signaling Pathway .Curr Mol Pharmacol. 2021;14(5):900-913. doi: 10.2174/1874467214666210126110627. 10.2174/1874467214666210126110627
REF00003647	"Histamine Receptor Antagonists, Loratadine and Azelastine, Sensitize P-gp-overexpressing Antimitotic Drug-resistant KBV20C Cells Through Different Molecular Mechanisms .Anticancer Res. 2019 Jul;39(7):3767-3775. doi: 10.21873/anticanres.13525. 10.21873/anticanres.13525"
REF00003648	Inhibition of Chemoresistance in Primary Tumor Cells by Camellia sinensis non fermentatum Extract Noviphenone (NPE ) .Anticancer Res. 2019 Aug;39(8):4101-4110. doi: 10.21873/anticanres.13568. 10.21873/anticanres.13568
REF00003649	In Vitro Effect and Mechanism of Action of Ergot Alkaloid Dihydroergocristine in Chemoresistant Prostate Cancer Cells .Anticancer Res. 2020 Nov;40(11):6051-6062. doi: 10.21873/anticanres.14626. 10.21873/anticanres.14626
REF00003650	Relationships of Ex-Vivo Drug Resistance Assay and Cytokine Production with Clinicopathological Features in the Primary Cell Culture of Thai Ovarian and Fallopian Tube Cancer Patients .Asian Pac J Cancer Prev. 2017 Nov 26;18(11):3063-3071. doi: 10.22034/APJCP.2017.18.11.3063. 10.22034/APJCP.2017.18.11.3063
REF00003651	A Brief Review on the Role of Vesicular Monoamine Transporter(2) Inhibitors in Hyperkinetic Movement Disorders .Iran J Child Neurol. 2021 Summer;15(3):29-33. doi: 10.22037/ijcn.v15i3.33144. 10.22037/ijcn.v15i3.33144
REF00003652	Synthesis and biological evaluation of novel quinoline analogs of ketoprofen as multidrug resistance protein 2 (MRP2) inhibitors .Iran J Basic Med Sci. 2021 Jun;24(6):815-825. doi: 10.22038/ijbms.2021.54554.12265. 10.22038/ijbms.2021.54554.12265
REF00003653	Assessment of Mouse Ileal loop Protection against Clinically Isolated Vibrio cholerae Outer Membrane Vesicles as a Vaccine Candidate .Arch Razi Inst. 2021 Jan;75(4):451-461. doi: 10.22092/ari.2019.126909.1365. Epub 2021 Jan 1. 10.22092/ari.2019.126909.1365
REF00003654	Drug resistance in human African trypanosomiasis .Future Microbiol. 2011 Sep;6(9):1037-47. doi: 10.2217/fmb.11.88. 10.2217/fmb.11.88
REF00003655	Diphenhydramine and levofloxacin combination therapy against antimicrobial resistance in respiratory tract infections .Future Microbiol. 2021 Apr;16:409-420. doi: 10.2217/fmb-2019-0346. Epub 2021 Apr 13. 10.2217/fmb-2019-0346
REF00003656	Etomidate inhibits the growth of MRSA and exhibits synergism with oxacillin .Future Microbiol. 2020 Nov;15:1611-1619. doi: 10.2217/fmb-2020-0078. Epub 2020 Nov 20. 10.2217/fmb-2020-0078
REF00003657	Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design .Future Oncol. 2020 Jan;16(2):4347-4358. doi: 10.2217/fon-2019-0431. Epub 2019 Dec 13. 10.2217/fon-2019-0431
REF00003658	Sargramostim and immune checkpoint inhibitors: combinatorial therapeutic studies in metastatic melanoma .Immunotherapy. 2021 Aug;13(12):1011-1029. doi: 10.2217/imt-2021-0119. Epub 2021 Jun 23. 10.2217/imt-2021-0119
REF00003659	Targeting bacteria causing otitis media using nanosystems containing nonspherical gold nanoparticles and ceragenins .Nanomedicine (Lond). 2021 Dec;16(30):2657-2678. doi: 10.2217/nnm-2021-0370. Epub 2021 Nov 26. 10.2217/nnm-2021-0370
REF00003660	Intraglomerular Dysfunction Predicts Kidney Failure in Type 2 Diabetes .Diabetes. 2021 Oct;70(10):2344-2352. doi: 10.2337/db21-0154. Epub 2021 Jul 13. 10.2337/db21-0154
REF00003661	Resistance band training after triamcinolone acetonide injection for subacromial bursitis: A randomized clinical trial .J Rehabil Med. 2021 Jan 5;53(1):jrm00140. doi: 10.2340/16501977-2752. 10.2340/16501977-2752
REF00003662	The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers .Am J Pathol. 2010 Jun;176(6):2607-15. doi: 10.2353/ajpath.2010.090780. Epub 2010 Apr 15. 10.2353/ajpath.2010.090780
REF00003663	Management of Darier disease: A review of the literature and update .Indian J Dermatol Venereol Leprol. 2021 Jan-Feb;87(1):14-21. doi: 10.25259/IJDVL_963_19. 10.25259/IJDVL_963_19
REF00003664	Dexpanthenol and ascorbic acid ameliorate colistin-induced nephrotoxicity in rats .Eur Rev Med Pharmacol Sci. 2021 Jan;25(2):1016-1023. doi: 10.26355/eurrev_202101_24671. 10.26355/eurrev_202101_24671
REF00003665	Prasugrel resistance: fact or fiction .Platelets. 2012;23(2):83-90. doi: 10.3109/09537104.2011.600478. Epub 2011 Jul 25. 10.3109/09537104.2011.600478
REF00003666	Nonsteroidal anti-inflammatory drugs affect the mammary epithelial barrier during inflammation .J Dairy Sci. 2020 Nov;103(11):10742-10753. doi: 10.3168/jds.2020-18818. Epub 2020 Sep 28. 10.3168/jds.2020-18818
REF00003667	Evolution of Sequence Type 4821 Clonal Complex Hyperinvasive and Quinolone-Resistant Meningococci .Emerg Infect Dis. 2021 Apr;27(4):1110-1122. doi: 10.3201/eid2704.203612. 10.3201/eid2704.203612
REF00003668	"Scabies: Epidemiology, Diagnosis, and Treatment .Dtsch Arztebl Int. 2021 Oct 15;118(41):695-704. doi: 10.3238/arztebl.m2021.0296. 10.3238/arztebl.m2021.0296"
REF00003669	Telmisartan to reduce insulin resistance in HIV-positive individuals on combination antiretroviral therapy: the TAILoR dose-ranging Phase II RCT .Southampton (UK): NIHR Journals Library; 2019 Jul. 10.3310/eme06060
REF00003670	WEE1 inhibition induces glutamine addiction in T-cell acute lymphoblastic leukemia .Haematologica. 2021 Jul 1;106(7):1816-1827. doi: 10.3324/haematol.2019.231126. 10.3324/haematol.2019.231126
REF00003671	Significance of clopidogrel resistance related to the stent-assisted angioplasty in patients with atherosclerotic cerebrovascular disease .J Korean Neurosurg Soc. 2011 Jul;50(1):40-4. doi: 10.3340/jkns.2011.50.1.40. Epub 2011 Jul 31. 10.3340/jkns.2011.50.1.40
REF00003672	Anti-VEGF-refractory exudative age-related macular degeneration: differential response according to features on optical coherence tomography .Korean J Ophthalmol. 2013 Dec;27(6):425-32. doi: 10.3341/kjo.2013.27.6.425. Epub 2013 Nov 15. 10.3341/kjo.2013.27.6.425
REF00003673	Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update .Korean J Parasitol. 2021 Jun;59(3):189-225. doi: 10.3347/kjp.2021.59.3.189. Epub 2021 Jun 21. 10.3347/kjp.2021.59.3.189
REF00003674	Auranofin Resistance in Toxoplasma gondii Decreases the Accumulation of Reactive Oxygen Species but Does Not Target Parasite Thioredoxin Reductase .Front Cell Infect Microbiol. 2021 Mar 19;11:618994. doi: 10.3389/fcimb.2021.618994. eCollection 2021. 10.3389/fcimb.2021.618994
REF00003675	Polymorphism of Antifolate Drug Resistance in Plasmodium vivax From Local Residents and Migrant Workers Returned From the China-Myanmar Border .Front Cell Infect Microbiol. 2021 Jun 24;11:683423. doi: 10.3389/fcimb.2021.683423. eCollection 2021. 10.3389/fcimb.2021.683423
REF00003676	Cysteamine Inhibits Glycine Utilisation and Disrupts Virulence in Pseudomonas aeruginosa .Front Cell Infect Microbiol. 2021 Sep 22;11:718213. doi: 10.3389/fcimb.2021.718213. eCollection 2021. 10.3389/fcimb.2021.718213
REF00003677	Molecular Mechanisms of Endocrine Resistance in Estrogen-Positive Breast Cancer .Front Endocrinol (Lausanne). 2021 Mar 25;12:599586. doi: 10.3389/fendo.2021.599586. eCollection 2021. 10.3389/fendo.2021.599586
REF00003678	Predictive Modeling of MAFLD Based on Hsp90Alpha and the Therapeutic Application of Teprenone in a Diet-Induced Mouse Model .Front Endocrinol (Lausanne). 2021 Sep 30;12:743202. doi: 10.3389/fendo.2021.743202. eCollection 2021. 10.3389/fendo.2021.743202
REF00003679	Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms .Front Endocrinol (Lausanne). 2022 Jan 12;12:791633. doi: 10.3389/fendo.2021.791633. eCollection 2021. 10.3389/fendo.2021.791633
REF00003680	Homozygous of MRP4 Gene rs1751034 C Allele Is Related to Increased Risk of Intravenous Immunoglobulin Resistance in Kawasaki Disease .Front Genet. 2021 Mar 15;12:510350. doi: 10.3389/fgene.2021.510350. eCollection 2021. 10.3389/fgene.2021.510350
REF00003681	Predictive Biomarkers of Dicycloplatin Resistance or Susceptibility in Prostate Cancer .Front Genet. 2021 Jul 27;12:669605. doi: 10.3389/fgene.2021.669605. eCollection 2021. 10.3389/fgene.2021.669605
REF00003682	Axitinib Reverses Resistance to Anti-Programmed Cell Death-1 Therapy in a Patient With Renal Cell Carcinoma .Front Immunol. 2021 Oct 26;12:728750. doi: 10.3389/fimmu.2021.728750. eCollection 2021. 10.3389/fimmu.2021.728750
REF00003683	Lactitol Supplementation Modulates Intestinal Microbiome in Liver Cirrhotic Patients .Front Med (Lausanne). 2021 Oct 14;8:762930. doi: 10.3389/fmed.2021.762930. eCollection 2021. 10.3389/fmed.2021.762930
REF00003684	Drug Resistance Mechanisms in Bacteria Causing Sexually Transmitted Diseases and Associated with Vaginosis .Front Microbiol. 2016 May 18;7:747. doi: 10.3389/fmicb.2016.00747. eCollection 2016. 10.3389/fmicb.2016.00747
REF00003685	Action of Dicumarol on Glucosamine-1-Phosphate Acetyltransferase of GlmU and Mycobacterium tuberculosis .Front Microbiol. 2019 Aug 20;10:1799. doi: 10.3389/fmicb.2019.01799. eCollection 2019. 10.3389/fmicb.2019.01799
REF00003686	"In vitro Activity of a New Fourth-Generation Cephalosporin, Cefoselis, Against Clinically Important Bacterial Pathogens in China .Front Microbiol. 2020 Feb 28;11:180. doi: 10.3389/fmicb.2020.00180. eCollection 2020. 10.3389/fmicb.2020.00180"
REF00003687	Structure-Based Virtual Screening to Identify Novel Potential Compound as an Alternative to Remdesivir to Overcome the RdRp Protein Mutations in SARS-CoV-2 .Front Mol Biosci. 2021 Apr 9;8:645216. doi: 10.3389/fmolb.2021.645216. eCollection 2021. 10.3389/fmolb.2021.645216
REF00003688	MDR-1 and MRP2 Gene Polymorphisms in Mexican Epileptic Pediatric Patients with Complex Partial Seizures .Front Neurol. 2014 Oct 9;5:184. doi: 10.3389/fneur.2014.00184. eCollection 2014. 10.3389/fneur.2014.00184
REF00003689	"Pharmacological and Biophysical Characteristics of Picrotoxin-Resistant, Delta Subunit-Containing GABA(A) Receptors .Front Synaptic Neurosci. 2021 Nov 18;13:763411. doi: 10.3389/fnsyn.2021.763411. eCollection 2021. 10.3389/fnsyn.2021.763411"
REF00003690	Digitoxin Inhibits Epithelial-to-Mesenchymal-Transition in Hereditary Castration Resistant Prostate Cancer .Front Oncol. 2019 Aug 2;9:630. doi: 10.3389/fonc.2019.00630. eCollection 2019. 10.3389/fonc.2019.00630
REF00003691	Quantitative Proteomic Profiling Identifies SOX8 as Novel Regulator of Drug Resistance in Gestational Trophoblastic Neoplasia .Front Oncol. 2020 Apr 28;10:557. doi: 10.3389/fonc.2020.00557. eCollection 2020. 10.3389/fonc.2020.00557
REF00003692	Case Report: Primary and Acquired Resistance Mechanisms of Nimotuzumab in Advanced Esophageal Squamous Cell Carcinoma Revealed by Targeted Sequencing .Front Oncol. 2020 Oct 29;10:574523. doi: 10.3389/fonc.2020.574523. eCollection 2020. 10.3389/fonc.2020.574523
REF00003693	Mifepristone as a Potential Therapy to Reduce Angiogenesis and P-Glycoprotein Associated With Glioblastoma Resistance to Temozolomide .Front Oncol. 2020 Oct 5;10:581814. doi: 10.3389/fonc.2020.581814. eCollection 2020. 10.3389/fonc.2020.581814
REF00003694	Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies .Front Oncol. 2020 Oct 26;10:591577. doi: 10.3389/fonc.2020.591577. 10.3389/fonc.2020.591577
REF00003695	Protein and Signaling Pathway Responses to rhIL-6 Intervention Before Lobaplatin Treatment in Osteosarcoma Cells .Front Oncol. 2021 Mar 9;11:602712. doi: 10.3389/fonc.2021.602712. eCollection 2021. 10.3389/fonc.2021.602712
REF00003696	"Azoximer Bromide: Mystery, Serendipity, and Promise .Front Oncol. 2021 Sep 10;11:699546. doi: 10.3389/fonc.2021.699546. eCollection 2021. 10.3389/fonc.2021.699546"
REF00003697	Adipocytic Glutamine Synthetase Upregulation via Altered Histone Methylation Promotes 5FU Chemoresistance in Peritoneal Carcinomatosis of Colorectal Cancer .Front Oncol. 2021 Oct 12;11:748730. doi: 10.3389/fonc.2021.748730. eCollection 2021. 10.3389/fonc.2021.748730
REF00003698	Case Report: Anlotinib Reverses Nivolumab Resistance in Advanced Primary Pulmonary Lymphoepithelioma-Like Carcinoma With FGFR3 Gene Amplification .Front Oncol. 2021 Oct 8;11:749682. doi: 10.3389/fonc.2021.749682. eCollection 2021. 10.3389/fonc.2021.749682
REF00003699	Recent Progress in Interferon Therapy for Myeloid Malignancies .Front Oncol. 2021 Oct 29;11:769628. doi: 10.3389/fonc.2021.769628. eCollection 2021. 10.3389/fonc.2021.769628
REF00003700	The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents .Front Pharmacol. 2020 Mar 20;11:343. doi: 10.3389/fphar.2020.00343. eCollection 2020. 10.3389/fphar.2020.00343
REF00003701	Matrine: A Promising Natural Product With Various Pharmacological Activities .Front Pharmacol. 2020 May 7;11:588. doi: 10.3389/fphar.2020.00588. eCollection 2020. 10.3389/fphar.2020.00588
REF00003702	Recommendation of Antimicrobial Dosing Optimization During Continuous Renal Replacement Therapy .Front Pharmacol. 2020 May 29;11:786. doi: 10.3389/fphar.2020.00786. eCollection 2020. 10.3389/fphar.2020.00786
REF00003703	Uric Acid and Cardiovascular Disease: An Update From Molecular Mechanism to Clinical Perspective .Front Pharmacol. 2020 Nov 16;11:582680. doi: 10.3389/fphar.2020.582680. eCollection 2020. 10.3389/fphar.2020.582680
REF00003704	Possible Tracheal Relaxant and Antimicrobial Effects of the Essential Oil of Ethiopian Thyme Species (Thymus serrulatus Hochst. ex Benth.): A Multiple Mechanistic Approach .Front Pharmacol. 2021 Apr 5;12:615228. doi: 10.3389/fphar.2021.615228. eCollection 2021. 10.3389/fphar.2021.615228
REF00003705	Upregulation of Thymidylate Synthase Induces Pemetrexed Resistance in Malignant Pleural Mesothelioma .Front Pharmacol. 2021 Sep 27;12:718675. doi: 10.3389/fphar.2021.718675. eCollection 2021. 10.3389/fphar.2021.718675
REF00003706	TdP Incidence in Methoxamine-Sensitized Rabbit Model Is Reduced With Age but Not Influenced by Hypercholesterolemia .Front Physiol. 2021 Jun 21;12:692921. doi: 10.3389/fphys.2021.692921. eCollection 2021. 10.3389/fphys.2021.692921
REF00003707	Dual Mode of the Saponin Aescin in Plant Protection: Antifungal Agent and Plant Defense Elicitor .Front Plant Sci. 2019 Nov 28;10:1448. doi: 10.3389/fpls.2019.01448. eCollection 2019. 10.3389/fpls.2019.01448
REF00003708	Molecular Epidemiology and Drug Resistant Mechanism of Carbapenem-Resistant Klebsiella pneumoniae in Elderly Patients With Lower Respiratory Tract Infection .Front Public Health. 2021 May 20;9:669173. doi: 10.3389/fpubh.2021.669173. eCollection 2021. 10.3389/fpubh.2021.669173
REF00003709	Effects of Zinc and Menthol-Based Diets on Co-Selection of Antibiotic Resistance among E. coli and Enterococcus spp. in Beef Cattle .Animals (Basel). 2021 Jan 21;11(2):259. doi: 10.3390/ani11020259. 10.3390/ani11020259
REF00003710	Antimicrobial Properties on Non-Antibiotic Drugs in the Era of Increased Bacterial Resistance .Antibiotics (Basel). 2020 Mar 2;9(3):107. doi: 10.3390/antibiotics9030107. 10.3390/antibiotics9030107
REF00003711	"Genetic Variation Putatively Associated with Mycobacterium tuberculosis Resistance to Perchlozone, a New Thiosemicarbazone: Clues from Whole Genome Sequencing and Implications for Treatment of Multidrug-Resistant Tuberculosis .Antibiotics (Basel). 2020 Oct 3;9(10):669. doi: 10.3390/antibiotics9100669. 10.3390/antibiotics9100669"
REF00003712	"Astaxanthin-, Beta-Carotene-, and Resveratrol-Rich Foods Support Resistance Training-Induced Adaptation .Antioxidants (Basel). 2021 Jan 14;10(1):113. doi: 10.3390/antiox10010113. 10.3390/antiox10010113"
REF00003713	Enhancement of Fear Extinction Memory and Resistance to Age-Related Cognitive Decline in Butyrylcholinesterase Knockout Mice and (R)-Bambuterol Treated Mice .Biology (Basel). 2021 May 5;10(5):404. doi: 10.3390/biology10050404. 10.3390/biology10050404
REF00003714	Antagonistic L1 Adhesion Molecule Mimetic Compounds Inhibit Glioblastoma Cell Migration In Vitro .Biomolecules. 2022 Mar 12;12(3):439. doi: 10.3390/biom12030439. 10.3390/biom12030439
REF00003715	Raloxifene Ameliorates Glucosamine-Induced Insulin Resistance in Ovariectomized Rats .Biomedicines. 2021 Aug 30;9(9):1114. doi: 10.3390/biomedicines9091114. 10.3390/biomedicines9091114
REF00003716	Dissecting the Transcriptomes of Multiple Metronidazole-Resistant and Sensitive Trichomonas vaginalis Strains Identified Distinct Genes and Pathways Associated with Drug Resistance and Cell Death .Biomedicines. 2021 Dec 2;9(12):1817. doi: 10.3390/biomedicines9121817. 10.3390/biomedicines9121817
REF00003717	"Antiparkinson Drug Benztropine Suppresses Tumor Growth, Circulating Tumor Cells, and Metastasis by Acting on SLC6A3/DAT and Reducing STAT3 .Cancers (Basel). 2020 Feb 24;12(2):523. doi: 10.3390/cancers12020523. 10.3390/cancers12020523"
REF00003718	Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition .Cancers (Basel). 2021 Apr 13;13(8):1852. doi: 10.3390/cancers13081852. 10.3390/cancers13081852
REF00003719	Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma .Cells. 2020 Jan 9;9(1):167. doi: 10.3390/cells9010167. 10.3390/cells9010167
REF00003720	Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments  .Cells. 2020 Oct 17;9(10):2310. doi: 10.3390/cells9102310. 10.3390/cells9102310
REF00003721	Resistance Training in Breast Cancer Survivors: A Systematic Review of Exercise Programs .Int J Environ Res Public Health. 2020 Sep 7;17(18):6511. doi: 10.3390/ijerph17186511. 10.3390/ijerph17186511
REF00003722	Exploring Tertiary Health Science Student Willingness or Resistance to Cultural Competency and Safety Pedagogy .Int J Environ Res Public Health. 2021 Aug 31;18(17):9184. doi: 10.3390/ijerph18179184. 10.3390/ijerph18179184
REF00003723	P-glycoprotein and drug resistance in systemic autoimmune diseases .Int J Mol Sci. 2014 Mar 20;15(3):4965-76. doi: 10.3390/ijms15034965. 10.3390/ijms15034965
REF00003724	A Molecular Modeling Study of the Hydroxyflutamide Resistance Mechanism Induced by Androgen Receptor Mutations .Int J Mol Sci. 2017 Aug 23;18(9):1823. doi: 10.3390/ijms18091823. 10.3390/ijms18091823
REF00003725	Targeting the ERK Signaling Pathway in Melanoma .Int J Mol Sci. 2019 Mar 25;20(6):1483. doi: 10.3390/ijms20061483. 10.3390/ijms20061483
REF00003726	Therapeutic Targeting Steroid Resistant Pro-Inflammatory NK and NKT-Like Cells in Chronic Inflammatory Lung Disease .Int J Mol Sci. 2019 Mar 26;20(6):1511. doi: 10.3390/ijms20061511. 10.3390/ijms20061511
REF00003727	"Trifluoperazine, an Antipsychotic Drug, Effectively Reduces Drug Resistance in Cisplatin-Resistant Urothelial Carcinoma Cells via Suppressing Bcl-xL: An In Vitro and In Vivo Study .Int J Mol Sci. 2019 Jun 30;20(13):3218. doi: 10.3390/ijms20133218. 10.3390/ijms20133218"
REF00003728	TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer .Int J Mol Sci. 2019 Aug 13;20(16):3936. doi: 10.3390/ijms20163936. 10.3390/ijms20163936
REF00003729	Chemoresistance in Pancreatic Cancer .Int J Mol Sci. 2019 Sep 11;20(18):4504. doi: 10.3390/ijms20184504. 10.3390/ijms20184504
REF00003730	Somatostatin Analogs in Clinical Practice: a Review .Int J Mol Sci. 2020 Feb 29;21(5):1682. doi: 10.3390/ijms21051682. 10.3390/ijms21051682
REF00003731	Alpha-Glucosidase Inhibitor Voglibose Suppresses Azoxymethane-Induced Colonic Preneoplastic Lesions in Diabetic and Obese Mice .Int J Mol Sci. 2020 Mar 23;21(6):2226. doi: 10.3390/ijms21062226. 10.3390/ijms21062226
REF00003732	Hexobarbital Sleep Test for Predicting the Susceptibility or Resistance to Experimental Posttraumatic Stress Disorder .Int J Mol Sci. 2020 Aug 17;21(16):5900. doi: 10.3390/ijms21165900. 10.3390/ijms21165900
REF00003733	Pharmacogenetics of Type 2 Diabetes-Progress and Prospects .Int J Mol Sci. 2020 Sep 18;21(18):6842. doi: 10.3390/ijms21186842. 10.3390/ijms21186842
REF00003734	Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies .Int J Mol Sci. 2020 Sep 19;21(18):6885. doi: 10.3390/ijms21186885. 10.3390/ijms21186885
REF00003735	The Effect of Deflazacort Treatment on the Functioning of Skeletal Muscle Mitochondria in Duchenne Muscular Dystrophy .Int J Mol Sci. 2020 Nov 19;21(22):8763. doi: 10.3390/ijms21228763. 10.3390/ijms21228763
REF00003736	The Mechanisms Underlying Autonomous Adrenocorticotropic Hormone Secretion in Cushing's Disease .Int J Mol Sci. 2020 Nov 30;21(23):9132. doi: 10.3390/ijms21239132. 10.3390/ijms21239132
REF00003737	Ibudilast Mitigates Delayed Bone Healing Caused by Lipopolysaccharide by Altering Osteoblast and Osteoclast Activity .Int J Mol Sci. 2021 Jan 25;22(3):1169. doi: 10.3390/ijms22031169. 10.3390/ijms22031169
REF00003738	Regulation of Inflammatory and Proliferative Pathways by Fotemustine and Dexamethasone in Endometriosis .Int J Mol Sci. 2021 Jun 1;22(11):5998. doi: 10.3390/ijms22115998. 10.3390/ijms22115998
REF00003739	Calcium-Deficiency during Pregnancy Affects Insulin Resistance in Offspring .Int J Mol Sci. 2021 Jun 29;22(13):7008. doi: 10.3390/ijms22137008. 10.3390/ijms22137008
REF00003740	Is Cenobamate the Breakthrough We Have Been Wishing for  .Int J Mol Sci. 2021 Aug 28;22(17):9339. doi: 10.3390/ijms22179339. 10.3390/ijms22179339
REF00003741	Midecamycin Is Inactivated by Several Different Sugar Moieties at Its Inactivation Site .Int J Mol Sci. 2021 Nov 23;22(23):12636. doi: 10.3390/ijms222312636. 10.3390/ijms222312636
REF00003742	Drug Repurposing of the Unithiol: Inhibition of Metallo-Beta-Lactamases for the Treatment of Carbapenem-Resistant Gram-Negative Bacterial Infections .Int J Mol Sci. 2022 Feb 6;23(3):1834. doi: 10.3390/ijms23031834. 10.3390/ijms23031834
REF00003743	Drug Repurposing to Treat Glucocorticoid Resistance in Asthma .J Pers Med. 2021 Mar 3;11(3):175. doi: 10.3390/jpm11030175. 10.3390/jpm11030175
REF00003744	Resistance to Neuromuscular Blockade by Rocuronium in Surgical Patients with Spastic Cerebral Palsy .J Pers Med. 2021 Aug 3;11(8):765. doi: 10.3390/jpm11080765. 10.3390/jpm11080765
REF00003745	"Recombinant Expression of Thrombolytic Agent Reteplase in Marine Microalga Tetraselmis subcordiformis (Chlorodendrales, Chlorophyta) .Mar Drugs. 2021 May 28;19(6):315. doi: 10.3390/md19060315. 10.3390/md19060315"
REF00003746	Understanding the Pyrimethamine Drug Resistance Mechanism via Combined Molecular Dynamics and Dynamic Residue Network Analysis .Molecules. 2020 Feb 18;25(4):904. doi: 10.3390/molecules25040904. 10.3390/molecules25040904
REF00003747	Artificial Caries Lesion Characteristics after Secondary Demineralization with Theobromine-Containing Protocol .Molecules. 2021 Jan 8;26(2):300. doi: 10.3390/molecules26020300. 10.3390/molecules26020300
REF00003748	"Palonosetron/Methyllycaconitine Deactivate Hippocampal Microglia 1, Inflammasome Assembly and Pyroptosis to Enhance Cognition in a Novel Model of Neuroinflammation .Molecules. 2021 Aug 21;26(16):5068. doi: 10.3390/molecules26165068. 10.3390/molecules26165068"
REF00003749	Analysis of Association between Vitamin D Deficiency and Insulin Resistance .Nutrients. 2019 Apr 6;11(4):794. doi: 10.3390/nu11040794. 10.3390/nu11040794
REF00003750	"Attenuation of Inflammation and Leptin Resistance by Pyrogallol-Phloroglucinol-6,6-Bieckol on in the Brain of Obese Animal Models .Nutrients. 2019 Nov 14;11(11):2773. doi: 10.3390/nu11112773. 10.3390/nu11112773"
REF00003751	Pharmacological Treatments for Patients with Treatment-Resistant Depression .Pharmaceuticals (Basel). 2020 Jun 4;13(6):116. doi: 10.3390/ph13060116. 10.3390/ph13060116
REF00003752	Recent Advances Regarding the Therapeutic Potential of Adapalene .Pharmaceuticals (Basel). 2020 Aug 28;13(9):217. doi: 10.3390/ph13090217. 10.3390/ph13090217
REF00003753	Quinolizidine-Derived Lucanthone and Amitriptyline Analogues Endowed with Potent Antileishmanial Activity .Pharmaceuticals (Basel). 2020 Oct 25;13(11):339. doi: 10.3390/ph13110339. 10.3390/ph13110339
REF00003754	Novel mTORC1 Inhibitors Kill Glioblastoma Stem Cells .Pharmaceuticals (Basel). 2020 Nov 24;13(12):419. doi: 10.3390/ph13120419. 10.3390/ph13120419
REF00003755	"Doxepin Exacerbates Renal Damage, Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Urinary Chromium Loss in Obese Mice .Pharmaceuticals (Basel). 2021 Mar 16;14(3):267. doi: 10.3390/ph14030267. 10.3390/ph14030267"
REF00003756	Identification of Novel Anthracycline Resistance Genes and Their Inhibitors .Pharmaceuticals (Basel). 2021 Oct 16;14(10):1051. doi: 10.3390/ph14101051. 10.3390/ph14101051
REF00003757	Acquired Drug Resistance Enhances Imidazoquinoline Efflux by P-Glycoprotein .Pharmaceuticals (Basel). 2021 Dec 10;14(12):1292. doi: 10.3390/ph14121292. 10.3390/ph14121292
REF00003758	"Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of New Anti-Migraine Drugs-Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies .Pharmaceutics. 2020 Dec 3;12(12):1180. doi: 10.3390/pharmaceutics12121180. 10.3390/pharmaceutics12121180"
REF00003759	In Vitro Degradation of Specimens Produced from PLA/PHB by Additive Manufacturing in Simulated Conditions .Polymers (Basel). 2021 May 11;13(10):1542. doi: 10.3390/polym13101542. 10.3390/polym13101542
REF00003760	A Review of Biomonitoring of Phthalate Exposures .Toxics. 2019 Apr 5;7(2):21. doi: 10.3390/toxics7020021. 10.3390/toxics7020021
REF00003761	Mycotoxin Dietary Exposure Assessment through Fruit Juices Consumption in Children and Adult Population .Toxins (Basel). 2019 Nov 22;11(12):684. doi: 10.3390/toxins11120684. 10.3390/toxins11120684
REF00003762	Influence of the H1 Antihistamine Mepyramine on the Antibacterial Effect of Florfenicol in Pigs .Vet Sci. 2021 Sep 16;8(9):197. doi: 10.3390/vetsci8090197. 10.3390/vetsci8090197
REF00003763	Topical Agents Currently in Phase II or Phase III Trials for Atopic Dermatitis .J Drugs Dermatol. 2020 Oct 1;19(10):956-959. doi: 10.36849/JDD.2020.5214. 10.36849/JDD.2020.5214
REF00003764	Pathogen profile and drug resistance analysis of spontaneous peritonitis in cirrhotic patients .World J Gastroenterol. 2015 Sep 28;21(36):10409-17. doi: 10.3748/wjg.v21.i36.10409. 10.3748/wjg.v21.i36.10409
REF00003765	Hepatitis B virus infection in Indonesia .World J Gastroenterol. 2015 Oct 14;21(38):10714-20. doi: 10.3748/wjg.v21.i38.10714. 10.3748/wjg.v21.i38.10714
REF00003766	Use of rifaximin in gastrointestinal and liver diseases .World J Gastroenterol. 2016 Aug 7;22(29):6638-51. doi: 10.3748/wjg.v22.i29.6638. 10.3748/wjg.v22.i29.6638
REF00003767	Resistance of Helicobacter pylori to furazolidone and levofloxacin: A viewpoint .World J Gastroenterol. 2017 Oct 7;23(37):6920-6922. doi: 10.3748/wjg.v23.i37.6920. 10.3748/wjg.v23.i37.6920
REF00003768	Pathogenesis and clinical management of Helicobacter pylori gastric infection .World J Gastroenterol. 2019 Oct 7;25(37):5578-5589. doi: 10.3748/wjg.v25.i37.5578. 10.3748/wjg.v25.i37.5578
REF00003769	[14-3-3Zeta protein mediates gemcitabine resistance in NK/T-cell lymphoma] .Zhonghua Xue Ye Xue Za Zhi. 2019 Nov 14;40(11):906-911. doi: 10.3760/cma.j.issn.0253-2727.2019.11.004. 10.3760/cma.j.issn.0253-2727.2019.11.004
REF00003770	A comprehensive surveillance of adamantane resistance among human influenza A virus isolated from mainland China between 1956 and 2009 .Antivir Ther. 2010;15(6):853-9. doi: 10.3851/IMP1656. 10.3851/IMP1656
REF00003771	Inhibition of Bcl-xL by ABT-737 enhances chemotherapy sensitivity in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor cells .Int J Mol Med. 2012 Aug;30(2):443-50. doi: 10.3892/ijmm.2012.1013. Epub 2012 May 29. 10.3892/ijmm.2012.1013
REF00003772	Effect of midkine on gemcitabine resistance in biliary tract cancer .Int J Mol Med. 2018 Apr;41(4):2003-2011. doi: 10.3892/ijmm.2018.3399. Epub 2018 Jan 18. 10.3892/ijmm.2018.3399
REF00003773	Analysis of mutational characteristics of the drug-resistant gene katG in multi-drug resistant Mycobacterium tuberculosis L-form among patients with pneumoconiosis complicated with tuberculosis .Mol Med Rep. 2014 May;9(5):2031-5. doi: 10.3892/mmr.2014.2045. Epub 2014 Mar 13. 10.3892/mmr.2014.2045
REF00003774	Expression of far upstream element binding protein 1 in B cell non Hodgkin lymphoma is correlated with tumor growth and cell adhesion mediated drug resistance .Mol Med Rep. 2016 Oct;14(4):3759-68. doi: 10.3892/mmr.2016.5718. Epub 2016 Sep 6. 10.3892/mmr.2016.5718
REF00003775	[Retracted] Anticancer activity of caffeic acid n butyl ester against A431 skin carcinoma cell line occurs via induction of apoptosis and inhibition of the mTOR/PI3K/AKT signaling pathway .Mol Med Rep. 2021 May;23(5):372. doi: 10.3892/mmr.2021.12011. Epub 2021 Mar 24. 10.3892/mmr.2021.12011
REF00003776	Effects of CD133 expression on chemotherapy and drug sensitivity of adenoid cystic carcinoma .Mol Med Rep. 2022 Jan;25(1):18. doi: 10.3892/mmr.2021.12534. Epub 2021 Nov 18. 10.3892/mmr.2021.12534
REF00003777	"Expression levels of MRP1, GST-Pi, and GSK3Beta in ovarian cancer and the relationship with drug resistance and prognosis of patients .Oncol Lett. 2019 Jul;18(1):22-28. doi: 10.3892/ol.2019.10315. Epub 2019 May 6. 10.3892/ol.2019.10315"
REF00003778	Clinical outcomes and influencing factors of PD-1/PD-L1 in hepatocellular carcinoma .Oncol Lett. 2021 Apr;21(4):279. doi: 10.3892/ol.2021.12540. Epub 2021 Feb 10. 10.3892/ol.2021.12540
REF00003779	"Perphenazine and prochlorperazine decrease glioblastoma U-87 MG cell migration and invasion: Analysis of the ABCB1 and ABCG2 transporters, E-cadherin, Alpha-tubulin and integrins (Alpha3, Alpha5, and Beta1) levels .Oncol Lett. 2022 Jun;23(6):182. doi: 10.3892/ol.2022.13302. Epub 2022 Apr 15. 10.3892/ol.2022.13302"
REF00003780	"Anticancer effects of NSC 631570 (Ukrain) in head and neck cancer cells: In vitro analysis of growth, invasion, angiogenesis and gene expression .Oncol Rep. 2020 Jan;43(1):282-295. doi: 10.3892/or.2019.7416. Epub 2019 Nov 25. 10.3892/or.2019.7416"
REF00003781	sATP binding cassette subfamily G member 2 enhances the multidrug resistance properties of human nasal natural killer/T cell lymphoma side population cells .Oncol Rep. 2020 Oct;44(4):1467-1478. doi: 10.3892/or.2020.7722. Epub 2020 Aug 10. 10.3892/or.2020.7722
REF00003782	HSH2D contributes to methotrexate resistance in human T cell acute lymphoblastic leukaemia .Oncol Rep. 2020 Nov;44(5):2121-2129. doi: 10.3892/or.2020.7772. Epub 2020 Sep 17. 10.3892/or.2020.7772
REF00003783	Mechanism of acquired 5FU resistance and strategy for overcoming 5FU resistance focusing on 5FU metabolism in colon cancer cell lines .Oncol Rep. 2021 Apr;45(4):27. doi: 10.3892/or.2021.7978. Epub 2021 Mar 2. 10.3892/or.2021.7978
REF00003784	Treatment-Resistant Depression: Approaches to Treatment .J Psychosoc Nurs Ment Health Serv. 2021 Sep;59(9):7-11. doi: 10.3928/02793695-20210816-01. Epub 2021 Sep 1. 10.3928/02793695-20210816-01
REF00003785	Mechanisms of resistance in castration-resistant prostate cancer (CRPC) .Transl Androl Urol. 2015 Jun;4(3):365-80. doi: 10.3978/j.issn.2223-4683.2015.05.02. 10.3978/j.issn.2223-4683.2015.05.02
REF00003786	Cocoon-like fibroadhesive tuberculous peritonitis in a peritoneal dialysis patient .Chin J Physiol. 2012 Oct 31;55(5):361-5. doi: 10.4077/CJP.2012.BAA060. 10.4077/CJP.2012.BAA060
REF00003787	Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus .Diabetes Metab J. 2021 May;45(3):326-336. doi: 10.4093/dmj.2020.0272. Epub 2021 Apr 19. 10.4093/dmj.2020.0272
REF00003788	Insulin Resistance: From Mechanisms to Therapeutic Strategies .Diabetes Metab J. 2022 Jan;46(1):15-37. doi: 10.4093/dmj.2021.0280. Epub 2021 Dec 30. 10.4093/dmj.2021.0280
REF00003789	"Efficacy of trospium for prevention of catheter-related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study .Korean J Anesthesiol. 2020 Apr;73(2):145-150. doi: 10.4097/kja.19198. Epub 2019 Oct 11. 10.4097/kja.19198"
REF00003790	Retapamulin: a newer topical antibiotic .J Postgrad Med. 2013 Apr-Jun;59(2):127-30. doi: 10.4103/0022-3859.113842. 10.4103/0022-3859.113842
REF00003791	Emerging antimicrobial resistance pattern of Helicobacter pylori in central Gujarat .Indian J Med Microbiol. 2014 Oct-Dec;32(4):408-13. doi: 10.4103/0255-0857.142256. 10.4103/0255-0857.142256
REF00003792	Resistance to bevacizumab in ovarian cancer SKOV3 xenograft due to EphB4 overexpression .J Cancer Res Ther. 2019 Oct-Dec;15(6):1282-1287. doi: 10.4103/0973-1482.204896. 10.4103/0973-1482.204896
REF00003793	Lichen Simplex Chronicus Secondary to Scald Injury and Skin Flap Transplantation .Indian J Dermatol. 2020 Jan-Feb;65(1):47-49. doi: 10.4103/ijd.IJD_88_19. 10.4103/ijd.IJD_88_19
REF00003794	Characterisation of virulence genes associated with pathogenicity in Klebsiella pneumoniae .Indian J Med Microbiol. 2019 Apr-Jun;37(2):210-218. doi: 10.4103/ijmm.IJMM_19_157. 10.4103/ijmm.IJMM_19_157
REF00003795	"Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors .Indian J Pharmacol. 2021 May-Jun;53(3):226-228. doi: 10.4103/ijp.IJP_615_20. 10.4103/ijp.IJP_615_20"
REF00003796	Haloperidol-related neutropenia .Indian J Psychiatry. 2019 May-Jun;61(3):307-310. doi: 10.4103/psychiatry.IndianJPsychiatry_152_18. 10.4103/psychiatry.IndianJPsychiatry_152_18
REF00003797	P-glycoprotein inhibition with verapamil overcomes mometasone resistance in Chronic Sinusitis with Nasal Polyps .Rhinology. 2021 Apr 1;59(2):205-211. doi: 10.4193/Rhin20.551. 10.4193/Rhin20.551
REF00003798	Atovaquone/Proguanil Resistance in an Imported Malaria Case in Chile .Am J Trop Med Hyg. 2021 Mar 29;104(5):1811-1813. doi: 10.4269/ajtmh.20-1095. 10.4269/ajtmh.20-1095
REF00003799	Distribution of injectates in the thoracic paravertebral space of the dog and cat: A cadaveric study .Open Vet J. 2021 Jan-Mar;11(1):27-35. doi: 10.4314/ovj.v11i1.5. Epub 2021 Jan 14. 10.4314/ovj.v11i1.5
REF00003800	Urinary tract infection in women .Prz Menopauzalny. 2021 Apr;20(1):40-47. doi: 10.5114/pm.2021.105382. Epub 2021 Apr 21. 10.5114/pm.2021.105382
REF00003801	Anti-Apoptotic Effects of Resistance Training and Tribulus Terrestris Consumption in the Heart Tissue of Rats Exposed to Stanozolol .Eurasian J Med. 2021 Jun;53(2):79-84. doi: 10.5152/eurasianjmed.2021.20051. 10.5152/eurasianjmed.2021.20051
REF00003802	Milnacipran for the Treatment of Fibromyalgia .Health Psychol Res. 2021 Jul 10;9(1):25532. doi: 10.52965/001c.25532. eCollection 2021. 10.52965/001c.25532
REF00003803	Neutralizing epitopes of RSV and palivizumab resistance in Japan .Fukushima J Med Sci. 2017 Dec 19;63(3):127-134. doi: 10.5387/fms.2017-09. Epub 2017 Sep 1. 10.5387/fms.2017-09
REF00003804	"Six-month efficacy and safety of amfepramone in obese Mexican patients: a double-blinded, randomized, controlled trial .Int J Clin Pharmacol Ther. 2015 Jul;53(7):541-9. doi: 10.5414/CP202135. 10.5414/CP202135"
REF00003805	Belatacept in renal transplantation in comparison to tacrolimus and molecular understanding of resistance pattern: Meta-analysis and systematic review .World J Transplant. 2021 Mar 18;11(3):70-86. doi: 10.5500/wjt.v11.i3.70. 10.5500/wjt.v11.i3.70
REF00003806	Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It's Time to Sound the Alarm .World J Mens Health. 2020 Jul;38(3):323-337. doi: 10.5534/wjmh.200012. Epub 2020 Mar 20. 10.5534/wjmh.200012
REF00003807	Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke .J Atheroscler Thromb. 2016 Oct 1;23(10):1188-1200. doi: 10.5551/jat.33290. Epub 2016 Mar 8. 10.5551/jat.33290
REF00003808	"[Lucifensin, Chymotrypsin Proteins and Molecular Characterization of Lucilia sericata] .Mikrobiyol Bul. 2021 Jan;55(1):81-90. doi: 10.5578/mb.20175. 10.5578/mb.20175"
REF00003809	Current treatment of atypical hemolytic uremic syndrome .Intractable Rare Dis Res. 2014 May;3(2):34-45. doi: 10.5582/irdr.2014.01001. 10.5582/irdr.2014.01001
REF00003810	Fluorescein diacetate and rapid molecular testing for the early identification of rifampicin resistance in Mali .Int J Tuberc Lung Dis. 2020 Aug 1;24(8):763-769. doi: 10.5588/ijtld.19.0698. 10.5588/ijtld.19.0698
REF00003811	Response to degarelix after resistance to leuprolide in a patient with metastatic prostate cancer .J Adv Pract Oncol. 2012 Sep;3(5):299-303. doi: 10.6004/jadpro.2012.3.5.3. 10.6004/jadpro.2012.3.5.3
REF00003812	miR34a/GOLPH3 Axis abrogates Urothelial Bladder Cancer Chemoresistance via Reduced Cancer Stemness .Theranostics. 2017 Oct 17;7(19):4777-4790. doi: 10.7150/thno.21713. eCollection 2017. 10.7150/thno.21713
REF00003813	Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma .Theranostics. 2019 Oct 22;9(26):8377-8391. doi: 10.7150/thno.37628. eCollection 2019. 10.7150/thno.37628
REF00003814	Indoxyl sulfate induces intestinal barrier injury through IRF1-DRP1 axis-mediated mitophagy impairment .Theranostics. 2020 Jun 5;10(16):7384-7400. doi: 10.7150/thno.45455. eCollection 2020. 10.7150/thno.45455
REF00003815	MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer .Theranostics. 2021 Mar 31;11(12):5794-5812. doi: 10.7150/thno.56604. eCollection 2021. 10.7150/thno.56604
REF00003816	"Expression of ERCC1, RRM1 and LRP in non-small cell lung cancers and their influence on chemotherapeutic efficacy of gemcitabine concomitant with nedaplatin .Asian Pac J Cancer Prev. 2014;15(17):7303-7. doi: 10.7314/apjcp.2014.15.17.7303. 10.7314/apjcp.2014.15.17.7303"
REF00003817	"Rifabutin-Based Triple Therapy (RHB-105) for Helicobacter pylori Eradication: A Double-Blind, Randomized, Controlled Trial .Ann Intern Med. 2020 Jun 16;172(12):795-802. doi: 10.7326/M19-3734. Epub 2020 May 5. 10.7326/M19-3734"
REF00003818	Tinea corporis: an updated review .Drugs Context. 2020 Jul 20;9:2020-5-6. doi: 10.7573/dic.2020-5-6. eCollection 2020. 10.7573/dic.2020-5-6
REF00003819	"In vitro and in vivo activities of the carbonic anhydrase inhibitor, dorzolamide, against vancomycin-resistant enterococci .PeerJ. 2021 Mar 30;9:e11059. doi: 10.7717/peerj.11059. eCollection 2021. 10.7717/peerj.11059"
REF00003820	"Diabetes Insipidus: Pathogenesis, Diagnosis, and Clinical Management .Cureus. 2021 Feb 23;13(2):e13523. doi: 10.7759/cureus.13523. 10.7759/cureus.13523"
REF00003821	Disopyramide for Hypertrophic Cardiomyopathy .Cureus. 2019 Apr 23;11(4):e4526. doi: 10.7759/cureus.4526. 10.7759/cureus.4526
REF00003822	Management of treatment-resistant generalized anxiety disorder .Ment Health Clin. 2020 Nov 5;10(6):326-334. doi: 10.9740/mhc.2020.11.326. eCollection 2020 Nov. 10.9740/mhc.2020.11.326
REF00003823	"Prolactin-inducible EDD E3 ubiquitin ligase promotes TORC1 signalling, anti-apoptotic protein expression, and drug resistance in breast cancer cells .Am J Cancer Res. 2019 Jul 1;9(7):1484-1503. eCollection 2019."
REF00003824	Determinants of parasite drug resistance in human lymphatic filariasis .Rev Esp Quimioter. 2016 Dec;29(6):288-295. Epub 2016 Nov 17.
REF00003825	Mutations in Helicobacter pylori porD and oorD genes may contribute to furazolidone resistance .Croat Med J. 2006 Jun;47(3):410-5.
REF00003826	"[The treatment of lupus nephritis, between consolidated strategies and new therapeutic options: a narrative review] .G Ital Nefrol. 2021 Aug 30;38(4):2021-vol4."
REF00003827	HIV Infection in Adults: Initial Management .Am Fam Physician. 2021 Apr 1;103(7):407-416.
REF00003828	Antibacterial drugs for community-acquired pneumonia .Med Lett Drugs Ther. 2021 Jan 25;63(1616):10-14.
REF00003829	Evaluation of the use of sitagliptin for insulin resistance in burn patients .Int J Burns Trauma. 2020 Oct 15;10(5):237-245. eCollection 2020.
REF00003830	Pioglitazone .Vnitr Lek. 2020 Spring;66(2):121-125.
REF00003831	Association Between Resistance to Cinacalcet and Parathyroid Gland Hyperplasia in Kidney Transplant Recipients with Persistent Hypercalcemia .Int J Organ Transplant Med. 2020;11(3):107-114.
REF00003832	Phenelzine .2022 Mar 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-.
REF00003833	Econazole nitrate reversed the resistance of breast cancer cells to Adriamycin through inhibiting the PI3K/AKT signaling pathway .Am J Cancer Res. 2020 Jan 1;10(1):263-274. eCollection 2020.
REF00003834	[Efficacy of Primary Prophylaxis with Pegfilgrastim after Docetaxel for Castration-Resistant Prostate Cancer] .Gan To Kagaku Ryoho. 2019 Nov;46(11):1721-1725.
REF00003835	Halogenated Anesthetics .2018 Jan 1. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.
REF00003836	Alpha 1 Adrenergic Receptor Antagonists .2018 Jan 8. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.
REF00003837	Antiandrogens .2014 Jun 10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.
REF00003838	Nafcillin .2020 Oct 20. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.
REF00003839	Multiple Sclerosis Agents .2021 Jul 15. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.
REF00003840	Alemtuzumab .2020 Apr 14. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.
REF00003841	Dicloxacillin .2020 Oct 20. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.
REF00003842	Tetracyclines .2019 Apr 10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.
REF00003843	Ethionamide .2020 Dec 26. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.
REF00003844	Emerging Landscape of Antibiotic Resistance and Use of Endoscopic Injection in Vesicoureteral Reflux .J Assoc Physicians India. 2018 Dec;66(12):68-72.
REF00003845	Amoxapine .2022 Feb 7. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-.
REF00003846	Pharmaceutical Approval Update .P T. 2019 May;44(5):251-254.
REF00003847	Felbamate .2021 Aug 25. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-.
REF00003848	Pamidronate resistance and associated low ras levels in breast cancer cells: a role for combinatorial therapy .Ann Clin Lab Sci. 2004 Summer;34(3):263-70.
REF00003849	Ventilator-Associated Pneumonia and Its Responsible Germs; an Epidemiological Study .Emerg (Tehran). 2017;5(1):e26. Epub 2017 Jan 10.
REF00003850	NVC-422 topical gel for the treatment of impetigo .Int J Clin Exp Pathol. 2011 Aug 15;4(6):587-95. Epub 2011 Jul 23.
REF00003851	Oral ivermectin for treatment of pediculosis capitis .Pediatr Infect Dis J. 2010 Nov;29(11):991-3.
REF00003852	Monitoring influenza virus oseltamivir resistance - our experience to date .Epidemiol Mikrobiol Imunol. 2021 Winter;70(4):241-246.
REF00003853	"In Vitro Cytotoxic Effects of Celecoxib, Mefenamic Acid, Aspirin and Indometacin on Several Cells Lines .J Dent (Shiraz). 2016 Sep;17(3):219-25."
REF00003854	Safety and efficiency of treatment with cinacalcet of haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism .Endokrynol Pol. 2013;64(3):176-81.
REF00003855	Is the antiproteinuric response to inhibition of the renin-angiotensin system less effective during the night  .Nephrol Dial Transplant. 1997;12 Suppl 2:53-6.
REF00003856	"[Response-oriented salvage chemotherapy with mitoxantrone, etoposide and enocitabine for previously treated acute myeloid leukemia. Tohoku Leukemia Study Group] .Gan To Kagaku Ryoho. 1995 Dec;22(14):2101-6."
REF00003857	Trimethoprim and brodimoprim resistance of gram-positive and gram-negative bacteria .J Chemother. 1993 Dec;5(6):458-64.
REF00003858	FluoroquinolonesInfect Dis Clin North Am. 1995 Sep;9(3):715-30.
REF00003859	"Review of cefonicid, a long-acting cephalosporinClin Pharm. 1984 Jan-Feb;3(1):23-32."
REF00003860	[Cefmenoxime]Jpn J Antibiot. 1983 Jun;36(6):1165-72.
REF00003861	Antibiotic cross-resistance patterns of ambodryl and promazine resistant mutantsBr J Exp Pathol. 1980 Oct;61(5):465-70.
REF00003862	Tiazofurin metabolism in human lymphoblastoid cells: evidence for phosphorylation by adenosine kinase and 5'-nucleotidaseCancer Res. 1986 Feb;46(2):532-7.
REF00003863	Topical halcinonide and betamethasone valerate effects on plasma cortisol: acute and subacute usage studiesArch Dermatol. 1977 Sep;113(9):1196-202.
REF00003864	[Ampicillin--pivampicillin--amoxicillin]Tidsskr Nor Laegeforen. 1977 Nov 30;97(33):1759-60.
REF00003865	An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1ACS Chem Biol. 2013;8(6):1324-34. doi: 10.1021/cb400133j. Epub 2013 Apr 24.
REF00003866	"Bufalin suppresses the migration and invasion of prostate cancer cells through HOTAIR, the sponge of miR-520bActa Pharmacol Sin. 2019 Sep;40(9):1228-1236. doi: 10.1038/s41401-019-0234-8. Epub 2019 Apr 26."
REF00003867	LncRNA EPIC1 downregulation mediates hydrogen peroxide-induced neuronal cell injuryAging (Albany NY). 2019 Dec 8;11(23):11463-11473. doi: 10.18632/aging.102545. Epub 2019 Dec 8.
REF00003868	Dopaminergic neuron injury in Parkinson's disease is mitigated by interfering lncRNA SNHG14 expression to regulate the miR-133b/ Alpha-synuclein pathwayAging (Albany NY). 2019 Nov 4;11(21):9264-9279. doi: 10.18632/aging.102330. Epub 2019 Nov 4.
REF00003869	Long non-coding RNA TUG1 enhances chemosensitivity in non-small cell lung cancer by impairing microRNA-221-dependent PTEN inhibitionAging (Albany NY). 2019 Sep 18;11(18):7553-7569. doi: 10.18632/aging.102271. Epub 2019 Sep 18.
REF00003870	Ultraconserved element uc.333 increases insulin sensitivity by binding to miR-223Aging (Albany NY). 2020 Apr 17;12(8):6667-6679. doi: 10.18632/aging.103020. Epub 2020 Apr 17.
REF00003871	Sirt1 antisense long non-coding RNA attenuates pulmonary fibrosis through sirt1-mediated epithelial-mesenchymal transitionAging (Albany NY). 2020 Mar 6;12(5):4322-4336. doi: 10.18632/aging.102882. Epub 2020 Mar 6.
REF00003872	M2698 is a potent dual-inhibitor of p70S6K and Akt that affects tumor growth in mouse models of cancer and crosses the blood-brain barrierAm J Cancer Res. 2016 Mar 15;6(4):806-18. eCollection 2016.
REF00003873	First evidence of a therapeutic effect of miransertib in a teenager with Proteus syndrome and ovarian carcinomaAm J Med Genet A. 2019 Jul;179(7):1319-1324. doi: 10.1002/ajmg.a.61160. Epub 2019 May 6.
REF00003874	Inhibition of ATP citrate lyase induces an anticancer effect via reactive oxygen species: AMPK as a predictive biomarker for therapeutic impactAm J Pathol. 2013 May;182(5):1800-10. doi: 10.1016/j.ajpath.2013.01.048. Epub 2013 Mar 15.
REF00003875	"Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal TypeAm J Pathol. 2017 May;187(5):980-986. doi: 10.1016/j.ajpath.2017.01.004. Epub 2017 Mar 9."
REF00003876	Knockdown of Long Noncoding RNAs of Maternally Expressed 3 Alleviates Hyperoxia-Induced Lung Injury via Inhibiting Thioredoxin-Interacting Protein-Mediated Pyroptosis by Binding to miR-18aAm J Pathol. 2020 May;190(5):994-1005. doi: 10.1016/j.ajpath.2019.12.013. Epub 2020 Feb 19.
REF00003877	lncRNA GAS5 restrains CCl(4)-induced hepatic fibrosis by targeting miR-23a through the PTEN/PI3K/Akt signaling pathwayAm J Physiol Gastrointest Liver Physiol. 2019 Apr 1;316(4):G539-G550. doi: 10.1152/ajpgi.00249.2018. Epub 2019 Feb 8.
REF00003878	LncRNA TUG1 regulates autophagy-mediated endothelial-mesenchymal transition of liver sinusoidal endothelial cells by sponging miR-142-3pAm J Transl Res. 2020 Mar 15;12(3):758-772. eCollection 2020.
REF00003879	Management and future directions in non-small cell lung cancer with known activating mutationsAm Soc Clin Oncol Educ Book. 2014:e353-65. doi: 10.14694/EdBook_AM.2014.34.e353.
REF00003880	A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivityAmino Acids. 2014 Jul;46(7):1635-48. doi: 10.1007/s00726-014-1716-0.
REF00003881	Effects and Mechanism of lncRNA CRNDE on Sepsis-Induced Acute Kidney InjuryAnal Cell Pathol (Amst). 2020 May 1;2020:8576234. doi: 10.1155/2020/8576234. eCollection 2020.
REF00003882	Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent PolypharmacologyAngew Chem Int Ed Engl. 2015 Jul 20;54(30):8717-21. doi: 10.1002/anie.201501104. Epub 2015 Jun 30.
REF00003883	Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damageAnn Hematol. 2015 Feb;94(2):223-31. doi: 10.1007/s00277-014-2207-9. Epub 2014 Sep 11.
REF00003884	Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibitionAnn Oncol. 2014 May;25(5):959-67. doi: 10.1093/annonc/mdu049. Epub 2014 Feb 6.
REF00003885	Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumorsAnn Oncol. 2015 Jul;26(7):1421-7. doi: 10.1093/annonc/mdv186. Epub 2015 Apr 21.
REF00003886	Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trialsAnn Oncol. 2016 Mar;27(3):423-9. doi: 10.1093/annonc/mdv593. Epub 2016 Jan 13.
REF00003887	Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapyAnn Oncol. 2016 Sep;27(9):1794-9. doi: 10.1093/annonc/mdw228. Epub 2016 Jul 1.
REF00003888	Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 studyAnn Oncol. 2017 Oct 1;28(10):2581-2587. doi: 10.1093/annonc/mdx339.
REF00003889	Selective RET kinase inhibition for patients with RET-altered cancersAnn Oncol. 2018 Aug 1;29(8):1869-1876. doi: 10.1093/annonc/mdy137.
REF00003890	Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancerAnn Oncol. 2018 Mar 1;29(3):640-645. doi: 10.1093/annonc/mdx784.
REF00003891	Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertionsAnn Oncol. 2018 Oct 1;29(10):2092-2097. doi: 10.1093/annonc/mdy336.
REF00003892	"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237. doi: 10.1093/annonc/mdy275."
REF00003893	EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancerAnn Oncol. 2019 Aug 1;30(8):1311-1320. doi: 10.1093/annonc/mdz141.
REF00003894	"Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation studyAnn Oncol. 2019 Feb 1;30(2):325-331. doi: 10.1093/annonc/mdy539."
REF00003895	Downregulation of lncRNA H19 sensitizes melanoma cells to cisplatin by regulating the miR-18b/IGF1 axisAnticancer Drugs. 2020 Jun;31(5):473-482. doi: 10.1097/CAD.0000000000000888.
REF00003896	Correlation between IDH1 gene mutation status and survival of patients treated for recurrent gliomaAnticancer Res. 2011 Dec;31(12):4457-63.
REF00003897	The pivotal role and mechanism of long non-coding RNA B3GALT5-AS1 in the diagnosis of acute pancreatitisArtif Cells Nanomed Biotechnol. 2019 Dec;47(1):2307-2315. doi: 10.1080/21691401.2019.1623231.
REF00003898	A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgensBiochem Biophys Res Commun. 1990 Dec 14;173(2):534-40. doi: 10.1016/s0006-291x(05)80067-1.
REF00003899	Long non-coding RNA MALAT1 interacts with transcription factor Foxo1 to regulate SIRT1 transcription in high glucose-induced HK-2 cells injuryBiochem Biophys Res Commun. 2018 Sep 5;503(2):849-855. doi: 10.1016/j.bbrc.2018.06.086. Epub 2018 Jul 14.
REF00003900	A drug targeting only p110Alpha can block phosphoinositide 3-kinase signalling and tumour growth in certain cell typesBiochem J. 2011 Aug 15;438(1):53-62. doi: 10.1042/BJ20110502.
REF00003901	Development of a new model system to dissect isoform specific Akt signalling in adipocytesBiochem J. 2015 Jun 15;468(3):425-34. doi: 10.1042/BJ20150191. Epub 2015 Apr 9.
REF00003902	Increase in constitutively active MEK1 species by introduction of MEK1 mutations identified in cancersBiochim Biophys Acta Proteins Proteom. 2019 Jan;1867(1):62-70. doi: 10.1016/j.bbapap.2018.05.004. Epub 2018 May 9.
REF00003903	Linc00221 modulates cisplatin resistance in non-small-cell lung cancer via sponging miR-519aBiochimie. 2019 Jul;162:134-143. doi: 10.1016/j.biochi.2019.04.019. Epub 2019 Apr 25.
REF00003904	Upregulation of JHDM1D-AS1 protects PDLSCs from H(2)O(2)-induced apoptosis by decreasing DNAJC10 via phosphorylation of eIF2AlphaBiochimie. 2019 Oct;165:48-56. doi: 10.1016/j.biochi.2019.06.018. Epub 2019 Jul 2.
REF00003905	Catalpol attenuates cardiomyocyte apoptosis in diabetic cardiomyopathy via Neat1/miR-140-5p/HDAC4 axisBiochimie. 2019 Oct;165:90-99. doi: 10.1016/j.biochi.2019.05.005. Epub 2019 May 9.
REF00003906	Simvastatin ameliorate memory deficits and inflammation in clinical and mouse model of Alzheimer's disease via modulating the expression of miR-106bBiomed Pharmacother. 2017 Aug;92:46-57. doi: 10.1016/j.biopha.2017.05.060. Epub 2017 May 18.
REF00003907	LncRNA H19 functions as an Aquaporin 1 competitive endogenous RNA to regulate microRNA-874 expression in LPS sepsisBiomed Pharmacother. 2018 Sep;105:1183-1191. doi: 10.1016/j.biopha.2018.06.007. Epub 2018 Jun 21.
REF00003908	Long noncoding RNA GAS5 modulates Alpha-Solanine-induced radiosensitivity by negatively regulating miR-18a in human prostate cancer cellsBiomed Pharmacother. 2019 Apr;112:108656. doi: 10.1016/j.biopha.2019.108656. Epub 2019 Mar 1.
REF00003909	Long noncoding RNA HCP5 contributes to cisplatin resistance in human triple-negative breast cancer via regulation of PTEN expressionBiomed Pharmacother. 2019 Jul;115:108869. doi: 10.1016/j.biopha.2019.108869. Epub 2019 Apr 24.
REF00003910	LncRNA-H19 acts as a ceRNA to regulate HE4 expression by sponging miR-140 in human umbilical vein endothelial cells under hyperglycemia with or without Alpha-MangostinBiomed Pharmacother. 2019 Oct;118:109256. doi: 10.1016/j.biopha.2019.109256. Epub 2019 Jul 27.
REF00003911	Long non-coding RNA XIST regulates hyperglycemia-associated apoptosis and migration in human retinal pigment epithelial cellsBiomed Pharmacother. 2020 May;125:109959. doi: 10.1016/j.biopha.2020.109959. Epub 2020 Feb 25.
REF00003912	LncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a/PPARGamma axis in non-alcoholic fatty liver diseaseBiosci Rep. 2019 Jul 15;39(7):BSR20181722. doi: 10.1042/BSR20181722. Print 2019 Jul 31.
REF00003913	Cardamonin exerts anti-gastric cancer activity via inhibiting LncRNA-PVT1-STAT3 axisBiosci Rep. 2019 May 17;39(5):BSR20190357. doi: 10.1042/BSR20190357. Print 2019 May 31.
REF00003914	RNA-sequencing analysis reveals the potential contribution of lncRNAs in palmitic acid-induced insulin resistance of skeletal muscle cellsBiosci Rep. 2020 Jan 31;40(1):BSR20192523. doi: 10.1042/BSR20192523.
REF00003915	Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangementBlood Adv. 2020 Jan 14;4(1):106-111. doi: 10.1182/bloodadvances.2019000769.
REF00003916	"Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasmsBlood Cancer J. 2011 Jul;1(7):e29. doi: 10.1038/bcj.2011.29. Epub 2011 Jul 22."
REF00003917	The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemiaBlood Cancer J. 2012 Aug 3;2(8):e81. doi: 10.1038/bcj.2012.28.
REF00003918	Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivoBlood Cancer J. 2018 Oct 4;8(10):94. doi: 10.1038/s41408-018-0133-0.
REF00003919	Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518Blood. 2004 Nov 1;104(9):2867-72. doi: 10.1182/blood-2003-12-4446. Epub 2004 Jul 15.
REF00003920	Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML)Blood. 2005 Jan 1;105(1):335-40. doi: 10.1182/blood-2004-02-0660. Epub 2004 Sep 2.
REF00003921	FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L)Blood. 2005 May 1;105(9):3679-85. doi: 10.1182/blood-2004-06-2459. Epub 2004 Dec 30.
REF00003922	High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2aBlood. 2006 Sep 15;108(6):2037-40. doi: 10.1182/blood-2006-03-009860. Epub 2006 May 18.
REF00003923	Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurinBlood. 2007 Dec 15;110(13):4476-9. doi: 10.1182/blood-2007-07-101238. Epub 2007 Sep 7.
REF00003924	FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphomaBlood. 2011 Oct 6;118(14):3911-21. doi: 10.1182/blood-2010-12-319467. Epub 2011 Aug 5.
REF00003925	Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1Blood. 2011 Sep 15;118(11):3096-106. doi: 10.1182/blood-2010-09-309674. Epub 2011 Jun 30.
REF00003926	"Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemiaBlood. 2012 May 17;119(20):4614-8. doi: 10.1182/blood-2011-12-400051. Epub 2012 Mar 15."
REF00003927	Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemiaBlood. 2012 Oct 25;120(17):3510-8. doi: 10.1182/blood-2012-03-415448. Epub 2012 Sep 6.
REF00003928	Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutationBlood. 2013 Jun 6;121(23):4655-62. doi: 10.1182/blood-2013-01-480228. Epub 2013 Apr 23.
REF00003929	The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibitionBlood. 2013 Nov 21;122(22):3628-31. doi: 10.1182/blood-2013-06-509976. Epub 2013 Sep 30.
REF00003930	Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitorsBlood. 2014 Feb 27;123(9):1372-83. doi: 10.1182/blood-2013-05-504555. Epub 2014 Jan 7.
REF00003931	Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutantsBlood. 2016 Mar 10;127(10):1325-35. doi: 10.1182/blood-2015-11-681932. Epub 2015 Dec 14.
REF00003932	Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemiaBlood. 2017 Aug 10;130(6):722-731. doi: 10.1182/blood-2017-04-779405. Epub 2017 Jun 6.
REF00003933	"A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutationsBlood. 2018 Jan 25;131(4):426-438. doi: 10.1182/blood-2017-05-786657. Epub 2017 Nov 29."
REF00003934	Medroxyprogesterone acetate causes the alterations of endoplasmic reticulum related mRNAs and lncRNAs in endometrial cancer cellsBMC Med Genomics. 2019 Nov 12;12(1):163. doi: 10.1186/s12920-019-0601-9.
REF00003935	Tanshinone IIA alleviates hypoxia/reoxygenation induced cardiomyocyte injury via lncRNA AK003290/miR-124-5p signalingBMC Mol Cell Biol. 2020 Mar 27;21(1):20. doi: 10.1186/s12860-020-00264-3.
REF00003936	KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancerBr J Cancer. 2008 Dec 16;99(12):2020-8. doi: 10.1038/sj.bjc.6604783. Epub 2008 Nov 18.
REF00003937	Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapyBr J Cancer. 2010 Jun 8;102(12):1724-30. doi: 10.1038/sj.bjc.6605714.
REF00003938	Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivoBr J Cancer. 2011 Jan 4;104(1):75-82. doi: 10.1038/sj.bjc.6606016. Epub 2010 Nov 30.
REF00003939	Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancerBr J Cancer. 2015 Jul 14;113(2):199-203. doi: 10.1038/bjc.2015.215. Epub 2015 Jun 30.
REF00003940	The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patientsBr J Clin Pharmacol. 2015 Nov;80(5):1139-48. doi: 10.1111/bcp.12688. Epub 2015 Jul 22.
REF00003941	G 6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cellsBr J Haematol. 2006 Nov;135(3):303-16. doi: 10.1111/j.1365-2141.2006.06291.x. Epub 2006 Sep 4.
REF00003942	Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndromeBr J Haematol. 2008 May;141(5):681-8. doi: 10.1111/j.1365-2141.2008.07081.x. Epub 2008 Apr 7.
REF00003943	"Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignanciesBr J Haematol. 2019 Nov;187(4):488-501. doi: 10.1111/bjh.16092. Epub 2019 Jul 15."
REF00003944	Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphomaBr J Haematol. 2019 Sep;186(6):e188-e191. doi: 10.1111/bjh.16069. Epub 2019 Jun 24.
REF00003945	Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinibCancer Biol Ther. 2014 Sep;15(9):1239-47. doi: 10.4161/cbt.29687. Epub 2014 Jul 14.
REF00003946	"EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profileCancer Biol Ther. 2016;17(2):199-207. doi: 10.1080/15384047.2016.1139231. Epub 2016 Jan 25."
REF00003947	Molecular mechanisms of heptaplatin effective against cisplatin-resistant cancer cell lines: less involvement of metallothioneinCancer Cell Int. 2004 Oct 19;4(1):6. doi: 10.1186/1475-2867-4-6.
REF00003948	"Anti-tumor effect of a novel PI3-kinase inhibitor, SF1126, in (12) V-Ha-Ras transgenic mouse glioma modelCancer Cell Int. 2014 Nov 12;14(1):105. doi: 10.1186/s12935-014-0105-9. eCollection 2014."
REF00003949	"CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)Cancer Cell. 2002 Jun;1(5):421-32. doi: 10.1016/s1535-6108(02)00070-3."
REF00003950	Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate allelesCancer Cell. 2007 Dec;12(6):501-13. doi: 10.1016/j.ccr.2007.11.005.
REF00003951	"Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia veraCancer Cell. 2008 Apr;13(4):311-20. doi: 10.1016/j.ccr.2008.02.009."
REF00003952	Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activationCancer Cell. 2009 Dec 8;16(6):463-74. doi: 10.1016/j.ccr.2009.10.016.
REF00003953	A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinomaCancer Cell. 2010 Jul 13;18(1):63-73. doi: 10.1016/j.ccr.2010.05.025.
REF00003954	Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemiaCancer Cell. 2012 Aug 14;22(2):153-66. doi: 10.1016/j.ccr.2012.06.005.
REF00003955	Allele-specific p53 mutant reactivationCancer Cell. 2012 May 15;21(5):614-625. doi: 10.1016/j.ccr.2012.03.042.
REF00003956	Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric propertiesCancer Cell. 2013 Apr 15;23(4):477-88. doi: 10.1016/j.ccr.2013.02.019.
REF00003957	A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic interventionCancer Cell. 2013 Jul 8;24(1):15-29. doi: 10.1016/j.ccr.2013.05.014.
REF00003958	Oncogenic ERBB3 mutations in human cancersCancer Cell. 2013 May 13;23(5):603-17. doi: 10.1016/j.ccr.2013.04.012.
REF00003959	Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway OncogenesCancer Cell. 2015 Aug 10;28(2):170-82. doi: 10.1016/j.ccell.2015.07.001.
REF00003960	Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanomaCancer Cell. 2015 Jan 12;27(1):85-96. doi: 10.1016/j.ccell.2014.11.006. Epub 2014 Dec 11.
REF00003961	"CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative NeoplasmsCancer Cell. 2015 Jul 13;28(1):15-28. doi: 10.1016/j.ccell.2015.06.006."
REF00003962	Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant CancersCancer Cell. 2015 Sep 14;28(3):384-98. doi: 10.1016/j.ccell.2015.08.002. Epub 2015 Sep 3.
REF00003963	A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian CarcinomasCancer Cell. 2016 Jan 11;29(1):90-103. doi: 10.1016/j.ccell.2015.12.002. Epub 2015 Dec 31.
REF00003964	ARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal MelanomaCancer Cell. 2016 Jun 13;29(6):889-904. doi: 10.1016/j.ccell.2016.04.015. Epub 2016 Jun 2.
REF00003965	"Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome ModulationCancer Cell. 2016 Sep 12;30(3):404-417. doi: 10.1016/j.ccell.2016.08.006."
REF00003966	An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF SignalingCancer Cell. 2016 Sep 12;30(3):485-498. doi: 10.1016/j.ccell.2016.06.024. Epub 2016 Aug 11.
REF00003967	Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and InvasionCancer Cell. 2018 Aug 13;34(2):298-314.e7. doi: 10.1016/j.ccell.2018.07.004.
REF00003968	Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA VariantsCancer Cell. 2019 May 13;35(5):738-751.e9. doi: 10.1016/j.ccell.2019.04.006.
REF00003969	Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 ActivityCancer Cell. 2019 Oct 14;36(4):444-457.e7. doi: 10.1016/j.ccell.2019.09.001. Epub 2019 Oct 3.
REF00003970	"Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancerCancer Chemother Pharmacol. 2015 Jan;75(1):17-23. doi: 10.1007/s00280-014-2609-3. Epub 2014 Oct 17."
REF00003971	Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumorsCancer Chemother Pharmacol. 2016 Apr;77(4):787-95. doi: 10.1007/s00280-016-2987-9. Epub 2016 Mar 1.
REF00003972	High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stabilityCancer Discov. 2011 Jul;1(2):170-85. doi: 10.1158/2159-8290.CD-11-0039. Epub 2011 Jun 7.
REF00003973	Janus kinase 3-activating mutations identified in natural killer/T-cell lymphomaCancer Discov. 2012 Jul;2(7):591-7. doi: 10.1158/2159-8290.CD-12-0028. Epub 2012 Jun 15.
REF00003974	EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenibCancer Discov. 2012 Mar;2(3):227-35. doi: 10.1158/2159-8290.CD-11-0341. Epub 2012 Jan 16.
REF00003975	BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitorsCancer Discov. 2012 Sep;2(9):791-7. doi: 10.1158/2159-8290.CD-12-0097. Epub 2012 Jul 13.
REF00003976	Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanomaCancer Discov. 2013 Feb;3(2):158-67. doi: 10.1158/2159-8290.CD-12-0386. Epub 2012 Dec 14.
REF00003977	Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitorsCancer Discov. 2013 Jul;3(7):742-50. doi: 10.1158/2159-8290.CD-13-0070. Epub 2013 Apr 24.
REF00003978	A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509Cancer Discov. 2013 Sep;3(9):1020-9. doi: 10.1158/2159-8290.CD-13-0226. Epub 2013 Jun 18.
REF00003979	MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibitionCancer Discov. 2014 Jan;4(1):61-8. doi: 10.1158/2159-8290.CD-13-0631. Epub 2013 Nov 21.
REF00003980	A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibitionCancer Discov. 2014 Jan;4(1):69-79. doi: 10.1158/2159-8290.CD-13-0279. Epub 2013 Nov 21.
REF00003981	Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinomaCancer Discov. 2014 Oct;4(10):1154-67. doi: 10.1158/2159-8290.CD-13-0830. Epub 2014 Aug 7.
REF00003982	FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal TumorsCancer Discov. 2015 Apr;5(4):438-51. doi: 10.1158/2159-8290.CD-14-0763. Epub 2015 Feb 11.
REF00003983	Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skippingCancer Discov. 2015 Aug;5(8):842-9. doi: 10.1158/2159-8290.CD-14-1467. Epub 2015 May 13.
REF00003984	Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitorsCancer Discov. 2015 Aug;5(8):850-9. doi: 10.1158/2159-8290.CD-15-0285. Epub 2015 May 13.
REF00003985	IDH1 inhibitor shows promising early resultsCancer Discov. 2015 Jan;5(1):4. doi: 10.1158/2159-8290.CD-NB2014-178. Epub 2014 Dec 8.
REF00003986	ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP InhibitorsCancer Discov. 2015 Jul;5(7):752-67. doi: 10.1158/2159-8290.CD-14-0849. Epub 2015 Jun 11.
REF00003987	Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal CancerCancer Discov. 2015 Jun;5(6):598-609. doi: 10.1158/2159-8290.CD-14-1432. Epub 2015 May 11.
REF00003988	"Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397Cancer Discov. 2015 Jun;5(6):668-79. doi: 10.1158/2159-8290.CD-15-0060. Epub 2015 Apr 6."
REF00003989	Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung CancerCancer Discov. 2015 Sep;5(9):960-971. doi: 10.1158/2159-8290.CD-15-0063. Epub 2015 Jun 2.
REF00003990	Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal CancerCancer Discov. 2016 Feb;6(2):147-153. doi: 10.1158/2159-8290.CD-15-1283. Epub 2015 Dec 7.
REF00003991	Diverse and Targetable Kinase Alterations Drive Histiocytic NeoplasmsCancer Discov. 2016 Feb;6(2):154-65. doi: 10.1158/2159-8290.CD-15-0913. Epub 2015 Nov 13.
REF00003992	Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal CancerCancer Discov. 2016 Jan;6(1):36-44. doi: 10.1158/2159-8290.CD-15-0940. Epub 2015 Nov 6.
REF00003993	BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination TherapyCancer Discov. 2016 Jun;6(6):594-600. doi: 10.1158/2159-8290.CD-15-1192. Epub 2016 Apr 5.
REF00003994	Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120Cancer Discov. 2016 Mar;6(3):300-15. doi: 10.1158/2159-8290.CD-15-0896. Epub 2016 Jan 5.
REF00003995	"Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)Cancer Discov. 2017 Apr;7(4):400-409. doi: 10.1158/2159-8290.CD-16-1237. Epub 2017 Feb 9."
REF00003996	A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid TumorsCancer Discov. 2017 Jan;7(1):102-113. doi: 10.1158/2159-8290.CD-16-0512. Epub 2016 Nov 21.
REF00003997	"Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid TumorsCancer Discov. 2017 Jul;7(7):704-715. doi: 10.1158/2159-8290.CD-16-1080. Epub 2017 Mar 22."
REF00003998	A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal CancerCancer Discov. 2017 Jun;7(6):610-619. doi: 10.1158/2159-8290.CD-16-0795. Epub 2017 Mar 31.
REF00003999	Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive CholangiocarcinomaCancer Discov. 2017 Mar;7(3):252-263. doi: 10.1158/2159-8290.CD-16-1000. Epub 2016 Dec 29.
REF00004000	"AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 MutationsCancer Discov. 2017 May;7(5):478-493. doi: 10.1158/2159-8290.CD-16-1034. Epub 2017 Feb 13."
REF00004001	A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid TumorsCancer Discov. 2017 Sep;7(9):963-972. doi: 10.1158/2159-8290.CD-17-0507. Epub 2017 Jun 3.
REF00004002	"Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF(V600E)-Mutant Colorectal CancerCancer Discov. 2018 Apr;8(4):428-443. doi: 10.1158/2159-8290.CD-17-1226. Epub 2018 Feb 5."
REF00004003	Rapid Responses to Avapritinib (BLU-285) in MastocytosisCancer Discov. 2018 Feb;8(2):133. doi: 10.1158/2159-8290.CD-NB2017-177. Epub 2017 Dec 12.
REF00004004	Accelerating Discovery of Functional Mutant Alleles in CancerCancer Discov. 2018 Feb;8(2):174-183. doi: 10.1158/2159-8290.CD-17-0321. Epub 2017 Dec 15.
REF00004005	First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyCancer Discov. 2018 Feb;8(2):184-195. doi: 10.1158/2159-8290.CD-17-1119. Epub 2017 Dec 15.
REF00004006	"Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 AlterationsCancer Discov. 2018 Jul;8(7):812-821. doi: 10.1158/2159-8290.CD-18-0229. Epub 2018 May 30."
REF00004007	Precision Targeted Therapy with BLU-667 for RET-Driven CancersCancer Discov. 2018 Jul;8(7):836-849. doi: 10.1158/2159-8290.CD-18-0338. Epub 2018 Apr 15.
REF00004008	Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision MedicineCancer Discov. 2018 Sep;8(9):1096-1111. doi: 10.1158/2159-8290.CD-18-0275. Epub 2018 Jun 14.
REF00004009	Capivasertib Active against AKT1-Mutated CancersCancer Discov. 2019 Jan;9(1):OF7. doi: 10.1158/2159-8290.CD-NB2018-153. Epub 2018 Nov 14.
REF00004010	Single and Dual Targeting of Mutant EGFR with an Allosteric InhibitorCancer Discov. 2019 Jul;9(7):926-943. doi: 10.1158/2159-8290.CD-18-0903. Epub 2019 May 15.
REF00004011	Distinct Colorectal Cancer-Associated APC Mutations Dictate Response to Tankyrase InhibitionCancer Discov. 2019 Oct;9(10):1358-1371. doi: 10.1158/2159-8290.CD-19-0289. Epub 2019 Jul 23.
REF00004012	V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon CancerCancer Discov. 2019 Sep;9(9):1182-1191. doi: 10.1158/2159-8290.CD-19-0356. Epub 2019 Jun 21.
REF00004013	A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOHCancer Genet. 2017 Oct;216-217:86-90. doi: 10.1016/j.cancergen.2017.07.008. Epub 2017 Jul 31.
REF00004014	Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274Cancer Lett. 2010 Mar 28;289(2):228-36. doi: 10.1016/j.canlet.2009.08.017. Epub 2009 Sep 23.
REF00004015	The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse modelCancer Lett. 2017 Aug 1;400:61-68. doi: 10.1016/j.canlet.2017.04.022. Epub 2017 Apr 26.
REF00004016	Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3KAlpha-selective inhibitor CYH33 in breast cancerCancer Lett. 2018 Oct 1;433:273-282. doi: 10.1016/j.canlet.2018.07.011. Epub 2018 Jul 9.
REF00004017	Piplartine suppresses proliferation and invasion of hepatocellular carcinoma by LINC01391-modulated Wnt/Beta-catenin pathway inactivation through ICATCancer Lett. 2019 Sep 28;460:119-127. doi: 10.1016/j.canlet.2019.06.008. Epub 2019 Jun 14.
REF00004018	Small molecule inhibition of Ewing sarcoma cell growth via targeting the long non coding RNA HULCCancer Lett. 2020 Jan 28;469:111-123. doi: 10.1016/j.canlet.2019.10.026. Epub 2019 Oct 19.
REF00004019	Long Non-Coding RNA LINC00511 Mediates the Effects of ESR1 on Proliferation and Invasion of Ovarian Cancer Through miR-424-5p and miR-370-5pCancer Manag Res. 2019 Dec 27;11:10807-10819. doi: 10.2147/CMAR.S232140. eCollection 2019.
REF00004020	Quercetin Inhibits Epithelial-to-Mesenchymal Transition (EMT) Process and Promotes Apoptosis in Prostate Cancer via Downregulating lncRNA MALAT1Cancer Manag Res. 2020 Mar 9;12:1741-1750. doi: 10.2147/CMAR.S241093. eCollection 2020.
REF00004021	Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALKCancer Med. 2015 Jul;4(7):953-65. doi: 10.1002/cam4.413. Epub 2015 Feb 26.
REF00004022	"A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation statusCancer Med. 2017 Aug;6(8):1904-1914. doi: 10.1002/cam4.1140. Epub 2017 Jul 18."
REF00004023	Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndromeCancer Res. 2003 Jan 1;63(1):149-53.
REF00004024	Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474Cancer Res. 2004 Dec 15;64(24):9101-4. doi: 10.1158/0008-5472.CAN-04-2360.
REF00004025	"PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinibCancer Res. 2007 Dec 15;67(24):11924-32. doi: 10.1158/0008-5472.CAN-07-1885."
REF00004026	Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibitedCancer Res. 2007 Jan 1;67(1):122-9. doi: 10.1158/0008-5472.CAN-06-1880.
REF00004027	Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategiesCancer Res. 2007 Nov 1;67(21):10417-27. doi: 10.1158/0008-5472.CAN-07-1248.
REF00004028	Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemiaCancer Res. 2008 Aug 15;68(16):6803-9. doi: 10.1158/0008-5472.CAN-08-0101.
REF00004029	Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinomaCancer Res. 2008 Jul 15;68(14):5524-8. doi: 10.1158/0008-5472.CAN-08-0099.
REF00004030	"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutationsCancer Res. 2008 Oct 1;68(19):8022-30. doi: 10.1158/0008-5472.CAN-08-1385."
REF00004031	Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogationCancer Res. 2008 Sep 1;68(17):6902-7. doi: 10.1158/0008-5472.CAN-08-0770.
REF00004032	FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitroCancer Res. 2009 Apr 1;69(7):3032-41. doi: 10.1158/0008-5472.CAN-08-2923. Epub 2009 Mar 24.
REF00004033	Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppressionCancer Res. 2009 Apr 1;69(7):3042-51. doi: 10.1158/0008-5472.CAN-08-3563. Epub 2009 Mar 10.
REF00004034	3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinomaCancer Res. 2009 Aug 1;69(15):6299-306. doi: 10.1158/0008-5472.CAN-09-0820. Epub 2009 Jul 14.
REF00004035	"RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancerCancer Res. 2009 Sep 1;69(17):6839-47. doi: 10.1158/0008-5472.CAN-09-0679. Epub 2009 Aug 25."
REF00004036	Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycinCancer Res. 2009 Sep 15;69(18):7311-9. doi: 10.1158/0008-5472.CAN-09-1077. Epub 2009 Aug 25.
REF00004037	"Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2Cancer Res. 2010 Jan 15;70(2):621-31. doi: 10.1158/0008-5472.CAN-09-2340. Epub 2010 Jan 12."
REF00004038	"CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activityCancer Res. 2010 May 1;70(9):3647-56. doi: 10.1158/0008-5472.CAN-09-3360. Epub 2010 Apr 13."
REF00004039	Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1Cancer Res. 2010 Nov 15;70(22):8981-7. doi: 10.1158/0008-5472.CAN-10-1666. Epub 2010 Nov 2.
REF00004040	Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutationCancer Res. 2011 Aug 15;71(16):5535-45. doi: 10.1158/0008-5472.CAN-10-4351. Epub 2011 Jun 24.
REF00004041	Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growthCancer Res. 2011 Jan 1;71(1):197-205. doi: 10.1158/0008-5472.CAN-10-1282.
REF00004042	Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancerCancer Res. 2012 Feb 1;72(3):779-89. doi: 10.1158/0008-5472.CAN-11-2941. Epub 2011 Dec 16.
REF00004043	Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinomaCancer Res. 2013 Aug 15;73(16):5195-205. doi: 10.1158/0008-5472.CAN-12-3950. Epub 2013 Jun 20.
REF00004044	Integrative radiogenomic profiling of squamous cell lung cancerCancer Res. 2013 Oct 15;73(20):6289-98. doi: 10.1158/0008-5472.CAN-13-1616. Epub 2013 Aug 26.
REF00004045	Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2Cancer Res. 2015 Aug 1;75(15):3139-46. doi: 10.1158/0008-5472.CAN-14-3771. Epub 2015 Jun 5.
REF00004046	SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation ComplexCancer Res. 2015 Dec 15;75(24):5211-8. doi: 10.1158/0008-5472.CAN-15-0885. Epub 2015 Nov 24.
REF00004047	Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare MutationsCancer Res. 2015 Dec 15;75(24):5341-54. doi: 10.1158/0008-5472.CAN-15-1654. Epub 2015 Dec 1.
REF00004048	Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating CellsCancer Res. 2015 Dec 15;75(24):5355-66. doi: 10.1158/0008-5472.CAN-14-3689. Epub 2015 Nov 16.
REF00004049	Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical ModelsCancer Res. 2015 Jun 15;75(12):2489-500. doi: 10.1158/0008-5472.CAN-14-3167. Epub 2015 Apr 13.
REF00004050	Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198Cancer Res. 2015 Nov 15;75(22):4790-802. doi: 10.1158/0008-5472.CAN-14-3603. Epub 2015 Sep 11.
REF00004051	Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53Cancer Res. 2015 Sep 15;75(18):3842-52. doi: 10.1158/0008-5472.CAN-13-1079. Epub 2015 Aug 20.
REF00004052	Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast CancerCancer Res. 2016 Apr 15;76(8):2301-13. doi: 10.1158/0008-5472.CAN-15-0728. Epub 2016 Mar 28.
REF00004053	Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal CancerCancer Res. 2016 Aug 1;76(15):4504-15. doi: 10.1158/0008-5472.CAN-16-0396. Epub 2016 Jun 16.
REF00004054	Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110BetaCancer Res. 2016 Mar 1;76(5):1193-203. doi: 10.1158/0008-5472.CAN-15-2201. Epub 2016 Jan 12.
REF00004055	The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 MutationsCancer Res. 2016 Mar 15;76(6):1528-37. doi: 10.1158/0008-5472.CAN-15-1580. Epub 2016 Jan 28.
REF00004056	EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF ReceptorCancer Res. 2016 Mar 15;76(6):1591-602. doi: 10.1158/0008-5472.CAN-15-2581. Epub 2016 Jan 29.
REF00004057	An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in MelanomaCancer Res. 2016 Sep 15;76(18):5455-66. doi: 10.1158/0008-5472.CAN-15-3384. Epub 2016 Aug 3.
REF00004058	MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung AdenocarcinomaCancer Res. 2017 Aug 15;77(16):4498-4505. doi: 10.1158/0008-5472.CAN-16-1944. Epub 2017 May 18.
REF00004059	A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung AdenocarcinomaCancer Res. 2017 Jan 1;77(1):153-163. doi: 10.1158/0008-5472.CAN-16-1639. Epub 2016 Nov 7.
REF00004060	Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of CancerCancer Res. 2017 Jul 1;77(13):3502-3512. doi: 10.1158/0008-5472.CAN-16-2745. Epub 2017 May 16.
REF00004061	SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung CancerCancer Res. 2017 Jun 1;77(11):2990-3000. doi: 10.1158/0008-5472.CAN-16-2300. Epub 2017 Apr 17.
REF00004062	Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 InhibitorsCancer Res. 2017 May 15;77(10):2712-2721. doi: 10.1158/0008-5472.CAN-16-3404. Epub 2017 Mar 31.
REF00004063	NRAS-Mutated Rhabdomyosarcoma Cells Are Vulnerable to Mitochondrial Apoptosis Induced by Coinhibition of MEK and PI3KAlphaCancer Res. 2018 Apr 15;78(8):2000-2013. doi: 10.1158/0008-5472.CAN-17-1737. Epub 2018 Feb 6.
REF00004064	A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in LeukemiaCancer Res. 2018 Dec 15;78(24):6762-6770. doi: 10.1158/0008-5472.CAN-18-1638. Epub 2018 Oct 22.
REF00004065	"Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAFCancer Res. 2018 Mar 15;78(6):1537-1548. doi: 10.1158/0008-5472.CAN-17-2033. Epub 2018 Jan 17."
REF00004066	ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KITCancer Res. 2019 Aug 15;79(16):4283-4292. doi: 10.1158/0008-5472.CAN-18-3139. Epub 2019 Jul 3.
REF00004067	"Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitorCancer Sci. 2007 Dec;98(12):1977-84. doi: 10.1111/j.1349-7006.2007.00613.x. Epub 2007 Sep 18."
REF00004068	Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinomaCancer Sci. 2010 Feb;101(2):530-5. doi: 10.1111/j.1349-7006.2009.01418.x. Epub 2009 Oct 28.
REF00004069	"Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutantsCancer Sci. 2014 Jan;105(1):117-25. doi: 10.1111/cas.12320. Epub 2014 Jan 4."
REF00004070	Delphinidin suppresses breast carcinogenesis through the HOTAIR/microRNA-34a axisCancer Sci. 2019 Oct;110(10):3089-3097. doi: 10.1111/cas.14133. Epub 2019 Sep 16.
REF00004071	"Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancerCancer. 2016 Dec 15;122(24):3856-3864. doi: 10.1002/cncr.30252. Epub 2016 Aug 15."
REF00004072	Oncogenic MAP2K1 mutations in human epithelial tumorsCarcinogenesis. 2012 May;33(5):956-61. doi: 10.1093/carcin/bgs099. Epub 2012 Feb 10.
REF00004073	Inhibition of lncRNA Neat1 by catalpol via suppressing transcriptional activity of NF-kB attenuates cardiomyocyte apoptosisCell Cycle. 2019 Dec;18(24):3432-3441. doi: 10.1080/15384101.2019.1673619. Epub 2019 Nov 17.
REF00004074	APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cellsCell Death Dis. 2015 Jun 18;6(6):e1794. doi: 10.1038/cddis.2015.143.
REF00004075	The long non-coding RNA TUG1-miR-9a-5p axis contributes to ischemic injuries by promoting cardiomyocyte apoptosis via targeting KLF5Cell Death Dis. 2019 Dec 2;10(12):908. doi: 10.1038/s41419-019-2138-4.
REF00004076	sPIF promotes myoblast differentiation and utrophin expression while inhibiting fibrosis in Duchenne muscular dystrophy via the H19/miR-675/let-7 and miR-21 pathwaysCell Death Dis. 2019 Jan 28;10(2):82. doi: 10.1038/s41419-019-1307-9.
REF00004077	LncRNA GASL1 is downregulated in chronic heart failure and regulates cardiomyocyte apoptosisCell Mol Biol Lett. 2019 Jun 13;24:41. doi: 10.1186/s11658-019-0165-x. eCollection 2019.
REF00004078	Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAFCell. 2010 Jan 22;140(2):209-21. doi: 10.1016/j.cell.2009.12.040.
REF00004079	A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block SignalingCell. 2016 Apr 21;165(3):643-55. doi: 10.1016/j.cell.2016.03.045.
REF00004080	Exploiting Temporal Collateral Sensitivity in Tumor Clonal EvolutionCell. 2016 Mar 24;165(1):234-246. doi: 10.1016/j.cell.2016.01.045. Epub 2016 Feb 25.
REF00004081	Multivalent Small-Molecule Pan-RAS InhibitorsCell. 2017 Feb 23;168(5):878-889.e29. doi: 10.1016/j.cell.2017.02.006.
REF00004082	NEAT1 contributes to the CSC-like traits of A549/CDDP cells via activating Wnt signaling pathwayChem Biol Interact. 2018 Dec 25;296:154-161. doi: 10.1016/j.cbi.2018.10.001. Epub 2018 Oct 3.
REF00004083	A structure-guided approach to creating covalent FGFR inhibitorsChem Biol. 2010 Mar 26;17(3):285-95. doi: 10.1016/j.chembiol.2010.02.007.
REF00004084	MiR-326 Inhibits Inflammation and Promotes Autophagy in Silica-Induced Pulmonary Fibrosis through Targeting TNFSF14 and PTBP1Chem Res Toxicol. 2019 Nov 18;32(11):2192-2203. doi: 10.1021/acs.chemrestox.9b00194. Epub 2019 Nov 5.
REF00004085	Transforming Mutations of Jak3 (A573V and M511I) Show Differential Sensitivity to Selective Jak3 InhibitorsClin Cancer Drugs. 2016;3(2):131-137. doi: 10.2174/2212697X03666160610085943.
REF00004086	Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01Clin Cancer Res. 2005 Nov 1;11(21):7841-50. doi: 10.1158/1078-0432.CCR-05-0421.
REF00004087	Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumorClin Cancer Res. 2007 Aug 15;13(16):4874-81. doi: 10.1158/1078-0432.CCR-07-0484.
REF00004088	Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapyClin Cancer Res. 2009 Jan 15;15(2):460-7. doi: 10.1158/1078-0432.CCR-08-1757.
REF00004089	Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistanceClin Cancer Res. 2009 May 15;15(10):3484-94. doi: 10.1158/1078-0432.CCR-08-2904. Epub 2009 May 15.
REF00004090	Ethnic differences and functional analysis of MET mutations in lung cancerClin Cancer Res. 2009 Sep 15;15(18):5714-23. doi: 10.1158/1078-0432.CCR-09-0070. Epub 2009 Sep 1.
REF00004091	Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical modelsClin Cancer Res. 2010 Jul 15;16(14):3670-83. doi: 10.1158/1078-0432.CCR-09-2828. Epub 2010 May 7.
REF00004092	PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53Clin Cancer Res. 2011 May 1;17(9):2830-41. doi: 10.1158/1078-0432.CCR-10-3168. Epub 2011 Mar 17.
REF00004093	"Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitorClin Cancer Res. 2011 May 15;17(10):3193-203. doi: 10.1158/1078-0432.CCR-10-1694. Epub 2011 Feb 15."
REF00004094	The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutationsClin Cancer Res. 2011 May 15;17(10):3272-81. doi: 10.1158/1078-0432.CCR-10-2882. Epub 2011 May 10.
REF00004095	"A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3Clin Cancer Res. 2011 Nov 15;17(22):7127-38. doi: 10.1158/1078-0432.CCR-11-1157. Epub 2011 Sep 14."
REF00004096	Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent mannerClin Cancer Res. 2012 Aug 15;18(16):4345-55. doi: 10.1158/1078-0432.CCR-11-3227. Epub 2012 Jun 25.
REF00004097	Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumorsClin Cancer Res. 2012 Aug 15;18(16):4375-84. doi: 10.1158/1078-0432.CCR-12-0625. Epub 2012 Jun 27.
REF00004098	"Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistanceClin Cancer Res. 2012 Jul 1;18(13):3552-61. doi: 10.1158/1078-0432.CCR-11-3086. Epub 2012 May 1."
REF00004099	Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomasClin Cancer Res. 2012 May 1;18(9):2515-25. doi: 10.1158/1078-0432.CCR-11-2683. Epub 2012 Mar 5.
REF00004100	"Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanomaClin Cancer Res. 2013 Apr 15;19(8):2257-64. doi: 10.1158/1078-0432.CCR-12-3476. Epub 2013 Feb 26."
REF00004101	Targeting SRC and tubulin in mucinous ovarian carcinomaClin Cancer Res. 2013 Dec 1;19(23):6532-43. doi: 10.1158/1078-0432.CCR-13-1305. Epub 2013 Oct 7.
REF00004102	Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanibClin Cancer Res. 2013 Dec 15;19(24):6935-42. doi: 10.1158/1078-0432.CCR-13-1266. Epub 2013 Oct 16.
REF00004103	Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancerClin Cancer Res. 2013 Mar 1;19(5):1232-43. doi: 10.1158/1078-0432.CCR-12-3529. Epub 2013 Feb 22.
REF00004104	Characteristics of lung cancers harboring NRAS mutationsClin Cancer Res. 2013 May 1;19(9):2584-91. doi: 10.1158/1078-0432.CCR-12-3173. Epub 2013 Mar 20.
REF00004105	Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2Clin Cancer Res. 2013 Oct 1;19(19):5390-401. doi: 10.1158/1078-0432.CCR-13-1038. Epub 2013 Aug 15.
REF00004106	PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model systemClin Cancer Res. 2013 Oct 1;19(19):5413-22. doi: 10.1158/1078-0432.CCR-13-0884. Epub 2013 Jul 25.
REF00004107	"Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanomaClin Cancer Res. 2014 Apr 15;20(8):2035-43. doi: 10.1158/1078-0432.CCR-13-2054. Epub 2014 Feb 28."
REF00004108	Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutationsClin Cancer Res. 2014 Aug 15;20(16):4251-61. doi: 10.1158/1078-0432.CCR-14-0341. Epub 2014 Jun 19.
REF00004109	"First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancerClin Cancer Res. 2014 Dec 1;20(23):5908-17. doi: 10.1158/1078-0432.CCR-14-1315. Epub 2014 Sep 17."
REF00004110	Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trialClin Cancer Res. 2014 Jan 15;20(2):490-8. doi: 10.1158/1078-0432.CCR-13-1311. Epub 2013 Oct 31.
REF00004111	Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patientsClin Cancer Res. 2014 Nov 15;20(22):5745-5755. doi: 10.1158/1078-0432.CCR-14-1397. Epub 2014 Sep 19.
REF00004112	"A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma PatientsClin Cancer Res. 2015 Aug 15;21(16):3610-8. doi: 10.1158/1078-0432.CCR-14-3220. Epub 2015 Apr 24."
REF00004113	EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIsClin Cancer Res. 2015 Dec 1;21(23):5305-13. doi: 10.1158/1078-0432.CCR-15-1046. Epub 2015 Jul 23.
REF00004114	Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancerClin Cancer Res. 2015 Jan 1;21(1):166-74. doi: 10.1158/1078-0432.CCR-14-1385. Epub 2014 Oct 28.
REF00004115	"First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumorsClin Cancer Res. 2015 Jan 1;21(1):77-86. doi: 10.1158/1078-0432.CCR-14-0947. Epub 2014 Nov 4."
REF00004116	Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patientsClin Cancer Res. 2015 Mar 15;21(6):1313-20. doi: 10.1158/1078-0432.CCR-14-2779. Epub 2015 Jan 14.
REF00004117	Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung CancerClin Cancer Res. 2015 May 15;21(10):2379-87. doi: 10.1158/1078-0432.CCR-14-1350. Epub 2015 Feb 16.
REF00004118	EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR InhibitorsClin Cancer Res. 2015 Sep 1;21(17):3913-23. doi: 10.1158/1078-0432.CCR-14-2789. Epub 2015 May 6.
REF00004119	MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell CarcinomaClin Cancer Res. 2015 Sep 1;21(17):3946-56. doi: 10.1158/1078-0432.CCR-14-3377. Epub 2015 May 14.
REF00004120	"Taselisib (GDC-0032), a Potent Beta-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA AlterationsClin Cancer Res. 2016 Apr 15;22(8):2009-19. doi: 10.1158/1078-0432.CCR-15-2245. Epub 2015 Nov 20."
REF00004121	"The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618IClin Cancer Res. 2016 Feb 1;22(3):757-64. doi: 10.1158/1078-0432.CCR-14-3100. Epub 2015 Oct 16."
REF00004122	Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway InhibitorsClin Cancer Res. 2016 Feb 15;22(4):1018-27. doi: 10.1158/1078-0432.CCR-15-1110. Epub 2015 Oct 21.
REF00004123	The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal CancerClin Cancer Res. 2016 Jul 1;22(13):3260-7. doi: 10.1158/1078-0432.CCR-15-2400. Epub 2016 Feb 17.
REF00004124	"Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid TumorsClin Cancer Res. 2016 Jun 15;22(12):2874-84. doi: 10.1158/1078-0432.CCR-15-2225. Epub 2016 Jan 19."
REF00004125	Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell CarcinomaClin Cancer Res. 2016 Jun 15;22(12):2939-49. doi: 10.1158/1078-0432.CCR-15-2314. Epub 2016 Jan 13.
REF00004126	An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to VismodegibClin Cancer Res. 2016 Mar 15;22(6):1325-9. doi: 10.1158/1078-0432.CCR-15-1588. Epub 2015 Nov 6.
REF00004127	Identification of a Novel Pathogenic Germline KDR Variant in MelanomaClin Cancer Res. 2016 May 15;22(10):2377-85. doi: 10.1158/1078-0432.CCR-15-1811. Epub 2015 Dec 2.
REF00004128	BRAF Status in Personalizing Treatment Approaches for Pediatric GliomasClin Cancer Res. 2016 Nov 1;22(21):5312-5321. doi: 10.1158/1078-0432.CCR-15-1101. Epub 2016 May 23.
REF00004129	The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical ModelsClin Cancer Res. 2016 Nov 15;22(22):5527-5538. doi: 10.1158/1078-0432.CCR-16-0569. Epub 2016 Oct 25.
REF00004130	Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung CancerClin Cancer Res. 2017 Aug 15;23(16):4929-4937. doi: 10.1158/1078-0432.CCR-16-3273. Epub 2017 Apr 10.
REF00004131	c-Myc Alteration Determines the Therapeutic Response to FGFR InhibitorsClin Cancer Res. 2017 Feb 15;23(4):974-984. doi: 10.1158/1078-0432.CCR-15-2448. Epub 2016 Jul 11.
REF00004132	Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or MutationsClin Cancer Res. 2017 Jun 15;23(12):2981-2990. doi: 10.1158/1078-0432.CCR-16-1887. Epub 2016 Dec 23.
REF00004133	The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder CancerClin Cancer Res. 2017 Nov 1;23(21):6580-6591. doi: 10.1158/1078-0432.CCR-17-0033. Epub 2017 Aug 14.
REF00004134	Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical ModelsClin Cancer Res. 2017 Nov 1;23(21):6661-6672. doi: 10.1158/1078-0432.CCR-17-1192. Epub 2017 Aug 1.
REF00004135	HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2(+) Breast CancerClin Cancer Res. 2017 Sep 1;23(17):5123-5134. doi: 10.1158/1078-0432.CCR-16-2191. Epub 2017 May 9.
REF00004136	Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS MutationsClin Cancer Res. 2017 Sep 15;23(18):5547-5560. doi: 10.1158/1078-0432.CCR-16-3250. Epub 2017 Jun 13.
REF00004137	Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic TherapiesClin Cancer Res. 2018 Aug 1;24(15):3550-3559. doi: 10.1158/1078-0432.CCR-18-0103. Epub 2018 Mar 27.
REF00004138	A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant GliomaClin Cancer Res. 2018 Aug 1;24(15):3611-3631. doi: 10.1158/1078-0432.CCR-17-0126. Epub 2018 Apr 27.
REF00004139	Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant MelanomasClin Cancer Res. 2018 Dec 15;24(24):6483-6494. doi: 10.1158/1078-0432.CCR-17-3384. Epub 2018 Jun 14.
REF00004140	EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung AdenocarcinomasClin Cancer Res. 2018 Dec 15;24(24):6548-6555. doi: 10.1158/1078-0432.CCR-18-1541. Epub 2018 Aug 28.
REF00004141	Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with OsimertinibClin Cancer Res. 2018 Jun 1;24(11):2594-2604. doi: 10.1158/1078-0432.CCR-17-1875. Epub 2018 Jan 3.
REF00004142	Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung CancerClin Cancer Res. 2019 Apr 1;25(7):2058-2063. doi: 10.1158/1078-0432.CCR-18-3325. Epub 2019 Jan 18.
REF00004143	"YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung CancerClin Cancer Res. 2019 Apr 15;25(8):2575-2587. doi: 10.1158/1078-0432.CCR-18-2906. Epub 2019 Jan 22."
REF00004144	"Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid TumorsClin Cancer Res. 2019 Aug 15;25(16):4888-4897. doi: 10.1158/1078-0432.CCR-18-3334. Epub 2019 May 14."
REF00004145	Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant MelanomaClin Cancer Res. 2019 Feb 15;25(4):1272-1279. doi: 10.1158/1078-0432.CCR-18-1680. Epub 2019 Jan 10.
REF00004146	"Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal TumorsClin Cancer Res. 2019 Jan 15;25(2):609-618. doi: 10.1158/1078-0432.CCR-18-1858. Epub 2018 Oct 1."
REF00004147	"A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene AlterationsClin Cancer Res. 2019 May 1;25(9):2699-2707. doi: 10.1158/1078-0432.CCR-18-1959. Epub 2019 Feb 11."
REF00004148	Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung AdenocarcinomaClin Lung Cancer. 2018 Sep;19(5):e775-e781. doi: 10.1016/j.cllc.2018.05.018. Epub 2018 Jun 5.
REF00004149	Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosingClin Pharmacol Ther. 2013 Dec;94(6):640-5. doi: 10.1038/clpt.2013.172. Epub 2013 Aug 29.
REF00004150	"Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access programClin Sarcoma Res. 2014 Dec 4;4:17. doi: 10.1186/2045-3329-4-17. eCollection 2014."
REF00004151	Urothelial carcinoma with an NRF1-BRAF rearrangement and response to targeted therapyCold Spring Harb Mol Case Stud. 2019 Jun 3;5(3):a003848. doi: 10.1101/mcs.a003848. Print 2019 Jun.
REF00004152	KDR Mutation as a Novel Predictive Biomarker of Exceptional Response to Regorafenib in Metastatic Colorectal CancerCureus. 2016 Feb 3;8(2):e478. doi: 10.7759/cureus.478.
REF00004153	HOTAIR Competitively Binds MiRNA330 as a Molecular Sponge to Increase the Resistance of Gastric Cancer to TrastuzumabCurr Cancer Drug Targets. 2020;20(9):700-709. doi: 10.2174/1568009620666200504114000.
REF00004154	H19 lncRNA Promotes Skeletal Muscle Insulin Sensitivity in Part by Targeting AMPKDiabetes. 2018 Nov;67(11):2183-2198. doi: 10.2337/db18-0370. Epub 2018 Sep 10.
REF00004155	Overexpression of CASC2 Improves Cisplatin Sensitivity in Hepatocellular Carcinoma Through Sponging miR-222DNA Cell Biol. 2019 Nov;38(11):1366-1373. doi: 10.1089/dna.2019.4882. Epub 2019 Oct 18.
REF00004156	Aspirin targets P4HA2 through inhibiting NF-kB and LMCD1-AS1/let-7g to inhibit tumour growth and collagen deposition in hepatocellular carcinomaEBioMedicine. 2019 Jul;45:168-180. doi: 10.1016/j.ebiom.2019.06.048. Epub 2019 Jul 2.
REF00004157	A kinase-independent function of AKT promotes cancer cell survivalElife. 2014 Dec 31;3:e03751. doi: 10.7554/eLife.03751.
REF00004158	Pharmacology and pathophysiology of mutated KCNJ5 found in adrenal aldosterone-producing adenomasEndocrinology. 2014 Apr;155(4):1353-62. doi: 10.1210/en.2013-1944. Epub 2014 Feb 7.
REF00004159	Regulatory loop between lncRNA FAS-AS1 and DNMT3b controls FAS expression in hydroquinone-treated TK6 cells and benzene-exposed workersEnviron Pollut. 2020 Jun;261:114147. doi: 10.1016/j.envpol.2020.114147. Epub 2020 Feb 11.
REF00004160	"A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreasEur J Cancer. 2014 Aug;50(12):2072-81. doi: 10.1016/j.ejca.2014.04.024. Epub 2014 Jun 7."
REF00004161	"Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation studyEur J Cancer. 2017 Sep;83:194-202. doi: 10.1016/j.ejca.2017.06.036. Epub 2017 Jul 24."
REF00004162	Inhibition mechanism exploration of investigational drug TAK-441 as inhibitor against Vismodegib-resistant Smoothened mutantEur J Pharmacol. 2014 Jan 15;723:305-13. doi: 10.1016/j.ejphar.2013.11.014. Epub 2013 Nov 28.
REF00004163	Inhibition of long noncoding RNA BLACAT1 protects anesthesia-induced neural cytotoxicity in human induced pluripotent stem cells derived neuronsEur J Pharmacol. 2019 Dec 15;865:172737. doi: 10.1016/j.ejphar.2019.172737. Epub 2019 Oct 14.
REF00004164	Overexpression of long non-coding RNA TUG1 alleviates TNF-Alpha-induced inflammatory injury in interstitial cells of CajalEur Rev Med Pharmacol Sci. 2019 Jan;23(1):312-320. doi: 10.26355/eurrev_201901_16778.
REF00004165	Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 monthsExp Hematol Oncol. 2017 Mar 21;6:6. doi: 10.1186/s40164-017-0067-4. eCollection 2017.
REF00004166	Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutationsExp Hematol. 2014 Apr;42(4):247-51. doi: 10.1016/j.exphem.2013.12.001. Epub 2013 Dec 11.
REF00004167	"LncRNA UCA1 promotes cell proliferation, invasion and migration of laryngeal squamous cell carcinoma cells by activating Wnt/Beta-catenin signaling pathwayExp Ther Med. 2019 Feb;17(2):1182-1189. doi: 10.3892/etm.2018.7097. Epub 2018 Dec 13."
REF00004168	High lncRNA MEG3 expression is associated with high mortality rates in patients with sepsis and increased lipopolysaccharide-induced renal epithelial cell and cardiomyocyte apoptosisExp Ther Med. 2019 Nov;18(5):3943-3947. doi: 10.3892/etm.2019.8049. Epub 2019 Sep 25.
REF00004169	"High levels of p110Delta PI3K expression in solid tumor cells suppress PTEN activity, generating cellular sensitivity to p110 Delta inhibitors through PTEN activationFASEB J. 2012 Jun;26(6):2498-508. doi: 10.1096/fj.11-198192. Epub 2012 Mar 5."
REF00004170	MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptorFASEB J. 2015 May;29(5):1817-29. doi: 10.1096/fj.14-267849. Epub 2015 Jan 30.
REF00004171	Down-regulation of Risa improves insulin sensitivity by enhancing autophagyFASEB J. 2016 Sep;30(9):3133-45. doi: 10.1096/fj.201500058R. Epub 2016 Jun 1.
REF00004172	Long noncoding RNA growth arrest-specific transcript 5 alleviates renal fibrosis in diabetic nephropathy by downregulating matrix metalloproteinase 9 through recruitment of enhancer of zeste homolog 2FASEB J. 2020 Feb;34(2):2703-2714. doi: 10.1096/fj.201901380RR. Epub 2020 Jan 9.
REF00004173	Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303)Front Oncol. 2019 Mar 11;9:132. doi: 10.3389/fonc.2019.00132. eCollection 2019.
REF00004174	KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancerFuture Oncol. 2015;11(13):1919-29. doi: 10.2217/fon.15.97.
REF00004175	Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutationsGenome Res. 2017 Apr;27(4):613-625. doi: 10.1101/gr.213546.116. Epub 2017 Feb 8.
REF00004176	Barley long non-coding RNAs (lncRNA) responsive to excess boronGenomics. 2020 Mar;112(2):1947-1955. doi: 10.1016/j.ygeno.2019.11.007. Epub 2019 Nov 12.
REF00004177	Down-regulation of lncRNA CASC9 aggravates sepsis-induced acute lung injury by regulating miR-195-5p/PDK4 axisInflamm Res. 2020 Jun;69(6):559-568. doi: 10.1007/s00011-020-01316-2. Epub 2020 Mar 27.
REF00004178	LncRNA analysis of lung tissues after hUC-MSCs and FTY720 treatment of lipopolysaccharide-induced acute lung injury in mouse modelsInt Immunopharmacol. 2019 Jun;71:68-75. doi: 10.1016/j.intimp.2019.03.017. Epub 2019 Mar 14.
REF00004179	Long non-coding RNA Mirt2 prevents TNF-Alpha-triggered inflammation via the repression of microRNA-101Int Immunopharmacol. 2019 Nov;76:105878. doi: 10.1016/j.intimp.2019.105878. Epub 2019 Sep 9.
REF00004180	LncRNA-H19 induces hepatic stellate cell activation via upregulating alcohol dehydrogenase III-mediated retinoic acid signalsInt Immunopharmacol. 2020 Jul;84:106470. doi: 10.1016/j.intimp.2020.106470. Epub 2020 Apr 15.
REF00004181	"Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activityInt J Cancer. 2011 Jul 1;129(1):245-55. doi: 10.1002/ijc.25864. Epub 2011 Apr 22."
REF00004182	"Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cellsInt J Cancer. 2013 Nov;133(9):2089-101. doi: 10.1002/ijc.28236. Epub 2013 May 29."
REF00004183	"BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse modelsInt J Cancer. 2017 Jan 15;140(2):449-459. doi: 10.1002/ijc.30457. Epub 2016 Oct 20."
REF00004184	Hyperbaric oxygen boosts long noncoding RNA MALAT1 exosome secretion to suppress microRNA-92a expression in therapeutic angiogenesisInt J Cardiol. 2019 Jan 1;274:271-278. doi: 10.1016/j.ijcard.2018.09.118. Epub 2018 Oct 2.
REF00004185	CDK4/6 inhibitor suppresses gastric cancer with CDKN2A mutationInt J Clin Exp Med. 2015 Jul 15;8(7):11692-700. eCollection 2015.
REF00004186	"HRAS G13D, a new mutation implicated in the resistance to anti-EGFR therapies in colorectal cancer, a case reportInt J Colorectal Dis. 2016 Jun;31(6):1245-6. doi: 10.1007/s00384-015-2448-7. Epub 2015 Nov 12."
REF00004187	A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cellsInt J Mol Med. 2009 Jul;24(1):97-101. doi: 10.3892/ijmm_00000212.
REF00004188	Anisomycin inhibits angiogenesis in ovarian cancer by attenuating the molecular sponge effect of the lncRNA Meg3/miR 421/PDGFRA axisInt J Oncol. 2019 Dec;55(6):1296-1312. doi: 10.3892/ijo.2019.4887. Epub 2019 Sep 30.
REF00004189	"LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft modelsInvest New Drugs. 2013 Aug;31(4):833-44. doi: 10.1007/s10637-012-9912-9. Epub 2012 Dec 29."
REF00004190	Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumorsInvest New Drugs. 2015 Feb;33(1):215-24. doi: 10.1007/s10637-014-0176-4. Epub 2014 Nov 4.
REF00004191	"A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancerInvest New Drugs. 2015 Jun;33(3):710-9. doi: 10.1007/s10637-015-0241-7. Epub 2015 Apr 24."
REF00004192	Long noncoding RNA XIST enhances ethanol-induced hepatic stellate cells autophagy and activation via miR-29b/HMGB1 axisIUBMB Life. 2019 Dec;71(12):1962-1972. doi: 10.1002/iub.2140. Epub 2019 Aug 16.
REF00004193	Shp2E76K mutant confers cytokine-independent survival of TF-1 myeloid cells by up-regulating Bcl-XLJ Biol Chem. 2007 Dec 14;282(50):36463-73. doi: 10.1074/jbc.M705789200. Epub 2007 Oct 17.
REF00004194	"EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activationJ Biol Chem. 2010 Jun 11;285(24):18575-85. doi: 10.1074/jbc.M109.075085. Epub 2010 Apr 1."
REF00004195	CBL linker region and RING finger mutations lead to enhanced granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling via elevated levels of JAK2 and LYNJ Biol Chem. 2013 Jul 5;288(27):19459-70. doi: 10.1074/jbc.M113.475087. Epub 2013 May 21.
REF00004196	Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor SpecificitiesJ Biol Chem. 2015 Nov 27;290(48):29022-34. doi: 10.1074/jbc.M115.670224. Epub 2015 Oct 7.
REF00004197	Feasibility of novel PPP1R15A and proposed ANXA11 single nucleotide polymorphisms as predictive markers for bevacizumab regimen in metastatic colorectal cancerJ Cancer Res Clin Oncol. 2016 Aug;142(8):1705-14. doi: 10.1007/s00432-016-2177-5. Epub 2016 May 13.
REF00004198	METase/lncRNA HULC/FoxM1 reduced cisplatin resistance in gastric cancer by suppressing autophagyJ Cancer Res Clin Oncol. 2019 Oct;145(10):2507-2517. doi: 10.1007/s00432-019-03015-w. Epub 2019 Sep 4.
REF00004199	Overexpression of Long Non-Coding RNA MEG3 Inhibits Proliferation of Hepatocellular Carcinoma Huh7 Cells via Negative Modulation of miRNA-664J Cell Biochem. 2017 Nov;118(11):3713-3721. doi: 10.1002/jcb.26018. Epub 2017 Aug 3.
REF00004200	c-Myc mediated upregulation of long noncoding RNA SNHG12 regulates proliferation and drug sensitivity in natural killer/T-cell lymphomaJ Cell Biochem. 2019 Aug;120(8):12628-12637. doi: 10.1002/jcb.28529. Epub 2019 Mar 1.
REF00004201	RNA-Seq analysis of potential lncRNAs and genes for the anti-renal fibrotic effect of norcantharidinJ Cell Biochem. 2019 Oct;120(10):17354-17367. doi: 10.1002/jcb.28999. Epub 2019 May 19.
REF00004202	LncRNA MEG3 contributes to adenosine-induced cytotoxicity in hepatoma HepG2 cells by downregulated ILF3 and autophagy inhibition via regulation PI3K-AKT-mTOR and beclin-1 signaling pathwayJ Cell Biochem. 2019 Oct;120(10):18172-18185. doi: 10.1002/jcb.29123. Epub 2019 May 29.
REF00004203	RNA-Seq analysis and functional characterization revealed lncRNA NONRATT007560.2 regulated cardiomyocytes oxidative stress and apoptosis induced by high glucoseJ Cell Biochem. 2019 Oct;120(10):18278-18287. doi: 10.1002/jcb.29134. Epub 2019 May 29.
REF00004204	Long non-coding RNA small nucleolar RNA host gene 7 facilitates cardiac hypertrophy via stabilization of SDA1 domain containing 1 mRNAJ Cell Biochem. 2019 Sep;120(9):15089-15097. doi: 10.1002/jcb.28770. Epub 2019 Apr 26.
REF00004205	The expression of long noncoding RNA CRCAL-3 in colorectal cancer and its impacts on cell proliferation and migrationJ Cell Biochem. 2019 Sep;120(9):15369-15377. doi: 10.1002/jcb.28804. Epub 2019 Apr 30.
REF00004206	LncRNA-UCA1 inhibits the astrocyte activation in the temporal lobe epilepsy via regulating the JAK/STAT signaling pathwayJ Cell Biochem. 2020 Oct;121(10):4261-4270. doi: 10.1002/jcb.29634. Epub 2020 Jan 7.
REF00004207	Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitorsJ Cell Mol Med. 2013 Nov;17(11):1397-409. doi: 10.1111/jcmm.12156. Epub 2013 Nov 19.
REF00004208	Long non-coding RNA MEG3 knockdown attenuates endoplasmic reticulum stress-mediated apoptosis by targeting p53 following myocardial infarctionJ Cell Mol Med. 2019 Dec;23(12):8369-8380. doi: 10.1111/jcmm.14714. Epub 2019 Oct 20.
REF00004209	LncRNA MEG3 inhibits rheumatoid arthritis through miR-141 and inactivation of AKT/mTOR signalling pathwayJ Cell Mol Med. 2019 Oct;23(10):7116-7120. doi: 10.1111/jcmm.14591. Epub 2019 Aug 14.
REF00004210	LncRNA ACART protects cardiomyocytes from apoptosis by activating PPAR-Gamma/Bcl-2 pathwayJ Cell Mol Med. 2020 Jan;24(1):737-746. doi: 10.1111/jcmm.14781. Epub 2019 Nov 20.
REF00004211	"Formononetin, J1 and J2 have different effects on endothelial cells via EWSAT1-TRAF6 and its downstream pathwayJ Cell Mol Med. 2020 Jan;24(1):875-885. doi: 10.1111/jcmm.14797. Epub 2019 Nov 19."
REF00004212	Metabolic changes during malignant transformation in primary cells of oral lichen planus: Succinate accumulation and tumour suppressionJ Cell Mol Med. 2020 Jan;24(2):1179-1188. doi: 10.1111/jcmm.14376. Epub 2019 Dec 2.
REF00004213	Long-chain noncoding RNA GAS5 mediates oxidative stress in cardiac microvascular endothelial cells injuryJ Cell Physiol. 2019 Aug;234(10):17649-17662. doi: 10.1002/jcp.28388. Epub 2019 Mar 1.
REF00004214	Tanshinone IIA protects lens epithelial cells from H(2) O (2) -induced injury by upregulation of lncRNA ANRILJ Cell Physiol. 2019 Jan 30. doi: 10.1002/jcp.28189. Online ahead of print.
REF00004215	Identification of lncRNA NEAT1/miR-21/RRM2 axis as a novel biomarker in breast cancerJ Cell Physiol. 2020 Apr;235(4):3372-3381. doi: 10.1002/jcp.29225. Epub 2019 Oct 17.
REF00004216	Long noncoding RNA MIAT2 alleviates lipopolysaccharide-induced inflammatory damage in WI-38 cells by sponging microRNA-15J Cell Physiol. 2020 Apr;235(4):3690-3697. doi: 10.1002/jcp.29263. Epub 2019 Sep 30.
REF00004217	LncRNA H19 is involved in myocardial ischemic preconditioning via increasing the stability of nucleolin proteinJ Cell Physiol. 2020 Sep;235(9):5985-5994. doi: 10.1002/jcp.29524. Epub 2020 Jan 24.
REF00004218	Long noncoding RNA NORAD regulates MPP+-induced Parkinson's disease model cellsJ Chem Neuroanat. 2019 Nov;101:101668. doi: 10.1016/j.jchemneu.2019.101668. Epub 2019 Aug 14.
REF00004219	The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathwayJ Clin Endocrinol Metab. 2011 Apr;96(4):E577-85. doi: 10.1210/jc.2010-2644. Epub 2011 Feb 2.
REF00004220	The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cellsJ Clin Endocrinol Metab. 2011 Jun;96(6):E991-5. doi: 10.1210/jc.2010-2381. Epub 2011 Apr 6.
REF00004221	"CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivoJ Clin Endocrinol Metab. 2014 Apr;99(4):E572-81. doi: 10.1210/jc.2013-2321. Epub 2014 Jan 1."
REF00004222	Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in miceJ Clin Invest. 2009 May;119(5):1216-29. doi: 10.1172/JCI38017. Epub 2009 Apr 20.
REF00004223	Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted modelsJ Clin Invest. 2009 Nov;119(11):3395-407. doi: 10.1172/JCI39703. Epub 2009 Oct 5.
REF00004224	Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinomaJ Clin Invest. 2014 Apr;124(4):1582-6. doi: 10.1172/JCI72763. Epub 2014 Feb 24.
REF00004225	Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110AlphaJ Clin Invest. 2014 Apr;124(4):1794-809. doi: 10.1172/JCI69927. Epub 2014 Feb 24.
REF00004226	Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodineJ Clin Invest. 2016 Nov 1;126(11):4119-4124. doi: 10.1172/JCI89067. Epub 2016 Sep 26.
REF00004227	MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanomaJ Clin Invest. 2017 Nov 1;127(11):4179-4192. doi: 10.1172/JCI91258. Epub 2017 Oct 16.
REF00004228	Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancerJ Clin Oncol. 2008 Dec 10;26(35):5705-12. doi: 10.1200/JCO.2008.18.0786. Epub 2008 Nov 10.
REF00004229	"Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancersJ Clin Oncol. 2008 May 1;26(13):2139-46. doi: 10.1200/JCO.2007.14.4956. Epub 2008 Apr 7."
REF00004230	"Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancerJ Clin Oncol. 2009 Dec 10;27(35):5924-30. doi: 10.1200/JCO.2008.21.6796. Epub 2009 Nov 2."
REF00004231	Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034J Clin Oncol. 2009 Mar 10;27(8):1268-74. doi: 10.1200/JCO.2008.17.5984. Epub 2009 Feb 9.
REF00004232	Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancerJ Clin Oncol. 2010 Feb 10;28(5):767-72. doi: 10.1200/JCO.2009.23.6604. Epub 2010 Jan 11.
REF00004233	The PI3K pathway as drug target in human cancerJ Clin Oncol. 2010 Feb 20;28(6):1075-83. doi: 10.1200/JCO.2009.25.3641. Epub 2010 Jan 19.
REF00004234	"Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3J Clin Oncol. 2010 Oct 1;28(28):4339-45. doi: 10.1200/JCO.2010.28.9678. Epub 2010 Aug 23."
REF00004235	Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profilingJ Clin Oncol. 2011 Aug 1;29(22):3085-96. doi: 10.1200/JCO.2010.33.2312. Epub 2011 Mar 7.
REF00004236	First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumorsJ Clin Oncol. 2011 Dec 10;29(35):4688-95. doi: 10.1200/JCO.2011.35.5263. Epub 2011 Oct 24.
REF00004237	"Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)J Clin Oncol. 2011 Jul 20;29(21):2866-74. doi: 10.1200/JCO.2010.33.4235. Epub 2011 Jun 13."
REF00004238	First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lungJ Clin Oncol. 2012 Apr 1;30(10):1122-8. doi: 10.1200/JCO.2011.36.8456. Epub 2012 Feb 27.
REF00004239	"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trialJ Clin Oncol. 2012 Jan 10;30(2):134-41. doi: 10.1200/JCO.2011.35.5040. Epub 2011 Oct 24."
REF00004240	Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trialJ Clin Oncol. 2012 Jul 1;30(19):2401-7. doi: 10.1200/JCO.2011.39.9394. Epub 2012 May 21.
REF00004241	Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancerJ Clin Oncol. 2012 Oct 10;30(29):3633-9. doi: 10.1200/JCO.2011.40.7783. Epub 2012 Sep 10.
REF00004242	Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitorJ Clin Oncol. 2013 Feb 1;31(4):482-9. doi: 10.1200/JCO.2012.43.5966. Epub 2012 Dec 17.
REF00004243	Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinomaJ Clin Oncol. 2013 Jan 10;31(2):181-6. doi: 10.1200/JCO.2012.43.3383. Epub 2012 Dec 3.
REF00004244	Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinomaJ Clin Oncol. 2013 Jun 1;31(16):e254-8. doi: 10.1200/JCO.2012.46.4289. Epub 2013 Apr 22.
REF00004245	Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutationsJ Clin Oncol. 2013 Sep 20;31(27):3327-34. doi: 10.1200/JCO.2012.44.2806. Epub 2013 Jul 1.
REF00004246	Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitorJ Clin Oncol. 2014 Nov 20;32(33):3697-704. doi: 10.1200/JCO.2014.57.3535. Epub 2014 Oct 6.
REF00004247	Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal CancerJ Clin Oncol. 2015 Dec 1;33(34):4023-31. doi: 10.1200/JCO.2015.63.2471. Epub 2015 Sep 21.
REF00004248	Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian CancerJ Clin Oncol. 2015 Dec 1;33(34):4099-105. doi: 10.1200/JCO.2015.62.4726. Epub 2015 Aug 31.
REF00004249	"Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid TumorsJ Clin Oncol. 2015 Oct 20;33(30):3401-8. doi: 10.1200/JCO.2014.60.7341. Epub 2015 Aug 31."
REF00004250	Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair DeficiencyJ Clin Oncol. 2016 Jul 1;34(19):2206-11. doi: 10.1200/JCO.2016.66.6552. Epub 2016 Mar 21.
REF00004251	Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With TrametinibJ Clin Oncol. 2016 Mar 10;34(8):871-8. doi: 10.1200/JCO.2015.62.9345. Epub 2016 Jan 25.
REF00004252	"Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion StudyJ Clin Oncol. 2017 Jan 10;35(2):157-165. doi: 10.1200/JCO.2016.67.2048. Epub 2016 Nov 21."
REF00004253	AKT Inhibition in Solid Tumors With AKT1 MutationsJ Clin Oncol. 2017 Jul 10;35(20):2251-2259. doi: 10.1200/JCO.2017.73.0143. Epub 2017 May 10.
REF00004254	Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating MutationsJ Clin Oncol. 2018 Aug 1;36(22):2244-2250. doi: 10.1200/JCO.2018.78.7994. Epub 2018 Jun 4.
REF00004255	Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid CancerJ Clin Oncol. 2018 Jan 1;36(1):7-13. doi: 10.1200/JCO.2017.73.6785. Epub 2017 Oct 26.
REF00004256	Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With TrametinibJ Clin Oncol. 2018 Mar 1;36(7):667-673. doi: 10.1200/JCO.2017.74.1025. Epub 2017 Oct 9.
REF00004257	Anticancer activity of polyphyllin I in nasopharyngeal carcinoma by modulation of lncRNA ROR and P53 signallingJ Drug Target. 2019 Aug;27(7):806-811. doi: 10.1080/1061186X.2018.1561887. Epub 2019 Feb 11.
REF00004258	Anti-tumor activity of motesanib in a medullary thyroid cancer modelJ Endocrinol Invest. 2012 Feb;35(2):181-90. doi: 10.3275/7609. Epub 2011 Mar 21.
REF00004259	LncRNA PU.1 AS regulates arsenic-induced lipid metabolism through EZH2/Sirt6/SREBP-1c pathwayJ Environ Sci (China). 2019 Nov;85:138-146. doi: 10.1016/j.jes.2019.05.019. Epub 2019 May 24.
REF00004260	Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumorsJ Exp Clin Cancer Res. 2010 Jul 15;29(1):96. doi: 10.1186/1756-9966-29-96.
REF00004261	Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft modelsJ Exp Clin Cancer Res. 2014 Jun 17;33(1):52. doi: 10.1186/1756-9966-33-52.
REF00004262	"Inhibition of COX-2, mPGES-1 and CYP4A by isoliquiritigenin blocks the angiogenic Akt signaling in glioma through ceRNA effect of miR-194-5p and lncRNA NEAT1J Exp Clin Cancer Res. 2019 Aug 22;38(1):371. doi: 10.1186/s13046-019-1361-2."
REF00004263	Long non-coding RNA MACC1-AS1 promoted pancreatic carcinoma progression through activation of PAX8/NOTCH1 signaling pathwayJ Exp Clin Cancer Res. 2019 Aug 7;38(1):344. doi: 10.1186/s13046-019-1332-7.
REF00004264	FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitorsJ Exp Med. 2007 Aug 6;204(8):1813-24. doi: 10.1084/jem.20070876. Epub 2007 Jul 23.
REF00004265	PI3K inhibitor provides durable response in metastatic metaplastic carcinoma of the breast: A hidden gem in the BELLE-4 studyJ Formos Med Assoc. 2019 Sep;118(9):1333-1338. doi: 10.1016/j.jfma.2018.12.004. Epub 2018 Dec 18.
REF00004266	Inhibition of HIF1A-AS1 impedes the arecoline-induced migration activity of human oral mucosal fibroblastsJ Formos Med Assoc. 2020 Apr;119(4):879-883. doi: 10.1016/j.jfma.2019.12.014. Epub 2020 Jan 18.
REF00004267	Combined dabrafenib and trametinib treatment in a case of chemotherapy-refractory extrahepatic BRAF V600E mutant cholangiocarcinoma: dramatic clinical and radiological response with a confusing synchronic new liver lesionJ Gastrointest Oncol. 2017 Apr;8(2):E32-E38. doi: 10.21037/jgo.2017.01.06.
REF00004268	Circulating lncRNA MHRT predicts survival of patients with chronic heart failureJ Geriatr Cardiol. 2019 Nov;16(11):818-821. doi: 10.11909/j.issn.1671-5411.2019.11.006.
REF00004269	Ammonia regulates chicken tracheal cell necroptosis via the LncRNA-107053293/MiR-148a-3p/FAF1 axisJ Hazard Mater. 2020 Mar 15;386:121626. doi: 10.1016/j.jhazmat.2019.121626. Epub 2019 Nov 22.
REF00004270	GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activationJ Hepatol. 2012 Jan;56(1):184-91. doi: 10.1016/j.jhep.2011.07.018. Epub 2011 Aug 9.
REF00004271	Effects of long non-coding RNA Gm14461 on pain transmission in trigeminal neuralgiaJ Inflamm (Lond). 2020 Jan 3;17:1. doi: 10.1186/s12950-019-0231-1. eCollection 2020.
REF00004272	Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2)J Med Chem. 2010 Mar 25;53(6):2482-93. doi: 10.1021/jm901645u.
REF00004273	"Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinasesJ Med Chem. 2013 Mar 14;56(5):2059-73. doi: 10.1021/jm301762v. Epub 2013 Feb 26."
REF00004274	Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11)J Med Chem. 2013 Sep 26;56(18):7212-21. doi: 10.1021/jm400474r. Epub 2013 Sep 4.
REF00004275	"A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer CellsJ Med Chem. 2015 Aug 27;58(16):6559-73. doi: 10.1021/acs.jmedchem.5b00991. Epub 2015 Aug 14."
REF00004276	"Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363J Natl Cancer Inst. 2017 Mar 1;109(3):1-4. doi: 10.1093/jnci/djw320."
REF00004277	Targeted MAPK Pathway Inhibitors in Patients With Disseminated Pilocytic AstrocytomasJ Natl Compr Canc Netw. 2017 Aug;15(8):978-982. doi: 10.6004/jnccn.2017.0139.
REF00004278	Concurrent BRAF/MEK Inhibitors in BRAF V600-Mutant High-Grade Primary Brain TumorsJ Natl Compr Canc Netw. 2018 Apr;16(4):343-347. doi: 10.6004/jnccn.2017.7052.
REF00004279	First-Line Treatment of Widely Metastatic BRAF-Mutated Salivary Duct Carcinoma With Combined BRAF and MEK InhibitionJ Natl Compr Canc Netw. 2018 Oct;16(10):1166-1170. doi: 10.6004/jnccn.2018.7056.
REF00004280	"Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in OncologyJ Natl Compr Canc Netw. 2019 Apr 1;17(4):367-402. doi: 10.6004/jnccn.2019.0018."
REF00004281	KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid CancerJ Natl Compr Canc Netw. 2019 May 1;17(5):409-413. doi: 10.6004/jnccn.2019.7292.
REF00004282	Intranasal Delivery of lincRNA-Cox2 siRNA Loaded Extracellular Vesicles Decreases Lipopolysaccharide-Induced Microglial Proliferation in MiceJ Neuroimmune Pharmacol. 2020 Sep;15(3):390-399. doi: 10.1007/s11481-019-09864-z. Epub 2019 Jul 20.
REF00004283	Low Long Noncoding RNA Growth Arrest-Specific Transcript 5 Expression in the Exosomes of Lung Cancer Cells Promotes Tumor AngiogenesisJ Oncol. 2019 May 2;2019:2476175. doi: 10.1155/2019/2476175. eCollection 2019.
REF00004284	Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancerJ Ovarian Res. 2016 May 14;9(1):27. doi: 10.1186/s13048-016-0239-6.
REF00004285	SF3B1 mutations constitute a novel therapeutic target in breast cancerJ Pathol. 2015 Mar;235(4):571-80. doi: 10.1002/path.4483. Epub 2014 Dec 22.
REF00004286	LncRNA MALAT1 regulates inflammatory cytokine production in lipopolysaccharide-stimulated human gingival fibroblasts through sponging miR-20a and activating TLR4 pathwayJ Periodontal Res. 2020 Apr;55(2):182-190. doi: 10.1111/jre.12700. Epub 2019 Sep 25.
REF00004287	Melatonin and inflammation-Story of a double-edged bladeJ Pineal Res. 2018 Nov;65(4):e12525. doi: 10.1111/jpi.12525. Epub 2018 Oct 12.
REF00004288	PIK3CA mutation status in Japanese esophageal squamous cell carcinomaJ Surg Res. 2008 Apr;145(2):320-6. doi: 10.1016/j.jss.2007.03.044. Epub 2008 Feb 11.
REF00004289	C609T polymorphism of NAD(P)H quinone oxidoreductase 1 as a predictive biomarker for response to amrubicinJ Thorac Oncol. 2011 Nov;6(11):1826-32. doi: 10.1097/JTO.0b013e318229137d.
REF00004290	RET mutation and expression in small-cell lung cancerJ Thorac Oncol. 2014 Sep;9(9):1316-23. doi: 10.1097/JTO.0000000000000234.
REF00004291	Intracranial Activity of Cabozantinib in MET Exon 14-Positive NSCLC with Brain MetastasesJ Thorac Oncol. 2017 Jan;12(1):152-156. doi: 10.1016/j.jtho.2016.09.127. Epub 2016 Sep 28.
REF00004292	Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to CrizotinibJ Thorac Oncol. 2018 Apr;13(4):e49-e53. doi: 10.1016/j.jtho.2017.10.028. Epub 2017 Nov 8.
REF00004293	"First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of ResistanceJ Thorac Oncol. 2018 Jul;13(7):968-977. doi: 10.1016/j.jtho.2018.03.025. Epub 2018 Apr 4."
REF00004294	Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In VitroJ Thorac Oncol. 2019 Oct;14(10):1753-1765. doi: 10.1016/j.jtho.2019.06.023. Epub 2019 Jul 3.
REF00004295	Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer modelsJ Thyroid Res. 2014;2014:638747. doi: 10.1155/2014/638747. Epub 2014 Sep 10.
REF00004296	"The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to TaxotereJ Transl Med. 2013 Oct 2;11:241. doi: 10.1186/1479-5876-11-241."
REF00004297	The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemiaJCI Insight. 2016 Mar;1(3):e85630. doi: 10.1172/jci.insight.85630.
REF00004298	"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisLancet Oncol. 2010 Aug;11(8):753-62. doi: 10.1016/S1470-2045(10)70130-3. Epub 2010 Jul 8."
REF00004299	"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialLancet Oncol. 2010 Feb;11(2):121-8. doi: 10.1016/S1470-2045(09)70364-X. Epub 2009 Dec 18."
REF00004300	Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trialLancet Oncol. 2012 Aug;13(8):782-9. doi: 10.1016/S1470-2045(12)70269-3. Epub 2012 Jul 16.
REF00004301	"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialLancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26."
REF00004302	Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trialLancet Oncol. 2012 May;13(5):539-48. doi: 10.1016/S1470-2045(12)70086-4. Epub 2012 Mar 26.
REF00004303	"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trialLancet Oncol. 2012 Nov;13(11):1087-95. doi: 10.1016/S1470-2045(12)70431-X. Epub 2012 Oct 8."
REF00004304	"MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 studyLancet Oncol. 2013 Mar;14(3):249-56. doi: 10.1016/S1470-2045(13)70024-X. Epub 2013 Feb 13."
REF00004305	Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b studyLancet Oncol. 2014 Aug;15(9):954-65. doi: 10.1016/S1470-2045(14)70301-8. Epub 2014 Jul 15.
REF00004306	"Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyLancet Oncol. 2014 Mar;15(3):323-32. doi: 10.1016/S1470-2045(14)70012-9. Epub 2014 Feb 7."
REF00004307	"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsLancet Oncol. 2015 Feb;16(2):141-51. doi: 10.1016/S1470-2045(14)71173-8. Epub 2015 Jan 12."
REF00004308	"Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trialLancet Oncol. 2016 Jul;17(7):984-993. doi: 10.1016/S1470-2045(16)30146-2. Epub 2016 Jun 6."
REF00004309	"Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trialLancet Oncol. 2016 May;17(5):642-50. doi: 10.1016/S1470-2045(16)00077-2. Epub 2016 Apr 11."
REF00004310	"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trialLancet Oncol. 2016 Sep;17(9):1248-60. doi: 10.1016/S1470-2045(16)30122-X. Epub 2016 Jul 30."
REF00004311	"Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF(V600)-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trialLancet Oncol. 2017 Apr;18(4):464-472. doi: 10.1016/S1470-2045(17)30171-7. Epub 2017 Mar 4."
REF00004312	"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trialLancet Oncol. 2017 Jan;18(1):75-87. doi: 10.1016/S1470-2045(16)30559-9. Epub 2016 Nov 29."
REF00004313	"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trialLancet Oncol. 2017 Nov;18(11):1454-1466. doi: 10.1016/S1470-2045(17)30608-3. Epub 2017 Sep 25."
REF00004314	"Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trialLancet Oncol. 2017 Oct;18(10):1307-1316. doi: 10.1016/S1470-2045(17)30679-4. Epub 2017 Sep 11."
REF00004315	"Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trialLancet Oncol. 2018 Feb;19(2):181-193. doi: 10.1016/S1470-2045(18)30015-9. Epub 2018 Jan 18."
REF00004316	"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trialLancet Oncol. 2018 May;19(5):603-615. doi: 10.1016/S1470-2045(18)30142-6. Epub 2018 Mar 21."
REF00004317	"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trialLancet Oncol. 2018 Oct;19(10):1315-1327. doi: 10.1016/S1470-2045(18)30497-2. Epub 2018 Sep 12."
REF00004318	"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trialLancet Oncol. 2019 Jul;20(7):1011-1022. doi: 10.1016/S1470-2045(19)30277-3. Epub 2019 May 28."
REF00004319	"Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trialLancet Respir Med. 2017 May;5(5):435-444. doi: 10.1016/S2213-2600(17)30129-7. Epub 2017 Apr 10."
REF00004320	Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trialLancet. 2006 Oct 14;368(9544):1329-38. doi: 10.1016/S0140-6736(06)69446-4.
REF00004321	Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndromeLancet. 2008 Oct 25;372(9648):1484-92. doi: 10.1016/S0140-6736(08)61341-0. Epub 2008 Sep 19.
REF00004322	"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialLancet. 2012 Jul 28;380(9839):358-65. doi: 10.1016/S0140-6736(12)60868-X. Epub 2012 Jun 25."
REF00004323	"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trialLancet. 2012 May 19;379(9829):1893-901. doi: 10.1016/S0140-6736(12)60398-5."
REF00004324	"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trialLancet. 2013 Jan 26;381(9863):295-302. doi: 10.1016/S0140-6736(12)61857-1. Epub 2012 Nov 22."
REF00004325	Identification of mutant alleles of JAK3 in pediatric patients with acute lymphoblastic leukemiaLeuk Lymphoma. 2015 May;56(5):1502-6. doi: 10.3109/10428194.2014.957204. Epub 2015 Jan 21.
REF00004326	Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemiaLeuk Res Rep. 2014 Aug 1;3(2):67-9. doi: 10.1016/j.lrr.2014.07.002. eCollection 2014.
REF00004327	"A phase 1 study of the Janus kinase 2 (JAK2)(V617F) inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemiaLeuk Res. 2017 Oct;61:89-95. doi: 10.1016/j.leukres.2017.08.010. Epub 2017 Aug 31."
REF00004328	Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitorLeukemia. 2002 Oct;16(10):2027-36. doi: 10.1038/sj.leu.2402674.
REF00004329	"AS602868, a dual inhibitor of IKK2 and FLT3 to target AML cellsLeukemia. 2007 May;21(5):877-85. doi: 10.1038/sj.leu.2404614. Epub 2007 Mar 1."
REF00004330	"Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2Leukemia. 2012 Feb;26(2):280-8. doi: 10.1038/leu.2011.292. Epub 2011 Oct 21."
REF00004331	AKT is a therapeutic target in myeloproliferative neoplasmsLeukemia. 2013 Sep;27(9):1882-90. doi: 10.1038/leu.2013.167. Epub 2013 Jun 10.
REF00004332	Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivoLeukemia. 2017 Oct;31(10):2020-2028. doi: 10.1038/leu.2017.46. Epub 2017 Jan 31.
REF00004333	Selective inhibition of leukemia-associated SHP2(E69K) mutant by the allosteric SHP2 inhibitor SHP099Leukemia. 2018 May;32(5):1246-1249. doi: 10.1038/s41375-018-0020-5. Epub 2018 Jan 30.
REF00004334	Time resolved quantitative phospho-tyrosine analysis reveals Bruton's Tyrosine kinase mediated signaling downstream of the mutated granulocyte-colony stimulating factor receptorsLeukemia. 2019 Jan;33(1):75-87. doi: 10.1038/s41375-018-0188-8. Epub 2018 Jul 5.
REF00004335	Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF(V600E) mutant cancerLife Sci. 2017 Aug 15;183:37-44. doi: 10.1016/j.lfs.2017.06.021. Epub 2017 Jun 21.
REF00004336	Knockdown of lncRNA MALAT1 alleviates bupivacaine-induced neurotoxicity via the miR-101-3p/PDCD4 axisLife Sci. 2019 Sep 1;232:116606. doi: 10.1016/j.lfs.2019.116606. Epub 2019 Jun 27.
REF00004337	Sinomenine retards LPS-elicited inflammation via down-regulating CCAT1 in HaCaT cellsLife Sci. 2019 Sep 15;233:116703. doi: 10.1016/j.lfs.2019.116703. Epub 2019 Jul 26.
REF00004338	Knockdown of lncRNA MFI2-AS1 inhibits lipopolysaccharide-induced osteoarthritis progression by miR-130a-3p/TCF4Life Sci. 2020 Jan 1;240:117019. doi: 10.1016/j.lfs.2019.117019. Epub 2019 Oct 31.
REF00004339	Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study)Lung Cancer. 2016 Dec;102:30-37. doi: 10.1016/j.lungcan.2016.10.007. Epub 2016 Oct 20.
REF00004340	"ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer modelsLung Cancer. 2016 May;95:57-64. doi: 10.1016/j.lungcan.2016.02.013. Epub 2016 Feb 27."
REF00004341	"Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro studyLung Cancer. 2018 Dec;126:72-79. doi: 10.1016/j.lungcan.2018.10.019. Epub 2018 Oct 17."
REF00004342	Case Report: Osimertinib achieved remarkable and sustained disease control in an advanced non-small-cell lung cancer harboring EGFR H773L/V774M mutation complexLung Cancer. 2018 Jul;121:1-4. doi: 10.1016/j.lungcan.2018.04.006. Epub 2018 Apr 5.
REF00004343	Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature reviewMed Oncol. 2012 Jun;29(2):704-6. doi: 10.1007/s12032-011-9884-1. Epub 2011 Mar 6.
REF00004344	lincRNA-p21 Mediates the Anti-Cancer Effect of Ginkgo Biloba Extract EGb 761 by Stabilizing E-Cadherin Protein in Colon CancerMed Sci Monit. 2018 Dec 30;24:9488-9496. doi: 10.12659/MSM.911924.
REF00004345	Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanomaMelanoma Res. 2014 Oct;24(5):504-8. doi: 10.1097/CMR.0000000000000099.
REF00004346	LncRNA MEG3 functions as a ceRNA in regulating hepatic lipogenesis by competitively binding to miR-21 with LRP6Metabolism. 2019 May;94:1-8. doi: 10.1016/j.metabol.2019.01.018. Epub 2019 Feb 1.
REF00004347	Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell linesMol Cancer Res. 2007 Feb;5(2):195-201. doi: 10.1158/1541-7786.MCR-06-0263.
REF00004348	"Identification of an ""Exceptional Responder"" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted TherapyMol Cancer Res. 2016 Feb;14(2):207-15. doi: 10.1158/1541-7786.MCR-15-0321. Epub 2015 Nov 18."
REF00004349	Effects of Oncogenic GAlpha(q) and GAlpha(11) Inhibition by FR900359 in Uveal MelanomaMol Cancer Res. 2019 Apr;17(4):963-973. doi: 10.1158/1541-7786.MCR-18-0574. Epub 2018 Dec 19.
REF00004350	The FGFR1 V561M Gatekeeper Mutation Drives AZD4547 Resistance through STAT3 Activation and EMTMol Cancer Res. 2019 Feb;17(2):532-543. doi: 10.1158/1541-7786.MCR-18-0429. Epub 2018 Sep 26.
REF00004351	Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cellsMol Cancer Ther. 2006 May;5(5):1154-65. doi: 10.1158/1535-7163.MCT-05-0446.
REF00004352	BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitorsMol Cancer Ther. 2008 Apr;7(4):737-9. doi: 10.1158/1535-7163.MCT-08-0145. Epub 2008 Mar 28.
REF00004353	"Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitorMol Cancer Ther. 2010 Apr;9(4):976-84. doi: 10.1158/1535-7163.MCT-09-0954. Epub 2010 Apr 6."
REF00004354	PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitorsMol Cancer Ther. 2011 Mar;10(3):558-65. doi: 10.1158/1535-7163.MCT-10-0994. Epub 2011 Jan 7.
REF00004355	"PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activityMol Cancer Ther. 2011 Nov;10(11):2189-99. doi: 10.1158/1535-7163.MCT-11-0185. Epub 2011 Jul 12."
REF00004356	"Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic backgroundMol Cancer Ther. 2012 Apr;11(4):873-87. doi: 10.1158/1535-7163.MCT-11-0824-T. Epub 2012 Jan 31."
REF00004357	"Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutationsMol Cancer Ther. 2012 Apr;11(4):909-20. doi: 10.1158/1535-7163.MCT-11-0989. Epub 2012 Mar 2."
REF00004358	CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activityMol Cancer Ther. 2012 Apr;11(4):930-41. doi: 10.1158/1535-7163.MCT-11-0645. Epub 2012 Feb 7.
REF00004359	"CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancersMol Cancer Ther. 2012 Mar;11(3):670-9. doi: 10.1158/1535-7163.MCT-11-0776. Epub 2011 Dec 27."
REF00004360	"Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer modelsMol Cancer Ther. 2012 Mar;11(3):690-9. doi: 10.1158/1535-7163.MCT-11-0450. Epub 2012 Jan 11."
REF00004361	Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-kB pathwaysMol Cancer Ther. 2012 Sep;11(9):1905-14. doi: 10.1158/1535-7163.MCT-12-0121. Epub 2012 May 31.
REF00004362	"VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancerMol Cancer Ther. 2013 Feb;12(2):151-61. doi: 10.1158/1535-7163.MCT-12-0466. Epub 2012 Dec 27."
REF00004363	The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomasMol Cancer Ther. 2013 Oct;12(10):1994-2005. doi: 10.1158/1535-7163.MCT-13-0206. Epub 2013 Jul 19.
REF00004364	Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical modelMol Cancer Ther. 2014 Apr;13(4):823-32. doi: 10.1158/1535-7163.MCT-13-0667. Epub 2014 Jan 21.
REF00004365	Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphomaMol Cancer Ther. 2014 Apr;13(4):842-54. doi: 10.1158/1535-7163.MCT-13-0773. Epub 2014 Feb 21.
REF00004366	Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespibMol Cancer Ther. 2014 Feb;13(2):353-63. doi: 10.1158/1535-7163.MCT-13-0481. Epub 2014 Jan 7.
REF00004367	Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathwayMol Cancer Ther. 2014 May;13(5):1078-91. doi: 10.1158/1535-7163.MCT-13-0709. Epub 2014 Mar 14.
REF00004368	"The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitorMol Cancer Ther. 2014 Nov;13(11):2547-58. doi: 10.1158/1535-7163.MCT-14-0248. Epub 2014 Aug 28."
REF00004369	ATF4 Gene Network Mediates Cellular Response to the Anticancer PAD Inhibitor YW3-56 in Triple-Negative Breast Cancer CellsMol Cancer Ther. 2015 Apr;14(4):877-88. doi: 10.1158/1535-7163.MCT-14-1093-T. Epub 2015 Jan 22.
REF00004370	The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor ModelsMol Cancer Ther. 2015 Apr;14(4):931-40. doi: 10.1158/1535-7163.MCT-14-0833. Epub 2015 Jan 30.
REF00004371	Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene AlterationsMol Cancer Ther. 2015 Aug;14(8):1916-27. doi: 10.1158/1535-7163.MCT-14-0892. Epub 2015 May 26.
REF00004372	"ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR InhibitorMol Cancer Ther. 2015 Dec;14(12):2831-9. doi: 10.1158/1535-7163.MCT-15-0497. Epub 2015 Oct 5."
REF00004373	The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK ExpressionMol Cancer Ther. 2015 Jun;14(6):1354-64. doi: 10.1158/1535-7163.MCT-14-0832. Epub 2015 Apr 14.
REF00004374	Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT InhibitorsMol Cancer Ther. 2015 Nov;14(11):2441-51. doi: 10.1158/1535-7163.MCT-15-0230. Epub 2015 Sep 8.
REF00004375	"BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal CancersMol Cancer Ther. 2015 Oct;14(10):2187-97. doi: 10.1158/1535-7163.MCT-15-0262. Epub 2015 Jul 24."
REF00004376	Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer CellsMol Cancer Ther. 2015 Oct;14(10):2292-302. doi: 10.1158/1535-7163.MCT-15-0032. Epub 2015 Aug 20.
REF00004377	"Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2Mol Cancer Ther. 2015 Sep;14(9):2023-34. doi: 10.1158/1535-7163.MCT-14-1105. Epub 2015 Aug 18."
REF00004378	The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid CancerMol Cancer Ther. 2016 Aug;15(8):1952-63. doi: 10.1158/1535-7163.MCT-15-0702. Epub 2016 May 24.
REF00004379	Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT MutationsMol Cancer Ther. 2016 Dec;15(12):2845-2852. doi: 10.1158/1535-7163.MCT-16-0224. Epub 2016 Oct 24.
REF00004380	"A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in MiceMol Cancer Ther. 2016 Jun;15(6):1163-76. doi: 10.1158/1535-7163.MCT-15-0973. Epub 2016 Apr 5."
REF00004381	Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR TherapiesMol Cancer Ther. 2016 May;15(5):1106-12. doi: 10.1158/1535-7163.MCT-15-0820. Epub 2016 Apr 1.
REF00004382	"Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell CarcinomaMol Cancer Ther. 2016 May;15(5):866-76. doi: 10.1158/1535-7163.MCT-15-0729-T. Epub 2016 Jan 28."
REF00004383	"Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3KAlpha and PI3K Delta, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast CancersMol Cancer Ther. 2016 May;15(5):877-89. doi: 10.1158/1535-7163.MCT-15-0687. Epub 2016 Feb 2."
REF00004384	"AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer PatientsMol Cancer Ther. 2016 Nov;15(11):2586-2597. doi: 10.1158/1535-7163.MCT-16-0281. Epub 2016 Aug 29."
REF00004385	"E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical ModelsMol Cancer Ther. 2016 Nov;15(11):2630-2639. doi: 10.1158/1535-7163.MCT-16-0261. Epub 2016 Aug 17."
REF00004386	"BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid LeukemiaMol Cancer Ther. 2016 Oct;15(10):2323-2333. doi: 10.1158/1535-7163.MCT-15-1006. Epub 2016 Aug 10."
REF00004387	"Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor GrowthMol Cancer Ther. 2016 Oct;15(10):2344-2356. doi: 10.1158/1535-7163.MCT-15-0996. Epub 2016 Jul 20."
REF00004388	APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal CancerMol Cancer Ther. 2017 Apr;16(4):752-762. doi: 10.1158/1535-7163.MCT-16-0578. Epub 2017 Feb 8.
REF00004389	The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug ClearanceMol Cancer Ther. 2017 Dec;16(12):2668-2676. doi: 10.1158/1535-7163.MCT-17-0309. Epub 2017 Oct 4.
REF00004390	N-Arachidonoyl Dopamine Inhibits NRAS Neoplastic Transformation by Suppressing Its Plasma Membrane TranslocationMol Cancer Ther. 2017 Jan;16(1):57-67. doi: 10.1158/1535-7163.MCT-16-0419. Epub 2016 Oct 19.
REF00004391	Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)Mol Cancer Ther. 2017 Nov;16(11):2351-2363. doi: 10.1158/1535-7163.MCT-17-0456. Epub 2017 Sep 22.
REF00004392	TTK Inhibitors as a Targeted Therapy for CTNNB1 (Beta-catenin) Mutant CancersMol Cancer Ther. 2017 Nov;16(11):2609-2617. doi: 10.1158/1535-7163.MCT-17-0342. Epub 2017 Jul 27.
REF00004393	Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged CancersMol Cancer Ther. 2017 Oct;16(10):2130-2143. doi: 10.1158/1535-7163.MCT-16-0909. Epub 2017 Jul 27.
REF00004394	Wnt/Beta-catenin Signaling Contributes to Tumor Malignancy and Is Targetable in Gastrointestinal Stromal TumorMol Cancer Ther. 2017 Sep;16(9):1954-1966. doi: 10.1158/1535-7163.MCT-17-0139. Epub 2017 Jun 13.
REF00004395	"Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung CancerMol Cancer Ther. 2018 Apr;17(4):740-750. doi: 10.1158/1535-7163.MCT-17-1033. Epub 2018 Feb 21."
REF00004396	"TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion MutationsMol Cancer Ther. 2018 Aug;17(8):1648-1658. doi: 10.1158/1535-7163.MCT-17-1206. Epub 2018 May 10."
REF00004397	Molecular Basis for Necitumumab Inhibition of EGFR Variants Associated with Acquired Cetuximab ResistanceMol Cancer Ther. 2018 Feb;17(2):521-531. doi: 10.1158/1535-7163.MCT-17-0575. Epub 2017 Nov 20.
REF00004398	"Discovery of A Novel EGFR-Targeting Antibody-Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR TherapiesMol Cancer Ther. 2019 Jun;18(6):1104-1114. doi: 10.1158/1535-7163.MCT-18-0854. Epub 2019 Apr 8."
REF00004399	"TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various EGFR Mutations Including T790M and Uncommon Mutations G719XMol Cancer Ther. 2019 May;18(5):920-928. doi: 10.1158/1535-7163.MCT-18-0645. Epub 2019 Mar 14."
REF00004400	Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell linesMol Cancer. 2012 Apr 19;11:22. doi: 10.1186/1476-4598-11-22.
REF00004401	Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanomaMol Cancer. 2014 Apr 16;13:83. doi: 10.1186/1476-4598-13-83.
REF00004402	"PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activationMol Cancer. 2017 Jun 28;16(1):112. doi: 10.1186/s12943-017-0684-x."
REF00004403	m(6)A-induced lncRNA RP11 triggers the dissemination of colorectal cancer cells via upregulation of Zeb1Mol Cancer. 2019 Apr 13;18(1):87. doi: 10.1186/s12943-019-1014-2.
REF00004404	Exosome-mediated lncRNA AFAP1-AS1 promotes trastuzumab resistance through binding with AUF1 and activating ERBB2 translationMol Cancer. 2020 Feb 5;19(1):26. doi: 10.1186/s12943-020-1145-5.
REF00004405	A novel IFNAlpha-induced long noncoding RNA negatively regulates immunosuppression by interrupting H3K27 acetylation in head and neck squamous cell carcinomaMol Cancer. 2020 Jan 6;19(1):4. doi: 10.1186/s12943-019-1123-y.
REF00004406	Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352Mol Cell Biol. 2002 Nov;22(21):7593-602. doi: 10.1128/MCB.22.21.7593-7602.2002.
REF00004407	YAP inhibition blocks uveal melanogenesis driven by GNAQ or GNA11 mutationsMol Cell Oncol. 2014 Dec 1;2(1):e970957. doi: 10.4161/23723548.2014.970957. eCollection 2015 Jan-Mar.
REF00004408	Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600EMol Cell Probes. 2004 Oct;18(5):349-52. doi: 10.1016/j.mcp.2004.05.004.
REF00004409	Hsa-miR-346 plays a role in the development of sepsis by downregulating SMAD3 expression and is negatively regulated by lncRNA MALAT1Mol Cell Probes. 2019 Oct;47:101444. doi: 10.1016/j.mcp.2019.101444. Epub 2019 Sep 5.
REF00004410	Indole-3-acetic acid has long-term effects on long non-coding RNA gene methylation and growth in Populus tomentosaMol Genet Genomics. 2019 Dec;294(6):1511-1525. doi: 10.1007/s00438-019-01593-5. Epub 2019 Jul 19.
REF00004411	Expression of cyclooxygenase-2 is correlated with lncRNA-COX-2 in cirrhotic mice induced by carbon tetrachlorideMol Med Rep. 2017 Apr;15(4):1507-1512. doi: 10.3892/mmr.2017.6161. Epub 2017 Feb 2.
REF00004412	Role of lncRNA uc.457 in the differentiation and maturation of cardiomyocytesMol Med Rep. 2019 Jun;19(6):4927-4934. doi: 10.3892/mmr.2019.10132. Epub 2019 Apr 4.
REF00004413	LncRNA BANCR participates in polycystic ovary syndrome by promoting cell apoptosisMol Med Rep. 2019 Mar;19(3):1581-1586. doi: 10.3892/mmr.2018.9793. Epub 2018 Dec 24.
REF00004414	Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancerMol Pathol. 2003 Oct;56(5):286-92. doi: 10.1136/mp.56.5.286.
REF00004415	Knockdown of Long Noncoding RNAs Hepatocyte Nuclear Factor 1Alpha Antisense RNA 1 and Hepatocyte Nuclear Factor 4Alpha Antisense RNA 1 Alters Susceptibility of Acetaminophen-Induced Cytotoxicity in HepaRG CellsMol Pharmacol. 2020 Apr;97(4):278-286. doi: 10.1124/mol.119.118778. Epub 2020 Feb 6.
REF00004416	Astrocyte EV-Induced lincRNA-Cox2 Regulates Microglial Phagocytosis: Implications for Morphine-Mediated NeurodegenerationMol Ther Nucleic Acids. 2018 Dec 7;13:450-463. doi: 10.1016/j.omtn.2018.09.019. Epub 2018 Sep 29.
REF00004417	Melatonin Regulates Breast Cancer Progression by the lnc010561/miR-30/FKBP3 AxisMol Ther Nucleic Acids. 2020 Mar 6;19:765-774. doi: 10.1016/j.omtn.2019.12.019. Epub 2019 Dec 24.
REF00004418	Long noncoding RNA glutathione peroxidase 3-antisense inhibits lens epithelial cell apoptosis by upregulating glutathione peroxidase 3 expression in age-related cataractMol Vis. 2019 Nov 14;25:734-744. eCollection 2019.
REF00004419	Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotypeN Engl J Med. 2005 Jan 20;352(3):254-66. doi: 10.1056/NEJMoa041974.
REF00004420	Molecular determinants of the response of glioblastomas to EGFR kinase inhibitorsN Engl J Med. 2005 Nov 10;353(19):2012-24. doi: 10.1056/NEJMoa051918.
REF00004421	HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancerN Engl J Med. 2006 Jun 15;354(24):2619-21. doi: 10.1056/NEJMc060020.
REF00004422	Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med. 2009 Sep 3;361(10):947-57. doi: 10.1056/NEJMoa0810699. Epub 2009 Aug 19.
REF00004423	Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med. 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530.
REF00004424	MYD88 L265P somatic mutation in Waldenstr m's macroglobulinemiaN Engl J Med. 2012 Aug 30;367(9):826-33. doi: 10.1056/NEJMoa1200710.
REF00004425	Improved survival with MEK inhibition in BRAF-mutated melanomaN Engl J Med. 2012 Jul 12;367(2):107-14. doi: 10.1056/NEJMoa1203421. Epub 2012 Jun 4.
REF00004426	Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutationsN Engl J Med. 2012 Nov 1;367(18):1694-703. doi: 10.1056/NEJMoa1210093. Epub 2012 Sep 29.
REF00004427	Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CMLN Engl J Med. 2013 May 9;368(19):1781-90. doi: 10.1056/NEJMoa1214514.
REF00004428	Combined vemurafenib and cobimetinib in BRAF-mutated melanomaN Engl J Med. 2014 Nov 13;371(20):1867-76. doi: 10.1056/NEJMoa1408868. Epub 2014 Sep 29.
REF00004429	Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanomaN Engl J Med. 2014 Nov 13;371(20):1877-88. doi: 10.1056/NEJMoa1406037. Epub 2014 Sep 29.
REF00004430	Improved overall survival in melanoma with combined dabrafenib and trametinibN Engl J Med. 2015 Jan 1;372(1):30-9. doi: 10.1056/NEJMoa1412690. Epub 2014 Nov 16.
REF00004431	Response to Idelalisib in a Patient with Stage IV Merkel-Cell CarcinomaN Engl J Med. 2015 Oct 15;373(16):1580-2. doi: 10.1056/NEJMc1507446.
REF00004432	Clinical Improvement with JAK2 Inhibition in Chuvash PolycythemiaN Engl J Med. 2016 Aug 4;375(5):494-6. doi: 10.1056/NEJMc1600337.
REF00004433	Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198FN Engl J Med. 2016 Jan 7;374(1):54-61. doi: 10.1056/NEJMoa1508887. Epub 2015 Dec 23.
REF00004434	Efficacy and Safety of Midostaurin in Advanced Systemic MastocytosisN Engl J Med. 2016 Jun 30;374(26):2530-41. doi: 10.1056/NEJMoa1513098.
REF00004435	Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 MutationN Engl J Med. 2017 Aug 3;377(5):454-464. doi: 10.1056/NEJMoa1614359. Epub 2017 Jun 23.
REF00004436	Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated MelanomaN Engl J Med. 2017 Nov 9;377(19):1813-1823. doi: 10.1056/NEJMoa1708539. Epub 2017 Sep 10.
REF00004437	Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and ChildrenN Engl J Med. 2018 Feb 22;378(8):731-739. doi: 10.1056/NEJMoa1714448.
REF00004438	Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung CancerN Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.
REF00004439	Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AMLN Engl J Med. 2018 Jun 21;378(25):2386-2398. doi: 10.1056/NEJMoa1716984. Epub 2018 Jun 2.
REF00004440	Erdafitinib in Locally Advanced or Metastatic Urothelial CarcinomaN Engl J Med. 2019 Jul 25;381(4):338-348. doi: 10.1056/NEJMoa1817323.
REF00004441	"Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast CancerN Engl J Med. 2019 May 16;380(20):1929-1940. doi: 10.1056/NEJMoa1813904."
REF00004442	"Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal CancerN Engl J Med. 2019 Oct 24;381(17):1632-1643. doi: 10.1056/NEJMoa1908075. Epub 2019 Sep 30."
REF00004443	Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung CancerN Engl J Med. 2020 Aug 27;383(9):813-824. doi: 10.1056/NEJMoa2005653.
REF00004444	"RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancersNat Cell Biol. 2018 Sep;20(9):1064-1073. doi: 10.1038/s41556-018-0169-1. Epub 2018 Aug 13."
REF00004445	A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cellsNat Chem Biol. 2012 Nov;8(11):890-6. doi: 10.1038/nchembio.1084. Epub 2012 Sep 30.
REF00004446	New IDH1 mutant inhibitors for treatment of acute myeloid leukemiaNat Chem Biol. 2015 Nov;11(11):878-86. doi: 10.1038/nchembio.1930. Epub 2015 Oct 5.
REF00004447	An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EEDNat Chem Biol. 2017 Apr;13(4):381-388. doi: 10.1038/nchembio.2304. Epub 2017 Jan 30.
REF00004448	Inhibition of RAS function through targeting an allosteric regulatory siteNat Chem Biol. 2017 Jan;13(1):62-68. doi: 10.1038/nchembio.2231. Epub 2016 Nov 7.
REF00004449	ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1ANat Commun. 2016 Dec 13;7:13837. doi: 10.1038/ncomms13837.
REF00004450	Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patientsNat Commun. 2018 Apr 10;9(1):1357. doi: 10.1038/s41467-018-03867-9.
REF00004451	Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapiesNat Commun. 2018 Nov 2;9(1):4583. doi: 10.1038/s41467-018-06949-w.
REF00004452	Chromosome-associated RNA-protein complexes promote pairing of homologous chromosomes during meiosis in Schizosaccharomyces pombeNat Commun. 2019 Dec 6;10(1):5598. doi: 10.1038/s41467-019-13609-0.
REF00004453	SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancerNat Commun. 2019 Feb 4;10(1):557. doi: 10.1038/s41467-019-08380-1.
REF00004454	Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanismsNat Commun. 2019 Jan 16;10(1):244. doi: 10.1038/s41467-018-08263-x.
REF00004455	Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutationsNat Commun. 2019 Jun 3;10(1):2385. doi: 10.1038/s41467-019-10363-1.
REF00004456	The Firre locus produces a trans-acting RNA molecule that functions in hematopoiesisNat Commun. 2019 Nov 13;10(1):5137. doi: 10.1038/s41467-019-12970-4.
REF00004457	Long non-coding RNA RAMS11 promotes metastatic colorectal cancer progressionNat Commun. 2020 May 1;11(1):2156. doi: 10.1038/s41467-020-15547-8.
REF00004458	The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapiesNat Genet. 2015 Mar;47(3):250-6. doi: 10.1038/ng.3218. Epub 2015 Feb 9.
REF00004459	Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNat Med. 2008 Dec;14(12):1351-6. doi: 10.1038/nm.1890. Epub 2008 Nov 30.
REF00004460	"Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicineNat Med. 2014 Jun;20(6):682-8. doi: 10.1038/nm.3559. Epub 2014 May 18."
REF00004461	Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancerNat Med. 2018 May;24(5):638-646. doi: 10.1038/s41591-018-0007-9. Epub 2018 Apr 23.
REF00004462	RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signalingNat Med. 2019 Feb;25(2):284-291. doi: 10.1038/s41591-018-0274-5. Epub 2018 Dec 17.
REF00004463	Mutations of the BRAF gene in human cancerNature. 2002 Jun 27;417(6892):949-54. doi: 10.1038/nature00766. Epub 2002 Jun 9.
REF00004464	A transforming mutation in the pleckstrin homology domain of AKT1 in cancerNature. 2007 Jul 26;448(7152):439-44. doi: 10.1038/nature05933. Epub 2007 Jul 4.
REF00004465	Frequent somatic mutations of GNAQ in uveal melanoma and blue naeviNature. 2009 Jan 29;457(7229):599-602. doi: 10.1038/nature07586. Epub 2008 Dec 10.
REF00004466	Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancersNature. 2013 Sep 12;501(7466):232-6. doi: 10.1038/nature12441. Epub 2013 Aug 11.
REF00004467	Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatmentNature. 2015 Jul 16;523(7560):352-6. doi: 10.1038/nature14430. Epub 2015 May 25.
REF00004468	Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformationNature. 2015 Mar 5;519(7541):102-5. doi: 10.1038/nature14119. Epub 2015 Feb 9.
REF00004469	RAF inhibitors that evade paradoxical MAPK pathway activationNature. 2015 Oct 22;526(7574):583-6. doi: 10.1038/nature14982. Epub 2015 Oct 14.
REF00004470	Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinasesNature. 2016 Jul 7;535(7610):148-52. doi: 10.1038/nature18621. Epub 2016 Jun 29.
REF00004471	Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitorsNature. 2016 Jun 2;534(7605):129-32. doi: 10.1038/nature17960. Epub 2016 May 25.
REF00004472	Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RASNature. 2017 Aug 10;548(7666):234-238. doi: 10.1038/nature23291. Epub 2017 Aug 2.
REF00004473	HER kinase inhibition in patients with HER2- and HER3-mutant cancersNature. 2018 Feb 8;554(7691):189-194. doi: 10.1038/nature25475. Epub 2018 Jan 31.
REF00004474	Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescenceNature. 2018 Jan 18;553(7688):351-355. doi: 10.1038/nature25170. Epub 2018 Jan 10.
REF00004475	Efficacy of MEK inhibition in patients with histiocytic neoplasmsNature. 2019 Mar;567(7749):521-524. doi: 10.1038/s41586-019-1012-y. Epub 2019 Mar 13.
REF00004476	"The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitorsNeoplasia. 2013 Aug;15(8):975-88. doi: 10.1593/neo.121106."
REF00004477	Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in MelanomaNeoplasia. 2016 Feb;18(2):121-32. doi: 10.1016/j.neo.2016.01.003.
REF00004478	Roscovitine-induced apoptosis of H1299 cells depends on functional status of p53Neoplasma. 2012;59(6):606-12. doi: 10.4149/neo_2012_077.
REF00004479	Steroid receptor RNA activator affects the development of poststroke depression by regulating the peroxisome proliferator-activated receptor Gamma signaling pathwayNeuroreport. 2020 Jan 8;31(1):48-56. doi: 10.1097/WNR.0000000000001367.
REF00004480	NEAT1 regulates MPP(+)-induced neuronal injury by targeting miR-124 in neuroblastoma cellsNeurosci Lett. 2019 Aug 24;708:134340. doi: 10.1016/j.neulet.2019.134340. Epub 2019 Jun 19.
REF00004481	Clinical responses to ERK inhibition in BRAF(V600E)-mutant colorectal cancer predicted using a computational modelNPJ Syst Biol Appl. 2017 Jun 2;3:14. doi: 10.1038/s41540-017-0016-1. eCollection 2017.
REF00004482	COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in CancerNucleic Acids Res. 2011 Jan;39(Database issue):D945-50. doi: 10.1093/nar/gkq929. Epub 2010 Oct 15.
REF00004483	Quantitative proteomics reveals that long non-coding RNA MALAT1 interacts with DBC1 to regulate p53 acetylationNucleic Acids Res. 2017 Sep 29;45(17):9947-9959. doi: 10.1093/nar/gkx600.
REF00004484	Long Non-Coding RNA DLEU1 Up-Regulates BIRC6 Expression by Competitively Sponging miR-381-3p to Promote Cisplatin Resistance in Nasopharyngeal CarcinomaOnco Targets Ther. 2020 Mar 9;13:2037-2045. doi: 10.2147/OTT.S237456. eCollection 2020.
REF00004485	The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3Oncogene. 2003 Oct 9;22(44):6909-18. doi: 10.1038/sj.onc.1206798.
REF00004486	Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitorsOncogene. 2004 Aug 12;23(36):6056-63. doi: 10.1038/sj.onc.1207810.
REF00004487	The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variantsOncogene. 2004 Jul 8;23(31):5387-93. doi: 10.1038/sj.onc.1207691.
REF00004488	CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutationsOncogene. 2009 Jan 8;28(1):85-94. doi: 10.1038/onc.2008.362. Epub 2008 Sep 15.
REF00004489	Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutationsOncogene. 2014 Sep 25;33(39):4724-34. doi: 10.1038/onc.2013.418. Epub 2013 Oct 21.
REF00004490	FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradationOncogene. 2017 Feb 9;36(6):787-796. doi: 10.1038/onc.2016.247. Epub 2016 Jul 11.
REF00004491	ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitorsOncogene. 2018 Aug;37(33):4611-4625. doi: 10.1038/s41388-018-0300-6. Epub 2018 May 15.
REF00004492	Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancerOncogenesis. 2013 Dec 23;2(12):e83. doi: 10.1038/oncsis.2013.46.
REF00004493	Epigenetic and genetic features of 24 colon cancer cell linesOncogenesis. 2013 Sep 16;2(9):e71. doi: 10.1038/oncsis.2013.35.
REF00004494	Silencing long intergenic non-coding RNA 00707 enhances cisplatin sensitivity in cisplatin-resistant non-small-cell lung cancer cells by sponging miR-145Oncol Lett. 2019 Dec;18(6):6261-6268. doi: 10.3892/ol.2019.10959. Epub 2019 Oct 3.
REF00004495	Long non-coding RNA NEF inhibits proliferation and promotes apoptosis of laryngeal squamous cell carcinoma cells by inhibiting Wnt/Beta-catenin signalingOncol Lett. 2019 Jun;17(6):4928-4934. doi: 10.3892/ol.2019.10150. Epub 2019 Mar 15.
REF00004496	Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin  A single center experienceOncotarget. 2011 Nov;2(11):850-61. doi: 10.18632/oncotarget.347.
REF00004497	Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implicationsOncotarget. 2013 Jun;4(6):884-9. doi: 10.18632/oncotarget.1021.
REF00004498	"5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograftOncotarget. 2013 Oct;4(10):1737-47. doi: 10.18632/oncotarget.1408."
REF00004499	Identifying the determinants of response to MDM2 inhibitionOncotarget. 2015 Apr 10;6(10):7701-12. doi: 10.18632/oncotarget.3116.
REF00004500	Mutant HRAS as novel target for MEK and mTOR inhibitorsOncotarget. 2015 Dec 8;6(39):42183-96. doi: 10.18632/oncotarget.5619.
REF00004501	"HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphomaOncotarget. 2015 Mar 10;6(7):4863-87. doi: 10.18632/oncotarget.3120."
REF00004502	The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cellsOncotarget. 2015 Nov 24;6(37):40141-57. doi: 10.18632/oncotarget.5653.
REF00004503	Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitorsOncotarget. 2015 Oct 20;6(32):32646-55. doi: 10.18632/oncotarget.5066.
REF00004504	Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genesOncotarget. 2015 Sep 29;6(29):27023-36. doi: 10.18632/oncotarget.4809.
REF00004505	Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical useOncotarget. 2016 Apr 26;7(17):24252-68. doi: 10.18632/oncotarget.8132.
REF00004506	Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and DabrafenibOncotarget. 2016 Aug 26;8(36):60094-60108. doi: 10.18632/oncotarget.11635. eCollection 2017 Sep 1.
REF00004507	Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinomaOncotarget. 2016 Feb 2;7(5):5461-9. doi: 10.18632/oncotarget.6684.
REF00004508	"Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockadeOncotarget. 2016 Jan 26;7(4):3947-65. doi: 10.18632/oncotarget.6600."
REF00004509	A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancersOncotarget. 2016 Mar 8;7(10):10696-709. doi: 10.18632/oncotarget.7372.
REF00004510	"Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and miceOncotarget. 2016 May 17;7(20):29011-22. doi: 10.18632/oncotarget.8508."
REF00004511	Benzene and its metabolite decreases cell proliferation via LncRNA-OBFC2A-mediated anti-proliferation effect involving NOTCH1 and KLF15Oncotarget. 2017 Jun 20;8(25):40857-40871. doi: 10.18632/oncotarget.16588.
REF00004512	Establishment and characterization of patient-derived xenograft models of gastrointestinal stromal tumor resistant to standard tyrosine kinase inhibitorsOncotarget. 2017 Sep 11;8(44):76712-76721. doi: 10.18632/oncotarget.20816. eCollection 2017 Sep 29.
REF00004513	Regression of BRAF (V600E) mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two casesOncotarget. 2019 Jun 4;10(38):3818-3826. eCollection 2019 Jun 4.
REF00004514	NEAT1 Promotes LPS-induced Inflammatory Injury in Macrophages by Regulating MiR-17-5p/TLR4Open Med (Wars). 2020 Jan 17;15:38-49. doi: 10.1515/med-2020-0007. eCollection 2020.
REF00004515	Thyroid Stimulating Hormone Triggers Hepatic Mitochondrial Stress through Cyclophilin D AcetylationOxid Med Cell Longev. 2020 Jan 6;2020:1249630. doi: 10.1155/2020/1249630. eCollection 2020.
REF00004516	Integration of ruxolitinib into dose-intensified therapy targeted against a novel JAK2 F694L mutation in B-precursor acute lymphoblastic leukemiaPediatr Blood Cancer. 2017 May;64(5):10.1002/pbc.26328. doi: 10.1002/pbc.26328. Epub 2016 Nov 15.
REF00004517	Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell linesPigment Cell Melanoma Res. 2014 Jul;27(4):590-600. doi: 10.1111/pcmr.12228. Epub 2014 Mar 6.
REF00004518	"Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitorsPigment Cell Melanoma Res. 2014 May;27(3):479-84. doi: 10.1111/pcmr.12218. Epub 2014 Feb 10."
REF00004519	MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasiaPLoS Med. 2006 Jul;3(7):e270. doi: 10.1371/journal.pmed.0030270.
REF00004520	Differential sensitivity of ERBB2 kinase domain mutations towards lapatinibPLoS One. 2011;6(10):e26760. doi: 10.1371/journal.pone.0026760. Epub 2011 Oct 28.
REF00004521	Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathwayPLoS One. 2011;6(12):e28973. doi: 10.1371/journal.pone.0028973. Epub 2011 Dec 14.
REF00004522	The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanomaPLoS One. 2012;7(1):e29622. doi: 10.1371/journal.pone.0029622. Epub 2012 Jan 12.
REF00004523	AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell linesPLoS One. 2012;7(10):e46869. doi: 10.1371/journal.pone.0046869. Epub 2012 Oct 2.
REF00004524	The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing micePLoS One. 2013 Dec 10;8(12):e81763. doi: 10.1371/journal.pone.0081763. eCollection 2013.
REF00004525	Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534)PLoS One. 2013 Oct 4;8(10):e76551. doi: 10.1371/journal.pone.0076551. eCollection 2013.
REF00004526	"Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastomaPLoS One. 2014 Apr 9;9(4):e94132. doi: 10.1371/journal.pone.0094132. eCollection 2014."
REF00004527	Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423PLoS One. 2014 Feb 4;9(2):e87220. doi: 10.1371/journal.pone.0087220. eCollection 2014.
REF00004528	Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitorPLoS One. 2014 Jun 30;9(6):e100880. doi: 10.1371/journal.pone.0100880. eCollection 2014.
REF00004529	"TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer CellsPLoS One. 2015 Jun 19;10(6):e0129838. doi: 10.1371/journal.pone.0129838. eCollection 2015."
REF00004530	Identification of Novel Small Molecule Inhibitors of Oncogenic RET KinasePLoS One. 2015 Jun 5;10(6):e0128364. doi: 10.1371/journal.pone.0128364. eCollection 2015.
REF00004531	Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination TreatmentPLoS One. 2015 Oct 13;10(10):e0140310. doi: 10.1371/journal.pone.0140310. eCollection 2015.
REF00004532	"Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092PLoS One. 2015 Oct 15;10(10):e0140479. doi: 10.1371/journal.pone.0140479. eCollection 2015."
REF00004533	Targeting the mTOR Complex by Everolimus in NRAS Mutant NeuroblastomaPLoS One. 2016 Jan 28;11(1):e0147682. doi: 10.1371/journal.pone.0147682. eCollection 2016.
REF00004534	A Novel Gonadotropin-Releasing Hormone 1 (Gnrh1) Enhancer-Derived Noncoding RNA Regulates Gnrh1 Gene Expression in GnRH Neuronal Cell ModelsPLoS One. 2016 Jul 7;11(7):e0158597. doi: 10.1371/journal.pone.0158597. eCollection 2016.
REF00004535	"Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR DysregulationPLoS One. 2016 Sep 14;11(9):e0162594. doi: 10.1371/journal.pone.0162594. eCollection 2016."
REF00004536	Rapid generation of drug-resistance alleles at endogenous loci using CRISPR-Cas9 indel mutagenesisPLoS One. 2017 Feb 23;12(2):e0172177. doi: 10.1371/journal.pone.0172177. eCollection 2017.
REF00004537	Loss of Malat1 does not modify age- or diet-induced adipose tissue accretion and insulin resistance in micePLoS One. 2018 May 10;13(5):e0196603. doi: 10.1371/journal.pone.0196603. eCollection 2018.
REF00004538	Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibitionPLoS One. 2019 Jun 3;14(6):e0217399. doi: 10.1371/journal.pone.0217399. eCollection 2019.
REF00004539	"Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinasesProc Natl Acad Sci U S A. 2005 Aug 2;102(31):11011-6. doi: 10.1073/pnas.0504952102. Epub 2005 Jul 26."
REF00004540	The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPProc Natl Acad Sci U S A. 2008 Feb 12;105(6):2070-5. doi: 10.1073/pnas.0709662105. Epub 2008 Jan 28.
REF00004541	Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activityProc Natl Acad Sci U S A. 2008 Feb 26;105(8):3041-6. doi: 10.1073/pnas.0711741105. Epub 2008 Feb 19.
REF00004542	Drug-sensitive FGFR2 mutations in endometrial carcinomaProc Natl Acad Sci U S A. 2008 Jun 24;105(25):8713-7. doi: 10.1073/pnas.0803379105. Epub 2008 Jun 13.
REF00004543	MEK1 mutations confer resistance to MEK and B-RAF inhibitionProc Natl Acad Sci U S A. 2009 Dec 1;106(48):20411-6. doi: 10.1073/pnas.0905833106. Epub 2009 Nov 13.
REF00004544	"Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibitionProc Natl Acad Sci U S A. 2009 Nov 24;106(47):20127-32. doi: 10.1073/pnas.0910957106. Epub 2009 Nov 9."
REF00004545	Deactivation of Akt by a small molecule inhibitor targeting pleckstrin homology domain and facilitating Akt ubiquitinationProc Natl Acad Sci U S A. 2011 Apr 19;108(16):6486-91. doi: 10.1073/pnas.1019062108. Epub 2011 Apr 4.
REF00004546	Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma modelProc Natl Acad Sci U S A. 2012 May 15;109(20):7859-64. doi: 10.1073/pnas.1114718109. Epub 2012 May 1.
REF00004547	Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14476-81. doi: 10.1073/pnas.1203201109. Epub 2012 Aug 20.
REF00004548	Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20224-9. doi: 10.1073/pnas.1314239110. Epub 2013 Nov 25.
REF00004549	Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivoProc Natl Acad Sci U S A. 2013 Mar 5;110(10):4015-20. doi: 10.1073/pnas.1216013110. Epub 2013 Feb 19.
REF00004550	Crenolanib is a selective type I pan-FLT3 inhibitorProc Natl Acad Sci U S A. 2014 Apr 8;111(14):5319-24. doi: 10.1073/pnas.1320661111. Epub 2014 Mar 12.
REF00004551	Discovery and functional characterization of a neomorphic PTEN mutationProc Natl Acad Sci U S A. 2015 Nov 10;112(45):13976-81. doi: 10.1073/pnas.1422504112. Epub 2015 Oct 26.
REF00004552	Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitorsProc Natl Acad Sci U S A. 2015 Sep 29;112(39):E5381-90. doi: 10.1073/pnas.1515281112. Epub 2015 Sep 8.
REF00004553	Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancerProc Natl Acad Sci U S A. 2016 Nov 22;113(47):13456-13461. doi: 10.1073/pnas.1610456113. Epub 2016 Nov 9.
REF00004554	Morphine post-conditioning-induced up-regulation of lncRNA TINCR protects cardiomyocytes from ischemia-reperfusion injury via inhibiting degradation and ubiquitination of FGF1QJM. 2020 Dec 1;113(12):859-869. doi: 10.1093/qjmed/hcaa088.
REF00004555	miR-489 inhibits silica-induced pulmonary fibrosis by targeting MyD88 and Smad3 and is negatively regulated by lncRNA CHRFSci Rep. 2016 Aug 10;6:30921. doi: 10.1038/srep30921.
REF00004556	Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosisSci Rep. 2016 Jan 20;6:19423. doi: 10.1038/srep19423.
REF00004557	Down-regulation of long non-coding RNA HOTAIR sensitizes breast cancer to trastuzumabSci Rep. 2019 Dec 27;9(1):19881. doi: 10.1038/s41598-019-53699-w.
REF00004558	Full-Length Transcriptome Survey and Expression Analysis of Parasitoid Wasp Chouioia cunea upon Exposure to 1-DodeceneSci Rep. 2019 Dec 3;9(1):18167. doi: 10.1038/s41598-019-54710-0.
REF00004559	lncRNA PSORS1C3 is regulated by glucocorticoids and fine-tunes OCT4 expression in non-pluripotent cellsSci Rep. 2019 Jun 10;9(1):8370. doi: 10.1038/s41598-019-44827-7.
REF00004560	LncRNA GABPB1-AS1 and GABPB1 regulate oxidative stress during erastin-induced ferroptosis in HepG2 hepatocellular carcinoma cellsSci Rep. 2019 Nov 7;9(1):16185. doi: 10.1038/s41598-019-52837-8.
REF00004561	Molecular mechanisms underlying nickel nanoparticle induced rat Sertoli-germ cells apoptosisSci Total Environ. 2019 Nov 20;692:240-248. doi: 10.1016/j.scitotenv.2019.07.107. Epub 2019 Jul 9.
REF00004562	Hydrogen sulfide exposure induces apoptosis and necroptosis through lncRNA3037/miR-15a/BCL2-A20 signaling in broiler tracheaSci Total Environ. 2020 Jan 10;699:134296. doi: 10.1016/j.scitotenv.2019.134296. Epub 2019 Sep 4.
REF00004563	Gatekeeper mutations mediate resistance to BRAF-targeted therapiesSci Transl Med. 2010 Jun 9;2(35):35ra41. doi: 10.1126/scitranslmed.3000758.
REF00004564	Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancerSci Transl Med. 2013 Mar 27;5(178):178ra39. doi: 10.1126/scitranslmed.3005414.
REF00004565	A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemiaSci Transl Med. 2014 Sep 3;6(252):252ra121. doi: 10.1126/scitranslmed.3009073.
REF00004566	Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapySci Transl Med. 2015 Mar 18;7(279):279ra40. doi: 10.1126/scitranslmed.aaa4642.
REF00004567	Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependenceSci Transl Med. 2016 Apr 13;8(334):334ra53. doi: 10.1126/scitranslmed.aad3001.
REF00004568	"AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastasesSci Transl Med. 2016 Dec 7;8(368):368ra172. doi: 10.1126/scitranslmed.aag0976."
REF00004569	MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutationsSci Transl Med. 2016 Feb 3;8(324):324ra14. doi: 10.1126/scitranslmed.aad5640.
REF00004570	Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancerSci Transl Med. 2016 Oct 19;8(361):361ra140. doi: 10.1126/scitranslmed.aaf8127.
REF00004571	2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivitySci Transl Med. 2017 Feb 1;9(375):eaal2463. doi: 10.1126/scitranslmed.aal2463.
REF00004572	The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activationSci Transl Med. 2017 May 24;9(391):eaal4682. doi: 10.1126/scitranslmed.aal4682.
REF00004573	A precision therapy against cancers driven by KIT/PDGFRA mutationsSci Transl Med. 2017 Nov 1;9(414):eaao1690. doi: 10.1126/scitranslmed.aao1690.
REF00004574	Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemiaSci Transl Med. 2018 Apr 11;10(436):eaao3003. doi: 10.1126/scitranslmed.aao3003.
REF00004575	Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiationScience. 2013 May 3;340(6132):622-6. doi: 10.1126/science.1234769. Epub 2013 Apr 4.
REF00004576	An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cellsScience. 2013 May 3;340(6132):626-30. doi: 10.1126/science.1236062. Epub 2013 Apr 4.
REF00004577	The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancerTarget Oncol. 2015 Jun;10(2):235-45. doi: 10.1007/s11523-014-0329-6. Epub 2014 Aug 1.
REF00004578	Evaluation of FGFR3 as a Therapeutic Target in Head and Neck Squamous Cell CarcinomaTarget Oncol. 2016 Oct;11(5):631-642. doi: 10.1007/s11523-016-0431-z.
REF00004579	Discovery of a Potent and Mutant-Selective EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Lung CancerTarget Oncol. 2018 Jun;13(3):389-398. doi: 10.1007/s11523-018-0568-z.
REF00004580	EGFR-AS1/HIF2A regulates the expression of FOXP3 to impact the cancer stemness of smoking-related non-small cell lung cancerTher Adv Med Oncol. 2019 Jun 13;11:1758835919855228. doi: 10.1177/1758835919855228. eCollection 2019.
REF00004581	Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumorsTher Adv Med Oncol. 2019 May 17;11:1758835919849757. doi: 10.1177/1758835919849757. eCollection 2019.
REF00004582	A Compound AC1Q3QWB Selectively Disrupts HOTAIR-Mediated Recruitment of PRC2 and Enhances Cancer Therapy of DZNepTheranostics. 2019 Jun 24;9(16):4608-4623. doi: 10.7150/thno.35188. eCollection 2019.
REF00004583	"In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancerThyroid. 2013 Dec;23(12):1569-77. doi: 10.1089/thy.2013.0137. Epub 2013 Sep 17."
REF00004584	"LncRNA-241 inhibits 1,2-Dichloroethane-induced hepatic apoptosisToxicol In Vitro. 2019 Dec;61:104650. doi: 10.1016/j.tiv.2019.104650. Epub 2019 Sep 11."
REF00004585	"Benzo(a)pyrene regulated A549 cell migration, invasion and epithelial-mesenchymal transition by up-regulating long non-coding RNA linc00673Toxicol Lett. 2020 Mar 1;320:37-45. doi: 10.1016/j.toxlet.2019.11.024. Epub 2019 Nov 25."
REF00004586	Andrographolide antagonizes the cigarette smoke-induced epithelial-mesenchymal transition and pulmonary dysfunction through anti-inflammatory inhibiting HOTAIRToxicology. 2019 Jun 15;422:84-94. doi: 10.1016/j.tox.2019.05.009. Epub 2019 May 23.
REF00004587	LCZ696 (sacubitril/valsartan) protects against cyclophosphamide-induced testicular toxicity in rats: Role of neprilysin inhibition and lncRNA TUG1 in ameliorating apoptosisToxicology. 2020 May 15;437:152439. doi: 10.1016/j.tox.2020.152439. Epub 2020 Mar 18.
REF00004588	CP-31398 inhibits the growth of p53-mutated liver cancer cells in vitro and in vivoTumour Biol. 2016 Jan;37(1):807-15. doi: 10.1007/s13277-015-3857-5. Epub 2015 Aug 7.
REF00004589	[The expression of LINC00052 during glycidyl methacrylate-induced malignant transformation of 16HBE cells]Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2019 Nov 20;37(11):806-809. doi: 10.3760/cma.j.issn.1001-9391.2019.11.002.
REF00004590	"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trialLancet Oncol. 2019 Jul;20(7):1011-1022. doi: 10.1016/S1470-2045(19)30277-3. Epub 2019 May 28."
REF00004591	Targeted therapy for BRAFV600E malignant astrocytomaClin Cancer Res. 2011 Dec 15;17(24):7595-604. doi: 10.1158/1078-0432.CCR-11-1456. Epub 2011 Oct 28.
REF00004592	"Abstract 1786: Characterization of the inhibitory capacity of EMD1214063, a novel small molecule inhibitor of the MET hepatocyte growth factor receptor on a panel of MET mutated variants."
REF00004593	Abstract CT103: Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: Preliminary results from KEYNOTE-0280.
REF00004594	"A Pooled Analysis of Reproductive Factors, Exogenous Hormone Use, and Risk of Multiple Myeloma among Women in the International Multiple Myeloma Consortium."
REF00004595	Turk J Haematol. 2016 Mar 5;33(1):41-7. doi: 10.4274/tjh.2014.0010. Epub 2014 May 21.
REF00004596	Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC).
REF00004597	Dose escalating study of crenolanib besylate in advanced GIST patients with PDGFRA D842V activating mutations.
REF00004598	Survival outcomes for various treatment modalities in advanced-stage grade 3 follicular lymphoma (FL3): A National Cancer Database (NCDB) study.
REF00004599	A phase II study of palbociclib (P) for previously treated cell cycle gene alteration positive patients (pts) with stage IV squamous cell lung cancer (SCC): Lung-MAP sub-study SWOG S1400C.
REF00004600	Activity of brigatinib (BRG) in crizotinib (CRZ)-resistant ALK+ NSCLC patients (pts) according to ALK plasma mutation status.
REF00004601	Indian J Med Paediatr Oncol. 2015 Apr-Jun;36(2):133-6. doi: 10.4103/0971-5851.158852.
REF00004602	STATISTICS/DATA TYPE - iGMDR.
REF00004603	STATISTICS/DATA TYPE - iGMDR.
REF00004604	STATISTICS/DATA TYPE - iGMDR.
REF00004605	STATISTICS/DATA TYPE - iGMDR.
REF00004606	STATISTICS/DATA TYPE - iGMDR.
REF00004607	U.S. Food and Drug Administration.
REF00004608	National Comprehensive Cancer Network.
REF00004609	Pseudomonas aeruginosa bacteremia among liver transplant recipientsInfect Drug Resist. 2018 Nov 16;11:2345-2356. doi: 10.2147/IDR.S180283. eCollection 2018.
REF00004610	"Characterization of antimicrobial susceptibility, extended-spectrum Beta-lactamase genes and phylogenetic groups of Shigatoxin producing Escherichia coli isolated from patients with diarrhea in IranAnn Clin Microbiol Antimicrob. 2021 Apr 15;20(1):24. doi: 10.1186/s12941-021-00430-1."
REF00004611	Erythropoietin Resistance in Patients with Chronic Kidney Disease: Current PerspectivesInt J Nephrol Renovasc Dis. 2020 Oct 8;13:231-237. doi: 10.2147/IJNRD.S239151. eCollection 2020.
REF00004612	Mechanisms of responsiveness to and resistance against trabectedin in murine models of human myxoid liposarcomaGenomics. 2021 Sep;113(5):3439-3448. doi: 10.1016/j.ygeno.2021.07.028. Epub 2021 Jul 30.
REF00004613	Immediate and controlled-release pregabalin for the treatment of epilepsyExpert Rev Neurother. 2019 Dec;19(12):1167-1177. doi: 10.1080/14737175.2019.1681265. Epub 2019 Oct 21.
REF00004614	Effect of Fufang Biejia Ruangan Tablet on lowering biochemical and virological parameters of hepatic fibrosis in patients with chronic hepatitis B: Protocol for a systematic review and meta-analysis of randomized controlled trials and cohort studiesMedicine (Baltimore). 2019 Apr;98(17):e15297. doi: 10.1097/MD.0000000000015297.
REF00004615	"Antimicrobial resistance of Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis and Tannerella forsythia in periodontitis patientsJ Glob Antimicrob Resist. 2020 Sep;22:215-218. doi: 10.1016/j.jgar.2020.02.024. Epub 2020 Mar 10."
REF00004616	Multiresistant Neisseria gonorrhoeae: a new threat in second decade of the XXI centuryMed Microbiol Immunol. 2020 Apr;209(2):95-108. doi: 10.1007/s00430-019-00651-4. Epub 2019 Dec 4.
REF00004617	Impact of mass drug administration of azithromycin for trachoma elimination on prevalence and azithromycin resistance of genital Mycoplasma genitalium infectionSex Transm Infect. 2019 Nov;95(7):522-528. doi: 10.1136/sextrans-2018-053938. Epub 2019 Apr 13.
REF00004618	Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance developmentNeuro Oncol. 2019 Mar 18;21(4):486-497. doi: 10.1093/neuonc/noz002.
REF00004619	Paediatric Osteomyelitis and Septic Arthritis Pathogen Distribution and Antimicrobial Resistance in a Single Centre: A 15-Year Retrospective AnalysisJ Trop Pediatr. 2022 Apr 5;68(3):fmac038. doi: 10.1093/tropej/fmac038.
REF00004620	Shotgun whole genome sequencing of drug-resistance Streptococcus anginosus strain 47S1 isolated from a patient with pharyngitis in Saudi ArabiaJ Infect Public Health. 2021 Dec;14(12):1740-1749. doi: 10.1016/j.jiph.2021.11.010. Epub 2021 Nov 16.
REF00004621	Update on Shigella and Nontyphoidal Salmonella Antimicrobial Drug Resistance: Implications on Empirical Treatment of Acute Infectious Diarrhea in CambodiaAntimicrob Agents Chemother. 2021 Oct 18;65(11):e0067121. doi: 10.1128/AAC.00671-21. Epub 2021 Aug 16.
REF00004622	Helicobacter pylori infection and antibiotic resistance - from biology to clinical implicationsNat Rev Gastroenterol Hepatol. 2021 Sep;18(9):613-629. doi: 10.1038/s41575-021-00449-x. Epub 2021 May 17.
REF00004623	Antimicrobial resistance profile and multidrug resistance patterns of Streptococcus pneumoniae isolates from patients suspected of pneumococcal infections in EthiopiaAnn Clin Microbiol Antimicrob. 2021 Apr 20;20(1):26. doi: 10.1186/s12941-021-00432-z.
REF00004624	Viral hepatitis: Guidelines by the American Society of Transplantation Infectious Disease Community of PracticeClin Transplant. 2019 Sep;33(9):e13514. doi: 10.1111/ctr.13514. Epub 2019 Apr 14.
REF00004625	Analysis of clinical distribution and drug resistance of klebsiella pneumoniae pulmonary infection in patients with hypertensive intra cerebral hemorrhage after minimally invasive surgeryPak J Med Sci. 2022 Jan-Feb;38(1):237-242. doi: 10.12669/pjms.38.1.4439.
REF00004626	Tuberculous Scleritis and Multidrug ResistanceOcul Immunol Inflamm. 2021 Jan 8:1-10. doi: 10.1080/09273948.2020.1853176. Online ahead of print.
REF00004627	"Prevalence and patterns of drug resistance among pulmonary tuberculosis patients in Hangzhou, ChinaAntimicrob Resist Infect Control. 2018 May 2;7:61. doi: 10.1186/s13756-018-0348-7. eCollection 2018."
REF00004628	Management of challenging myelofibrosis after JAK inhibitor failure and/or progressionBlood Rev. 2020 Jul;42:100716. doi: 10.1016/j.blre.2020.100716. Epub 2020 May 30.
REF00004629	Single-cell RNA-seq reveals the immune escape and drug resistance mechanisms of mantle cell lymphomaCancer Biol Med. 2020 Aug 15;17(3):726-739. doi: 10.20892/j.issn.2095-3941.2020.0073.
REF00004630	A tale of two antibodies: obinutuzumab versus rituximabBr J Haematol. 2018 Jul;182(1):29-45. doi: 10.1111/bjh.15232. Epub 2018 May 9.
REF00004631	Study of treatment outcomes of multidrug-resistant tuberculosis under programmatic conditions and factors influencing the outcomes in Hyderabad DistrictIndian J Tuberc. 2021 Jul;68(3):379-383. doi: 10.1016/j.ijtb.2020.12.008. Epub 2021 Jan 4.
REF00004632	Comparison of Rifamycins for Efficacy Against Mycobacterium avium Complex and Resistance Emergence in the Hollow Fiber Model SystemFront Pharmacol. 2021 Apr 15;12:645264. doi: 10.3389/fphar.2021.645264. eCollection 2021.
REF00004633	Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 DrugsPathogens. 2020 Apr 26;9(5):320. doi: 10.3390/pathogens9050320.
REF00004634	"The role of microRNAs in the pathogenesis, grading and treatment of hepatic fibrosis in schistosomiasisParasit Vectors. 2019 Dec 30;12(1):611. doi: 10.1186/s13071-019-3866-0."
REF00004635	"Pathogens and drug-resistance of hospital-acquired pneumonia in an EICU in Tianjin, ChinaInt J Biochem Mol Biol. 2021 Apr 15;12(2):49-54. eCollection 2021."
REF00004636	Emerging Gram-positive bacteria and drug resistance in cirrhosis patients with spontaneous bacterial peritonitis: A retrospective studyExp Ther Med. 2019 Jun;17(6):4568-4576. doi: 10.3892/etm.2019.7502. Epub 2019 Apr 18.
REF00004637	Phenotypes in Children With SYNGAP1 Encephalopathy in ChinaFront Neurosci. 2021 Dec 2;15:761473. doi: 10.3389/fnins.2021.761473. eCollection 2021.
REF00004638	Benefit of rebiopsy for deciding treatment strategy in rectal cancer: A case reportOncol Lett. 2017 Sep;14(3):3697-3700. doi: 10.3892/ol.2017.6601. Epub 2017 Jul 18.
REF00004639	"Study on risk factors, bacterial species, and drug resistance of acute pyelonephritis associated with ureteral stent after percutaneous nephrolithotomyEur J Clin Microbiol Infect Dis. 2021 Apr;40(4):707-713. doi: 10.1007/s10096-020-04050-z. Epub 2020 Oct 9."
REF00004640	[Progress in the treatment of intra-abdominal anaerobic infection]Zhonghua Wei Chang Wai Ke Za Zhi. 2020 Nov 25;23(11):1028-1031. doi: 10.3760/cma.j.cn.441530-20200812-00478.
REF00004641	Prevalence and Therapies of Antibiotic-Resistance in Staphylococcus aureusFront Cell Infect Microbiol. 2020 Mar 17;10:107. doi: 10.3389/fcimb.2020.00107. eCollection 2020.
REF00004642	Clinico-bacteriological and antibiotic drug resistance profile of chronic suppurative otitis media at a tertiary care hospital in Western RajasthanJ Family Med Prim Care. 2021 Jul;10(7):2572-2579. doi: 10.4103/jfmpc.jfmpc_2480_20. Epub 2021 Jul 30.
REF00004643	Drug-Resistant Juvenile Myoclonic Epilepsy: Misdiagnosis of Progressive Myoclonus EpilepsyFront Neurol. 2019 Sep 10;10:946. doi: 10.3389/fneur.2019.00946. eCollection 2019.
REF00004644	Community-acquired Pseudomonas aeruginosa pneumonia manifested by bloody pleural effusion in a previously healthy infant: A case reportJ Clin Lab Anal. 2022 Jun;36(6):e24466. doi: 10.1002/jcla.24466. Epub 2022 May 13.
REF00004645	Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemiaDrug Resist Updat. 2022 Mar;61:100805. doi: 10.1016/j.drup.2022.100805. Epub 2022 Jan 21.
REF00004646	Drug resistance in Giardia: Mechanisms and alternative treatments for GiardiasisAdv Parasitol. 2020;107:201-282. doi: 10.1016/bs.apar.2019.11.003. Epub 2020 Jan 17.
REF00004647	[Overview of resistance mechanisms in Campylobacter]Zhonghua Yu Fang Yi Xue Za Zhi. 2018 Oct 6;52(10):1072-1077. doi: 10.3760/cma.j.issn.0253-9624.2018.10.021.
REF00004648	Hospital-acquired infection in patients with systemic lupus erythematosus: a case-control study in a southern Chinese populationClin Rheumatol. 2018 Mar;37(3):709-717. doi: 10.1007/s10067-017-3919-8. Epub 2017 Nov 27.
REF00004649	Strain Distribution and Drug Susceptibility of Invasive Fungal Infection in Clinical Patients With Systemic Internal DiseasesFront Bioeng Biotechnol. 2021 Feb 11;8:625024. doi: 10.3389/fbioe.2020.625024. eCollection 2020.
REF00004650	[Association between duration of fever before treatment and intravenous immunoglobulin resistance in Kawasaki disease]Zhongguo Dang Dai Er Ke Za Zhi. 2022 Apr 15;24(4):399-404. doi: 10.7499/j.issn.1008-8830.2110137.
REF00004651	Hepatocellular Carcinoma: Etiology and Current and Future DrugsJ Clin Exp Hepatol. 2019 Mar-Apr;9(2):221-232. doi: 10.1016/j.jceh.2019.01.004. Epub 2019 Jan 25.
REF00004652	Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic optionsDrug Discov Today. 2019 Jul;24(7):1355-1369. doi: 10.1016/j.drudis.2019.05.007. Epub 2019 May 15.
REF00004653	Microbiology and antimicrobial susceptibility of otitis externa: a changing pattern of antimicrobial resistanceJ Laryngol Otol. 2018 Apr;132(4):314-317. doi: 10.1017/S0022215118000191. Epub 2018 Feb 12.
REF00004654	Photodynamic therapy of oral lichen planusPhotochem Photobiol Sci. 2020 Oct 14;19(10):1271-1279. doi: 10.1039/d0pp00249f.
REF00004655	Prevalence of Shigella species and its drug resistance pattern in Ethiopia: a systematic review and meta-analysisAnn Clin Microbiol Antimicrob. 2019 Jul 9;18(1):22. doi: 10.1186/s12941-019-0321-1.
REF00004656	Emerging serotype III sequence type 17 group B streptococcus invasive infection in infants: the clinical characteristics and impacts on outcomesBMC Infect Dis. 2019 Jun 19;19(1):538. doi: 10.1186/s12879-019-4177-y.
REF00004657	Ultrasound-responsive alkaline nanorobots for the treatment of lactic acidosis-mediated doxorubicin resistanceNanoscale. 2020 Jul 2;12(25):13801-13810. doi: 10.1039/d0nr03726e.
REF00004658	Review of aspirin and clopidogrel resistance in peripheral arterial diseaseJ Vasc Surg. 2017 Nov;66(5):1576-1586. doi: 10.1016/j.jvs.2017.07.065.
REF00004659	"Epidemiology, drug resistance, and pathophysiology of Plasmodium vivax malariaJ Vector Borne Dis. 2018 Jan-Mar;55(1):1-8. doi: 10.4103/0972-9062.234620."
REF00004660	"Infectious Complications in Severe Acute Pancreatitis: Pathogens, Drug Resistance, and Status of Nosocomial Infection in a University-Affiliated Teaching HospitalDig Dis Sci. 2020 Jul;65(7):2079-2088. doi: 10.1007/s10620-019-05924-9. Epub 2019 Nov 5."
REF00004661	Bleomycin Induces Drug Efflux in Lungs. A Pitfall for Pharmacological Studies of Pulmonary FibrosisAm J Respir Cell Mol Biol. 2020 Feb;62(2):178-190. doi: 10.1165/rcmb.2018-0147OC.
REF00004662	Managing antibiotic resistance in nontuberculous mycobacterial pulmonary disease: challenges and new approachesExpert Rev Respir Med. 2019 Sep;13(9):851-861. doi: 10.1080/17476348.2019.1638765. Epub 2019 Jul 8.
REF00004663	"Anti-herpes virus activity of the carnivorous botanical, Sarracenia purpureaSci Rep. 2020 Nov 3;10(1):18953. doi: 10.1038/s41598-020-76151-w."
REF00004664	Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibilityAntimicrob Agents Chemother. 2012 May;56(5):2305-13. doi: 10.1128/AAC.05487-11. Epub 2012 Feb 13.
REF00004665	Genotypic predictors of human immunodeficiency virus type 1 drug resistanceProc Natl Acad Sci U S A. 2006 Nov 14;103(46):17355-60. doi: 10.1073/pnas.0607274103. Epub 2006 Oct 25.
REF00004666	Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavirJ Virol. 2006 Nov;80(21):10794-801. doi: 10.1128/JVI.00712-06. Epub 2006 Aug 23.
REF00004667	Genotypic and phenotypic analyses of human immunodeficiency virus type 1 in antiretroviral drug-naive Nigerian patientsAIDS Res Hum Retroviruses. 2006 Jan;22(1):22-6. doi: 10.1089/aid.2006.22.22.
REF00004668	Virologic characterization of HIV type 1 with a codon 70 deletion in reverse transcriptaseJ Acquir Immune Defic Syndr. 2007 Aug 15;45(5):494-500. doi: 10.1097/QAI.0b013e31806ada48.
REF00004669	Phenotypic drug resistance patterns in subtype A HIV-1 clones with nonnucleoside reverse transcriptase resistance mutationsAIDS Res Hum Retroviruses. 2006 Mar;22(3):289-93. doi: 10.1089/aid.2006.22.289.
REF00004670	"Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlatesJ Virol. 2005 Mar;79(6):3329-38. doi: 10.1128/JVI.79.6.3329-3338.2005."
REF00004671	"Antiretroviral drug susceptibility among drug-naive adults with recent HIV infection in Rakai, UgandaAIDS. 2009 Apr 27;23(7):845-52. doi: 10.1097/QAD.0b013e328327957a."
REF00004672	"Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlatesAIDS. 2002 Oct 18;16(15):F41-7. doi: 10.1097/00002030-200210180-00002."
REF00004673	The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitnessJ Acquir Immune Defic Syndr. 2012 Jan 1;59(1):47-54. doi: 10.1097/QAI.0b013e31823aca74.
REF00004674	Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimensAntimicrob Agents Chemother. 2011 Jun;55(6):2872-9. doi: 10.1128/AAC.01695-10. Epub 2011 Apr 4.
REF00004675	Panel of prototypical infectious molecular HIV-1 clones containing multiple nucleoside reverse transcriptase inhibitor resistance mutationsAIDS. 2005 Apr 29;19(7):731-3. doi: 10.1097/01.aids.0000166098.54564.0c.
REF00004676	"Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirineAntimicrob Agents Chemother. 2012 Aug;56(8):4522-4. doi: 10.1128/AAC.00648-12. Epub 2012 Jun 4."
REF00004677	The K101P and K103R/V179D mutations in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nonnucleoside reverse transcriptase inhibitorsAntimicrob Agents Chemother. 2006 Jan;50(1):351-4. doi: 10.1128/AAC.50.1.351-354.2006.
REF00004678	Molecular basis of antagonism between K70E and K65R tenofovir-associated mutations in HIV-1 reverse transcriptaseAntiviral Res. 2007 Sep;75(3):210-8. doi: 10.1016/j.antiviral.2007.03.006. Epub 2007 Apr 4.
REF00004679	"A rare HIV reverse transcriptase mutation, K65N, confers reduced susceptibility to tenofovir, lamivudine and didanosineAIDS. 2006 Mar 21;20(5):787-9. doi: 10.1097/01.aids.0000216387.60481.0e."
REF00004680	HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillanceJ Infect Dis. 2005 Aug 1;192(3):456-65. doi: 10.1086/431601. Epub 2005 Jul 5.
REF00004681	Comparative analysis of two commercial phenotypic assays for drug susceptibility testing of human immunodeficiency virus type 1J Clin Microbiol. 2002 Jan;40(1):31-5. doi: 10.1128/JCM.40.1.31-35.2002.
REF00004682	HIV-1 protease mutations and protease inhibitor cross-resistanceAntimicrob Agents Chemother. 2010 Oct;54(10):4253-61. doi: 10.1128/AAC.00574-10. Epub 2010 Jul 26.
REF00004683	"96-week efficacy and safety of atazanavir, with and without ritonavir, in a HAART regimen in treatment-naive patientsJ Int Assoc Physicians AIDS Care (Chic). 2010 Jan-Feb;9(1):34-42. doi: 10.1177/1545109709355828."
REF00004684	Evolution of human immunodeficiency virus type 1 protease genotypes and phenotypes in vivo under selective pressure of the protease inhibitor ritonavirJ Virol. 2005 Aug;79(16):10638-49. doi: 10.1128/JVI.79.16.10638-10649.2005.
REF00004685	Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypesJ Clin Virol. 2004 Nov;31(3):215-20. doi: 10.1016/j.jcv.2004.03.015.
REF00004686	Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimensJ Infect Dis. 2004 May 15;189(10):1802-10. doi: 10.1086/386291. Epub 2004 Apr 27.
REF00004687	Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimensJ Acquir Immune Defic Syndr. 2004 May 1;36(1):600-3. doi: 10.1097/00126334-200405010-00008.
REF00004688	Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1Antimicrob Agents Chemother. 2004 Feb;48(2):437-43. doi: 10.1128/AAC.48.2.437-443.2004.
REF00004689	Colinearity of reverse transcriptase inhibitor resistance mutations detected by population-based sequencingJ Acquir Immune Defic Syndr. 2003 Dec 1;34(4):398-402. doi: 10.1097/00126334-200312010-00006.
REF00004690	Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivoClin Infect Dis. 2001 Dec 15;33(12):2075-7. doi: 10.1086/324510. Epub 2001 Nov 7.
REF00004691	Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patientsJ Virol. 2001 Aug;75(16):7462-9. doi: 10.1128/JVI.75.16.7462-7469.2001.
REF00004692	"A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavirJ Virol. 2000 May;74(9):4414-9. doi: 10.1128/jvi.74.9.4414-4419.2000."
REF00004693	Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimenAIDS. 2004 Sep 24;18(14):1965-6. doi: 10.1097/00002030-200409240-00016.
REF00004694	Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatmentsJ Virol. 2003 Apr;77(8):4836-47. doi: 10.1128/jvi.77.8.4836-4847.2003.
REF00004695	Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 proteaseJ Virol. 2002 Feb;76(3):1359-68. doi: 10.1128/jvi.76.3.1359-1368.2002.
REF00004696	"Human immunodeficiency virus type 1 reverse-transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a northern California clinic-based populationJ Infect Dis. 2001 Oct 15;184(8):998-1006. doi: 10.1086/323601. Epub 2001 Sep 10."
REF00004697	Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugsAIDS. 2001 Aug 17;15(12):1471-5. doi: 10.1097/00002030-200108170-00003.
REF00004698	Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patientsAIDS. 2000 Dec 22;14(18):2877-87. doi: 10.1097/00002030-200012220-00009.
REF00004699	Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic responseJ Acquir Immune Defic Syndr. 2000 Mar 1;23(3):221-6. doi: 10.1097/00126334-200003010-00002.
REF00004700	A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1Antimicrob Agents Chemother. 2000 Apr;44(4):920-8. doi: 10.1128/AAC.44.4.920-928.2000.
REF00004701	"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeksLancet. 2012 Jun 30;379(9835):2439-2448. doi: 10.1016/S0140-6736(12)60917-9."
REF00004702	Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavirAntimicrob Agents Chemother. 2004 Jun;48(6):2159-65. doi: 10.1128/AAC.48.6.2159-2165.2004.
REF00004703	"Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority studyLancet Infect Dis. 2012 Jan;12(1):27-35. doi: 10.1016/S1473-3099(11)70249-3. Epub 2011 Oct 18."
REF00004704	Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypesAIDS. 2008 Mar 12;22(5):611-6. doi: 10.1097/QAD.0b013e3282f51eb9.
REF00004705	Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replicationAntimicrob Agents Chemother. 2007 Feb;51(2):732-5. doi: 10.1128/AAC.00690-06. Epub 2006 Nov 13.
REF00004706	"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trialLancet. 2012 Jun 30;379(9835):2429-2438. doi: 10.1016/S0140-6736(12)60918-0."
REF00004707	Protease and reverse transcriptase mutation patterns in HIV type 1 isolates from heavily treated persons: comparison of isolates from Northern California with isolates from other regionsAIDS Res Hum Retroviruses. 2003 Oct;19(10):909-15. doi: 10.1089/088922203322493085.
REF00004708	The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adultsJ Acquir Immune Defic Syndr. 2012 Nov 1;61(3):297-301. doi: 10.1097/QAI.0b013e31826bfd02.
REF00004709	Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcomeJ Infect Dis. 1999 Jun;179(6):1375-81. doi: 10.1086/314775.
REF00004710	HIV protease mutations associated with amprenavir resistance during salvage therapy: importance of I54MJ Clin Virol. 2004 May;30(1):62-7. doi: 10.1016/j.jcv.2003.08.013.
REF00004711	Amprenavir resistance imparted by the I50V mutation in HIV-1 protease can be suppressed by the N88S mutationClin Infect Dis. 2003 Nov 1;37(9):1273-4. doi: 10.1086/378894.
REF00004712	Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitorsAIDS. 2003 Apr 11;17(6):791-9. doi: 10.1097/00002030-200304110-00003.
REF00004713	"Association of a novel human immunodeficiency virus type 1 protease substrate cleft mutation, L23I, with protease inhibitor therapy and in vitro drug resistanceAntimicrob Agents Chemother. 2004 Dec;48(12):4864-8. doi: 10.1128/AAC.48.12.4864-4868.2004."
REF00004714	In vitro development of resistance to human immunodeficiency virus protease inhibitor GW640385Antimicrob Agents Chemother. 2006 Mar;50(3):1092-5. doi: 10.1128/AAC.50.3.1092-1095.2006.
REF00004715	Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replicationJ Virol. 2003 Jan;77(2):1512-23. doi: 10.1128/jvi.77.2.1512-1523.2003.
REF00004716	Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitnessAntimicrob Agents Chemother. 2013 Jun;57(6):2654-63. doi: 10.1128/AAC.02568-12. Epub 2013 Mar 25.
REF00004717	Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimensHIV Med. 2004 Nov;5(6):394-9. doi: 10.1111/j.1468-1293.2004.00243.x.
REF00004718	"Antiviral activity and cross-resistance profile of P-1946, a novel human immunodeficiency virus type 1 protease inhibitorAntiviral Res. 2006 Jun;70(2):17-20. doi: 10.1016/j.antiviral.2005.12.006. Epub 2006 Jan 20."
REF00004719	"Distribution of human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns in 4,183 persons undergoing genotypic resistance testingAntimicrob Agents Chemother. 2004 Aug;48(8):3122-6. doi: 10.1128/AAC.48.8.3122-3126.2004."
REF00004720	Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapyAntiviral Res. 2010 Jan;85(1):101-18. doi: 10.1016/j.antiviral.2009.11.004. Epub 2009 Nov 17.
REF00004721	Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressureRetrovirology. 2013 Feb 22;10:22. doi: 10.1186/1742-4690-10-22.
REF00004722	Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacityAIDS. 2002 May 3;16(7):1009-17. doi: 10.1097/00002030-200205030-00007.
REF00004723	Multiple genetic pathways involving amino acid position 143 of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvitegravirAntimicrob Agents Chemother. 2013 Sep;57(9):4105-13. doi: 10.1128/AAC.00204-13. Epub 2013 Jun 3.
REF00004724	"Substitutions at amino acid positions 143, 148, and 155 of HIV-1 integrase define distinct genetic barriers to raltegravir resistance in vivoJ Virol. 2012 Jul;86(13):7249-55. doi: 10.1128/JVI.06618-11. Epub 2012 May 2."
REF00004725	Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathwaysJ Virol. 2009 Nov;83(22):11440-6. doi: 10.1128/JVI.01168-09. Epub 2009 Sep 16.
REF00004726	Resistance profile after viral rebound on atazanavir-containing therapy: focus on protease inhibitor naive subjects in the IMPACT study (BMS AI424-128).
REF00004727	Miscellaneous Clinical Isolates.
REF00004728	Phenotypic susceptibility to TMC-114 and tipranavir before and after lopinavir/ritonavir-based treatment in subjects demonstrating evolution of lopinavir resistance.
REF00004729	"HIV-1 reverse transcriptase mutations that suppress zidovudine resistance also increase in vitro susceptibility to tenofovir, but not stavudine."
REF00004730	Bictegravir Resistance Profile: Data for External Experts.
REF00004731	Pre-existing HIV-1 integrase polymorphisms do not impact treatment response to elvitegravir-containing fixed-dose combination regimens in treatment-naive patients.
REF00004732	Phenotypic evidence for NRTI resistance in HIV-1 isolates with the RT mutation K64H.
REF00004733	Atazanavir resistance in a protease inhibitor-naive patient treated with atazanavir/ritonavir associated with development of high-level atazanavir resistance and the N88S mutation in protease.
REF00004734	Genotypic (and phenotypic) predictors of a response to DDI monotherapy in ZDV-experienced patients.
REF00004735	Susceptibility to saquinavir and atazanavir in highly protease inhibitor(PI) resistant HIV-1 is caused by lopinavir-induced drug resistance mutation L76V.
REF00004736	Discordance between genotype-based predictions of protease inhibitor susceptibility and actual phenotype in HIV-1 isolates containing mutations at positions 82 and 90: Modulatory effects of mutations at secondary positions.
REF00004737	Integrase Inhibitor Resistance Selections Initiated with Drug Resistant HIV-1.
REF00004738	Characterization of resistance mutation patterns emerging over 2 years during first-line antiretroviral treatment with tenofovir DF or stavudine and efavirenz.
REF00004739	Comparison of the Antivirogram and PhenoSense assays to determine phenotypic susceptibility to rilpivirine in patient samples from the Phase III ECHO and THRIVE trials.
REF00004740	Genotypic and phenotypic analysis of a large database of patient samples reveals distinct patterns of protease inhibitor cross-resistance.
REF00004741	Patterns of protease inhibitor cross resistance in viral isolates with reduced susceptibility to lopinavir.
REF00004742	Complex interactions involving multiple amino acid substitutions alter NNRTI susceptibility.
REF00004743	Combinations of HIV-1 reverse transcriptase mutations L100I+K103N/S and L100I+K103R+V179D reduce susceptibility to rilpivirine.
REF00004744	Residual Antiviral Activity of Raltegravir in Patients with Resistance Mutations: A Prospective Study (RAL-dyn Study)
REF00004745	"Resistance profile of HIV-1 mutants in vitro selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-303). ."
REF00004746	Cross-resistance profile of the novel lysine-containing HIV-1 protease inhibitor PL-100.
REF00004747	Understanding the Resistance Profile of the HIV-1 NNRTI Doravirine in Combination With the Novel NRTTI MK-8591.
REF00004748	G190A substitution is associated with delavirdine(DLV) hypersusceptibility in vitro and clinical response with DLV intensification.
REF00004749	A novel HIV-1 RT mutation (M230L) confers NNRTI resistance and dose-dependent stimulation of replication.
REF00004750	Mutation Y188L of HIV-1 reverse transcriptase is strongly associated with reduced susceptibility to rilpivirine
REF00004751	Rapid development of high level resistance to dolutegravir with emergence of T97A mutation in two treatment experienced individuals with baseline partial sensitivity to dolutegravir.
REF00004752	Systematic identification of genomic markers of drug sensitivity in cancer cellsNature. 2012 Mar 28;483(7391):570-5. doi: 10.1038/nature11005.
REF00004753	Methods for High-throughput Drug Combination Screening and Synergy ScoringMethods Mol Biol. 2018;1711:351-398. doi: 10.1007/978-1-4939-7493-1_17.
REF00004754	Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugsNat Methods. 2016 Jun;13(6):521-7. doi: 10.1038/nmeth.3853. Epub 2016 May 2.
REF00004755	Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testingBlood Cancer J. 2015 May 1;5(5):e309. doi: 10.1038/bcj.2015.30.
REF00004756	Drug sensitivity in cancer cell lines is not tissue-specificMol Cancer. 2015 Feb 15;14:40. doi: 10.1186/s12943-015-0312-6.
REF00004757	The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature. 2012 Mar 28;483(7391):603-7. doi: 10.1038/nature11003.
REF00004758	A Landscape of Pharmacogenomic Interactions in CancerCell. 2016 Jul 28;166(3):740-754. doi: 10.1016/j.cell.2016.06.017. Epub 2016 Jul 7.
REF00004759	Pharmacogenomic agreement between two cancer cell line data setsNature. 2015 Dec 3;528(7580):84-7. doi: 10.1038/nature15736. Epub 2015 Nov 16.
REF00004760	Reproducible pharmacogenomic profiling of cancer cell line panelsNature. 2016 May 19;533(7603):333-7. doi: 10.1038/nature17987.
REF00004761	Genomics of drug sensitivity in bladder cancer: an integrated resource for pharmacogenomic analysis in bladder cancerBMC Med Genomics. 2018 Oct 3;11(1):88. doi: 10.1186/s12920-018-0406-2.
REF00004762	PharmacoDB: an integrative database for mining in vitro anticancer drug screening studiesNucleic Acids Res. 2018 Jan 4;46(D1):D994-D1002. doi: 10.1093/nar/gkx911.
REF00004763	More than fishing for a cure: The promises and pitfalls of high throughput cancer cell line screensPharmacol Ther. 2018 Nov;191:178-189. doi: 10.1016/j.pharmthera.2018.06.014. Epub 2018 Jun 25.
REF00004764	High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell linesNat Biotechnol. 2016 Apr;34(4):419-23. doi: 10.1038/nbt.3460. Epub 2016 Feb 29.
REF00004765	Drug screening of cancer cell lines and human primary tumors using droplet microfluidicsSci Rep. 2017 Aug 22;7(1):9109. doi: 10.1038/s41598-017-08831-z.
REF00004766	Cell-Based Assays on Microfluidics for Drug ScreeningACS Sens. 2019 Jun 28;4(6):1465-1475. doi: 10.1021/acssensors.9b00479. Epub 2019 May 17.
REF00004767	Development of a Microfluidic Array to Study Drug Response in Breast CancerMolecules. 2019 Nov 30;24(23):4385. doi: 10.3390/molecules24234385.
REF00004768	Predicting chemosensitivity using drug perturbed gene dynamicsBMC Bioinformatics. 2021 Jan 7;22(1):15. doi: 10.1186/s12859-020-03947-y.
REF00004769	"Concerted changes in transcriptional regulation of genes involved in DNA methylation, demethylation, and folate-mediated one-carbon metabolism pathways in the NCI-60 cancer cell line panel in response to cancer drug treatmentClin Epigenetics. 2016 Jun 24;8:73. doi: 10.1186/s13148-016-0240-3. eCollection 2016."
REF00004770	Predicting cancer drug response by proteomic profilingClin Cancer Res. 2006 Aug 1;12(15):4583-9. doi: 10.1158/1078-0432.CCR-06-0290.
REF00004771	Chemosensitivity prediction by transcriptional profilingProc Natl Acad Sci U S A. 2001 Sep 11;98(19):10787-92. doi: 10.1073/pnas.191368598.
REF00004772	In vitro pharmacogenomic database and chemosensitivity predictive genes in gastric cancerGenomics. 2009 Jan;93(1):52-61. doi: 10.1016/j.ygeno.2008.08.002. Epub 2008 Oct 22.
REF00004773	An integrative genomic and proteomic approach to chemosensitivity predictionInt J Oncol. 2009 Jan;34(1):107-15. doi: 10.3892/ijo_00000134.
REF00004774	Prediction of broad spectrum resistance of tumors towards anticancer drugsClin Cancer Res. 2008 Apr 15;14(8):2405-12. doi: 10.1158/1078-0432.CCR-07-4525.
REF00004775	Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metricsSci Data. 2017 Nov 7;4:170166. doi: 10.1038/sdata.2017.166.
REF00004776	Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity DatasetCancer Discov. 2015 Nov;5(11):1210-23. doi: 10.1158/2159-8290.CD-15-0235. Epub 2015 Oct 19.
REF00004777	An interactive resource to identify cancer genetic and lineage dependencies targeted by small moleculesCell. 2013 Aug 29;154(5):1151-1161. doi: 10.1016/j.cell.2013.08.003.
REF00004778	Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agentsNat Rev Cancer. 2010 Apr;10(4):241-53. doi: 10.1038/nrc2820. Epub 2010 Mar 19.
REF00004779	"The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and diseaseScience. 2006 Sep 29;313(5795):1929-35. doi: 10.1126/science.1132939."
REF00004780	"A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 ProfilesCell. 2017 Nov 30;171(6):1437-1452.e17. doi: 10.1016/j.cell.2017.10.049."
REF00004781	Data Mining Approaches for Genomic Biomarker Development: Applications Using Drug Screening Data from the Cancer Genome Project and the Cancer Cell Line EncyclopediaPLoS One. 2015 Jul 1;10(7):e0127433. doi: 10.1371/journal.pone.0127433. eCollection 2015.
REF00004782	Integrating constitutive gene expression and chemoactivity: mining the NCI60 anticancer screenPLoS One. 2012;7(10):e44631. doi: 10.1371/journal.pone.0044631. Epub 2012 Oct 2.
REF00004783	RNA Sequencing of the NCI-60: Integration into CellMiner and CellMiner CDBCancer Res. 2019 Jul 1;79(13):3514-3524. doi: 10.1158/0008-5472.CAN-18-2047. Epub 2019 May 21.
REF00004784	Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profilingProc Natl Acad Sci U S A. 2007 Dec 11;104(50):19936-41. doi: 10.1073/pnas.0707498104. Epub 2007 Dec 6.
REF00004785	Tumor-Derived Cell Lines as Molecular Models of Cancer PharmacogenomicsMol Cancer Res. 2016 Jan;14(1):3-13. doi: 10.1158/1541-7786.MCR-15-0189. Epub 2015 Aug 6.
REF00004786	A novel heterogeneous network-based method for drug response prediction in cancer cell linesSci Rep. 2018 Feb 20;8(1):3355. doi: 10.1038/s41598-018-21622-4.
REF00004787	Integrating Domain Specific Knowledge and Network Analysis to Predict Drug Sensitivity of Cancer Cell LinesPLoS One. 2016 Sep 8;11(9):e0162173. doi: 10.1371/journal.pone.0162173. eCollection 2016.
REF00004788	Predicting breast cancer drug response using a multiple-layer cell line drug response network modelBMC Cancer. 2021 May 31;21(1):648. doi: 10.1186/s12885-021-08359-6.
REF00004789	Improved anticancer drug response prediction in cell lines using matrix factorization with similarity regularizationBMC Cancer. 2017 Aug 2;17(1):513. doi: 10.1186/s12885-017-3500-5.
REF00004790	Identifying anti-cancer drug response related genes using an integrative analysis of transcriptomic and genomic variations with cell line-based drug perturbationsOncotarget. 2016 Feb 23;7(8):9404-19. doi: 10.18632/oncotarget.7012.
REF00004791	A link prediction approach to cancer drug sensitivity predictionBMC Syst Biol. 2017 Oct 3;11(Suppl 5):94. doi: 10.1186/s12918-017-0463-8.
REF00004792	Dual-Layer Strengthened Collaborative Topic Regression Modeling for Predicting Drug SensitivityIEEE/ACM Trans Comput Biol Bioinform. 2020 Mar-Apr;17(2):587-598. doi: 10.1109/TCBB.2018.2864739. Epub 2018 Aug 10.
REF00004793	Prediction of cancer cell sensitivity to natural products based on genomic and chemical propertiesPeerJ. 2015 Nov 26;3:e1425. doi: 10.7717/peerj.1425. eCollection 2015.
REF00004794	Cell Index Database (CELLX): a web tool for cancer precision medicinePac Symp Biocomput. 2015:10-9.
REF00004795	A community effort to assess and improve drug sensitivity prediction algorithmsNat Biotechnol. 2014 Dec;32(12):1202-12. doi: 10.1038/nbt.2877. Epub 2014 Jun 1.
REF00004796	A single-cell analysis of breast cancer cell lines to study tumour heterogeneity and drug responseNat Commun. 2022 Mar 31;13(1):1714. doi: 10.1038/s41467-022-29358-6.
REF00004797	Predicting Anticancer Drug Resistance Mediated by MutationsPharmaceuticals (Basel). 2022 Jan 24;15(2):136. doi: 10.3390/ph15020136.
REF00004798	The Genomic Landscape and Pharmacogenomic Interactions of Clock Genes in Cancer ChronotherapyCell Syst. 2018 Mar 28;6(3):314-328.e2. doi: 10.1016/j.cels.2018.01.013. Epub 2018 Mar 7.
REF00004799	Improved large-scale prediction of growth inhibition patterns using the NCI60 cancer cell line panelBioinformatics. 2016 Jan 1;32(1):85-95. doi: 10.1093/bioinformatics/btv529. Epub 2015 Sep 8.
REF00004800	Precision and recall oncology: combining multiple gene mutations for improved identification of drug-sensitive tumoursOncotarget. 2017 Sep 15;8(57):97025-97040. doi: 10.18632/oncotarget.20923. eCollection 2017 Nov 14.
REF00004801	Open source machine-learning algorithms for the prediction of optimal cancer drug therapiesPLoS One. 2017 Oct 26;12(10):e0186906. doi: 10.1371/journal.pone.0186906. eCollection 2017.
REF00004802	Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arraysMol Cancer Ther. 2005 Mar;4(3):399-412. doi: 10.1158/1535-7163.MCT-04-0234.
REF00004803	mRNA and microRNA expression profiles of the NCI-60 integrated with drug activitiesMol Cancer Ther. 2010 May;9(5):1080-91. doi: 10.1158/1535-7163.MCT-09-0965. Epub 2010 May 4.
REF00004804	Subtype and pathway specific responses to anticancer compounds in breast cancerProc Natl Acad Sci U S A. 2012 Feb 21;109(8):2724-9. doi: 10.1073/pnas.1018854108. Epub 2011 Oct 14.
REF00004805	Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60Clin Cancer Res. 2015 Sep 1;21(17):3841-52. doi: 10.1158/1078-0432.CCR-15-0335. Epub 2015 Jun 5.
REF00004806	CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line setCancer Res. 2012 Jul 15;72(14):3499-511. doi: 10.1158/0008-5472.CAN-12-1370.
REF00004807	CellMiner: a relational database and query tool for the NCI-60 cancer cell linesBMC Genomics. 2009 Jun 23;10:277. doi: 10.1186/1471-2164-10-277.
REF00004808	The NCI60 human tumour cell line anticancer drug screenNat Rev Cancer. 2006 Oct;6(10):813-23. doi: 10.1038/nrc1951.
REF00004809	SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic SignaturesCell Rep. 2020 Oct 20;33(3):108296. doi: 10.1016/j.celrep.2020.108296.
REF00004810	Candidate biomarker assessment for pharmacological responseTransl Oncol. 2020 Oct;13(10):100830. doi: 10.1016/j.tranon.2020.100830. Epub 2020 Jul 8.
REF00004811	Implementation of the NCI-60 Human Tumor Cell Line Panel to Screen 2260 Cancer Drug Combinations to Generate >3 Million Data Points Used to Populate a Large Matrix of Anti-Neoplastic Agent Combinations (ALMANAC) DatabaseSLAS Discov. 2019 Mar;24(3):242-263. doi: 10.1177/2472555218812429. Epub 2018 Nov 30.
REF00004812	Drug Sensitivity Assays of Human Cancer Organoid CulturesMethods Mol Biol. 2019;1576:339-351. doi: 10.1007/7651_2016_10.
REF00004813	Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cellsNucleic Acids Res. 2013 Jan;41(Database issue):D955-61. doi: 10.1093/nar/gks1111. Epub 2012 Nov 23.
REF00004814	A Computational Approach for Identifying Synergistic Drug CombinationsPLoS Comput Biol. 2017 Jan 13;13(1):e1005308. doi: 10.1371/journal.pcbi.1005308. eCollection 2017 Jan.
REF00004815	PI3K-xigama and PI3K-beta inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models.Chem Biol. 2013 Nov 21;20(11):1364-74. doi: 10.1016/j.chembiol.2013.09.017. Epub 2013 Nov 7.
REF00004816	"SGI-1776, an imidazo pyridazine compound, inhibits the proliferation of ovarian cancer cells by inactivating Pim-1. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2014 Jul;39(7):649-57."
REF00004817	"AZD1208, a Pan-Pim Kinase Inhibitor, Has Anti-Growth Effect on 93T449 Human Liposarcoma Cells via Control of the Expression and Phosphorylation of Pim-3, mTOR, 4EBP-1, S6, STAT-3 and AMPK. Int J Mol Sci. 2019 Jan 16;20(2):363. doi: 10.3390/ijms20020363."
REF00004818	Chemical Inhibition of Histone Deacetylases 1 and 2 Induces Fetal Hemoglobin through Activation of GATA2.
REF00004819	Research Progress of Small Molecule VEGFR/c-Met Inhibitors as Anticancer Agents (2016-Present). Molecules. 2020 Jun 8;25(11):2666. 
REF00004820	Role of arsenic and its resistance in nature. Can J Microbiol. 2011 Oct;57(10):769-74. doi: 10.1139/w11-062. Epub 2011 Sep 21.
REF00004821	"Effect of para-Substituents in Ethylene Copolymerizations with 1-Decene, 1-Dodecene, and with 2-Methyl-1-Pentene Using Phenoxide Modified Half-Titanocenes-MAO Catalyst Systems. ChemistryOpen. 2021 Sep;10(9):867-876. doi: 10.1002/open.202100047."
REF00004822	Indole-3-acetic acid biosynthesis and its regulation in plant-associated bacteria. Appl Microbiol Biotechnol. 2020 Oct;104(20):8607-8619.
REF00004823	MEK inhibitors for the treatment of non-small cell lung cancer.J Hematol Oncol. 2021 Jan 5;14(1):1. doi: 10.1186/s13045-020-01025-7.
REF00004824	K252a and staurosporine microbial alkaloid toxins as prototype of neurotropic drugs. Adv Exp Med Biol. 1996;391:367-77. doi: 10.1007/978-1-4613-0361-9_31.
REF00004825	Lack of a point mutation of human DNA topoisomerase II in multidrug-resistant anaplastic thyroid carcinoma cell lines. Cancer Lett. 1997 Jun 3;116(1):33-9.
REF00004826	Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol Ther. 2010 Oct 15;10(8):788-95.